



# **STIC Search Report**

## **Biotech-Chem Library**

**STIC Database Tracking Number: 110656**

**TO: James Schultz**  
**Location: CM1/12E18/11E12**  
**Art Unit: 1635**  
**Thursday, December 18, 2003**

**Case Serial Number: 09/960143**

**From: David Schreiber**  
**Location: Biotech-Chem Library**  
**CM1-6A03**  
**Phone: 308-4292**

**david.schreiber@uspto.gov**

### **Search Notes**

# SEARCH REQUEST FORM

Requestor's Name: \_\_\_\_\_ Serial Number: \_\_\_\_\_  
Date: \_\_\_\_\_ Phone: \_\_\_\_\_ Art Unit: \_\_\_\_\_

## Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

## STAFF USE ONLY

Date completed: 12/18  
Searcher: D Schreiber 308-4292  
Terminal time: 90  
Elapsed time: 13  
CPU time: \_\_\_\_\_  
Total time: \_\_\_\_\_  
Number of Searches: \_\_\_\_\_  
Number of Databases: \_\_\_\_\_

Search Site  
\_\_\_\_ STIC  
☒ CM-1 CA 13  
\_\_\_\_ Pre-S  
Type of Search  
15 N.A. Sequence  
\_\_\_\_ A.A. Sequence  
\_\_\_\_ Structure  
\_\_\_\_ Bibliographic

Vendors  
\_\_\_\_ IG  
\_\_\_\_ STN  
\_\_\_\_ Dialog  
\_\_\_\_ APS  
\_\_\_\_ Geninfo  
\_\_\_\_ SDC  
\_\_\_\_ DARC/Questel  
☒ Other CompuLink



GenCore version 5.1.6  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 18, 2003, 07:17:07 ; Search time 14 Seconds  
(without alignments)

2.891 Million cell updates/sec

Title: us-09-960-143-3

Perfect score: 1249

Sequence: 1 aaaaattcattctctgtggt.....atataattgtctcaagt 1249

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 947 seqs, 16203 residues

Total number of hits satisfying chosen parameters: 1894

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 984 summaries

Database : rge.seq.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	30	2.4	30	1	ACCESSION:AX419968
C 2	30	2.4	30	1	ACCESSION:BD182174
C 3	30	2.4	30	1	ACCESSION:BD182175
C 4	26	2.1	26	1	ACCESSION:AX280042
C 5	25	2.0	26	1	ACCESSION:AX280041
C 6	24	1.9	24	1	ACCESSION:AX207732
C 7	24	1.9	24	1	ACCESSION:AX265058
C 8	21	1.7	21	1	ACCESSION:AX040833
C 9	21	1.7	21	1	ACCESSION:AX133222
C 10	21	1.7	21	1	ACCESSION:AX133224
C 11	21	1.7	21	1	ACCESSION:AX419973
C 12	21	1.7	21	1	ACCESSION:AX419975
C 13	20	1.6	20	1	ACCESSION:AX130442
C 14	20	1.6	20	1	ACCESSION:AX419972
C 15	18.2	1.5	24	1	ACCESSION:AX084499
C 16	17.4	1.4	21	1	ACCESSION:AX236360
C 17	17	1.4	17	1	ACCESSION:AX419971
C 18	16.6	1.3	26	1	ACCESSION:AX280042
C 19	16.2	1.3	22	1	ACCESSION:AX051334
C 20	16.2	1.3	23	1	ACCESSION:AX059999
C 21	16.2	1.3	23	1	ACCESSION:BD081029
C 22	15.8	1.3	20	1	ACCESSION:AX295620
C 23	15.8	1.3	20	1	ACCESSION:BD090846
C 24	15.8	1.3	21	1	ACCESSION:AX092810
C 25	15.6	1.2	22	1	ACCESSION:AX164318
C 26	15.6	1.2	22	1	ACCESSION:AX164319
C 27	15.6	1.2	22	1	ACCESSION:AX131810
C 28	15.6	1.2	22	1	ACCESSION:AX131811
C 29	15.6	1.2	22	1	ACCESSION:AX169407
C 30	15.6	1.2	22	1	ACCESSION:AX169408
C 31	15.6	1.2	26	1	ACCESSION:AX280041
C 32	15.4	1.2	17	1	ACCESSION:AX500365
C 33	15.4	1.2	17	1	ACCESSION:AX24434

34	15.4	1.2	18	1	AR076329
C 35	15.4	1.2	20	1	AR168620
C 36	15.4	1.2	21	1	ACCESSION:AX555826
C 37	15.2	1.2	20	1	AR031041
C 38	15.2	1.2	20	1	ACCESSION:AX232302
C 39	15.2	1.2	20	1	ACCESSION:AX429785
C 40	15.2	1.2	20	1	BD144143
C 41	15.2	1.2	21	1	ACCESSION:AX26944
C 42	15.2	1.2	21	1	AR050156
C 43	15.2	1.2	21	1	AR130275
C 44	15.2	1.2	21	1	ACCESSION:AX008949
C 45	15.2	1.2	21	1	ACCESSION:AX23731
C 46	15.2	1.2	21	1	ACCESSION:AX528526
C 47	15	1.2	15	1	AX419974
C 48	14.8	1.2	18	1	ACCESSION:AX67086
C 49	14.8	1.2	19	1	AX129263
C 50	14.8	1.2	20	1	AR181777
C 51	14.8	1.2	20	1	AR181778
C 52	14.8	1.2	20	1	ACCESSION:AX269437
C 53	14.8	1.2	20	1	AX270968
C 54	14.8	1.2	20	1	AX599078
C 55	14.8	1.2	20	1	BD138313
C 56	14.8	1.2	20	1	AX599078
C 57	14.8	1.2	21	1	AX599078
C 58	14.8	1.2	21	1	AR069029
C 59	14.8	1.2	21	1	AR299016
C 60	14.4	1.2	17	1	AX500364
C 61	14.4	1.2	17	1	AX500366
C 62	14.4	1.2	17	1	AX722454
C 63	14.4	1.2	17	1	AX731903
C 64	14.4	1.2	17	1	BD017427
C 65	14.4	1.2	18	1	AX599380
C 66	14.4	1.2	20	1	AX119636
C 67	14.4	1.2	20	1	AX149130
C 68	14.4	1.2	20	1	AX149130
C 69	14.2	1.1	19	1	ATHS21162
C 70	14.2	1.1	19	1	AR178736
C 71	14.2	1.1	19	1	AR205441
C 72	14.2	1.1	19	1	AR220133
C 73	14.2	1.1	19	1	AR221522
C 74	14.2	1.1	19	1	AR254234
C 75	14.2	1.1	19	1	AR282430
C 76	14.2	1.1	19	1	AX129503
C 77	14.2	1.1	19	1	AX599113
C 78	14.2	1.1	20	1	AR030970
C 79	14.2	1.1	20	1	AR108815
C 80	14.2	1.1	20	1	AR145988
C 81	14.2	1.1	20	1	AR145989
C 82	14.2	1.1	20	1	AR159242
C 83	14.2	1.1	20	1	AR159243
C 84	14.2	1.1	20	1	AR159247
C 85	14.2	1.1	20	1	AR159248
C 86	14.2	1.1	20	1	AR180879
C 87	14.2	1.1	20	1	AR180880
C 88	14.2	1.1	20	1	ACCESSION:AX205764
C 89	14.2	1.1	20	1	ACCESSION:AX224476
C 90	14.2	1.1	20	1	AR272014
C 91	14.2	1.1	20	1	AR315173
C 92	14.2	1.1	20	1	AR315173
C 93	14.2	1.1	20	1	BD161924
C 94	14	1.1	15	1	YSGMT021
C 95	14	1.1	15	1	AR041399
C 96	14	1.1	15	1	AR041407
C 97	14	1.1	15	1	AR041916
C 98	14	1.1	15	1	AR041917
C 99	14	1.1	15	1	AR041918
C 100	14	1.1	15	1	AX636857
C 101	14	1.1	15	1	AX636872
C 102	14	1.1	15	1	AX637381
C 103	14	1.1	15	1	AX637383
C 104	14	1.1	15	1	AX637385
C 105	14	1.1	17	1	AX738727
C 106	14	1.1	17	1	BD067874
C 106	14	1.1	18	1	AX069089

107	C	107	1.1	20	1	AR067181	180	13.4	1.1	15	1	AR041921	ACCESSION:AR041921
108		14	1.1	20	1	AR315239	181	13.4	1.1	15	1	AR041922	ACCESSION:AR041922
109		14	1.1	20	1	ATW552863	182	13.4	1.1	15	1	AR041923	ACCESSION:AR041923
110	C	13.8	1.1	17	1	AR046179	183	13.4	1.1	15	1	AR041924	ACCESSION:AR041924
111	C	13.8	1.1	17	1	AR047260	184	13.4	1.1	15	1	AR041925	ACCESSION:AR041925
112	C	13.8	1.1	17	1	AR020789	185	13.4	1.1	15	1	AR041926	ACCESSION:AR041926
113	C	13.8	1.1	17	1	AX500623	186	13.4	1.1	15	1	AR041931	ACCESSION:AR041931
114	C	13.8	1.1	17	1	AX580024	187	13.4	1.1	15	1	AR074423	ACCESSION:AR074423
115	C	13.8	1.1	17	1	AX580024	188	13.4	1.1	15	1	AR174801	ACCESSION:AR174801
116	C	13.8	1.1	17	1	AX673523	189	13.4	1.1	15	1	AX577646	ACCESSION:AX577646
117	C	13.8	1.1	17	1	AX734639	190	13.4	1.1	15	1	AX636858	ACCESSION:AX636858
118	C	13.8	1.1	17	1	IS3231	191	13.4	1.1	15	1	AX636860	ACCESSION:AX636860
119	C	13.8	1.1	17	1	IS4312	192	13.4	1.1	15	1	AX636874	ACCESSION:AX636874
120	C	13.8	1.1	18	1	AR297659	193	13.4	1.1	15	1	AX636876	ACCESSION:AX636876
121	C	13.8	1.1	18	1	AR297664	194	13.4	1.1	15	1	AX636878	ACCESSION:AX636878
122	C	13.8	1.1	18	1	AX132978	195	13.4	1.1	15	1	AX636880	ACCESSION:AX636880
123	C	13.8	1.1	18	1	AX599395	196	13.4	1.1	15	1	AX637387	ACCESSION:AX637387
124	C	13.8	1.1	18	1	E12707	197	13.4	1.1	15	1	AX637389	ACCESSION:AX637389
125	C	13.8	1.1	19	1	A88564	198	13.4	1.1	15	1	AX637391	ACCESSION:AX637391
126	C	13.8	1.1	19	1	A90531	199	13.4	1.1	15	1	AX637393	ACCESSION:AX637393
127	C	13.8	1.1	19	1	AR030969	200	13.4	1.1	15	1	AX637395	ACCESSION:AX637395
128	C	13.8	1.1	19	1	AR030972	201	13.4	1.1	15	1	AX637397	ACCESSION:AX637397
129	C	13.8	1.1	19	1	AR030974	202	13.4	1.1	15	1	AX637399	ACCESSION:AX637399
130	C	13.8	1.1	19	1	AR030975	203	13.4	1.1	15	1	AX637401	ACCESSION:AX637401
131	C	13.8	1.1	19	1	AR030976	204	13.4	1.1	15	1	AX637411	ACCESSION:AX637411
132	C	13.8	1.1	19	1	AR030977	205	13.4	1.1	15	1	E11393	ACCESSION:E11393
133	C	13.8	1.1	19	1	AR030978	206	13.4	1.1	15	1	I30514	ACCESSION:I30514
134	C	13.8	1.1	19	1	AR030981	207	13.4	1.1	15	1	I30530	ACCESSION:I30530
135	C	13.8	1.1	19	1	AR030982	208	13.4	1.1	15	1	I34061	ACCESSION:I34061
136	C	13.8	1.1	19	1	AR030983	209	13.4	1.1	15	1	I30516	ACCESSION:I30516
137	C	13.8	1.1	19	1	AR030984	210	13.4	1.1	16	1	I30521	ACCESSION:I30521
138	C	13.8	1.1	19	1	AR108814	211	13.4	1.1	16	1	ATH552647	ACCESSION:ATH552647
139	C	13.8	1.1	19	1	AR108817	212	13.4	1.1	17	1	A08233	ACCESSION:A08233
140	C	13.8	1.1	19	1	AR108819	213	13.4	1.1	17	1	A08234	ACCESSION:A08234
141	C	13.8	1.1	19	1	AR108820	214	13.4	1.1	17	1	A13281	ACCESSION:A13281
142	C	13.8	1.1	19	1	AR108821	215	13.4	1.1	17	1	A13282	ACCESSION:A13282
143	C	13.8	1.1	19	1	AR108822	216	13.4	1.1	17	1	AR046177	ACCESSION:AR046177
144	C	13.8	1.1	19	1	AR108823	217	13.4	1.1	17	1	AR047258	ACCESSION:AR047258
145	C	13.8	1.1	19	1	AR108826	218	13.4	1.1	17	1	AR053084	ACCESSION:AR053084
146	C	13.8	1.1	19	1	AR108827	219	13.4	1.1	17	1	AR065045	ACCESSION:AR065045
147	C	13.8	1.1	19	1	AR108828	220	13.4	1.1	17	1	AR186811	ACCESSION:AR186811
148	C	13.8	1.1	19	1	AR108829	221	13.4	1.1	17	1	AR187297	ACCESSION:AR187297
149	C	13.8	1.1	19	1	AR205763	222	13.4	1.1	17	1	AR192330	ACCESSION:AR192330
150	C	13.8	1.1	19	1	AR205766	223	13.4	1.1	17	1	AX421942	ACCESSION:AX421942
151	C	13.8	1.1	19	1	AR205768	224	13.4	1.1	17	1	AX421943	ACCESSION:AX421943
152	C	13.8	1.1	19	1	AR205769	225	13.4	1.1	17	1	AX500363	ACCESSION:AX500363
153	C	13.8	1.1	19	1	AR205770	226	13.4	1.1	17	1	AX500367	ACCESSION:AX500367
154	C	13.8	1.1	19	1	AR205771	227	13.4	1.1	17	1	AX672147	ACCESSION:AX672147
155	C	13.8	1.1	19	1	AR205772	228	13.4	1.1	17	1	AX722330	ACCESSION:AX722330
156	C	13.8	1.1	19	1	AR205776	229	13.4	1.1	17	1	AX724050	ACCESSION:AX724050
157	C	13.8	1.1	19	1	AR205777	230	13.4	1.1	17	1	AX724812	ACCESSION:AX724812
158	C	13.8	1.1	19	1	AR205778	231	13.4	1.1	17	1	AX725086	ACCESSION:AX725086
159	C	13.8	1.1	19	1	AR297082	232	13.4	1.1	17	1	AX725462	ACCESSION:AX725462
160	C	13.8	1.1	19	1	AX130049	233	13.4	1.1	17	1	AX728738	ACCESSION:AX728738
161	C	13.8	1.1	19	1	BD066077	234	13.4	1.1	17	1	AX729041	ACCESSION:AX729041
162	C	13.8	1.1	19	1	162823	235	13.4	1.1	17	1	AX733613	ACCESSION:AX733613
163	C	13.6	1.1	20	1	BD161924	236	13.4	1.1	17	1	AX736985	ACCESSION:AX736985
164	C	13.6	1.1	22	1	AR164318	237	13.4	1.1	17	1	AX738625	ACCESSION:AX738625
165	C	13.6	1.1	22	1	AR164319	238	13.4	1.1	17	1	I04892	ACCESSION:I04892
166	C	13.6	1.1	22	1	I31810	239	13.4	1.1	17	1	I32590	ACCESSION:I32590
167	C	13.6	1.1	22	1	I31811	240	13.4	1.1	17	1	I53229	ACCESSION:I53229
168	C	13.6	1.1	22	1	169407	241	13.4	1.1	17	1	I54310	ACCESSION:I54310
169	C	13.6	1.1	22	1	169408	242	13.4	1.1	17	1	AR087081	ACCESSION:AR087081
170	C	13.6	1.1	30	1	BD182175	243	13.4	1.1	18	1	AR165969	ACCESSION:AR165969
171	C	13.4	1.1	15	1	AR041400	244	13.4	1.1	18	1	AR285276	ACCESSION:AR285276
172	C	13.4	1.1	15	1	AR041401	245	13.4	1.1	18	1	AX032800	ACCESSION:AX032800
173	C	13.4	1.1	15	1	AR041402	246	13.4	1.1	18	1	AX092726	ACCESSION:AX092726
174	C	13.4	1.1	15	1	AR041408	247	13.4	1.1	18	1	AX643248	ACCESSION:AX643248
175	C	13.4	1.1	15	1	AR041409	248	13.4	1.1	18	1	AX643251	ACCESSION:AX643251
176	C	13.4	1.1	15	1	AR041410	249	13.4	1.1	18	1	E60081	ACCESSION:E60081
177	C	13.4	1.1	15	1	AR041411	250	13.4	1.1	19	1	AR293234	ACCESSION:AR293234
178	C	13.4	1.1	15	1	AR041919	251	13.4	1.1	19	1	AX079136	ACCESSION:AX079136
179	C	13.4	1.1	15	1	AR041920	252	13.4	1.1	19	1		

C 253	13.4	1.1	19	1	AX130601	ACCESSION:AX130601	C 326	12.8	1.0	17	1	AR186678	ACCESSION:AR186678
C 254	13.4	1.1	19	1	AX149204	ACCESSION:AX149204	C 327	12.8	1.0	17	1	AR187068	ACCESSION:AR187068
C 255	13.4	1.1	19	1	AX183607	ACCESSION:AX183607	C 328	12.8	1.0	17	1	AR187069	ACCESSION:AR187069
C 256	13.4	1.1	19	1	I31433	ACCESSION:I31433	C 329	12.8	1.0	17	1	AR187340	ACCESSION:AR187340
C 257	13.2	1.1	18	1	A67082	ACCESSION:A67082	C 330	12.8	1.0	17	1	AR188362	ACCESSION:AR188362
C 258	13.2	1.1	18	1	A67087	ACCESSION:A67087	C 331	12.8	1.0	17	1	AR188737	ACCESSION:AR188737
C 259	13.2	1.1	18	1	A67088	ACCESSION:A67088	C 332	12.8	1.0	17	1	AR188738	ACCESSION:AR188738
C 260	13.2	1.1	18	1	A67090	ACCESSION:A67090	C 333	12.8	1.0	17	1	AR308284	ACCESSION:AR308284
C 261	13.2	1.1	18	1	A81026	ACCESSION:A81026	C 334	12.8	1.0	17	1	AR308286	ACCESSION:AR308286
C 262	13.2	1.1	18	1	A95480	ACCESSION:A95480	C 335	12.8	1.0	17	1	AX029041	ACCESSION:AX029041
C 263	13.2	1.1	18	1	AX130089	ACCESSION:AX130089	C 336	12.8	1.0	17	1	AX029043	ACCESSION:AX029043
C 264	13.2	1.1	18	1	AR208426	ACCESSION:AR208426	C 337	12.8	1.0	17	1	AX076472	ACCESSION:AX076472
C 265	13.2	1.1	18	1	AR222905	ACCESSION:AR222905	C 338	12.8	1.0	17	1	AX132943	ACCESSION:AX132943
C 266	13.2	1.1	18	1	AR222919	ACCESSION:AR222919	C 339	12.8	1.0	17	1	AX214988	ACCESSION:AX214988
C 267	13.2	1.1	18	1	AR241972	ACCESSION:AR241972	C 340	12.8	1.0	17	1	AX215015	ACCESSION:AX215015
C 268	13.2	1.1	18	1	AR293701	ACCESSION:AR293701	C 341	12.8	1.0	17	1	AX215874	ACCESSION:AX215874
C 269	13.2	1.1	18	1	AX085252	ACCESSION:AX085252	C 342	12.8	1.0	17	1	AX216170	ACCESSION:AX216170
C 270	13.2	1.1	18	1	AX571969	ACCESSION:AX571969	C 343	12.8	1.0	17	1	AX216751	ACCESSION:AX216751
C 271	13.2	1.1	18	1	AX599270	ACCESSION:AX599270	C 344	12.8	1.0	17	1	AX263368	ACCESSION:AX263368
C 272	13.2	1.1	18	1	BD104062	ACCESSION:BD104062	C 345	12.8	1.0	17	1	AX263369	ACCESSION:AX263369
C 273	13.2	1.1	18	1	I25305	ACCESSION:I25305	C 346	12.8	1.0	17	1	AX264068	ACCESSION:AX264068
C 274	13.2	1.1	18	1	AT529366	ACCESSION:AT529366	C 347	12.8	1.0	17	1	AX264069	ACCESSION:AX264069
C 275	13.2	1.1	18	1	Y5WTP021	ACCESSION:Y5WTP021	C 348	12.8	1.0	17	1	AX422979	ACCESSION:AX422979
C 276	13	1.0	15	1	A63576	ACCESSION:A63576	C 349	12.8	1.0	17	1	AX423008	ACCESSION:AX423008
C 277	13	1.0	15	1	AR041398	ACCESSION:AR041398	C 350	12.8	1.0	17	1	AX500622	ACCESSION:AX500622
C 278	13	1.0	15	1	AR041406	ACCESSION:AR041406	C 351	12.8	1.0	17	1	AX500624	ACCESSION:AX500624
C 279	13	1.0	15	1	AR041915	ACCESSION:AR041915	C 352	12.8	1.0	17	1	AX503015	ACCESSION:AX503015
C 280	13	1.0	15	1	AR041930	ACCESSION:AR041930	C 353	12.8	1.0	17	1	AX503016	ACCESSION:AX503016
C 281	13	1.0	15	1	AX636855	ACCESSION:AX636855	C 354	12.8	1.0	17	1	AX531353	ACCESSION:AX531353
C 282	13	1.0	15	1	AX636870	ACCESSION:AX636870	C 355	12.8	1.0	17	1	AX531354	ACCESSION:AX531354
C 283	13	1.0	15	1	AX637379	ACCESSION:AX637379	C 356	12.8	1.0	17	1	AX578728	ACCESSION:AX578728
C 284	13	1.0	15	1	AX637409	ACCESSION:AX637409	C 357	12.8	1.0	17	1	AX579226	ACCESSION:AX579226
C 285	13	1.0	15	1	AX638326	ACCESSION:AX638326	C 358	12.8	1.0	17	1	AX579385	ACCESSION:AX579385
C 286	13	1.0	15	1	I77803	ACCESSION:I77803	C 359	12.8	1.0	17	1	AX579496	ACCESSION:AX579496
C 287	13	1.0	17	1	AR072365	ACCESSION:AR072365	C 360	12.8	1.0	17	1	AX579591	ACCESSION:AX579591
C 288	13	1.0	17	1	AR078337	ACCESSION:AR078337	C 361	12.8	1.0	17	1	AX634813	ACCESSION:AX634813
C 289	13	1.0	17	1	AX264383	ACCESSION:AX264383	C 362	12.8	1.0	17	1	AX671653	ACCESSION:AX671653
C 290	13	1.0	17	1	AX264384	ACCESSION:AX264384	C 363	12.8	1.0	17	1	AX671834	ACCESSION:AX671834
C 291	13	1.0	17	1	AX264387	ACCESSION:AX264387	C 364	12.8	1.0	17	1	AX672853	ACCESSION:AX672853
C 292	13	1.0	17	1	AX264388	ACCESSION:AX264388	C 365	12.8	1.0	17	1	AX673783	ACCESSION:AX673783
C 293	13	1.0	17	1	AX421944	ACCESSION:AX421944	C 366	12.8	1.0	17	1	AX673947	ACCESSION:AX673947
C 294	13	1.0	17	1	AX578689	ACCESSION:AX578689	C 367	12.8	1.0	17	1	AX673993	ACCESSION:AX673993
C 295	13	1.0	17	1	AX580015	ACCESSION:AX580015	C 368	12.8	1.0	17	1	AX674214	ACCESSION:AX674214
C 296	13	1.0	17	1	AX572466	ACCESSION:AX572466	C 369	12.8	1.0	17	1	AX722385	ACCESSION:AX722385
C 297	13	1.0	17	1	AX728692	ACCESSION:AX728692	C 370	12.8	1.0	17	1	AX722396	ACCESSION:AX722396
C 298	13	1.0	17	1	BD067674	ACCESSION:BD067674	C 371	12.8	1.0	17	1	AX723547	ACCESSION:AX723547
C 299	13	1.0	17	1	BD067675	ACCESSION:BD067675	C 372	12.8	1.0	17	1	AX726127	ACCESSION:AX726127
C 300	13	1.0	17	1	BD067676	ACCESSION:BD067676	C 373	12.8	1.0	17	1	AX726135	ACCESSION:AX726135
C 301	13	1.0	17	1	BD067677	ACCESSION:BD067677	C 374	12.8	1.0	17	1	AX726286	ACCESSION:AX726286
C 302	13	1.0	17	1	I09655	ACCESSION:I09655	C 375	12.8	1.0	17	1	AX726492	ACCESSION:AX726492
C 303	13	1.0	17	1	I26476	ACCESSION:I26476	C 376	12.8	1.0	17	1	AX727740	ACCESSION:AX727740
C 304	13	1.0	18	1	AX004292	ACCESSION:AX004292	C 377	12.8	1.0	17	1	AX727854	ACCESSION:AX727854
C 305	13	1.0	18	1	AX383945	ACCESSION:AX383945	C 378	12.8	1.0	17	1	AX728103	ACCESSION:AX728103
C 306	13	1.0	18	1	AX417565	ACCESSION:AX417565	C 379	12.8	1.0	17	1	AX728686	ACCESSION:AX728686
C 307	13	1.0	18	1	AX599862	ACCESSION:AX599862	C 380	12.8	1.0	17	1	AX728701	ACCESSION:AX728701
C 308	13	1.0	18	1	BD094132	ACCESSION:BD094132	C 381	12.8	1.0	17	1	AX729056	ACCESSION:AX729056
C 309	13	1.0	18	1	BD094138	ACCESSION:BD094138	C 382	12.8	1.0	17	1	AX729980	ACCESSION:AX729980
C 310	13	1.0	30	1	BD0941968	ACCESSION:BD0941968	C 383	12.8	1.0	17	1	AX730354	ACCESSION:AX730354
C 311	12.8	1.0	16	1	A89384	ACCESSION:A89384	C 384	12.8	1.0	17	1	AX730419	ACCESSION:AX730419
C 312	12.8	1.0	16	1	AX083145	ACCESSION:AX083145	C 385	12.8	1.0	17	1	AX731759	ACCESSION:AX731759
C 313	12.8	1.0	16	1	AX015629	ACCESSION:AX015629	C 386	12.8	1.0	17	1	AX732065	ACCESSION:AX732065
C 314	12.8	1.0	16	1	BD066897	ACCESSION:BD066897	C 387	12.8	1.0	17	1	AX732416	ACCESSION:AX732416
C 315	12.8	1.0	17	1	AR046181	ACCESSION:AR046181	C 388	12.8	1.0	17	1	AX733161	ACCESSION:AX733161
C 316	12.8	1.0	17	1	AR047244	ACCESSION:AR047244	C 389	12.8	1.0	17	1	AX733379	ACCESSION:AX733379
C 317	12.8	1.0	17	1	AR047262	ACCESSION:AR047262	C 390	12.8	1.0	17	1	AX733381	ACCESSION:AX733381
C 318	12.8	1.0	17	1	AR047360	ACCESSION:AR047360	C 391	12.8	1.0	17	1	AX733982	ACCESSION:AX733982
C 319	12.8	1.0	17	1	AR047362	ACCESSION:AR047362	C 392	12.8	1.0	17	1	AX734084	ACCESSION:AX734084
C 320	12.8	1.0	17	1	AR054096	ACCESSION:AR054096	C 393	12.8	1.0	17	1	AX734468	ACCESSION:AX734468
C 321	12.8	1.0	17	1	AR057779	ACCESSION:AR057779	C 394	12.8	1.0	17	1	AX735132	ACCESSION:AX735132
C 322	12.8	1.0	17	1	AR083146	ACCESSION:AR083146	C 395	12.8	1.0	17	1	AX735198	ACCESSION:AX735198
C 323	12.8	1.0	17	1	AR101662	ACCESSION:AR101662	C 396	12.8	1.0	17	1	AX735395	ACCESSION:AX735395
C 324	12.8	1.0	17	1	AR101663	ACCESSION:AR101663	C 397	12.8	1.0	17	1	AX736068	ACCESSION:AX736068
C 325	12.8	1.0	17	1	AR115537	ACCESSION:AR115537	C 398	12.8	1.0	17	1	AX736295	ACCESSION:AX736295

C 399	12.8	1.0	17	1	AX736998	ACCESSION:AX736998
C 400	12.8	1.0	17	1	AX737306	ACCESSION:AX737306
C 401	12.8	1.0	17	1	AX737543	ACCESSION:AX737543
C 402	12.8	1.0	17	1	AX738128	ACCESSION:AX738128
C 403	12.8	1.0	17	1	AX738442	ACCESSION:AX738442
C 404	12.8	1.0	17	1	AX739113	ACCESSION:AX739113
C 405	12.8	1.0	17	1	BD009326	ACCESSION:BD009326
C 406	12.8	1.0	17	1	BD009328	ACCESSION:BD009328
C 407	12.8	1.0	17	1	153233	ACCESSION:153233
C 408	12.8	1.0	17	1	154296	ACCESSION:154296
C 409	12.8	1.0	17	1	154314	ACCESSION:154314
C 410	12.8	1.0	17	1	154412	ACCESSION:154412
C 411	12.8	1.0	17	1	154414	ACCESSION:154414
C 412	12.8	1.0	18	1	A58293	ACCESSION:A58293
C 413	12.8	1.0	18	1	A88563	ACCESSION:A88563
C 414	12.8	1.0	18	1	A90530	ACCESSION:A90530
C 415	12.8	1.0	18	1	A91289	ACCESSION:A91289
C 416	12.8	1.0	18	1	A96945	ACCESSION:A96945
C 417	12.8	1.0	18	1	A97456	ACCESSION:A97456
C 418	12.8	1.0	18	1	A99272	ACCESSION:A99272
C 419	12.8	1.0	18	1	AR083978	ACCESSION:AR083978
C 420	12.8	1.0	18	1	AR087025	ACCESSION:AR087025
C 421	12.8	1.0	18	1	AR144082	ACCESSION:AR144082
C 422	12.8	1.0	18	1	AR171914	ACCESSION:AR171914
C 423	12.8	1.0	18	1	AR215601	ACCESSION:AR215601
C 424	12.8	1.0	18	1	AR223848	ACCESSION:AR223848
C 425	12.8	1.0	18	1	AR223849	ACCESSION:AR223849
C 426	12.8	1.0	18	1	AR242371	ACCESSION:AR242371
C 427	12.8	1.0	18	1	AR275401	ACCESSION:AR275401
C 428	12.8	1.0	18	1	AR275453	ACCESSION:AR275453
C 429	12.8	1.0	18	1	AR293515	ACCESSION:AR293515
C 430	12.8	1.0	18	1	AR294351	ACCESSION:AR294351
C 431	12.8	1.0	18	1	AX132977	ACCESSION:AX132977
C 432	12.8	1.0	18	1	AX132979	ACCESSION:AX132979
C 433	12.8	1.0	18	1	AX133131	ACCESSION:AX133131
C 434	12.8	1.0	18	1	AX235061	ACCESSION:AX235061
C 435	12.8	1.0	18	1	AX252918	ACCESSION:AX252918
C 436	12.8	1.0	18	1	AX348483	ACCESSION:AX348483
C 437	12.8	1.0	18	1	AX349206	ACCESSION:AX349206
C 438	12.8	1.0	18	1	AX468612	ACCESSION:AX468612
C 439	12.8	1.0	18	1	AX599210	ACCESSION:AX599210
C 440	12.8	1.0	18	1	AX599319	ACCESSION:AX599319
C 441	12.8	1.0	18	1	AX599396	ACCESSION:AX599396
C 442	12.8	1.0	18	1	AX599722	ACCESSION:AX599722
C 443	12.8	1.0	18	1	AX657871	ACCESSION:AX657871
C 444	12.8	1.0	18	1	AX705830	ACCESSION:AX705830
C 445	12.8	1.0	18	1	BD066076	ACCESSION:BD066076
C 446	12.8	1.0	18	1	BD080876	ACCESSION:BD080876
C 447	12.8	1.0	18	1	AX129503	ACCESSION:AX129503
C 448	12.6	1.0	17	1	AX207847	ACCESSION:AX207847
C 449	12.6	1.0	18	1	AX417571	ACCESSION:AX417571
C 450	12.6	1.0	24	1	AX084499	ACCESSION:AX084499
C 451	12.4	1.0	14	1	AR131430	ACCESSION:AR131430
C 452	12.4	1.0	14	1	AR154236	ACCESSION:AR154236
C 453	12.4	1.0	14	1	AR176706	ACCESSION:AR176706
C 454	12.4	1.0	14	1	AR221843	ACCESSION:AR221843
C 455	12.4	1.0	14	1	107800	ACCESSION:107800
C 456	12.4	1.0	15	1	AR029016	ACCESSION:AR029016
C 457	12.4	1.0	15	1	AR029017	ACCESSION:AR029017
C 458	12.4	1.0	15	1	AR041403	ACCESSION:AR041403
C 459	12.4	1.0	15	1	AR041412	ACCESSION:AR041412
C 460	12.4	1.0	15	1	AR041927	ACCESSION:AR041927
C 461	12.4	1.0	15	1	AR056307	ACCESSION:AR056307
C 462	12.4	1.0	15	1	AR056547	ACCESSION:AR056547
C 463	12.4	1.0	15	1	AR087176	ACCESSION:AR087176
C 464	12.4	1.0	15	1	AR113771	ACCESSION:AR113771
C 465	12.4	1.0	15	1	AR114065	ACCESSION:AR114065
C 466	12.4	1.0	15	1	AR114305	ACCESSION:AR114305
C 467	12.4	1.0	15	1	AR132468	ACCESSION:AR132468
C 468	12.4	1.0	15	1	AR133635	ACCESSION:AR133635
C 469	12.4	1.0	15	1	AR1370387	ACCESSION:AR1370387
C 470	12.4	1.0	15	1	AR170388	ACCESSION:AR170388
C 471	12.4	1.0	15	1	AR170388	ACCESSION:AR170388

472	12.4	1.0	15	1	AR193000
473	12.4	1.0	15	1	AR241892
474	12.4	1.0	15	1	AX374587
475	12.4	1.0	15	1	AX419993
476	12.4	1.0	15	1	AX554013
477	12.4	1.0	15	1	AX587124
478	12.4	1.0	15	1	AX633104
479	12.4	1.0	15	1	AX633459
480	12.4	1.0	15	1	AX633577
481	12.4	1.0	15	1	AX635377
482	12.4	1.0	15	1	AX635379
483	12.4	1.0	15	1	AX636864
484	12.4	1.0	15	1	AX636882
485	12.4	1.0	15	1	AX637403
486	12.4	1.0	15	1	AX637884
487	12.4	1.0	15	1	E29991
488	12.4	1.0	15	1	E31788
489	12.4	1.0	15	1	E31789
490	12.4	1.0	15	1	E31790
491	12.4	1.0	15	1	E31791
492	12.4	1.0	15	1	E31792
493	12.4	1.0	15	1	E31793
494	12.4	1.0	15	1	E36075
495	12.4	1.0	15	1	E39422
496	12.4	1.0	15	1	E39423
497	12.4	1.0	15	1	E49631
498	12.4	1.0	15	1	E77618
499	12.4	1.0	15	1	E81253
500	12.4	1.0	15	1	E89848
501	12.4	1.0	16	1	A08781
502	12.4	1.0	16	1	A88098
503	12.4	1.0	16	1	A88522
504	12.4	1.0	16	1	A88613
505	12.4	1.0	16	1	A90065
506	12.4	1.0	16	1	A90489
507	12.4	1.0	16	1	A90580
508	12.4	1.0	16	1	AX088232
509	12.4	1.0	16	1	AX235073
510	12.4	1.0	16	1	AX235096
511	12.4	1.0	16	1	BD065611
512	12.4	1.0	16	1	BD066035
513	12.4	1.0	16	1	BD066126
514	12.4	1.0	16	1	BD091246
515	12.4	1.0	17	1	A89165
516	12.4	1.0	17	1	A8046644
517	12.4	1.0	17	1	AR186350
518	12.4	1.0	17	1	AR186590
519	12.4	1.0	17	1	AR186859
520	12.4	1.0	17	1	AR186885
521	12.4	1.0	17	1	AR188361
522	12.4	1.0	17	1	AR188739
523	12.4	1.0	17	1	AR190158
524	12.4	1.0	17	1	AR192044
525	12.4	1.0	17	1	AR192329
526	12.4	1.0	17	1	AR192331
527	12.4	1.0	17	1	AR215016
528	12.4	1.0	17	1	AR215685
529	12.4	1.0	17	1	AR216740
530	12.4	1.0	17	1	AR217082
531	12.4	1.0	17	1	AR217114
532	12.4	1.0	17	1	AR226925
533	12.4	1.0	17	1	AR226926
534	12.4	1.0	17	1	AR226927
535	12.4	1.0	17	1	AR263192
536	12.4	1.0	17	1	AR263193
537	12.4	1.0	17	1	AR265663
538	12.4	1.0	17	1	AR265664
539	12.4	1.0	17	1	AR272720
540	12.4	1.0	17	1	AR272721
541	12.4	1.0	17	1	AR383942
542	12.4	1.0	17	1	AX421941
543	12.4	1.0	17	1	AX423390
544	12.4	1.0	17	1	AX500362

C 545	12.4	1.0	17	1	AX500368	ACCESSION:AX500368	618	12.2	1.0	17	1	AR047358	ACCESSION:AR047358
C 546	12.4	1.0	17	1	AX500620	ACCESSION:AX500620	619	12.2	1.0	17	1	AR047364	ACCESSION:AR047364
C 547	12.4	1.0	17	1	AX500621	ACCESSION:AX500621	C 620	12.2	1.0	17	1	AR047604	ACCESSION:AR047604
C 548	12.4	1.0	17	1	AX578723	ACCESSION:AX578723	621	12.2	1.0	17	1	AR051620	ACCESSION:AR051620
C 549	12.4	1.0	17	1	AX579367	ACCESSION:AX579367	622	12.2	1.0	17	1	AR051641	ACCESSION:AR051641
C 550	12.4	1.0	17	1	AX671564	ACCESSION:AX671564	623	12.2	1.0	17	1	AR057785	ACCESSION:AR057785
C 551	12.4	1.0	17	1	AX671663	ACCESSION:AX671663	624	12.2	1.0	17	1	AR057803	ACCESSION:AR057803
C 552	12.4	1.0	17	1	AX672450	ACCESSION:AX672450	625	12.2	1.0	17	1	AR057805	ACCESSION:AR057805
C 553	12.4	1.0	17	1	AX672835	ACCESSION:AX672835	626	12.2	1.0	17	1	AR065109	ACCESSION:AR065109
C 554	12.4	1.0	17	1	AX673316	ACCESSION:AX673316	627	12.2	1.0	17	1	AR080426	ACCESSION:AR080426
C 555	12.4	1.0	17	1	AX673453	ACCESSION:AX673453	628	12.2	1.0	17	1	AR092550	ACCESSION:AR092550
C 556	12.4	1.0	17	1	AX674582	ACCESSION:AX674582	C 629	12.2	1.0	17	1	AR092550	ACCESSION:AR092550
C 557	12.4	1.0	17	1	AX674587	ACCESSION:AX674587	630	12.2	1.0	17	1	AR115378	ACCESSION:AR115378
C 558	12.4	1.0	17	1	AX722336	ACCESSION:AX722336	631	12.2	1.0	17	1	AR115399	ACCESSION:AR115399
C 559	12.4	1.0	17	1	AX722545	ACCESSION:AX722545	632	12.2	1.0	17	1	AR115543	ACCESSION:AR115543
C 560	12.4	1.0	17	1	AX723257	ACCESSION:AX723257	633	12.2	1.0	17	1	AR115561	ACCESSION:AR115561
C 561	12.4	1.0	17	1	AX724038	ACCESSION:AX724038	634	12.2	1.0	17	1	AR115563	ACCESSION:AR115563
C 562	12.4	1.0	17	1	AX724983	ACCESSION:AX724983	635	12.2	1.0	17	1	AR157370	ACCESSION:AR157370
C 563	12.4	1.0	17	1	AX725250	ACCESSION:AX725250	636	12.2	1.0	17	1	AR186327	ACCESSION:AR186327
C 564	12.4	1.0	17	1	AX726061	ACCESSION:AX726061	C 637	12.2	1.0	17	1	AR186562	ACCESSION:AR186562
C 565	12.4	1.0	17	1	AX726396	ACCESSION:AX726396	638	12.2	1.0	17	1	AR186699	ACCESSION:AR186699
C 566	12.4	1.0	17	1	AX727438	ACCESSION:AX727438	639	12.2	1.0	17	1	AR186816	ACCESSION:AR186816
C 567	12.4	1.0	17	1	AX729724	ACCESSION:AX729724	640	12.2	1.0	17	1	AR186817	ACCESSION:AR186817
C 568	12.4	1.0	17	1	AX730214	ACCESSION:AX730214	C 641	12.2	1.0	17	1	AR186851	ACCESSION:AR186851
C 569	12.4	1.0	17	1	AX730221	ACCESSION:AX730221	642	12.2	1.0	17	1	AR186887	ACCESSION:AR186887
C 570	12.4	1.0	17	1	AX730379	ACCESSION:AX730379	C 643	12.2	1.0	17	1	AR187067	ACCESSION:AR187067
C 571	12.4	1.0	17	1	AX731157	ACCESSION:AX731157	C 644	12.2	1.0	17	1	AR187212	ACCESSION:AR187212
C 572	12.4	1.0	17	1	AX731513	ACCESSION:AX731513	C 645	12.2	1.0	17	1	AR187213	ACCESSION:AR187213
C 573	12.4	1.0	17	1	AX731889	ACCESSION:AX731889	646	12.2	1.0	17	1	AR187227	ACCESSION:AR187227
C 574	12.4	1.0	17	1	AX732329	ACCESSION:AX732329	C 647	12.2	1.0	17	1	AR187306	ACCESSION:AR187306
C 575	12.4	1.0	17	1	AX733592	ACCESSION:AX733592	C 648	12.2	1.0	17	1	AR187339	ACCESSION:AR187339
C 576	12.4	1.0	17	1	AX735084	ACCESSION:AX735084	C 649	12.2	1.0	17	1	AR187369	ACCESSION:AR187369
C 577	12.4	1.0	17	1	AX735477	ACCESSION:AX735477	C 650	12.2	1.0	17	1	AR188360	ACCESSION:AR188360
C 578	12.4	1.0	17	1	AX736558	ACCESSION:AX736558	C 651	12.2	1.0	17	1	AR188498	ACCESSION:AR188498
C 579	12.4	1.0	17	1	AX736937	ACCESSION:AX736937	C 652	12.2	1.0	17	1	AR188771	ACCESSION:AR188771
C 580	12.4	1.0	17	1	AX737227	ACCESSION:AX737227	C 653	12.2	1.0	17	1	AR192457	ACCESSION:AR192457
C 581	12.4	1.0	17	1	AX738005	ACCESSION:AX738005	654	12.2	1.0	17	1	AR192474	ACCESSION:AR192474
C 582	12.4	1.0	17	1	AX738018	ACCESSION:AX738018	C 655	12.2	1.0	17	1	AR192646	ACCESSION:AR192646
C 583	12.4	1.0	17	1	AX738565	ACCESSION:AX738565	C 656	12.2	1.0	17	1	AR196327	ACCESSION:AR196327
C 584	12.4	1.0	17	1	AX739077	ACCESSION:AX739077	657	12.2	1.0	17	1	AR207848	ACCESSION:AR207848
C 585	12.4	1.0	17	1	AX739138	ACCESSION:AX739138	658	12.2	1.0	17	1	AR207851	ACCESSION:AR207851
C 586	12.4	1.0	17	1	AX739438	ACCESSION:AX739438	659	12.2	1.0	17	1	AR207853	ACCESSION:AR207853
C 587	12.4	1.0	17	1	AX739515	ACCESSION:AX739515	C 660	12.2	1.0	17	1	AR207853	ACCESSION:AR207853
C 588	12.4	1.0	17	1	AX739551	ACCESSION:AX739551	661	12.2	1.0	17	1	AR221781	ACCESSION:AR221781
C 589	12.4	1.0	17	1	AX739830	ACCESSION:AX739830	662	12.2	1.0	17	1	AR2254826	ACCESSION:AR2254826
C 590	12.4	1.0	17	1	BD066678	ACCESSION:BD066678	C 663	12.2	1.0	17	1	AR258348	ACCESSION:AR258348
C 591	12.4	1.0	17	1	BD067358	ACCESSION:BD067358	C 664	12.2	1.0	17	1	AR262898	ACCESSION:AR262898
C 592	12.4	1.0	17	1	BD092096	ACCESSION:BD092096	C 665	12.2	1.0	17	1	AR266625	ACCESSION:AR266625
C 593	12.4	1.0	17	1	I37415	ACCESSION:I37415	666	12.2	1.0	17	1	AR286163	ACCESSION:AR286163
C 594	12.4	1.0	17	1	I53696	ACCESSION:I53696	C 667	12.2	1.0	17	1	AX206986	ACCESSION:AX206986
C 595	12.4	1.0	17	1	I94265	ACCESSION:I94265	C 668	12.2	1.0	17	1	AX214665	ACCESSION:AX214665
C 596	12.4	1.0	17	1	BD182174	ACCESSION:BD182174	669	12.2	1.0	17	1	AX215017	ACCESSION:AX215017
C 597	12.2	1.0	17	1	A04026	ACCESSION:A04026	C 670	12.2	1.0	17	1	AX215079	ACCESSION:AX215079
C 598	12.2	1.0	17	1	A04027	ACCESSION:A04027	C 671	12.2	1.0	17	1	AX215079	ACCESSION:AX215079
C 599	12.2	1.0	17	1	A09201	ACCESSION:A09201	672	12.2	1.0	17	1	AX215156	ACCESSION:AX215156
C 600	12.2	1.0	17	1	A64296	ACCESSION:A64296	C 673	12.2	1.0	17	1	AX215198	ACCESSION:AX215198
C 601	12.2	1.0	17	1	A88483	ACCESSION:A88483	674	12.2	1.0	17	1	AX215220	ACCESSION:AX215220
C 602	12.2	1.0	17	1	A90450	ACCESSION:A90450	675	12.2	1.0	17	1	AX215570	ACCESSION:AX215570
C 603	12.2	1.0	17	1	A97833	ACCESSION:A97833	676	12.2	1.0	17	1	AX216249	ACCESSION:AX216249
C 604	12.2	1.0	17	1	AR045943	ACCESSION:AR045943	677	12.2	1.0	17	1	AX216420	ACCESSION:AX216420
C 605	12.2	1.0	17	1	AR045999	ACCESSION:AR045999	678	12.2	1.0	17	1	AX216599	ACCESSION:AX216599
C 606	12.2	1.0	17	1	AR045999	ACCESSION:AR045999	C 679	12.2	1.0	17	1	AX216808	ACCESSION:AX216808
C 607	12.2	1.0	17	1	AR046167	ACCESSION:AR046167	680	12.2	1.0	17	1	AX217250	ACCESSION:AX217250
C 608	12.2	1.0	17	1	AR046169	ACCESSION:AR046169	C 681	12.2	1.0	17	1	AX217422	ACCESSION:AX217422
C 609	12.2	1.0	17	1	AR046255	ACCESSION:AR046255	682	12.2	1.0	17	1	AX218022	ACCESSION:AX218022
C 610	12.2	1.0	17	1	AR046255	ACCESSION:AR046255	C 683	12.2	1.0	17	1	AX218103	ACCESSION:AX218103
C 611	12.2	1.0	17	1	AR046255	ACCESSION:AR046255	684	12.2	1.0	17	1	AX218166	ACCESSION:AX218166
C 612	12.2	1.0	17	1	AR047078	ACCESSION:AR047078	685	12.2	1.0	17	1	AX2227049	ACCESSION:AX2227049
C 613	12.2	1.0	17	1	AR047092	ACCESSION:AR047092	686	12.2	1.0	17	1	AX227468	ACCESSION:AX227468
C 614	12.2	1.0	17	1	AR047108	ACCESSION:AR047108	687	12.2	1.0	17	1	AX263172	ACCESSION:AX263172
C 615	12.2	1.0	17	1	AR047190	ACCESSION:AR047190	C 688	12.2	1.0	17	1	AX263173	ACCESSION:AX263173
C 616	12.2	1.0	17	1	AR047354	ACCESSION:AR047354	689	12.2	1.0	17	1	AX263380	ACCESSION:AX263380
C 617	12.2	1.0	17	1	AR047356	ACCESSION:AR047356	C 690	12.2	1.0	17	1	AX263381	ACCESSION:AX263381

691	12.2	1.0	17	1	AX364332	ACCESSION:AX264332
692	12.2	1.0	17	1	AX364333	ACCESSION:AX264333
693	12.2	1.0	17	1	AX364767	ACCESSION:AX264767
694	12.2	1.0	17	1	AX364768	ACCESSION:AX264768
695	12.2	1.0	17	1	AX365047	ACCESSION:AX265047
696	12.2	1.0	17	1	AX365048	ACCESSION:AX265048
697	12.2	1.0	17	1	AX365051	ACCESSION:AX265051
698	12.2	1.0	17	1	AX365052	ACCESSION:AX265052
699	12.2	1.0	17	1	AX365147	ACCESSION:AX265147
700	12.2	1.0	17	1	AX365148	ACCESSION:AX265148
701	12.2	1.0	17	1	AX365151	ACCESSION:AX265151
702	12.2	1.0	17	1	AX365152	ACCESSION:AX265152
703	12.2	1.0	17	1	AX366795	ACCESSION:AX266795
704	12.2	1.0	17	1	AX366796	ACCESSION:AX266796
705	12.2	1.0	17	1	AX366797	ACCESSION:AX266797
706	12.2	1.0	17	1	AX366798	ACCESSION:AX266798
707	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
708	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
709	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
710	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
711	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
712	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
713	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
714	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
715	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
716	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
717	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
718	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
719	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
720	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
721	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
722	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
723	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
724	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
725	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
726	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
727	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
728	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
729	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
730	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
731	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
732	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
733	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
734	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
735	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
736	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
737	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
738	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
739	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
740	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
741	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
742	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
743	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
744	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
745	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
746	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
747	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
748	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
749	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
750	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
751	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
752	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
753	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
754	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
755	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
756	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
757	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
758	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
759	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
760	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
761	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
762	12.2	1.0	17	1	AX366799	ACCESSION:AX266799
763	12.2	1.0	17	1	AX366799	ACCESSION:AX266799

764	12.2	1.0	17	1	AX648467	ACCESSION:AX648467
765	12.2	1.0	17	1	AX648579	ACCESSION:AX648579
766	12.2	1.0	17	1	AX648581	ACCESSION:AX648581
767	12.2	1.0	17	1	AX648667	ACCESSION:AX648667
768	12.2	1.0	17	1	AX671571	ACCESSION:AX671571
769	12.2	1.0	17	1	AX671600	ACCESSION:AX671600
770	12.2	1.0	17	1	AX671657	ACCESSION:AX671657
771	12.2	1.0	17	1	AX672578	ACCESSION:AX672578
772	12.2	1.0	17	1	AX672799	ACCESSION:AX672799
773	12.2	1.0	17	1	AX672898	ACCESSION:AX672898
774	12.2	1.0	17	1	AX673031	ACCESSION:AX673031
775	12.2	1.0	17	1	AX673430	ACCESSION:AX673430
776	12.2	1.0	17	1	AX674727	ACCESSION:AX674727
777	12.2	1.0	17	1	AX674800	ACCESSION:AX674800
778	12.2	1.0	17	1	AX687406	ACCESSION:AX687406
779	12.2	1.0	17	1	AX687451	ACCESSION:AX687451
780	12.2	1.0	17	1	AX691337	ACCESSION:AX691337
781	12.2	1.0	17	1	AX692522	ACCESSION:AX692522
782	12.2	1.0	17	1	AX692526	ACCESSION:AX692526
783	12.2	1.0	17	1	AX722376	ACCESSION:AX722376
784	12.2	1.0	17	1	AX722391	ACCESSION:AX722391
785	12.2	1.0	17	1	AX723177	ACCESSION:AX723177
786	12.2	1.0	17	1	AX723495	ACCESSION:AX723495
787	12.2	1.0	17	1	AX723876	ACCESSION:AX723876
788	12.2	1.0	17	1	AX724563	ACCESSION:AX724563
789	12.2	1.0	17	1	AX726475	ACCESSION:AX726475
790	12.2	1.0	17	1	AX726611	ACCESSION:AX726611
791	12.2	1.0	17	1	AX726698	ACCESSION:AX726698
792	12.2	1.0	17	1	AX727922	ACCESSION:AX727922
793	12.2	1.0	17	1	AX728060	ACCESSION:AX728060
794	12.2	1.0	17	1	AX728122	ACCESSION:AX728122
795	12.2	1.0	17	1	AX728315	ACCESSION:AX728315
796	12.2	1.0	17	1	AX728823	ACCESSION:AX728823
797	12.2	1.0	17	1	AX728846	ACCESSION:AX728846
798	12.2	1.0	17	1	AX728945	ACCESSION:AX728945
799	12.2	1.0	17	1	AX728965	ACCESSION:AX728965
800	12.2	1.0	17	1	AX731415	ACCESSION:AX731415
801	12.2	1.0	17	1	AX732425	ACCESSION:AX732425
802	12.2	1.0	17	1	AX733105	ACCESSION:AX733105
803	12.2	1.0	17	1	AX733543	ACCESSION:AX733543
804	12.2	1.0	17	1	AX735047	ACCESSION:AX735047
805	12.2	1.0	17	1	AX735909	ACCESSION:AX735909
806	12.2	1.0	17	1	AX735978	ACCESSION:AX735978
807	12.2	1.0	17	1	AX736175	ACCESSION:AX736175
808	12.2	1.0	17	1	AX736626	ACCESSION:AX736626
809	12.2	1.0	17	1	AX737074	ACCESSION:AX737074
810	12.2	1.0	17	1	AX738139	ACCESSION:AX738139
811	12.2	1.0	17	1	AX738829	ACCESSION:AX738829
812	12.2	1.0	17	1	AX738984	ACCESSION:AX738984
813	12.2	1.0	17	1	AX744141	ACCESSION:AX744141
814	12.2	1.0	17	1	AX745054	ACCESSION:AX745054
815	12.2	1.0	17	1	AX745056	ACCESSION:AX745056
816	12.2	1.0	17	1	BD065996	ACCESSION:BD065996
817	12.2	1.0	17	1	BD067425	ACCESSION:BD067425
818	12.2	1.0	17	1	BD067935	ACCESSION:BD067935
819	12.2	1.0	17	1	BD073195	ACCESSION:BD073195
820	12.2	1.0	17	1	BD087253	ACCESSION:BD087253
821	12.2	1.0	17	1	I32318	ACCESSION:I32318
822	12.2	1.0	17	1	I32319	ACCESSION:I32319
823	12.2	1.0	17	1	I53001	ACCESSION:I53001
824	12.2	1.0	17	1	I53051	ACCESSION:I53051
825	12.2	1.0	17	1	I53051	ACCESSION:I53051
826	12.2	1.0	17	1	I53219	ACCESSION:I53219
827	12.2	1.0	17	1	I53221	ACCESSION:I53221
828	12.2	1.0	17	1	I53307	ACCESSION:I53307
829	12.2	1.0	17	1	I53317	ACCESSION:I53317
830	12.2	1.0	17	1	I54130	ACCESSION:I54130
831	12.2	1.0	17	1	I54144	ACCESSION:I54144
832	12.2	1.0	17	1	I54160	ACCESSION:I54160
833	12.2	1.0	17	1	I54242	ACCESSION:I54242
834	12.2	1.0	17	1	I54406	ACCESSION:I54406
835	12.2	1.0	17	1	I54408	ACCESSION:I54408

837	12.2	1.0	17	1	I54410	ACCESSION:I54410	C 910	12	1.0	15	1	I77804	ACCESSION:I77804
838	12.2	1.0	17	1	I54416	ACCESSION:I54416	C 911	12	1.0	15	1	I77891	ACCESSION:I77891
839	12.2	1.0	17	1	I54556	ACCESSION:I54556	C 912	12	1.0	16	1	A88497	ACCESSION:A88497
840	12.2	1.0	17	1	I54556	ACCESSION:I54556	C 913	12	1.0	16	1	A88647	ACCESSION:A88647
841	12.2	1.0	17	1	ATH529445	ACCESSION:ATH529445	C 914	12	1.0	16	1	A90464	ACCESSION:A90464
842	12.2	1.0	18	1	AR165969	ACCESSION:AR165969	C 915	12	1.0	16	1	A90614	ACCESSION:A90614
843	12.2	1.0	18	1	AR285276	ACCESSION:AR285276	C 916	12	1.0	16	1	A906130	ACCESSION:A906130
844	12.2	1.0	18	1	AX643248	ACCESSION:AX643248	C 917	12	1.0	16	1	BD066010	ACCESSION:BD066010
845	12.2	1.0	18	1	AX643251	ACCESSION:AX643251	C 918	12	1.0	16	1	BD066160	ACCESSION:BD066160
846	12.2	1.0	18	1	E60081	ACCESSION:E60081	C 919	12	1.0	17	1	AX736998	ACCESSION:AX736998
847	12.2	1.0	18	1	AX598396	ACCESSION:AX598396	C 920	12	1.0	17	1	A88498	ACCESSION:A88498
848	12.2	1.0	20	1	AX149972	ACCESSION:AX149972	C 921	12	1.0	17	1	A90465	ACCESSION:A90465
849	12.2	1.0	20	1	BD138313	ACCESSION:BD138313	C 922	12	1.0	17	1	AR047246	ACCESSION:AR047246
850	12.2	1.0	20	1	ATH552863	ACCESSION:ATH552863	C 923	12	1.0	17	1	AR186564	ACCESSION:AR186564
851	12.2	1.0	21	1	AC236360	ACCESSION:AC236360	C 924	12	1.0	17	1	AR187325	ACCESSION:AR187325
852	12.2	1.0	21	1	A61502	ACCESSION:A61502	C 925	12	1.0	17	1	AR187326	ACCESSION:AR187326
853	12.2	1.0	12	1	AR199094	ACCESSION:AR199094	C 926	12	1.0	17	1	AR190442	ACCESSION:AR190442
854	12.2	1.0	12	1	AR241715	ACCESSION:AR241715	C 927	12	1.0	17	1	AR190443	ACCESSION:AR190443
855	12.2	1.0	14	1	A88495	ACCESSION:A88495	C 928	12	1.0	17	1	AR190444	ACCESSION:AR190444
856	12.2	1.0	14	1	A88649	ACCESSION:A88649	C 929	12	1.0	17	1	AX214676	ACCESSION:AX214676
857	12.2	1.0	14	1	A90462	ACCESSION:A90462	C 930	12	1.0	17	1	AX214677	ACCESSION:AX214677
858	12.2	1.0	14	1	A90616	ACCESSION:A90616	C 931	12	1.0	17	1	AX214678	ACCESSION:AX214678
859	12.2	1.0	14	1	BD066008	ACCESSION:BD066008	C 932	12	1.0	17	1	AX214795	ACCESSION:AX214795
860	12.2	1.0	14	1	BD066162	ACCESSION:BD066162	C 933	12	1.0	17	1	AX214989	ACCESSION:AX214989
861	12.2	1.0	15	1	A15311	ACCESSION:A15311	C 934	12	1.0	17	1	AX214990	ACCESSION:AX214990
862	12.2	1.0	15	1	A16511	ACCESSION:A16511	C 935	12	1.0	17	1	AX214991	ACCESSION:AX214991
863	12.2	1.0	15	1	A88496	ACCESSION:A88496	C 936	12	1.0	17	1	AX215858	ACCESSION:AX215858
864	12.2	1.0	15	1	A88646	ACCESSION:A88646	C 937	12	1.0	17	1	AX216684	ACCESSION:AX216684
865	12.2	1.0	15	1	A90463	ACCESSION:A90463	C 938	12	1.0	17	1	AX216730	ACCESSION:AX216730
866	12.2	1.0	15	1	A90613	ACCESSION:A90613	C 939	12	1.0	17	1	AX217071	ACCESSION:AX217071
867	12.2	1.0	15	1	AR041397	ACCESSION:AR041397	C 940	12	1.0	17	1	AX263360	ACCESSION:AX263360
868	12.2	1.0	15	1	AR041405	ACCESSION:AR041405	C 941	12	1.0	17	1	AX263361	ACCESSION:AX263361
869	12.2	1.0	15	1	AR041418	ACCESSION:AR041418	C 942	12	1.0	17	1	AX264543	ACCESSION:AX264543
870	12.2	1.0	15	1	AR041419	ACCESSION:AR041419	C 943	12	1.0	17	1	AX264544	ACCESSION:AX264544
871	12.2	1.0	15	1	AR041420	ACCESSION:AR041420	C 944	12	1.0	17	1	AX272719	ACCESSION:AX272719
872	12.2	1.0	15	1	AR041913	ACCESSION:AR041913	C 945	12	1.0	17	1	AX273119	ACCESSION:AX273119
873	12.2	1.0	15	1	AR041914	ACCESSION:AR041914	C 946	12	1.0	17	1	AX500360	ACCESSION:AX500360
874	12.2	1.0	15	1	AR041929	ACCESSION:AR041929	C 947	12	1.0	17	1	AX500361	ACCESSION:AX500361
875	12.2	1.0	15	1	AR041939	ACCESSION:AR041939	C 948	12	1.0	17	1	AX500436	ACCESSION:AX500436
876	12.2	1.0	15	1	AR041940	ACCESSION:AR041940	C 949	12	1.0	17	1	AX500437	ACCESSION:AX500437
877	12.2	1.0	15	1	AR041941	ACCESSION:AR041941	C 950	12	1.0	17	1	AX500438	ACCESSION:AX500438
878	12.2	1.0	15	1	AR056012	ACCESSION:AR056012	C 951	12	1.0	17	1	AX500439	ACCESSION:AX500439
879	12.2	1.0	15	1	AR056294	ACCESSION:AR056294	C 952	12	1.0	17	1	AX500440	ACCESSION:AX500440
880	12.2	1.0	15	1	AR056374	ACCESSION:AR056374	C 953	12	1.0	17	1	AX500441	ACCESSION:AX500441
881	12.2	1.0	15	1	AR113770	ACCESSION:AR113770	C 954	12	1.0	17	1	AX578690	ACCESSION:AX578690
882	12.2	1.0	15	1	AR114052	ACCESSION:AR114052	C 955	12	1.0	17	1	AX671598	ACCESSION:AX671598
883	12.2	1.0	15	1	AR114132	ACCESSION:AR114132	C 956	12	1.0	17	1	AX672197	ACCESSION:AX672197
884	12.2	1.0	15	1	AX633102	ACCESSION:AX633102	C 957	12	1.0	17	1	AX672415	ACCESSION:AX672415
885	12.2	1.0	15	1	AX633446	ACCESSION:AX633446	C 958	12	1.0	17	1	AX672536	ACCESSION:AX672536
886	12.2	1.0	15	1	AX633616	ACCESSION:AX633616	C 959	12	1.0	17	1	AX723252	ACCESSION:AX723252
887	12.2	1.0	15	1	AX635389	ACCESSION:AX635389	C 960	12	1.0	17	1	AX723252	ACCESSION:AX723252
888	12.2	1.0	15	1	AX635391	ACCESSION:AX635391	C 961	12	1.0	17	1	AX723252	ACCESSION:AX723252
889	12.2	1.0	15	1	AX635393	ACCESSION:AX635393	C 962	12	1.0	17	1	AX725994	ACCESSION:AX725994
890	12.2	1.0	15	1	AX635413	ACCESSION:AX635413	C 963	12	1.0	17	1	AX725994	ACCESSION:AX725994
891	12.2	1.0	15	1	AX636853	ACCESSION:AX636853	C 964	12	1.0	17	1	AX726152	ACCESSION:AX726152
892	12.2	1.0	15	1	AX636868	ACCESSION:AX636868	C 965	12	1.0	17	1	AX727032	ACCESSION:AX727032
893	12.2	1.0	15	1	AX636894	ACCESSION:AX636894	C 966	12	1.0	17	1	AX727182	ACCESSION:AX727182
894	12.2	1.0	15	1	AX636896	ACCESSION:AX636896	C 967	12	1.0	17	1	AX727214	ACCESSION:AX727214
895	12.2	1.0	15	1	AX636898	ACCESSION:AX636898	C 968	12	1.0	17	1	AX728795	ACCESSION:AX728795
896	12.2	1.0	15	1	AX637375	ACCESSION:AX637375	C 969	12	1.0	17	1	AX728795	ACCESSION:AX728795
897	12.2	1.0	15	1	AX637377	ACCESSION:AX637377	C 970	12	1.0	17	1	AX730870	ACCESSION:AX730870
898	12.2	1.0	15	1	AX637407	ACCESSION:AX637407	C 971	12	1.0	17	1	AX731363	ACCESSION:AX731363
899	12.2	1.0	15	1	AX637423	ACCESSION:AX637423	C 972	12	1.0	17	1	AX732412	ACCESSION:AX732412
900	12.2	1.0	15	1	AX637424	ACCESSION:AX637424	C 973	12	1.0	17	1	AX732979	ACCESSION:AX732979
901	12.2	1.0	15	1	AX637425	ACCESSION:AX637425	C 974	12	1.0	17	1	AX733611	ACCESSION:AX733611
902	12.2	1.0	15	1	AX638328	ACCESSION:AX638328	C 975	12	1.0	17	1	AX734657	ACCESSION:AX734657
903	12.2	1.0	15	1	AX638404	ACCESSION:AX638404	C 976	12	1.0	17	1	BD066011	ACCESSION:BD066011
904	12.2	1.0	15	1	BD066009	ACCESSION:BD066009	C 977	12	1.0	17	1	BD066011	ACCESSION:BD066011
905	12.2	1.0	15	1	BD066159	ACCESSION:BD066159	C 978	12	1.0	17	1	BD067356	ACCESSION:BD067356
906	12.2	1.0	15	1	I35095	ACCESSION:I35095	C 979	12	1.0	17	1	BD067357	ACCESSION:BD067357
907	12.2	1.0	15	1	I39128	ACCESSION:I39128	C 980	12	1.0	17	1	BD067873	ACCESSION:BD067873
908	12.2	1.0	15	1	I39129	ACCESSION:I39129	C 981	11.8	0.9	15	1	I54298	ACCESSION:I54298
909	12.2	1.0	15	1	I39130	ACCESSION:I39130	C 982	11.8	0.9	15	1	AR041398	ACCESSION:AR041398
					I39140	ACCESSION:I39140						AR041915	ACCESSION:AR041915



C 983 11.8 0.9 15 1 AX636855  
 C 984 11.8 0.9 15 1 AX637379  
 ACCESSION:AX636855  
 ACCESSION:AX637379

## ALIGNMENTS

RESULT 1  
 LOCUS AX419968/c 30 bp DNA linear PAT 18-JUN-2002  
 DEFINITION Sequence 305 from Patent WO019537.  
 ACCESSION AX419968  
 VERSION AX419968.1 GI:21524335  
 KEYWORDS synthetic construct  
 ORGANISM synthetic construct  
 SOURCE artificial sequences.  
 REFERENCE 1  
 AUTHORS Lyamichev, V., Allawi, H., Dong, P., Neri, B. P. and Vener, I. T.  
 TITLE Nucleic acid accessible hybridization sites  
 JOURNAL Patent: WO 019537-A 305 27-DEC-2001;  
 THIRD WAVE TECHNOLOGIES, INC. (US)  
 FEATURES  
 Location/Qualifiers  
 1..30  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 13 a 4 c 2 g 11 t  
 BASE COUNT  
 Query Match 2.4%; Score 30; DB 1; Length 30;  
 Best Local Similarity 100.0%; Pred. No. 0.056;  
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1165 ATGATGTTTATAGATAAATTCATCAG 1194  
 |||||  
 DB 30 ATGATGTTTATAGATAAATTCATCAG 1

RESULT 2  
 LOCUS BD182174 30 bp DNA linear PAT 15-MAY-2003  
 DEFINITION Method for synthesizing of nucleic acid.  
 ACCESSION BD182174  
 VERSION BD182174.1 GI:30793092  
 KEYWORDS WO 02090538-A/6.  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 SOURCE artificial sequences.  
 REFERENCE 1 (bases 1 to 30)  
 AUTHORS Nagamine, K.  
 TITLE Method for synthesizing of nucleic acid  
 JOURNAL Patent: WO 02090538-A 6 14-NOV-2002;  
 EIKEN CHEMICAL CO LTD, KENTARO NAGAMINE  
 COMMENT OS Artificial Sequence  
 PN WO 02090538-A/6  
 PD 14-NOV-2002  
 PF 08-MAY-2002 WO 2002JP004479  
 PR 08-MAY-2001 JP 01P 137060, 18-JUN-2001 JP 01P 184131 PI  
 PC C12N15/09, C12Q1/68  
 CC Description of Artificial Sequence: an artificially synthesized

RESULT 3  
 LOCUS AX280042 26 bp DNA linear PAT 02-NOV-2001  
 DEFINITION Sequence 17 from Patent WO0177382.  
 ACCESSION AX280042  
 VERSION AX280042.1 GI:16607493  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 REFERENCE 1  
 AUTHORS Hull, J. and Kwiatkowski, D. P.  
 TITLE Genetic factor affecting cytokine expression  
 JOURNAL Patent: WO 0177382-A 17 18-OCT-2001;  
 ISIS INNOVATION LIMITED (GB)  
 FEATURES  
 Location/Qualifiers  
 1..26  
 /organism="synthetic construct"  
 13 a 3 c 5 g 9 t  
 BASE COUNT

Query Match 2.4%; Score 30; DB 1; Length 30;  
 Best Local Similarity 100.0%; Pred. No. 0.056;  
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1065 CATCAATATTTGTGCAAGATTTGGAAAA 1094  
 |||||  
 DB 1 CATCAATATTTGTGCAAGATTTGGAAAA 30

RESULT 3  
 LOCUS BD182175/c 30 bp DNA linear PAT 15-MAY-2003  
 DEFINITION Method for synthesizing of nucleic acid.  
 ACCESSION BD182175  
 VERSION BD182175.1 GI:30793093  
 KEYWORDS WO 02090538-A/7.  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 SOURCE artificial sequences.  
 REFERENCE 1 (bases 1 to 30)  
 AUTHORS Nagamine, K.  
 TITLE Method for synthesizing of nucleic acid  
 JOURNAL Patent: WO 02090538-A 7 14-NOV-2002;  
 EIKEN CHEMICAL CO LTD, KENTARO NAGAMINE  
 COMMENT OS Artificial Sequence  
 PN WO 02090538-A/7  
 PD 14-NOV-2002  
 PF 08-MAY-2002 WO 2002JP004479  
 PR 08-MAY-2001 JP 01P 137060, 18-JUN-2001 JP 01P 184131 PI  
 PC C12N15/09, C12Q1/68  
 CC Description of Artificial Sequence: an artificially synthesized

CC sequence primer  
 CC key Location/Qualifiers  
 FT source 1..30  
 FT /organism="Artificial Sequence".  
 FEATURES  
 source 1..30  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 15 a 2 c 2 g 11 t  
 BASE COUNT

Query Match 2.4%; Score 30; DB 1; Length 30;  
 Best Local Similarity 100.0%; Pred. No. 0.056;  
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1045 TATTATGTTATTTAAGCATCAATAT 1074  
 |||||  
 DB 30 TATTATGTTATTTAAGCATCAATAT 1

RESULT 4  
 LOCUS AX280042 26 bp DNA linear PAT 02-NOV-2001  
 DEFINITION Sequence 17 from Patent WO0177382.  
 ACCESSION AX280042  
 VERSION AX280042.1 GI:16607493  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.

REFERENCE 1  
 AUTHORS Hull, J. and Kwiatkowski, D. P.  
 TITLE Genetic factor affecting cytokine expression  
 JOURNAL Patent: WO 0177382-A 17 18-OCT-2001;  
 ISIS INNOVATION LIMITED (GB)  
 FEATURES  
 Location/Qualifiers  
 1..26  
 /organism="synthetic construct"



```

/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Oligonucleotide"
10 t
BASE COUNT      9 a      5 c      2 g      10 t
Query Match
Best Local Similarity 2.1%; Score 26; DB 1; Length 26;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1228 CCAGTTAAATTTTCATTTCAGATA 1253
Db 1 CCAGTTAAATTTTCATTTCAGATA 26

RESULT 5
AX280041
LOCUS
DEFINITION
Sequence 16 from Patent WO0177382.
ACCESSION
AX280041
VERSION
AX280041.1 GI:16607492
KEYWORDS
synthetic construct
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1 Hull, J. and Kwiatkowski, D.P.
AUTHORS
Genetic factor affecting cytokine expression
TITLE
Patent: WO 0177382-A 16 18-OCT-2001;
JOURNAL
ISIS INNOVATION LIMITED (GB)
FEATURES
Location/Qualifiers
source
1..26
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Oligonucleotide"
11 t
BASE COUNT      8 a      5 c      2 g      11 t
Query Match
Best Local Similarity 2.0%; Score 25; DB 1; Length 26;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1228 CCAGTTAAATTTTCATTTCAGATA 1252
Db 1 CCAGTTAAATTTTCATTTCAGATA 25

RESULT 6
AR207732/c
LOCUS
DEFINITION
Sequence 72 from patent US 6379897.
ACCESSION
AR207732
VERSION
AR207732.1 GI:21507563
KEYWORDS
Unknown.
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 24)
AUTHORS
Weidenhammer, E.M., Wang, L., Xu, X., Heller, M.J. and Kahl, B.F.
TITLE
Methods for gene expression monitoring on electronic microarrays
JOURNAL
Patent: US 6379897-A 72 30-APR-2002;
FEATURES
Location/Qualifiers
source
1..24
/organism="unknown"
BASE COUNT      9 a      11 c      3 g      1 t
Query Match
Best Local Similarity 1.9%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GTGTGGTCTGTGTAGGTTGCC 498
Db 24 GTGTGGTCTGTGTAGGTTGCC 1

/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Oligonucleotide"
10 t
BASE COUNT      9 a      5 c      2 g      10 t
Query Match
Best Local Similarity 2.1%; Score 26; DB 1; Length 26;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1228 CCAGTTAAATTTTCATTTCAGATA 1253
Db 1 CCAGTTAAATTTTCATTTCAGATA 26

RESULT 5
AX280041
LOCUS
DEFINITION
Sequence 16 from Patent WO0177382.
ACCESSION
AX280041
VERSION
AX280041.1 GI:16607492
KEYWORDS
synthetic construct
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1 Hull, J. and Kwiatkowski, D.P.
AUTHORS
Genetic factor affecting cytokine expression
TITLE
Patent: WO 0177382-A 16 18-OCT-2001;
JOURNAL
ISIS INNOVATION LIMITED (GB)
FEATURES
Location/Qualifiers
source
1..26
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Oligonucleotide"
11 t
BASE COUNT      8 a      5 c      2 g      11 t
Query Match
Best Local Similarity 2.0%; Score 25; DB 1; Length 26;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1228 CCAGTTAAATTTTCATTTCAGATA 1252
Db 1 CCAGTTAAATTTTCATTTCAGATA 25

RESULT 6
AR207732/c
LOCUS
DEFINITION
Sequence 72 from patent US 6379897.
ACCESSION
AR207732
VERSION
AR207732.1 GI:21507563
KEYWORDS
Unknown.
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 24)
AUTHORS
Weidenhammer, E.M., Wang, L., Xu, X., Heller, M.J. and Kahl, B.F.
TITLE
Methods for gene expression monitoring on electronic microarrays
JOURNAL
Patent: US 6379897-A 72 30-APR-2002;
FEATURES
Location/Qualifiers
source
1..24
/organism="unknown"
BASE COUNT      9 a      11 c      3 g      1 t
Query Match
Best Local Similarity 1.9%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GTGTGGTCTGTGTAGGTTGCC 498
Db 24 GTGTGGTCTGTGTAGGTTGCC 1

```

```

RESULT 7
AR265058/c
LOCUS
DEFINITION
Sequence 72 from patent US 6492122.
ACCESSION
AR265058
VERSION
AR265058.1 GI:29693445
KEYWORDS
Unknown.
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 24)
AUTHORS
Weidenhammer, E.M., Wang, L., Xu, X., Heller, M.J. and Kahl, B.F.
TITLE
Quantitative analysis methods on active electronic microarrays
JOURNAL
Patent: US 6492122-A 72 10-DEC-2002;
FEATURES
Location/Qualifiers
source
1..24
/organism="unknown"
BASE COUNT      9 a      11 c      3 g      1 t
Query Match
Best Local Similarity 1.9%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GTGTGGTCTGTGTAGGTTGCC 498
Db 24 GTGTGGTCTGTGTAGGTTGCC 1

RESULT 8
AR040833/c
LOCUS
DEFINITION
Sequence 16 from patent US 5811233.
ACCESSION
AR040833
VERSION
AR040833.1 GI:5961329
KEYWORDS
Unknown.
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 21)
AUTHORS
Bowcock, A., Tonfrohde, J., Menter, A. and Gaynor, R.
TITLE
Compositions and uses thereof in the diagnosis of psoriasis
JOURNAL
Patent: US 5811233-A 16 22-SEP-1998;
FEATURES
Location/Qualifiers
source
1..21
/organism="unknown"
BASE COUNT      6 a      5 c      4 g      6 t
Query Match
Best Local Similarity 1.7%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 403 TCTGTGGTATCCAGATCAG 423
Db 21 TCTGTGGTATCCAGATCAG 1

RESULT 9
AX133222
LOCUS
DEFINITION
Sequence 4440 from Patent WO0130362.
ACCESSION
AX133222
VERSION
AX133222.1 GI:14139532
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Robbins, J.M. and Tritz, R.
AUTHORS
Ribozyme therapy for the treatment of proliferative skin and eye
TITLE
diseases
JOURNAL
Patent: WO 0130362-A 4440 03-MAY-2001;

```

[illegible]

```

DEFINITION      Sequence 309 from Patent WO0198537.
ACCESSION       AX419972
VERSION         AX419972.1 GI:21524339
KEYWORDS        synthetic construct
SOURCE          synthetic construct
ORGANISM        artificial sequences.
REFERENCE       1
AUTHORS         Lyamichev,V., Allawi,H., Dong,F., Neri,B.P. and Vener,I.T.
TITLE           Nucleic acid accessible hybridization sites
JOURNAL         Patent: WO 0198537-A 309 27-DEC-2001;
                THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES        Location/Qualifiers
                source
                1..20
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"
                7 a 5 c 2 g 6 t
BASE COUNT      7 a 5 c 2 g 6 t
Query Match     1.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.9.3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 557 CATTGTACCATGAATATCC 576
Db 1 CATTGTACCATGAATATCC 20

RESULT 15
LOCUS           AX084499                24 bp mRNA linear PAT 28-FEB-2001
DEFINITION     Sequence 41 from Patent WO0112213.
ACCESSION      AX084499
VERSION        AX084499.1 GI:13185910
KEYWORDS       Mus musculus
SOURCE         Mus musculus (house mouse)
ORGANISM       Mus musculus
REFERENCE       1
AUTHORS        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
TITLE          Blackshear,P.J., Lai,W.S. and Carballo-Jane,P.
JOURNAL        Ttp-related zinc finger domains and methods of use
                Patent: WO 0112213-A 41 22-FEB-2001;
                THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US)
FEATURES        Location/Qualifiers
                source
                1..24
                /organism="Mus musculus"
                /mol_type="mRNA"
                /db_xref="taxon:10090"
                6 a 0 c 0 g 18 t
BASE COUNT      6 a 0 c 0 g 18 t
Query Match     1.5%; Score 18.2; DB 1; Length 24;
Best Local Similarity 87.0%; Pred.No.39;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1038 TATTATTATTATGATTATT 1060
Db 2 TATTATTATTATGATTATT 24

RESULT 16
LOCUS           AR236360                21 bp RNA linear PAT 20-DEC-2002
DEFINITION     Sequence 8 from patent US 6465176.
ACCESSION      AR236360
VERSION        AR236360.1 GI:27280288
KEYWORDS       Unknown.
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE       1 (bases 1 to 21)
AUTHORS        Giordano,T., Beach,D.L. and Temeles,G.L.
TITLE          Method for identifying compounds RNA/RNA binding protein

```

```

interactions
JOURNAL         Patent: US 6465176-A 8 15-OCT-2002;
FEATURES        Location/Qualifiers
                source
                1..21
                /organism="unknown"
                6 a 0 c 0 g 15 t
BASE COUNT      6 a 0 c 0 g 15 t
Query Match     1.4%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred.No.48;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTATTATTTA 1062
Db 3 TTATTATGTTATTATTTA 21

RESULT 17
LOCUS           AX419971                17 bp DNA linear PAT 18-JUN-2002
DEFINITION     Sequence 308 from Patent WO0198537.
ACCESSION      AX419971
VERSION        AX419971.1 GI:21524338
KEYWORDS       synthetic construct
SOURCE         synthetic construct
ORGANISM       artificial sequences.
REFERENCE       1
AUTHORS        Lyamichev,V., Allawi,H., Dong,F., Neri,B.P. and Vener,I.T.
TITLE           Nucleic acid accessible hybridization sites
JOURNAL        Patent: WO 0198537-A 308 27-DEC-2001;
                THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES        Location/Qualifiers
                source
                1..17
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"
                6 a 3 c 5 g 3 t
BASE COUNT      6 a 3 c 5 g 3 t
Query Match     1.4%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred.No.39;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 417 GAATCAGTGAAGATGCC 433
Db 1 GAATCAGTGAAGATGCC 17

RESULT 18
LOCUS           AX280042/c              26 bp DNA linear PAT 02-NOV-2001
DEFINITION     Sequence 17 from Patent WO0177382.
ACCESSION      AX280042
VERSION        AX280042.1 GI:16607493
KEYWORDS       synthetic construct
SOURCE         synthetic construct
ORGANISM       artificial sequences.
REFERENCE       1
AUTHORS        Hull,J. and Kwiatkowski,D.P.
TITLE           Genetic factor affecting cytokine expression
JOURNAL        Patent: WO 0177382-A 17 18-OCT-2001;
                ISIS INNOVATION LIMITED (GB)
FEATURES        Location/Qualifiers
                source
                1..26
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"
                /note="Oligonucleotide"
                9 a 5 c 2 g 10 t
BASE COUNT      9 a 5 c 2 g 10 t
Query Match     1.3%; Score 16.6; DB 1; Length 26;
Best Local Similarity 82.6%; Pred.No.1.1e+02;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

901 CTTGGTTTCTCCTTATT 919

Db 1 CTGGGTTCTGCTTTATTT 19

BD090846  
LOCUS Mammalian osteo regulin.  
DEFINITION BD090846  
ACCESSION BD090846  
VERSION BD090846.1 GI:22636456  
KEYWORDS JP 2001321187-A/30.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
AUTHORS Brown, I.A., Wet, J.R.D., Gowen, L.C. and Hames, L.M.  
TITLE Mammalian osteo regulin  
JOURNAL Patent: JP 2001321187-A 30 20-NOV-2001;  
COMMENT PFIZER PRODUCTS INC  
OS Homo sapiens (human)  
PN JP 2001321187-A/30  
PD 20-NOV-2001  
PF 28-FEB-2001 JP 2001055757  
PR 29-FEB-2000 US 60/185617, 22-SEP-2000 US 60/234500 PI  
THOMAS AQUINAS BROWN, JEFFREY ROUX DE WET, LORI CHRISTINE GOWEN, PI  
LYNN MARIE HAMES  
PC C12N15/09, A01K67/027, A61K38/00, A61K45/00, A61P3/04, A61P9/10, PC  
A61P9/10  
PC A61P9/00, A61P19/10, A61P43/00, C07K14/47, C07K16/18, C12N1/15, PC  
C12N1/19  
PC C12N1/21, C12N5/10, C12N5/10, C12P21/02, C12Q1/02, C12Q1/68 PC  
'G01N33/15, G01N33/50,  
PC G01N33/566, G01N33/68//C12P21/08, (C12P21/02, C12R1:91), C12N15/00, PC  
A61K37/02  
PC C12N5/00, C12N5/00  
CC Mammalian osteo regulin  
FH Key Location/Qualifiers  
FT source 1..20  
FT Location/Qualifiers  
1..20  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/db\_4c 1 g 6 t

BASE COUNT 9 a 4 c 1 g 6 t

Query Match 1.3%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 1.1e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 716 CGAAGTTTAAATTCAGGAA 734  
Db 1 CAAAGTTTAAATTCAGGAA 19

RESULT 24  
AX092810/c  
LOCUS AX092810  
DEFINITION Sequence 222 from Patent WO0115676.  
ACCESSION AX092810  
VERSION AX092810.1 GI:13444867  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Hayden, M.R., Brooks-Wilson, A.R., Pimstone, S.N. and Clee, S.M.  
TITLE Compositions and methods for modulating hdl cholesterol and triglyceride levels  
JOURNAL Patent: WO 0115676-A 222 08-MAR-2001;  
University of British Columbia (CA); Xenon Genetics Inc. (CA)

FEATURES source

Location/Qualifiers  
1..21  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
/note="Synthetic primer"  
7 a 5 c 3 g 6 t

BASE COUNT 7 a 5 c 3 g 6 t

Query Match 1.3%; Score 15.9; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 516 CCTGGTTAAATTTGAATTT 534  
Db 21 CCTGGAGAAATTTGAATTT 3

RESULT 25  
ARI64318/c  
LOCUS ARI64318  
DEFINITION Sequence 1 from patent US 6271369.  
ACCESSION ARI64318  
VERSION ARI64318.1 GI:16235432  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 22)  
AUTHORS Torrence, P.F., Silverman, R.H., Maitra, R.K. and Lesiak, K.  
TITLE Chimeric molecules targeted to viral RNAs  
JOURNAL Patent: US 6271369-A 1 07-AUG-2001;  
LOCATION/Qualifiers  
source 1..22  
/organism="unknown"  
4 a 0 c 0 g 18 t

BASE COUNT 4 a 0 c 0 g 18 t

Query Match 1.2%; Score 15.6; DB 1; Length 22;  
Best Local Similarity 81.8%; Pred. No. 1.5e+02;  
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 616 ACAAAAACCAAAATTAATTT 637  
Db 22 AAAAAAATAAAAAAATTTT 1

RESULT 26  
ARI64319/c  
LOCUS ARI64319  
DEFINITION Sequence 2 from patent US 6271369.  
ACCESSION ARI64319  
VERSION ARI64319.1 GI:16235434  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 22)  
AUTHORS Torrence, P.F., Silverman, R.H., Maitra, R.K. and Lesiak, K.  
TITLE Chimeric molecules targeted to viral RNAs  
JOURNAL Patent: US 6271369-A 2 07-AUG-2001;  
LOCATION/Qualifiers  
source 1..22  
/organism="unknown"  
4 a 0 c 0 g 18 t

BASE COUNT 4 a 0 c 0 g 18 t

Query Match 1.2%; Score 15.6; DB 1; Length 22;  
Best Local Similarity 81.8%; Pred. No. 1.5e+02;  
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 616 ACAAAAACCAAAATTAATTT 637  
Db 22 AAAAAAATAAAAAAATTTT 1

```
RESULT 27
LOCUS      I31810
DEFINITION Sequence 1 from patent US 5583032.
ACCESSION  I31810
VERSION     I31810.1 GI:1822601
KEYWORDS   'Unknown.'
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 22)
AUTHORS     Torrence,P., Silverman,R., Maitra,R. and Lesiak,K.
TITLE       Method of cleaving specific strands of RNA
JOURNAL     Patent: US 5583032-A 1 10-DEC-1996;
FEATURES    Location/Qualifiers
             source
             1..22
BASE COUNT  4 a 0 c 0 g 18 t

Query Match      1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      616 ACAAAAACACAAATAATTTT 637
Db      22 AAAAAAAAAAAAAAAAAAATTTT 1

RESULT 28
LOCUS      I31811
DEFINITION Sequence 2 from patent US 5583032.
ACCESSION  I31811
VERSION     I31811.1 GI:1822602
KEYWORDS   'Unknown.'
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 22)
AUTHORS     Torrence,P., Silverman,R., Maitra,R. and Lesiak,K.
TITLE       Method of cleaving specific strands of RNA
JOURNAL     Patent: US 5583032-A 2 10-DEC-1996;
FEATURES    Location/Qualifiers
             source
             1..22
BASE COUNT  4 a 0 c 0 g 18 t

Query Match      1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      616 ACAAAAACACAAATAATTTT 637
Db      22 AAAAAAAAAAAAAAAAAAATTTT 1

RESULT 29
LOCUS      I69407
DEFINITION Sequence 1 from patent US 5677289.
ACCESSION  I69407
VERSION     I69407.1 GI:12831529
KEYWORDS   'Unknown.'
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 22)
AUTHORS     Torrence,P., Silverman,R., Maitra,R. and Lesiak,K.
TITLE       Method of cleaving specific strands of RNA and medical treatments
JOURNAL     Patent: US 5677289-A 1 14-OCT-1997;
FEATURES    Location/Qualifiers
             source
             1..22
BASE COUNT  4 a 0 c 0 g 18 t

Query Match      1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      616 ACAAAAACACAAATAATTTT 637
Db      22 AAAAAAAAAAAAAAAAAAATTTT 1

RESULT 30
LOCUS      I69408
DEFINITION Sequence 2 from patent US 5677289.
ACCESSION  I69408
VERSION     I69408.1 GI:2831530
KEYWORDS   'Unknown.'
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 22)
AUTHORS     Torrence,P., Silverman,R., Maitra,R. and Lesiak,K.
TITLE       Method of cleaving specific strands of RNA and medical treatments
JOURNAL     Patent: US 5677289-A 2 14-OCT-1997;
FEATURES    Location/Qualifiers
             source
             1..22
BASE COUNT  4 a 0 c 0 g 18 t

Query Match      1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      616 ACAAAAACACAAATAATTTT 637
Db      22 AAAAAAAAAAAAAAAAAAATTTT 1

RESULT 31
LOCUS      AX280041/c
DEFINITION Sequence 16 from Patent WO0177382.
ACCESSION  AX280041
VERSION     AX280041.1 GI:16607492
KEYWORDS   'synthetic construct'
SOURCE      'synthetic construct'
ORGANISM    'artificial sequences.'
REFERENCE   1
AUTHORS     Hull,J. and Kwiatkowski,D.P.
TITLE       Genetic factor affecting cytokine expression
JOURNAL     Patent: WO 0177382-A 16 18-OCT-2001;
FEATURES    Location/Qualifiers
             source
             1..26
             /organism="synthetic construct"
             /mol_type="genomic DNA"
             /db_xref="taxon:32630"
             /note="Oligonucleotide"
BASE COUNT  8 a 5 c 2 g 11 t

Query Match      1.2%; Score 15.6; DB 1; Length 26;
Best Local Similarity 81.8%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      1291 TATCTGAATTTTAAATGAACT 1312
Db      25 TATCTGAATGAAATTTAACT 4
```

```
BASE COUNT  4 a 0 c 0 g 18 t

Query Match      1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      616 ACAAAAACACAAATAATTTT 637
Db      22 AAAAAAAAAAAAAAAAAAATTTT 1

RESULT 30
LOCUS      I69408
DEFINITION Sequence 2 from patent US 5677289.
ACCESSION  I69408
VERSION     I69408.1 GI:2831530
KEYWORDS   'Unknown.'
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 22)
AUTHORS     Torrence,P., Silverman,R., Maitra,R. and Lesiak,K.
TITLE       Method of cleaving specific strands of RNA and medical treatments
JOURNAL     Patent: US 5677289-A 2 14-OCT-1997;
FEATURES    Location/Qualifiers
             source
             1..22
BASE COUNT  4 a 0 c 0 g 18 t

Query Match      1.2%; Score 15.6; DB 1; Length 22;
Best Local Similarity 81.8%; Pred. No. 1.5e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      616 ACAAAAACACAAATAATTTT 637
Db      22 AAAAAAAAAAAAAAAAAAATTTT 1

RESULT 31
LOCUS      AX280041/c
DEFINITION Sequence 16 from Patent WO0177382.
ACCESSION  AX280041
VERSION     AX280041.1 GI:16607492
KEYWORDS   'synthetic construct'
SOURCE      'synthetic construct'
ORGANISM    'artificial sequences.'
REFERENCE   1
AUTHORS     Hull,J. and Kwiatkowski,D.P.
TITLE       Genetic factor affecting cytokine expression
JOURNAL     Patent: WO 0177382-A 16 18-OCT-2001;
FEATURES    Location/Qualifiers
             source
             1..26
             /organism="synthetic construct"
             /mol_type="genomic DNA"
             /db_xref="taxon:32630"
             /note="Oligonucleotide"
BASE COUNT  8 a 5 c 2 g 11 t

Query Match      1.2%; Score 15.6; DB 1; Length 26;
Best Local Similarity 81.8%; Pred. No. 2e+02;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      1291 TATCTGAATTTTAAATGAACT 1312
Db      25 TATCTGAATGAAATTTAACT 4
```

RESULT 32  
AX500365/c  
LOCUS 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 1672 from Patent EP1229046.  
ACCESSION AX500365  
VERSION AX500365.1 GI:23382658  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 1672 07-AUG-2002;  
Aeonica, Inc. (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 4 a 1 c 1 g 11 t  
Query Match 1.2%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 675 TATACAAATAGCAAAAT 691  
|||||  
Db 17 TATATAAATAGCAAAAT 1  
Unknown.  
LOCUS 124434 17 bp DNA linear PAT 07-OCT-1996  
DEFINITION Sequence 9 from patent US 5543499.  
ACCESSION 124434  
VERSION 124434.1 GI:1604304  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Brewer, G.  
TITLE DNA sequence encoding a polypeptide with anti-tumor properties  
JOURNAL Patent: US 5543499-A 9 06-AUG-1996;  
FEATURES  
source  
1..17  
/organism="unknown"  
BASE COUNT 5 a 0 c 0 g 12 t  
Query Match 1.2%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1046 ATTATGATATTATTATTA 1062  
|||||  
Db 1 ATTATATTATTATTATTA 17  
Unknown.  
LOCUS 124434 18 bp DNA linear PAT 30-AUG-2000  
DEFINITION Sequence 43 from patent US 5958771.  
ACCESSION AR076329  
VERSION AR076329.1 GI:10003075  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Bennett, C. Frank., Ackermann, E. J. and Cowse, J. M.  
TITLE Antisense modulation of cellular inhibitor of Apoptosis-2

expression  
JOURNAL Patent: US 5958771-A 43 28-SEP-1999;  
FEATURES  
source  
1..18  
/organism="unknown"  
BASE COUNT 6 a 1 c 3 g 8 t  
Query Match 1.2%; Score 15.4; DB 1; Length 18;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1294 CTGAAATTTTAAATGAA 1310  
|||||  
Db 1 CTGAAATTTTAAATGAA 17  
Unknown.  
LOCUS 1294 20 bp DNA linear PAT 17-DEC-2001  
DEFINITION Sequence 83 from patent US 6287860.  
ACCESSION AR168620  
VERSION AR168620.1 GI:17904633  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia, B. P.; Gaarde, W.; Ward, D. T.; Freier, S. M. and Wyatt, J.  
TITLE Antisense inhibition of MRK2 expression  
JOURNAL Patent: US 6287860-A 83 11-SEP-2001;  
FEATURES  
source  
1..20  
/organism="unknown"  
BASE COUNT 11 a 3 c 2 g 4 t  
Query Match 1.2%; Score 15.4; DB 1; Length 20;  
Best Local Similarity 94.1%; Pred. No. 1.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 512 GATTCCTGTTAAATTT 528  
|||||  
Db 17 GATTCCTGTTAAATTT 1  
Unknown.  
LOCUS 512 21 bp DNA linear PAT 27-NOV-2002  
DEFINITION Sequence 422 from Patent WO02070755.  
ACCESSION AX555826  
VERSION AX555826.1 GI:25899299  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Lyamichev, V. I., Kaiser, M. W. and Lyamicheva, N.  
TITLE Fen endonucleases  
JOURNAL Patent: WO 02070755-A 422 12-SEP-2002;  
Third Wave Technologies, Inc. (US)  
FEATURES  
source  
1..21  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
BASE COUNT 12 a 1 c 6 g 2 t  
Query Match 1.2%; Score 15.4; DB 1; Length 21;  
Best Local Similarity 94.1%; Pred. No. 1.5e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 900 CCTTGTTTCCTTTA 916  
|||||  
Db 21 CCTTGTTTCCTTTA 5

RESULT 37  
AR031041/c  
LOCUS  
DEFINITION Sequence 29 from patent US 5861504.  
ACCESSION AR031041  
VERSION AR031041.1 GI:5944255  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Polymeropoulos,M.H. and Merrill,C.R.  
TITLE Eleven highly informative microsatellite repeat polymorphic DNA markers  
JOURNAL Patent: US 5861504-A 29 19-JAN-1999;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
BASE COUNT 4 a 3 c 7 g 6 t  
Query Match 1.2%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 427 ACATGCCAGTGAACCTTCAA 446  
DB 20 ACATGCCAGTGAACCTTCAA 1  
RESULT 38  
AR232302/c  
LOCUS  
DEFINITION Sequence 92 from patent US 6455307.  
ACCESSION AR232302  
VERSION AR232302.1 GI:27274294  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS McKay,R., Preier,S.M. and Wyatt,J.  
TITLE Antisense modulation of casein kinase 2-alpha prime expression  
JOURNAL Patent: US 6455307-A 92 24-SEP-2002;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
BASE COUNT 9 a 3 c 0 g 8 t  
Query Match 1.2%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 633 ATTTTGAATATAAGGATTT 652  
DB 20 ATATTGAATATAAGGATTT 1  
RESULT 39  
AX429785  
LOCUS  
DEFINITION Sequence 13 from Patent EP1203826.  
ACCESSION AX429785  
VERSION AX429785.1 GI:21540961  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Ishizuka,T., Ishiguro,T. and Saitoh,J.  
TITLE Oligonucleotide for detection of hiv-1 and detection method  
JOURNAL Patent: EP 1203826-A 13 08-MAY-2002;  
Tosoh Corporation (JP)  
Location/Qualifiers  
1..20  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
/note="Oligonucleotide hybridizable with a specific site of HIV-1 RNA"  
BASE COUNT 6 a 2 c 0 g 12 t  
Query Match 1.2%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1476 ATCTTATAATATTATTAA 1495  
DB 1 ATCTTATAATATTATTAA 20  
RESULT 40  
BD144143  
LOCUS  
DEFINITION Oligonucleotide for detecting HIV-1 and detection method.  
ACCESSION BD144143  
VERSION BD144143.1 GI:27849901  
KEYWORDS JP 2002125687-A/13.  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Ishizuka,T., Ishiguro,T. and Saitoh,J.  
TITLE Oligonucleotide for detecting HIV-1 and detection method  
JOURNAL Patent: JP 2002125687-A 13 08-MAY-2002;  
COMMENT TOSOH CORP  
OS Artificial Sequence  
PN JP 2002125687-A/13  
PD 08-MAY-2002  
PF 30-OCT-2000 JP 2000334937  
PI TETSUYA ISHIZUKA,TAKAHIKO ISHIGURO, JUICHI SAITO PC  
C12N15/09,C12Q1/68,G01N33/58,C12N15/00  
CC Oligonucleotide capable of binding specifically to a specified site of  
CC HIV-1 RNA  
CC Key Location/Qualifiers  
FH 1..20  
FT source /organism='Artificial Sequence'.  
FEATURES Location/Qualifiers  
1..20  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
BASE COUNT 6 a 2 c 0 g 12 t  
Query Match 1.2%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1476 ATCTTATAATATTATTAA 1495  
DB 1 ATCTTATAATATTATTAA 20  
RESULT 41  
AZ6944/c  
LOCUS  
DEFINITION Oligonucleotide QWE28.  
ACCESSION AZ6944  
VERSION AZ6944.1 GI:1248367  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Ishizuka,T., Ishiguro,T. and Saitoh,J.  
TITLE Oligonucleotide for detection of hiv-1 and detection method  
JOURNAL Patent: EP 1203826-A 13 08-MAY-2002;



REFERENCE 1 (bases 1 to 21)  
AUTHORS Broekaert, W.F., Cammue, B.P.A., Terras, F.R.G., Vanderleyden, J., Osborn, R.W., and Rees, S.B.  
TITLE BIOCIDAL PROTEINS  
JOURNAL Patent: WO 9305153-A 2 18-MAR-1993;  
ICI PLC (GB)  
FEATURES Location/Qualifiers  
source 1..21  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630" 7 t  
BASE COUNT 3 a 7 c 4 g 7 t  
Query Match 1.2%; Score 15.2; DB 1; Length 21;  
Best Local Similarity 85.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 688 AAATTGGCCCAAGGCCCAAG 707  
DB 20 AAGTTGTGCCAAAGGCCCAAG 1  
RESULT 42  
LOCUS AR050156/c 21 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 53 from patent US 5824869.  
ACCESSION AR050156  
VERSION AR050156.1 GI:5972148  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Broekaert, W.F., Cammue, B.P.A., Osborn, R.W., Rees, S.B., Terras, F.R.G., and Vanderleyden, J.  
TITLE Biocidal proteins  
JOURNAL Patent: US 5824869-A 53 20-OCT-1998;  
FEATURES Location/Qualifiers  
source 1..21  
/organism="unknown"  
BASE COUNT 3 a 7 c 4 g 7 t  
Query Match 1.2%; Score 15.2; DB 1; Length 21;  
Best Local Similarity 85.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 688 AAATTGGCCCAAGGCCCAAG 707  
DB 20 AAGTTGTGCCAAAGGCCCAAG 1  
RESULT 43  
LOCUS AR130275/c 21 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 53 from patent US 6187904.  
ACCESSION AR130275  
VERSION AR130275.1 GI:14118172  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Broekaert, W.F., Cammue, B.P.A., Osborn, R.W., Rees, S.B., Terras, F.R.G., and Vanderleyden, J.  
TITLE Biocidal proteins  
JOURNAL Patent: US 6187904-A 53 13-FEB-2001;  
FEATURES Location/Qualifiers  
source 1..21  
/organism="unknown"  
BASE COUNT 3 a 7 c 4 g 7 t  
Query Match 1.2%; Score 15.2; DB 1; Length 21;  
Best Local Similarity 85.0%; Pred. No. 1.7e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 688 AAATTGGCCCAAGGCCCAAG 707  
DB 20 AAGTTGTGCCAAAGGCCCAAG 1  
RESULT 44  
LOCUS AX008949/c 21 bp DNA linear PAT 06-SEP-2000  
DEFINITION Sequence 9 from Patent WO9964448.  
ACCESSION AX008949  
VERSION AX008949.1 GI:9996338  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
artificial sequences.  
REFERENCE 1  
AUTHORS Ruelle, J.L., Vinals-Bassols, C. and Tommassen, J.P.  
TITLE Novel compounds  
JOURNAL Patent: WO 9964448-A 9 16-DEC-1999;  
RUBLE JEAN LOUIS (BE); SMITHKLINE BEECHAM BIOLOG (BE); VINALS  
BASSOLS CARLOTA (BE); TOMMASSEN JOHANNES PETRUS MARI (NL)  
FEATURES Location/Qualifiers  
source 1..21  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
/note="Primer sequence"  
BASE COUNT 8 a 5 c 2 g 6 t  
Query Match 1.2%; Score 15.2; DB 1; Length 21;  
Best Local Similarity 85.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1420 ACAGTCAATATTAGTAATTT 1439  
DB 20 ACTGTCATATGGGTAAATTT 1  
RESULT 45  
LOCUS I23731/c 21 bp DNA linear PAT 07-OCT-1996  
DEFINITION Sequence 53 from patent US 5538525.  
ACCESSION I23731  
VERSION I23731.1 GI:1603601  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Broekaert, W.F., Cammue, B.P.A., Osborn, R.W., Rees, S.B., Terras, F.R.G., and Vanderleyden, J.  
TITLE Biocidal proteins  
JOURNAL Patent: US 5538525-A 53 23-JUL-1996;  
FEATURES Location/Qualifiers  
source 1..21  
/organism="unknown"  
BASE COUNT 3 a 7 c 4 g 7 t  
Query Match 1.2%; Score 15.2; DB 1; Length 21;  
Best Local Similarity 85.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 688 AAATTGGCCCAAGGCCCAAG 707  
DB 20 AAGTTGTGCCAAAGGCCCAAG 1  
RESULT 46  
LOCUS ATH528526/c 21 bp DNA linear PLN 29-MAR-2003  
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone

```

166G10.
ACCESSION AJ528526
VERSION AJ528526.1 GI:26796786
SOURCE left border; T-DNA flanking sequence.
ORGANISM Arabidopsis thaliana (thale cress)
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicaceae; Arabidopsis.
1
REFERENCE
AUTHORS Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PUBMED 12446565
REFERENCE
AUTHORS Balzerque,S.
TITLE Direct Submision
JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr/).
FEATURES
source
1..21
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiliewskija"
/db_xref="taxon:3702"
/clone="166G10"
misc_feature
1..21
/notes="T-DNA flanking sequence
left border"
BASE COUNT 7 a 4 c 2 g 8 t
Query Match 1.2%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 539 AACCAATGATGATGTTTCA 558
DB 21 AAAGAATGTATGTTTGTCA 2
RESULT 47
AX1419974
LOCUS AX1419974 15 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 311 from Patent WO0198537.
ACCESSION AX1419974
VERSION AX1419974.1 GI:21524341
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
1
REFERENCE
AUTHORS Lyamichev,V., Allawi,H., Dong,F., Neri,B.P. and Vener,I.T.
TITLE Nucleic acid accessible hybridization sites
JOURNAL Patent: WO 0198537-A 311 27-DEC-2001;
THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
source
1..15
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
4 t
BASE COUNT 2 a 6 c 3 g
Query Match 1.2%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 856 CCTAGTCTGCTAGC 870
DB 1 CCCTAGTCTGCTAGC 15
RESULT 48
A67086
LOCUS A67086 18 bp DNA linear PAT 29-MAR-1999
DEFINITION Sequence 253 from Patent WO9740193.
ACCESSION A67086
VERSION A67086.1 GI:4538457
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
1
REFERENCE
AUTHORS Stuyver,L., Rossau,R. and Maertens,G.
TITLE METHOD FOR TYPING AND DETECTING HBV
JOURNAL Patent: WO 9740193-A 253 30-OCT-1997;
INNOGENETICS NV (BE)
FEATURES
source
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
7 t
BASE COUNT 8 a 0 c 3 g
Query Match 1.2%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1123 TATAAGATGTATAGTA 1140
DB 1 TATATAGATGATATAGTA 18
RESULT 49
AX129263/c
LOCUS AX129263 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 481 from Patent WO0130362.
ACCESSION AX129263
VERSION AX129263.1 GI:14135568
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
1
REFERENCE
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
diseases
JOURNAL Patent: WO 0130362-A 481 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
source
1..19
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
7 t
BASE COUNT 2 a 2 c 8 g
Query Match 1.2%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 1404 AAACAGCCAAATCCAC 1421  
Db 18 ATACAGCCAACTCCAC 1

RESULT 50  
AR181777  
LOCUS 20 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 239 from patent US 6335194.  
ACCESSION AR181777  
VERSION AR181777.1 GI:20223991  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)  
AUTHORS Bennett,C.Frank., Ackermann,E.J., Swayze,E.E. and Cowsert,L.M.  
TITLE Antisense modulation of survivin expression  
JOURNAL Patent: US 6335194-A 239 01-JAN-2002;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
BASE COUNT 5 a 0 c 3 g 12 t

Query Match 1.2%; Score 14.8; DB 1; Length 20;  
Best Local Similarity 88.9%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1039 ATTATATTATTATGTTAT 1056  
Db 2 AGTTATATTATTGTTAT 19

RESULT 51  
AR181778  
LOCUS 20 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 240 from patent US 6335194.  
ACCESSION AR181778  
VERSION AR181778.1 GI:20223992  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)  
AUTHORS Bennett,C.Frank., Ackermann,E.J., Swayze,E.E. and Cowsert,L.M.  
TITLE Antisense modulation of survivin expression  
JOURNAL Patent: US 6335194-A 240 01-JAN-2002;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
BASE COUNT 6 a 0 c 2 g 12 t

Query Match 1.2%; Score 14.8; DB 1; Length 20;  
Best Local Similarity 88.9%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1039 ATTATATTATTATGTTAT 1056  
Db 3 AGTTATATTATTGTTAT 20

RESULT 52  
AX269437/c  
LOCUS 20 bp DNA linear PAT 30-NOV-2001  
DEFINITION Sequence 68 from Patent WO0164876.  
ACCESSION AX269437  
VERSION AX269437.1 GI:16542213  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE 1  
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Stefansson,H., Steinhorsdottir,V. and Gulcher,J.R.  
TITLE Human schizophrenia gene  
JOURNAL Patent: WO 0164876-A 68 07-SEP-2001;  
DECODE Genetics EHF. (IS)  
FEATURES Location/Qualifiers  
source 1..20  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 9 a 6 c 4 g 1 t

Query Match 1.2%; Score 14.8; DB 1; Length 20;  
Best Local Similarity 88.9%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1352 GCTGTGTTGTTAGTCTG 1369  
Db 20 GCTGTGTTGTTAGTCTG 3

RESULT 53  
AX270968/c  
LOCUS 20 bp DNA linear PAT 30-NOV-2001  
DEFINITION Sequence 68 from Patent WO0164877.  
ACCESSION AX270968  
VERSION AX270968.1 GI:16543705  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens

REFERENCE 1  
AUTHORS Stefansson,H., Steinhorsdottir,V. and Gulcher,J.R.  
TITLE Human schizophrenia gene  
JOURNAL Patent: WO 0164877-A 68 07-SEP-2001;  
DECODE Genetics EHF. (IS)  
FEATURES Location/Qualifiers  
source 1..20  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 9 a 6 c 4 g 1 t

Query Match 1.2%; Score 14.8; DB 1; Length 20;  
Best Local Similarity 88.9%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1352 GCTGTGTTGTTAGTCTG 1369  
Db 20 GCTGTGTTGTTAGTCTG 3

RESULT 54  
AX599078  
LOCUS 20 bp DNA linear PAT 14-FEB-2003  
DEFINITION Sequence 418 from Patent WO0207272.  
ACCESSION AX599078  
VERSION AX599078.1 GI:28399218  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.

REFERENCE 1  
AUTHORS Berlin,K., Braun,A., Distler,J., Quetig,D., Howe,A., Mueller,J.,  
Olek,A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leh,R.,  
Lewin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,  
Pellet,C. and Ziebarth,H.  
TITLE Methods and nucleic acids for the analysis of hematopoietic cell  
proliferative disorders  
JOURNAL Patent: WO 0207272-A 418 03-OCT-2002;  
FEATURES Epigenomics AG (DE)  
Location/Qualifiers

source 1..20  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
/note="Detection primer for ABL1"  
8 a 8 c 0 g 4 t  
BASE COUNT 8 a 8 c 0 g 4 t  
Query Match 1.2%; Score 14.8; DB 1; Length 20;  
Best Local Similarity 88.9%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 439 AACTTCAAGCAATCTAC 456  
|||||  
Db 3 AACTTCAAGCAATCTCC 20  
|||||  
RESULT 55  
BD138313/c  
LOCUS BD138313 20 bp DNA linear PAT 18-SEP-2002  
DEFINITION Antisense modulation of human MDM2 expression.  
ACCESSION BD138313  
VERSION BD138313.1 GI:23233258  
KEYWORDS JP 2002508944-A/239.  
SOURCE unidentified  
ORGANISM unidentified  
FEATURES  
1 (bases 1 to 20)  
Miraglia,L.J., Nero,P., Graham,M.J., Monia,B.P. and Cowsert,L.M.  
Antisense modulation of human MDM2 expression  
TITLE Antisense modulation of human MDM2 expression  
JOURNAL Patent: JP 2002508944-A 239 26-MAR-2002;  
ISIS PHARMACEUTICALS INC  
COMMENT OS Unidentified  
FN JP 2002508944-A/239  
PD 26-MAR-2002  
PF 26-MAR-1999 JP 2000538025  
PR 26-MAR-1998 US 09/048810  
PI LOREN J MIRAGLIA,PAVELA NERO,MARK J GRAHAM,BRETT P MONIA,LEX M  
COWSERT  
PI COWSERT  
PC C12N15/09,A61K48/00,A61P9/10,A61P17/06,A61P35/00,C07H21/04//  
PC C12Q1/68.  
PC C12N15/00  
CC Strandedness: Single;  
CC Topology: Linear;  
CC Antisense modulation of human MDM2 expression FH Key  
Location/Qualifiers  
FT source 1..20  
FT Location/Qualifiers  
1..20 /organism='Unidentified'.  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
9 a 1 c 2 g 8 t  
BASE COUNT 9 a 1 c 2 g 8 t  
Query Match 1.2%; Score 14.8; DB 1; Length 20;  
Best Local Similarity 88.9%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1017 TTCAGTGTAACTATTATTA 1034  
|||||  
Db 18 TTAAATGTAAGTATTATTA 1  
|||||  
RESULT 56  
E15986  
LOCUS E15986 20 bp DNA linear PAT 28-JUL-1999  
DEFINITION Oligonucleotide.  
ACCESSION E15986  
VERSION E15986.1 GI:5710669  
KEYWORDS JP 1998127286-A/11.  
SOURCE unidentified  
ORGANISM unidentified

unclassified.  
1 (bases 1 to 20)  
Ishikawa,T., Shigematsu,T. and Yamamoto,A.  
OLIGONUCLEOTIDE FOR SUPPRESSING PRODUCTION OF HGF  
Patent: JP 1998127286-A 11 19-MAY-1998;  
TERUMO CORP  
COMMENT OS None  
OC Artificial sequences.  
PN JP 1998127286-A/11  
PD 19-MAY-1998  
PF 01-NOV-1996 JP 1996291499  
PI ISHIKAWA TETSUYA, SHIGEMATSU TAKASHI, YAMAMOTO AKIHIRO PC  
C12N15/09,A61K31/70,A61K31/70,C07H21/04;  
CC strandedness: Single;  
CC topology: Linear;  
CC hypothetical: No;  
FH Key  
FT source 1..20  
FT Location/Qualifiers  
1..20 /organism='Artificial sequences'.  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
0 a 0 c 11 g 9 t  
BASE COUNT 0 a 0 c 11 g 9 t  
Query Match 1.2%; Score 14.8; DB 1; Length 20;  
Best Local Similarity 88.9%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 477 GTGGGTCGTGTAGGGT 494  
|||||  
Db 1 GTGGGTCGTGTGTGGGT 18  
|||||  
RESULT 57  
AR069029/c  
LOCUS AR069029 21 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 7 from patent US 5854395.  
ACCESSION AR069029  
VERSION AR069029.1 GI:6001236  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
FEATURES  
1 (bases 1 to 21)  
Champion,C.I., Lovett,M.A., Haake,D.A., Miller,J.N. and Blanco,D.R.  
Cloned borrelia burgdorferi virulence protein  
TITLE Cloned borrelia burgdorferi virulence protein  
JOURNAL Patent: US 5854395-A 7 29-DEC-1998;  
FEATURES Location/Qualifiers  
source 1..21  
/organism="unknown"  
10 a 0 c 4 g 7 t  
BASE COUNT 10 a 0 c 4 g 7 t  
Query Match 1.2%; Score 14.8; DB 1; Length 21;  
Best Local Similarity 88.9%; Pred. No. 2.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 542 CAATGAATAGTTTTCAT 559  
|||||  
Db 18 CAATAAATATTTTTCAT 1  
|||||  
RESULT 58  
AR299016/c  
LOCUS AR299016 21 bp DNA linear PAT 12-JUN-2003  
DEFINITION Sequence 10751 from patent US 6537751.  
ACCESSION AR299016  
VERSION AR299016.1 GI:31686300  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

Unclassified.  
 1 (bases 1 to 21)  
 Cohen, D., Chumakov, I. and Blumenfeld, M.  
 Biallelic markers for use in constructing a high density  
 disequilibrium map of the human genome  
 Patent: US 6537751-A 10751 25-MAR-2003;  
 Location/Qualifiers  
 1. .21  
 /organism="unknown"  
 3 a 7 c 0 g 11 t  
 Query Match 1.2%; Score 14.8; DB 1; Length 21;  
 Best Local Similarity 88.9%; Pred. No. 2.1e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1593 TATAAAGTAAATGAA 1610  
 |||||  
 20 TATAAAGGAGTAA 3  
 RESULT 59  
 LOCUS 126583/c  
 DEFINITION Sequence 7 from patent US 5558993.  
 ACCESSION 126583  
 VERSION 126583.1 GI:1606453  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 Unclassified.  
 1 (bases 1 to 21)  
 Champion, C.I., Lovett, M.A., Haake, D.A., Miller, J.N. and Blanco, D.R.  
 Cloned Borrelia burgdorferi virulence protein  
 Patent: US 5558993-A 7 24-SEP-1996;  
 Location/Qualifiers  
 1. .21  
 /organism="unknown"  
 10 a 0 c 4 g 7 t  
 Query Match 1.2%; Score 14.8; DB 2; Length 21;  
 Best Local Similarity 88.9%; Pred. No. 2.1e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 542 CAATGATAGTTTTCAT 559  
 |||||  
 18 CAATAATATTTTCAT 1  
 Db  
 RESULT 60  
 LOCUS AX500364/c  
 DEFINITION Sequence 1671 from Patent EPI229046.  
 ACCESSION AX500364  
 VERSION AX500364.1 GI:23382657  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 Zhan, J.  
 Human testis expressed patched like protein  
 Patent: EP 1229046-A 1671 07-AUG-2002;  
 Location/Qualifiers  
 1. .17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 3 a 1 c 1 g 12 t  
 Query Match 1.2%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 576 ATACAAATAGCAAAAT 691  
 |||||  
 17 ATAAATAGCAAAAT 2  
 Db  
 RESULT 61  
 LOCUS AX500366/c  
 DEFINITION Sequence 1673 from Patent EPI229046.  
 ACCESSION AX500366  
 VERSION AX500366.1 GI:23382659  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 Zhan, J.  
 Human testis expressed patched like protein  
 Patent: EP 1229046-A 1673 07-AUG-2002;  
 Location/Qualifiers  
 1. .17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 4 a 1 c 1 g 11 t  
 Query Match 1.2%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 675 TATCAATAGCAAAA 690  
 |||||  
 16 TATAAAATAGCAAAA 1  
 Db  
 RESULT 62  
 LOCUS AX722454/c  
 DEFINITION Sequence 141 from Patent WO03025176.  
 ACCESSION AX722454  
 VERSION AX722454.1 GI:30422955  
 KEYWORDS  
 SOURCE Mus musculus (house mouse)  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 Tellerman, A., Amson, R. and Tuijinder, M.  
 Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or virus resistance and their use as  
 medicines  
 Patent: WO 03025176-A 141 27-MAR-2003;  
 Location/Qualifiers  
 1. .17  
 /organism="Mus musculus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:10090"  
 10 a 1 c 1 g 5 t  
 Query Match 1.2%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1144 TTATTTTATTTAGAT 1159  
 |||||  
 17 TTATTTTATTTAGAT 2  
 Db

```

RESULT 63
AX731903/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman, A., Anson, R. and Tuijinder, M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL
Patent: WO 03025175-A 3537 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
7 a 1 c 1 g 8 t
BASE COUNT
7 a 1 c 1 g 8 t
Query Match
1.2%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1616 TAAATATATATTTGTT 1631
DB 17 TAAATATATATTTGAT 2

RESULT 64
BD017427/c
LOCUS
DEFINITION
Nucleic acid for assaying genus Shigella or genus Salmonella and
detection method.
ACCESSION
BD017427
VERSION
BD017427.1 GI:22558603
KEYWORDS
JP 2001245677-A/38
SOURCE
synthetic construct
ORGANISM
artificial sequences.
REFERENCE
1 (bases 1 to 17)
AUTHORS
Fukushima, M., Kakinuma, K. and Kawaguchi, R.
TITLE
Nucleic acid for assaying genus Shigella or genus Salmonella and
detection method
JOURNAL
Patent: JP 2001245677-A 38 11-SEP-2001;
SRL INC, MARINE BIOTECHNOLOGY INSTITUTE CO LTD, NIPPON GENE CO LTD
COMMENT
OS Artificial Sequence
PN JP 2001245677-A/38
PD 11-SEP-2001
PF 27-DEC-2000 JP 2000398087
PI MASAO FUKUSHIMA, KENICHI KAKINUMA, RYUJI KAWAGUCHI PC
C12N15/09, C12N15/09, C12M1/00, C12Q1/68, G01N33/53, G01N33/566, PC
G01N33/569//
PC (C12Q1/68, C12R1.42), (C12Q1/68, C12R1.01), C12N15/00, C12N15/00 CC
DNA probe for detecting Salmonella typhi, Salmonella CC
typhimurium and
CC Salmonella aerogenes
FH Key
FT Source
1..17
Location/Qualifiers
/organism="Artificial Sequence"
1..17
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
3 a 6 c 0 g 8 t
BASE COUNT
3 a 6 c 0 g 8 t
Query Match
1.2%; Score 14.4; DB 1; Length 17;

```

```

Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1088 TGGAAAAATAGAGAT 1103
DB 16 TGGAGAAATAGAGAT 1

RESULT 65
AX599320/c
LOCUS
DEFINITION
Sequence 660 from Patent WO02077272.
ACCESSION
AX599320
VERSION
AX599320.1 GI:28399462
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
artificial sequences.
REFERENCE
1
AUTHORS
Berlin, K., Braun, A., Distler, J., Gueig, D., Howe, A., Mueller, J.,
Olek, A., Pispembrock, C., Adorjan, P., Grabs, G., Lesche, R., Leu, E.,
Lewin, A., Lipscher, E., Maier, S., Model, F., Mueller, V., Otto, T.,
Pelet, C. and Ziebarth, H.
TITLE
Methods and nucleic acids for the analysis of hematopoietic cell
proliferative disorders
JOURNAL
Patent: WO 02077272-A 660 03-OCT-2002;
Epigenomics AG (DE)
FEATURES
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Detection oligonucleotide for ARH1"
4 a 0 c 4 g 10 t
BASE COUNT
4 a 0 c 4 g 10 t
Query Match
1.2%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 620 AAAACAACAATAATT 635
DB 17 AAAACTACAATAATT 2

RESULT 66
AX119636
LOCUS
DEFINITION
Sequence 29 from Patent WO0129213.
ACCESSION
AX119636
VERSION
AX119636.1 GI:14036534
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
artificial sequences.
REFERENCE
1
AUTHORS
Todd, J.A., Twella, R.C., Hess, J.W., Hey, P., Hey, P., Caskey, C.T.,
Hammond, H. and Metzker, M.L.
TITLE
Human si4 associated proteins like (sap1) proteins and encoding
genes; uses thereof
JOURNAL
Patent: WO 0129213-A 29 26-APR-2001;
The Wellcome Trust Limited as Trustee to the Wellcome Trust (GB) ;
Merck & Co., Inc. (US)
FEATURES
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Primer"
6 a 3 c 7 g 4 t
BASE COUNT
6 a 3 c 7 g 4 t
Query Match
1.2%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 2.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

http://dbgap.versailles.inra.fr/publiclines/. This sequence has been generated in the framework of the French plant genomics program 'Genoplatte' (http://www.genoplatte.com and http://genoplatte-info.infobiogen.fr).  
 Location/Qualifiers  
 1..20  
 /organism="Arabidopsis thaliana"  
 /mol\_type="genomic DNA"  
 /cultivar="Wassiljewskaja"  
 /db\_xref="taxon:3702"  
 /clone="053B05"  
 /clone\_lib="Arabidopsis thaliana T-DNA insertion lines"  
 misc\_feature  
 1..20  
 /note="T-DNA flanking sequence  
 left border"  
 6 a 3 c 2 g 9 t  
 BASE COUNT 6 a 3 c 2 g 9 t  
 Query Match 1..2; Score 14.4; DB 1; Length 20;  
 Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1135 ATAGTAAATTTATTTT 1150  
 |||||  
 Db 5 ATAGTAACTTTATTTT 20  
 |||||  
 RESULT 69  
 ARI78736  
 LOCUS ARI78736 19 bp DNA linear PAT 20-APR-2002  
 DEFINITION Sequence 23 from patent US 6319714.  
 ACCESSION ARI78736  
 VERSION ARI78736.1 GI:20219874  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 19)  
 AUTHORS Cramer, A., Stemmer, W.P.C., Minshull, J., Bass, S.H., Welch, M.,  
 Ness, J.S., Gustafsson, C. and Patten, P.A.  
 TITLE Oligonucleotide mediated nucleic acid recombination  
 JOURNAL Patent: US 6319714-A 23 20-NOV-2001;  
 FEATURES Location/Qualifiers  
 1..19  
 /organism="unknown"  
 9 a 0 c 3 g 7 t  
 BASE COUNT 9 a 0 c 3 g 7 t  
 Query Match 1..1; Score 14.2; DB 1; Length 19;  
 Best Local Similarity 84.2%; Pred. No. 2.4e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1102 ATGATCATTTGATTTGATA 1120  
 |||||  
 Db 1 ATGATTAATGATTTGATA 19  
 |||||  
 RESULT 70  
 AR205441  
 LOCUS AR205441 19 bp DNA linear PAT 20-JUN-2002  
 DEFINITION Sequence 23 from patent US 6368861.  
 ACCESSION AR205441  
 VERSION AR205441.1 GI:21503024  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 19)  
 AUTHORS Cramer, A., Stemmer, W.P.C., Minshull, J., Bass, S.H., Welch, M.,  
 Ness, J.S., Gustafsson, C. and Patten, P.A.  
 TITLE Oligonucleotide mediated nucleic acid recombination  
 JOURNAL Patent: US 6368861-A 23 09-APR-2002;  
 FEATURES Location/Qualifiers  
 1..19  
 /organism="unknown"  
 1102 ATGATCATTTGATTTGATA 1120  
 |||||  
 Db 1 ATGATTAATGATTTGATA 19  
 |||||

1097 AGAGATGAATCATTC 1112  
 |||||  
 Db 4 AGAGATGAATCATTC 19  
 |||||  
 RESULT 67  
 AX149130  
 LOCUS AX149130 20 bp DNA linear PAT 08-JUN-2001  
 DEFINITION Sequence 332 from Patent WO0136625.  
 ACCESSION AX149130  
 VERSION AX149130.1 GI:14347654  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 1  
 REFERENCE Wright, J.A., Young, A.H. and Dugourd, D.  
 AUTHORS Antisense oligonucleotide sequences derived from groel and groes as  
 TITLE Inhibitors of microorganisms  
 JOURNAL Patent: WO 0136625-A 332 25-MAY-2001;  
 GenSense Technologies Inc. (CA)  
 FEATURES Location/Qualifiers  
 1..20  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 /note="Antisense oligonucleotide"  
 15 a 4 c 1 g 0 t  
 BASE COUNT 15 a 4 c 1 g 0 t  
 Query Match 1..2; Score 14.4; DB 1; Length 20;  
 Best Local Similarity 93.8%; Pred. No. 2.4e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 618 AAAAAACACCAATAA 633  
 |||||  
 Db 4 AAAAAACACCAAGAA 19  
 |||||  
 RESULT 68  
 ATH521162  
 LOCUS ATH521162 20 bp DNA linear PLN 29-MAR-2003  
 DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone  
 053B05.  
 ACCESSION AJ521162  
 VERSION AJ521162.1 GI:26789398  
 KEYWORDS left border; T-DNA flanking sequence.  
 SOURCE Arabidopsis thaliana (thale cress)  
 ORGANISM Arabidopsis thaliana  
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.  
 1  
 REFERENCE Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,  
 Chauvin, S., Bechtold, N., Cruaud, C., Dekosse, R., Pelletier, G.,  
 Lepiniec, L., Caboche, M. and Lecharny, A.  
 TITLE T-DNA integration into the Arabidopsis genome depends on sequences  
 of pre-insertion sites  
 JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)  
 MEDLINE 22363535  
 PUBMED 1246565  
 REFERENCE 2 (bases 1 to 20)  
 Balzerque, S.  
 SOURCE Direct Submission  
 TITLE Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue  
 Gaston Cremieux, 91057 Evry cedex, FRANCE  
 COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana  
 plants from INRA (Versailles). The DNA fragment(s) resulting from  
 the PCR were directly sequenced from the left or the right border  
 to determine the genomic sequence flanking the insertion. T-DNA  
 derived sequences were removed. Information to order the  
 corresponding mutant line and a link to a database providing a  
 graphical display of the insertion site are available at

```

BASE COUNT      9 a      0 c      3 g      7 t

Query Match
Best Local Similarity 1.1%; Score 14.2; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1102 ATGAATCATTGATTGAATA 1120
Db 1 ATGAATAATGTTTGAATA 19

RESULT 71
LOCUS AR220133 19 bp DNA PAT 26-SEP-2002
DEFINITION Sequence 23 from patent US 6423542.
ACCESSION AR220133
VERSION AR220133.1 GI:23324575
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Crameri,A., Stemmer,W.P.C., Minshull,J., Bass,S.H., Welch,M.,
Ness,J.E., Gustafsson,C. and Patten,P.A.
TITLE Oligonucleotide mediated nucleic acid recombination
JOURNAL Patent: US 6423542-A 23 23-JUL-2002;
FEATURES Location/Qualifiers
source 1. .19
/organism="unknown"

BASE COUNT      9 a      0 c      3 g      7 t

Query Match
Best Local Similarity 1.1%; Score 14.2; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1102 ATGAATCATTGATTGAATA 1120
Db 1 ATGAATAATGTTTGAATA 19

RESULT 72
LOCUS AR221522 19 bp DNA PAT 26-SEP-2002
DEFINITION Sequence 23 from patent US 6426224.
ACCESSION AR221522
VERSION AR221522.1 GI:23328572
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Crameri,A., Stemmer,W.P.C., Minshull,J., Bass,S.H., Welch,M.,
Ness,J.E., Gustafsson,C. and Patten,P.A.
TITLE Oligonucleotide mediated nucleic acid recombination
JOURNAL Patent: US 6426224-A 23 30-JUL-2002;
FEATURES Location/Qualifiers
source 1. .19
/organism="unknown"

BASE COUNT      9 a      0 c      3 g      7 t

Query Match
Best Local Similarity 1.1%; Score 14.2; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1102 ATGAATCATTGATTGAATA 1120
Db 1 ATGAATAATGTTTGAATA 19

RESULT 73
LOCUS AR254224 19 bp DNA PAT 20-DEC-2002
DEFINITION Sequence 23 from patent US 6479652.

```

```

ACCESSION AR254224
VERSION AR254224.1 GI:27302961
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Crameri,A., Stemmer,W.P.C., Minshull,J., Bass,S.H., Welch,M.,
Ness,J.E., Gustafsson,C. and Patten,P.A.
TITLE Oligonucleotide mediated nucleic acid recombination
JOURNAL Patent: US 6479652-A 23 12-NOV-2002;
FEATURES Location/Qualifiers
source 1. .19
/organism="unknown"

BASE COUNT      9 a      0 c      3 g      7 t

Query Match
Best Local Similarity 1.1%; Score 14.2; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1102 ATGAATCATTGATTGAATA 1120
Db 1 ATGAATAATGTTTGAATA 19

RESULT 74
LOCUS AR282430 19 bp DNA PAT 10-APR-2003
DEFINITION Sequence 23 from patent US 6521453.
ACCESSION AR282430
VERSION AR282430.1 GI:29718586
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Crameri,A., Stemmer,W.P.C., Minshull,J., Bass,S.H., Welch,M.,
Ness,J.E., Gustafsson,C. and Patten,P.A.
TITLE Oligonucleotide mediated nucleic acid recombination
JOURNAL Patent: US 6521453-A 23 18-FEB-2003;
FEATURES Location/Qualifiers
source 1. .19
/organism="unknown"

BASE COUNT      9 a      0 c      3 g      7 t

Query Match
Best Local Similarity 1.1%; Score 14.2; DB 1; Length 19;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1102 ATGAATCATTGATTGAATA 1120
Db 1 ATGAATAATGTTTGAATA 19

RESULT 75
LOCUS AX129503 19 bp DNA PAT 15-MAY-2001
DEFINITION Sequence 721 from Patent WO0130362.
ACCESSION AX129503
VERSION AX129503.1 GI:14135808
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
JOURNAL Patent: WO 0130362-A 721 03-MAY-2001;
FEATURES Location/Qualifiers
source 1. .19
/organism="unknown"

```



BASE COUNT 5 a 1 c 4 g 9 t

Query Match 1.1%; Score 14.2; DB 1; Length 19;  
 Best Local Similarity 84.2%; Pred. No. 2.4e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1574 GTTCTGATGTATGGA 1592  
 DB 1 GTCTTTGATTTATGGAAA 19

RESULT 76  
 LOCUS AX599113/c 19 bp DNA linear PAT 14-FEB-2003  
 DEFINITION Sequence 453 from Patent WO02077272.  
 ACCESSION AX599113  
 VERSION AX599113.1 GI:28399253  
 KEYWORDS synthetic construct  
 SOURCE artificial sequences  
 ORGANISM  
 REFERENCE 1  
 AUTHORS Berlin, K., Braun, A., Distler, J., Guetig, D., Howe, A., Mueller, J.,  
 Olek, A., Piepenbrock, C., Adorjan, P., Grabs, G., Lesche, R., Leu, E.,  
 Lewin, A., Lipscher, S., Maier, S., Model, P., Mueller, V., Otto, T.,  
 Pelet, C. and Ziebarth, H.  
 TITLE Methods and nucleic acids for the analysis of hematopoietic cell  
 proliferative disorders  
 JOURNAL Patent: WO 02077272-A 453 03-OCT-2002;  
 Epigenomics AG (DE)  
 FEATURES Location/Qualifiers  
 source 1..19  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 /note="Detection primer for MOS"  
 BASE COUNT 7 a 9 c 0 g 3 t

Query Match 1.1%; Score 14.2; DB 1; Length 19;  
 Best Local Similarity 84.2%; Pred. No. 2.4e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 476 TGCGGCTCTGTGTAGGGT 494  
 DB 1 TGAGGGATTGTGTAGGGT 1

RESULT 77  
 LOCUS AR030970 20 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 2 from patent US 5861501.  
 ACCESSION AR030970  
 VERSION AR030970.1 GI:5944184  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Benseler, P., Cole, J.L., Olsen, D.B. and Kuo, L.C.  
 TITLE Capped synthetic RNA, analogs, and aptamers  
 JOURNAL Patent: US 5861501-A 2 19-JAN-1999;  
 FEATURES Location/Qualifiers  
 source 1..20  
 /organism="unknown"  
 BASE COUNT 3 a 1 c 2 g 14 t

Query Match 1.1%; Score 14.2; DB 1; Length 20;  
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1519 GCTTTATATTTTAACTTT 1537  
 DB 1 GCTTTTATTTTAAATTT 19

RESULT 78  
 LOCUS AR108815 20 bp DNA linear PAT 14-FEB-2001  
 DEFINITION Sequence 2 from patent US 6111095.  
 ACCESSION AR108815  
 VERSION AR108815.1 GI:12824302  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Benseler, P., Cole, J.L., Olsen, D.B. and Kuo, L.C.  
 TITLE Capped synthetic RNA, analogs, and aptamers  
 JOURNAL Patent: US 6111095-A 2 29-AUG-2000;  
 FEATURES Location/Qualifiers  
 source 1..20  
 /organism="unknown"  
 BASE COUNT 3 a 1 c 2 g 14 t

Query Match 1.1%; Score 14.2; DB 1; Length 20;  
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1519 GCTTTATATTTTAACTTT 1537  
 DB 1 GCTTTTATTTTAAATTT 19

RESULT 79  
 LOCUS AR145988 20 bp DNA linear PAT 08-AUG-2001  
 DEFINITION Sequence 53 from patent US 6218150.  
 ACCESSION AR145988  
 VERSION AR145988.1 GI:15109177  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Demori, T., Sato, Y., Fujita, T., Miyake, K., Mukai, H., Asada, K. and  
 Kato, I.  
 TITLE DNA polymerase-related factors  
 JOURNAL Patent: US 6218150-A 53 17-APR-2001;  
 FEATURES Location/Qualifiers  
 source 1..20  
 /organism="unknown"  
 BASE COUNT 5 a 2 c 4 g 9 t

Query Match 1.1%; Score 14.2; DB 1; Length 20;  
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 583 TACTTATATGTAAAGTATT 601  
 DB 1 TTCTGCTATGTAAAGTATT 19

RESULT 80  
 LOCUS AR145989/c 20 bp DNA linear PAT 08-AUG-2001  
 DEFINITION Sequence 54 from patent US 6218150.  
 ACCESSION AR145989  
 VERSION AR145989.1 GI:15109178  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Benseler, P., Cole, J.L., Olsen, D.B. and Kuo, L.C.  
 TITLE Capped synthetic RNA, analogs, and aptamers  
 JOURNAL Patent: US 6218150-A 54 17-APR-2001;  
 FEATURES Location/Qualifiers  
 source 1..20  
 /organism="unknown"  
 BASE COUNT 5 a 2 c 4 g 9 t

Query Match 1.1%; Score 14.2; DB 1; Length 20;  
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

REFERENCE 1 (bases 1 to 20)  
 AUTHORS Umori,T., Sato,Y., Fujita,T., Miyake,K., Mukai,H., Asada,K. and Kato,I.  
 TITLE DNA polymerase-related factors  
 JOURNAL Patent: US 6218150-A 54 17-APR-2001;  
 FEATURES Location/Qualifiers  
 source 1..20  
 BASE COUNT 9 a 4 c 2 g 5 t  
 Query Match 1.1%; Score 14.2; DB 1; Length 20;  
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 583 TACTTATATGTAAGTATT 601  
 Db 20 TTCTGCTAATGTAAGTATT 2

RESULT 81  
 ARI59242/c  
 LOCUS ARI59242 20 bp DNA linear PAT 17-OCT-2001  
 DEFINITION Sequence 864 from patent US 6251588.  
 ACCESSION ARI59242  
 VERSION ARI59242.1 GI:16221866  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and Kincaid,R.H.  
 TITLE Method for evaluating oligonucleotide probe sequences  
 JOURNAL Patent: US 6251588-A 864 26-JUN-2001;  
 FEATURES Location/Qualifiers  
 source 1..20  
 BASE COUNT 9 a 1 c 5 g 5 t  
 Query Match 1.1%; Score 14.2; DB 1; Length 20;  
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 982 GCACCTTAAGTTTTCAT 1000  
 Db 20 GCACCTTAAGTTTTCAT 2

RESULT 82  
 ARI59243/c  
 LOCUS ARI59243 20 bp DNA linear PAT 17-OCT-2001  
 DEFINITION Sequence 865 from patent US 6251588.  
 ACCESSION ARI59243  
 VERSION ARI59243.1 GI:16221867  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and Kincaid,R.H.  
 TITLE Method for evaluating oligonucleotide probe sequences  
 JOURNAL Patent: US 6251588-A 865 26-JUN-2001;  
 FEATURES Location/Qualifiers  
 source 1..20  
 BASE COUNT 9 a 1 c 5 g 5 t  
 Query Match 1.1%; Score 14.2; DB 1; Length 20;  
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 982 GCACCTTAAGTTTTCAT 1000

Db 19 GCACCTTAAGTTTTCAT 1

RESULT 83  
 ARI59247/c  
 LOCUS ARI59247 20 bp DNA linear PAT 17-OCT-2001  
 DEFINITION Sequence 869 from patent US 6251588.  
 ACCESSION ARI59247  
 VERSION ARI59247.1 GI:16221872  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and Kincaid,R.H.  
 TITLE Method for evaluating oligonucleotide probe sequences  
 JOURNAL Patent: US 6251588-A 869 26-JUN-2001;  
 FEATURES Location/Qualifiers  
 source 1..20  
 BASE COUNT 10 a 3 c 3 g 4 t  
 Query Match 1.1%; Score 14.2; DB 1; Length 20;  
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 977 TGGAGGACACTTTAAGTTT 995  
 Db 20 TGGTTGCACITTAAGTTT 2

RESULT 84  
 ARI59248/c  
 LOCUS ARI59248 20 bp DNA linear PAT 17-OCT-2001  
 DEFINITION Sequence 870 from patent US 6251588.  
 ACCESSION ARI59248  
 VERSION ARI59248.1 GI:16221873  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Shannon,K.W., Wolber,P.K., Delenstarr,G.C., Webb,P.G. and Kincaid,R.H.  
 TITLE Method for evaluating oligonucleotide probe sequences  
 JOURNAL Patent: US 6251588-A 870 26-JUN-2001;  
 FEATURES Location/Qualifiers  
 source 1..20  
 BASE COUNT 11 a 3 c 2 g 4 t  
 Query Match 1.1%; Score 14.2; DB 1; Length 20;  
 Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 977 TGGAGGACACTTTAAGTTT 995  
 Db 19 TGGTTGCACITTAAGTTT 1

RESULT 85  
 ARI80879  
 LOCUS ARI80879 20 bp DNA linear PAT 20-APR-2002  
 DEFINITION Sequence 53 from patent US 6333158.  
 ACCESSION ARI80879  
 VERSION ARI80879.1 GI:20222912  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 20)

AUTHORS Umori,T., Sato,Y., Fujita,T., Miyake,K., Mukai,H., Asada,K. and Kato,I.  
TITLE DNA polymerase-related factors  
JOURNAL Patent: US 6333158-A 53 25-DEC-2001;  
FEATURES Location/Qualifiers  
source 1..20  
BASE COUNT 5 a 2 c 4 g 9 t  
Query Match 1.1%; Score 14.2; DB 1; Length 20;  
Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 583 TACTTATATGTAAGTATT 601  
Db 1 TTCTGCTATGTAAGTATT 19  
RESULT 86  
AR180880/c  
LOCUS AR180880 20 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 54 from patent US 6333158.  
ACCESSION AR180880  
VERSION AR180880.1 GI:20222913  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Umori,T., Sato,Y., Fujita,T., Miyake,K., Mukai,H., Asada,K. and Kato,I.  
TITLE DNA polymerase-related factors  
JOURNAL Patent: US 6333158-A 54 25-DEC-2001;  
FEATURES Location/Qualifiers  
source 1..20  
BASE COUNT 9 a 4 c 2 g 5 t  
Query Match 1.1%; Score 14.2; DB 1; Length 20;  
Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 583 TACTTATATGTAAGTATT 601  
Db 20 TTCTGCTATGTAAGTATT 2  
RESULT 87  
AR205764  
LOCUS AR205764 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 2 from patent US 6369208.  
ACCESSION AR205764  
VERSION AR205764.1 GI:21503429  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Cole,J.L., Kuo,L.C., Olsen,D.B. and Benseler,F.  
TITLE Capped synthetic RNA, analogs, and aptamers  
JOURNAL Patent: US 6369208-A 2 09-APR-2002;  
FEATURES Location/Qualifiers  
source 1..20  
BASE COUNT 3 a 1 c 2 g 14 t  
Query Match 1.1%; Score 14.2; DB 1; Length 20;  
Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1519 GCCTTATATTTTAACTTT 1537  
Db 1 GGTATTATTTTAAATTT 19

RESULT 88  
AR224476  
LOCUS AR224476 20 bp DNA linear PAT 26-SEP-2002  
DEFINITION Sequence 21 from patent US 6440737.  
ACCESSION AR224476  
VERSION AR224476.1 GI:23333316  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Freier,S.M.  
TITLE Antisense modulation of cellular apoptosis susceptibility gene expression  
JOURNAL Patent: US 6440737-A 21 27-AUG-2002;  
FEATURES Location/Qualifiers  
source 1..20  
BASE COUNT 8 a 3 c 3 g 6 t  
Query Match 1.1%; Score 14.2; DB 1; Length 20;  
Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1307 TGAACATAACATCTAGTT 1325  
Db 1 TGAATAAATACATCTAGTT 19  
RESULT 89  
AR272014/c  
LOCUS AR272014 20 bp DNA linear PAT 10-APR-2003  
DEFINITION Sequence 84 from patent US 6503756.  
ACCESSION AR272014  
VERSION AR272014.1 GI:29703582  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Freier,S.M. and Wyatt,J.  
TITLE Antisense modulation of syntaxin 4 interacting protein expression  
JOURNAL Patent: US 6503756-A 84 07-JAN-2003;  
FEATURES Location/Qualifiers  
source 1..20  
BASE COUNT 10 a 1 c 2 g 7 t  
Query Match 1.1%; Score 14.2; DB 1; Length 20;  
Best Local Similarity 84.2%; Pred. No. 2.7e+02;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1045 TATTTATCTATTATTAA 1063  
Db 19 TATTTCTGTATACATTAA 1  
RESULT 90  
AR315173/c  
LOCUS AR315173 20 bp DNA linear PAT 12-JUN-2003  
DEFINITION Sequence 5710 from patent US 6559294.  
ACCESSION AR315173  
VERSION AR315173.1 GI:31708599  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Griffiths,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A., Santaran,B. and Fletcher,L.D.  
TITLE Chlamydia pneumoniae polynucleotides and uses thereof

JOURNAL	Patent: US 6559294-A 5710 06-MAY-2003;	CC	substrate	Location/Qualifiers	
FEATURES	Location/Qualifiers	PH	Key	1..20	
source	/organism="unknown"	FT	source	/organism="Artificial Sequence".	
BASE COUNT	5 a 6 c 4 g 5 t	FT	Location/Qualifiers		
	1.1%; Score 14.2; DB 1; Length 20;		1..20		
Query Match	Best Local Similarity 84.2%; Pred. No. 2.7e+02;		/organism="synthetic construct"		
Matches	16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;		/mol_type="genomic DNA"		
	/db_xref="taxon:32630"		/db_xref="taxon:32630"		
QY	968 GAGGACATCTGGAAGCACT 986		3 a 0 c 0 g 17 t		
Db	19 GAGGATATTGGAGGCCT 1				
RESULT 91					
AXI49154	20 bp DNA linear PAT 08-JUN-2001				
LOCUS	Sequence 356 from Patent WO0136625.				
DEFINITION	AXI49154				
ACCESSION	AXI49154				
VERSION	AXI49154.1 GI:14347678				
KEYWORDS	synthetic construct				
SOURCE	synthetic construct				
ORGANISM	artificial sequences.				
REFERENCE	1 Wright J.A., Young A.H. and Dugourd D.				
AUTHORS	Antisense oligonucleotide sequences derived from groel and groes as				
TITLE	inhibitors of microorganisms				
JOURNAL	Patent: WO 0136625-A 356 25-MAY-2001;				
	GenSense Technologies Inc. (CA)				
FEATURES	Location/Qualifiers				
source	1..20				
	/organism="synthetic construct"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:32630"				
	/notes="Antisense oligonucleotide"				
BASE COUNT	3 a 5 c 2 g 10 t				
Query Match	1.1%; Score 14.2; DB 1; Length 20;				
Best Local Similarity	84.2%; Pred. No. 2.7e+02;				
Matches	16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;				
QY	1566 TTTTACTGTTCTGATTG 1584				
Db	2 TTTTACCGCTTCTCATG 20				
RESULT 92					
BD161924/c	20 bp DNA linear PAT 17-JAN-2003				
LOCUS	Method for carrying out thermal cycle of PCR using DNA-immobilized				
DEFINITION	substrate.				
ACCESSION	BD161924				
VERSION	BD161924.1 GI:27867682				
KEYWORDS	JP 2002191369-A/1				
SOURCE	synthetic construct				
ORGANISM	artificial sequences.				
REFERENCE	1 (bases 1 to 20)				
AUTHORS	Tanga, M., Okamura, H. and Takahashi, K.				
TITLE	Method for carrying out thermal cycle of PCR using DNA-immobilized				
JOURNAL	substrate				
COMMENT	Patent: JP 2002191369-A 1 09-JUL-2002;				
	TOYO KOKAN CO LTD, KOJIRO TAKAHASHI				
	OS Artificial Sequence				
	JP 2002191369-A/1				
	PD 09-JUL-2002				
	PF 27-DEC-2000 JP 2000399573				
	PI MICHIFUMI TANGA, HIROSHI OKAMURA, KOJIRO TAKAHASHI PC				
	C12N15/09, C12N15/00, C12N15/00 CC Method for				
	carrying out thermal cycle of PCR using DNA- CC				
	immobilized				
CC	substrate				
PH	Key				
FT	source				
FEATURES	Location/Qualifiers				
source	1..20				
	/organism="synthetic construct"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:32630"				
BASE COUNT	3 a 0 c 0 g 17 t				
Query Match	1.1%; Score 14.2; DB 1; Length 20;				
Best Local Similarity	84.2%; Pred. No. 2.7e+02;				
Matches	16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;				
QY	618 AAAAAACACAAATAATTT 636				
Db	19 AAAAAAATAATAATTT 1				
RESULT 93					
YSCWTP021	20 bp DNA linear PLN 04-AUG-1993				
LOCUS	Yeast (S.cerevisiae) mitochondrial petite mutant excision seq 2,				
DEFINITION	left end.				
ACCESSION	J01510				
VERSION	J01510.1 GI:343846				
KEYWORDS	AT-rich region; GC rich region.				
SEGMENT	1 of 2				
SOURCE	mitochondrion Saccharomyces cerevisiae (baker's yeast)				
ORGANISM	Saccharomyces cerevisiae				
REFERENCE	Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;				
AUTHORS	Saccharomycetales; Saccharomycetaceae; Saccharomyces.				
TITLE	1 (bases 1 to 20)				
JOURNAL	de Zamaroczy, M., Faugeron-Fonty, G. and Bernardi, G.				
MEDLINE	Excision sequences in the mitochondrial genome of yeast				
PUBMED	Gene 21 (3), 193-202 (1983)				
COMMENT	83210931				
	Original source text: Yeast (Saccharomyces cerevisiae)				
	mitochondrial DNA.				
	Additional sequences reported in [1], but sequenced in earlier				
	papers, appear in separate entries.				
FEATURES	Location/Qualifiers				
source	1..20				
	/organism="Saccharomyces cerevisiae"				
	/organelle="mitochondrion"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:4932"				
BASE COUNT	7 a 0 c 0 g 13 t				
Query Match	1.1%; Score 14.2; DB 1; Length 20;				
Best Local Similarity	84.2%; Pred. No. 2.7e+02;				
Matches	16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;				
QY	1143 TTTATTTATTTTAGATAT 1161				
Db	2 TATATTATTTTATATAT 20				
RESULT 94					
AR041399	15 bp DNA linear PAT 29-SEP-1999				
LOCUS	Sequence 189 from patent US 5811300.				
DEFINITION	AR041399				
ACCESSION	AR041399				
VERSION	AR041399.1 GI:5961895				
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1 (bases 1 to 15)				
AUTHORS	Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.				
TITLE	TNF-alpha ribozymes				

JOURNAL Patent: US 5811300-A 189 22-SEP-1998;  
 FEATURES  
 source  
 BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 14; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051  
 Db 1 TATTATTATTAT 14

RESULT 95  
 AR041407  
 LOCUS AR041407 15 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 197 from patent US 5811300.  
 ACCESSION AR041407  
 VERSION AR041407.1 GI:5961903  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.  
 TITLE TNF- $\alpha$ . ribozymes  
 JOURNAL Patent: US 5811300-A 197 22-SEP-1998;  
 FEATURES Location/Qualifiers  
 source 1..15  
 1 TATTATTATTAT 14

Query Match 1.1%; Score 14; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051  
 Db 1 TATTATTATTAT 14

RESULT 96  
 AR041916  
 LOCUS AR041916 15 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 706 from patent US 5811300.  
 ACCESSION AR041916  
 VERSION AR041916.1 GI:5962412  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.  
 TITLE TNF- $\alpha$ . ribozymes  
 JOURNAL Patent: US 5811300-A 706 22-SEP-1998;  
 FEATURES Location/Qualifiers  
 source 1..15  
 1 TATTATTATTAT 14

Query Match 1.1%; Score 14; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051  
 Db 1 TATTATTATTAT 14

RESULT 97  
 AR041917  
 LOCUS AR041917 15 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 707 from patent US 5811300.  
 ACCESSION AR041917  
 VERSION AR041917.1 GI:5962413  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.  
 TITLE TNF- $\alpha$ . ribozymes  
 JOURNAL Patent: US 5811300-A 707 22-SEP-1998;  
 FEATURES Location/Qualifiers  
 source 1..15  
 1 TATTATTATTAT 14

Query Match 1.1%; Score 14; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051  
 Db 1 TATTATTATTAT 14

RESULT 98  
 AR041918  
 LOCUS AR041918 15 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 708 from patent US 5811300.  
 ACCESSION AR041918  
 VERSION AR041918.1 GI:5962414  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.  
 TITLE TNF- $\alpha$ . ribozymes  
 JOURNAL Patent: US 5811300-A 708 22-SEP-1998;  
 FEATURES Location/Qualifiers  
 source 1..15  
 1 TATTATTATTAT 14

Query Match 1.1%; Score 14; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATTAT 1051  
 Db 1 TATTATTATTAT 14

RESULT 99  
 AR041919  
 LOCUS AR041919 15 bp mRNA linear PAT 21-FEB-2003  
 DEFINITION Sequence 3996 from Patent EP1260585.  
 ACCESSION AR041919  
 VERSION AR041919.1 GI:28472471  
 KEYWORDS  
 SOURCE unidentified  
 ORGANISM unidentified  
 REFERENCE 1  
 AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and Woolf, T.  
 TITLE Method and reagent for inhibiting the expression of disease related genes  
 JOURNAL Patent: EP 1260586-A 3996 27-NOV-2002;

FEATURES	source	Location/Qualifiers
BASE COUNT	4 a	0 c 0 g 11 t
Query Match	1.1%	Score 14; DB 1; Length 15;
Best Local Similarity	100.0%	Pred. No. 1.8e+02;
Matches 14;	Conservative 0;	Mismatches 0; Indels 0; Gaps 0;
QY	1038	TATTATTATTATTAT 1051
DB	1	TATTATTATTATTAT 14
RESULT 100		
AX637381		
LOCUS	AX637381	15 bp mRNA linear PAT 21-FEB-2003
DEFINITION	Sequence 4520 from Patent EP1260586.	
ACCESSION	AX637381	
VERSION	AX637381.1	GI:28472995
KEYWORDS		
SOURCE	unidentified	
ORGANISM	unclassified	
REFERENCE	1	
AUTHORS	Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.	
TITLE	Method and reagent for inhibiting the expression of disease related genes	
JOURNAL	Patent: EP 1260586-A 4011 27-NOV-2002;	
FEATURES		
source	1.15	
Location/Qualifiers	/organism="unidentified"	
/mol_type="mRNA"		
/db_xref="taxon:32644"		
BASE COUNT	4 a	0 c 0 g 11 t
Query Match	1.1%	Score 14; DB 1; Length 15;
Best Local Similarity	100.0%	Pred. No. 1.8e+02;
Matches 14;	Conservative 0;	Mismatches 0; Indels 0; Gaps 0;
QY	1038	TATTATTATTATTAT 1051
DB	1	TATTATTATTATTAT 14
RESULT 101		
AX637381		
LOCUS	AX637381	15 bp mRNA linear PAT 21-FEB-2003
DEFINITION	Sequence 4520 from Patent EP1260586.	
ACCESSION	AX637381	
VERSION	AX637381.1	GI:28472995
KEYWORDS		
SOURCE	unidentified	
ORGANISM	unclassified	
REFERENCE	1	
AUTHORS	Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.	
TITLE	Method and reagent for inhibiting the expression of disease related genes	
JOURNAL	Patent: EP 1260586-A 4520 27-NOV-2002;	
FEATURES		
source	1.15	
Location/Qualifiers	/organism="unidentified"	
/mol_type="mRNA"		
/db_xref="taxon:32644"		
BASE COUNT	4 a	0 c 0 g 11 t
Query Match	1.1%	Score 14; DB 1; Length 15;
Best Local Similarity	100.0%	Pred. No. 1.8e+02;
Matches 14;	Conservative 0;	Mismatches 0; Indels 0; Gaps 0;
QY	1038	TATTATTATTATTAT 1051
DB	1	TATTATTATTATTAT 14
RESULT 102		
AX637383		
LOCUS	AX637383	15 bp mRNA linear PAT 21-FEB-2003
DEFINITION	Sequence 4522 from Patent EP1260586.	
ACCESSION	AX637383	
VERSION	AX637383.1	GI:28472997
KEYWORDS		
SOURCE	unidentified	
ORGANISM	unclassified	
REFERENCE	1	
AUTHORS	Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.	
TITLE	Method and reagent for inhibiting the expression of disease related genes	
JOURNAL	Patent: EP 1260586-A 4522 27-NOV-2002;	
FEATURES		
source	1.15	
Location/Qualifiers	/organism="unidentified"	
/mol_type="mRNA"		
/db_xref="taxon:32644"		
BASE COUNT	4 a	0 c 0 g 11 t
Query Match	1.1%	Score 14; DB 1; Length 15;
Best Local Similarity	100.0%	Pred. No. 1.8e+02;
Matches 14;	Conservative 0;	Mismatches 0; Indels 0; Gaps 0;
QY	1038	TATTATTATTATTAT 1051
DB	1	TATTATTATTATTAT 14
RESULT 103		
AX637385		
LOCUS	AX637385	15 bp mRNA linear PAT 21-FEB-2003
DEFINITION	Sequence 4524 from Patent EP1260586.	
ACCESSION	AX637385	
VERSION	AX637385.1	GI:28472999
KEYWORDS		
SOURCE	unidentified	
ORGANISM	unclassified	
REFERENCE	1	
AUTHORS	Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.	
TITLE	Method and reagent for inhibiting the expression of disease related genes	
JOURNAL	Patent: EP 1260586-A 4524 27-NOV-2002;	
FEATURES		
source	1.15	
Location/Qualifiers	/organism="unidentified"	
/mol_type="mRNA"		
/db_xref="taxon:32644"		
BASE COUNT	4 a	0 c 0 g 11 t
Query Match	1.1%	Score 14; DB 1; Length 15;
Best Local Similarity	100.0%	Pred. No. 1.8e+02;
Matches 14;	Conservative 0;	Mismatches 0; Indels 0; Gaps 0;
QY	1038	TATTATTATTATTAT 1051
DB	1	TATTATTATTATTAT 14

```
source 1. .15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.1%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATTAT 1051
|||||
Db 1 TATTATTATTAT 14

RESULT 104
AX738727/c
LOCUS AX738727 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4317 from Patent WO03025177.
ACCESSION AX738727
VERSION AX738727.1 GI:30518017
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4317 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 4 c 2 g 5 t
Query Match 1.1%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1076 TGTGCAAGATTG 1089
|||||
Db 17 TGTGCAAGATTG 4

RESULT 105
BD067874
LOCUS BD067874 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION BD067874
VERSION BD067874.1 GI:22613477
KEYWORDS JP 2001511003-A/714.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar S., Fell P. and McSwiggen, J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 714 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC, ASTON UNIV
COMMENT OS JP 2001511003-A/714
PD 07-AUG-2001
PP 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036475, 04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR, PATRICIA FELL, JAMES A MCSWIGGEN PC
C12N9/00, C07K14/71
```

```
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC levels of epidermal growth factor receptors
FH Key 1. .17
FT source /organism="Unidentified".
FEATURES
source 1. .17
Location/Qualifiers
1. .17
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"
BASE COUNT 9 a 1 c 2 g 5 t
Query Match 1.1%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1599 AGTAATATGAAC 1612
|||||
Db 2 AGTAATATGAAC 15

RESULT 106
AX069089/c
LOCUS AX069089 18 bp DNA linear PAT 25-JAN-2001
DEFINITION Sequence 7 from Patent WO0102604.
ACCESSION AX069089
VERSION AX069089.1 GI:12578971
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Tournier-Lasserre, E., Laberge-Le, S. and Labauge, P.
TITLE Use of the krt11 gene in angiogenesis
JOURNAL Patent: WO 0102604-A 7 11-JAN-2001;
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM).
(FR)
FEATURES
source 1. .18
Location/Qualifiers
1. .18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/Note="Amorce sens"
BASE COUNT 0 a 0 c 5 g 13 t
Query Match 1.1%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 616 ACAAAAACACAA 629
|||||
Db 15 ACAAAAACACAA 2

RESULT 107
AR067181/c
LOCUS AR067181 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 529 from patent US 5851760.
ACCESSION AR067181
VERSION AR067181.1 GI:5998403
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Evans, G.A. and Smith, M.W.
TITLE Method for generation of sequence sampled maps of complex genomes
JOURNAL Patent: US 5851760-A 529 22-DEC-1998;
FEATURES
source 1. .20
Location/Qualifiers
```

BASE COUNT 6 a 5 c 6 g 3 t  
Query Match 1.1%; Score 14; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 3e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 889 GTTCCACTGTGCT 902  
Db 17 GTTCCACTGTGCT 4

RESULT 108  
AR315239 20 bp DNA PAT 12-JUN-2003  
DEFINITION Sequence 5776 from patent US 6559294.  
ACCESSION AR315239  
VERSION AR315239.1 GI:31708665  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Griffais, R., Hoiseth, S.K., Zagursky, R.J., Metcalf, B.J., Peek, J.A., Sankaran, B. and Fletcher, L.D.  
TITLE Chlamydia pneumoniae polynucleotides and uses thereof  
JOURNAL Patent: US 6559294-A 5776 06-MAY-2003;  
FEATURES  
Location/Qualifiers  
1..20  
/organism="unknown"

BASE COUNT 4 a 7 c 3 g 6 t  
Query Match 1.1%; Score 14; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 3e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 644 TAAGGATTTTCTTA 657  
Db 7 TAAGGATTTTCTTA 20

RESULT 109  
ATH552863 20 bp DNA PAT 29-MAR-2003  
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 345309.  
ACCESSION AJ552863  
VERSION AJ552863.1 GI:29369014  
KEYWORDS left border; T-DNA flanking sequence.  
SOURCE Arabidopsis thaliana (thale cress)  
ORGANISM Arabidopsis thaliana  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.  
REFERENCE 1  
AUTHORS Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharny, A.  
TITLE T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites  
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)  
MEDLINE 22363535  
PubMed 12446565  
REFERENCE 2 (bases 1 to 20)  
AUTHORS Balzerque, S.  
TITLE Direct Submision  
JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE  
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the

corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES  
Location/Qualifiers  
1..20  
/organism="Arabidopsis thaliana"  
/mol\_type="genomic DNA"  
/cultivar="Wassillewskija"  
/db\_xref="taxon:3702"  
/clone="345E03"  
/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

misc\_feature 1..20  
/note="T-DNA flanking sequence left border"

BASE COUNT 13 a 4 c 0 g 3 t  
Query Match 1.1%; Score 14; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 3e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1207 AACCAACAAACAA 1220  
Db 1 AACCAACAAACAA 14

RESULT 110  
AR046179/c 17 bp DNA PAT 29-SEP-1999  
LOCUS AR046179  
DEFINITION Sequence 972 from patent US 5817796.  
ACCESSION AR046179  
VERSION AR046179.1 GI:5967644  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.  
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues  
JOURNAL Patent: US 5817796-A 972 06-OCT-1998;  
FEATURES  
Location/Qualifiers  
1..17  
/organism="unknown"

BASE COUNT 9 a 0 c 0 g 8 t  
Query Match 1.1%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1615 TTAATAATATAATTGTT 1631  
Db 17 TAAATAATATAATTTTT 1

RESULT 111  
AR047260/c 17 bp DNA PAT 29-SEP-1999  
LOCUS AR047260  
DEFINITION Sequence 2053 from patent US 5817796.  
ACCESSION AR047260  
VERSION AR047260.1 GI:5968725  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.  
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues  
JOURNAL Patent: US 5817796-A 2053 06-OCT-1998;  
FEATURES  
Location/Qualifiers  
1..17  
/organism="unknown"



RESULT 114	AX580024	17 bp	mRNA	linear	PAT 10-JAN-2003
LOCUS	Sequence 1862 from Patent WO0211674.				
DEFINITION	AX580024				
ACCESSION	AX580024				
VERSION	AX580024.1	GI:27649226			
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.				
AUTHORS	Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.				
TITLE	Method and reagent for the inhibition of calcium activated chloride channel-1 (clica-1)				
JOURNAL	Patent: WO 0211674-A 1862 14-FEB-2002;				
FEATURES	RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ; Thompson, James (US)				
source	1..17				
	/organism="Homo sapiens"				
	/mol_type="mRNA"				
	/db_xref="taxon:9606"				
BASE COUNT	6 a 1 c 1 g 9 t				
Query Match	1.1%;	Score 13.8;	DB 1;	Length 17;	
Best Local Similarity	88.2%;	Pred. No. 2.5e+02;			
Matches	15; Conservative	0; Mismatches	2; Indels	0; Gaps	0;
QY	1134 TATAGTAATTTATTTT 1150				
DB	1 TATAGTAATTTATTTT 17				
RESULT 115	AX673523	17 bp	DNA	linear	PAT 27-MAR-2003
LOCUS	Sequence 1968 from Patent WO03004526.				
DEFINITION	AX673523				
ACCESSION	AX673523				
VERSION	AX673523.1	GI:29331871			
KEYWORDS					
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.				
AUTHORS	Telerman,A., Anson,R. and Tuijnder,M.				
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines				
JOURNAL	Patent: WO 03004526-A 1968 16-JAN-2003;				
FEATURES	Molecular Engines Laboratories (FR)				
source	1..17				
	/organism="Homo sapiens"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:9606"				
BASE COUNT	7 a 5 c 1 g 4 t				
Query Match	1.1%;	Score 13.8;	DB 1;	Length 17;	
Best Local Similarity	88.2%;	Pred. No. 2.5e+02;			
Matches	15; Conservative	0; Mismatches	2; Indels	0; Gaps	0;
QY	755 GTGATTTTGAAGCATC 771				
DB	17 GTGATTTTGAAGCATC 1				
RESULT 116	AX734639	17 bp	DNA	linear	PAT 08-MAY-2003
LOCUS	Sequence 229 from Patent WO03025177.				
DEFINITION	AX734639				

ACCESSION AX734639  
 VERSION AX734639.1 GI:30513916  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 REFERENCE Telerman, A., Anson, R. and Tuijinder, M.  
 AUTHORS Sequences involved in phenomena of tumour suppression, tumour  
 TITLE reversion, apoptosis and/or resistance to viruses and the use  
 thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 229 27-MAR-2003;  
 FEATURES Molecular Engines Laboratories (FR)  
 source Location/Qualifiers  
 1.17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 3 a 3 c 1 g 10 t  
 Query Match 1.1%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1092 AAAATAGAGATGAATC 1108  
 Db 17 AAAATAGAGATGAATC 1  
 RESULT 117  
 I53231/c 153231 17 bp DNA linear PAT 07-OCT-1997  
 LOCUS Sequence 972 from patent US 5646042.  
 DEFINITION 153231  
 ACCESSION 153231 GI:2474434  
 VERSION 153231.1  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.  
 TITLE C-myb targeted ribozymes  
 JOURNAL Patent: US 5646042-A 972 08-JUL-1997;  
 FEATURES Location/Qualifiers  
 1.17  
 /organism="unknown"  
 BASE COUNT 9 a 0 c 0 g 8 t  
 Query Match 1.1%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1615 TTAATAATATAATTGTT 1631  
 Db 17 TTAATAATATAATTGTT 1  
 RESULT 118  
 I54312/c 154312 17 bp DNA linear PAT 07-OCT-1997  
 LOCUS Sequence 2053 from patent US 5646042.  
 DEFINITION 154312  
 ACCESSION 154312 GI:2475515  
 VERSION 154312.1  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.  
 TITLE C-myb targeted ribozymes  
 JOURNAL Patent: US 5646042-A 2053 08-JUL-1997;  
 FEATURES Location/Qualifiers  
 1.17  
 /organism="unknown"  
 BASE COUNT 9 a 0 c 0 g 8 t  
 Query Match 1.1%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 2.5e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1615 TTAATAATATAATTGTT 1631  
 Db 17 TTAATAATATAATTGTT 1  
 RESULT 119  
 AR297659 18 bp DNA linear PAT 12-JUN-2003  
 LOCUS Sequence 9394 from patent US 6537751.  
 DEFINITION AR297659  
 ACCESSION AR297659  
 VERSION AR297659.1 GI:31684943  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 18)  
 AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.  
 TITLE Biallelic markers for use in constructing a high density  
 disequilibrium map of the human genome  
 JOURNAL Patent: US 6537751-A 9394 25-MAR-2003;  
 FEATURES Location/Qualifiers  
 1.18  
 /organism="unknown"  
 BASE COUNT 0 a 6 c 3 g 9 t  
 Query Match 1.1%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 895 CTGTGCTTGTCTTC 911  
 Db 2 CTGTGCTTGTCTTC 18  
 RESULT 120  
 AR297664 18 bp DNA linear PAT 12-JUN-2003  
 LOCUS Sequence 9399 from patent US 6537751.  
 DEFINITION AR297664  
 ACCESSION AR297664  
 VERSION AR297664.1 GI:31684948  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 18)  
 AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.  
 TITLE Biallelic markers for use in constructing a high density  
 disequilibrium map of the human genome  
 JOURNAL Patent: US 6537751-A 9399 25-MAR-2003;  
 FEATURES Location/Qualifiers  
 1.18  
 /organism="unknown"  
 BASE COUNT 0 a 6 c 3 g 9 t  
 Query Match 1.1%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 895 CTGTGCTTGTCTTC 911  
 Db 2 CTGTGCTTGTCTTC 18  
 RESULT 121  
 AX132978/c

LOCUS AX132978 18 bp DNA linear PAT 15-MAY-2001  
 DEFINITION Sequence 4196 from Patent WO0130362.  
 ACCESSION AX132978  
 VERSION AX132978.1 GI:14139288  
 KEYWORDS Homo sapiens (human)  
 SOURCE  
 ORGANISM Homo sapiens  
 AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 TITLE Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 JOURNAL Robbins, J.M. and Tritz, R.  
 RIBOSOME RIBOSOME therapy for the treatment of proliferative skin and eye  
 DISEASES  
 PATENT: WO 0130362-A 4196 03-MAY-2001;  
 IMMUSOL, INC. (US)  
 FEATURES  
 source  
 1..18 Location/Qualifiers  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /note="Hammerhead ribozyme recognition site for cdc 2  
 kinase"  
 BASE COUNT 7 a 2 c 2 g 7 t  
 Query Match 1..18; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1172 TTTATTAGATAAATTC 1188  
 |||||  
 DB 18 TTTAATAGAGAAATTC 2  
 RESULT 122  
 LOCUS AX599395 18 bp DNA linear PAT 14-FEB-2003  
 DEFINITION Sequence 735 from Patent WO0207272.  
 ACCESSION AX599395  
 VERSION AX599395.1 GI:28399539  
 KEYWORDS  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 artificial sequences.  
 REFERENCE  
 AUTHORS Berlin, K., Braun, A., Distler, J., Guetig, D., Howe, A., Mueller, J.,  
 Olek, A., Piepenbrock, C., Adorjan, P., Grabs, G., Lesche, R., Leu, E.,  
 Lewin, A., Lipscher, E., Maier, S., Model, P., Mueller, V., Otto, T.,  
 Pelet, C. and Ziebarth, H.  
 TITLE Methods and nucleic acids for the analysis of hematopoietic cell  
 proliferative disorders  
 JOURNAL Patent: WO 0207272-A 735 03-OCT-2002;  
 Epigenomics AG (DE)  
 FEATURES  
 source  
 1..18 Location/Qualifiers  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 /note="Detection oligonucleotide for DAPK1"  
 BASE COUNT 3 a 1 c 4 g 10 t  
 Query Match 1..18; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1286 TTGTTTATCTGGAATTT 1302  
 |||||  
 DB 1 TTGTTTTCGGAATTT 17  
 RESULT 123  
 LOCUS E12707/c 18 bp DNA linear PAT 27-APR-1998  
 DEFINITION Primer.

ACCESSION E12707  
 VERSION E12707.1 GI:3251539  
 KEYWORDS JP 1997056382-A/3.  
 SOURCE unidentified  
 ORGANISM unidentified  
 unclassified.  
 REFERENCE 1 (bases 1 to 18)  
 AUTHORS Mitsuoka, N. and Robaato, E.U.  
 TITLE GENE CODING FOR PROTEIN CONTROLLING MORPHOGENESIS OF PLANT  
 JOURNAL Patent: JP 1997056382-A 3 04-MAR-1997;  
 CHIKYU KANKYO SANGYO GIJUTSU KENKYU KIKO, MITSUI GYOSAI SHOKUBUTSU  
 BIO KENKYUSHO:KK  
 COMMENT OS None  
 OC Artificial sequences.  
 FN JP 1997056382-A/3  
 PD 04-MAR-1997  
 PF 24-AUG-1995 JP 1995216187  
 PI MITSUKAWA NORIHIRO, ROBAATO EFU UITSUTSUA  
 PC C12N15/09, A01H5/00, C12N5/10;  
 CC strandedness: Single;  
 CC topology: Linear;  
 FH Key Location/Qualifiers  
 FT source 1..18  
 PT Location/Qualifiers  
 /organism="Artificial sequences".  
 1..18 Location/Qualifiers  
 /organism="unidentified"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32644"  
 BASE COUNT 7 a 4 c 3 g 4 t  
 Query Match 1..18; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 2.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1498 GACTGCATTTTAAATA 1514  
 |||||  
 DB 17 GACTGCGTTTATAGATA 1  
 RESULT 124  
 LOCUS A88564 19 bp DNA linear PAT 22-JAN-2000  
 DEFINITION Sequence 712 from Patent WO9833904.  
 ACCESSION A88564  
 VERSION A88564.1 GI:6737134  
 KEYWORDS  
 SOURCE unidentified  
 ORGANISM unidentified  
 unclassified.  
 REFERENCE 1 (bases 1 to 19)  
 AUTHORS Brysch, W. and Schlingensiepen, K.  
 TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD  
 JOURNAL Patent: WO 9833904-A 712 06-AUG-1998;  
 BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)  
 FEATURES  
 source  
 1..19 Location/Qualifiers  
 /organism="unidentified"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32644"  
 BASE COUNT 6 a 1 c 1 g 11 t  
 Query Match 1..19; Score 13.8; DB 1; Length 19;  
 Best Local Similarity 88.2%; Pred. No. 3e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1172 TTTATTAGATAAATTC 1188  
 |||||  
 DB 1 TTTTAAAGATAAATTC 17  
 RESULT 125

```

A90531
LOCUS       A90531               19 bp    DNA
DEFINITION   Sequence 712 from Patent EP0856579.
ACCESSION    A90531
VERSION      A90531.1   GI:6739045
KEYWORDS     unidentified
SOURCE       unidentified
ORGANISM     unclassified.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Brysch,W.D. and Schlingensiepen,K.D.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: EP 0856579-A 712 05-AUG-1998;
              BIOGNOSTIK GES (DB)
FEATURES
  source
    1..19
    /organism="unidentified"
    /col_type="genomic DNA"
    /db_xref="taxon:32644"
  BASE COUNT      6 a      1 c      1 g      11 t
    Query Match      1.1%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
    Matches 15; Conservative 0; Mismatches 0;

QY      1172 TTTATTAGATAAATTC 1188
Db      1 TTTTAAAGATAAATTC 17

RESULT 126
LOCUS       AR030969             19 bp    DNA
DEFINITION   Sequence 1 from patent US 5861501.
ACCESSION    AR030969
VERSION      AR030969.1   GI:5944183
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE        Capped synthetic RNA, analogs, and aptamers
JOURNAL      Patent: US 5861501-A 1 19-JAN-1999;
              Location/Qualifiers
FEATURES
  source
    1..19
    /organism="unknown"
  BASE COUNT      3 a      1 c      1 g      14 t
    Query Match      1.1%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
    Matches 15; Conservative 0; Mismatches 0;

QY      1521 TTTATATTTTAACTTT 1537
Db      2 TTTTATTTTAAATTT 18

RESULT 127
LOCUS       AR030972             19 bp    DNA
DEFINITION   Sequence 4 from patent US 5861501.
ACCESSION    AR030972
VERSION      AR030972.1   GI:5944186
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE        Capped synthetic RNA, analogs, and aptamers
JOURNAL      Patent: US 5861501-A 4 19-JAN-1999;
              Location/Qualifiers
FEATURES
  source
    1..19
    /organism="unknown"
  BASE COUNT      3 a      1 c      1 g      14 t
    Query Match      1.1%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
    Matches 15; Conservative 0; Mismatches 0;

QY      1521 TTTATATTTTAACTTT 1537
Db      2 TTTTATTTTAAATTT 18

RESULT 128
LOCUS       AR030974             19 bp    DNA
DEFINITION   Sequence 6 from patent US 5861501.
ACCESSION    AR030974
VERSION      AR030974.1   GI:5944188
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE        Capped synthetic RNA, analogs, and aptamers
JOURNAL      Patent: US 5861501-A 6 19-JAN-1999;
              Location/Qualifiers
FEATURES
  source
    1..19
    /organism="unknown"
  BASE COUNT      3 a      1 c      1 g      14 t
    Query Match      1.1%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
    Matches 15; Conservative 0; Mismatches 0;

QY      1521 TTTATATTTTAACTTT 1537
Db      2 TTTTATTTTAAATTT 18

RESULT 129
LOCUS       AR030975             19 bp    DNA
DEFINITION   Sequence 7 from patent US 5861501.
ACCESSION    AR030975
VERSION      AR030975.1   GI:5944189
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE        Capped synthetic RNA, analogs, and aptamers
JOURNAL      Patent: US 5861501-A 7 19-JAN-1999;
              Location/Qualifiers
FEATURES
  source
    1..19
    /organism="unknown"
  BASE COUNT      3 a      1 c      1 g      14 t
    Query Match      1.1%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
    Matches 15; Conservative 0; Mismatches 0;

QY      1521 TTTATATTTTAACTTT 1537
Db      2 TTTTATTTTAAATTT 18

RESULT 130
LOCUS       AR030976             19 bp    DNA
DEFINITION   Sequence 8 from patent US 5861501.

```

```

ACCESSION AR030976 GI:5944190
VERSION AR030976.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 8 19-JAN-1999;
FEATURES
    source 1..19
    /organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1521 TTTATATTTTAACTTT 1537
    ||| ||||| |||
Db 2 TTTTATTTTAAATTT 18

RESULT 133
LOCUS AR030976
DEFINITION Sequence 9 from patent US 5861501.
ACCESSION AR030977
VERSION AR030977.1 GI:5944191
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 9 19-JAN-1999;
FEATURES
    source 1..19
    /organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1521 TTTATATTTTAACTTT 1537
    ||| ||||| |||
Db 2 TTTTATTTTAAATTT 18

RESULT 132
LOCUS AR030977
DEFINITION Sequence 10 from patent US 5861501.
ACCESSION AR030978
VERSION AR030978.1 GI:5944192
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 10 19-JAN-1999;
FEATURES
    source 1..19
    /organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1521 TTTATATTTTAACTTT 1537
    ||| ||||| |||
Db 2 TTTTATTTTAAATTT 18

RESULT 131
LOCUS AR030977
DEFINITION Sequence 9 from patent US 5861501.
ACCESSION AR030977
VERSION AR030977.1 GI:5944191
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 9 19-JAN-1999;
FEATURES
    source 1..19
    /organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1521 TTTATATTTTAACTTT 1537
    ||| ||||| |||
Db 2 TTTTATTTTAAATTT 18

RESULT 132
LOCUS AR030978
DEFINITION Sequence 10 from patent US 5861501.
ACCESSION AR030978
VERSION AR030978.1 GI:5944192
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 10 19-JAN-1999;
FEATURES
    source 1..19
    /organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1521 TTTATATTTTAACTTT 1537
    ||| ||||| |||
Db 2 TTTTATTTTAAATTT 18

RESULT 133
LOCUS AR030978
DEFINITION Sequence 10 from patent US 5861501.
ACCESSION AR030978
VERSION AR030978.1 GI:5944192
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 10 19-JAN-1999;
FEATURES
    source 1..19
    /organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1521 TTTATATTTTAACTTT 1537
    ||| ||||| |||
Db 2 TTTTATTTTAAATTT 18

RESULT 134
LOCUS AR030982
DEFINITION Sequence 14 from patent US 5861501.
ACCESSION AR030982
VERSION AR030982.1 GI:5944196
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 14 19-JAN-1999;
FEATURES
    source 1..19
    /organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1521 TTTATATTTTAACTTT 1537
    ||| ||||| |||
Db 2 TTTTATTTTAAATTT 18

RESULT 135
LOCUS AR030983
DEFINITION Sequence 15 from patent US 5861501.
ACCESSION AR030983
VERSION AR030983.1 GI:5944197
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 15 19-JAN-1999;
FEATURES
    source 1..19
    /organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1521 TTTATATTTTAACTTT 1537
    ||| ||||| |||
Db 2 TTTTATTTTAAATTT 18

RESULT 136
LOCUS AR030983
DEFINITION Sequence 15 from patent US 5861501.
ACCESSION AR030983
VERSION AR030983.1 GI:5944197
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.
TITLE Capped synthetic RNA, analogs, and aptamers
JOURNAL Patent: US 5861501-A 15 19-JAN-1999;
FEATURES
    source 1..19
    /organism="unknown"
BASE COUNT 3 a 1 c 1 g 14 t
Query Match 1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1521 TTTATATTTTAACTTT 1537
    ||| ||||| |||
Db 2 TTTTATTTTAAATTT 18

```



[illegible]

AR108823.1 GI:12824310					
VERSION	Unknown.				
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1 (bases 1 to 19)				
AUTHORS	Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.				
TITLE	Capped synthetic RNA, analogs, and aptamers				
JOURNAL	Patent: US 6111095-A 10 29-AUG-2000;				
FEATURES	Location/Qualifiers				
source	1..19				
BASE COUNT	3 a 1 c 1 g 14 t				
Query Match	1.1%; Score 13.8; DB 1; Length 19;				
Best Local Similarity	88.2%; Pred.No.3e+02; 2; Indels 0; Gaps 0;				
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	1521 TTTATATTTTTAACTTT 1537				
DB	2 TTTTATTTTAAATTT 18				
RESULT 144					
LOCUS	AR108826				
DEFINITION	Sequence 13 from patent US 6111095.				
ACCESSION	AR108826				
VERSION	AR108826.1 GI:12824313				
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1 (bases 1 to 19)				
AUTHORS	Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.				
TITLE	Capped synthetic RNA, analogs, and aptamers				
JOURNAL	Patent: US 6111095-A 13 29-AUG-2000;				
FEATURES	Location/Qualifiers				
source	1..19				
BASE COUNT	3 a 1 c 1 g 14 t				
Query Match	1.1%; Score 13.8; DB 1; Length 19;				
Best Local Similarity	88.2%; Pred.No.3e+02; 2; Indels 0; Gaps 0;				
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY	1521 TTTATATTTTTAACTTT 1537				
DB	2 TTTTATTTTAAATTT 18				
RESULT 145					
LOCUS	AR108827				
DEFINITION	Sequence 14 from patent US 6111095.				
ACCESSION	AR108827				
VERSION	AR108827.1 GI:12824314				
KEYWORDS	Unknown.				
SOURCE	Unknown.				
ORGANISM	Unclassified.				
REFERENCE	1 (bases 1 to 19)				
AUTHORS	Benseler,F., Cole,J.L., Olsen,D.B. and Kuo,L.C.				
TITLE	Capped synthetic RNA, analogs, and aptamers				
JOURNAL	Patent: US 6111095-A 14 29-AUG-2000;				
FEATURES	Location/Qualifiers				
source	1..19				
BASE COUNT	3 a 1 c 1 g 14 t				
Query Match	1.1%; Score 13.8; DB 1; Length 19;				
Best Local Similarity	88.2%; Pred.No.3e+02; 2; Indels 0; Gaps 0;				
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					





<hr/>					
RESULT 151	AR205769	Sequence 7 from patent US 6369208.	19 bp	DNA	linear
LOCUS	AR205769				
DEFINITION	Accession				
ACCESSION	AR205769				
VERSION	AR205769.1	GI:21503435			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 19)				
TITLE	Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseler, F.				
JOURNAL	Capped synthetic RNA, analogs, and aptamers				
FEATURES	Patent: US 6369208-A 7 09-APR-2002;				
	Location/Qualifiers				
	1..19				
	/organism="unknown"				
BASE COUNT	3 a	1 c	1 g	14 t	
Query Match	1..1%; Score 13.8; DB 1; Length 19;				
Best Local Similarity	88.2%; Pred. No. 3e+02;				
Matches	15; Conservative	0; Mismatches	2; Indels	0; Gaps	0;
<hr/>					
QY	1521 TTTATATTTTAACTTT	1537			
Db	2 TTTTATTTTAAATTT	18			
<hr/>					
RESULT 152	AR205770	Sequence 8 from patent US 6369208.	19 bp	DNA	linear
LOCUS	AR205770				
DEFINITION	Accession				
ACCESSION	AR205770				
VERSION	AR205770.1	GI:21503437			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 19)				
TITLE	Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseler, F.				
JOURNAL	Capped synthetic RNA, analogs, and aptamers				
FEATURES	Patent: US 6369208-A 8 09-APR-2002;				
	Location/Qualifiers				
	1..19				
	/organism="unknown"				
BASE COUNT	3 a	1 c	1 g	14 t	
Query Match	1..1%; Score 13.8; DB 1; Length 19;				
Best Local Similarity	88.2%; Pred. No. 3e+02;				
Matches	15; Conservative	0; Mismatches	2; Indels	0; Gaps	0;
<hr/>					
QY	1521 TTTATATTTTAACTTT	1537			
Db	2 TTTTATTTTAAATTT	18			
<hr/>					
RESULT 153	AR205771	Sequence 9 from patent US 6369208.	19 bp	DNA	linear
LOCUS	AR205771				
DEFINITION	Accession				
ACCESSION	AR205771				
VERSION	AR205771.1	GI:21503438			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 19)				
TITLE	Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseler, F.				
JOURNAL	Capped synthetic RNA, analogs, and aptamers				
FEATURES	Patent: US 6369208-A 9 09-APR-2002;				
	Location/Qualifiers				
	1..19				
	/organism="unknown"				

```
KEYWORDS
SOURCE      Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseler, F.
TITLE        Capped synthetic RNA, analogs, and aptamers
JOURNAL      Patent: US 6369208-A 14 09-APR-2002;
FEATURES     Location/Qualifiers
source       1..19
              /organism="unknown"
BASE COUNT   3 a 1 c 1 g 14 t
Query Match   1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18
RESULT 157
LOCUS      AR205777
DEFINITION Sequence 15 from patent US 6369208.
ACCESSION  AR205777
VERSION     AR205777.1 GI:21503445
KEYWORDS    Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseler, F.
TITLE        Capped synthetic RNA, analogs, and aptamers
JOURNAL      Patent: US 6369208-A 15 09-APR-2002;
FEATURES     Location/Qualifiers
source       1..19
              /organism="unknown"
BASE COUNT   3 a 1 c 1 g 14 t
Query Match   1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18
RESULT 158
LOCUS      AR205778
DEFINITION Sequence 16 from patent US 6369208.
ACCESSION  AR205778
VERSION     AR205778.1 GI:21503447
KEYWORDS    Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseler, F.
TITLE        Capped synthetic RNA, analogs, and aptamers
JOURNAL      Patent: US 6369208-A 16 09-APR-2002;
FEATURES     Location/Qualifiers
source       1..19
              /organism="unknown"
BASE COUNT   3 a 1 c 1 g 14 t
Query Match   1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18
KEYWORDS
SOURCE      Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Cole, J.L., Kuo, L.C., Olsen, D.B. and Benseler, F.
TITLE        Capped synthetic RNA, analogs, and aptamers
JOURNAL      Patent: US 6369208-A 14 09-APR-2002;
FEATURES     Location/Qualifiers
source       1..19
              /organism="unknown"
BASE COUNT   3 a 1 c 1 g 14 t
Query Match   1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1521 TTTATATTTTAACTTT 1537
Db 2 TTTTATTTTAAATTT 18
LOCUS      AR297082
DEFINITION Sequence 8817 from patent US 6537751.
ACCESSION  AR297082
VERSION     AR297082.1 GI:31684366
KEYWORDS    Unknown.
ORGANISM     Unknown.
REFERENCE    1 (bases 1 to 19)
AUTHORS      Cohen, D., Chumakov, I. and Blumenfeld, M.
TITLE        Biallelic markers for use in constructing a high density
              disequilibrium map of the human genome
JOURNAL      Patent: US 6537751-A 8817 25-MAR-2003;
FEATURES     Location/Qualifiers
source       1..19
              /organism="unknown"
BASE COUNT   11 a 6 c 1 g 1 t
Query Match   1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1208 AACAAACAACAATGG 1224
Db 1 AACAAACAACAATAG 17
RESULT 160
LOCUS      AX130049
DEFINITION Sequence 1267 from Patent WO0130362.
ACCESSION  AX130049
VERSION     AX130049.1 GI:14136354
KEYWORDS    Homo sapiens (human)
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1
AUTHORS      Robbins, J.M. and Tritz, R.
TITLE        Ribozyme therapy for the treatment of proliferative skin and eye
              diseases
JOURNAL      Patent: WO 0130362-A 1267 03-MAY-2001;
              IMMUSOL, INC. (US)
FEATURES     Location/Qualifiers
source       1..19
              /organism="Homo sapiens"
              /mol_type="genomic DNA"
              /db_xref="taxon:9606"
              /note="cdk-we-hu ribozyme binding site"
BASE COUNT   7 a 4 c 3 g 5 t
Query Match   1.1%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1378 TACCGAATAATGAGTTA 1394
Db 2 TACAGAATCATGAGTTA 18
RESULT 161
LOCUS      BD066077
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION  BD066077
```

VERSION BD066077.1 GI:22611680  
 KEYWORDS JP 2001511000-A/712.  
 SOURCE unclassified  
 ORGANISM unclassified  
 REFERENCE 1 (bases 1 to 19)  
 AUTHORS Schlengensteden, K.H. and Brysch, W.  
 TITLE An antisense oligonucleotide preparation method  
 JOURNAL Patent: JP 2001511000-A 712 07-AUG-2001;  
 COMMENT BIOLOGISTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK MBH  
 OS Unknown  
 PN JP 2001511000-A/712  
 PD 07-AUG-2001  
 PF 30-JAN-1998 JP 1998532633  
 PR 31-JAN-1997 EP 97101531.8  
 PI KARL HERMANN SCHLINGENSTEDEN, WOLFGANG BRYSCH  
 PC C12N15/11, C07H21/04, A61K31/70  
 CC An antisense oligonucleotide preparation method  
 FT source 1.19  
 FT Location/Qualifiers  
 /organism="Unknown"  
 /organism="unidentified"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32644"  
 BASE COUNT 6 a 1 c 1 g 11 t  
 Query Match 1.1%; Score 13.8; DB 1; Length 19;  
 Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1172 TTATTAGATAAATTC 1188  
 Db 1 TTATTAGATAAATTC 17  
 RESULT 162  
 LOCUS 162823  
 DEFINITION Sequence 1 from patent US 5660989.  
 ACCESSION 162823  
 VERSION 162823.1 GI:2480531  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 19)  
 AUTHORS Cole, J.L., Kuo, L.C. and Olsen, D.B.  
 TITLE DNA polymerase extension assay for influenza virus endonuclease  
 JOURNAL Patent: US 5660989-A 1 26-AUG-1997;  
 FEATURES Location/Qualifiers  
 source 1.19  
 /organism="unknown"  
 BASE COUNT 3 a 1 c 1 g 14 t  
 Query Match 1.1%; Score 13.8; DB 1; Length 19;  
 Best Local Similarity 88.2%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1521 TTATATATTTTAACTTT 1537  
 Db 2 TTATATATTTTAACTTT 18  
 RESULT 163  
 LOCUS BD161924  
 DEFINITION Method for carrying out thermal cycle of PCR using DNA-immobilized substrate.  
 ACCESSION BD161924  
 VERSION BD161924.1 GI:27867682  
 KEYWORDS JP 2002191369-A/1.

SOURCE synthetic construct  
 ORGANISM synthetic construct  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Tanga, M., Okamura, H. and Takahashi, K.  
 TITLE Method for carrying out thermal cycle of PCR using DNA-immobilized substrate  
 JOURNAL Patent: JP 2002191369-A 1 09-JUL-2002;  
 COMMENT TOYO KOKAN CO LTD, KOJIRO TAKAHASHI  
 OS Artificial Sequence  
 PN JP 2002191369-A/1  
 PD 09-JUL-2002  
 PF 27-DEC-2000 JP 2000399573  
 PI MICHIFUMI TANGA, HIROSHI OKAMURA, KOJIRO TAKAHASHI  
 PC C12N15/09, C12N15/09, C12N15/00, C12N15/00 CC Method for carrying out thermal cycle of PCR using DNA-immobilized substrate  
 CC substrate  
 FT Key  
 FT source 1.20  
 FT Location/Qualifiers  
 /organism="Artificial Sequence"  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 BASE COUNT 3 a 0 c 0 g 17 t  
 Query Match 1.1%; Score 13.6; DB 1; Length 20;  
 Best Local Similarity 80.0%; Pred. No. 3.7e+02; 4; Indels 0; Gaps 0;  
 Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
 QY 1560 AAATTTTCTACTCTCTCT 1579  
 Db 1 AAATTTTCTACTCTCTCT 20  
 RESULT 164  
 LOCUS AR164318  
 DEFINITION Sequence 1 from patent US 6271369.  
 ACCESSION AR164318  
 VERSION AR164318.1 GI:16235432  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 22)  
 AUTHORS Torrence, P.F., Silverman, R.H., Maitra, R.K. and Lesiak, K.  
 TITLE Chimeric molecules targeted to viral RNAs  
 JOURNAL Patent: US 6271369-A 1 07-AUG-2001;  
 FEATURES Location/Qualifiers  
 source 1.22  
 /organism="unknown"  
 BASE COUNT 4 a 0 c 0 g 18 t  
 Query Match 1.1%; Score 13.6; DB 1; Length 22;  
 Best Local Similarity 80.0%; Pred. No. 4.3e+02; 4; Indels 0; Gaps 0;  
 Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
 QY 1560 AAATTTTCTACTCTCTCT 1579  
 Db 2 AAATTTTCTACTCTCTCT 21  
 RESULT 165  
 LOCUS AR164319  
 DEFINITION Sequence 2 from patent US 6271369.  
 ACCESSION AR164319  
 VERSION AR164319.1 GI:16235434  
 KEYWORDS Unknown.

```
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 22)
AUTHORS Torrence,P., Silverman,R.H., Maitra,R.K. and Lesiak,K.
TITLE Chimeric molecules targeted to viral RNAs
JOURNAL Patent: US 6221369-A 2 07-AUG-2001;
FEATURES
    source
    1..22
    /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
    Query Match 1..1%; Score 13.6; DB 1; Length 22;
    Best Local Similarity 80.0%; Pred. No. 4.3e+02;
    Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21
RESULT 166
LOCUS I31810 22 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 1 from patent US 5583032.
ACCESSION I31810
VERSION I31810.1 GI:1822601
KEYWORDS
    source
    1..22
    /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
    Query Match 1..1%; Score 13.6; DB 1; Length 22;
    Best Local Similarity 80.0%; Pred. No. 4.3e+02;
    Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21
RESULT 167
LOCUS I31811 22 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 2 from patent US 5583032.
ACCESSION I31811
VERSION I31811.1 GI:1822602
KEYWORDS
    source
    1..22
    /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
    Query Match 1..1%; Score 13.6; DB 1; Length 22;
    Best Local Similarity 80.0%; Pred. No. 4.3e+02;
    Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21
RESULT 168
LOCUS I69407 22 bp DNA linear PAT 04-FEB-1998
DEFINITION Sequence 1 from patent US 5677289.
ACCESSION I69407
VERSION I69407.1 GI:2831529
KEYWORDS
    source
    1..22
    /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
    Query Match 1..1%; Score 13.6; DB 1; Length 22;
    Best Local Similarity 80.0%; Pred. No. 4.3e+02;
    Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21
RESULT 169
LOCUS I69408 22 bp DNA linear PAT 04-FEB-1998
DEFINITION Sequence 2 from patent US 5677289.
ACCESSION I69408
VERSION I69408.1 GI:2831530
KEYWORDS
    source
    1..22
    /organism="unknown"
BASE COUNT 4 a 0 c 0 g 18 t
    Query Match 1..1%; Score 13.6; DB 1; Length 22;
    Best Local Similarity 80.0%; Pred. No. 4.3e+02;
    Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1560 AAATTTTTTTTACTGTTTCT 1579
Db 2 AAATTTTTTTTCTTTTCT 21
RESULT 170
LOCUS BD182175 30 bp DNA linear PAT 15-MAY-2003
DEFINITION Method for synthesizing of nucleic acid.
ACCESSION BD182175
VERSION BD182175.1 GI:30793093
KEYWORDS WO 02090538-A/7.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 30)
AUTHORS Nagamine,K.
```

TITLE Method for synthesizing of nucleic acid  
 JOURNAL Patent: WO 02090538-A 7 14-NOV-2002;  
 COMMENT BIKEN CHEMICAL CO LTD,KENTARO NAGAMINE  
 OS Artificial Sequence  
 PN WO 02090538-A/7  
 PD 14-NOV-2002  
 PF 08-MAY-2002 WO 2002JP004479  
 PR 08-MAY-2001 JP 01P 137060,18-JUN-2001 JP 01P 184131 PI  
 PC C12N15/09,C12Q1/68  
 CC Description of Artificial Sequence:an artificially synthesized

CC sequence primer  
 CC key Location/Qualifiers  
 FT source 1..30  
 FT /organism='Artificial Sequence'.  
 FEATURES  
 source 1..30  
 Location/Qualifiers  
 1..30  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 15 a 2 c 2 g 11 t

BASE COUNT 15 a 2 c 2 g 11 t

Query Match 1.1%; Score 13.6; DB 1; Length 30;  
 Best Local Similarity 67.9%; Pred. No. 6.3e+02;  
 Matches 19; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 753 ATTGATATTGAGCATCATCAATAAAA 780  
 |||||  
 Db 3 ATTGATGCTTAATAATAACATAATA 30

RESULT 171  
 AR041400  
 LOCUS AR041400 15 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 190 from patent US 5811300.  
 ACCESSION AR041400  
 VERSION AR041400.1 GI:5961896  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 UNCLASSIFIED  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
 TITLE TNF- $\alpha$ . ribozymes  
 JOURNAL Patent: US 5811300-A 190 22-SEP-1998;  
 FEATURES  
 source 1..15  
 Location/Qualifiers  
 1..15  
 /organism="unknown"  
 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATATGT 1053  
 |||||  
 Db 1 ATTATTATTATTT 15

RESULT 172  
 AR041401  
 LOCUS AR041401 15 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 191 from patent US 5811300.  
 ACCESSION AR041401  
 VERSION AR041401.1 GI:5961897  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 UNCLASSIFIED  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.

TITLE TNF- $\alpha$ . ribozymes  
 JOURNAL Patent: US 5811300-A 191 22-SEP-1998;  
 FEATURES  
 source 1..15  
 Location/Qualifiers  
 1..15  
 /organism="unknown"  
 4 a 0 c 0 g 11 t

BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGTAT 1055  
 |||||  
 Db 1 TTATTATTATTTAT 15

RESULT 173  
 AR041402  
 LOCUS AR041402 15 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 192 from patent US 5811300.  
 ACCESSION AR041402  
 VERSION AR041402.1 GI:5961898  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 UNCLASSIFIED  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
 TITLE TNF- $\alpha$ . ribozymes  
 JOURNAL Patent: US 5811300-A 192 22-SEP-1998;  
 FEATURES  
 source 1..15  
 Location/Qualifiers  
 1..15  
 /organism="unknown"  
 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TATTATTATGTATT 1056  
 |||||  
 Db 1 TATTATTATTTATT 15

RESULT 174  
 AR041408  
 LOCUS AR041408 15 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 198 from patent US 5811300.  
 ACCESSION AR041408  
 VERSION AR041408.1 GI:5961904  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 UNCLASSIFIED  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
 TITLE TNF- $\alpha$ . ribozymes  
 JOURNAL Patent: US 5811300-A 198 22-SEP-1998;  
 FEATURES  
 source 1..15  
 Location/Qualifiers  
 1..15  
 /organism="unknown"  
 4 a 0 c 0 g 11 t

BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGT 1053  
 |||||  
 Db 1 ATTATTATTATTT 15

RESULT 175

AR041409  
LOCUS AR041409 15 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 199 from patent US 5811300.  
ACCESSION AR041409  
VERSION AR041409.1 GI:5961905  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 199 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGATTT 1055  
|||||  
Db 1 TTATTATTATTTAT 15

RESULT 176  
AR041410  
LOCUS AR041410 15 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 200 from patent US 5811300.  
ACCESSION AR041410  
VERSION AR041410.1 GI:5961906  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 200 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TATTATTATGATTT 1056  
|||||  
Db 1 TATTATTATTTATTT 15

RESULT 177  
AR041411  
LOCUS AR041411 15 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 201 from patent US 5811300.  
ACCESSION AR041411  
VERSION AR041411.1 GI:5961907  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 201 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 TATTATTATGATTT 1057  
|||||  
Db 1 ATTATTATTATTT 15

RESULT 178  
AR041919  
LOCUS AR041919 15 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 709 from patent US 5811300.  
ACCESSION AR041919  
VERSION AR041919.1 GI:5962415  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 709 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGATTT 1053  
|||||  
Db 1 ATTATTATTATTT 15

RESULT 179  
AR041920  
LOCUS AR041920 15 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 710 from patent US 5811300.  
ACCESSION AR041920  
VERSION AR041920.1 GI:5962416  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 710 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGATTT 1053  
|||||  
Db 1 ATTATTATTATTT 15

RESULT 180  
AR041921  
LOCUS AR041921 15 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 711 from patent US 5811300.  
ACCESSION AR041921  
VERSION AR041921.1 GI:5962417  
KEYWORDS

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATTATGATTT 1057  
|||||  
Db 1 ATTATTATTATTT 15

RESULT 178  
AR041919  
LOCUS AR041919 15 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 709 from patent US 5811300.  
ACCESSION AR041919  
VERSION AR041919.1 GI:5962415  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 709 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGATTT 1053  
|||||  
Db 1 ATTATTATTATTT 15

RESULT 179  
AR041920  
LOCUS AR041920 15 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 710 from patent US 5811300.  
ACCESSION AR041920  
VERSION AR041920.1 GI:5962416  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 710 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGATTT 1053  
|||||  
Db 1 ATTATTATTATTT 15

RESULT 180  
AR041921  
LOCUS AR041921 15 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 711 from patent US 5811300.  
ACCESSION AR041921  
VERSION AR041921.1 GI:5962417  
KEYWORDS

SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 711 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 4 a 0 c 0 g 11 t  
Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1039 ATTATTATTATGAT 1053  
Db 1 ATTATTATTATTT 15

RESULT 181  
AR041922  
LOCUS AR041922 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 712 from patent US 5811300.  
ACCESSION AR041922  
VERSION AR041922.1 GI:5962418  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 712 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 4 a 0 c 0 g 11 t  
Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1041 TTATTATTATGAT 1055  
Db 1 TTATTATTATTTAT 15

RESULT 182  
AR041923  
LOCUS AR041923 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 713 from patent US 5811300.  
ACCESSION AR041923  
VERSION AR041923.1 GI:5962419  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 713 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 4 a 0 c 0 g 11 t  
Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1041 TTATTATTATGAT 1055  
Db 1 TTATTATTATTTAT 15

RESULT 183  
AR041924  
LOCUS AR041924 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 714 from patent US 5811300.  
ACCESSION AR041924  
VERSION AR041924.1 GI:5962420  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 714 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 4 a 0 c 0 g 11 t  
Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1041 TTATTATTATGAT 1055  
Db 1 TTATTATTATTTAT 15

RESULT 184  
AR041925  
LOCUS AR041925 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 715 from patent US 5811300.  
ACCESSION AR041925  
VERSION AR041925.1 GI:5962421  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 715 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 4 a 0 c 0 g 11 t  
Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1042 TATTATTATGAT 1056  
Db 1 TATTATTATTTAT 15

RESULT 185  
AR041926  
LOCUS AR041926 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 716 from patent US 5811300.  
ACCESSION AR041926  
VERSION AR041926.1 GI:5962422  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes

Db 1 TTATTATTATTTAT 15

RESULT 183  
AR041924  
LOCUS AR041924 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 714 from patent US 5811300.  
ACCESSION AR041924  
VERSION AR041924.1 GI:5962420  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 714 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 4 a 0 c 0 g 11 t  
Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1041 TTATTATTATGAT 1055  
Db 1 TTATTATTATTTAT 15

RESULT 184  
AR041925  
LOCUS AR041925 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 715 from patent US 5811300.  
ACCESSION AR041925  
VERSION AR041925.1 GI:5962421  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 715 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 4 a 0 c 0 g 11 t  
Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1042 TATTATTATGAT 1056  
Db 1 TATTATTATTTAT 15

RESULT 185  
AR041926  
LOCUS AR041926 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 716 from patent US 5811300.  
ACCESSION AR041926  
VERSION AR041926.1 GI:5962422  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes

```

JOURNAL Patent: US 5811300-A 716 22-SEP-1998;
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unknown"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match
  1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TTATTATTATGTTT 1056
Db 1 TTATTATTATTT 15

RESULT 186
LOCUS AR041931
DEFINITION Sequence 721 from patent US 5811300.
ACCESSION AR041931
VERSION AR041931.1 GI:5962427
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-alpha ribozymes
JOURNAL Patent: US 5811300-A 721 22-SEP-1998;
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unknown"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match
  1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTT 1057
Db 1 ATTATTATTT 15

RESULT 187
LOCUS AR074423/c
DEFINITION Sequence 13 from patent US 5955072.
ACCESSION AR074423
VERSION AR074423.1 GI:10001173
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Takahashi,T., Serizawa,N., Koishi,R. and Kawashima,I.
TITLE Expression systems utilizing autolyzing fusion proteins and a
reducing polypeptide
JOURNAL Patent: US 5955072-A 13 21-SEP-1999;
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unknown"
BASE COUNT      11 a      0 c      0 g      4 t

Query Match
  1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTT 1058
Db 15 TTATTATTT 1

RESULT 188
LOCUS AR041931
DEFINITION Sequence 721 from patent US 5811300.
ACCESSION AR041931
VERSION AR041931.1 GI:5962427
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-alpha ribozymes
JOURNAL Patent: US 5811300-A 721 22-SEP-1998;
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unknown"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match
  1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTT 1057
Db 1 ATTATTATTT 15

RESULT 187
LOCUS AR074423/c
DEFINITION Sequence 13 from patent US 5955072.
ACCESSION AR074423
VERSION AR074423.1 GI:10001173
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Takahashi,T., Serizawa,N., Koishi,R. and Kawashima,I.
TITLE Expression systems utilizing autolyzing fusion proteins and a
reducing polypeptide
JOURNAL Patent: US 5955072-A 13 21-SEP-1999;
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unknown"
BASE COUNT      11 a      0 c      0 g      4 t

Query Match
  1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTT 1058
Db 15 TTATTATTT 1

RESULT 188
LOCUS AR041931
DEFINITION Sequence 721 from patent US 5811300.
ACCESSION AR041931
VERSION AR041931.1 GI:5962427
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-alpha ribozymes
JOURNAL Patent: US 5811300-A 721 22-SEP-1998;
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unknown"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match
  1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTT 1057
Db 1 ATTATTATTT 15

RESULT 187
LOCUS AR074423/c
DEFINITION Sequence 13 from patent US 5955072.
ACCESSION AR074423
VERSION AR074423.1 GI:10001173
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Takahashi,T., Serizawa,N., Koishi,R. and Kawashima,I.
TITLE Expression systems utilizing autolyzing fusion proteins and a
reducing polypeptide
JOURNAL Patent: US 5955072-A 13 21-SEP-1999;
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"
      /note="PCR Primer"
BASE COUNT      11 a      0 c      0 g      4 t

Query Match
  1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTT 1058
Db 15 TTATTATTT 1

RESULT 190
LOCUS AX636858
DEFINITION Sequence 3997 from Patent EP1260586.
ACCESSION AX636858
VERSION AX636858.1 GI:28472472
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,

```

```

ARI174801/c
LOCUS ARI174801
DEFINITION Sequence 13 from patent US 6307038.
ACCESSION ARI174801
VERSION ARI174801.1 GI:17915121
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Takahashi,T., Serizawa,N., Koishi,R. and Kawashima,I.
TITLE Expression systems utilizing autolyzing fusion proteins and a novel
reducing polypeptide
JOURNAL Patent: US 6307038-A 13 23-OCT-2001;
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unknown"
BASE COUNT      11 a      0 c      0 g      4 t

Query Match
  1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTT 1058
Db 15 TTATTATTT 1

RESULT 189
LOCUS AX577646/c
DEFINITION Sequence 13 from Patent EP1251176.
ACCESSION AX577646
VERSION AX577646.1 GI:27646929
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Takahashi,T., Koishi,R., Kawashima,I. and Serizawa,N.
TITLE Expression systems utilizing autolyzing fusion proteins and a
reducing polypeptide
JOURNAL Patent: EP 1251176-A 13 23-OCT-2002;
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"
      /note="PCR Primer"
BASE COUNT      11 a      0 c      0 g      4 t

Query Match
  1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATGTTT 1058
Db 15 TTATTATTT 1

RESULT 190
LOCUS AX636858
DEFINITION Sequence 3997 from Patent EP1260586.
ACCESSION AX636858
VERSION AX636858.1 GI:28472472
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,

```



Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 3997 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
Location/Qualifiers  
1. 15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053  
|||||  
1 ATTATTATTATTT 15

RESULT 191  
AX636860  
LOCUS AX636860 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 3999 from Patent EP1260586.  
ACCESSION AX636860  
VERSION AX636860.1 GI:28472474  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 3997 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
Location/Qualifiers  
1. 15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGAT 1055  
|||||  
1 TTATTATTATTTAT 15

RESULT 192  
AX636862  
LOCUS AX636862 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 4001 from Patent EP1260586.  
ACCESSION AX636862  
VERSION AX636862.1 GI:28472476  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 3997 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
Location/Qualifiers  
1. 15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGAT 1055  
|||||  
1 TTATTATTATTTAT 15

RESULT 193  
AX636874  
LOCUS AX636874 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 4013 from Patent EP1260586.  
ACCESSION AX636874  
VERSION AX636874.1 GI:28472488  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 4013 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
Location/Qualifiers  
1. 15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053  
|||||  
1 ATTATTATTATTT 15

RESULT 194  
AX636876  
LOCUS AX636876 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 4015 from Patent EP1260586.  
ACCESSION AX636876  
VERSION AX636876.1 GI:28472490  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 4013 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
Location/Qualifiers  
1. 15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053  
|||||  
1 ATTATTATTATTT 15

McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 4001 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
Location/Qualifiers  
1. 15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TATTATTATGAT 1056  
|||||  
1 TATTATTATTTAT 15

RESULT 193  
AX636874  
LOCUS AX636874 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 4013 from Patent EP1260586.  
ACCESSION AX636874  
VERSION AX636874.1 GI:28472488  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 4013 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
Location/Qualifiers  
1. 15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053  
|||||  
1 ATTATTATTATTT 15

RESULT 194  
AX636876  
LOCUS AX636876 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 4015 from Patent EP1260586.  
ACCESSION AX636876  
VERSION AX636876.1 GI:28472490  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 4013 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
Location/Qualifiers  
1. 15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATGAT 1053  
|||||  
1 ATTATTATTATTT 15

Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 4015 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)

TITLE  
JOURNAL  
FEATURES  
source

BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGTTAT 1055  
|||||  
1 TTATTATTATTTAT 15

Db

RESULT 195  
AX636878 15 bp mRNA linear PAT 21-FEB-2003  
LOCUS  
DEFINITION Sequence 4017 from Patent EP1260586.  
ACCESSION AX636878  
VERSION AX636878.1 GI:28472492  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.

REFERENCE  
AUTHORS  
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.

TITLE  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 4017 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)

TITLE  
JOURNAL  
FEATURES  
source

BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TATTATTATGTTAT 1056  
|||||  
1 TATTATTATTTAT 15

Db

RESULT 196  
AX636880 15 bp mRNA linear PAT 21-FEB-2003  
LOCUS  
DEFINITION Sequence 4019 from Patent EP1260586.  
ACCESSION AX636880  
VERSION AX636880.1 GI:28472494  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.

REFERENCE  
AUTHORS  
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.

Woolf,T.  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 4019 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)

TITLE  
JOURNAL  
FEATURES  
source

BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTATTT 1057  
|||||  
1 ATTATTATTTATTT 15

Db

RESULT 197  
AX637387 15 bp mRNA linear PAT 21-FEB-2003  
LOCUS  
DEFINITION Sequence 4526 from Patent EP1260586.  
ACCESSION AX637387  
VERSION AX637387.1 GI:28473001  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.

REFERENCE  
AUTHORS  
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.

TITLE  
Method and reagent for inhibiting the expression of disease related genes  
Patent: EP 1260586-A 4526 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)

TITLE  
JOURNAL  
FEATURES  
source

BASE COUNT 4 a 0 c 0 g 11 t

Query Match 1.1%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATGTTATTT 1053  
|||||  
1 ATTATTATTTATTT 15

Db

RESULT 198  
AX637389 15 bp mRNA linear PAT 21-FEB-2003  
LOCUS  
DEFINITION Sequence 4528 from Patent EP1260586.  
ACCESSION AX637389  
VERSION AX637389.1 GI:28473003  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.

REFERENCE  
AUTHORS  
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.

```

TITLE      Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL    Patent: EP 1260586-A 4528 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES   Location/Qualifiers
source     1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. NO. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATCT 1053
      |||||
Db 1 ATTATTATTATTT 15

RESULT 199
AX637391 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4530 from Patent EP1260586.
ACCESSION AX637391
VERSION AX637391.1 GI:28473005
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and
Woolf,T.
TITLE      Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL    Patent: EP 1260586-A 4530 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES   Location/Qualifiers
source     1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. NO. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1039 ATTATTATTATCT 1053
      |||||
Db 1 ATTATTATTATTT 15

RESULT 200
AX637393 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4532 from Patent EP1260586.
ACCESSION AX637393
VERSION AX637393.1 GI:28473007
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and
Woolf,T.
TITLE      Method and reagent for inhibiting the expression of disease related

```

```

Genes
JOURNAL    Patent: EP 1260586-A 4532 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES   Location/Qualifiers
source     1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. NO. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATCTAT 1055
      |||||
Db 1 TTATTATTATTTAT 15

RESULT 201
AX637395 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4534 from Patent EP1260586.
ACCESSION AX637395
VERSION AX637395.1 GI:28473009
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and
Woolf,T.
TITLE      Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL    Patent: EP 1260586-A 4534 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES   Location/Qualifiers
source     1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. NO. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATCTAT 1055
      |||||
Db 1 TTATTATTATTTAT 15

RESULT 202
AX637397 15 bp mRNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 4536 from Patent EP1260586.
ACCESSION AX637397
VERSION AX637397.1 GI:28473011
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and
Woolf,T.
TITLE      Method and reagent for inhibiting the expression of disease related

```

```

JOURNAL Patent: EP 1260586-A 4536 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unidentified"
      /mol_type="mRNA"
      /db_xref="taxon:32644"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TTATTATTATGTTAT 1055
DB 1 TTATTATTATTTAT 15

RESULT 203
AX637399
LOCUS AX637399 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4538 from Patent EP1260586.
ACCESSION AX637399
VERSION AX637399.1 GI:28473013
KEYWORDS
SOURCE
  ORGANISM
    unidentified
    unclassified.
REFERENCE
  1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
    Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
    McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
    Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
    Woolf,T.
  Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 4538 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unidentified"
      /mol_type="mRNA"
      /db_xref="taxon:32644"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1042 TATTATTATGTTAT 1056
DB 1 TATTATTATTTAT 15

RESULT 204
AX637401
LOCUS AX637401 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4540 from Patent EP1260586.
ACCESSION AX637401
VERSION AX637401.1 GI:28473015
KEYWORDS
SOURCE
  ORGANISM
    unidentified
    unclassified.
REFERENCE
  1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
    Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
    McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
    Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
    Woolf,T.
  Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 4540 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unidentified"
      /mol_type="mRNA"
      /db_xref="taxon:32644"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTAT 1057
DB 1 ATTATTATTTAT 15

RESULT 205
AX637411
LOCUS AX637411 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4550 from Patent EP1260586.
ACCESSION AX637411
VERSION AX637411.1 GI:28473025
KEYWORDS
SOURCE
  ORGANISM
    unidentified
    unclassified.
REFERENCE
  1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
    Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
    McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
    Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
    Woolf,T.
  Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 4550 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    Location/Qualifiers
      1..15
      /organism="unidentified"
      /mol_type="mRNA"
      /db_xref="taxon:32644"
BASE COUNT      4 a      0 c      0 g      11 t

Query Match      1.1%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1043 ATTATTATGTTAT 1057
DB 1 ATTATTATTTAT 15

RESULT 206
E11393/c
LOCUS E11393 15 bp DNA linear PAT 29-SEP-1997
DEFINITION DNA probe for detecting human novel enzyme.
ACCESSION E11393
VERSION E11393.1 GI:22025027
KEYWORDS
SOURCE
  ORGANISM
    unidentified
    unclassified.
REFERENCE
  1 (bases 1 to 15)
  Koishi,R., Kawashima,I. and Serizawa,N.
  REDUCTIVE PROTEIN, AND DNA CODING THE SAME
  Patent: JP 1996131178-A 2 28-MAY-1996;
  SANKYO CO LTD
  OS None
  OC Artificial sequences.
  PN JP 1996131178-A/2
  PD 28-MAY-1996
  PF 12-SEP-1995 JP 1995233833

```

```
PR 13-SEP-1994 JP 94P 218392
PI KOISHI RYUTA, KAWASHIMA ICHIRO, SERIZAWA NOBUKI PC
C12N15/09, C07H21/04, C07K16/44, C12N1/21, C12N5/10, PC
C12N15/02,
PC C12P21/02, C12P21/08//A61K38/00, A61K38/00, A61K38/00,
PC A61K38/00,
PC A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00,
PC A61K38/00,
PC A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/44,
PC A61K39/395,
PC
G01N33/53, G01N33/573, G01N33/577, (C12N1/21, C12R1:19), (C12P21/02, PC
C12R1:19),
PC (C12P21/02, C12R1:91), (C12P21/08, C12R1:91);
CC strandcns8: Single;
CC topology: Linear;
CC hypothetical: No;
CC anti-sense: No;
FH Key Location/Qualifiers
FT source 1..15
FT Location/Qualifiers
FEATURES
source 1..15
Location/Qualifiers
BASE COUNT 11 a 0 c 0 g 4 t
Query Match 1..15; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1044 TTATTATGTTATTTA 1058
Db ||||| |||||
15 TTTATTTATTTATTTA 1
RESULT 207
I30514/c
LOCUS 15 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 5 from patent US 5580967.
ACCESSION I30514
VERSION I30514.1 GI:1821305
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Joyce, G.F.
TITLE Optimized catalytic DNA-cleaving ribozymes
JOURNAL Patent: US 5580967-A 5 03-DEC-1996;
FEATURES
source 1..15
Location/Qualifiers
BASE COUNT 12 a 0 c 0 g 3 t
Query Match 1..15; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1047 TTTATGTTATTTATTT 1061
Db ||||| |||||
15 TTTATTTATTTATTT 1
RESULT 208
I30530
LOCUS 15 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 21 from patent US 5580967.
ACCESSION I30530
VERSION I30530.1 GI:1821321
KEYWORDS
QY 1047 TTTATGTTATTTATTT 1061
Db ||||| |||||
15 TTTATTTATTTATTT 1
```

```
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Joyce, G.F.
TITLE Optimized catalytic DNA-cleaving ribozymes
JOURNAL Patent: US 5580967-A 21 03-DEC-1996;
FEATURES
source 1..15
Location/Qualifiers
BASE COUNT 3 a 0 c 0 g 12 t
Query Match 1..15; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1047 TTTATGTTATTTATTT 1061
Db ||||| |||||
1 TTTATTTATTTATTT 15
RESULT 209
I34061
LOCUS 15 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 6 from patent US 5595873.
ACCESSION I34061
VERSION I34061.1 GI:1824852
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Joyce, G.F.
TITLE T. thermophila group I introns that cleave amide bonds
JOURNAL Patent: US 5595873-A 6 21-JAN-1997;
FEATURES
source 1..15
Location/Qualifiers
BASE COUNT 3 a 0 c 0 g 12 t
Query Match 1..15; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1047 TTTATGTTATTTATTT 1061
Db ||||| |||||
1 TTTATTTATTTATTT 15
RESULT 210
I30516
LOCUS 16 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 7 from patent US 5580967.
ACCESSION I30516
VERSION I30516.1 GI:1821307
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Joyce, G.F.
TITLE Optimized catalytic DNA-cleaving ribozymes
JOURNAL Patent: US 5580967-A 7 03-DEC-1996;
FEATURES
source 1..16
Location/Qualifiers
BASE COUNT 3 a 1 c 0 g 12 t
Query Match 1..16; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1047 TTTATGTTATTTATTT 1061
```

```
Db      1 TTTATTATTATTATT 15
/mol type="genomic DNA"
/cultivar="Wassiljewskija"
/db_xref="taxon:3702"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature 9 a 0 c 0 g 7 t
BASE COUNT 9 a 0 c 0 g 7 t
Query Match 1.1%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1140 AATTATTATTATT 1154
Db 16 AATTATTATTATT 2
RESULT 213
A08233
LOCUS A08233 17 bp DNA linear PAT 02-SEP-1993
DEFINITION Synthetic nucleotide asymmetric hybrid sequence 17.
ACCESSION A08233
VERSION A08233.1 GI:411583
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS
JOURNAL
FEATURES
Source
Patent: WO 8909256-A 9 05-OCT-1989;
Location/Qualifiers
1..17
/organism="synthetic construct"
/mol type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 5 a 0 c 2 g 10 t
Query Match 1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1046 ATTATTGTTATTATT 1060
Db 1 ATTAAAGTATTATTATT 15
RESULT 214
A08234/c
LOCUS A08234 17 bp DNA linear PAT 02-SEP-1993
DEFINITION Synthetic nucleotide (reverse complement) asymmetric hybrid
sequence 17.
ACCESSION A08234
VERSION A08234.1 GI:411584
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS
JOURNAL
FEATURES
Source
Patent: WO 8909256-A 10 05-OCT-1989;
Location/Qualifiers
1..17
/organism="synthetic construct"
/mol type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 10 a 0 c 0 g 5 t
Query Match 1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 1046 ATTATGATTTATT 1060  
 Db 17 ATTATGATTTATT 3

RESULT 215  
 A13281  
 LOCUS 17 bp DNA linear PAT 03-JAN-1994  
 DEFINITION oligonucleotide.  
 ACCESSION A13281  
 VERSION A13281.1 GI:491595  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Hollis.M., Pioli.D. and Valenzuela.D.  
 TITLE Regulation of Gene expression  
 JOURNAL Patent: EP 0338690-A 12 25-OCT-1989;  
 IMPERIAL CHEMICAL INDUSTRIES PLC; PRESIDENT AND FELLOWS OF HARVARD  
 COLLEGE; IMPERIAL CHEMICAL INDUSTRIES PLC; THE PRESIDENT AND  
 FELLOWS OF HARVARD COLLEGE  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 BASE COUNT 5 a 2 g 10 t  
 Query Match 1..1%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1046 ATTATGATTTATT 1060  
 Db 1 ATTATGATTTATT 15

RESULT 215  
 A13282/c  
 LOCUS 17 bp DNA linear PAT 03-JAN-1994  
 DEFINITION oligonucleotide.  
 ACCESSION A13282  
 VERSION A13282.1 GI:491596  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Hollis.M., Pioli.D. and Valenzuela.D.  
 TITLE Regulation of Gene expression  
 JOURNAL Patent: EP 0338690-A 13 25-OCT-1989;  
 IMPERIAL CHEMICAL INDUSTRIES PLC; PRESIDENT AND FELLOWS OF HARVARD  
 COLLEGE; IMPERIAL CHEMICAL INDUSTRIES PLC; THE PRESIDENT AND  
 FELLOWS OF HARVARD COLLEGE  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 BASE COUNT 10 a 2 c 0 g 5 t  
 Query Match 1..1%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1046 ATTATGATTTATT 1060  
 Db 17 ATTATGATTTATT 3

RESULT 217  
 AR046177/c

LOCUS AR046177 17 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 970 from patent US 5817796.  
 ACCESSION AR046177  
 VERSION AR046177.1 GI:5967642  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
 TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues  
 JOURNAL Patent: US 5817796-A 970 06-OCT-1998;  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="unknown"  
 BASE COUNT 8 a 0 c 0 g 9 t  
 Query Match 1..1%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1617 AAAATATATTTTGT 1631  
 Db 16 AAAATATATTTT 2

RESULT 218  
 AR047258/c  
 LOCUS 17 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 2051 from patent US 5817796.  
 ACCESSION AR047258  
 VERSION AR047258.1 GI:5968723  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
 TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues  
 JOURNAL Patent: US 5817796-A 2051 06-OCT-1998;  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="unknown"  
 BASE COUNT 8 a 0 c 1 g 8 t  
 Query Match 1..1%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1617 AAAATATATTTTGT 1631  
 Db 16 AAAATATATTTT 2

RESULT 219  
 AR053084/c  
 LOCUS 17 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 54 from patent US 5834181.  
 ACCESSION AR053084  
 VERSION AR053084.1 GI:5977946  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Shuber,A.P.  
 TITLE High throughput screening method for sequences or genetic  
 alterations in nucleic acids  
 JOURNAL Patent: US 5834181-A 54 10-NOV-1998;  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="unknown"  
 BASE COUNT 1 a 1 c 3 g 12 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1207 AACAAACAACAAT 1221  
Db 16 AACAAACAACAAT 2  
|||||

RESULT 220  
AR065045/c 17 bp DNA PAT 29-SEP-1999  
LOCUS Sequence 54 from patent US 5849483.  
DEFINITION AR065045  
ACCESSION AR065045.1 GI:5995261  
VERSION AR065045.1  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Shuber,A.P.  
TITLE High throughput screening method for sequences or genetic alterations in nucleic acids  
JOURNAL Patent: US 5849483-A 54 15-DEC-1998;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 1 a 1 c 3 g 12 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1207 AACAAACAACAAT 1221  
Db 16 AACAAACAACAAT 2  
|||||

RESULT 221  
AR186811/c 17 bp DNA PAT 20-APR-2002  
LOCUS Sequence 2299 from patent US 6346398.  
DEFINITION AR186811  
ACCESSION AR186811.1 GI:20232776  
VERSION AR186811.1  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 2299 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 7 a 3 c 2 g 5 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 749 TAGAATGTGATTT 763  
Db 17 TAGAATGTGACATT 3  
|||||

RESULT 222  
AR187297 17 bp DNA PAT 20-APR-2002  
LOCUS Sequence 2785 from patent US 6346398.  
DEFINITION AR187297  
ACCESSION

VERSION AR187297.1 GI:2023262  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 2785 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 9 a 2 c 0 g 6 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 803 ATAAAGTCAATTTA 817  
Db 2 ATAAAGTCAATTTA 16  
|||||

RESULT 223  
AR192330/c 17 bp DNA PAT 20-APR-2002  
LOCUS Sequence 7818 from patent US 6346398.  
DEFINITION AR192330  
ACCESSION AR192330.1 GI:20238295  
VERSION AR192330.1  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 7818 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 0 a 0 c 2 g 15 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 616 ACAAAAACAACAA 630  
Db 15 ACAAAAACAACAA 1  
|||||

RESULT 224  
AX421942/c 17 bp mRNA PAT 18-JUN-2002  
LOCUS Sequence 278 from Patent WO0188124.  
DEFINITION AX421942  
ACCESSION AX421942.1 GI:21525324  
VERSION AX421942.1  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and Randi,A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 278 22-NOV-2001;  
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)  
Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"



```
QY 1504 ATTTTAAATACAG 1518
Db 16 ATTTTAAATACAG 2

/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 8 a 2 c 1 g 6 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 225
AX421943/c
LOCUS AX421943 Sequence 279 from Patent WO188124.
DEFINITION AX421943
ACCESSION AX421943
VERSION AX421943.1 GI:21525325
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, P.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 2 c 2 g 6 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1504 ATTTTAAATACAG 1518
Db 15 ATTTTAAATACAG 1

/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 2 c 2 g 6 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 226
AX500363/c
LOCUS AX500363 Sequence 1670 from Patent EPI229046.
DEFINITION AX500363
ACCESSION AX500363
VERSION AX500363.1 GI:23382656
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1670 07-AUG-2002;
Aeonica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 3 a 1 c 1 g 12 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 677 TACAATAGCAAAAT 691
Db 17 TAAAATAGCAAAAT 3

/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 2 c 1 g 10 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 675 TATCAATAGCAAA 689
Db 15 TATAAATAGCAAA 1

/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 2 c 1 g 10 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 227
AX500367/c
LOCUS AX500367 Sequence 1674 from Patent EPI229046.
DEFINITION AX500367
ACCESSION AX500367
VERSION AX500367.1 GI:23382660
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1674 07-AUG-2002;
Aeonica, Inc. (US)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 2 c 1 g 10 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 228
AX672147
LOCUS AX672147 Sequence 592 from Patent WO03004536.
DEFINITION AX672147
ACCESSION AX672147
VERSION AX672147.1 GI:29330495
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman, A., Anson, R. and Tuijnder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 592 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 8 a 3 c 3 g 3 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 534 TCAGTAAACAAATGAA 548
Db 3 TCAGTAAACAAATGAA 17

/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 8 a 3 c 3 g 3 t

Query Match 1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 229
AX722330
```

```

LOCUS       AX722330                      17 bp      DNA          linear      PAT 08-MAY-2003
DEFINITION   Sequence 17 from Patent WO03025176.
ACCESSION    AX722330
VERSION      AX722330.1  GI:30422831
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 17 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     Location/Qualifiers
              source
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   12 a 2 c 1 g 2 t

Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 612 ATCTACAAAAACAA 626
Db 2 ATCTACAAAAAAA 16

RESULT 230
LOCUS       AX724050                      17 bp      DNA          linear      PAT 08-MAY-2003
DEFINITION   Sequence 1737 from Patent WO03025176.
ACCESSION    AX724050
VERSION      AX724050.1  GI:30503393
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 1737 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     Location/Qualifiers
              source
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   4 a 6 c 3 g 4 t

Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 424 TGAAGATGCCAGTGA 438
Db 17 TGAAGATGCCGTGA 3

RESULT 231
LOCUS       AX724812                      17 bp      DNA          linear      PAT 08-MAY-2003
DEFINITION   Sequence 2499 from Patent WO03025176.
ACCESSION    AX724812
VERSION      AX724812.1  GI:30504155
KEYWORDS

```

```

SOURCE       Mus musculus (house mouse)
ORGANISM     Mus musculus
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 2499 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     Location/Qualifiers
              source
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   1 a 3 c 3 g 10 t

Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 825 ATCTCGGATTTTTT 839
Db 2 ATCTCGGATTTTTT 16

RESULT 232
LOCUS       AX725086                      17 bp      DNA          linear      PAT 08-MAY-2003
DEFINITION   Sequence 2773 from Patent WO03025176.
ACCESSION    AX725086
VERSION      AX725086.1  GI:30504429
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 2773 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     Location/Qualifiers
              source
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   8 a 1 c 3 g 5 t

Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1237 ATTTCATTTCAGAT 1251
Db 16 ATTTCATTTCAGAT 2

RESULT 233
LOCUS       AX725462                      17 bp      DNA          linear      PAT 08-MAY-2003
DEFINITION   Sequence 3149 from Patent WO03025176.
ACCESSION    AX725462
VERSION      AX725462.1  GI:30504805
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus
REFERENCE    1

```

AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
 JOURNAL Patent: WO 03025176-A 3149 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Mus musculus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:10090"  
 6 a 4 c 1 g 6 t  
 BASE COUNT 6 a 4 c 1 g 6 t  
 Query Match 1.1%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 458 TCAACACTTCATGTA 472  
 Db 3 TCAACACTTCATGTA 17  
 RESULT 234  
 LOCUS AX728738 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 372 from Patent WO03025175.  
 ACCESSION AX728738  
 VERSION AX728738.1 GI:30508081  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
 JOURNAL Patent: WO 03025175-A 372 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 8 a 3 c 3 g 3 t  
 BASE COUNT 8 a 3 c 3 g 3 t  
 Query Match 1.1%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 534 TCAGTACCAATGAA 548  
 Db 3 TCAGTACCAATGAA 17  
 RESULT 235  
 LOCUS AX729041/c 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 675 from Patent WO03025175.  
 ACCESSION AX729041  
 VERSION AX729041.1 GI:30508384  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
 JOURNAL Patent: WO 03025175-A 675 27-MAR-2003;

FEATURES Molecular Engines Laboratories (FR)  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 9 a 1 c 3 g 4 t  
 BASE COUNT 9 a 1 c 3 g 4 t  
 Query Match 1.1%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1237 ATTTCATTTCAGAT 1251  
 Db 16 ATTTCATTTCAGAT 2  
 RESULT 236  
 LOCUS AX733613 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 5247 from Patent WO03025175.  
 ACCESSION AX733613  
 VERSION AX733613.1 GI:30512956  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
 JOURNAL Patent: WO 03025175-A 5247 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 6 a 1 c 2 g 8 t  
 BASE COUNT 6 a 1 c 2 g 8 t  
 Query Match 1.1%; Score 13.4; DB 1; Length 17;  
 Best Local Similarity 93.3%; Pred. No. 3.1e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1149 TTATTTAGATATTA 1163  
 Db 3 TCATTTAGATATTA 17  
 RESULT 237  
 LOCUS AX736985 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 2575 from Patent WO03025177.  
 ACCESSION AX736985  
 VERSION AX736985.1 GI:30516273  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 2575 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"

```

BASE COUNT      8 a      2 c      3 g      4 t
Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 534 TCAGTAACAATGAA 548
Db 3 TCAGTATACAAATGAA 17

RESULT 238
AX738625
LOCUS      AX738625
DEFINITION Sequence 4215 from Patent WO03025177.
ACCESSION  AX738625
VERSION     AX738625.1 GI:30517915
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE      Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL    Telerman,A., Anson,R. and Tuijinder,M.
FEATURES   Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
            Patent: WO 03025177-A 4215 27-MAR-2003;
            Molecular Engines Laboratories (PR)
            Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      8 a      3 c      3 g      3 t
Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 534 TCAGTAACAATGAA 548
Db 3 TCAGTATACAAATGAA 17

RESULT 239
I04892/c
LOCUS      I04892
DEFINITION Sequence 16 from Patent EP 0215594.
ACCESSION  I04892
VERSION     I04892.1 GI:591423
KEYWORDS   Unknown.
SOURCE     Unclassified.
ORGANISM   Berka,R.M., Cullen,D., Gray,G.L., Hayenga,K.J. and Lawlis,V.B.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Heterologous polypeptide expressed in filamentous fungi, processes
TITLE      for their preparation, and vectors for their preparation
JOURNAL    Patent: EP 0215594-A2 16 25-MAR-1987;
FEATURES   Location/Qualifiers
            source
            1..17
            /organism="unknown"
BASE COUNT      11 a      2 c      0 g      4 t
Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1047 TTTATGTTATTTATTT 1061
Db 17 TTTATGTTATTTATTT 3

RESULT 240
I32590/c
LOCUS      I32590
DEFINITION Sequence 54 from patent US 5569330.
ACCESSION  I32590
VERSION     I32590.1 GI:1823381
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Shuber,A.P.
TITLE      High-throughput screening method for sequence or genetic
            alterations in nucleic acids using elution and sequencing of
            complementary oligonucleotides
            Patent: US 5589330-A 54 31-DEC-1996;
            Location/Qualifiers
            source
            1..17
            /organism="unknown"
BASE COUNT      1 a      1 c      3 g      12 t
Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1207 AACAAACAAACAAT 1221
Db 16 AACAAACAAACAAT 2

RESULT 241
I53229/c
LOCUS      I53229
DEFINITION Sequence 970 from patent US 5646042.
ACCESSION  I53229
VERSION     I53229.1 GI:2474432
KEYWORDS   Unknown.
SOURCE     Unclassified.
ORGANISM   1 (bases 1 to 17)
REFERENCE  Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
AUTHORS    C-myb targeted ribozymes
TITLE      Patent: US 5646042-A 970 08-JUL-1997;
JOURNAL    Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
BASE COUNT      8 a      0 c      0 g      9 t
Query Match      1.1%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1617 AAAATATATTTGTT 1631
Db 16 AAAATATATTTTTT 2

RESULT 242
I54310/c
LOCUS      I54310
DEFINITION Sequence 2051 from patent US 5646042.
ACCESSION  I54310
VERSION     I54310.1 GI:2475513
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 17)
AUTHORS    Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE      C-myb targeted ribozymes
```

```
JOURNAL Patent: US 5646042-A 2051 08-JUL-1997;
FEATURES
  source
    1.17
    /organism="unknown"
BASE COUNT      8 a      0 c      1 g      8 t

Query Match
  Best Local Similarity 1.1%; Score 13.4; DB 1; Length 17;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1617 AAAATATAATTTGTT 1631
Db 16 AAAATATAATTTT 2

RESULT 243
AR087081
LOCUS AR087081 18 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 31 from patent US 5985664.
ACCESSION AR087081
VERSION AR087081.1 GI:10013847
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 18)
  Baker,B.F. and Cowser,L.M.
  TITLE
  Antisense modulation of Sentrin expression
  JOURNAL
  Patent: US 5985664-A 31 16-NOV-1999;
FEATURES
  source
    1.18
    /organism="unknown"
BASE COUNT      8 a      4 c      1 g      5 t

Query Match
  Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1179 GATAAATTCATCA 1193
Db 1 GATAAATTCATCA 15

RESULT 244
AR165969
LOCUS AR165969 18 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 22 from patent US 6280942.
ACCESSION AR165969
VERSION AR165969.1 GI:16241085
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 18)
  Morishima,N., Mizumura,H. and Shibata,T.
  TITLE
  Endonuclease
  JOURNAL
  Patent: US 6280942-A 22 28-AUG-2001;
FEATURES
  source
    1.18
    /organism="unknown"
BASE COUNT      4 a      1 c      4 g      9 t

Query Match
  Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1282 ATTATTGTTATCTG 1296
Db 3 ATTATTGTTATCTG 17

RESULT 245
AR285276
LOCUS AR285276 18 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 22 from patent US 6528296.
ACCESSION AR285276
VERSION AR285276.1 GI:29722376
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1 (bases 1 to 18)
  Morishima,N., Mizumura,H. and Shibata,T.
  TITLE
  Endonuclease
  JOURNAL
  Patent: US 6528296-A 22 04-MAR-2003;
FEATURES
  source
    1.18
    /organism="unknown"
BASE COUNT      4 a      1 c      4 g      9 t

Query Match
  Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1282 ATTATTGTTATCTG 1296
Db 3 ATTATTGTTATCTG 17

RESULT 246
AX032800
LOCUS AX032800 18 bp DNA linear PAT 21-SEP-2000
DEFINITION Sequence 40 from Patent WO0046358.
ACCESSION AX032800
VERSION AX032800.1 GI:10279776
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1
  Dean,C., West,J. and Johanson,U.
  TITLE
  Plant Gene
  JOURNAL
  Patent: WO 0046358-A 40 10-AUG-2000;
  DEAN CAROLINE (GB) ; WEST JOANNE (GB) ; PLANT BIOSCIENCE LTD (GB) ;
  JOHANSON URBAN (SE)
FEATURES
  source
    1.18
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"
    /note="Primer"
BASE COUNT      3 a      4 c      3 g      8 t

Query Match
  Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;
  Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1545 TTTTATGTCCTCTCC 1559
Db 4 TTTGATGTCCTCTCC 18

RESULT 247
AX092726
LOCUS AX092726 18 bp DNA linear PAT 21-MAR-2001
DEFINITION Sequence 138 from Patent WO0115676.
ACCESSION AX092726
VERSION AX092726.1 GI:13444783
KEYWORDS
SOURCE
ORGANISM
REFERENCE
  1
  Hayden,M.R., Brooks-Wilson,A.R., Pimstone,S.N. and Clee,S.M.
  TITLE
  Compositions and methods for modulating hdl cholesterol and
```

triglyceride levels  
 Patent: WO 0115676-A 138 08-MAR-2001;  
 University of British Columbia (CA); Xenon Genetics Inc. (CA)

FEATURES  
 source  
 1. .18  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"

BASE COUNT  
 10 a 1 c 5 g 2 t

Query Match  
 Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 705 AGAGAAATATCCGAA 719  
 Db 2 AGAGAAATATCAGNA 16

RESULT 248  
 AX643248/c  
 LOCUS  
 DEFINITION  
 Sequence 114 from Patent WO2099099.  
 ACCESSION  
 AX643248  
 VERSION  
 AX643248.1 GI:28550445  
 KEYWORDS  
 synthetic construct  
 ORGANISM  
 synthetic construct  
 artificial sequences.

REFERENCE  
 1  
 Penger, A., Sprenger, R. and Brinkmann, U.  
 Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8  
 and their use in diagnostic and therapeutic applications  
 Patent: WO 02099099-A 114 12-DEC-2002;  
 Epidauros Biotechnologie AG (DE)

FEATURES  
 source  
 1. .18  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"

BASE COUNT  
 4 a 0 c 3 g 11 t

Query Match  
 Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 998 CATCAATACATAAAT 1012  
 Db 17 CATATAACATAAAT 3

RESULT 249  
 AX643251  
 LOCUS  
 DEFINITION  
 Sequence 117 from Patent WO2099099.  
 ACCESSION  
 AX643251  
 VERSION  
 AX643251.1 GI:28550449  
 KEYWORDS  
 synthetic construct  
 ORGANISM  
 synthetic construct  
 artificial sequences.

REFERENCE  
 1  
 Penger, A., Sprenger, R. and Brinkmann, U.  
 Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8  
 and their use in diagnostic and therapeutic applications  
 Patent: WO 02099099-A 117 12-DEC-2002;  
 Epidauros Biotechnologie AG (DE)

FEATURES  
 source  
 1. .18  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"

BASE COUNT  
 11 a 3 c 0 g 4 t

Query Match  
 Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 998 CATCAATACATAAAT 1012  
 Db 2 CATATAACATAAAT 16

RESULT 250  
 E60081  
 LOCUS  
 DEFINITION  
 Endonuclease.  
 ACCESSION  
 E60081  
 VERSION  
 E60081.1 GI:13023331  
 KEYWORDS  
 JP 2000041686-A/21  
 SOURCE  
 synthetic construct  
 ORGANISM  
 synthetic construct  
 artificial sequences.

REFERENCE  
 1 (bases 1 to 18)  
 Nobuhiro, M., Hikaru, M. and Takehiko, S.  
 Endonuclease  
 Patent: JP 2000041686-A 21 15-FEB-2000;  
 RIXAGAKU KENKYUSHO  
 CS Artificial Sequence  
 PN JP 2000041686-A/21  
 PD 15-FEB-2000  
 PF 24-MAY-1999 JP 1999144005  
 PR  
 PI NOBUHIRO MORISHIMA, HIKARU WIZUMURA, TAKEHIKO SHIBATA PC  
 C12N15/09, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12N9/16// PC  
 C12N15/16, C12R1/19, C12N15/00, C12N5/00  
 CC  
 FH Key  
 FT source  
 Location/Qualifiers  
 1. .18  
 /organism="Artificial Sequence".

FEATURES  
 source  
 1. .18  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"

BASE COUNT  
 4 a 1 c 4 g 9 t

Query Match  
 Best Local Similarity 1.1%; Score 13.4; DB 1; Length 18;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1282 ATTATTGTTATCTG 1296  
 Db 3 ATTATTGTTATCTG 17

RESULT 251  
 AR293234  
 LOCUS  
 DEFINITION  
 Sequence 4969 from patent US 6537751.  
 ACCESSION  
 AR293234  
 VERSION  
 AR293234.1 GI:31680518  
 KEYWORDS  
 UNKNOWN.  
 ORGANISM  
 UNKNOWN.  
 UNCLASSIFIED.

REFERENCE  
 1 (bases 1 to 19)  
 Cohen, D., Chumakov, I. and Blumenfeld, M.  
 Biallelic markers for use in constructing a high density  
 disequilibrium map of the human genome  
 Patent: US 6537751-A 4969 25-MAR-2003;  
 Location/Qualifiers  
 1. .19  
 /organism="unknown"

BASE COUNT  
 2 a 5 c 2 g 10 t

Query Match 1.1%; Score 13.4; DB 1; Length 19;  
 Best Local Similarity 93.3%; Pred. No. 3.7e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1567 TTTTACTGTTCTCA 1581  
 |||||  
 Db 1 TTTTACTGTTCTCA 15

RESULT 252  
 AX079136/c  
 LOCUS 19 bp DNA linear PAT 22-FEB-2001  
 DEFINITION Sequence 16 from Patent WO0106004.  
 ACCESSION AX079136  
 VERSION AX079136.1 GI:13158709  
 KEYWORDS synthetic construct  
 ORGANISM synthetic construct  
 SOURCE artificial sequences.  
 REFERENCE 1  
 AUTHORS Richardson,P. and Cox,P.  
 TITLE A method for amplifying low abundance nucleic acid sequences and means for performing said method  
 JOURNAL Patent: WO 0106004-A 16 25-JAN-2001;  
 CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB)  
 FEATURES Location/Qualifiers  
 source 1..19  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 /note="oligonucleotide"  
 BASE COUNT 6 a 6 c 4 g 3 t  
 Query Match 1.1%; Score 13.4; DB 1; Length 19;  
 Best Local Similarity 93.3%; Pred. No. 3.7e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1348 GCCAGCTGTTCTGT 1362  
 |||||  
 Db 19 GCCAGCTTCTGT 5

RESULT 253  
 AX130601/c  
 LOCUS 19 bp DNA linear PAT 15-MAY-2001  
 DEFINITION Sequence 1819 from Patent WO0130362.  
 ACCESSION AX130601  
 VERSION AX130601.1 GI:14136906  
 KEYWORDS Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Robbins,J.M. and Tritz,R.  
 TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
 JOURNAL Patent: WO 0130362-A 1819 03-MAY-2001;  
 IMMUSOL, INC. (US)  
 FEATURES Location/Qualifiers  
 source 1..19  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /note="Cyclin C ribozyme binding site"  
 BASE COUNT 8 a 3 c 4 g 4 t  
 Query Match 1.1%; Score 13.4; DB 1; Length 19;  
 Best Local Similarity 93.3%; Pred. No. 3.7e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 913 TTTTATTCTAAGTGG 927  
 |||||

Db 19 TTTATTCCAACTGG 5

RESULT 254  
 AX149204/c  
 LOCUS 19 bp DNA linear PAT 08-JUN-2001  
 DEFINITION Sequence 406 from Patent WO0136625.  
 ACCESSION AX149204  
 VERSION AX149204.1 GI:14347728  
 KEYWORDS synthetic construct  
 ORGANISM synthetic construct  
 SOURCE artificial sequences.  
 REFERENCE 1  
 AUTHORS Wright,J.A., Young,A.H. and Dugourd,D.  
 TITLE Antisense oligonucleotide sequences derived from groel and groes as inhibitors of microorganisms  
 JOURNAL Patent: WO 0136625-A 406 25-MAY-2001;  
 GeneSense Technologies Inc. (CA)  
 FEATURES Location/Qualifiers  
 source 1..19  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 /note="Antisense oligonucleotide"  
 BASE COUNT 6 a 1 c 0 g 12 t  
 Query Match 1.1%; Score 13.4; DB 1; Length 19;  
 Best Local Similarity 93.3%; Pred. No. 3.7e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1591 AATATAAAGTAAAT 1605  
 |||||  
 Db 15 AATATAAATTAAT 1

RESULT 255  
 AX183607  
 LOCUS 19 bp DNA linear PAT 06-AUG-2001  
 DEFINITION Sequence 1360 from Patent WO0142511.  
 ACCESSION AX183607  
 VERSION AX183607.1 GI:15134927  
 KEYWORDS Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Daly,M., Hudson,T.J., Lander,E.S., Rioux,J. and Siminovitch,K.  
 TITLE Ibd-related polymorphisms  
 JOURNAL Patent: WO 0142511-A 1360 14-JUN-2001;  
 WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Ellipsis  
 Biotherapeutics Corporation (CA)  
 FEATURES Location/Qualifiers  
 source 1..19  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 5 a 1 g 12 t 1 others  
 Query Match 1.1%; Score 13.4; DB 1; Length 19;  
 Best Local Similarity 87.5%; Pred. No. 3.7e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1140 AAATTATTATTATT 1155  
 |||||  
 Db 4 AAATTATTATTATT 19

RESULT 256  
 I31433/c  
 LOCUS 19 bp DNA linear PAT 06-FEB-1997  
 DEFINITION Sequence 345 from patent US 5562979.

```
ACCESSION I31433
VERSION I31433.1 GI:18222224
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Weber J.L.
TITLE Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and
JOURNAL Patent: US 5582979-A 345 10-DEC-1996;
FEATURES Location/Qualifiers
source 1..19
BASE COUNT 4 a 10 c 1 g 4 t
Query Match 1.1%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. NO. 3.7e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 957 AGTGATGTTGTGAGG 971
Db 17 AGTGATGTTGTGAGG 3

RESULT 257
LOCUS A67082 18 bp DNA linear PAT 29-MAR-1999
DEFINITION Sequence 249 from Patent WO9740193.
ACCESSION A67082
VERSION A67082.1 GI:4538453
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stuyver, L., Rossau, R. and Maertens, G.
TITLE METHOD FOR TYPING AND DETECTING HBV
JOURNAL Patent: WO 9740193-A 249 30-OCT-1997;
INNOGENETICS NV (BE)
FEATURES Location/Qualifiers
source 1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 7 a 0 c 4 g 7 t
Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. NO. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1123 TATAAGATGTTATAGTA 1140
Db 1 TATATGGATGATATAGTA 18

RESULT 258
LOCUS A67087 18 bp DNA linear PAT 29-MAR-1999
DEFINITION Sequence 254 from Patent WO9740193.
ACCESSION A67087
VERSION A67087.1 GI:4538458
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stuyver, L., Rossau, R. and Maertens, G.
TITLE METHOD FOR TYPING AND DETECTING HBV
JOURNAL Patent: WO 9740193-A 254 30-OCT-1997;
INNOGENETICS NV (BE)
FEATURES Location/Qualifiers
source 1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 7 a 0 c 4 g 7 t
Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. NO. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1123 TATAAGATGTTATAGTA 1140
Db 1 TATATGGATGATATAGTA 18

RESULT 259
LOCUS A67088 18 bp DNA linear PAT 29-MAR-1999
DEFINITION Sequence 255 from Patent WO9740193.
ACCESSION A67088
VERSION A67088.1 GI:4538459
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stuyver, L., Rossau, R. and Maertens, G.
TITLE METHOD FOR TYPING AND DETECTING HBV
JOURNAL Patent: WO 9740193-A 255 30-OCT-1997;
INNOGENETICS NV (BE)
FEATURES Location/Qualifiers
source 1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 7 a 0 c 3 g 8 t
Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. NO. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1123 TATAAGATGTTATAGTA 1140
Db 1 TATATAGATGATATCGTA 18

RESULT 260
LOCUS A67090 18 bp DNA linear PAT 29-MAR-1999
DEFINITION Sequence 257 from Patent WO9740193.
ACCESSION A67090
VERSION A67090.1 GI:4538461
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stuyver, L., Rossau, R. and Maertens, G.
TITLE METHOD FOR TYPING AND DETECTING HBV
JOURNAL Patent: WO 9740193-A 257 30-OCT-1997;
INNOGENETICS NV (BE)
FEATURES Location/Qualifiers
source 1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 7 a 0 c 4 g 7 t
Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. NO. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1123 TATAAGATGTTATAGTA 1140
Db 1 TATATGGATGATATAGTA 18

RESULT 261
LOCUS A67091 18 bp DNA linear PAT 29-MAR-1999
DEFINITION Sequence 258 from Patent WO9740193.
ACCESSION A67091
VERSION A67091.1 GI:4538462
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stuyver, L., Rossau, R. and Maertens, G.
TITLE METHOD FOR TYPING AND DETECTING HBV
JOURNAL Patent: WO 9740193-A 258 30-OCT-1997;
INNOGENETICS NV (BE)
FEATURES Location/Qualifiers
source 1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 7 a 0 c 4 g 7 t
Query Match 1.1%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. NO. 3.8e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1123 TATAAGATGTTATAGTA 1140
Db 1 TATATGGATGATATAGTA 18
```



Db 1 TATGTAGATGATATAGTA 18

RESULT 261  
A81026  
LOCUS 18 bp DNA linear PAT 21-JAN-2000  
DEFINITION Sequence 5 from Patent EP0916726.  
ACCESSION A81026  
VERSION A81026.1 GI:6731598  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1 (bases 1 to 18)  
TITLE Attaching substances to micro-organisms  
JOURNAL Patent: EP 0916726-A 5 19-MAY-1999;  
UNIV GROWINGEN (NL)  
FEATURES  
source 1. .18  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
BASE COUNT 7 a 2 c 2 g 7 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;  
Best Local Similarity 83.3%; Pred. No. 3.8e+02;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1313 AACAACTCCTAGTTTGATA 1330  
Db 1 AGCAATAGTATTGTTATA 18

RESULT 262  
A95480  
LOCUS 18 bp DNA linear PAT 26-JAN-2000  
DEFINITION Sequence 5 from Patent WO925836.  
ACCESSION A95480  
VERSION A95480.1 GI:6779514  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Leenhouts, C.J. and Buist, G.  
TITLE ATTACHING SUBSTANCES TO MICRO-ORGANISMS  
JOURNAL Patent: WO 925836-A 5 27-MAY-1999;  
LEENHOUTS CORNELIS JOHANNES (NL); BUIST GIRBE (NL)  
FEATURES  
source 1. .18  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
BASE COUNT 7 a 2 c 2 g 7 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;  
Best Local Similarity 83.3%; Pred. No. 3.8e+02;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1313 AACAACTCCTAGTTTGATA 1330  
Db 1 AGCAATAGTATTGTTATA 18

RESULT 263  
AR130089/c  
LOCUS 18 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 81 from patent US 6187586.  
ACCESSION AR130089  
VERSION AR130089.1 GI:14117986  
KEYWORDS  
SOURCE Unknown.

ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Montu, B.P., Cowsett, L.M. and Roth, R.A.  
TITLE Antisense modulation of AKT-3 expression  
JOURNAL Patent: US 6187586-A 81 13-FEB-2001;  
FEATURES  
source 1. .18  
/organism="unknown"  
BASE COUNT 3 a 3 c 1 g 11 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;  
Best Local Similarity 83.3%; Pred. No. 3.8e+02;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1596 AAAAGTAAATATGAACA 1613  
Db 18 AAAAGAAATTATGACCA 1

RESULT 264  
AR208426/c  
LOCUS 18 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 6 from patent US 6383754.  
ACCESSION AR208426  
VERSION AR208426.1 GI:21509577  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Kaufman, J.C., Roth, M.E., Lizardi, P.M., Peng, L. and Latimer, D.R.  
TITLE Binary encoded sequence tags  
JOURNAL Patent: US 6383754-A 6 07-MAY-2002;  
FEATURES  
source 1. .18  
/organism="unknown"  
BASE COUNT 0 a 0 c 1 g 17 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;  
Best Local Similarity 83.3%; Pred. No. 3.8e+02;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 616 ACACAAAACACACATATA 633  
Db 18 ACACAAAACACACATATA 1

RESULT 265  
AR222905  
LOCUS 18 bp DNA linear PAT 26-SEP-2002  
DEFINITION Sequence 15 from patent US 6432639.  
ACCESSION AR222905  
VERSION AR222905.1 GI:23330742  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Lichter, J.B. and Guida, M.  
TITLE Isolated CYP3A4 nucleic acid molecules and detection methods  
JOURNAL Patent: US 6432639-A 15 13-AUG-2002;  
FEATURES  
source 1. .18  
/organism="unknown"  
BASE COUNT 10 a 2 c 6 g 0 t

Query Match 1.1%; Score 13.2; DB 1; Length 18;  
Best Local Similarity 83.3%; Pred. No. 3.8e+02;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 414 CAGATCATGTCAGATG 431

[illegible]

```

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1570 TACTGTTCTGATGAT 1587
      |||||
      18 TACTGTTCTGATTTT 1

Db

RESULT 271
AX599270
LOCUS
DEFINITION
Sequence 610 from Patent WO02077272.
ACCESSION
AX599270
VERSION
AX599270.1 GI:28399412
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
artificial sequences.
REFERENCE
1
AUTHORS
Berlin, K., Braun, A., Distler, J., Guetig, D., Howe, A., Mueller, J.,
Olek, A., Piepenbrock, C., Adorjan, P., Grabe, G., Lesche, R., Ieu, R.,
Lewin, A., Lipscher, R., Maier, S., Model, F., Mueller, V., Otto, T.,
Pelet, C. and Ziebarth, H.
TITLE
Methods and nucleic acids for the analysis of hematopoietic cell
proliferative disorders
JOURNAL
Patent: WO 02077272-A 610 03-OCT-2002;
Epigenomics AG (DE)
FEATURES
Location/Qualifiers
source
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Detection oligonucleotide for MYOD1"
BASE COUNT
7 a 0 c 4 g 7 t

Query Match
Best Local Similarity 83.3%; Score 13.2; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1457 GTTATTATGACAAATA 1474
      |||||
      1 GGTATTATGACAAATA 18

Db

RESULT 272
BD104062
LOCUS
DEFINITION
Kit and method for determining HLA type.
ACCESSION
BD104062
VERSION
BD104062.1 GI:22649636
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
artificial sequences.
REFERENCE
1 (bases 1 to 18)
AUTHORS
Inoko, H., Kagiya, T., Ichihara, T., Matsumura, Y., Moriya, S. and
Nishida, M.
TITLE
Kit and method for determining HLA type
JOURNAL
Patent: WO 0192572-A 166 06-DEC-2001;
NTSSHINO INDUSTRIES INC. SYSTEM RESEARCH INC. HIDEOTOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
NISHIDA
COMMENT
OS Artificial Sequence
PN WO 0192572-A/166
PD 06-DEC-2001
PR 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP OOP 164798
PI HIDEOTOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA, MICHIO NISHIDA
PC C12Q1/68, C12M1/00, C12N15/09, G01N33/53
CC Description of Artificial Sequence: capture
FH Key
FT source
1..18

```

```

FEATURES
source
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT
5 a 2 c 4 g 7 t

Query Match
Best Local Similarity 83.3%; Score 13.2; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 519 GCTTAAATTTGAAATTC 536
      |||||
      1 GCTTAAATTTGAAATTC 18

Db

RESULT 273
I25305/c
LOCUS
DEFINITION
Sequence 92 from patent US 5550020.
ACCESSION
I25305
VERSION
I25305.1 GI:1605175
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 18)
AUTHORS
Gallie, B.L., Dunn, J.M. and Stevens, J.K.
TITLE
Method, reagents and kit for diagnosis and targeted screening for
retinoblastoma
JOURNAL
Patent: US 5550020-A 92 27-AUG-1996;
FEATURES
Location/Qualifiers
source
1..18
/organism="unknown"
BASE COUNT
10 a 3 c 1 g 4 t

Query Match
Best Local Similarity 83.3%; Score 13.2; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1566 TTTTACTGTTCTGATT 1583
      |||||
      18 TTTTACTGTTCTGATT 1

Db

RESULT 274
ATH529366
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
185F08.
ACCESSION
AJ529366
VERSION
AJ529366.1 GI:26797626
KEYWORDS
left border; T-DNA flanking sequence.
SOURCE
Arabidopsis thaliana (thale cress)
ORGANISM
Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.
REFERENCE
1
AUTHORS
Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,
Lepoint, L., Caboche, M. and Lecharny, A.
TITLE
T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
JOURNAL
EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE
22363535
PUBMED
12446565
REFERENCE
2 (bases 1 to 18)
AUTHORS
Balzerque, S.
TITLE
Direct Submission
JOURNAL
Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE

```

COMMENT PCR was performed on DNA from transformants of *Arabidopsis thaliana* plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbgap.versailles.inra.fr/publicines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.inbioigen.fr>).

FEATURES  
source  
1..18  
/organism="Arabidopsis thaliana"  
/mol\_type="genomic DNA"  
/cultivar="Massillowskija"  
/db\_xref="taxon:3702"  
/clone="185P08"  
misc\_feature  
1..18  
/note="T-DNA flanking sequence  
left border"  
BASE COUNT 5 a 2 c 0 g 11 t  
Query Match 1.1%; Score 13.2; DB 1; Length 18;  
Best Local Similarity 83.3%; Pred. No. 3.8e+02;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1040 TTTTATTATTATGTTT 1057  
|||||  
Db 1 TTTATTATTATCCATT 18

RESULT 275  
YSOWTP021/c 20 bp DNA linear PLN 04-AUG-1993  
LOCUS YSOWTP021  
DEFINITION Yeast (S.cerevisiae) mitochondrial petite mutant excision seq 2, left end.  
ACCESSION J01510  
VERSION J01510.1 GI:343846  
KEYWORDS AT-rich region; GC rich region.  
SEGMENT 1 of 2  
SOURCE mitochondrion *Saccharomyces cerevisiae* (baker's yeast)  
ORGANISM *Saccharomyces cerevisiae*  
Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes; Saccharomycetales; Saccharomycetaceae; Saccharomycetes.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS de Zamaroczy, M., Faugeron-Fonty, G. and Bernardi, G.  
TITLE Excision sequences in the mitochondrial genome of yeast  
JOURNAL Gene 21 (3), 193-202 (1983)  
MEDLINE 83210931  
PUBMED 6343188  
COMMENT Original source text: Yeast (*Saccharomyces cerevisiae*) mitochondrial DNA.  
Additional sequences reported in [1], but sequenced in earlier papers, appear in separate entries.

FEATURES  
source  
1..20  
/organism="Saccharomyces cerevisiae"  
/organelle="mitochondrion"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:4932"  
BASE COUNT 7 a 2 c 0 g 13 t  
Query Match 1.1%; Score 13.2; DB 1; Length 20;  
Best Local Similarity 83.3%; Pred. No. 4.5e+02;  
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1611 ACATTATAAATAATTT 1628  
|||||  
Db 20 ATATATAAATAATATAT 3

RESULT 276  
A63576/c 15 bp DNA linear PAT 12-MAR-1998  
LOCUS A63576  
DEFINITION Sequence 17 from Patent WO9720924.  
ACCESSION A63576  
A63576.1 GI:3717231  
KEYWORDS unidentified  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Scaggiante, B. and Quadrioglio, F.  
TITLE A CLASS OF OLIGONUCLEOTIDES, THERAPEUTICALLY USEFUL AS ANTITUMORAL AGENTS  
JOURNAL Patent: WO 9720924-A 17 12-JUN-1997;  
COMMENT SAICOM S R L (IT)  
Other publication IT MI952539 19970604  
Other publication AU 1175497 19970627.  
FEATURES  
source  
1..15  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
BASE COUNT 0 a 0 c 4 g 11 t  
Query Match 1.0%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 3.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1207 AACCAACCAACA 1219  
|||||  
Db 13 AACCAACCAACA 1

RESULT 277  
AR041398 15 bp DNA linear PAT 29-SEP-1999  
LOCUS AR041398  
DEFINITION Sequence 188 from patent US 5811300.  
ACCESSION AR041398  
VERSION AR041398.1 GI:5961894  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.  
TITLE TNP-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 188 22-SEP-1998;  
MEDLINE Location/Qualifiers  
FEATURES  
source  
1..15  
/organism="unknown"  
BASE COUNT 5 a 0 c 0 g 10 t  
Query Match 1.0%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 3.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTATTATTATTA 1050  
|||||  
Db 3 TATTATTATTATTA 15

RESULT 278  
AR041406 15 bp DNA linear PAT 29-SEP-1999  
LOCUS AR041406  
DEFINITION Sequence 196 from patent US 5811300.  
ACCESSION AR041406  
VERSION AR041406.1 GI:5961902  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)

AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF- $\alpha$  ribozymes  
JOURNAL Patent: US 581300-A 196 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 4 a 0 c 0 g 11 t  
Query Match 1.0%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred.No. 3.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1038 TATTATTATTATTA 1050  
Db 3 TATTATTATTATTA 15  
RESULT 279  
LOCUS AR041915 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 705 from patent US 5811300.  
ACCESSION AR041915  
VERSION AR041915.1 GI:5962411  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF- $\alpha$  ribozymes  
JOURNAL Patent: US 581300-A 705 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 5 a 0 c 0 g 10 t  
Query Match 1.0%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred.No. 3.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1038 TATTATTATTATTA 1050  
Db 3 TATTATTATTATTA 15  
RESULT 280  
LOCUS AR041930 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 720 from patent US 5811300.  
ACCESSION AR041930  
VERSION AR041930.1 GI:5962426  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF- $\alpha$  ribozymes  
JOURNAL Patent: US 581300-A 720 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 4 a 0 c 0 g 11 t  
Query Match 1.0%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred.No. 3.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1038 TATTATTATTATTA 1050  
Db 3 TATTATTATTATTA 15

RESULT 281  
LOCUS AX636855 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 3994 from Patent EP1260586.  
ACCESSION AX636855  
VERSION AX636855.1 GI:28472469  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 3994 27-NOV-2002;  
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)  
source 1..15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
BASE COUNT 5 a 0 c 0 g 10 t  
Query Match 1.0%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred.No. 3.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1038 TATTATTATTATTA 1050  
Db 3 TATTATTATTATTA 15  
RESULT 282  
LOCUS AX636870 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 4009 from Patent EP1260586.  
ACCESSION AX636870  
VERSION AX636870.1 GI:28472484  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 4009 27-NOV-2002;  
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)  
source 1..15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
BASE COUNT 4 a 0 c 0 g 11 t  
Query Match 1.0%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred.No. 3.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1038 TATTATTATTATTA 1050  
Db 3 TATTATTATTATTA 15  
RESULT 283

AX637379  
LOCUS AX637379 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 4518 from Patent EP1260586.  
ACCESSION AX637379  
VERSION AX637379.1 GI:28472993  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,  
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,  
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,  
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and  
Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related  
genes  
JOURNAL Patent: EP 1260586-A 4518 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES  
source  
1..15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
BASE COUNT 5 a 0 c 0 g 10 t  
Query Match 1.0%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 3.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1038 TATTATTATTATTA 1050  
|||||  
Db 3 TATTATTATTATTA 15  
RESULT 284  
AX637409  
LOCUS AX637409 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 4548 from Patent EP1260586.  
ACCESSION AX637409  
VERSION AX637409.1 GI:28473023  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,  
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,  
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,  
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and  
Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related  
genes  
JOURNAL Patent: EP 1260586-A 4548 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES  
source  
1..15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
BASE COUNT 4 a 0 c 0 g 11 t  
Query Match 1.0%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 3.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1038 TATTATTATTATTA 1050  
|||||  
Db 3 TATTATTATTATTA 15  
RESULT 285  
AX638326/c

AX638326  
LOCUS AX638326 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 5465 from Patent EP1260586.  
ACCESSION AX638326  
VERSION AX638326.1 GI:28473940  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,  
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,  
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,  
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and  
Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related  
genes  
JOURNAL Patent: EP 1260586-A 5465 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES  
source  
1..15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
BASE COUNT 7 a 1 g 4 t  
Query Match 1.0%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 3.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 525 ATTGAATTTCAG 537  
|||||  
Db 13 ATTGAATTTCAG 1  
RESULT 286  
I77803/c  
LOCUS I77803 15 bp DNA linear PAT 03-APR-1998  
DEFINITION Sequence 510 from patent US 5693532.  
ACCESSION I77803  
VERSION I77803.1 GI:3013957  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.  
TITLE Respiratory syncytial virus ribozymes  
JOURNAL Patent: US 5693532-A 510 02-DEC-1997;  
FEATURES  
source  
1..15  
/organism="unknown"  
BASE COUNT 7 a 3 c 1 g 4 t  
Query Match 1.0%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 3.1e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 525 ATTGAATTTCAG 537  
|||||  
Db 13 ATTGAATTTCAG 1  
RESULT 287  
AR072365/c  
LOCUS AR072365 17 bp DNA linear PAT 28-AUG-2000  
DEFINITION Sequence 168 from patent US 5948611.  
ACCESSION AR072365  
VERSION AR072365.1 GI:9999129  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)

AUTHORS Prockop,D.J., Ala-Kokko,L., Williams,C.J., Ritvaniemi,P.,  
Baldwin,C., Hopkinson,I. and Ahmad,N.Nina.  
TITLE Primers and methods for detecting mutations in the procollagen II  
gene (COL2A1) that indicate a genetic predisposition for a  
COL2A1-associated disease  
JOURNAL Patent: US 5948611-A 169 07-SEP-1999;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 6 a 3 c 3 g 5 t  
Query Match 1.0%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.8e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 744 TTTCCTAGATGT 756  
Db 15 TTTCCTAGATGT 3  
RESULT 288  
LOCUS AR078137 17 bp DNA linear PAT 31-AUG-2000  
DEFINITION Sequence 17 from patent US 5962289.  
ACCESSION AR078137  
VERSION AR078137.1 GI:10004883  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Kilburn,D.G., Miller,R.C., Warren,R.A.J. and Gilkes,N.R.  
TITLE Polyaccharide binding fusion proteins and conjugates  
JOURNAL Patent: US 5962289-A 17 05-OCT-1999;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 8 a 0 c 3 g 6 t  
Query Match 1.0%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.8e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1084 AATTGGAAAAAT 1096  
Db 1 AATTGGAAAAAT 13  
RESULT 289  
LOCUS AX264383 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 1774 from Patent WO0173002.  
ACCESSION AX264383  
VERSION AX264383.1 GI:16513182  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Kniec,E.B., Gamper,H.B. and Rice,M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 1774 04-OCT-2001;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 8 a 3 c 3 g 3 t  
Query Match 1.0%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.8e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 3.8e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 510 AAGATTCCTGGTT 522  
Db 17 AAGATTCCTGGTT 5  
RESULT 290  
LOCUS AX264384 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 1775 from Patent WO0173002.  
ACCESSION AX264384  
VERSION AX264384.1 GI:16513183  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Kniec,E.B., Gamper,H.B. and Rice,M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 1775 04-OCT-2001;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 3 a 3 c 3 g 8 t  
Query Match 1.0%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.8e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 510 AAGATTCCTGGTT 522  
Db 1 AAGATTCCTGGTT 13  
RESULT 291  
LOCUS AX264387 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 1778 from Patent WO0173002.  
ACCESSION AX264387  
VERSION AX264387.1 GI:16513186  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Kniec,E.B., Gamper,H.B. and Rice,M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 1778 04-OCT-2001;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 8 a 3 c 3 g 3 t  
Query Match 1.0%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.8e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 510 AAGATTCCTGGTT 522  
Db 16 AAGATTCCTGGTT 4

```
RESULT 292
AX264388
LOCUS      17 bp      DNA      linear      PAT 26-OCT-2001
DEFINITION Sequence 1779 from Patent WO0173002.
ACCESSION AX264388
VERSION   AX264388.1 GI:16513187
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
REFERENCE 1
AUTHORS   Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE     Targeted chromosomal genomic alterations with modified single
          stranded oligonucleotides
JOURNAL   Patent: WO 0173002-A 1779 04-OCT-2001;
          UNIVERSITY OF DELAWARE (US)
FEATURES  Location/Qualifiers
          source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT 3 a 3 c 3 g 8 t
          Query Match      1.0%; Score 13; DB 1; Length 17;
          Best Local Similarity 100.0%; Pred. No. 3.8e+02;
          Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 510 AAGATTCCTGGTT 522
Db 2 AAGATTCCTGGTT 14
          RESULT 293
          AX21944/c
          LOCUS      17 bp      mRNA      linear      PAT 18-JUN-2002
          DEFINITION Sequence 280 from Patent WO0189124.
          ACCESSION AX21944
          VERSION   AX21944.1 GI:21525326
          KEYWORDS  Homo sapiens (human)
          SOURCE    Homo sapiens
          ORGANISM  Homo sapiens
          REFERENCE 1
          AUTHORS   Jarvis, T., von Carlwiz, I., Mcswiggen, J.A., McLaughlin, F.G. and
          Randi, A.M.
          TITLE     Method and reagent for the inhibition of erg
          JOURNAL   Patent: WO 0189124-A 280 22-NOV-2001;
          RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
          FEATURES  Location/Qualifiers
          source
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT 7 a 1 c 2 g 7 t
          Query Match      1.0%; Score 13; DB 1; Length 17;
          Best Local Similarity 100.0%; Pred. No. 3.8e+02;
          Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1504 ATTTTAAATACA 1516
Db 14 ATTTTAAATACA 2
          RESULT 294
          AX578689/c
          LOCUS      17 bp      mRNA      linear      PAT 10-JAN-2003
          DEFINITION Sequence 527 from Patent WO0211674.
          ACCESSION AX578689
          VERSION   AX578689.1 GI:27647891
          KEYWORDS  Homo sapiens (human)
          SOURCE    Homo sapiens
          ORGANISM  Homo sapiens
          REFERENCE 1
          AUTHORS   Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
          and Grupe, A.
          TITLE     Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
          JOURNAL   Patent: WO 0211674-A 1853 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US) ;
          Thompson, James (US)
          FEATURES  Location/Qualifiers
          source
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT 11 a 1 c 0 g 5 t
          Query Match      1.0%; Score 13; DB 1; Length 17;
          Best Local Similarity 100.0%; Pred. No. 3.8e+02;
          Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1142 ATTTATTTTATT 1154
Db 14 ATTTATTTTATT 2
          RESULT 296
          AX672466
          LOCUS      17 bp      DNA      linear      PAT 27-MAR-2003
          DEFINITION Sequence 911 from Patent WO03004526.
          ACCESSION AX672466
          VERSION   AX672466.1 GI:293330814
          KEYWORDS  Homo sapiens (human)
          SOURCE    Homo sapiens
          ORGANISM  Homo sapiens
          REFERENCE 1
          AUTHORS   Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
          and Grupe, A.
          TITLE     Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
          JOURNAL   Patent: WO 0211674-A 1853 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US) ;
          Thompson, James (US)
          FEATURES  Location/Qualifiers
          source
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT 12 a 1 g 4 t
          Query Match      1.0%; Score 13; DB 1; Length 17;
          Best Local Similarity 100.0%; Pred. No. 3.8e+02;
          Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1142 ATTTATTTTATT 1154
Db 17 ATTTATTTTATT 5
          RESULT 295
          AX580015/c
          LOCUS      17 bp      mRNA      linear      PAT 10-JAN-2003
          DEFINITION Sequence 1853 from Patent WO0211674.
          ACCESSION AX580015
          VERSION   AX580015.1 GI:27649217
          KEYWORDS  Homo sapiens (human)
          SOURCE    Homo sapiens
          ORGANISM  Homo sapiens
          REFERENCE 1
          AUTHORS   Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.
          and Grupe, A.
          TITLE     Method and reagent for the inhibition of calcium activated chloride
          channel-1 (clca-1)
          JOURNAL   Patent: WO 0211674-A 1853 14-FEB-2002;
          RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US) ;
          Thompson, James (US)
          FEATURES  Location/Qualifiers
          source
            1..17
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
BASE COUNT 12 a 1 g 4 t
          Query Match      1.0%; Score 13; DB 1; Length 17;
          Best Local Similarity 100.0%; Pred. No. 3.8e+02;
          Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1142 ATTTATTTTATT 1154
Db 17 ATTTATTTTATT 5
```



```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1
REFERENCE
AUTHORS    Telerman,A., Anson,R. and Tuijnder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
           reversion, apoptosis and/or resistance to viruses and their use as
           medicines
JOURNAL    Patent: WO 03004526-A 911 16-JAN-2003;
           Molecular Engines Laboratories (FR)
FEATURES   .
source     1. .17
           /organism="Homo sapiens"
           /mol_type="genomic DNA"
           /db_xref="taxon:9606"
BASE COUNT 6 a 2 c 4 g 5 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1073 ATTGTGTCAGAA 1085
Db      |||||
5 ATTGTGTCAGAA 17

RESULT 297
LOCUS    AX728692 17 bp DNA linear PAT 08-MAY-2003
DEFINITION
Sequence 326 from Patent WO03025175.
ACCESSION
AX728692
VERSION  AX728692.1 GI:30508035
KEYWORDS
SOURCE    Homo sapiens (human)
ORGANISM  Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1
REFERENCE
AUTHORS    Telerman,A., Anson,R. and Tuijnder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
           reversion, apoptosis and/or virus resistance and their use as
           medicines
JOURNAL    Patent: WO 03025175-A 326 27-MAR-2003;
           Molecular Engines Laboratories (FR)
FEATURES   .
source     1. .17
           /organism="Homo sapiens"
           /mol_type="genomic DNA"
           /db_xref="taxon:9606"
BASE COUNT 7 a 1 c 5 g 4 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 419 ATCAGTGAAGATG 431
Db      |||||
2 ATCAGTGAAGATG 14

RESULT 298
LOCUS    BD067674 17 bp RNA linear PAT 27-AUG-2002
DEFINITION
Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
BD067674
ACCESSION
BD067674.1 GI:22613277
VERSION  JP 2001511003-A/514.
KEYWORDS
unidentified
SOURCE    unclassified.
ORGANISM  1 (bases 1 to 17)
           Akhtar,S., Fell,P. and Mcswiggen,J.A.
           Enzymatic nucleic acid treatment of diseases or conditions related
           to levels of epidermal growth factor receptors
REFERENCE
AUTHORS    Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE      Enzymatic nucleic acid treatment of diseases or conditions related
           to levels of epidermal growth factor receptors

```

```

to levels of epidermal growth factor receptors
Patent: JP 2001511003-A 514 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
OS      Unidentified
PN      JP 2001511003-A/514
PD      07-AUG-2001
PF      14-JAN-1998 JP 1998532913
PR      31-JAN-1997 US 60/036476 04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC      Strandedness: Single;
CC      Topology: Linear;
CC      Enzymatic nucleic acid treatment of diseases or conditions CC
           related to
CC      Levels of epidermal growth factor receptors
PH      Key Location/Qualifiers
FT      source 1. .17
           /organism="Unidentified".
           Location/Qualifiers
           1. .17
           /organism="unidentified"
           /mol_type="genomic RNA"
           /db_xref="taxon:32644"
BASE COUNT 2 a 1 c 4 g 10 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 550 ACTTTTTCATTGT 562
Db      |||||
5 ACTTTTTCATTGT 17

RESULT 299
LOCUS    BD067675 17 bp RNA linear PAT 27-AUG-2002
DEFINITION
Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
BD067675
ACCESSION
BD067675.1 GI:22613278
VERSION  JP 2001511003-A/515.
KEYWORDS
unidentified
SOURCE    unclassified.
ORGANISM  1 (bases 1 to 17)
           Akhtar,S., Fell,P. and Mcswiggen,J.A.
           Enzymatic nucleic acid treatment of diseases or conditions related
           to levels of epidermal growth factor receptors
REFERENCE
AUTHORS    Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE      Enzymatic nucleic acid treatment of diseases or conditions related
           to levels of epidermal growth factor receptors
JOURNAL    Patent: JP 2001511003-A 515 07-AUG-2001;
           RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT    OS      Unidentified
           PN      JP 2001511003-A/515
           PD      07-AUG-2001
           PF      14-JAN-1998 JP 1998532913
           PR      31-JAN-1997 US 60/036476 04-DEC-1997 US 08/985162 PI
           SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
           C12N9/00,C07K14/71
           CC      Strandedness: Single;
           CC      Topology: Linear;
           CC      Enzymatic nucleic acid treatment of diseases or conditions CC
           related to
           CC      Levels of epidermal growth factor receptors
           PH      Key Location/Qualifiers
           FT      source 1. .17
           /organism="Unidentified".
           Location/Qualifiers
           1. .17
           /organism="unidentified"
           /mol_type="genomic RNA"
           /db_xref="taxon:32644"
BASE COUNT 2 a 2 c 4 g 9 t

```

```

Query Match      1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 550 AGTTTTCATTGT 562
DB 4 AGTTTTCATTGT 16

RESULT 300
LOCUS BD067676
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION BD067676
VERSION BD067676.1 GI:22613279
KEYWORDS JP 2001511003-A/516.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 516 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/516
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC levels of epidermal growth factor receptors
FH Key 17 bp RNA linear PAT 27-AUG-2002
FT source Location/Qualifiers
FEATURES
source
1..17
/organism="unclassified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"
BASE COUNT 2 a 2 c 5 g 8 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 550 AGTTTTCATTGT 562
DB 3 AGTTTTCATTGT 15

RESULT 301
LOCUS BD067677
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION BD067677
VERSION BD067677.1 GI:22613280
KEYWORDS JP 2001511003-A/517.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 517 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/516
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC levels of epidermal growth factor receptors
FH Key 17 bp RNA linear PAT 27-AUG-2002
FT source Location/Qualifiers
FEATURES
source
1..17
/organism="unclassified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"
BASE COUNT 2 a 2 c 5 g 8 t
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 550 AGTTTTCATTGT 562
DB 1 AGTTTTCATTGT 13

RESULT 303
LOCUS BD067678
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION BD067678
VERSION BD067678.1 GI:1606346
KEYWORDS JP 2001511003-A/517.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 17)
AUTHORS Prockop,D.J., Ala-Kokko,L. and Ritvanemi,P.
TITLE Primers and methods for detecting mutations in the procollagen II

```

gene that indicate a genetic predisposition for osteoarthritis  
Patent: US 5559888-A 168 24-SEP-1996;  
Location/Qualifiers

source  
1. .17  
/organism="unknown"

BASE COUNT 6 a 3 c 3 g 5 t  
Query Match 1.0%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 3.8e+02; Indels 0; Gaps 0;  
Matches 13; Conservative 0; Mismatches 0;

744 TTGCTAGAAATGT 756  
|||||  
15 TTGCTAGAAATGT 3

RESULT 304  
AX004292/c  
LOCUS  
DEFINITION  
Sequence 44 from Patent WO9919492. PAT 24-AUG-2000  
ACCESSION  
AX004292  
VERSION  
AX004292.1 GI:9927774  
KEYWORDS  
synthetic construct  
SOURCE  
synthetic construct  
artificial sequences.

REFERENCE  
1  
Betzner A.S. and Doutriaux M.P.  
METHODS for obtaining plant varieties  
TITLE  
Patent: WO 9919492-A 44 22-APR-1999;  
JOURNAL  
BETZNER ANDREAS STEFAN (AU); DOUTRIAUX MARIE PASCALE (FR)  
FEATURES  
Location/Qualifiers  
source  
1. .18  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
/note="Forward primer for PCR amplification of NGA63 SSLP  
marker in Arabidopsis thaliana subspecies"

BASE COUNT 8 a 5 c 5 g 0 t  
Query Match 1.0%; Score 13; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 4.2e+02; Indels 0; Gaps 0;  
Matches 13; Conservative 0; Mismatches 0;

895 CTGTGCTTGGTT 907  
|||||  
13 CTGTGCTTGGTT 1

RESULT 305  
AX383945/c  
LOCUS  
DEFINITION  
Sequence 48 from Patent WO0214546. PAT 19-MAR-2002  
ACCESSION  
AX383945  
VERSION  
AX383945.1 GI:19577516  
KEYWORDS  
Salmonella typhimurium  
SOURCE  
Salmonella typhimurium  
Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
Enterobacteriaceae; Salmonella.

REFERENCE  
1  
Fritzsche M.  
Use of microbial dna sequences for the identification of human  
diseases  
TITLE  
Patent: WO 0214546-A 48 21-FEB-2002;  
JOURNAL  
Fritzsche, Markus (CH)  
FEATURES  
Location/Qualifiers  
source  
1. .18  
/organism="Salmonella typhimurium"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:602"

BASE COUNT 8 a 2 c 1 g 7 t  
Query Match 1.0%; Score 13; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 4.2e+02; Indels 0; Gaps 0;  
Matches 13; Conservative 0; Mismatches 0;

Query Match 1.0%; Score 13; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 4.2e+02; Indels 0; Gaps 0;  
Matches 13; Conservative 0; Mismatches 0;

1050 ATGTATTATTATTA 1062  
|||||  
15 ATGTATTATTATTA 3

RESULT 306  
AX417565/c  
LOCUS  
DEFINITION  
Sequence 13 from Patent WO0231157. PAT 19-JUN-2002  
ACCESSION  
AX417565  
VERSION  
AX417565.1 GI:21522804  
KEYWORDS  
synthetic construct  
SOURCE  
synthetic construct  
artificial sequences.

REFERENCE  
1  
Gardner R., Nilsen I. and Oeverboe K.  
TITLE  
Shrimp alkaline phosphatase  
JOURNAL  
Patent: WO 0231157-A 13 18-APR-2002;  
NORWEGIAN INST OF FISHERIES & (NO)  
FEATURES  
Location/Qualifiers  
source  
1. .18  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
/note="Primer"

modified\_base 6 /mod\_base=1  
BASE COUNT 7 a 4 g 2 t 4 others  
Query Match 1.0%; Score 13; DB 1; Length 18;  
Best Local Similarity 72.2%; Pred. No. 4.2e+02; Indels 0; Gaps 0;  
Matches 13; Conservative 2; Mismatches 3;

886 CTGTTCACCTGTGCTT 903  
|||||  
18 YTTTTCCTTANGCCTT 1

RESULT 307  
AX599862/c  
LOCUS  
DEFINITION  
Sequence 1202 from Patent WO02077272. PAT 14-FEB-2003  
ACCESSION  
AX599862  
VERSION  
AX599862.1 GI:28400012  
KEYWORDS  
synthetic construct  
SOURCE  
synthetic construct  
artificial sequences.

REFERENCE  
1  
Berlin K., Braun A., Dietler J., Guetig D., Howe A., Mueller J.,  
Olek A., Piepenbrock C., Adorjan P., Grabs G., Lesche R., Leu E.,  
Lewin A., Lipscher E., Maier S., Model F., Mueller V., Otto T.,  
Pelet C. and Ziebarth H.  
TITLE  
Methods and nucleic acids for the analysis of hematopoietic cell  
proliferative disorders  
JOURNAL  
Patent: WO 02077272-A 1202 03-OCT-2002;  
EpiGenomics AG (DE)  
FEATURES  
Location/Qualifiers  
source  
1. .18  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
/note="Detection oligonucleotide for CMYCex3"

BASE COUNT 4 a 0 c 3 g 11 t  
Query Match 1.0%; Score 13; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 4.2e+02; Indels 0; Gaps 0;  
Matches 13; Conservative 0; Mismatches 0;

QY 1205 TTAAACCAACAA 1217  
 Db 15 TTAAACCAACAA 3

RESULT 308  
 BD094192  
 LOCUS 18 bp DNA linear PAT 27-AUG-2002  
 DEFINITION Genes for heat resistant enzymes of amino acid biosynthetic pathway derived from thermophilic coryneform bacteria.  
 ACCESSION BD094192  
 VERSION WO 0125447-A/50  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 REFERENCE 1 (bases 1 to 18)  
 AUTHORS Hirano,S., Nonaka,G., Matsuzaki,Y., Akiyoshi,N., Nakamura,K., Kimura,E., Osumi,T., Matsui,K., Kawahara,Y., Kurahashi,O., Nakamatsu,T. and Sugimoto,S.  
 TITLE Genes for heat resistant enzymes of amino acid biosynthetic pathway  
 JOURNAL AJINOMOTO CO INC,SEIKO HIRANO,GEN NONAKA,YUMI MATSUZAKI, NAOKI AKIYOSHI, KANAE NAKAMURA,EIICHIRO KIMURA,TSUYOSHI OSUMI,KAZUHIKO MATSUI, YOSHIO KAWAHARA,OSAMU KURAHASHI,TSUYOSHI NAKAMATSU, SHINICHI SUGIMOTO  
 COMMENT OS Artificial Sequence  
 PN WO 0125447-A/50  
 PD 12-APR-2001  
 PF 04-OCT-2000 WO 2000JP006913  
 PR 04-OCT-1999 JP 99P 282716,01-NOV-1999 JP 99P 311147 PR 21-APR-2000 JP 00P 120687  
 PI SEIKO HIRANO,GEN NONAKA,YUMI MATSUZAKI,NAOKI AKIYOSHI, KANAE NAKAMURA,EIICHIRO KIMURA,TSUYOSHI OSUMI,KAZUHIKO MATSUI, YOSHIO KAWAHARA,OSAMU KURAHASHI,TSUYOSHI NAKAMATSU, SHINICHI SUGIMOTO  
 PI NAKAMURA,  
 PI EIICHIRO KIMURA,TSUYOSHI OSUMI,KAZUHIKO MATSUI,YOSHIO KAWAHARA,  
 PI OSAMU KURAHASHI,TSUYOSHI NAKAMATSU,SHINICHI SUGIMOTO PC C12N15/60,C12N15/54,C12N15/53,C12N15/31,C12N15/56,C12N9/88, PC C12N9/12,  
 PC C12N9/04,C07K14/34,C12N9/26,C12N13/04  
 CC Description of Artificial Sequence: primer for LA cloning of  
 CC icd Location/Qualifiers.  
 FH Key Location/Qualifiers  
 source 1..18  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"

BASE COUNT 7 a 3 c 6 g 2 t

Query Match 1.0%; Score 13; DB 1; Length 18;  
 Best Local Similarity 100.0%; Pred. No. 4.2e+02;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 883 GTCCTGTGTCAC 895  
 Db 15 GTCCTGTGTCAC 3

RESULT 310  
 BD0941968  
 LOCUS 30 bp DNA linear PAT 18-JUN-2002  
 DEFINITION Sequence 305 from Patent WO0198537.  
 ACCESSION AX419968  
 VERSION AX419968.1 GI:21524335  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 REFERENCE 1  
 AUTHORS Lyamichev,V., Allawi,H., Dong,P., Neri,B.P. and Vener,I.T.  
 TITLE Nucleic acid accessible hybridization sites  
 JOURNAL Patent: WO 0198537-A 305 27-DEC-2001;  
 THIRD WAVE TECHNOLOGIES, INC. (US)  
 FEATURES Location/Qualifiers  
 source 1..30  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"

BASE COUNT 13 a 4 c 2 g 11 t

Query Match 1.0%; Score 13; DB 1; Length 30;  
 Best Local Similarity 76.2%; Pred. No. 7.7e+02;  
 Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1444 CTGGTTGAACCTGTTTATTA 1464  
 Db 1 CTGGTTGAACCTGTTTATTA 21

RESULT 311  
A89384  
LOCUS A89384 16 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 1532 from Patent WO9833904.  
ACCESSION A89384  
VERSION A89384.1 GI:6737954  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W. and Schlingensiepen,K.  
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD  
JOURNAL Patent: WO 9833904-A 1532 06-AUG-1998;  
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)  
FEATURES  
source  
1. .16  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
BASE COUNT 5 a 3 c 5 g 3 t  
Query Match 1.0%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 586 CAAATTTGGCCAGG 701  
|||||  
Db 1 CAAATTTGGCCAGG 16  
RESULT 312  
AR083145/c  
LOCUS AR083145 16 bp DNA linear PAT 01-SEP-2000  
DEFINITION Sequence 28 from patent US 5976805.  
ACCESSION AR083145  
VERSION AR083145.1 GI:10009935  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS You,Q.  
TITLE Neisseria gonorrhoeae specific DNA fragment--GC3  
JOURNAL Patent: US 5976805-A 28 02-NOV-1999;  
FEATURES  
source  
1. .16  
/organism="unknown"  
BASE COUNT 5 a 3 c 4 g 4 t  
Query Match 1.0%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 756 TGATATTGGAGCATC 771  
|||||  
Db 16 TGATATTGGAGCATC 1  
RESULT 313  
AX015629/c  
LOCUS AX015629 16 bp DNA linear PAT 07-SEP-2000  
DEFINITION Sequence 4 from Patent WO9950451.  
ACCESSION AX015629  
VERSION AX015629.1 GI:10041458  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
artificial sequences.  
REFERENCE 1  
AUTHORS Bhattacharyya,S., Leaves,N., Cookson,W.O. and Moffatt,M.P.  
TITLE Polymorphism i: linkage of asthma to a locus on chromosome 2

JOURNAL Patent: WO 9950451-A 4 07-OCT-1999;  
BHATTACHARYYA SUMIT (GB); ISIS INNOVATION (GB); LEAVES NICHOLAS  
(GB); COOKSON WILLIAM OSMOND CHARLES (GB); MOFFATT MIRIAM FLEUR  
(GB)  
FEATURES  
source  
Location/Qualifiers  
1. .16  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
/note="Synthetic DNA"  
BASE COUNT 1 a 5 c 3 g 7 t  
Query Match 1.0%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 685 GCAAAATTGGCCAAAG 700  
|||||  
Db 16 GCAAAATTGGCCAAAG 1  
RESULT 314  
BD066897  
LOCUS BD066897 16 bp DNA linear PAT 27-AUG-2002  
DEFINITION An antisense oligonucleotide preparation method.  
ACCESSION BD066897  
VERSION BD066897.1 GI:22612500  
KEYWORDS JP 2001511000-A/1532.  
SOURCE unidentified  
ORGANISM unclassified,  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Schlingensiepen,K.H. and Brysch,W.  
TITLE An antisense oligonucleotide preparation method  
JOURNAL Patent: JP 2001511000-A 1532 07-AUG-2001;  
BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH  
COMMENT OS Unknown  
FN JP 2001511000-A/1532  
PD 07-AUG-2001  
PF 30-JAN-1998 JP 1998532533  
PR 31-JAN-1997 EP 97101531.8  
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH  
PC C12N15/11,C07H21/04,A61K31/70  
CC An antisense oligonucleotide preparation method FH Key  
FT source  
1. .16  
Location/Qualifiers  
/organism="Unknown".  
1. .16  
Location/Qualifiers  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
BASE COUNT 5 a 3 c 5 g 3 t  
Query Match 1.0%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 3.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 686 CAAATTTGGCCAAAG 701  
|||||  
Db 1 CAAATTTGGCCAGG 16  
RESULT 315  
AR046181/c  
LOCUS AR046181 17 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 974 from patent US 5817796.  
ACCESSION AR046181  
VERSION AR046181.1 GI:5967646  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.

```

REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 974 06-OCT-1998;
FEATURES
source
BASE COUNT 7 a 0 c 0 g 10 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1613 ATTAAATATATATTT 1628
Db 17 AATAAATATATATTT 2

RESULT 316
AR047244 17 bp DNA linear PAT 29-SEP-1999
LOCUS
DEFINITION Sequence 2037 from patent US 5817796.
ACCESSION AR047244
VERSION AR047244.1 GI:5968709
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 2037 06-OCT-1998;
FEATURES
source
BASE COUNT 6 a 0 c 3 g 8 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1460 TATTATGTACAAATAG 1475
Db 1 TATTATGTATGAATAG 16

RESULT 317
AR047262/c 17 bp DNA linear PAT 29-SEP-1999
LOCUS
DEFINITION Sequence 2055 from patent US 5817796.
ACCESSION AR047262
VERSION AR047262.1 GI:5968727
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 2055 06-OCT-1998;
FEATURES
source
BASE COUNT 7 a 0 c 0 g 10 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1613 ATTAAATATATATTT 1628
Db 17 AATAAATATATATTT 2

RESULT 318
AR047360 17 bp DNA linear PAT 29-SEP-1999
LOCUS
DEFINITION Sequence 2153 from patent US 5817796.
ACCESSION AR047360
VERSION AR047360.1 GI:5968825
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 2153 06-OCT-1998;
FEATURES
source
BASE COUNT 4 a 0 c 0 g 13 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1040 TTTATTTATTTATGAT 1055
Db 2 TTTATTTTATATATAT 17

RESULT 319
AR047362 17 bp DNA linear PAT 29-SEP-1999
LOCUS
DEFINITION Sequence 2155 from patent US 5817796.
ACCESSION AR047362
VERSION AR047362.1 GI:5968827
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylylate residues
JOURNAL Patent: US 5817796-A 2155 06-OCT-1998;
FEATURES
source
BASE COUNT 5 a 0 c 0 g 12 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1040 TTTATTTATTTATGAT 1055
Db 1 TTTATTTTATATATAT 16

RESULT 320
AR054096/c 17 bp DNA linear PAT 29-SEP-1999
LOCUS
DEFINITION Sequence 23 from patent US 5834440.
ACCESSION AR054096
VERSION AR054096.1 GI:5978958
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Goldenberg,T. and Tritz,R.
TITLE Ribozyme therapy for the inhibition of restenosis
JOURNAL Patent: US 5834440-A 23 10-NOV-1998;
FEATURES
source

```

<hr/>					
ACCESSION	AR101662	GI:12812460			
VERSION	AR101662.1				
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 17)				
TITLE	Olsen,S.Jon., Angelly,T.Staton., Lawrence,T., Lescallett,J.Lee.,				
JOURNAL	Murphy,P.Davis., Allen,A.Preisinger., Thurber,D.Bernadette.,				
FEATURES	White,M.Belle., Zeng,B. and Sadzewicz,L.K. Cancer susceptibility mutations of BRCA1 Patent: US 6083698-A 17 04-JUL-2000; Location/Qualifiers 1..17 /organism="unknown"				
BASE COUNT	6 a 2 c 3 g 6 t				
Query Match	1.0%; Score 12.8; DB 1; Length 17;				
Best Local Similarity	87.5%; Pred. No. 4.3e+02;				
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
QY	524 AATTGAATTCAGTA 539				
DB	 17 AATTGCAATTCAGTA 2				
RESULT 324					
LOCUS	AR101663	17 bp DNA linear PAT 14-FEB-2001			
DEFINITION	Sequence 18 from patent US 6083698.				
ACCESSION	AR101663				
VERSION	AR101663.1	GI:12812461			
KEYWORDS	.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 17)				
TITLE	Olsen,S.Jon., Angelly,T.Staton., Lawrence,T., Lescallett,J.Lee.,				
JOURNAL	Murphy,P.Davis., Allen,A.Preisinger., Thurber,D.Bernadette.,				
FEATURES	White,M.Belle., Zeng,B. and Sadzewicz,L.K. Cancer susceptibility mutations of BRCA1 Patent: US 6083698-A 18 04-JUL-2000; Location/Qualifiers 1..17 /organism="unknown"				
source	6 a 3 c 3 g 5 t				
Query Match	1.0%; Score 12.8; DB 1; Length 17;				
Best Local Similarity	87.5%; Pred. No. 4.3e+02;				
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
QY	524 AATTGAATTCAGTA 539				
DB	 17 AATTGCAATTCAGTA 2				
RESULT 325					
LOCUS	AR115537	17 bp DNA linear PAT 16-MAY-2001			
DEFINITION	Sequence 1983 from patent US 6132967.				
ACCESSION	AR115537				
VERSION	AR115537.1	GI:14095859			
KEYWORDS	.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 17)				
TITLE	Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and				
JOURNAL	Draper,K.G Ribozyme treatment of diseases or conditions related to levels of				
FEATURES	intercellular adhesion molecule-1 (ICAM-1) Patent: US 6132967-A 1983 17-OCT-2000; Location/Qualifiers				

```

source
1. .17
/organism="unknown"
BASE COUNT      5 a      0 c      3 g      9 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1047 TTTATGATTTATTATTA 1062
    |||||
Db 2 TTGATGATTTATTATTA 17

RESULT 326
ARI86678/c
LOCUS      ARI86678      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 2166 from patent US 6346398.
ACCESSION  ARI86678
VERSION     ARI86678.1 GI:20232643
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6346398-A 2166 12-FEB-2002;
FEATURES    Location/Qualifiers
            source
            1. .17
BASE COUNT      3 a      5 c      1 g      8 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1586 ATGGAATATATAAAGT 1601
    |||||
Db 16 ATGGAAGATAAAGT 1

RESULT 327
ARI87068/c
LOCUS      ARI87068      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 2556 from patent US 6346398.
ACCESSION  ARI87068
VERSION     ARI87068.1 GI:20233033
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6346398-A 2556 12-FEB-2002;
FEATURES    Location/Qualifiers
            source
            1. .17
BASE COUNT      3 a      2 c      0 g      12 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1085 ATTTGGAATAATAGAA 1100
    |||||
Db 17 ATTTGGAATAATAGAA 2

RESULT 328
ARI87069/c

```

```

LOCUS      ARI87069      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 2557 from patent US 6346398.
ACCESSION  ARI87069
VERSION     ARI87069.1 GI:20233034
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6346398-A 2557 12-FEB-2002;
FEATURES    Location/Qualifiers
            source
            1. .17
BASE COUNT      3 a      3 c      0 g      11 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1085 ATTTGGAATAATAGAA 1100
    |||||
Db 16 ATTTGGAATAATAGAA 1

RESULT 329
ARI87340/c
LOCUS      ARI87340      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 2828 from patent US 6346398.
ACCESSION  ARI87340
VERSION     ARI87340.1 GI:20233305
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6346398-A 2828 12-FEB-2002;
FEATURES    Location/Qualifiers
            source
            1. .17
BASE COUNT      2 a      2 c      2 g      11 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1201 TAGATTAACAACAACAA 1216
    |||||
Db 16 TAGATAACAACAACAA 1

RESULT 330
ARI88362/c
LOCUS      ARI88362      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 3850 from patent US 6346398.
ACCESSION  ARI88362
VERSION     ARI88362.1 GI:20234327
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE    1 (bases 1 to 17)
AUTHORS     Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6346398-A 3850 12-FEB-2002;
FEATURES    Location/Qualifiers
            source
            1. .17

```



```

BASE COUNT      6 a      2 c      2 g      7 t
Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1457 GTTATATATCTACAAA 1472
Db 2 GCTATATTATACATA 17

RESULT 331
AR188737
LOCUS AR188737 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4225 from patent US 6346398.
ACCESSION AR188737
VERSION AR188737.1 GI:20234702
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4225 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 7 a 0 c 4 g 6 t
Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1116 GAATAGTATTAAAGAT 1131
Db 2 GGATATTATTAAGAT 17

RESULT 332
AR188738
LOCUS AR188738 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4226 from patent US 6346398.
ACCESSION AR188738
VERSION AR188738.1 GI:20234703
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4226 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 7 a 1 c 3 g 6 t
Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1116 GAATAGTATTAAAGAT 1131
Db 1 GGATATTATTAAGAT 16

RESULT 333
AR308284
LOCUS AR308284 17 bp DNA linear PAT 12-JUN-2003

```

```

DEFINITION Sequence 2 from patent US 6555311.
ACCESSION AR308284
VERSION AR308284.1 GI:31699677
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Locarnini,S.A., Bartholomeusz,A.I., Aye,T.T. and de Man,R.A.
TITLE Viral variants and methods for detecting same
JOURNAL Patent: US 6555311-A 2 29-APR-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 4 c 1 g 7 t
Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1556 CTCCAAATTTTATA 1571
Db 2 CTCCAAATTTTATA 17

RESULT 334
AR308286
LOCUS AR308286 17 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 4 from patent US 6555311.
ACCESSION AR308286
VERSION AR308286.1 GI:31699679
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Locarnini,S.A., Bartholomeusz,A.I., Aye,T.T. and de Man,R.A.
TITLE Viral variants and methods for detecting same
JOURNAL Patent: US 6555311-A 4 29-APR-2003;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
BASE COUNT 5 a 4 c 1 g 7 t
Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1556 CTCCAAATTTTATA 1571
Db 2 CTCCAAATTTTATA 17

RESULT 335
AR3029041
LOCUS AR3029041 17 bp DNA linear PAT 16-SEP-2000
DEFINITION Sequence 2 from Patent WO9821317.
ACCESSION AR3029041
VERSION AR3029041.1 GI:10190029
KEYWORDS
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1
AUTHORS Bartholomeusz,A.I., Locarnini,S.A., Aye,T.T. and de Man,R.
TITLE Viral variants and methods for detecting same
JOURNAL Patent: WO 9821317-A 2 22-MAY-1998;
BARTHOLOMEUSZ ANGELINE INGRID (AU) ; LOCARNINI STEPHEN ALISTER (AU)
; WESTERN HEALTH CARE NETWORK (AU) ; AYE THEIN THEIN (AU) ; MAN
ROBERT A DE (AU)
FEATURES Location/Qualifiers
source 1..17
/organism="Hepatitis B virus"

```

```

Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

BASE COUNT      5 a      4 c      1 g      7 t

/mol_type="genomic DNA"
/db_xref="taxon:10407"

QY 1556 CTCGAAATTTTCTTATA 1571
Db 2 CTCGAAATTTTCTTATA 17

RESULT 336
LOCUS AX029043
DEFINITION Sequence 4 from Patent WO9821317.
ACCESSION AX029043
VERSION AX029043.1 GI:10190031
KEYWORDS
SOURCE Hepatitis B virus
ORGANISM Hepatitis B virus
REFERENCE 1
AUTHORS Bartholomusz,A.I., Locarnini,S.A., Aye,T.T. and de Man,R.
TITLE Viral variants and methods for detecting same
JOURNAL Patent: WO 9821317-A 4 22-MAY-1998; LOCARNINI STEPHEN ALISTER (AU)
; BARTHOLOMEUSZ ANGELINE INGRID (AU) ; AYE THEIN THEIN (AU) ; MAN
; WESTERN HEALTH CARE NETWORK (AU) ; AYE THEIN THEIN (AU) ; MAN
ROBERT A DE (AU)
FEATURES
source
1. .17
/organism="Hepatitis B virus"
/mol_type="genomic DNA"
/db_xref="taxon:10407"

BASE COUNT      5 a      4 c      1 g      7 t

Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1556 CTCGAAATTTTCTTATA 1571
Db 2 CTCGAAATTTTCTTATA 17

RESULT 337
LOCUS AX076472/c
DEFINITION Sequence 17 from Patent WO0103686.
ACCESSION AX076472
VERSION AX076472.1 GI:12711025
KEYWORDS Staphylococcus aureus
SOURCE Staphylococcus aureus
ORGANISM Staphylococcus aureus
REFERENCE 1
AUTHORS Hurlburt,B.K., Smeltzer,M.S. and Reichtin,T.M.
TITLE Inhibitors of staphylococcus sara protein and their use in treating
staphylococcal infections
JOURNAL Patent: WO 0103686-A 17 18-JAN-2001;
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US)
FEATURES
source
1. .17
/organism="Staphylococcus aureus"
/mol_type="genomic DNA"
/db_xref="taxon:1280"

BASE COUNT      9 a      2 c      1 g      5 t

Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1556 CTCGAAATTTTCTTATA 1571
Db 2 CTCGAAATTTTCTTATA 17

RESULT 338
LOCUS AX132943/c
DEFINITION Sequence 4161 from Patent WO0130362.
ACCESSION AX132943
VERSION AX132943.1 GI:14139253
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
diseases
JOURNAL Patent: WO 0130362-A 4161 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/note="Hammerhead ribozyme recognition site for cdc 2
kinase"

BASE COUNT      7 a      2 c      1 g      7 t

Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1172 TTTATTAGATAAATTT 1187
Db 16 TTTAATAGAGAAATTT 1

RESULT 339
LOCUS AX214988
DEFINITION Sequence 430 from Patent WO0159103.
ACCESSION AX214988
VERSION AX214988.1 GI:15525031
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 430 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

BASE COUNT      5 a      2 c      1 g      9 t

Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 909 CTCCTTTATTTCTAAG 924
Db 2 CTTATTATTTCTAAG 17

```

RESULT 340  
AX215015/c  
LOCUS AX215015 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 457 from Patent WO0159103.  
ACCESSION AX215015  
VERSION AX215015.1 GI:15525058  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and  
JOURNAL nogo gene expression  
PATEENT: WO 0159103-A 457 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
BASE COUNT 5 a 3 c 1 g 8 t  
Query Match 1.0%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1096 TAGAAGATGATCATT 1111  
Db 17 TAGAAGATGATCAGT 2  
RESULT 341  
AX215874/c  
LOCUS AX215874 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 1316 from Patent WO0159103.  
ACCESSION AX215874  
VERSION AX215874.1 GI:15525917  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and  
JOURNAL nogo gene expression  
PATEENT: WO 0159103-A 1316 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
BASE COUNT 5 a 3 c 1 g 8 t  
Query Match 1.0%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1096 TAGAAGATGATCATT 1111  
Db 16 TAGAAGATGATCAGT 1  
RESULT 342  
AX216170  
LOCUS AX216170 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 1612 from Patent WO0159103.

ACCESSION AX216170  
VERSION AX216170.1 GI:15526213  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and  
JOURNAL nogo gene expression  
PATEENT: WO 0159103-A 1612 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
BASE COUNT 4 a 3 c 4 g 6 t  
Query Match 1.0%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 429 ATGCCAGTCAAACTTC 444  
Db 1 ATGTCACTGACCTTC 16  
RESULT 343  
AX216751/c  
LOCUS AX216751 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 2193 from Patent WO0159103.  
ACCESSION AX216751  
VERSION AX216751.1 GI:15526812  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and  
JOURNAL nogo gene expression  
PATEENT: WO 0159103-A 2193 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;  
McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES  
source  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
BASE COUNT 9 a 2 c 3 g 3 t  
Query Match 1.0%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1276 AAGTACATTATTGTTT 1291  
Db 16 AAGTCCATTATTGTTT 1  
RESULT 344  
AX263368/c  
LOCUS AX263368 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 759 from Patent WO0173002.  
ACCESSION AX263368  
VERSION AX263368.1 GI:16512167  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens



```

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1235 AATTTTCATTTCAGA 1250
DB 16 AATTTTCATTTCAGA 1

RESULT 349
AX423008/c
LOCUS AX423008 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1344 from Patent WO0188124.
ACCESSION AX423008
VERSION AX423008.1 GI:21526390
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,P.G. and
Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1344 22-NOV-2001.
KEYWORDS RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)
FEATURES
LOCATION/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 9 a 0 c 3 g 5 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1171 TTTTATTAGTAAATT 1186
DB 17 TTTTATTAGTAAATT 2

RESULT 350
AX500622/c
LOCUS AX500622 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1929 from Patent EP1229046.
ACCESSION AX500622
VERSION AX500622.1 GI:23382915
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1929 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
LOCATION/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 2 g 7 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1457 GTTTATTATGTACAAA 1472
DB 17 GCTTATGATGTACAAA 2

```

```

RESULT 351
AX500624/c
LOCUS AX500624 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1931 from Patent EP1229046.
ACCESSION AX500624
VERSION AX500624.1 GI:23382917
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1931 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
LOCATION/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 3 c 3 g 5 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1456 TGTATTATGTACAA 1471
DB 16 TGTATTATGTACAA 1

RESULT 352
AX503015/c
LOCUS AX503015 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 4322 from Patent EP1229046.
ACCESSION AX503015
VERSION AX503015.1 GI:23385308
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 4322 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
LOCATION/Qualifiers
SOURCE 1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 2 c 2 g 8 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 603 TTTATTGATCTACA 618
DB 2 TTTATTGATCTACA 17

RESULT 353
AX503016/c
LOCUS AX503016 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 4323 from Patent EP1229046.
ACCESSION AX503016
VERSION AX503016.1 GI:23385309
KEYWORDS

```

FEATURES	Location/Qualifiers
source	1. .17
	/organism="Homo sapiens"
	/mol_type="genomic DNA"
	/db_xref="taxon:9606"
BASE COUNT	7 a 2 c 7 g 1 t
Query Match	1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity	87.5%; Pred. NO. 4.3e+02;
Matches 14; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	1335 CAGTCTTGTCATTGCC 1350
Db	11
	16 CACTCTTGTCCTTGCC 1
RESULT 356	
LOCUS	AX578728 17 bp mRNA linear PAT 10-JAN-2003
DEFINITION	Sequence 566 from Patent WO0211674.
ACCESSION	AX578728
VERSION	AX578728.1 GI:27647930
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
	1 Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
	and Grupe,A.
TITLE	Method and reagent for the inhibition of calcium activated chloride
JOURNAL	channel-1 (Clca-1)
	Patent: WO 0211674-A 566 14-FEB-2002;
	RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)	
FEATURES	Location/Qualifiers
source	1. .17
	/organism="Homo sapiens"
	/mol_type="mRNA"
	/db_xref="taxon:9606"
BASE COUNT	6 a 1 c 1 g 9 t
Query Match	1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity	87.5%; Pred. NO. 4.3e+02;
Matches 14; Conservative	0; Mismatches 2; Indels 0; Gaps 0;
QY	1133 TTATAGTAAATTATT 1148
Db	11
	2 TTATAGTAAATTATT 17
RESULT 357	
LOCUS	AX579226 17 bp mRNA linear PAT 10-JAN-2003
DEFINITION	Sequence 1064 from Patent WO0211674.
ACCESSION	AX579226
VERSION	AX579226.1 GI:27648428
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
	1 Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
	and Grupe,A.
TITLE	Method and reagent for the inhibition of calcium activated chloride
JOURNAL	channel-1 (Clca-1)
	Patent: WO 0211674-A 1064 14-FEB-2002;
	RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)	
FEATURES	Location/Qualifiers
source	1. .17
	/organism="Homo sapiens"

```
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      8 a      4 c      2 g      3 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 722 TTAATTTCAGGAATTG 737
    |||||
Db 17 TTAATTTCAGGTCCTG 2

RESULT 358
AX579385
LOCUS      AX579385
DEFINITION Sequence 1223 from Patent WO0211674.
ACCESSION AX579385
VERSION    AX579385.1 GI:27648587
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Rukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE      Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
JOURNAL    Patent: WO 0211674-A 1223 14-FEB-2002;
           RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
           Thompson, James (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
BASE COUNT      8 a      4 c      2 g      3 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1245 TTCAGATAAACACAA 1260
    |||||
Db 2 TTCAGCTGAACACAA 17

RESULT 359
AX579496/c
LOCUS      AX579496/c
DEFINITION Sequence 1334 from Patent WO0211674.
ACCESSION AX579496
VERSION    AX579496.1 GI:27648698
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Rukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE      Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
JOURNAL    Patent: WO 0211674-A 1334 14-FEB-2002;
           RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
           Thompson, James (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
BASE COUNT      8 a      3 c      2 g      4 t
```

```
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 722 TTAATTTCAGGAATTG 737
    |||||
Db 16 TTAATTTCAGGTCCTG 1

RESULT 360
AX579591
LOCUS      AX579591
DEFINITION Sequence 1429 from Patent WO0211674.
ACCESSION AX579591
VERSION    AX579591.1 GI:27648793
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Rukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE      Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
JOURNAL    Patent: WO 0211674-A 1429 14-FEB-2002;
           RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
           Thompson, James (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
BASE COUNT      6 a      1 c      2 g      8 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1136 TAGTAATTTATTTTA 1151
    |||||
Db 1 TACTAAATGTATTTTA 16

RESULT 361
AX634813
LOCUS      AX634813
DEFINITION Sequence 1952 from Patent EP1260586.
ACCESSION AX634813
VERSION    AX634813.1 GI:28470427
KEYWORDS   unidentified
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1
AUTHORS    Stinchcomb, D.T., Dudycz, L.W., Chowira, B., Grimm, S., Drenzo, A.,
           Karpeisky, A., Draper, K.G., Kisch, K., Matulic-Adamic, J.,
           McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
           Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
           Woolf, T.
TITLE      Method and reagent for inhibiting the expression of disease related
           genes
JOURNAL    Patent: EP 1260586-A 1952 27-NOV-2002;
           RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="unidentified"
                /mol_type="mRNA"
                /db_xref="taxon:32644"
BASE COUNT      5 a      0 c      3 g      9 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
```

Best Local Similarity 87.5%; Pred. No. 4.3e+02; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		2 ATCACATAAAACAGAT 17	
QY	1047 TTTATGCTATTATTAA 1062		
Db	2 TTGATGCTATTATTAA 17		
RESULT 362			
AX671653/c			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity 87.5%; Pred. No. 4.3e+02;			
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	454 TACTTCAACACTTCAT 469		
Db	17 TACTTCAACACTTCAT 2		
RESULT 363			
AX671834			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity 87.5%; Pred. No. 4.3e+02;			
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	769 ATCACATAAAATCAT 784		
Db	17 TTTTATTTTATTAGAT 2		
RESULT 364			
AX672853			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity 87.5%; Pred. No. 4.3e+02;			
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	1144 TTATTATTATTAGAT 1159		
Db	17 TTTTATTTTATTAGAT 2		
RESULT 365			
AX673783/c			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity 87.5%; Pred. No. 4.3e+02;			
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	1144 TTATTATTATTAGAT 1159		
Db	17 TTTTATTTTATTAGAT 2		
RESULT 366			
AX673947/c			

Best Local Similarity 87.5%; Pred. No. 4.3e+02; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		2 ATCACATAAAACAGAT 17	
QY	1047 TTTATGCTATTATTAA 1062		
Db	2 TTGATGCTATTATTAA 17		
RESULT 362			
AX671653/c			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity 87.5%; Pred. No. 4.3e+02;			
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	454 TACTTCAACACTTCAT 469		
Db	17 TACTTCAACACTTCAT 2		
RESULT 363			
AX671834			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity 87.5%; Pred. No. 4.3e+02;			
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	769 ATCACATAAAATCAT 784		
Db	17 TTTTATTTTATTAGAT 2		
RESULT 364			
AX672853			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity 87.5%; Pred. No. 4.3e+02;			
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	1144 TTATTATTATTAGAT 1159		
Db	17 TTTTATTTTATTAGAT 2		
RESULT 365			
AX673783/c			
LOCUS			
DEFINITION			
ACCESSION			
VERSION			
KEYWORDS			
SOURCE			
ORGANISM			
REFERENCE			
AUTHORS			
TITLE			
JOURNAL			
FEATURES			
source			
BASE COUNT			
Query Match			
Best Local Similarity 87.5%; Pred. No. 4.3e+02;			
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	1144 TTATTATTATTAGAT 1159		
Db	17 TTTTATTTTATTAGAT 2		
RESULT 366			
AX673947/c			



LOCUS AX673947 17 bp DNA linear PAT 27-MAR-2003  
 DEFINITION Sequence 2392 from Patent WO03004526.  
 ACCESSION AX673947  
 VERSION AX673947.1 GI:293322295  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or resistance to viruses and their use as  
 medicines  
 JOURNAL Patent: WO 03004526-A 2392 16-JAN-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES  
 source  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 7 a 3 c 1 g 6 t  
 Query Match 1.0%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1462 TTATGTACAAATAGAT 1477  
 |||||  
 Db 17 TTATGTATAGATAGAT 2  
 RESULT 367  
 AX673993/c  
 LOCUS AX673993 17 bp DNA linear PAT 27-MAR-2003  
 DEFINITION Sequence 2438 from Patent WO03004526.  
 ACCESSION AX673993  
 VERSION AX673993.1 GI:29332341  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or resistance to viruses and their use as  
 medicines  
 JOURNAL Patent: WO 03004526-A 2438 16-JAN-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES  
 source  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 5 a 1 c 3 g 8 t  
 Query Match 1.0%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1462 TTATGTACAAATAGAT 1477  
 |||||  
 Db 17 TAACTCACAATAGAT 2  
 RESULT 368  
 AX674214  
 LOCUS AX674214 17 bp DNA linear PAT 27-MAR-2003  
 DEFINITION Sequence 2659 from Patent WO03004526.  
 ACCESSION AX674214  
 VERSION AX674214.1 GI:29332562  
 KEYWORDS

SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or resistance to viruses and their use as  
 medicines  
 JOURNAL Patent: WO 03004526-A 2659 16-JAN-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES  
 source  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 6 a 1 c 3 g 7 t  
 Query Match 1.0%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 525 ATTGAATTCAGTAA 540  
 |||||  
 Db 2 ATCTGAATTTAGTAA 17  
 RESULT 369  
 AX722385  
 LOCUS AX722385 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 72 from Patent WO03025176.  
 ACCESSION AX722385  
 VERSION AX722385.1 GI:30422886  
 KEYWORDS  
 SOURCE Mus musculus (house mouse)  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE 1  
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or virus resistance and their use as  
 medicines  
 JOURNAL Patent: WO 03025176-A 72 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES  
 source  
 1..17  
 /organism="Mus musculus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:10090"  
 BASE COUNT 3 a 4 c 3 g 7 t  
 Query Match 1.0%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 825 ATCTGGATTTTTC 840  
 |||||  
 Db 2 ATCTGGACTTTATTC 17  
 RESULT 370  
 AX722936/c  
 LOCUS AX722936 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 623 from Patent WO03025176.  
 ACCESSION AX722936  
 VERSION AX722936.1 GI:30423437  
 KEYWORDS  
 SOURCE Mus musculus (house mouse)  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 REFERENCE 1

```

Molecular Engines Laboratories (PR)
FEATURES
source
    1..17
        /organism="Mus musculus"
        /mol_type="genomic DNA"
        /db_xref="taxon:10090"
BASE COUNT      8 a      4 c      1 g      4 t
Query Match          1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      756 TCATATTGAAGCATC 771
DB      16 TGTATTGAAGGATC 1

RESULT 373
AX726135
LOCUS       AX726135
DEFINITION Sequence 3822 from Patent WO03025176.
ACCESSION  AX726135
VERSION     AX726135.1 GI:30505478
KEYWORDS   Mus musculus (house mouse)
SOURCE      Mus musculus
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuilinder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 3822 27-MAR-2003;
            Molecular Engines Laboratories (PR)
FEATURES
source
    1..17
        /organism="Mus musculus"
        /mol_type="genomic DNA"
        /db_xref="taxon:10090"
BASE COUNT      6 a      1 c      2 g      8 t
Query Match          1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1292 ATCTGAAATTTTAATT 1307
DB      2 ATCTGAAATTTTATT 17

RESULT 374
AX726286
LOCUS       AX726286
DEFINITION Sequence 3973 from Patent WO03025176.
ACCESSION  AX726286
VERSION     AX726286.1 GI:30505629
KEYWORDS   Mus musculus (house mouse)
SOURCE      Mus musculus
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuilinder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 3973 27-MAR-2003;
            Molecular Engines Laboratories (PR)
FEATURES
source
    1..17
        /organism="Mus musculus"
        /mol_type="genomic DNA"

```

```

BASE COUNT      5 a      5 c      3 g      4 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      874 GATCCACAAGTCTTGG 889
Db      1 GATCCACAAGTCTTAG 16

RESULT 375
AX726492/c
LOCUS      AX726492      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 4179 from Patent WO03025176.
ACCESSION  AX726492
VERSION     AX726492.1 GI:30505835
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM
REFERENCE
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 4179 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Mus musculus"
            /mol_type="genomic DNA"
            /db_xref="taxon:10090"
BASE COUNT      3 a      2 c      2 g      10 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      499 AGATGCAATACAGAT 514
Db      17 AGATAAATACAGAT 2

RESULT 376
AX727740
LOCUS      AX727740      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 5427 from Patent WO03025176.
ACCESSION  AX727740
VERSION     AX727740.1 GI:30507083
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM
REFERENCE
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 5427 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Mus musculus"
            /mol_type="genomic DNA"
            /db_xref="taxon:10090"
BASE COUNT      9 a      3 c      2 g      3 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;

```

```

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      769 ATCATATAAAATGAT 784
Db      2 ATCATATAAAACAGAT 17

RESULT 377
AX727854
LOCUS      AX727854      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 5541 from Patent WO03025176.
ACCESSION  AX727854
VERSION     AX727854.1 GI:30507197
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM
REFERENCE
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 5541 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Mus musculus"
            /mol_type="genomic DNA"
            /db_xref="taxon:10090"
BASE COUNT      8 a      2 c      2 g      5 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      999 ATCATATAAAATTTA 1014
Db      2 ATCATATAAAATTTA 17

RESULT 378
AX728103
LOCUS      AX728103      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 5790 from Patent WO03025176.
ACCESSION  AX728103
VERSION     AX728103.1 GI:30507446
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM
REFERENCE
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025176-A 5790 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Mus musculus"
            /mol_type="genomic DNA"
            /db_xref="taxon:10090"
BASE COUNT      7 a      2 c      2 g      6 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1604 ATATGAACATTATA 1619
Db      2 ATATGAACATTATA 17

```

```

RESULT 379
AX728686/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
BASE COUNT
Query Match
Best Local Similarity
Matches
QY
Db
RESULT 380
AX728701/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
BASE COUNT
Query Match
Best Local Similarity
Matches
QY
Db
RESULT 381
AX729056/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
BASE COUNT
Query Match
Best Local Similarity
Matches
QY
Db
RESULT 382
AX729980
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
BASE COUNT
Query Match
Best Local Similarity
Matches
QY
Db
RESULT 383
AX730354/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
BASE COUNT
Query Match
Best Local Similarity
Matches
QY
Db
RESULT 384
AX730354
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
BASE COUNT
Query Match
Best Local Similarity
Matches
QY
Db

```

Sequence 320 from Patent WO03025175.  
 Homo sapiens (human)  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 Telerman, A., Anson, R. and Tuijinder, M.  
 Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or virus resistance and their use as  
 medicines  
 Patent: WO 03025175-A 320 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 Location/Qualifiers  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 2 a 5 g 8 t  
 16 AAATCCAGCAGATC 1

Sequence 335 from Patent WO03025175.  
 Homo sapiens (human)  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 Telerman, A., Anson, R. and Tuijinder, M.  
 Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or virus resistance and their use as  
 medicines  
 Patent: WO 03025175-A 335 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 Location/Qualifiers  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 5 a 1 c 3 g 8 t  
 16 AAATCCAGCAGATC 1

Sequence 1614 from Patent WO03025175.  
 Homo sapiens (human)  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 Telerman, A., Anson, R. and Tuijinder, M.  
 Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or virus resistance and their use as  
 medicines  
 Patent: WO 03025175-A 1614 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 Location/Qualifiers  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 9 a 2 c 1 g 5 t  
 16 ATGAATATCCAGATC 1

Sequence 1988 from Patent WO03025175.  
 Homo sapiens (human)  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 Telerman, A., Anson, R. and Tuijinder, M.  
 Sequences involved in phenomena of tumour suppression, tumour  
 reversion, apoptosis and/or virus resistance and their use as  
 medicines  
 Patent: WO 03025175-A 1988 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 Location/Qualifiers  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 17  
 2 ATCAATAAATACATTA 17

ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
AUTHORS  
TITLE  
Telerman, A., Amson, R. and Tuijnder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines

JOURNAL  
Patent: WO 03025175-A 1988 27-MAR-2003;  
Molecular Engines Laboratories (FR)

FEATURES  
source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

BASE COUNT  
5 a 2 c 4 g 6 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1462 TTATGTCACAAATGAT 1477  
Db 17 TTATGTCACACAGAT 2

RESULT 384  
AX730419/c  
LOCUS  
Sequence 2053 from Patent WO03025175.  
ACCESSION  
AX730419.1 GI:30509762  
VERSION  
KEYWORDS  
SOURCE  
Homo sapiens (human)  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
AUTHORS  
TITLE  
Telerman, A., Amson, R. and Tuijnder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines

JOURNAL  
Patent: WO 03025175-A 2003 27-MAR-2003;  
Molecular Engines Laboratories (FR)

FEATURES  
source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

BASE COUNT  
6 a 3 c 3 g 5 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 744 TTTCGTAGATGTCAT 759  
Db 17 TATGTCACAAATGAT 2

RESULT 385  
AX731759  
LOCUS  
Sequence 3393 from Patent WO03025175.  
ACCESSION  
AX731759.1 GI:30511102  
VERSION  
KEYWORDS  
SOURCE  
Homo sapiens (human)  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
AUTHORS  
TITLE  
Telerman, A., Amson, R. and Tuijnder, M.

TITLE  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines

JOURNAL  
Patent: WO 03025175-A 3393 27-MAR-2003;  
Molecular Engines Laboratories (FR)

FEATURES  
source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

BASE COUNT  
9 a 3 c 2 g 3 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 769 ATCCATATAAAATGAT 784  
Db 2 ATCCATATAAACAGAT 17

RESULT 386  
AX732065  
LOCUS  
Sequence 3699 from Patent WO03025175.  
ACCESSION  
AX732065.1 GI:30511408  
VERSION  
KEYWORDS  
SOURCE  
Homo sapiens (human)  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
AUTHORS  
TITLE  
Telerman, A., Amson, R. and Tuijnder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines

JOURNAL  
Patent: WO 03025175-A 3699 27-MAR-2003;  
Molecular Engines Laboratories (FR)

FEATURES  
source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

BASE COUNT  
8 a 3 c 3 g 3 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 573 ATCCAGACATACCTTA 588  
Db 2 ATCCAGACATACCTAA 17

RESULT 387  
AX732416/c  
LOCUS  
Sequence 4050 from Patent WO03025175.  
ACCESSION  
AX732416.1 GI:30511759  
VERSION  
KEYWORDS  
SOURCE  
Homo sapiens (human)  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
AUTHORS  
TITLE  
Telerman, A., Amson, R. and Tuijnder, M.  
Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines

JOURNAL  
Patent: WO 03025175-A 4050 27-MAR-2003;  
Molecular Engines Laboratories (FR)

```

FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT      3 a      3 c      2 g      9 t
Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1099 AAGATGAATCATGTAT 1114
| | | | | | | | | | | | | | | | |
Db 17 AAGATGAACATAGAT 2

RESULT 388
AX733161/C
LOCUS
DEFINITION
Sequence 4795 from Patent WO03025175.
ACCESSION
AX733161
VERSION
AX733161.1 GI:30512504
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Anson,R. and Tuijinder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL
Patent: WO 03025175-A 4795 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT      4 a      3 c      2 g      8 t
Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1608 GAAACATTTAAATAT 1623
| | | | | | | | | | | | | | | | |
Db 17 GGAACATTTAAAGAT 2

RESULT 389
AX733379
LOCUS
DEFINITION
Sequence 5013 from Patent WO03025175.
ACCESSION
AX733379
VERSION
AX733379.1 GI:30512722
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Anson,R. and Tuijinder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL
Patent: WO 03025175-A 5013 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT      3 a      3 c      2 g      9 t
Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1243 ATTCAGATAAACAC 1258
| | | | | | | | | | | | | | | | |
Db 2 ATTCAGATAAACAC 17

RESULT 390
AX733381
LOCUS
DEFINITION
Sequence 5015 from Patent WO03025175.
ACCESSION
AX733381
VERSION
AX733381.1 GI:30512724
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Anson,R. and Tuijinder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL
Patent: WO 03025175-A 5015 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT      5 a      2 c      2 g      8 t
Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1292 ATCTGAAATTTTAATT 1307
| | | | | | | | | | | | | | | | |
Db 2 ATCTGAAATTTTAATT 17

RESULT 391
AX733982/C
LOCUS
DEFINITION
Sequence 5616 from Patent WO03025175.
ACCESSION
AX733982
VERSION
AX733982.1 GI:30513325
KEYWORDS
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Anson,R. and Tuijinder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL
Patent: WO 03025175-A 5616 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT      6 a      3 c      2 g      6 t
Query Match
Best Local Similarity 1.0%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 1462 TTATGTACAAATAGAT 1477
Db 17 TTTCTGTAGAAATAGAT 2

RESULT 392
AX734084 LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5718 from Patent WO03025175.
ACCESSION AX734084
VERSION AX734084.1 GI:30513427
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
as medicines
JOURNAL Patent: WO 03025175-A 5718 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 3 c 2 g 6 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1066 ATCAAAATATTGTGCA 1081
Db 2 ATCAAAATCTTTGACA 17

RESULT 393
AX734468 LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 58 from Patent WO03025177.
ACCESSION AX734468
VERSION AX734468.1 GI:30513745
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
as medicines
JOURNAL Patent: WO 03025177-A 58 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 10 a 2 c 1 g 4 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1535 TTTAAGATGTTTTTAT 1550
Db 17 TTTAATATGTTTGAT 2

```

```

RESULT 394
AX735132 LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 722 from Patent WO03025177.
ACCESSION AX735132
VERSION AX735132.1 GI:30514409
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
as medicines
JOURNAL Patent: WO 03025177-A 722 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 3 c 2 g 6 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 573 ATCCGAGACATCTTA 588
Db 2 ATCCGTAACATATTTA 17

RESULT 395
AX735198 LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 788 from Patent WO03025177.
ACCESSION AX735198
VERSION AX735198.1 GI:30514475
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
as medicines
JOURNAL Patent: WO 03025177-A 788 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 9 a 3 c 2 g 3 t
Query Match 1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 TTTTACTGCTTTCTGAT 1582
Db 17 TTTTACTGTTTGAGAT 2

RESULT 396
AX735395 LOCUS 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 985 from Patent WO03025177.

```

ACCESSION AX735395  
 VERSION AX735395.1 GI:30514672  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 985 27-MAR-2003;  
 FEATURES Molecular Engines Laboratories (FR)  
 source Location/Qualifiers  
 1.17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 3 a 3 c 2 g 9 t  
 Query Match 1.0%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1099 AGATGATCATGAT 1114  
 Db 17 AGATGATCATGAT 2  
 RESULT 397  
 AX736068  
 LOCUS AX736068  
 DEFINITION Sequence 1658 from Patent WO03025177.  
 ACCESSION AX736068  
 VERSION AX736068.1 GI:30515345  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 1658 27-MAR-2003;  
 FEATURES Molecular Engines Laboratories (FR)  
 source Location/Qualifiers  
 1.17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 7 a 3 c 3 g 4 t  
 Query Match 1.0%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 573 ATCCAGACATCTTA 588  
 Db 2 ATCCAGACATCTTA 17  
 RESULT 398  
 AX736295  
 LOCUS AX736295  
 DEFINITION Sequence 1885 from Patent WO03025177.  
 ACCESSION AX736295  
 VERSION AX736295.1 GI:30515572  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 1885 27-MAR-2003;  
 FEATURES Molecular Engines Laboratories (FR)  
 source Location/Qualifiers  
 1.17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 9 a 4 c 1 g 3 t  
 Query Match 1.0%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1243 ATTCAGATAACACAC 1258  
 Db 2 ATTCAGATAACACAC 17  
 RESULT 399  
 AX736998/c  
 LOCUS AX736998/c  
 DEFINITION Sequence 2588 from Patent WO03025177.  
 ACCESSION AX736998  
 VERSION AX736998.1 GI:30516286  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 2588 27-MAR-2003;  
 FEATURES Molecular Engines Laboratories (FR)  
 source Location/Qualifiers  
 1.17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 8 a 3 c 1 g 5 t  
 Query Match 1.0%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1541 ATGTTTTTATGTGCTC 1556  
 Db 16 AAGTTTTTATGTGATC 1  
 RESULT 400  
 AX737306/c  
 LOCUS AX737306/c  
 DEFINITION Sequence 2896 from Patent WO03025177.  
 ACCESSION AX737306  
 VERSION AX737306.1 GI:30516594  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour



```

reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 2896 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
    source
    1..17
    /organism="Homo sapiens"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"
BASE COUNT      3 a      4 c      3 g      7 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 415 AAGATCAGTGAAGAT 430
    17 bp DNA linear PAT 08-MAY-2003
Db 17 AAGATCAGTGAAGAT 2
    17 bp DNA linear PAT 08-MAY-2003
    Sequence 3133 from Patent WO03025177.
AX737543
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
    source
    1..17
    /organism="Homo sapiens"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"
BASE COUNT      8 a      4 c      1 g      4 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 635 TTGTGATGTAAGCAT 650
    17 bp DNA linear PAT 08-MAY-2003
Db 17 TTGTGATGTAAGCAT 2
    17 bp DNA linear PAT 08-MAY-2003
    Sequence 3718 from Patent WO03025177.
AX738128
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
    source
    1..17
    /organism="Homo sapiens"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"
BASE COUNT      8 a      4 c      1 g      4 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 619 AAAACACACAAATAT 634
    17 bp DNA linear PAT 08-MAY-2003
Db 17 AAAACACACAAATAT 2
    17 bp DNA linear PAT 08-MAY-2003
    Sequence 4703 from Patent WO03025177.
AX739113
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
    source
    1..17
    /organism="Homo sapiens"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"
BASE COUNT      4 a      1 c      3 g      9 t

```

```

source
    1..17
    /organism="Homo sapiens"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"
BASE COUNT      13 a      1 c      1 g      2 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTATTTTATTTAGAT 1159
    17 bp DNA linear PAT 08-MAY-2003
Db 17 TTATTTTATTTAGAT 2
    17 bp DNA linear PAT 08-MAY-2003
    Sequence 4032 from Patent WO03025177.
AX738442
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
    source
    1..17
    /organism="Homo sapiens"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"
BASE COUNT      2 a      2 c      3 g      10 t
Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 619 AAAACACACAAATAT 634
    17 bp DNA linear PAT 08-MAY-2003
Db 17 AAAACACACAAATAT 2
    17 bp DNA linear PAT 08-MAY-2003
    Sequence 4703 from Patent WO03025177.
AX739113
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
    source
    1..17
    /organism="Homo sapiens"
    /mol_type="genomic DNA"
    /db_xref="taxon:9606"
BASE COUNT      4 a      1 c      3 g      9 t

```

```

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1250 ATAAACAACAATAAT 1265
DB 17 ATTAACAACAATGAT 2

RESULT 405
BD009326          17 bp DNA linear PAT 31-JAN-2002
LOCUS            Viral variants and methods for detecting same.
DEFINITION       BD009326
ACCESSION        BD009326.1 GI:18637699
VERSION          JP 2001503277-A/2.
KEYWORDS         unidentified
SOURCE           unidentified
ORGANISM         unclassified.
REFERENCE        1 (bases 1 to 17)
AUTHORS          Locarnini,S.A., Bartholomeusz,A.I., Aye,T.T. and Man,R.A.D.
TITLE            Viral variants and methods for detecting same
JOURNAL          Patent: JP 2001503277-A 2 13-MAR-2001;
                  NORTH WESTERN HEALTH CARE NETWORK
COMMENT          OS Hepatitis virus (hepatitis B virus)
                  PN JP 2001503277-A/2
                  PD 13-MAR-2001
                  PP 15-AUG-1997 JP 1998521944
                  PR 08-NOV-1996 AU PO 3519
                  PI STEPHEN ALISTER LOCARNINI,ANGELINE INGRID BARTHOLOMEUSZ, PI
                  THIN THEIN AYE,
                  PC C12N7/01.C12N7/00.C12N15/36.C12N15/54.CO7K14/02 CC
                  PH Key Location/Qualifiers
                  FT source 1..17
                     /organism='Hepatitis virus (hepatitis B virus)'

FEATURES
source            Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

BASE COUNT      5 a 4 c 1 g 7 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1556 CTCCAAAATTTTATA 1571
DB 2 CTCCAAAATTTTATA 17

RESULT 406
BD009328          17 bp DNA linear PAT 31-JAN-2002
LOCUS            Viral variants and methods for detecting same.
DEFINITION       BD009328
ACCESSION        BD009328
VERSION          BD009328.1 GI:18637701
KEYWORDS         unidentified
SOURCE           unidentified
ORGANISM         unclassified.
REFERENCE        1 (bases 1 to 17)
AUTHORS          Locarnini,S.A., Bartholomeusz,A.I., Aye,T.T. and Man,R.A.D.
TITLE            Viral variants and methods for detecting same
JOURNAL          Patent: JP 2001503277-A 4 13-MAR-2001;
                  NORTH WESTERN HEALTH CARE NETWORK
COMMENT          OS Hepatitis virus (hepatitis B virus)
                  PN JP 2001503277-A/4
                  PD 13-MAR-2001
                  PP 15-AUG-1997 JP 1998521944

```

```

PR 08-NOV-1996 AU PO 3519
PI STEPHEN ALISTER LOCARNINI,ANGELINE INGRID BARTHOLOMEUSZ, PI
THIN THEIN AYE,
PI ROBERT A DE MAN
PC C12N7/01.C12N7/00.C12N15/36.C12N15/54.CO7K14/02 CC
PH Key Location/Qualifiers
FT source 1..17
   /organism='Hepatitis virus (hepatitis B virus)'

FEATURES
source            Location/Qualifiers
1..17
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

BASE COUNT      5 a 4 c 1 g 7 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1556 CTCCAAAATTTTATA 1571
DB 2 CTCCAAAATTTTATA 17

RESULT 407
BD009328          17 bp DNA linear PAT 07-OCT-1997
LOCUS            Sequence 974 from patent US 5646042.
DEFINITION       BD009328
ACCESSION        BD009328
VERSION          BD009328.1 GI:2474436
KEYWORDS         Unknow.
SOURCE           Unknow.
ORGANISM         Unclassified.
REFERENCE        1 (bases 1 to 17)
AUTHORS          Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE            C-myb targeted ribozymes
JOURNAL          Patent: US 5646042-A 974 08-JUL-1997;
FEATURES         Location/Qualifiers
source            1..17
                  /organism='unknown'

BASE COUNT      7 a 0 c 0 g 10 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 4.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1613 ATTTAAATAATATTT 1628
DB 17 AATAAATAATATTT 2

RESULT 408
BD009328          17 bp DNA linear PAT 07-OCT-1997
LOCUS            Sequence 2037 from patent US 5646042.
DEFINITION       BD009328
ACCESSION        BD009328
VERSION          BD009328.1 GI:2475499
KEYWORDS         Unknow.
SOURCE           Unknow.
ORGANISM         Unclassified.
REFERENCE        1 (bases 1 to 17)
AUTHORS          Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE            C-myb targeted ribozymes
JOURNAL          Patent: US 5646042-A 2037 08-JUL-1997;
FEATURES         Location/Qualifiers
source            1..17
                  /organism='unknown'

BASE COUNT      6 a 0 c 3 g 8 t

Query Match      1.0%; Score 12.8; DB 1; Length 17;

```

Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1460 TATTATGTAACAATAG 1475  
|||||  
Db 1 TATTATGTAACAATAG 16

RESULT 409  
154314/c  
LOCUS 154314 17 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 2055 from patent US 5646042.  
ACCESSION 154314  
VERSION 154314.1 GI:2475517  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb targeted ribozymes  
JOURNAL Patent: US 5646042-A 2055 08-JUL-1997;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 7 a 0 c 0 g 10 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1613 ATTAAATAATATATTT 1628  
|||||  
Db 17 AATAAATAATATATTT 2

RESULT 410  
154412  
LOCUS 154412 17 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 2153 from patent US 5646042.  
ACCESSION 154412  
VERSION 154412.1 GI:2475615  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb targeted ribozymes  
JOURNAL Patent: US 5646042-A 2153 08-JUL-1997;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 4 a 0 c 0 g 13 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1040 TTATATTTATATGAT 1055  
|||||  
Db 2 TTATATTTATATAT 17

RESULT 411  
154414  
LOCUS 154414 17 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 2155 from patent US 5646042.  
ACCESSION 154414  
VERSION 154414.1 GI:2475617  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

Unclassified.  
1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb targeted ribozymes  
JOURNAL Patent: US 5646042-A 2155 08-JUL-1997;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 5 a 0 c 0 g 12 t

Query Match 1.0%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 4.3e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1040 TTATATTTATATGAT 1055  
|||||  
Db 1 TTATATTTATATAT 16

RESULT 412  
A58293  
LOCUS A58293 18 bp DNA linear PAT 05-MAR-1998  
DEFINITION Sequence 5 from Patent WO9634980.  
ACCESSION A58293  
VERSION A58293.1 GI:3713957  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Laurent,C., Mallet,J. and Meloni,R.  
TITLE METHOD FOR DIAGNOSING SCHIZOPHRENIA  
JOURNAL Patent: WO 9634980-A 5 07-NOV-1996;  
COMMENT RHONE POULENC RORER SA (FR)  
Other publication AU 5767896 961121  
Other publication FR 2733766 961108.  
FEATURES Location/Qualifiers  
source 1..18  
BASE COUNT 1 a 8 c 1 g 8 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 905 GTTCTCCCTTATTTTC 920  
|||||  
Db 1 GTTCTCCCTTATTTTC 16

RESULT 413  
A88563  
LOCUS A88563 18 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 711 from Patent WO9833904.  
ACCESSION A88563  
VERSION A88563.1 GI:6737133  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Brysch,W. and Schlingensiepen,K.  
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD  
JOURNAL Patent: WO 9833904-A 711 06-AUG-1998;  
FEATURES BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)  
Location/Qualifiers  
source 1..18  
BASE COUNT 6 a 1 c 1 g 10 t

```

Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1173 TTATTAGATAAATTC 1188
Db 1 TTTTAAGATAAATTC 16

RESULT 414
LOCUS A90530 18 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 711 from Patent EP0856579.
ACCESSION A90530
VERSION A90530.1 GI:6739044
KEYWORDS
SOURCE unidentified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 18)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 711 05-AUG-1998;
FEATURES BIOGOSTIK GES (DE)
source Location/Qualifiers
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 6 a 1 c 1 g 10 t

Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1173 TTATTAGATAAATTC 1188
Db 1 TTTTAAGATAAATTC 16

RESULT 415
LOCUS A91289 18 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 35 from Patent WO9826075.
ACCESSION A91289
VERSION A91289.1 GI:6740302
KEYWORDS
SOURCE unidentified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 18)
AUTHORS Lousert-Ajaka,I. and Mauciere,P.
TITLE NON-M NON-O HIV STRAINS, FRAGMENTS AND APPLICATIONS
JOURNAL Patent: WO 9826075-A 35 18-JUN-1998;
ASSIST PUBL HOPITAUX DE PARIS (FR); INST NAT SANTE RECH MED (FR)
FEATURES
source Location/Qualifiers
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 6 a 4 c 4 g 4 t

Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 410 TATCCAGGATCAGTG 425
Db 3 TATCCAGGATCAGAG 18

RESULT 416
LOCUS A9272 18 bp DNA linear PAT 26-JAN-2000
DEFINITION Sequence 48 from Patent WO9907839.
ACCESSION A9272
VERSION A9272.1 GI:6782201
KEYWORDS
SOURCE unidentified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 18)

```

---

```

A96945/c
LOCUS A96945 18 bp DNA linear PAT 26-JAN-2000
DEFINITION Sequence 23 from Patent WO9922023.
ACCESSION A96945
VERSION A96945.1 GI:6780386
KEYWORDS
SOURCE unidentified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 18)
AUTHORS Epping,B. and Leiser,M.
TITLE METHOD FOR IDENTIFYING MICRO-ORGANISMS
JOURNAL Patent: WO 9922023-A 23 06-MAY-1999;
FEATURES MIRA DIAGNOSTICA GMBH (DE); EPPING BERND (DE)
source Location/Qualifiers
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 5 c 5 t

Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 726 TTTCCAGGAATGGAATG 741
Db 17 TTTCCAGGATCGCATG 2

RESULT 417
A97456/c
LOCUS A97456 18 bp DNA linear PAT 26-JAN-2000
DEFINITION Sequence 12 from Patent WO9916780.
ACCESSION A97456
VERSION A97456.1 GI:6780802
KEYWORDS
SOURCE unidentified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 18)
AUTHORS Gala,J. and Vannuffel,P.
TITLE GENETIC SEQUENCES, DIAGNOSTIC AND/OR QUANTIFICATION METHODS AND
DEVICES FOR THE IDENTIFICATION OF STAPHYLOCOCCI STRAINS
JOURNAL Patent: WO 9916780-A 12 08-APR-1999;
GALA JEAN LUC (BE); UNIV LOUVAIN (BE)
FEATURES
source Location/Qualifiers
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 12 a 1 c 3 g 2 t

Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1562 ATTTTCTTACTGTTT 1577
Db 16 ATTTTCTTACTGTTT 1

RESULT 418
LOCUS A9272 18 bp DNA linear PAT 26-JAN-2000
DEFINITION Sequence 48 from Patent WO9907839.
ACCESSION A9272
VERSION A9272.1 GI:6782201
KEYWORDS
SOURCE unidentified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 18)

```

AUTHORS Min.J.W. and Piers.W.  
TITLE NEW IMMUNOPROTECTIVE INFLUENZA ANTIGEN AND ITS USE IN VACCINATION  
JOURNAL Patent: WO 9907839-A 48 18-FEB-1999;  
VLAAMS INTERUNIV INST BIOTEC (BE); MIN JOU WILLY (BE)  
FEATURES  
source  
1. .18  
Location/Qualifiers  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
BASE COUNT 7 a 0 c 6 g 5 t  
Query Match 1.0%; Score 12.8; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1155 TAGATATTAAGATG 1170  
|||||  
Db 3 TAGATATTAAGATG 18  
RESULT 419  
AR083978/c  
LOCUS AR083978 18 bp DNA linear PAT 01-SEP-2000  
DEFINITION Sequence 37 from patent US 5977337.  
ACCESSION AR083978  
VERSION AR083978.1 GI:10010749  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Loomore,S.M., Du,R.-P., Wang,Q., Yang,Y.-P. and Klein,M.H.  
TITLE Lactoferrin receptor genes of Moraxella  
JOURNAL Patent: US 5977337-A 37 02-NOV-1999;  
FEATURES  
source  
1. .18  
Location/Qualifiers  
/organism="unknown"  
BASE COUNT 7 a 1 c 3 g 7 t  
Query Match 1.0%; Score 12.8; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1233 TTAAATTTTCATTCA 1248  
|||||  
Db 18 TTAAACTTCATTCA 3  
RESULT 420  
AR087025/c  
LOCUS AR087025 18 bp DNA linear PAT 07-SEP-2000  
DEFINITION Sequence 22 from patent US 5985663.  
ACCESSION AR087025  
VERSION AR087025.1 GI:10013791  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Bennett,C.Frank. and Cowser,L.M.  
TITLE Antisense inhibition of interleukin-15 expression  
JOURNAL Patent: US 5985663-A 22 16-NOV-1999;  
FEATURES  
source  
1. .18  
Location/Qualifiers  
/organism="unknown"  
BASE COUNT 4 a 3 c 8 g 3 t  
Query Match 1.0%; Score 12.8; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1339 CTGTCATTCAGCT 1354  
|||||

Db 16 CTGTCATTCAGCT 1  
RESULT 421  
AR144082  
LOCUS AR144082 18 bp DNA linear PAT 08-AUG-2001  
DEFINITION Sequence 5 from patent US 6210879.  
ACCESSION AR144082  
VERSION AR144082.1 GI:15105949  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Meloni,R., Laurent,C. and Mallet,J.  
TITLE Method for diagnosing schizophrenia  
JOURNAL Patent: US 6210879-A 5 03-APR-2001;  
FEATURES  
source  
1. .18  
Location/Qualifiers  
/organism="unknown"  
BASE COUNT 1 a 8 c 1 g 8 t  
Query Match 1.0%; Score 12.8; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 905 GTTCTCTCTTATTC 920  
|||||  
Db 1 GTTCTCTCTTATTC 16  
RESULT 422  
AR173914  
LOCUS AR173914 18 bp DNA linear PAT 17-DEC-2001  
DEFINITION Sequence 112 from patent US 6306606.  
ACCESSION AR173914  
VERSION AR173914.1 GI:17914234  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Weber,M.J., Wyatt,J. and Cowser,L.M.  
TITLE Antisense modulation of MP-1 expression  
JOURNAL Patent: US 6306606-A 112 23-OCT-2001;  
FEATURES  
source  
1. .18  
Location/Qualifiers  
/organism="unknown"  
BASE COUNT 1 a 5 c 5 g 7 t  
Query Match 1.0%; Score 12.8; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1353 CTGTCCTGCTAGCT 1368  
|||||  
Db 3 CTGTCCTGCTAGCT 18  
RESULT 423  
AR215601/c  
LOCUS AR215601 18 bp DNA linear PAT 25-SEP-2002  
DEFINITION Sequence 149 from patent US 6410323.  
ACCESSION AR215601  
VERSION AR215601.1 GI:23313857  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Roberts,M.L. and Cowser,L.M.  
TITLE Antisense modulation of human Rho family gene expression  
JOURNAL Patent: US 6410323-A 149 25-JUN-2002;

```

FEATURES          Location/Qualifiers
source            1..18
BASE COUNT       7 a 5 c 4 g 2 t
Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 827 CCTGGATTTTCTG 842
Db 18 CCTGGATTTTCTG 3

RESULT 424
AR223848
LOCUS            18 bp mRNA linear PAT 26-SEP-2002
DEFINITION      Sequence 15 from patent US 6440660.
ACCESSION       AR223848
VERSION         AR223848.1 GI:23332430
KEYWORDS
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 18)
AUTHORS        Barker,R.H. Jr., Rapaport,E. and Zamecnik,P.C.
TITLE          Oligonucleotide mediated reversal of drug resistance
JOURNAL        Patent: US 6440660-A 15 27-AUG-2002;
FEATURES
source          1..18
BASE COUNT      7 a 2 c 2 g 7 t
Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1259 AAATAATTTTCTAGTA 1274
Db 2 AAATAATTTTCTCGTA 17

RESULT 425
AR223849/c
LOCUS            18 bp mRNA linear PAT 26-SEP-2002
DEFINITION      Sequence 16 from patent US 6440660.
ACCESSION       AR223849
VERSION         AR223849.1 GI:23332431
KEYWORDS
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 18)
AUTHORS        Barker,R.H. Jr., Rapaport,E. and Zamecnik,P.C.
TITLE          Oligonucleotide mediated reversal of drug resistance
JOURNAL        Patent: US 6440660-A 15 27-AUG-2002;
FEATURES
source          1..18
BASE COUNT      7 a 2 c 2 g 7 t
Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1259 AAATAATTTTCTAGTA 1274
Db 17 AAATAATTTTCTCGTA 2

RESULT 426
AR242371/c
LOCUS            18 bp DNA linear PAT 20-DEC-2002

```

---

```

DEFINITION      Sequence 12 from patent US 6472200.
ACCESSION       AR242371
VERSION         AR242371.1 GI:27288303
KEYWORDS
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 18)
AUTHORS        Mitran,I.
TITLE          Device and method for performing a biological modification of a fluid
JOURNAL        Patent: US 6472200-A 12 29-OCT-2002;
FEATURES
source          1..18
BASE COUNT      2 a 4 c 5 g 7 t
Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 496 GCCGATGCAATACAA 511
Db 18 GCCTGAGGCAATACAA 3

RESULT 427
AR275401
LOCUS            18 bp DNA linear PAT 10-APR-2003
DEFINITION      Sequence 35 from patent US 6509018.
ACCESSION       AR275401
VERSION         AR275401.1 GI:29708514
KEYWORDS
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 18)
AUTHORS        Mauciere,P., Lousert-Ajaka,I., Simon,P., Saragosti,S. and Barre-Sinoussi,F.
TITLE          Non-M non-O HIV strains, fragments and uses
JOURNAL        Patent: US 6509018-A 35 21-JAN-2003;
FEATURES
source          1..18
BASE COUNT      6 a 4 c 4 g 4 t
Query Match      1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 410 TATCCAGATCAGTG 425
Db 3 TATCCAGATCAGAG 18

RESULT 428
AR275453
LOCUS            18 bp DNA linear PAT 10-APR-2003
DEFINITION      Sequence 91 from patent US 6509018.
ACCESSION       AR275453
VERSION         AR275453.1 GI:29708566
KEYWORDS
SOURCE          Unknown.
ORGANISM        Unclassified.
REFERENCE       1 (bases 1 to 18)
AUTHORS        Mauciere,P., Lousert-Ajaka,I., Simon,P., Saragosti,S. and Barre-Sinoussi,F.
TITLE          Non-M non-O HIV strains, fragments and uses
JOURNAL        Patent: US 6509018-A 91 21-JAN-2003;
FEATURES
source          1..18
/organism="unknown"

```

BASE COUNT 6 a 4 c 4 g 4 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;  
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 410 TATCCAGATCAAGTG 425  
 Db 3 TATCCAGATCAAG 18

RESULT 429  
 AR293515/c  
 LOCUS 18 bp DNA linear PAT 12-JUN-2003  
 DEFINITION Sequence 5250 from patent US 6537751.  
 ACCESSION AR293515  
 VERSION AR293515.1 GI:31680799  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 18)  
 AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.  
 TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome  
 JOURNAL Patent: US 6537751-A 5250 25-MAR-2003;  
 FEATURES Location/Qualifiers  
 source 1..18  
 /organism="unknown"

BASE COUNT 6 a 6 c 3 g 3 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;  
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 820 TGGAAATCCTGGATT 835  
 Db 17 TGGAAAGCCTGGTTT 2

RESULT 430  
 AR294351  
 LOCUS 18 bp DNA linear PAT 12-JUN-2003  
 DEFINITION Sequence 6086 from patent US 6537751.  
 ACCESSION AR294351  
 VERSION AR294351.1 GI:31681635  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 18)  
 AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.  
 TITLE Biallelic markers for use in constructing a high density disequilibrium map of the human genome  
 JOURNAL Patent: US 6537751-A 6086 25-MAR-2003;  
 FEATURES Location/Qualifiers  
 source 1..18  
 /organism="unknown"

BASE COUNT 2 a 2 c 6 g 8 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;  
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1566 TTTTACTGTTCTGA 1581  
 Db 1 TGTTACTGTTCTGA 16

RESULT 431  
 AX132977/c  
 LOCUS 18 bp DNA linear PAT 15-MAY-2001  
 DEFINITION Sequence 4195 from Patent WO0130362.

ACCESSION AX132977  
 VERSION AX132977.1 GI:14139287  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Robbins, J.M. and Tritz, R.  
 TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
 JOURNAL Patent: WO 0130362-A 4195 03-MAY-2001;  
 IMUSOL, INC. (US)  
 FEATURES Location/Qualifiers  
 source 1..18  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /note="Hammerhead ribozyme recognition site for cdc 2 kinase"

BASE COUNT 6 a 2 c 3 g 7 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;  
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1173 TTATTAGATAAATTC 1188  
 Db 18 TTATTAGATAAATTC 3

RESULT 432  
 AX132979/c  
 LOCUS 18 bp DNA linear PAT 15-MAY-2001  
 DEFINITION Sequence 4197 from Patent WO0130362.  
 ACCESSION AX132979  
 VERSION AX132979.1 GI:14139289  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Robbins, J.M. and Tritz, R.  
 TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
 JOURNAL Patent: WO 0130362-A 4197 03-MAY-2001;  
 IMUSOL, INC. (US)  
 FEATURES Location/Qualifiers  
 source 1..18  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /note="Hammerhead ribozyme recognition site for cdc 2 kinase"

BASE COUNT 7 a 2 c 2 g 7 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;  
 Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1172 TTATTAGATAAATTC 1187  
 Db 16 TTATTAGATAAATTC 1

RESULT 433  
 AX133131/c  
 LOCUS 18 bp DNA linear PAT 15-MAY-2001  
 DEFINITION Sequence 4349 from Patent WO0130362.  
 ACCESSION AX133131  
 VERSION AX133131.1 GI:14139441  
 KEYWORDS

SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 Robbins,J.M. and Tritz,R.  
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
JOURNAL Patent: WO 0130362-A 4349 03-MAY-2001;  
IMMUSOL, INC. (US)  
FEATURES Location/Qualifiers  
source 1..18  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/note="Hammerhead ribozyme recognition site for cdc 2 kinase"  
BASE COUNT 7 a 3 c 3 g 5 t  
Query Match 1.0%; Score 12.8; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 795 ATTTTCCATAAAGTC 810 18 bp DNA linear PAT 11-SEP-2001  
Db 18 ATTTTCCAGAAATTC 3  
RESULT 434  
AX235061/c  
LOCUS AX235061 18 bp DNA linear PAT 11-SEP-2001  
DEFINITION Sequence 18 from Patent WO0163540.  
ACCESSION AX235061  
VERSION AX235061.1 GI:15593709  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Bureau,T.  
TITLE Method for identifying transposons from a nucleic acid database  
JOURNAL Patent: WO 0163540-A 18 30-AUG-2001;  
MCGILL UNIVERSITY (CA)  
FEATURES Location/Qualifiers  
source 1..18  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
/note="sequence from gi 2264308"  
BASE COUNT 7 a 1 c 2 g 8 t  
Query Match 1.0%; Score 12.8; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1593 TATAAAGTAAATATG 1608 18 bp DNA linear PAT 05-OCT-2001  
Db 18 TATAAATCTAAATATG 3  
RESULT 435  
AX252918  
LOCUS AX252918 18 bp DNA linear PAT 05-OCT-2001  
DEFINITION Sequence 388 from Patent WO0168910.  
ACCESSION AX252918  
VERSION AX252918.1 GI:15986189  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Berlin,K.  
TITLE Oligonucleotides or pna oligomers and a method for detecting the

methylation state of genomic dna in a parallel manner  
Patent: WO 0168910-A 388 20-SEP-2001;  
Epigenomics AG (DE)  
FEATURES Location/Qualifiers  
source 1..18  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
/note="Beschreibung der kunstlichen Sequenz:Oligonukleotid"  
BASE COUNT 4 a 0 c 3 g 11 t  
Query Match 1.0%; Score 12.8; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1143 TTATTATTTATTAGA 1158 18 bp DNA linear PAT 06-FEB-2002  
Db 3 TTATGTTGATTAGA 18  
RESULT 436  
AX348483/c  
LOCUS AX348483 18 bp DNA linear PAT 06-FEB-2002  
DEFINITION Sequence 178 from Patent WO0202806.  
ACCESSION AX348483  
VERSION AX348483.1 GI:18614519  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Olek,A., Piepenbrock,C. and Berlin,K.  
TITLE Method and nucleic acids for pharmacogenomic methylation analysis  
JOURNAL Patent: WO 0202806-A 178 10-JAN-2002;  
Epigenomics AG (DE)  
FEATURES Location/Qualifiers  
source 1..18  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
/note="SOD1 detection oligomer"  
BASE COUNT 2 a 0 c 5 g 11 t  
Query Match 1.0%; Score 12.8; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1400 ATTAAACAGCCAAA 1415 18 bp DNA linear PAT 06-FEB-2002  
Db 17 ATTAAACACCCAAA 2  
RESULT 437  
AX349206  
LOCUS AX349206 18 bp DNA linear PAT 06-FEB-2002  
DEFINITION Sequence 132 from Patent WO0202808.  
ACCESSION AX349206  
VERSION AX349206.1 GI:18615241  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Olek,A., Piepenbrock,C. and Berlin,K.  
TITLE Method and nucleic acids for the analysis of astrocytomas  
JOURNAL Patent: WO 0202808-A 132 10-JAN-2002;  
Epigenomics AG (DE)  
FEATURES Location/Qualifiers  
source 1..18  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"



BASE COUNT 11 a 4 c 0 g 3 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1400 ATTAACACAGCCAAA 1415  
Db 2 ATTAACACACCTAAA 17

RESULT 438

AX468612  
LOCUS AX468612 18 bp DNA linear PAT 16-JUL-2002  
DEFINITION Sequence 7 from Patent WO0240710.  
ACCESSION AX468612  
VERSION AX468612.1 GI:21901410

KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
artificial sequences.

REFERENCE 1

AUTHORS Olek.A., Piepenbrock,C. and Berlin.K.

TITLE Method for detecting methylation states for a toxicological

JOURNAL diagnostic

PATENT: WO 0240710-A 7 23-MAY-2002;

Epigenomics AG (DE)

FEATURES  
source Location/Qualifiers

1. .18 /organism="synthetic construct"

/mol\_type="genomic DNA"

/db\_xref="taxon:32630"

/note="chemically treated genomic DNA (Homo sapiens)"

BASE COUNT 2 a 0 c 4 g 12 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 4.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1143 TTTATTTTATTAGTA 1158  
Db 2 TTTTATTTGTTTAGA 17

RESULT 439

AX599210  
LOCUS AX599210 18 bp DNA linear PAT 14-FEB-2003  
DEFINITION Sequence 550 from Patent WO02077272.  
ACCESSION AX599210  
VERSION AX599210.1 GI:28399352

KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
artificial sequences.

REFERENCE 1

AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,

Olek.A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,

Levin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,

Pelet,C. and Ziebarth,H.

TITLE Methods and nucleic acids for the analysis of hematopoietic cell

proliferative disorders

JOURNAL Patent: WO 02077272-A 550 03-OCT-2002;

Epigenomics AG (DE)

FEATURES  
source Location/Qualifiers

1. .18 /organism="synthetic construct"

/mol\_type="genomic DNA"

/db\_xref="taxon:32630"

/note="Detection oligonucleotide for EGR4"

BASE COUNT 8 a 0 c 2 g 8 t

Query Match

Best Local Similarity 1.0%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 4.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1124 ATTAAGATCTTAGT 1139  
Db 2 ATTAATAATCTTAGT 17

RESULT 440

AX599319/c  
LOCUS AX599319 18 bp DNA linear PAT 14-FEB-2003  
DEFINITION Sequence 659 from Patent WO02077272.  
ACCESSION AX599319  
VERSION AX599319.1 GI:28399461

KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
artificial sequences.

REFERENCE 1

AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,

Olek.A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,

Levin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,

Pelet,C. and Ziebarth,H.

TITLE Methods and nucleic acids for the analysis of hematopoietic cell

proliferative disorders

JOURNAL Patent: WO 02077272-A 659 03-OCT-2002;

Epigenomics AG (DE)

FEATURES  
source Location/Qualifiers

1. .18 /organism="synthetic construct"

/mol\_type="genomic DNA"

/db\_xref="taxon:32630"

/note="Detection oligonucleotide for ARHI"

BASE COUNT 4 a 1 c 4 g 9 t

Query Match

Best Local Similarity 1.0%; Score 12.8; DB 1; Length 18;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 620 AAAACACAAATAATT 635  
Db 17 AAAACTACGAATAATT 2

RESULT 441

AX599396/c  
LOCUS AX599396 18 bp DNA linear PAT 14-FEB-2003  
DEFINITION Sequence 736 from Patent WO02077272.  
ACCESSION AX599396  
VERSION AX599396.1 GI:28399540

KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
artificial sequences.

REFERENCE 1

AUTHORS Berlin,K., Braun,A., Distler,J., Guetig,D., Howe,A., Mueller,J.,

Olek.A., Piepenbrock,C., Adorjan,P., Grabs,G., Lesche,R., Leu,E.,

Levin,A., Lipscher,E., Maier,S., Model,F., Mueller,V., Otto,T.,

Pelet,C. and Ziebarth,H.

TITLE Methods and nucleic acids for the analysis of hematopoietic cell

proliferative disorders

JOURNAL Patent: WO 02077272-A 736 03-OCT-2002;

Epigenomics AG (DE)

FEATURES  
source Location/Qualifiers

1. .18 /organism="synthetic construct"

/mol\_type="genomic DNA"

/db\_xref="taxon:32630"

/note="Detection oligonucleotide for DAPK1"

BASE COUNT 3 a 0 c 4 g 11 t

Query Match

Best Local Similarity 1.0%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 4.7e+02;

```

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 611 AATCTACAAAACAA 626
Db 16 AATTTCCAAAACAA 1

RESULT 442
AX7059722
LOCUS AX599722
DEFINITION Sequence 1062 from Patent WO02077272.
ACCESSION AX599722
VERSION AX599722.1 GI:28399870
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Berlin, K., Braun, A., Distler, J., Guetig, D., Howe, A., Mueller, J.,
Olek, A., Piepenbrock, C., Adorian, P., Grabs, G., Lesche, R., Leu, E.,
Lewin, A., Lipscher, E., Maier, S., Model, F., Mueller, V., Otto, T.,
Pellet, C., and Ziebarth, H.
TITLE Methods and nucleic acids for the analysis of hematopoietic cell
proliferative disorders
JOURNAL Patent: WO 02077272-A 1062 03-OCT-2002;
Epigenomics AG (DE)
FEATURES
source
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Detection oligonucleotide for ELK1"
BASE COUNT 4 a 1 c 1 g 12 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 833 TTTTTCGTTAAAT 848
Db 1 TTTTTCGTTAAAT 15

RESULT 443
AX657871
LOCUS AX657871
DEFINITION Sequence 116 from Patent WO02103042.
ACCESSION AX657871
VERSION AX657871.1 GI:29160567
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Distler, J., Model, F., and Adorian, P.
TITLE Method and nucleic acids for the differentiation of prostate tumors
JOURNAL Patent: WO 02103042-A 116 27-DEC-2002;
Epigenomics AG (DE)
FEATURES
source
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="TCFA detection oligomer"
BASE COUNT 2 a 4 g 12 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1143 TTTATTATTATTAGA 1158
Db 2 TTTTTCGTTAAAT 17

```

```

RESULT 444
AX705830
LOCUS AX705830
DEFINITION Sequence 499 from Patent WO03014388.
ACCESSION AX705830
VERSION AX705830.1 GI:29562495
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Distler, J., Model, F., and Taubert, H.
TITLE Method and nucleic acids for the analysis of colon cancer
JOURNAL Patent: WO 03014388-A 499 20-FEB-2003;
Epigenomics AG (DE)
FEATURES
source
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Detection oligonucleotide for CEA"
BASE COUNT 4 a 0 c 4 g 10 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1535 TTTAAGATGTTTAT 1550
Db 2 TGTAAAGATGTTTGT 17

RESULT 445
BD066076
LOCUS BD066076
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066076
VERSION BD066076.1 GI:22611679
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Schlingsiepen, K.H. and Brysch, W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 711 07-AUG-2001;
BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT
OS Unknown
PN JP 2001511000-A/711
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGSIEPEN, WOLFGANG BRYSCH
PC C12N15/11.C07H21/04.A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FT source
Location/Qualifiers
1..18
/organism="Unknown"
FEATURES
source
Location/Qualifiers
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 6 a 1 c 1 g 10 t

Query Match 1.0%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1173 TTATTAGATAATTC 1188
Db 2 TTTTTCGTTAAAT 17

```

Db 1 TTTAAGATAAATTC 16

RESULT 446  
BD080876/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

BD080876 18 bp DNA linear PAT 27-AUG-2002  
Gene sequence for identification of Staphylococci strains,  
diagnosis and/or quantitation method, and apparatus.  
BD080876  
BD080876.1 GI:22626479  
JP 2001518283-A/12.  
unidentified  
unidentified  
unclassified.  
1 (bases 1 to 18)  
Vannuffel, P. and Gala, J.L.  
Gene sequence for identification of Staphylococci strains,  
diagnosis and/or quantitation method, and apparatus  
Patent: JP 2001518283-A 12 15-OCT-2001.  
UNIVERSITE CATHOLIQUE DE LOUVAIN, MINISTERE DE LA DEFENSE NATIONALE

OS Fsq2S  
FN JP 2001518283-A/12  
PD 16-OCT-2001  
PF 28-SEP-1998 JP 2000513862  
PR 26-SEP-1997 EP 97870146.4  
PI PASCAL, VANNUPPEL, JEAN LUC GALA  
PC C12Q1/68, C12N15/09, C12N15/00  
CC Strandedness: Single;  
CC Topology: Linear;  
CC Gene sequence for identification of Staphylococci strains, CC  
diagnosis  
and/or quantitation method, and apparatus

CC  
FH Key Location/Qualifiers  
FT source 1..18  
/organism='Fsq2S'.  
Location/Qualifiers  
1..18  
/organism='unidentified'  
/mol type='genomic DNA'  
/db xref='taxon:32644'

BASE COUNT 12 a 1 c 3 g 2 t

Query Match 1.0%; Score 12.9; DB 1; Length 18;  
Best Local Similarity 87.5%; Pred. No. 4.7e+02;  
Matches 14; Conservative 0; Mismatches 2; Gaps 0;

QY 1562 ATTCTTTTACTGCTTT 1577  
||||| ||| |||  
16 ATTCTTTTACTGCTTT 1

Db

RESULT 447  
AX129503/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

AX129503 19 bp DNA linear PAT 15-MAY-2001  
Sequence 721 from Patent WO0130362.  
AX129503  
AX129503.1 GI:14135808  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
Robbins, J.M. and Tritz, R.  
Ribosome therapy for the treatment of proliferative skin and eye  
diseases  
Patent: WO 0130362-A 721 03-MAY-2001;  
IMMUSOL, INC. (US)  
Location/Qualifiers  
1..19  
/organism='Homo sapiens'  
/mol type='genomic DNA'  
/db xref='taxon:9606'

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
FEATURES  
source

RESULT 450  
AX084499/C  
LOCUS AX084499 24 bp mRNA linear PAT 28-FEB-2001  
DEFINITION Sequence 41 from Patent WO0112213.  
ACCESSION AX084499  
VERSION AX084499.1 GI:13185910  
KEYWORDS Mus musculus (house mouse)  
SOURCE Mus musculus  
ORGANISM Mus musculus  
REFERENCE 1  
AUTHORS Blackshear, P.J., Lai, W.S. and Carballo-Jane, E.  
TITLE Ttp-related zinc finger domains and methods of use  
JOURNAL Patent: WO 0112213-A 41 22-FEB-2001;  
THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US)  
FEATURES  
source Location/Qualifiers  
1 . . 24  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/db\_xref="taxon:10090"  
BASE COUNT 6 a 0 c 0 g 18 t  
Query Match 1.0%; Score 12.6; DB 1; Length 24;  
Best Local Similarity 78.9%; Pred. No. 7.5e+02;  
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;  
QY 1248 AGATAAACACCAATTAATT 1266  
Db 21 AATAAATAATAATAATAAT 3  
RESULT 451  
AR131430  
LOCUS AR131430 14 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 14 from patent US 6194144.  
ACCESSION AR131430  
VERSION AR131430.1 GI:14120333  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 14)  
AUTHORS Koster, H.  
TITLE DNA sequencing by mass spectrometry  
JOURNAL Patent: US 6194144-A 14 27-FEB-2001;  
FEATURES  
source Location/Qualifiers  
1 . . 14  
/organism="unknown"  
BASE COUNT 4 a 4 c 2 g 4 t  
Query Match 1.0%; Score 12.4; DB 1; Length 14;  
Best Local Similarity 92.9%; Pred. No. 3.8e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 458 TCACACTTCATGT 471  
Db 1 TCACACTGCATGT 14  
RESULT 452  
AR154236  
LOCUS AR154236 14 bp DNA linear PAT 08-AUG-2001  
DEFINITION Sequence 14 from patent US 6238871.  
ACCESSION AR154236  
VERSION AR154236.1 GI:15122289  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 14)  
AUTHORS Koster, H.  
TITLE DNA sequences by mass spectrometry

JOURNAL Patent: US 6238871-A 14 29-MAY-2001;  
FEATURES  
source Location/Qualifiers  
1 . . 14  
/organism="unknown"  
BASE COUNT 4 a 4 c 2 g 4 t  
Query Match 1.0%; Score 12.4; DB 1; Length 14;  
Best Local Similarity 92.9%; Pred. No. 3.8e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 458 TCACACTTCATGT 471  
Db 1 TCACACTGCATGT 14  
RESULT 453  
AR176706  
LOCUS AR176706 14 bp DNA linear PAT 17-DEC-2001  
DEFINITION Sequence 37 from patent US 6312894.  
ACCESSION AR176706  
VERSION AR176706.1 GI:17919061  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 14)  
AUTHORS Hedgpeth, J., Afonina, I.A., Kutyavin, I.V., Lukhtanov, E.A., Seiousov, E.S. and Meyer, R.B. Jr.  
TITLE Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders  
JOURNAL Patent: US 6312894-A 37 06-NOV-2001;  
FEATURES  
source Location/Qualifiers  
1 . . 14  
/organism="unknown"  
BASE COUNT 1 a 1 c 2 g 10 t  
Query Match 1.0%; Score 12.4; DB 1; Length 14;  
Best Local Similarity 92.9%; Pred. No. 3.8e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1564 TTTTCTTACTGT 1577  
Db 1 TTTTCTTACTGT 14  
RESULT 454  
AR221843  
LOCUS AR221843 14 bp mRNA linear PAT 26-SEP-2002  
DEFINITION Sequence 24 from patent US 6428955.  
ACCESSION AR221843  
VERSION AR221843.1 GI:23328958  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 14)  
AUTHORS Koster, H., Tang, K., Fu, D.-J., Siegert, C.W., Little, D.P., Braun, A., Darnhofer-Demar, B., Jurinke, C. and Van den Boom, D.  
TITLE DNA diagnostics based on mass spectrometry  
JOURNAL Patent: US 6428955-A 24 06-AUG-2002;  
FEATURES  
source Location/Qualifiers  
1 . . 14  
/organism="unknown"  
BASE COUNT 4 a 4 c 2 g 4 t  
Query Match 1.0%; Score 12.4; DB 1; Length 14;  
Best Local Similarity 92.9%; Pred. No. 3.8e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 458 TCACACTTCATGT 471  
Db 1 TCACACTGCATGT 14

RESULT 455  
107800  
LOCUS 107800  
DEFINITION Sequence 2 from Patent EP 0337799.  
ACCESSION 107800  
VERSION 107800.1 GI:589936  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS Nedwin,G.E., Bringham,T.S. and Couraud,P.-O.  
TITLE 14-Beta-gal mammalian lectins  
JOURNAL Patent: EP 0337799-A2 2 18-OCT-1989;  
FEATURES  
Source 1-14  
Location/Qualifiers  
1..15  
/organism="unknown"  
BASE COUNT 6 a 1 c 0 g 7 t  
Query Match 1.0%; Score 12.4; DB 1; Length 14;  
Best Local Similarity 92.9%; Pred. No. 3.8e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1294 CTGAATTTTAATT 1307  
Db 1 CTAATTTTAATT 14  
RESULT 456  
AR029016  
LOCUS AR029016  
DEFINITION Sequence 3 from patent US 5858988.  
ACCESSION AR029016  
VERSION AR029016.1 GI:5940989  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS Wang,J.H.  
TITLE Poly-substituted-phenyl-oligoribo nucleotides having enhanced  
JOURNAL stability and membrane permeability and methods of use  
Patent: US 5858988-A 3 12-JAN-1999;  
FEATURES  
Source 1..15  
Location/Qualifiers  
1..15  
/organism="unknown"  
BASE COUNT 6 a 3 c 4 g 2 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 781 TGATGGACAATAA 794  
Db 2 TGATGGACAACAA 15  
RESULT 457  
AR029017/c  
LOCUS AR029017  
DEFINITION Sequence 4 from patent US 5858988.  
ACCESSION AR029017  
VERSION AR029017.1 GI:5940990  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS Wang,J.H.  
TITLE Poly-substituted-phenyl-oligoribo nucleotides having enhanced  
JOURNAL stability and membrane permeability and methods of use  
Patent: US 5858988-A 4 12-JAN-1999;

FEATURES  
Source 1..15  
Location/Qualifiers  
2 a 4 c 3 g 6 t  
BASE COUNT  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 781 TGATGGACAATAA 794  
Db 14 TGATGGACAACAA 1  
RESULT 458  
AR041403  
LOCUS AR041403  
DEFINITION Sequence 193 from patent US 5811300.  
ACCESSION AR041403  
VERSION AR041403.1 GI:5961899  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS Sullivan,S., Draper,K., Kiseich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 193 22-SEP-1998;  
FEATURES  
Source 1..15  
Location/Qualifiers  
1..15  
/organism="unknown"  
BASE COUNT 5 a 0 c 0 g 10 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1043 ATTATTATGATT 1056  
Db 1 ATTATTATGATT 14  
RESULT 459  
AR041412  
LOCUS AR041412  
DEFINITION Sequence 202 from patent US 5811300.  
ACCESSION AR041412  
VERSION AR041412.1 GI:5961908  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS Sullivan,S., Draper,K., Kiseich,K., Stinchcomb,D.T. and McSwiggen,J.  
TITLE TNF-.alpha. ribozymes  
JOURNAL Patent: US 5811300-A 202 22-SEP-1998;  
FEATURES  
Source 1..15  
Location/Qualifiers  
1..15  
/organism="unknown"  
BASE COUNT 4 a 1 c 0 g 10 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1045 TATTATGATTATTA 1058  
Db 1 TATTATGATTATTA 14  
RESULT 460  
AR041927  
LOCUS AR041927  
DEFINITION Sequence 15 bp DNA  
ACCESSION AR041927  
VERSION AR041927.1  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
Patent: US 5811300-A 15 29-SEP-1999;  
FEATURES  
Source 1..15  
Location/Qualifiers  
1..15  
/organism="unknown"  
BASE COUNT 15 bp DNA  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 15 bp DNA  
Db 15 bp DNA  
RESULT 461  
AR041927  
LOCUS AR041927  
DEFINITION Sequence 15 bp DNA  
ACCESSION AR041927  
VERSION AR041927.1  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
Patent: US 5811300-A 15 29-SEP-1999;  
FEATURES  
Source 1..15  
Location/Qualifiers  
1..15  
/organism="unknown"  
BASE COUNT 15 bp DNA  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 15 bp DNA  
Db 15 bp DNA  
RESULT 462  
AR041927  
LOCUS AR041927  
DEFINITION Sequence 15 bp DNA  
ACCESSION AR041927  
VERSION AR041927.1  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
Patent: US 5811300-A 15 29-SEP-1999;  
FEATURES  
Source 1..15  
Location/Qualifiers  
1..15  
/organism="unknown"  
BASE COUNT 15 bp DNA  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 15 bp DNA  
Db 15 bp DNA

```

DEFINITION Sequence 717 from patent US 5811300.
ACCESSION AR041927
VERSION AR041927.1 GI:5962423
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-alpha ribozymes
JOURNAL Patent: US 5811300-A 717 22-SEP-1998;
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="unknown"
BASE COUNT 5 a 0 c 0 g 10 t

Query Match
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DEFINITION Sequence 217 from patent US 5837542.
ACCESSION AR056013
VERSION AR056013.1 GI:5981590
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 217 17-NOV-1998;
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="unknown"
BASE COUNT 4 a 1 c 1 g 9 t

Query Match
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DEFINITION Sequence 511 from patent US 5837542.
ACCESSION AR056307
VERSION AR056307.1 GI:5981884
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 511 17-NOV-1998;
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="unknown"
BASE COUNT 4 a 0 c 2 g 9 t

DEFINITION Sequence 717 from patent US 5811300.
ACCESSION AR041927
VERSION AR041927.1 GI:5962423
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE TNF-alpha ribozymes
JOURNAL Patent: US 5811300-A 717 22-SEP-1998;
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="unknown"
BASE COUNT 5 a 0 c 0 g 10 t

Query Match
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DEFINITION Sequence 217 from patent US 5837542.
ACCESSION AR056013
VERSION AR056013.1 GI:5981590
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 217 17-NOV-1998;
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="unknown"
BASE COUNT 4 a 1 c 1 g 9 t

Query Match
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DEFINITION Sequence 511 from patent US 5837542.
ACCESSION AR056307
VERSION AR056307.1 GI:5981884
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 511 17-NOV-1998;
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="unknown"
BASE COUNT 4 a 0 c 2 g 9 t

DEFINITION Sequence 751 from patent US 5837542.
ACCESSION AR056547
VERSION AR056547.1 GI:5982124
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 751 17-NOV-1998;
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="unknown"
BASE COUNT 4 a 0 c 2 g 9 t

Query Match
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DEFINITION Sequence 52 from patent US 5986053.
ACCESSION AR087176
VERSION AR087176.1 GI:10013939
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Ecker,D.J., Buchardt,O., Egholm,M., Nielsen,P.E., Berg,R.H. and Mollegaard,N.B.
TITLE Peptide nucleic acids complexes of two peptide nucleic acid strands and one nucleic acid strand
JOURNAL Patent: US 5986053-A 52 16-NOV-1999;
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="unknown"
BASE COUNT 4 a 2 c 4 g 5 t

Query Match
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 15;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DEFINITION Sequence 217 from patent US 6132967.
ACCESSION AR113771
VERSION AR113771
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 217 17-NOV-1998;
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="unknown"
BASE COUNT 4 a 0 c 2 g 9 t

```

```

ACCESSION AR113771          GI:14094093
VERSION    AR113771.1
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
           Draper,K.G.
TITLE      Ribozyme treatment of diseases or conditions related to levels of
           intercellular adhesion molecule-1 (ICAM-1)
JOURNAL    Patent: US 6132967-A 217 17-OCT-2000;
           Location/Qualifiers
FEATURES   source
           1..15
           /organism="unknown"
BASE COUNT 4 a 1 c 1 g 9 t
           Query Match      1.0%; Score 12.4; DB 1; Length 15;
           Best Local Similarity 92.9%; Pred. No. 4.3e+02;
           Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1049 TATGATATTATTATTA 1062
Db 1 TATGATATTATTATCA 14

RESULT 466
LOCUS      AR114065          15 bp      DNA
DEFINITION Sequence 511 from patent US 6132967.
ACCESSION  AR114065
VERSION    AR114065.1 GI:14094387
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
           Draper,K.G.
TITLE      Ribozyme treatment of diseases or conditions related to levels of
           intercellular adhesion molecule-1 (ICAM-1)
JOURNAL    Patent: US 6132967-A 511 17-OCT-2000;
           Location/Qualifiers
FEATURES   source
           1..15
           /organism="unknown"
BASE COUNT 4 a 0 c 2 g 9 t
           Query Match      1.0%; Score 12.4; DB 1; Length 15;
           Best Local Similarity 92.9%; Pred. No. 4.3e+02;
           Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1047 TTTATGTATTATTATT 1060
Db 1 TTGATGTATTATTATT 14

RESULT 467
LOCUS      AR114305          15 bp      DNA
DEFINITION Sequence 751 from patent US 6132967.
ACCESSION  AR114305
VERSION    AR114305.1 GI:14094627
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
           Draper,K.G.
TITLE      Ribozyme treatment of diseases or conditions related to levels of
           intercellular adhesion molecule-1 (ICAM-1)
JOURNAL    Patent: US 6132967-A 751 17-OCT-2000;
           Location/Qualifiers
FEATURES   source
           1..15
           /organism="unknown"
BASE COUNT 4 a 0 c 2 g 9 t
           Query Match      1.0%; Score 12.4; DB 1; Length 15;
           Best Local Similarity 92.9%; Pred. No. 4.3e+02;
           Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1047 TTTATGTATTATTATT 1060
Db 1 TTGATGTATTATTATT 14

RESULT 468
LOCUS      AR1132468/c       15 bp      DNA
DEFINITION Sequence 893 from patent US 6194150.
ACCESSION  AR132468
VERSION    AR132468.1 GI:14121373
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS    Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE      Nucleic acid based inhibition of CD40
JOURNAL    Patent: US 6194150-A 893 27-FEB-2001;
           Location/Qualifiers
FEATURES   source
           1..15
           /organism="unknown"
BASE COUNT 9 a 0 c 0 g 6 t
           Query Match      1.0%; Score 12.4; DB 1; Length 15;
           Best Local Similarity 92.9%; Pred. No. 4.3e+02;
           Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1038 TATTATTATTATTAT 1051
Db 15 TATTATAATTATTAT 2

RESULT 469
LOCUS      AR133635/c       15 bp      DNA
DEFINITION Sequence 2060 from patent US 6194150.
ACCESSION  AR133635
VERSION    AR133635.1 GI:14122540
KEYWORDS   Unknown.
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS    Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE      Nucleic acid based inhibition of CD40
JOURNAL    Patent: US 6194150-A 2060 27-FEB-2001;
           Location/Qualifiers
FEATURES   source
           1..15
           /organism="unknown"
BASE COUNT 8 a 3 c 1 g 3 t
           Query Match      1.0%; Score 12.4; DB 1; Length 15;
           Best Local Similarity 92.9%; Pred. No. 4.3e+02;
           Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1456 TGTTTATTATGTAC 1469
Db 15 TGTTTATTATGTAC 2

RESULT 470
LOCUS      AR170387         15 bp      DNA
DEFINITION Sequence 13 from patent US 6291438.

```

ACCESSION ARI70387  
VERSION ARI70387.1 GI:17908346  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15).  
AUTHORS Wang,J.H.  
TITLE Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use  
JOURNAL Patent: US 6291438-A 13 18-SEP-2001;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 6 a 3 c 4 g 2 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
RESULT 471  
LOCUS ARI70388/c 15 bp DNA linear PAT 17-DEC-2001  
DEFINITION Sequence 14 from patent US 6291438.  
ACCESSION ARI70388  
VERSION ARI70388.1 GI:17908347  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15).  
AUTHORS Wang,J.H.  
TITLE Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use  
JOURNAL Patent: US 6291438-A 14 18-SEP-2001;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 2 a 4 c 3 g 6 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
RESULT 472  
LOCUS ARI93000 15 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 8488 from patent US 6346398.  
ACCESSION ARI93000  
VERSION ARI93000.1 GI:20238965  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15).  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 8488 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 4 a 2 c 2 g 7 t

ACCESSION ARI70387  
VERSION ARI70387.1 GI:17908346  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15).  
AUTHORS Wang,J.H.  
TITLE Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use  
JOURNAL Patent: US 6291438-A 13 18-SEP-2001;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 6 a 3 c 4 g 2 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
RESULT 471  
LOCUS ARI70388/c 15 bp DNA linear PAT 17-DEC-2001  
DEFINITION Sequence 14 from patent US 6291438.  
ACCESSION ARI70388  
VERSION ARI70388.1 GI:17908347  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15).  
AUTHORS Wang,J.H.  
TITLE Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use  
JOURNAL Patent: US 6291438-A 14 18-SEP-2001;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 2 a 4 c 3 g 6 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
RESULT 472  
LOCUS ARI93000 15 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 8488 from patent US 6346398.  
ACCESSION ARI93000  
VERSION ARI93000.1 GI:20238965  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15).  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 8488 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 4 a 2 c 2 g 7 t

Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1457 GTTATTATTGTACA 1470  
DB 1 GTCTATTATTGTACA 14  
RESULT 473  
LOCUS AR241892 15 bp DNA linear PAT 20-DEC-2002  
DEFINITION Sequence 180 from patent US 6472154.  
ACCESSION AR241892  
VERSION AR241892.1 GI:27287704  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15).  
AUTHORS Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.  
TITLE Polymorphic repeats in human genes  
JOURNAL Patent: US 6472154-A 180 29-OCT-2002;  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 2 a 5 c 4 g 4 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 402 CTCGTGGTATCCA 415  
DB 1 CTCGTGGCATCCA 14  
RESULT 474  
LOCUS AX374587 15 bp DNA linear PAT 01-MAR-2002  
DEFINITION Sequence 8 from Patent WO0210454.  
ACCESSION AX374587  
VERSION AX374587.1 GI:19169484  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Choi,J.Y., Koshy,B., Kilem,S. and Stephens,J.C.  
TITLE Haplotypes of the alas2 gene  
JOURNAL Patent: WO 0210454-A 8 07-FEB-2002;  
GENEAISSANCE Pharmaceuticals, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..15  
BASE COUNT 2 a 4 c 6 g 2 t 1 others  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 691 TTGGGCCCAAGGCC 704  
DB 2 TTGGGCCRAAGGCC 15  
RESULT 475  
LOCUS AX419993 15 bp DNA linear PAT 18-JUN-2002



```

DEFINITION Sequence 330 from Patent WO0198537.
ACCESSION AX419993
VERSION AX419993.1 GI:21524360
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Lyamichev,V., Allawi,H., Dong,F., Neri,B.P. and Vener,I.T.
TITLE Nucleic acid accessible hybridization sites
JOURNAL Patent: WO 0198537-A 330 27-DEC-2001;
THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
source
1. .15
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
BASE COUNT 5 a 2 c 3 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1511 AATACAGGCTTTA 1524
Db | |||||
2 ATTACAGGCTTTA 15

RESULT 476
AX554013
LOCUS AX554013 15 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 36 from Patent WO02074799.
ACCESSION AX554013
VERSION AX554013.1 GI:25897950
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Freysinet,G., Rang,C. and Prutos,R.
TITLE Pepsin-sensitive modified bacillus thuringiensis insecticidal toxin
JOURNAL Patent: WO 02074799-A 36 26-SEP-2002;
AVENTIS CROPS SCIENCE S.A. (FR)
FEATURES
source
1. .15
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="mutant 24"
BASE COUNT 7 a 0 c 1 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1392 TTAGAACTATTAAA 1405
Db | |||||
1 TTAGAACTATTAAA 14

RESULT 477
AX587124/c
LOCUS AX587124 15 bp DNA linear PAT 10-JAN-2003
DEFINITION Sequence 146 from Patent WO02072883.
ACCESSION AX587124
VERSION AX587124.1 GI:27655999
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1
AUTHORS Roetger,A.
TITLE Nucleotide carrier for diagnosing and treating oral diseases

```

```

JOURNAL Patent: WO 02072883-A 146 19-SEP-2002;
ROETGER, Antje (DE)
FEATURES
source
1. .15
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
/notes="Bacteria"
BASE COUNT 2 a 1 c 7 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 938 AGCCACCATCTTAC 951
Db | |||||
14 AGCCACCATCTTAC 1

RESULT 478
AX633104
LOCUS AX633104 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 243 from Patent EP1260586.
ACCESSION AX633104
VERSION AX633104.1 GI:28468718
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
Genes
JOURNAL Patent: EP 1260586-A 243 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1. .15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 1 c 1 g 9 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1049 TATGTATTATTATTA 1062
Db | |||||
1 TATGTATTATTATTA 14

RESULT 479
AX633459
LOCUS AX633459 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 598 from Patent EP1260586.
ACCESSION AX633459
VERSION AX633459.1 GI:28469073
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
Genes

```

```

JOURNAL Patent: EP 1260586-A 598 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    1. .15
    /organism="unidentified"
    /mol_type="mRNA"
    /db_xref="taxon:32644"
BASE COUNT 4 a 0 c 2 g 9 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1047 TTATGCTATTATT 1060
  |||||
  1 TTGATGCTATTATT 14
Db

RESULT 480
AX635377
LOCUS AX635377 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 716 from Patent EP1260586.
ACCESSION AX635377
VERSION AX635377.1 GI:28469191
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.
REFERENCE
  1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
  Karpetsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 716 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    1. .15
    /organism="unidentified"
    /mol_type="mRNA"
    /db_xref="taxon:32644"
BASE COUNT 4 a 0 c 2 g 9 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1047 TTATGCTATTATT 1060
  |||||
  1 TTGATGCTATTATT 14
Db

RESULT 481
AX635377
LOCUS AX635377 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 2516 from Patent EP1260586.
ACCESSION AX635377
VERSION AX635377.1 GI:28470991
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.
REFERENCE
  1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
  Karpetsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 2516 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    1. .15
    /organism="unidentified"
    /mol_type="mRNA"
    /db_xref="taxon:32644"
BASE COUNT 7 a 0 c 3 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1081 AAGAAATTTGGAAA 1094
  |||||
  1 AAGAAATTTGGTAAA 14
Db

RESULT 482
AX635379
LOCUS AX635379 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 2518 from Patent EP1260586.
ACCESSION AX635379
VERSION AX635379.1 GI:28470993
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.
REFERENCE
  1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
  Karpetsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 2518 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
  source
    1. .15
    /organism="unidentified"
    /mol_type="mRNA"
    /db_xref="taxon:32644"
BASE COUNT 7 a 0 c 3 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1081 AAGAAATTTGGAAA 1094
  |||||
  2 AAGAAATTTGGTAAA 15
Db

RESULT 483
AX636864
LOCUS AX636864 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4003 from Patent EP1260586.
ACCESSION AX636864
VERSION AX636864.1 GI:28472478
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.
REFERENCE
  1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
  Karpetsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
  McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
  Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
  Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
  genes
JOURNAL Patent: EP 1260586-A 4003 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)

```

FEATURES source Location/Qualifiers  
1.15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
BASE COUNT 5 a 0 c 0 g 10 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. NO. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1043 ATTATTATGATT 1056  
|||||  
1 ATTATTATGATT 14  
Db 1 ATTATTATGATT 14  
RESULT 484  
AX637403  
LOCUS AX637403 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 4542 from Patent EPI260586.  
ACCESSION AX637403  
VERSION AX637403.1 GI:28473017  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 4021 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES source Location/Qualifiers  
1.15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
BASE COUNT 4 a 1 c 0 g 10 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. NO. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1045 TATTATGATT 1058  
|||||  
1 TATTATGATT 14  
Db 1 TATTATGATT 14  
RESULT 485  
AX637403  
LOCUS AX637403 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 4542 from Patent EPI260586.  
ACCESSION AX637403  
VERSION AX637403.1 GI:28473017  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 4542 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES source Location/Qualifiers

source 1.15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
BASE COUNT 5 a 0 c 0 g 10 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. NO. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1043 ATTATTATGATT 1056  
|||||  
1 ATTATTATGATT 14  
Db 1 ATTATTATGATT 14  
RESULT 486  
AX637884/c  
LOCUS AX637884 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 5023 from Patent EP1260586.  
ACCESSION AX637884  
VERSION AX637884.1 GI:28473498  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 5023 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES source Location/Qualifiers  
1.15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
BASE COUNT 7 a 3 c 1 g 4 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. NO. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1453 ACTTGTTATTATG 1466  
|||||  
15 ACTTGTTATTATG 2  
Db 15 ACTTGTTATTATG 2  
RESULT 487  
E29991/c  
LOCUS E29991 15 bp DNA linear PAT 18-JUN-2001  
DEFINITION Method for detecting higher-order structure of RNA.  
ACCESSION E29991  
VERSION E29991.1 GI:13021377  
KEYWORDS JP 1999285386-A/17.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Hiroyuki, K., Satoshi, K., Kaname, I. and Akihiko, T.  
TITLE Method for detecting higher-order structure of RNA  
JOURNAL Patent: JP 1999285386-A 17 19-OCT-1999;  
EUNSHI BIO HOTONIKUSU KENKYUSHO  
COMMENT OS Unidentified  
PN JP 1999285386-A/17  
PF 19-OCT-1999  
PR 03-APR-1998 JP 1998091580  
PI HIROYUKI KOSHIMOTO, SATOSHI KONDO, KANAME ISHIBASHI, PI AKIHIKO TSUJI

```
PC C12N15/09,C12Q1/68,G01N21/78,G01N33/58//G01N21/64,C12N15/00 CC
Strandedness: Double;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..15
FT /organism='Unidentified'.
FT Location/Qualifiers
1..15
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'
BASE COUNT 9 a 0 g 5 t 1 others
Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1148 TTTATTTAGATATT 1162
DB 15 TTTATTTAAATATT 1

RESULT 488
E31788/c
LOCUS E31788 15 bp RNA linear PAT 18-JUN-2001
DEFINITION Pyrene-modified RNA and method for analyzing RNA.
ACCESSION E31788
VERSION E31788.1 GI:13018622
KEYWORDS JP 2000032999-A/1.
SOURCE synthetic construct
ORGANISM artificial construct.
REFERENCE 1 (bases 1 to 15)
AUTHORS Kazunari,Y., Hirofumi,Z., Hidehiko,N., Reiko,I. and Akira,M.
TITLE Pyrene-modified RNA and method for analyzing RNA
JOURNAL Patent: JP 2000032999-A 1 02-FEB-2000;
TOGOSSEI CHEM IND CO LTD
OS Artificial Sequence
PN JP 2000032999-A/1
PD 02-FEB-2000
PF 17-JUL-1998 JP 1998202589
PR KAZUNARI YAMANA,HIROFUMI ZAKKO,HIDEHIKO NAKANO,REIKO IWASE, PI
AKIRA MURAKAMI
PC C12Q1/68,C12Q1/69,G01N15/09,G01N33/53,G01N33/566,C12N15/00 CC

FH Key Location/Qualifiers
FT modified base (4).
1..15
/organism='synthetic construct'
/mol_type='genomic RNA'
/db_xref='taxon:32630'
BASE COUNT 4 a 2 c 4 g 5 t

Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 TCAACACTTCATGT 471
DB 14 TCAACACTGCATGT 1

RESULT 489
E31789/c
LOCUS E31789 15 bp RNA linear PAT 18-JUN-2001
DEFINITION Pyrene-modified RNA and method for analyzing RNA.
ACCESSION E31789
VERSION E31789.1 GI:13018623
KEYWORDS JP 2000032999-A/2.
SOURCE synthetic construct
ORGANISM synthetic construct.
```

```
artificial sequences.
1 (bases 1 to 15)
Kazunari,Y., Hirofumi,Z., Hidehiko,N., Reiko,I. and Akira,M.
Pyrene-modified RNA and method for analyzing RNA
Patent: JP 2000032999-A 2 02-FEB-2000;
TOGOSSEI CHEM IND CO LTD
OS Artificial Sequence
PN JP 2000032999-A/2
PD 02-FEB-2000
PF 17-JUL-1998 JP 1998202589
PR KAZUNARI YAMANA,HIROFUMI ZAKKO,HIDEHIKO NAKANO,REIKO IWASE, PI
AKIRA MURAKAMI
PC C12Q1/68,C12Q1/69,G01N15/09,G01N33/53,G01N33/566,C12N15/00 CC

FH Key Location/Qualifiers
FT modified base (9).
1..15
/organism='synthetic construct'
/mol_type='genomic RNA'
/db_xref='taxon:32630'
BASE COUNT 4 a 2 c 4 g 5 t

Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 TCAACACTTCATGT 471
DB 14 TCAACACTGCATGT 1

RESULT 490
E31790/c
LOCUS E31790 15 bp RNA linear PAT 18-JUN-2001
DEFINITION Pyrene-modified RNA and method for analyzing RNA.
ACCESSION E31790
VERSION E31790.1 GI:13018624
KEYWORDS JP 2000032999-A/3.
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 15)
AUTHORS Kazunari,Y., Hirofumi,Z., Hidehiko,N., Reiko,I. and Akira,M.
TITLE Pyrene-modified RNA and method for analyzing RNA
JOURNAL Patent: JP 2000032999-A 3 02-FEB-2000;
TOGOSSEI CHEM IND CO LTD
OS Artificial Sequence
PN JP 2000032999-A/3
PD 02-FEB-2000
PF 17-JUL-1998 JP 1998202589
PR KAZUNARI YAMANA,HIROFUMI ZAKKO,HIDEHIKO NAKANO,REIKO IWASE, PI
AKIRA MURAKAMI
PC C12Q1/68,C12Q1/69,G01N15/09,G01N33/53,G01N33/566,C12N15/00 CC

FH Key Location/Qualifiers
FT modified base (11).
1..15
/organism='synthetic construct'
/mol_type='genomic RNA'
/db_xref='taxon:32630'
BASE COUNT 4 a 2 c 4 g 5 t

Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 TCAACACTTCATGT 471
DB 14 TCAACACTGCATGT 1
```

BASE COUNT		4 a	2 c	4 g	5 t		
Query Match		1.0%;		Score 12.4;	DB 1;	Length 15;	
Best Local Similarity		92.9%;		Pred. No. 4.3e+02;			
Matches 13;		Conservative	0;	Mismatches	1;	Indels	0; Gaps 0;
Qy	458	TCAACACTTCATGT	471				
Db	14	TCAACACTGCATGT	1				
<p>RESULT 493</p> <p>E31793/ c</p> <p>LOCUS</p> <p>DEFINITION</p> <p>Pyrene-modified RNA and method for analyzing RNA.</p> <p>ACCESSION</p> <p>E31793</p> <p>VERSION</p> <p>E31793.1 GI:13018627</p> <p>KEYWORDS</p> <p>JP 2000032999-A/6.</p> <p>SOURCE</p> <p>synthetic construct</p> <p>ORGANISM</p> <p>artificial sequences.</p> <p>REFERENCE</p> <p>1 (bases 1 to 15)</p> <p>AUTHORS</p> <p>Kazunari, Y., Hirofumi, Z., Hidehiko, N., Reiko, I. and Akira, M.</p> <p>TITLE</p> <p>Pyrene-modified RNA and method for analyzing RNA</p> <p>JOURNAL</p> <p>Patent: JP 2000032999-A 6 02-FEB-2000;</p> <p>COMMENT</p> <p>TOAGOSEI CHEM IND CO LTD</p> <p>OS Artificial Sequence</p> <p>FN JP 2000032999-A/6</p> <p>PD 02-FEB-2000</p> <p>PF 17-JUL-1998 JP 19980202589</p> <p>PR</p> <p>PT KAZUNARI YAMANA, HIROFUMI ZAKKO, HIDEHIKO NAKANO, REIKO IWASE, PI</p> <p>PC C12Q1/68.C12Q1/68, C12N15/09, G01N33/53, G01N33/566, C12N15/00 CC</p>							
FEATURES		source					
PH	Key	Location/Qualifiers					
FT	modified base	(11).					
		1..15	Location/Qualifiers				
		/organism="synthetic construct"					
		/mol_type="genomic DNA"					
		/db_xref="taxon:32630"					
BASE COUNT		4 a	2 c	4 g	5 t		
Query Match		1.0%;		Score 12.4;	DB 1;	Length 15;	
Best Local Similarity		92.9%;		Pred. No. 4.3e+02;			
Matches 13;		Conservative	0;	Mismatches	1;	Indels	0; Gaps 0;
Qy	458	TCAACACTTCATGT	471				
Db	14	TCAACACTGCATGT	1				
<p>RESULT 494</p> <p>E36075/ c</p> <p>LOCUS</p> <p>DEFINITION</p> <p>Higher-order structure and binding of peptide nucleic acid.</p> <p>ACCESSION</p> <p>E36075</p> <p>VERSION</p> <p>E36075.1 GI:13022477</p> <p>KEYWORDS</p> <p>JP 1999236396-A/20.</p> <p>SOURCE</p> <p>unidentified</p> <p>ORGANISM</p> <p>unclassified.</p> <p>REFERENCE</p> <p>1 (bases 1 to 15)</p> <p>AUTHORS</p> <p>Bushato, O., Eguhorumu, M., Nielsen, P.A., Berg, R.H., Ekka, D.J. and Morugado, N.A.</p> <p>TITLE</p> <p>Higher-order structure and binding of peptide nucleic acid</p> <p>JOURNAL</p> <p>Patent: JP 1999236396-A 20 31-AUG-1999;</p> <p>ISIS PHARMACEUTICALS INC. BUCHARDT DORUTE, EGUHORUMU MICHAEL, IELSEN</p> <p>FATER A., BERGH RORUFU HO</p> <p>OS Unidentified</p>							

RESULT 491	E31791/c	LOCUS	15 bp	DNA	linear	PAT 18-JUN-2001
DEFINITION	E31791	Pyrene-modified RNA and method for analyzing RNA.				
ACCESSION	E31791					
VERSION	E31791.1	GI:13018625				
KEYWORDS	JP 2000032999-A/4					
SOURCE		synthetic construct				
ORGANISM		artificial sequences.				
REFERENCE		1 (bases 1 to 15)				
AUTHORS	Kazunari, Y., Hirofumi, Z., Hidehiko, N., Reiko, I. and Akira, M.					
TITLE	Pyrene-modified RNA and method for analyzing RNA					
JOURNAL	Patent: JP 2000032999-A 4 02-FEB-2000;					
COMMENT	TOAGOSEI CHEM IND CO LTD					
	OS Artificial Sequence					
	PN JP 2000032999-A/4					
	PD 02-FEB-2000					
	PP 17-JUL-1998 JP 1998202589					
	PR					
	PI KAZUNARI YAMANA, HIROFUMI ZAKKO, HIDEHIKO NAKANO, REIKO IWASE, PI AKIRA MURAKAMI					
PC	CI2Q1/68, CI2Q1/68, CI2N15/09, G01N33/53, G01N33/566, CI2N15/00 CC					
PH	Key	Location/Qualifiers				
FT	modified_base (4).					
FEATURES	source	Location/Qualifiers				
	1..15	/organism="synthetic construct"				
	/mol_type="genomic DNA"					
	/db_xref="taxon:32630"					
BASE COUNT	4 a 2 c 4 g 5 t					
Query Match	1.0%	Score 12.4; DB 1; Length 15;				
Best Local Similarity	92.9%;	Pred. No. 4.3e+02;				
Matches 13; Conservative	0; Mismatches 1; Indels 0; Gaps 0;					
QY	458 TCACACTTCATGT 471					
DB	14 TCACACTGCATGT 1					
RESULT 492	E31792/c	LOCUS	15 bp	DNA	linear	PAT 18-JUN-2001
DEFINITION	E31792	Pyrene-modified RNA and method for analyzing RNA.				
ACCESSION	E31792					
VERSION	E31792.1	GI:13018626				
KEYWORDS	JP 2000032999-A/5.					
SOURCE		synthetic construct				
ORGANISM		artificial sequences.				
REFERENCE		1 (bases 1 to 15)				
AUTHORS	Kazunari, Y., Hirofumi, Z., Hidehiko, N., Reiko, I. and Akira, M.					
TITLE	Pyrene-modified RNA and method for analyzing RNA					
JOURNAL	Patent: JP 2000032999-A 5 02-FEB-2000;					
COMMENT	TOAGOSEI CHEM IND CO LTD					
	OS Artificial Sequence					
	PN JP 2000032999-A/5					
	PD 02-FEB-2000					
	PP 17-JUL-1998 JP 1998202589					
	PR					
	PI KAZUNARI YAMANA, HIROFUMI ZAKKO, HIDEHIKO NAKANO, REIKO IWASE, PI AKIRA MURAKAMI					
PC	CI2Q1/68, CI2Q1/68, CI2N15/09, G01N33/53, G01N33/566, CI2N15/00 CC					
PH	Key	Location/Qualifiers				
FT	modified_base (9).					
FEATURES	source	Location/Qualifiers				
	1..15	/organism="synthetic construct"				

```
PN JP 1999236396-A/20
PD 31-AUG-1999
PF 14-OCT-1998 JP 1998291590
PR 02-JUL-1993 US 088638
PI BUSHATO ORE, EGUHORUMU MICHAEL, NIELSEN PATER A, BERG RORUFU HO,
PI EKKA DAVID JAY, MORUCADO NILUS A
PC C07H21/04, A61K31/00, A61K31/00, A61K31/00, A61K48/00,
PC C07H21/02
PC C12N15/09, C12Q1/68, C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Key Location/Qualifiers
FT source 1. .15
FT Location/Qualifiers
FT /organism="Unidentified".

FEATURES
source
1. .15
/organism="Unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
4 a 2 c 4 g 5 t

Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 TCACACTTCATCT 471
DB 14 TCACACTGCATCT 1

RESULT 495
LOCUS I39122 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 160 from patent US 5616488.
ACCESSION I39122
VERSION I39122.1 GI:2083602
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
TITLE IL-5 targeted ribozymes
JOURNAL Patent: US 5616488-A 160 01-APR-1997;
FEATURES
source
1. .15
/organism="unknown"
7 a 0 c 3 g 5 t

Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1081 AGAATTGGAAAA 1094
DB 2 AGAATTGGTAAA 15

RESULT 496
LOCUS I39123 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 161 from patent US 5616488.
ACCESSION I39123
VERSION I39123.1 GI:2083603
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
TITLE IL-5 targeted ribozymes
JOURNAL Patent: US 5616488-A 161 01-APR-1997;
FEATURES
source
1. .15
/organism="unknown"
7 a 0 c 3 g 5 t

PN JP 1999236396-A/20
PD 31-AUG-1999
PF 14-OCT-1998 JP 1998291590
PR 02-JUL-1993 US 088638
PI BUSHATO ORE, EGUHORUMU MICHAEL, NIELSEN PATER A, BERG RORUFU HO,
PI EKKA DAVID JAY, MORUCADO NILUS A
PC C07H21/04, A61K31/00, A61K31/00, A61K31/00, A61K48/00,
PC C07H21/02
PC C12N15/09, C12Q1/68, C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Key Location/Qualifiers
FT source 1. .15
FT Location/Qualifiers
FT /organism="Unidentified".

FEATURES
source
1. .15
/organism="Unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
4 a 2 c 4 g 5 t

Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 458 TCACACTTCATCT 471
DB 14 TCACACTGCATCT 1

RESULT 495
LOCUS I39122 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 160 from patent US 5616488.
ACCESSION I39122
VERSION I39122.1 GI:2083602
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
TITLE IL-5 targeted ribozymes
JOURNAL Patent: US 5616488-A 160 01-APR-1997;
FEATURES
source
1. .15
/organism="unknown"
7 a 0 c 3 g 5 t

Query Match 1.0%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 4.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1081 AGAATTGGAAAA 1094
DB 2 AGAATTGGTAAA 15

RESULT 496
LOCUS I39123 15 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 161 from patent US 5616488.
ACCESSION I39123
VERSION I39123.1 GI:2083603
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.
TITLE IL-5 targeted ribozymes
JOURNAL Patent: US 5616488-A 161 01-APR-1997;
FEATURES
source
1. .15
/organism="unknown"
7 a 0 c 3 g 5 t
```

DEFINITION Sequence 4 from patent US 5710028.  
ACCESSION I81253  
VERSION I81253.1 GI:3209543  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE Unclassified.  
AUTHORS 1 (bases 1 to 15)  
TITLE Eyal,N. and Navot,N.  
METHOD of quick screening and identification of specific DNA  
sequences by single nucleotide primer extension and kits therefor  
JOURNAL Patent: US 5710028-A 4 20-JAN-1998;  
FEATURES Location/Qualifiers  
source  
1. .15  
BASE COUNT 2 a 3 c 3 g 7 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1438 TTCTTCTGCTGA 1451  
Db 2 TTCTTCTGCTGA 15

RESULT 500  
S89848/c  
LOCUS  
DEFINITION XPAC-XP group A complementing [exon 3] [human, mRNA Partial Mutant,  
15 nt].  
ACCESSION S89848  
VERSION S89848.1 GI:247717  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
AUTHORS 1 (bases 1 to 15)  
TITLE Satokata,I., Tanaka,K. and Okada,Y.  
Molecular basis of group A xeroderma pigmentosum: a missense  
mutation and two deletions located in a zinc finger consensus  
sequence of the XPAC gene  
JOURNAL Hum. Genet. 88 (6), 603-607 (1992)  
MEDLINE 92201821  
PubMed 133937  
REMARK GenBank staff at the National Library of Medicine created this  
entry [NCBI Gibbsq 89848] from the original journal article.  
This sequence comes from Figure 6.  
COMMENT G to T transversion at nucleotide 323, alters the Cys-108 codon to  
a Phe codon.

FEATURES  
source  
1. .15  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
1. .15  
/gene="XPAC"  
/note="XP group A complementing"  
BASE COUNT 6 a 1 c 1 g 7 t  
Query Match 1.0%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 4.3e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1000 TCATACATAAAT 1013  
Db 14 TCATACATAAAT 1

RESULT 501  
A08781  
LOCUS

DEFINITION reverse complement.  
ACCESSION A08781  
VERSION A08781.1 GI:489060  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 16)  
AUTHORS  
TITLE COMPLETE NUCLEOTIDIC SEQUENCE OF THE COMPLEMENTARY DNA OF THE  
GENOMIC RNA OF THE POTYVIRUS, GENES CODING FOR THE POTYVIRUS  
CAPSID PROTEIN AND APPLICATION OF SAID GENES TO THE CREATION OF  
POTYVIRUS-RESISTANT TRANSGENIC PLANTS  
JOURNAL Patent: WO 8912100-A 6 14-DEC-1989;  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
1 a 5 c 3 g 7 t  
BASE COUNT 1 a 5 c 3 g 7 t  
Query Match 1.0%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 4.7e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 901 CTGTGTTTCTCTT 914  
Db 1 CATGTTTCTCTT 14

RESULT 502  
A88098/c  
LOCUS  
DEFINITION Sequence 246 from Patent WO9833904.  
ACCESSION A88098  
VERSION A88098.1 GI:6736668  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W. and Schlingensiepen,K.  
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD  
JOURNAL Patent: WO 9833904-A 246 06-AUG-1998;  
BIOLOGICAL GENE (DE); BRYSCH WOLFGANG (DE)  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
9 a 2 c 1 g 4 t  
BASE COUNT 9 a 2 c 1 g 4 t  
Query Match 1.0%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 4.7e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1045 TATTATGTATTATTA 1058  
Db 16 TATTATGTATTATTA 3

RESULT 503  
A88522/c  
LOCUS  
DEFINITION Sequence 670 from Patent WO9833904.  
ACCESSION A88522  
VERSION A88522.1 GI:6737092  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W. and Schlingensiepen,K.

TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD									
JOURNAL Patent: WO 9833904-A 670 06-AUG-1998; BRYSCH WOLFGANG (DE)									
FEATURES	Location/Qualifiers								
	1. .16								
	/organism="unidentified"								
source	/mol_type="genomic DNA"								
	/db_xref="taxon:32644"								
	6 t								
BASE COUNT 8 a 1 c 1 g									
Query Match 1.0%; Score 12.4; DB 1; Length 16;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	1171 TTTTATTAGATAAA 1184								
	14 TTTTATTAGCTAAA 1								
Db									
RESULT 504									
A88613/c									
LOCUS 16 bp DNA linear PAT 22-JAN-2000									
DEFINITION Sequence 761 from Patent WO9833904.									
ACCESSION A88613									
VERSION A88613.1 GI:6737183									
KEYWORDS	unidentified								
	unclassified								
	ORGANISM								
REFERENCE	1 (bases 1 to 16)								
	Brysch,W.D. and Schlingensiepen,K.								
	AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD								
AUTHORS	Patent: WO 9833904-A 761 06-AUG-1998;								
	BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)								
	JOURNAL								
FEATURES	Location/Qualifiers								
	1. .16								
	/organism="unidentified"								
source	/mol_type="genomic DNA"								
	/db_xref="taxon:32644"								
	9 t								
BASE COUNT 5 a 0 c 2 g									
Query Match 1.0%; Score 12.4; DB 1; Length 16;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	1204 ATTAACAAACAAA 1217								
	14 ATTAACAACTCAA 1								
Db									
RESULT 505									
A90065/c									
LOCUS 16 bp DNA linear PAT 22-JAN-2000									
DEFINITION Sequence 246 from Patent EP0856579.									
ACCESSION A90065									
VERSION A90065.1 GI:6738579									
KEYWORDS	unidentified								
	unclassified								
	ORGANISM								
REFERENCE	1 (bases 1 to 16)								
	Brysch,W.D. and Schlingensiepen,K.D.								
	An antisense oligonucleotide preparation method								
AUTHORS	Patent: EP 0856579-A 246 05-AUG-1998;								
	BIOGNOSTIK GES (DE)								
	JOURNAL								
FEATURES	Location/Qualifiers								
	1. .16								
	/organism="unidentified"								
source	/mol_type="genomic DNA"								
	/db_xref="taxon:32644"								
	4 t								
BASE COUNT 9 a 2 c 1 g									
Query Match 1.0%; Score 12.4; DB 1; Length 16;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	1204 ATTAACAAACAAA 1217								
	14 ATTAACAACTCAA 1								
Db									
RESULT 508									
AX088232/c									
LOCUS 16 bp DNA linear PAT 17-MAR-2001									
DEFINITION Sequence 761 from Patent EP0856579.									
ACCESSION A90580									
VERSION A90580.1 GI:6739094									
KEYWORDS	unidentified								
	unclassified								
	ORGANISM								
REFERENCE	1 (bases 1 to 16)								
	Brysch,W.D. and Schlingensiepen,K.D.								
	An antisense oligonucleotide preparation method								
AUTHORS	Patent: EP 0856579-A 761 05-AUG-1998;								
	BIOGNOSTIK GES (DE)								
	JOURNAL								
FEATURES	Location/Qualifiers								
	1. .16								
	/organism="unidentified"								
source	/mol_type="genomic DNA"								
	/db_xref="taxon:32644"								
	9 t								
BASE COUNT 5 a 0 c 2 g									
Query Match 1.0%; Score 12.4; DB 1; Length 16;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	1204 ATTAACAAACAAA 1217								
	14 ATTAACAACTCAA 1								
Db									
RESULT 509									
AX088232/c									
LOCUS 16 bp DNA linear PAT 17-MAR-2001									
DEFINITION Sequence 761 from Patent EP0856579.									
ACCESSION A90580									
VERSION A90580.1 GI:6739094									
KEYWORDS	unidentified								
	unclassified								
	ORGANISM								
REFERENCE	1 (bases 1 to 16)								
	Brysch,W.D. and Schlingensiepen,K.D.								
	An antisense oligonucleotide preparation method								
AUTHORS	Patent: EP 0856579-A 761 05-AUG-1998;								
	BIOGNOSTIK GES (DE)								
	JOURNAL								
FEATURES	Location/Qualifiers								
	1. .16								
	/organism="unidentified"								
source	/mol_type="genomic DNA"								
	/db_xref="taxon:32644"								
	9 t								
BASE COUNT 5 a 0 c 2 g									
Query Match 1.0%; Score 12.4; DB 1; Length 16;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	1204 ATTAACAAACAAA 1217								
	14 ATTAACAACTCAA 1								
Db									
RESULT 506									
A90489/c									
LOCUS 16 bp DNA linear PAT 22-JAN-2000									
DEFINITION Sequence 670 from Patent EP0856579.									
ACCESSION A90489									
VERSION A90489.1 GI:6739003									
KEYWORDS	unidentified								
	unclassified								
	ORGANISM								
REFERENCE	1 (bases 1 to 16)								
	Brysch,W.D. and Schlingensiepen,K.D.								
	An antisense oligonucleotide preparation method								
AUTHORS	Patent: EP 0856579-A 670 05-AUG-1998;								
	BIOGNOSTIK GES (DE)								
	JOURNAL								
FEATURES	Location/Qualifiers								
	1. .16								
	/organism="unidentified"								
source	/mol_type="genomic DNA"								
	/db_xref="taxon:32644"								
	6 t								
BASE COUNT 8 a 1 c 1 g									
Query Match 1.0%; Score 12.4; DB 1; Length 15;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	1171 TTTTATTAGATAAA 1184								
	14 TTTTATTAGCTAAA 1								
Db									
RESULT 507									
A90580/c									
LOCUS 16 bp DNA linear PAT 22-JAN-2000									
DEFINITION Sequence 761 from Patent EP0856579.									
ACCESSION A90580									
VERSION A90580.1 GI:6739094									
KEYWORDS	unidentified								
	unclassified								
	ORGANISM								
REFERENCE	1 (bases 1 to 16)								
	Brysch,W.D. and Schlingensiepen,K.D.								
	An antisense oligonucleotide preparation method								
AUTHORS	Patent: EP 0856579-A 761 05-AUG-1998;								
	BIOGNOSTIK GES (DE)								
	JOURNAL								
FEATURES	Location/Qualifiers								
	1. .16								
	/organism="unidentified"								
source	/mol_type="genomic DNA"								
	/db_xref="taxon:32644"								
	9 t								
BASE COUNT 5 a 0 c 2 g									
Query Match 1.0%; Score 12.4; DB 1; Length 16;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	1204 ATTAACAAACAAA 1217								
	14 ATTAACAACTCAA 1								
Db									
RESULT 508									
AX088232/c									
LOCUS 16 bp DNA linear PAT 17-MAR-2001									
DEFINITION Sequence 761 from Patent EP0856579.									
ACCESSION A90580									
VERSION A90580.1 GI:6739094									
KEYWORDS	unidentified								
	unclassified								
	ORGANISM								
REFERENCE	1 (bases 1 to 16)								
	Brysch,W.D. and Schlingensiepen,K.D.								
	An antisense oligonucleotide preparation method								
AUTHORS	Patent: EP 0856579-A 761 05-AUG-1998;								
	BIOGNOSTIK GES (DE)								
	JOURNAL								
FEATURES	Location/Qualifiers								
	1. .16								
	/organism="unidentified"								
source	/mol_type="genomic DNA"								
	/db_xref="taxon:32644"								
	9 t								
BASE COUNT 5 a 0 c 2 g									
Query Match 1.0%; Score 12.4; DB 1; Length 16;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	1204 ATTAACAAACAAA 1217								
	14 ATTAACAACTCAA 1								
Db									
RESULT 509									
AX088232/c									
LOCUS 16 bp DNA linear PAT 17-MAR-2001									
DEFINITION Sequence 761 from Patent EP0856579.									
ACCESSION A90580									
VERSION A90580.1 GI:6739094									
KEYWORDS	unidentified								
	unclassified								
	ORGANISM								
REFERENCE	1 (bases 1 to 16)								
	Brysch,W.D. and Schlingensiepen,K.D.								
	An antisense oligonucleotide preparation method								
AUTHORS	Patent: EP 0856579-A 761 05-AUG-1998;								
	BIOGNOSTIK GES (DE)								
	JOURNAL								
FEATURES	Location/Qualifiers								
	1. .16								
	/organism="unidentified"								
source	/mol_type="genomic DNA"								
	/db_xref="taxon:32644"								
	9 t								
BASE COUNT 5 a 0 c 2 g									
Query Match 1.0%; Score 12.4; DB 1; Length 16;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	1204 ATTAACAAACAAA 1217								
	14 ATTAACAACTCAA 1								
Db									
RESULT 506									
A90489/c									
LOCUS 16 bp DNA linear PAT 22-JAN-2000									
DEFINITION Sequence 670 from Patent EP0856579.									
ACCESSION A90489									
VERSION A90489.1 GI:6739003									
KEYWORDS	unidentified								
	unclassified								
	ORGANISM								
REFERENCE	1 (bases 1 to 16)								
	Brysch,W.D. and Schlingensiepen,K.D.								
	An antisense oligonucleotide preparation method								
AUTHORS	Patent: EP 0856579-A 670 05-AUG-1998;								
	BIOGNOSTIK GES (DE)								
	JOURNAL								
FEATURES	Location/Qualifiers								
	1. .16								
	/organism="unidentified"								
source	/mol_type="genomic DNA"								
	/db_xref="taxon:32644"								
	6 t								
BASE COUNT 8 a 1 c 1 g									
Query Match 1.0%; Score 12.4; DB 1; Length 15;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	1045 TATTATGATTTA 1058								
	16 TATTTGATTTA 3								
Db									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
Best Local Similarity 92.9%; Pred. No. 4.7e+02;									
Matches 13; Conservative									



```

DEFINITION Sequence 16 from Patent WO0114520.
ACCESSION AX088232
VERSION AX088232.1 GI:13397143
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Wadskov-Hansen,S.L., Hammer,K. and Martinussen,J.
TITLE Phage resistant lactic acid bacterial mutants
JOURNAL Patent: WO 0114520-A 16 01-MAR-2001;
Chr. Hansen A/S (DK)
FEATURES
source
Location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="Oligonucleotide SLH6 used for PCR"
BASE COUNT 8 a 2 c 3 g 3 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1626 TTGCTGTCAGT 1639
Db 14 TTTTGTGCAAGT 1
RESULT 509
AX235073/c
LOCUS AX235073 16 bp DNA linear PAT 11-SEP-2001
DEFINITION Sequence 30 from Patent WO0163540.
ACCESSION AX235073
VERSION AX235073.1 GI:15593721
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Bureau,T.
TITLE Method for identifying transposons from a nucleic acid database
JOURNAL Patent: WO 0163540-A 30 30-AUG-2001;
McGILL UNIVERSITY (CA)
FEATURES
source
Location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="sequence from gi 2245031"
BASE COUNT 5 a 2 c 2 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 798 TTGCATATAAGTCA 811
Db 15 TTGACATATAAGTCA 2
RESULT 510
AX235096/c
LOCUS AX235096 16 bp DNA linear PAT 11-SEP-2001
DEFINITION Sequence 53 from Patent WO0163540.
ACCESSION AX235096
VERSION AX235096.1 GI:15593744
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Bureau,T.
TITLE Method for identifying transposons from a nucleic acid database
JOURNAL Patent: WO 0163540-A 30 30-AUG-2001;
McGILL UNIVERSITY (CA)
FEATURES
source
Location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="sequence from gi 3243214"
BASE COUNT 8 a 0 c 2 g 6 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 995 TTTTCATCAAT 1008
Db 15 TTTTCATCAATAT 2
RESULT 511
BD065611/c
LOCUS BD065611 16 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD065611
VERSION BD065611.1 GI:22611214
KEYWORDS JP 2001511000-A/246.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Schlingensiefen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 246 07-AUG-2001;
BIOGEN IDEC INC.
COMMENT OS Unknown
PN JP 2001511000-A/246
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 JP 97101531.8
PI KARL HERMANN SCHLINGENSIEFEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers
FT source 1..16
PT /organism="Unknown".
FEATURES
source
Location/Qualifiers
1..16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 9 a 2 c 1 g 4 t
Query Match 1.0%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 4.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1045 TATTATGATTTA 1058
Db 16 TATTATGATTTA 3
RESULT 512
BD066035/c
LOCUS BD066035 16 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066035
VERSION BD066035.1 GI:22611638
KEYWORDS JP 2001511000-A/670.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 16)

```

LOCUS	BD091246	15 bp	RNA	linear	PAT 27-AUG-2002
DEFINITION	RNase L activators and antisense oligonucleotides effective to treat RSV infections.				
ACCESSION	BD091246				
VERSION	BD091246.1	GI:22636856			
KEYWORDS	JP 2001523636-A/21.				
SOURCE	Respiratory syncytial virus				
ORGANISM	Respiratory syncytial virus				
REFERENCE	Viruses; ssRNA negative-strand viruses; Mononegavirales; Paramyxoviridae; Pneumovirinae; Pneumovirus.				
AUTHORS	1 (bases 1 to 16) Torrence,P.F., Silverman,R.H., Cirino,N.M., Li,G., Xiao,W. and Player,M.R.				
TITLE	RNase L activators and antisense oligonucleotides effective to treat RSV infections				
JOURNAL	Patent: JP 2001523636-A 21 27-NOV-2001; THE CLEVELAND CLINIC FOUNDATION, NATIONAL INSTITUTES OF HEALTH				
COMMENT	OS Respiratory syncytial virus PN JP 2001523636-A/21 PD 27-NOV-2001 PF 02-NOV-1998 JP 2000518674 PR 03-NOV-1997 US 08/962690 PI PAUL F TORRENCE, ROBERT H SILVERMAN, NICK M CIRINO, GUIYING LI, WEI XIAO, PI MARK R PLAYER PC A61K31/711, A61K9/12, A61K48/00, A61P31/14, C12N15/09, C12N15/00 CC n=a,c,g, or u Location/Qualifiers FH modified base (10). FT Location/Qualifiers				
FEATURES	source 1..16 /organism="Respiratory syncytial virus" /mol_type="genomic RNA" /db_xref="taxon:12814"				
BASE COUNT	5 a	1 c	0 g	9 t	1 others
Query Match	1.0%; Score 12.4; DB 1; Length 16;				
Best Local Similarity	86.7%; Pred. No. 4.7e+02;				
Matches	13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;				
QY	1521	TTTATATTTTAACT 1535 			
DB	2	TTTATATTTTAACT 16 			
RESULT 515	A89165				
LOCUS	A89165				
DEFINITION	Sequence 1313 from Patent WO9833904.				
ACCESSION	A89165				
VERSION	A89165.1				
KEYWORDS	unidentified				
SOURCE	unidentified				
ORGANISM	unclassified				
REFERENCE	1 (bases 1 to 17) Brysch,W. and Schlingensiepen,K.				
AUTHORS	AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD				
TITLE	Patent: WO 9833904-A 1313 06-AUG-1998;				
JOURNAL	BIOGHOSTIK GES (DE); BRYSCH WOLFGANG (DE)				
FEATURES	Location/Qualifiers 1..17 /organism="unidentified" /mol_type="genomic DNA" /db_xref="taxon:32644"				
BASE COUNT	4 a	2 c	4 g	7 t	
Query Match	1.0%; Score 12.4; DB 1; Length 17;				
Best Local Similarity	92.9%; Pred. No. 5.2e+02;				
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;				

Qy 720 CTTTAATTCAGGA 733  
Db 1 CTTTAATTCAGGA 14

RESULT 516  
LOCUS AR046644 17 bp DNA PAT 29-SEP-1999  
DEFINITION Sequence 1437 from patent US 5817796.  
ACCESSION AR046644  
VERSION AR046644.1 GI:5968109  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myb ribozymes having 2'-5'-linked adenylyate residues  
JOURNAL Patent: US 5817796-A 1437 06-OCT-1998;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 7 a 6 c 2 g 2 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1354 TGTGTGTGTAATGC 1367  
Db 17 TGTGTGTGTAATGC 4

RESULT 517  
LOCUS AR186350 17 bp DNA PAT 20-APR-2002  
DEFINITION Sequence 1838 from patent US 6346398.  
ACCESSION AR186350  
VERSION AR186350.1 GI:20232315  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 1838 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 11 a 4 c 1 g 1 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 516 ACAAAATACACAA 629  
Db 2 ACAAAATACACAA 15

RESULT 518  
LOCUS AR186590 17 bp DNA PAT 20-APR-2002  
DEFINITION Sequence 2078 from patent US 6346398.  
ACCESSION AR186590  
VERSION AR186590.1 GI:20232555  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 2078 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 5 a 3 c 3 g 6 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 714 TCCGAAGTTTAATT 727  
Db 1 TCCGAAGTTTAATT 14

RESULT 519  
LOCUS AR186885 17 bp DNA PAT 20-APR-2002  
DEFINITION Sequence 2373 from patent US 6346398.  
ACCESSION AR186885  
VERSION AR186885.1 GI:20232850  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 2373 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 5 a 5 c 2 g 5 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 980 AAGCACTTTAAGTT 993  
Db 2 AAGCACTTTAAGTT 15

RESULT 520  
LOCUS AR186886 17 bp DNA PAT 20-APR-2002  
DEFINITION Sequence 2374 from patent US 6346398.  
ACCESSION AR186886  
VERSION AR186886.1 GI:20232851  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 2374 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
BASE COUNT 5 a 5 c 2 g 5 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 980 AAGCACTTTAAGTT 993  
Db 2 AAGCACTTTAAGTT 15

```

Db      1  AAGCACTTTAAGCT 14
RESULT 521
LOCUS   ARI188361
DEFINITION
Sequence 3849 from patent US 6346398.
ACCESSION ARI188361
VERSION   ARI188361.1 GI:20234326
KEYWORDS
SOURCE   Unknown.
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE    Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL  Patent: US 6346398-A 3849 12-FEB-2002;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 5 a 3 c 2 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      1457 GTTATTATGTAC 1470
Db      3 GTCATTATGTAC 16
RESULT 522
LOCUS   ARI188739
DEFINITION
Sequence 4227 from patent US 6346398.
ACCESSION ARI188739
VERSION   ARI188739.1 GI:20234704
KEYWORDS
SOURCE   Unknown.
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE    Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL  Patent: US 6346398-A 4227 12-FEB-2002;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 8 a 2 c 1 g 6 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      1118 ATAGTTATAAGAT 1131
Db      1 ATATTATAAGAT 14
RESULT 523
LOCUS   ARI190158/c
DEFINITION
Sequence 5646 from patent US 6346398.
ACCESSION ARI190158
VERSION   ARI190158.1 GI:20236123
KEYWORDS
SOURCE   Unknown.
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE    Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL  Patent: US 6346398-A 5646 12-FEB-2002;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 0 a 1 c 3 g 13 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      617 CAAAAAACACACAA 630
Db      17 CAAAAAACACAAAA 4
TITLE    Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL  Patent: US 6346398-A 5646 12-FEB-2002;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 5 a 5 c 2 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      467 CATGTATTGTGTGG 480
Db      14 CATGTAAATGTGTGG 1
RESULT 524
LOCUS   ARI192044
DEFINITION
Sequence 7532 from patent US 6346398.
ACCESSION ARI192044
VERSION   ARI192044.1 GI:20238009
KEYWORDS
SOURCE   Unknown.
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE    Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL  Patent: US 6346398-A 7532 12-FEB-2002;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 11 a 4 c 1 g 1 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      616 ACAMAAACACACAA 629
Db      2 ACAMAAATACACAA 15
RESULT 525
LOCUS   ARI192329/c
DEFINITION
Sequence 7817 from patent US 6346398.
ACCESSION ARI192329
VERSION   ARI192329.1 GI:20238294
KEYWORDS
SOURCE   Unknown.
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE    Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL  Patent: US 6346398-A 7817 12-FEB-2002;
FEATURES
Location/Qualifiers
1..17
/organism="unknown"
BASE COUNT 0 a 1 c 3 g 13 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      617 CAAAAAACACACAA 630
Db      17 CAAAAAACACAAAA 4

```

```

RESULT 526
AR192331/c
LOCUS       AR192331        17 bp    DNA          linear          PAT 20-APR-2002
DEFINITION   Sequence 7819 from patent US 6346398.
ACCESSION   AR192331
VERSION     AR192331.1   GI:20238296
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS    Pavco, P.; McSwiggen, J., Stinchcomb, D. and Bacabedo, J.
TITLE      Method and reagent for the treatment of diseases or conditions
           related to levels of vascular endothelial growth factor receptor
JOURNAL     Patent: US 6346398-A 7819 12-FEB-2002;
FEATURES    Location/Qualifiers
             source          1..17
             /organism="unknown"
BASE COUNT  0 a      0 c      2 g      15 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      616  ACAAACCAACCAACAA 629
Db      14  ACAAACCAACCAAAA 1

RESULT 527
AX215016/c
LOCUS       AX215016        17 bp    mRNA          linear          PAT 07-SEP-2001
DEFINITION   Sequence 458 from Patent WO0159103.
ACCESSION   AX215016
VERSION     AX215016.1   GI:15525059
KEYWORDS
SOURCE      synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE   1
AUTHORS    Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE      Method and reagent for the modulation and diagnosis of cd20 and
           nogo gene expression
JOURNAL     Patent: WO 0159103-A 458 16-AUG-2001;
           RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
           McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES    Location/Qualifiers
             source          1..17
             /organism="synthetic construct"
             /mol_type="mRNA"
             /db_xref="taxon:32630"
             /note="Nucleic Acid"
BASE COUNT  5 a      2 c      1 g      9 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1096  TAGAAGATGAATCA 1109
Db      14  TAGAAGATGAATCA 1

RESULT 528
AX215685
LOCUS       AX215685        17 bp    mRNA          linear          PAT 07-SEP-2001
DEFINITION   Sequence 1127 from Patent WO0159103.
ACCESSION   AX215685
VERSION     AX215685.1   GI:15525728
KEYWORDS
SOURCE      synthetic construct

```

```

ORGANISM    synthetic construct
           artificial sequences.
REFERENCE   1
AUTHORS    Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE      Method and reagent for the modulation and diagnosis of cd20 and
           nogo gene expression
JOURNAL     Patent: WO 0159103-A 1127 16-AUG-2001;
           RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
           McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES    Location/Qualifiers
             source          1..17
             /organism="synthetic construct"
             /mol_type="mRNA"
             /db_xref="taxon:32630"
             /note="Nucleic Acid"
BASE COUNT  7 a      3 c      2 g      5 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      623  ACAACAATAAATT 636
Db      4    ACAACAATAAATT 17

RESULT 529
AX216740
LOCUS       AX216740        17 bp    mRNA          linear          PAT 07-SEP-2001
DEFINITION   Sequence 2182 from Patent WO0159103.
ACCESSION   AX216740
VERSION     AX216740.1   GI:15526801
KEYWORDS
SOURCE      synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE   1
AUTHORS    Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE      Method and reagent for the modulation and diagnosis of cd20 and
           nogo gene expression
JOURNAL     Patent: WO 0159103-A 2182 16-AUG-2001;
           RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
           McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES    Location/Qualifiers
             source          1..17
             /organism="synthetic construct"
             /mol_type="mRNA"
             /db_xref="taxon:32630"
             /note="Nucleic Acid"
BASE COUNT  9 a      3 c      1 g      4 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      623  ACAACAATAAATT 636
Db      2    ACAACAATAAATT 15

RESULT 530
AX217082
LOCUS       AX217082        17 bp    mRNA          linear          PAT 07-SEP-2001
DEFINITION   Sequence 2524 from Patent WO0159103.
ACCESSION   AX217082
VERSION     AX217082.1   GI:15527143
KEYWORDS
SOURCE      synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE   1
AUTHORS    Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE      Method and reagent for the modulation and diagnosis of cd20 and

```

```

nogo gene expression
Patent: WO 0159103-A 2524 16-AUG-2001; Blatt, Lawrence (US) ;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Chowrira, Bharat M. (US)
McSwiggen, James (US) ; Location/Qualifiers
FEATURES
    source
        1..17
            /organism="synthetic construct"
            /mol_type="mRNA"
            /db_xref="taxon:32630"
BASE COUNT      8 a      3 c      1 g      5 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 623 ACAACAGATAATT 536
|||||
DB 3 ACAACAGATAATT 16

RESULT 531
AX217114
LOCUS      AX217114      17 bp      mRNA      linear      PAT 07-SEP-2001
DEFINITION Sequence 2556 from Patent WO0159103.
ACCESSION AX217114
VERSION   AX217114.1 GI:15527175
KEYWORDS
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE 1
AUTHORS   Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE     Method and reagent for the modulation and diagnosis of cd20 and
           nogo gene expression
JOURNAL   RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
           McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
    source
        1..17
            /organism="synthetic construct"
            /mol_type="mRNA"
            /db_xref="taxon:32630"
            /note="Nucleic Acid"
BASE COUNT      11 a      1 c      2 g      3 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1204 ATTAAACAAACAA 1217
|||||
DB 3 ATTAAACAAACAA 16

RESULT 532
AX226925
LOCUS      AX226925      17 bp      mRNA      linear      PAT 10-SEP-2001
DEFINITION Sequence 297 from Patent WO0157206.
ACCESSION AX226925
VERSION   AX226925.1 GI:15556066
KEYWORDS
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE 1
AUTHORS   Fattaey, A.R., Jarvis, T., McSwiggen, J., Boohar, R.N. and Holman, P.S.
TITLE     Method and reagent for the inhibition of checkpoint kinase-1 (CHK
           1) enzyme
JOURNAL   RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
    source
        1..17
            /organism="synthetic construct"
            /mol_type="mRNA"
            /db_xref="taxon:32630"
BASE COUNT      3 a      0 c      2 g      12 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

nogo gene expression
Patent: WO 0159103-A 2524 16-AUG-2001; Blatt, Lawrence (US) ;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Chowrira, Bharat M. (US)
McSwiggen, James (US) ; Location/Qualifiers
FEATURES
    source
        1..17
            /organism="synthetic construct"
            /mol_type="mRNA"
            /db_xref="taxon:32630"
BASE COUNT      3 a      2 c      1 g      11 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1141 AATTATTATTATT 1154
|||||
DB 4 AATTATTATTATT 17

RESULT 533
AX226926
LOCUS      AX226926      17 bp      mRNA      linear      PAT 10-SEP-2001
DEFINITION Sequence 298 from Patent WO0157206.
ACCESSION AX226926
VERSION   AX226926.1 GI:15556067
KEYWORDS
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE 1
AUTHORS   Fattaey, A.R., Jarvis, T., McSwiggen, J., Boohar, R.N. and Holman, P.S.
TITLE     Method and reagent for the inhibition of checkpoint kinase-1 (CHK
           1) enzyme
JOURNAL   RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
    source
        1..17
            /organism="synthetic construct"
            /mol_type="mRNA"
            /db_xref="taxon:32630"
BASE COUNT      3 a      1 c      2 g      11 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1141 AATTATTATTATT 1154
|||||
DB 2 AATTATTATTATT 15

RESULT 534
AX226927
LOCUS      AX226927      17 bp      mRNA      linear      PAT 10-SEP-2001
DEFINITION Sequence 299 from Patent WO0157206.
ACCESSION AX226927
VERSION   AX226927.1 GI:15556068
KEYWORDS
SOURCE     synthetic construct
           synthetic construct
           artificial sequences.
REFERENCE 1
AUTHORS   Fattaey, A.R., Jarvis, T., McSwiggen, J., Boohar, R.N. and Holman, P.S.
TITLE     Method and reagent for the inhibition of checkpoint kinase-1 (CHK
           1) enzyme
JOURNAL   RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
FEATURES
    source
        1..17
            /organism="synthetic construct"
            /mol_type="mRNA"
            /db_xref="taxon:32630"
BASE COUNT      3 a      0 c      2 g      12 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1141 AATTATTTTATTTT 1154  
Db 1 AATTATTTTGT 14

RESULT 535  
AX263192  
LOCUS AX263192 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 583 from Patent WO0173002.  
ACCESSION AX263192  
VERSION AX263192.1 GI:16511991  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 583 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. 17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 9 a 2 c 1 g 5 t  
Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1204 ATTAACACAA 1217  
Db 3 ATTAACACAA 16

RESULT 536  
AX263193/c  
LOCUS AX263193 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 584 from Patent WO0173002.  
ACCESSION AX263193  
VERSION AX263193.1 GI:16511992  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 584 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. 17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 5 a 1 c 2 g 9 t  
Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1204 ATTAACACAA 1217  
Db 15 ATTAACACAA 2

RESULT 537  
AX265663

LOCUS AX265663 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 3054 from Patent WO0173002.  
ACCESSION AX265663  
VERSION AX265663.1 GI:16514462  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 3054 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. 17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 6 a 3 c 3 g 5 t  
Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 533 TTCAGTAAACAATG 546  
Db 4 TTCAGTAAACAATG 17

RESULT 538  
AX265664/c  
LOCUS AX265664 17 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 3055 from Patent WO0173002.  
ACCESSION AX265664  
VERSION AX265664.1 GI:16514463  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 3055 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. 17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 5 a 3 c 3 g 6 t  
Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 533 TTCAGTAAACAATG 546  
Db 14 TTCAGTAAACAATG 1

RESULT 539  
AX272720  
LOCUS AX272720 17 bp mRNA linear PAT 29-OCT-2001  
DEFINITION Sequence 289 from Patent WO0162911.  
ACCESSION AX272720  
VERSION AX272720.1 GI:16545457  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens

```

REFERENCE
AUTHORS      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
TITLE        Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
              Ellis, J.H.
JOURNAL      Method and reagent for the inhibition of grid
PATENT       Patent: WO 0162911-A 289 30-AUG-2001;
RIBOZYME     RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source       Location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="mRNA"
              /db_xref="taxon:9606"
BASE COUNT   5 a 5 c 3 g 4 t

Query Match   1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 457 TTCAACACTTCATG 470
Db 3 TTCAACACTTCAG 16

RESULT 540
AX383942 LOCUS AX272721 17 bp mRNA linear PAT 29-OCT-2001
DEFINITION Sequence 290 from Patent WO0162911.
ACCESSION AX272721
VERSION AX272721.1 GI:16545458
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., Hamblin, P.A. and
              Ellis, J.H.
TITLE Method and reagent for the inhibition of grid
JOURNAL Patent: WO 0162911-A 290 30-AUG-2001;
RIBOZYME RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source       Location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="mRNA"
              /db_xref="taxon:9606"
BASE COUNT   5 a 5 c 2 g 5 t

Query Match   1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 457 TTCAACACTTCATG 470
Db 1 TTCAACACTTCAG 14

RESULT 541
AX383942 LOCUS AX383942 17 bp DNA linear PAT 19-MAR-2002
DEFINITION Sequence 45 from Patent WO0214546.
ACCESSION AX383942
VERSION AX383942.1 GI:19577513
KEYWORDS Plasmodium falciparum (malaria parasite P. falciparum)
SOURCE Plasmodium falciparum
ORGANISM Plasmodium falciparum
Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
REFERENCE 1
AUTHORS Fritzsche, M.
TITLE Use of microbial dna sequences for the identification of human
              diseases
JOURNAL Patent: WO 0214546-A 45 21-FEB-2002;
              Fritzsche, Markus (CH)

```

---

```

FEATURES
source       Location/Qualifiers
              1..17
              /organism="Plasmodium falciparum"
              /mol_type="genomic DNA"
              /db_xref="taxon:5833"
BASE COUNT   8 a 1 c 1 g 7 t

Query Match   1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1604 ATATGAACACTTAA 1617
Db 1 ATATGAACACTTAA 14

RESULT 542
AX421941 LOCUS AX421941 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 277 from Patent WO0188124.
ACCESSION AX421941
VERSION AX421941.1 GI:21525323
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, P.G. and
              Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 277 22-NOV-2001;
RIBOZYME RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source       Location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="mRNA"
              /db_xref="taxon:9606"
BASE COUNT   7 a 3 c 1 g 6 t

Query Match   1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1505 TTTTAAATACAG 1518
Db 17 TTTTAAATACAG 4

RESULT 543
AX423390 LOCUS AX423390 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1726 from Patent WO0188124.
ACCESSION AX423390
VERSION AX423390.1 GI:21526772
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, P.G. and
              Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1726 22-NOV-2001;
RIBOZYME RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source       Location/Qualifiers
              1..17
              /organism="Homo sapiens"
              /mol_type="mRNA"
              /db_xref="taxon:9606"
BASE COUNT   9 a 1 c 1 g 6 t

```



```

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1233 TTAAATTTTCATTT 1246
Db 14 TAAAAATTTTCATTT 1

RESULT 544
AX500362/c
LOCUS      AX500362      17 bp      DNA      linear      PAT 27-SEP-2002
DEFINITION Sequence 1669 from Patent EP1229046.
ACCESSION  AX500362
VERSION     AX500362.1 GI:23382655
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Zhan,J.
TITLE       Human testis expressed patched like protein
JOURNAL     Patent: EP 1229046-A 1669 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            2 a 1 c 2 g 12 t

BASE COUNT    2 a 1 c 2 g 12 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 678 ACAATAGCAAAAT 691
Db 17 AAAAAATAGCAAAAT 4

RESULT 545
AX500368/c
LOCUS      AX500368      17 bp      DNA      linear      PAT 27-SEP-2002
DEFINITION Sequence 1675 from Patent EP1229046.
ACCESSION  AX500368
VERSION     AX500368.1 GI:23382661
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Zhan,J.
TITLE       Human testis expressed patched like protein
JOURNAL     Patent: EP 1229046-A 1675 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            5 a 2 c 1 g 9 t

BASE COUNT    5 a 2 c 1 g 9 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 675 TATACAAATAGCAA 698
Db 14 TATACAAATAGCAA 1

```

```

RESULT 546
AX500620/c
LOCUS      AX500620      17 bp      DNA      linear      PAT 27-SEP-2002
DEFINITION Sequence 1927 from Patent EP1229046.
ACCESSION  AX500620
VERSION     AX500620.1 GI:23382913
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Zhan,J.
TITLE       Human testis expressed patched like protein
JOURNAL     Patent: EP 1229046-A 1927 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            5 a 2 c 2 g 8 t

BASE COUNT    5 a 2 c 2 g 8 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1459 TTATTATGTACAAA 1472
Db 17 TTATGATGTACAAA 4

RESULT 547
AX500621/c
LOCUS      AX500621      17 bp      DNA      linear      PAT 27-SEP-2002
DEFINITION Sequence 1928 from Patent EP1229046.
ACCESSION  AX500621
VERSION     AX500621.1 GI:23382914
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Zhan,J.
TITLE       Human testis expressed patched like protein
JOURNAL     Patent: EP 1229046-A 1928 07-AUG-2002;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            5 a 2 c 3 g 7 t

BASE COUNT    5 a 2 c 3 g 7 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1459 TTATTATGTACAAA 1472
Db 16 TTATGATGTACAAA 3

RESULT 548
AX578723/c
LOCUS      AX578723      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 561 from Patent WO0211674.
ACCESSION  AX578723
VERSION     AX578723.1 GI:27647925
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens

```

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE
Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL
Patent: WO 0211674-A 561 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
7 a 1 c 1 g 8 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1134 TATAGTAAATTTAT 1147
|||||
Db 3 TATAGTACATTTAT 16

RESULT 549
AX579367
LOCUS
DEFINITION
Sequence 1205 from Patent WO0211674.
ACCESSION
AX579367
VERSION
AX579367.1 GI:27648569
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE
Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL
Patent: WO 0211674-A 1205 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
6 a 2 c 1 g 8 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1134 TATAGTAAATTTAT 1147
|||||
Db 1 TATAGTACATTTAT 14

RESULT 550
AX671564/c
LOCUS
DEFINITION
Sequence 9 from Patent WO03004526.
ACCESSION
AX671564
VERSION
AX671564.1 GI:29329912
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE

```

```

Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 9 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
7 a 2 c 3 g 5 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 527 CAAATATTTTTCGA 640
|||||
Db 16 CAAATAGTTTTCGA 3

RESULT 551
AX671663/c
LOCUS
DEFINITION
Sequence 108 from Patent WO03004526.
ACCESSION
AX671663
VERSION
AX671663.1 GI:29330011
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 108 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
9 a 3 c 4 g 1 t
BASE COUNT
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. NO. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1438 TTCTTGTGTTGA 1451
|||||
Db 16 TTCTTGTGTTGA 3

RESULT 552
AX672450/c
LOCUS
DEFINITION
Sequence 895 from Patent WO03004526.
ACCESSION
AX672450
VERSION
AX672450.1 GI:29330798
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS
Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
Patent: WO 03004526-A 895 16-JAN-2003;
JOURNAL

```

FEATURES  
source  
1. .17  
Molecular Engines Laboratories (FR)  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
6 a 2 c 1 g 8 t

BASE COUNT  
Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1156 AGATATTATATGAT 1169  
Db 15 ATATATTATATGAT 2

RESULT 553  
AX672835/c  
LOCUS AX672835 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 1280 from Patent WO03004526.  
ACCESSION AX672835  
VERSION AX672835.1 GI:29331183  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
JOURNAL Patent: WO 03004526-A 1280 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
5 a 4 c 3 g 5 t

BASE COUNT  
Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1101 GATGAATCATGAT 1114  
Db 15 GATGAATCATGAT 2

RESULT 554  
AX673316/c  
LOCUS AX673316 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 1761 from Patent WO03004526.  
ACCESSION AX673316  
VERSION AX673316.1 GI:29331664  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
JOURNAL Patent: WO 03004526-A 1761 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"

BASE COUNT 6 a 6 c 3 g 2 t  
/db\_xref="taxon:9606"

Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 959 TGATGTTGTGAGGA 972  
Db 16 TGCTGTGTGAGGA 3

RESULT 555  
AX673453/c  
LOCUS AX673453 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 1898 from Patent WO03004526.  
ACCESSION AX673453  
VERSION AX673453.1 GI:29331801  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
JOURNAL Patent: WO 03004526-A 1898 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
5 a 3 c 5 g 4 t

BASE COUNT  
Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 864 TGCTAGCCAGGATC 877  
Db 14 TTCTAGCCAGGATC 1

RESULT 556  
AX674582  
LOCUS AX674582 17 bp DNA linear PAT 27-MAR-2003  
DEFINITION Sequence 3027 from Patent WO03004526.  
ACCESSION AX674582  
VERSION AX674582.1 GI:29332930  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and their use as  
medicines  
JOURNAL Patent: WO 03004526-A 3027 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
7 a 5 c 2 g 3 t

BASE COUNT  
Query Match 1.0%; Score 12.4; DB 1; Length 17;  
Best Local Similarity 92.9%; Pred. No. 5.2e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY 1399 TATTAAACAGCCA 1412	
DB 3 TCTTAAACAGCCA 16	
RESULT 557	
AX674587/c	
LOCUS	AX674587 17 bp DNA linear PAT 27-MAR-2003
DEFINITION	Sequence 3032 from Patent WO03004526.
ACCESSION	AX674587
VERSION	AX674587.1 GI:29332935
KEYWORDS	Hom sapiens (human)
SOURCE	ORGANISM
REFERENCE	1. .17
AUTHORS	Telerman,A., Amson,R. and Tuijnder,M.
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines
JOURNAL	Patent: WO 03004526-A 3032 16-JAN-2003;
FEATURES	Location/Qualifiers
source	1. .17
BASE COUNT	8 a 1 c 1 g 7 t
Query Match	
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 17;	
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY 1146 ATTTTATTATGAT 1159	
DB 15 ATTTTATTATGAT 2	
RESULT 558	
AX722326/c	
LOCUS	AX722326 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 13 from Patent WO03025176.
ACCESSION	AX722326
VERSION	AX722326.1 GI:30422827
KEYWORDS	Mus musculus (house mouse)
SOURCE	ORGANISM
REFERENCE	1. .17
AUTHORS	Telerman,A., Amson,R. and Tuijnder,M.
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL	Patent: WO 03025176-A 13 27-MAR-2003;
FEATURES	Location/Qualifiers
source	1. .17
BASE COUNT	6 a 3 c 3 g 5 t
Query Match	
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 17;	
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY 1076 TGTGCAAGATTG 1089	
DB 17 TGTCCAGATTG 4	
RESULT 559	
AX722545	
LOCUS	AX722545 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 232 from Patent WO03025176.
ACCESSION	AX722545
VERSION	AX722545.1 GI:30423046
KEYWORDS	Mus musculus (house mouse)
SOURCE	ORGANISM
REFERENCE	1. .17
AUTHORS	Telerman,A., Amson,R. and Tuijnder,M.
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL	Patent: WO 03025176-A 232 27-MAR-2003;
FEATURES	Location/Qualifiers
source	1. .17
BASE COUNT	9 a 1 c 4 g 3 t
Query Match	
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 17;	
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY 414 CAAGATCAAGTGAA 427	
DB 4 CAAGATCAAGTGAA 17	
RESULT 560	
AX723257/c	
LOCUS	AX723257 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 944 from Patent WO03025176.
ACCESSION	AX723257
VERSION	AX723257.1 GI:30423758
KEYWORDS	Mus musculus (house mouse)
SOURCE	ORGANISM
REFERENCE	1. .17
AUTHORS	Telerman,A., Amson,R. and Tuijnder,M.
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL	Patent: WO 03025176-A 944 27-MAR-2003;
FEATURES	Location/Qualifiers
source	1. .17
BASE COUNT	7 a 2 c 1 g 7 t
Query Match	
Best Local Similarity 1.0%; Score 12.4; DB 1; Length 17;	
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY 1613 ATTAAATATATAT 1626	
DB 15 ATTAAATATATAT 2	
RESULT 561	
AX724038	
LOCUS	AX724038 17 bp DNA linear PAT 08-MAY-2003

Sequence 1725 from Patent WO03025176.					
DEFINITION	AX724038				
ACCESSION	AX724038.1 GI:30503381				
VERSION					
KEYWORDS	Mus musculus (house mouse)				
SOURCE	Mus musculus				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus;				
REFERENCE	1 Telerman,A., Anson,R. and Tuijnder,M.				
AUTHORS	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines				
TITLE	Patent: WO 03025176-A 1725 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers 1. .17 /organism="Mus musculus" /mol_type="genomic DNA" /db_xref="taxon:10090"				
JOURNAL	Molecular Engines Laboratories (FR) Location/Qualifiers 1. .17 /organism="Mus musculus" /mol_type="genomic DNA" /db_xref="taxon:10090"				
FEATURES	source 1. .17 /organism="Mus musculus" /mol_type="genomic DNA" /db_xref="taxon:10090"				
BASE COUNT	6 a                  4 c                  2 g                  5 t				
Query Match	1.0%; Score 12.4; DB 1; Length 17;				
Best Local Similarity	92.9%; Pred.No. 5.2e+02;				
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;				
QY	1419 CACAGTCACTATTA 1432 				
DB	4 CACAGTCACTATTA 17 				
RESULT 562					
AX724983					
LOCUS	AX724983 17 bp DNA linear PAT 08-MAY-2003				
DEFINITION	Sequence 2670 from Patent WO03025176.				
ACCESSION	AX724983				
VERSION	AX724983.1 GI:30504326				
KEYWORDS	Mus musculus (house mouse)				
SOURCE	Mus musculus				
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus;				
REFERENCE	1 Telerman,A., Anson,R. and Tuijnder,M.				
AUTHORS	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines				
TITLE	Patent: WO 03025176-A 2670 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers 1. .17 /organism="Mus musculus" /mol_type="genomic DNA" /db_xref="taxon:10090"				
JOURNAL	Molecular Engines Laboratories (FR) Location/Qualifiers 1. .17 /organism="Mus musculus" /mol_type="genomic DNA" /db_xref="taxon:10090"				
FEATURES	source 1. .17 /organism="Mus musculus" /mol_type="genomic DNA" /db_xref="taxon:10090"				
BASE COUNT	8 a                  2 c                  1 g                  6 t				
Query Match	1.0%; Score 12.4; DB 1; Length 17;				
Best Local Similarity	92.9%; Pred.No. 5.2e+02;				
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;				
QY	802 CATAAACTCAATT 815 				
DB	4 CATAAACTCAATT 17 				
RESULT 563					
AX725250					
LOCUS	AX725250 17 bp DNA linear PAT 08-MAY-2003				
DEFINITION	Sequence 2937 from Patent WO03025176.				
ACCESSION	AX725250				
VERSION	AX725250.1 GI:30504593				
KEYWORDS	Mus musculus (house mouse)				
SOURCE	Mus musculus (house mouse)				

```

TITLE      Sequences involved in phenomena of tumour suppression, tumour
           reversion, apoptosis and/or virus resistance and their use as
           medicines
JOURNAL    Patent: WO 03025176-A 4083 27-MAR-2003;
           Molecular Engines Laboratories (FR)
FEATURES
  source
  1..17
  /organism="Mus musculus"
  /mol_type="genomic DNA"
  /db_xref="taxon:10090"
  /db_xref="taxon:10090"
BASE COUNT      8 a      4 c      1 g      4 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      612 ATCTACAAARACA 625
Db      2 ATCTACAAATACA 15

RESULT 566
LOCUS      AX727438/c      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION      Sequence 5125 from Patent WO03025176.
ACCESSION      AX727438
VERSION      AX727438.1 GI:30506781
KEYWORDS
SOURCE      Mus musculus (house mouse)
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus; Mus.
REFERENCE
  1
AUTHORS      Telerman, A., Anson, R. and Tuijinder, M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
           reversion, apoptosis and/or virus resistance and their use as
           medicines
JOURNAL    Patent: WO 03025176-A 5125 27-MAR-2003;
           Molecular Engines Laboratories (FR)
FEATURES
  source
  1..17
  /organism="Mus musculus"
  /mol_type="genomic DNA"
  /db_xref="taxon:10090"
  /db_xref="taxon:10090"
BASE COUNT      8 a      2 c      2 g      5 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1489 TATTTAATGACTG 1502
Db      17 TATTTAATGACTG 4

RESULT 567
LOCUS      AX729724/c      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION      Sequence 1358 from Patent WO03025175.
ACCESSION      AX729724
VERSION      AX729724.1 GI:30509067
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
AUTHORS      Telerman, A., Anson, R. and Tuijinder, M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
           reversion, apoptosis and/or virus resistance and their use as
           medicines
JOURNAL    Patent: WO 03025175-A 1358 27-MAR-2003;
           Molecular Engines Laboratories (FR)

```

```

FEATURES
  source
  1..17
  /organism="Homo sapiens"
  /mol_type="genomic DNA"
  /db_xref="taxon:9606"
  /db_xref="taxon:9606"
BASE COUNT      10 a      3 c      1 g      3 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1146 ATTTTATTTAGAT 1159
Db      15 ATTTTATTTAGAT 2

RESULT 568
LOCUS      AX730214      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION      Sequence 1848 from Patent WO03025175.
ACCESSION      AX730214
VERSION      AX730214.1 GI:30509557
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
AUTHORS      Telerman, A., Anson, R. and Tuijinder, M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
           reversion, apoptosis and/or virus resistance and their use as
           medicines
JOURNAL    Patent: WO 03025175-A 1848 27-MAR-2003;
           Molecular Engines Laboratories (FR)
FEATURES
  source
  1..17
  /organism="Homo sapiens"
  /mol_type="genomic DNA"
  /db_xref="taxon:9606"
  /db_xref="taxon:9606"
BASE COUNT      5 a      2 c      6 g      4 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      953 TCACAGTGATGTG 966
Db      3 TCACAGTGATGTG 16

RESULT 569
LOCUS      AX730221/c      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION      Sequence 1855 from Patent WO03025175.
ACCESSION      AX730221
VERSION      AX730221.1 GI:30509564
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1
AUTHORS      Telerman, A., Anson, R. and Tuijinder, M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
           reversion, apoptosis and/or virus resistance and their use as
           medicines
JOURNAL    Patent: WO 03025175-A 1855 27-MAR-2003;
           Molecular Engines Laboratories (FR)
FEATURES
  source
  1..17
  /organism="Homo sapiens"
  /mol_type="genomic DNA"
  /db_xref="taxon:9606"
  /db_xref="taxon:9606"

```

```

BASE COUNT      3 a      4 c      4 g      6 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 413 CCAAGATCAGTGA 426
Db 16 CCAAGATCAGTGA 3

RESULT 570
AX730379      17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 2013 from Patent WO03025175.
ACCESSION AX730379
VERSION AX730379.1 GI:30509722
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Telerman,A., Amson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 2013 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      4 a      1 c      1 g      11 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1142 ATTATTTATTTT 1155
Db 2 ATCTATTTATTTT 15

RESULT 571
AX731157      17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 2791 from Patent WO03025175.
ACCESSION AX731157
VERSION AX731157.1 GI:30510500
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Telerman,A., Amson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 2791 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      2 a      3 c      1 g      11 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 908 TCTCTTTATTTCT 921
Db 3 TCTCTTTATTTCT 16

RESULT 572
AX731513      17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 3147 from Patent WO03025175.
ACCESSION AX731513
VERSION AX731513.1 GI:30510856
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Telerman,A., Amson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 3147 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      4 a      3 c      2 g      8 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 910 TCTCTTTATTTCTAA 923
Db 3 TCTCTTTATTTCTGA 16

RESULT 573
AX731889      17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 3523 from Patent WO03025175.
ACCESSION AX731889
VERSION AX731889.1 GI:30511232
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Telerman,A., Amson,R. and Tuijnder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 3523 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      6 a      2 c      4 g      5 t

Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 839 TCTGTAAATCTCG 852
Db 3 TCTGTAAATCTCG 16

```

```

RESULT 574
AX732329/c
LOCUS      AX732329 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3963 from Patent WO03025175.
ACCESSION  AX732329
VERSION     AX732329.1 GI:30511672
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025175-A 3963 27-MAR-2003;
            Molecular Engines Laboratories (PR)
FEATURES    Location/Qualifiers
             source
              1..17
               /organism="Homo sapiens"
               /mol_type="genomic DNA"
               /db_xref="taxon:9606"
BASE COUNT  8 a 1 c 1 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 ATTTATTATTAGAT 1159
Db 15 ATTTATTATTAGAT 2

RESULT 575
AX733592
LOCUS      AX733592 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 5226 from Patent WO03025175.
ACCESSION  AX733592
VERSION     AX733592.1 GI:30512935
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025175-A 5226 27-MAR-2003;
            Molecular Engines Laboratories (PR)
FEATURES    Location/Qualifiers
             source
              1..17
               /organism="Homo sapiens"
               /mol_type="genomic DNA"
               /db_xref="taxon:9606"
BASE COUNT  4 a 2 c 4 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 809 TCAATTTTACTGCG 822
Db 3 TCAATTTTCTGCG 16

RESULT 576
AX735084
LOCUS      AX735084 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 674 from Patent WO03025177.
ACCESSION  AX735084
VERSION     AX735084.1 GI:30515846
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
JOURNAL     Patent: WO 03025177-A 674 27-MAR-2003;
            Molecular Engines Laboratories (PR)
FEATURES    Location/Qualifiers
             source
              1..17
               /organism="Homo sapiens"
               /mol_type="genomic DNA"
               /db_xref="taxon:9606"
BASE COUNT  2 a 4 c 4 g 7 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 893 CACTGTGCTTGGT 906
Db 4 CACTGTTCCTTGGT 17

RESULT 577
AX735477
LOCUS      AX735477 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1067 from Patent WO03025177.
ACCESSION  AX735477
VERSION     AX735477.1 GI:30514754
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Telerman,A., Amson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or resistance to viruses and the use
            thereof as medicaments
JOURNAL     Patent: WO 03025177-A 1067 27-MAR-2003;
            Molecular Engines Laboratories (PR)
FEATURES    Location/Qualifiers
             source
              1..17
               /organism="Homo sapiens"
               /mol_type="genomic DNA"
               /db_xref="taxon:9606"
BASE COUNT  6 a 3 c 3 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1317 ATCTAGTTTGATA 1330
Db 2 ATCCAAGTTTGATA 15

RESULT 578
AX736558/c
LOCUS      AX736558 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2148 from Patent WO03025177.
ACCESSION  AX736558
VERSION     AX736558.1 GI:30515846
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens

```



```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL
Patent: WO 03025177-A 2148 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      2 a      7 c      3 g      5 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 425 GAAGATGCCAGTGA 438
16 GAAGAGGCCAGTGA 3
|||||
RESULT 579
AX736937/c
LOCUS
DEFINITION
Sequence 2527 from Patent WO03025177.
ACCESSION
AX736937
VERSION
AX736937.1 GI:30516225
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Anson,R. and Tuijnder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL
Patent: WO 03025177-A 2527 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      8 a      1 c      4 g      4 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1238 TTTCATTTCAGAT 1251
15 TTTCATTACAGAT 2
|||||
RESULT 580
AX737227/c
LOCUS
DEFINITION
Sequence 2817 from Patent WO03025177.
ACCESSION
AX737227
VERSION
AX737227.1 GI:30516515
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Anson,R. and Tuijnder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour

```

```

reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 2817 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      8 a      2 c      1 g      6 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 ATTATTATTAGAT 1159
15 ATTATTATTAGAT 2
|||||
RESULT 581
AX738005/c
LOCUS
DEFINITION
Sequence 3595 from Patent WO03025177.
ACCESSION
AX738005
VERSION
AX738005.1 GI:30517293
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Anson,R. and Tuijnder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL
Patent: WO 03025177-A 3595 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT     10 a      1 c      2 g      4 t
Query Match      1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 ATTATTATTAGAT 1159
15 ATTATTATTAGAT 2
|||||
RESULT 582
AX738018/c
LOCUS
DEFINITION
Sequence 3608 from Patent WO03025177.
ACCESSION
AX738018
VERSION
AX738018.1 GI:30517306
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Anson,R. and Tuijnder,M.
TITLE
Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL
Patent: WO 03025177-A 3608 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers

```

```
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
7 a 3 c 1 g 6 t
BASE COUNT 7 a 3 c 1 g 6 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 864 TGCTAGCCAGGATC 877
Db 14 TTCTAGCCAGGATC 1
RESULT 585
AX739138 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4728 from Patent WO03025177.
ACCESSION AX739138
VERSION AX739138.1 GI:30518435
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4728 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
8 a 3 c 1 g 5 t
BASE COUNT 8 a 3 c 1 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 612 ATCTACAAAACA 625
Db 2 ATCTACAAAACA 15
RESULT 586
AX739438 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 5028 from Patent WO03025177.
ACCESSION AX739438
VERSION AX739438.1 GI:30518735
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 5028 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
7 a 2 c 3 g 5 t
BASE COUNT 7 a 2 c 3 g 5 t
Query Match 1.0%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 478 TGGGTCTGTGTAG 491
Db 3 TCGGTCTGTGTAG 16
RESULT 584
AX739077/c 17 bp DNA linear PAT 08-MAY-2003
LOCUS
DEFINITION Sequence 4667 from Patent WO03025177.
ACCESSION AX739077
VERSION AX739077.1 GI:30518374
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4667 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
Location/Qualifiers
source
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
5 a 3 c 5 g 4 t
BASE COUNT 5 a 3 c 5 g 4 t
```

QY 627 CAAATAAATTTTGA 640  
 Db 16 CAAATAGTTTGA 3

RESULT 587  
 AX739515/c  
 LOCUS 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 5105 from Patent WO03025177.  
 ACCESSION AX739515  
 VERSION AX739515.1 GI:30518812  
 KEYWORDS Homo sapiens (human)  
 SOURCE  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 5105 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES  
 source  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 9 a 3 c 4 g 1 t  
 Query Match 1.0%; Score 12.4; DB 1; Length 17;  
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1438 TTCTTGTGTTTGA 1451  
 Db 16 TTCTTGTGTTTGA 3

RESULT 588  
 AX739551/c  
 LOCUS 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 5141 from Patent WO03025177.  
 ACCESSION AX739551  
 VERSION AX739551.1 GI:30518848  
 KEYWORDS Homo sapiens (human)  
 SOURCE  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 5141 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES  
 source  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 5 a 1 c 5 g 5 t  
 Query Match 1.0%; Score 12.4; DB 1; Length 17;  
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1444 CTGCTTGAACCTTG 1457  
 Db 4 CTGCTTGAACCTTG 17

RESULT 589  
 AX739830/c  
 LOCUS 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 5420 from Patent WO03025177.  
 ACCESSION AX739830  
 VERSION AX739830.1 GI:30519127  
 KEYWORDS Homo sapiens (human)  
 SOURCE  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 5420 27-MAR-2003;  
 Molecular Engines Laboratories (FR)  
 FEATURES  
 source  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 8 a 1 c 1 g 7 t  
 Query Match 1.0%; Score 12.4; DB 1; Length 17;  
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 ATTTTATTTAGAT 1159  
 Db 15 ATTTTATTTAGAT 2

RESULT 590  
 BD066678  
 LOCUS 17 bp DNA linear PAT 27-AUG-2002  
 DEFINITION An antisense oligonucleotide preparation method.  
 ACCESSION BD066678  
 VERSION BD066678.1 GI:22612281  
 KEYWORDS JP 2001511000-A/1313.  
 SOURCE unidentified  
 ORGANISM unclassified.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Schlingensiepen,K.H. and Brysch,W.  
 TITLE An antisense oligonucleotide preparation method  
 JOURNAL Patent: JP 2001511000-A 1313 07-AUG-2001;  
 BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH  
 COMMENT OS Unknown  
 FN JP 2001511000-A/1313  
 PD 07-AUG-2001  
 PF 30-JAN-1998 JP 1998532533  
 PR 31-JAN-1997 EP 97101531.8  
 PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH  
 PC C12N15/11.C07H21/04,A61K31/70  
 CC An antisense oligonucleotide preparation method FH Key  
 FEATURES  
 source  
 1..16  
 Location/Qualifiers  
 FT  
 /organism="Unknown".  
 1..17  
 Location/Qualifiers  
 /organism="unidentified"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32644"  
 BASE COUNT 4 a 2 c 4 g 7 t  
 Query Match 1.0%; Score 12.4; DB 1; Length 17;  
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 720 CTTTAAATTCAGGA 733  
 Db 15 CTTTAAATTCAGGA 2

Db	PI	NOBORU NAKAMICHI, YOSHIKO HIROTA, MAMIKO ITO, TAKUJI MAEDA, HUA
RESULT 591	PI	YAN,
BD067358	PI	TOSHIHARU MATSUMURA
LOCUS	PC	C12N15/85, C12N5/10
DEFINITION	CC	
Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors.		
ACCESSION	EH	Key Location/Qualifiers.
BD067358		1.17
VERSION		/organism="unidentified"
KEYWORDS		/mol_type="genomic DNA"
JP 2001511003-A/198		/db_xref="taxon:32644"
UNIDENTIFIED		4 a 0 c 0 g 13 t
SOURCE		
ORGANISM		
REFERENCE		
1 (bases 1 to 17)		1.0%; Score 12.4; DB 1; Length 17;
Akhtar S., Fell, P. and McSwiggen, J.A.		Best Local Similarity 92.9%; Pred. No. 5.2e+02;
Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors		Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
PATENT: JP 2001511003-A 198 07-AUG-2001;		
RIBOZYME PHARMACEUTICALS INC. ASTON UNIV		
OS Unidentified		
JP 2001511003-A/198		
PD 07-AUG-2001		
PF 14-JAN-1998 JP 1998532913		
PR 31-JAN-1997 US 60/036476, 04-DEC-1997 US 08/985162 PI		
SAGHIR AKHTAR, PATRICIA FELL, JAMES A MCSWIGGEN PC		
C12N9/00, C07K14/71		
CC Strandedness: Single;		
CC Topology: Linear;		
CC Enzymatic nucleic acid treatment of diseases or conditions related to		
CC levels of epidermal growth factor receptors		
EH Key Location/Qualifiers		
PT source 1.17		
PT /organism="Unidentified".		
Location/Qualifiers		
1.17		
/organism="unidentified"		
/mol_type="genomic RNA"		
/db_xref="taxon:32644"		
BASE COUNT	8 a 2 c 3 g 4 t	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	530 AATTTCAGTAACA 543	
DB	4 AATTTCAGTAACA 17	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	
DB	14 TCCTGGATTTT 1	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	
DB	14 TCCTGGATTTT 1	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	
DB	14 TCCTGGATTTT 1	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	
DB	14 TCCTGGATTTT 1	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	
DB	14 TCCTGGATTTT 1	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	
DB	14 TCCTGGATTTT 1	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	
DB	14 TCCTGGATTTT 1	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	
DB	14 TCCTGGATTTT 1	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	
DB	14 TCCTGGATTTT 1	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	
DB	14 TCCTGGATTTT 1	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	
DB	14 TCCTGGATTTT 1	
Query Match	1.0%; Score 12.4; DB 1; Length 17;	
Best Local Similarity	92.9%; Pred. No. 5.2e+02;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	826 TCCTGGATTTT 839	

Qy 1354 TGTGTTGGTAGTC 1367  
 |||||  
 Db 17 TGTGTTGGTAATGC 4

## RESULT 595

A04265/c  
 LOCUS 194265  
 DEFINITION Sequence 428 from patent US 5731295.  
 ACCESSION 194265  
 VERSION 194265.1 GI:3938735  
 KEYWORDS Unknown.  
 SOURCE Unknown.  
 ORGANISM Unclassified.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS Draper, K.G., Pavco, P., McSwiggen, J., Gustofson, J. and Stinchcomb, D.T.  
 TITLE Method of reducing stromelysin RNA via ribozymes  
 JOURNAL Patent: US 5731295-A 428 24-MAR-1998;  
 FEATURES  
 source  
 1..17  
 Location/Qualifiers  
 /organism="unknown"  
 BASE COUNT 12 a 2 c 1 g 2 t

Query Match 1.0%; Score 12.4; DB 1; Length 17;  
 Best Local Similarity 92.9%; Pred. No. 5.2e+02;  
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 826 TCCTGGATTTTTT 839  
 |||||  
 Db 14 TCTTGGATTTTTT 1

## RESULT 596

BD182174/c  
 LOCUS BD182174  
 DEFINITION Method for synthesizing of nucleic acid.  
 ACCESSION BD182174  
 VERSION BD182174.1 GI:30793092  
 KEYWORDS WO 02090538-A/6.  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 REFERENCE 1 (bases 1 to 30)  
 AUTHORS Nagamine, K.  
 TITLE Method for synthesizing of nucleic acid  
 JOURNAL Patent: WO 02090538-A 6 14-NOV-2002;  
 COMMENT EIKEN CHEMICAL CO LTD, KENTARO NAGAMINE  
 OS Artificial Sequence  
 PN WO 02090538-A/6  
 PD 14-NOV-2002  
 PP 08-MAY-2002 WO 2002JP004479  
 PR 08-MAY-2001 JP 01P 137060, 18-JUN-2001 JP 01P 184131 PI  
 KENTARO NAGAMINE  
 PC C12N15/09, C12Q1/68  
 CC Description of Artificial Sequence: an artificially synthesized

CC primer  
 CC sequence  
 FH Key  
 FT source  
 FT Location/Qualifiers

1..30  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 BASE COUNT 13 a 3 c 5 g 9 t

Query Match 1.0%; Score 12.4; DB 1; Length 30;  
 Best Local Similarity 72.7%; Pred. No. 9e+02;

Matches 16; Conservative 0; Mismatches 6; Indels 0; Gaps 0;  
 Qy 1068 CAAATATTTGCAAGATTTC 1089  
 |||||  
 Db 25 CAAATCTTGCAAAATATTTC 4

## RESULT 597

A04026/c  
 LOCUS A04026  
 DEFINITION Synthetic probe P6.  
 ACCESSION A04026  
 VERSION A04026.1 GI:412366  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS  
 JOURNAL  
 FEATURES  
 source  
 1..17  
 Location/Qualifiers  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 BASE COUNT 8 a 0 c 4 g 5 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1231 AGTTAAATTTTCATTC 1247  
 |||||  
 Db 17 ACTTCAATTTTCATTC 1

## RESULT 598

A04027  
 LOCUS A04027  
 DEFINITION Synthetic sequence P6 (Reverse complement).  
 ACCESSION A04027  
 VERSION A04027.1 GI:410971  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 REFERENCE 1 (bases 1 to 17)  
 AUTHORS  
 JOURNAL  
 FEATURES  
 source  
 1..17  
 Location/Qualifiers  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 BASE COUNT 5 a 4 c 0 g 8 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1231 AGTTAAATTTTCATTC 1247  
 |||||  
 Db 1 ACTTCAATTTTCATTC 17

## RESULT 599

A09201  
 LOCUS A09201  
 DEFINITION Nucleotide sequence 17 from patent number EP0365894.  
 ACCESSION A09201  
 VERSION A09201.1 GI:411948  
 KEYWORDS unidentified  
 SOURCE

Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1231 AGTTAAATTTTCATTC 1247  
 |||||  
 Db 1 ACTTCAATTTTCATTC 17

```

ORGANISM      unidentified
REFERENCE      1 (bases 1 to 17)
AUTHORS        Brandazza,A., Sarmientos,P. and Orsini,G.
TITLE          Production of human prourokinase
JOURNAL        Patent: EP 0365894-A 17 02-MAY-1990;
               FARMITALIA CARLO ERBA S.r.L
FEATURES       Location/Qualifiers
source         1..17
               /organism="unidentified"
               /mol_type="genomic DNA"
               /db_xref="taxon:32644"
BASE COUNT    5 a      4 c      0 g      8 t

Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1231 AGTTAAATTTTCATTC 1247
DB 1 ACTTCAATTTTCATTC 17

RESULT 600
A64296/c
LOCUS         A64296               17 bp      DNA      linear      PAT 29-MAR-1999
DEFINITION    Sequence 84 from Patent WO9727332.
ACCESSION     A64296
VERSION       A64296.1 GI:3717727
KEYWORDS
SOURCE        unidentified
ORGANISM      unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS       Stuyver,L., Louwagie,J. and Rossau,R.
TITLE         METHOD FOR DETECTION OF DRUG-INDUCED MUTATIONS IN THE REVERSE
              TRANSCRIPTASE GENE
JOURNAL       Patent: WO 9727332-A 84 31-JUL-1997;
              INNOGENETICS NV (BE)
COMMENT       Other publication AU 144397 19970820.
FEATURES      Location/Qualifiers
source        1..17
               /organism="unidentified"
               /mol_type="genomic DNA"
               /db_xref="taxon:32644"
BASE COUNT    8 a      2 c      2 g      5 t

Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1043 ATTATTATGATTTAT 1059
DB 17 ATCTCATGATTTGAT 1

RESULT 601
A88483/c
LOCUS         A88483               17 bp      DNA      linear      PAT 22-JAN-2000
DEFINITION    Sequence 631 from Patent WO9833904.
ACCESSION     A88483
VERSION       A88483.1 GI:6737053
KEYWORDS
SOURCE        unidentified
ORGANISM      unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS       Brysch,W. and Schlingensiepen,K.
TITLE         AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL       Patent: WO 9833904-A 631 06-AUG-1998;
              BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES      Location/Qualifiers
source        1..17

ORGANISM      unidentified
REFERENCE      1 (bases 1 to 17)
AUTHORS        Brandazza,A., Sarmientos,P. and Orsini,G.
TITLE          Production of human prourokinase
JOURNAL        Patent: EP 0365894-A 17 02-MAY-1990;
               FARMITALIA CARLO ERBA S.r.L
FEATURES       Location/Qualifiers
source         1..17
               /organism="unidentified"
               /mol_type="genomic DNA"
               /db_xref="taxon:32644"
BASE COUNT    4 a      3 c      5 g      5 t

Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 639 GAATATAGGATTTTCC 655
DB 17 GCATACAGGATCTTCC 1

RESULT 602
A90450/c
LOCUS         A90450               17 bp      DNA      linear      PAT 22-JAN-2000
DEFINITION    Sequence 631 from Patent EP0856579.
ACCESSION     A90450
VERSION       A90450.1 GI:6738964
KEYWORDS
SOURCE        unidentified
ORGANISM      unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS       Brysch,W.D. and Schlingensiepen,K.D.
TITLE         An antisense oligonucleotide preparation method
JOURNAL       Patent: EP 0856579-A 631 05-AUG-1998;
              BIOGNOSTIK GES (DE)
FEATURES      Location/Qualifiers
source        1..17
               /organism="unidentified"
               /mol_type="genomic DNA"
               /db_xref="taxon:32644"
BASE COUNT    4 a      3 c      5 g      5 t

Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 639 GAATATAGGATTTTCC 655
DB 17 GCATACAGGATCTTCC 1

RESULT 603
A97833
LOCUS         A97833               17 bp      DNA      linear      PAT 26-JAN-2000
DEFINITION    Sequence 110 from Patent WO9914377.
ACCESSION     A97833
VERSION       A97833.1 GI:6781071
KEYWORDS
SOURCE        unidentified
ORGANISM      unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS       Quint,W. and Kleter,B.
TITLE         DETECTION AND IDENTIFICATION OF HUMAN PAPILLOMAVIRUS BY PCR AND
              TYPE-SPECIFIC REVERSE HYBRIDIZATION
JOURNAL       Patent: WO 9914377-A 110 25-MAR-1999;
              INNOGENETICS NV (BE); DELFTS DIAGNOSTIC LAB B V (NL)
FEATURES      Location/Qualifiers
source        1..17
               /organism="unidentified"
               /mol_type="genomic DNA"
               /db_xref="taxon:32644"
BASE COUNT    5 a      1 c      5 g      6 t

Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1619 AATATAATTGTGTCTCA 1635

```

JOURNAL	Patent: US 5817796-A 792 06-OCT-1998;	Location/Qualifiers	1. .17	11 a	1 c	1 g	4 t	Query Match	1.0%; Score 12.2; DB 1; Length 17;	Best Local Similarity	82.4%; Pred. No. 5.8e+02;	Matches	14; Conservative	0; Mismatches	3; Indels	0; Gaps
Db	1	AATGGGAAATTTGGCA	17													
RESULT 604																
LOCUS	AR045949															
DEFINITION	Sequence 742 from patent US 5817796.															
ACCESSION	AR045949															
VERSION	AR045949.1	GI:5967414														
KEYWORDS	Unknown.															
ORGANISM	Unknown.															
REFERENCE	1 (bases 1 to 17)															
AUTHORS	Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.															
TITLE	C-myb ribozymes having 2'-5'-linked adenylylate residues															
JOURNAL	Patent: US 5817796-A 742 06-OCT-1998;															
FEATURES	Location/Qualifiers															
source	1. .17															
BASE COUNT	9 a	0 c	2 g	6 t												
Query Match	1.0%; Score 12.2; DB 1; Length 17;															
Best Local Similarity	82.4%; Pred. No. 5.8e+02;															
Matches	14; Conservative	0; Mismatches	3; Indels	0; Gaps	0;											
Qy	1081	AGCAATTTGGAAATA	1097													
Db	1	AGCAATTTTAAATA	17													
RESULT 605																
LOCUS	AR045999															
DEFINITION	Sequence 792 from patent US 5817796.															
ACCESSION	AR045999															
VERSION	AR045999.1	GI:5967454														
KEYWORDS	Unknown.															
SOURCE	Unknown.															
ORGANISM	Unclassified.															
REFERENCE	1 (bases 1 to 17)															
AUTHORS	Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.															
TITLE	C-myb ribozymes having 2'-5'-linked adenylylate residues															
JOURNAL	Patent: US 5817796-A 792 06-OCT-1998;															
FEATURES	Location/Qualifiers															
source	1. .17															
BASE COUNT	11 a	1 c	1 g	4 t												
Query Match	1.0%; Score 12.2; DB 1; Length 17;															
Best Local Similarity	82.4%; Pred. No. 5.8e+02;															
Matches	14; Conservative	0; Mismatches	3; Indels	0; Gaps	0;											
Qy	619	AAAAACACAAATATT	635													
Db	1	AAAAACATAAATGATT	17													
RESULT 606																
LOCUS	AR045999/c															
DEFINITION	Sequence 792 from patent US 5817796.															
ACCESSION	AR045999															

Query Match	1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. No. 5.8e+02;
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1583 TGATGCAATATAAAA 1599	
Db 17 TGTATATATATAAAA 1	
RESULT 612	
AR047078	17 bp DNA linear PAT 29-SEP-1999
LOCUS	
DEFINITION	Sequence 1871 from patent US 5817796.
ACCESSION	AR047078
VERSION	AR047078.1 GI:5968543
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 17)
TITLE	Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
JOURNAL	C-myb ribozymes having 2'-5'-linked adenylylate residues
FEATURES	Patent: US 5817796-A 1871 06-OCT-1998; Location/Qualifiers 1..17 /organism="unknown"
BASE COUNT	6 a 0 c 2 g 9 t
Query Match	1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. No. 5.8e+02;
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1259 AAATAATTTTGTAT 1275	
Db 1 AAATGATTTTGTAT 17	
RESULT 613	
AR047092	17 bp DNA linear PAT 29-SEP-1999
LOCUS	
DEFINITION	Sequence 1885 from patent US 5817796.
ACCESSION	AR047092
VERSION	AR047092.1 GI:5968557
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 17)
TITLE	Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
JOURNAL	C-myb ribozymes having 2'-5'-linked adenylylate residues
FEATURES	Patent: US 5817796-A 1885 06-OCT-1998; Location/Qualifiers 1..17 /organism="unknown"
BASE COUNT	6 a 0 c 3 g 8 t
Query Match	1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. No. 5.8e+02;
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1147 TTTTATTTTATAGATTA 1163	
Db 1 TTGTATTTTATAGATA 17	
RESULT 614	
AR047108/c	17 bp DNA linear PAT 29-SEP-1999
LOCUS	
DEFINITION	Sequence 1901 from patent US 5817796.
ACCESSION	AR047108
VERSION	AR047108.1 GI:5968573
KEYWORDS	
SOURCE	Unknown.



<b>ORGANISM</b>						Unknwn.					
<b>REFERENCE</b>						Unclassified.					
<b>AUTHORS</b>						1 (bases 1 to 17)					
<b>TITLE</b>						Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.					
<b>JOURNAL</b>						C-myb ribozymes having 2'-5'-linked adenylyate residues					
<b>FEATURES</b>						Patent: US 5817796-A 1901 06-OCT-1998;					
<b>source</b>						Location/Qualifiers					
						1..17					
<b>BASE COUNT</b>						3 a 1 c 5 g 8 t					
<b>Query Match</b>						1.0%; Score 12.2; DB 1; Length 17;					
<b>Best Local Similarity</b>						82.4%; Pred. No. 5.8e+02;					
<b>Matches</b>						14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;					
<b>QY</b>						1418 CCACAGTCATATTAGT 1434					
<b>Db</b>											
						17 CCACAGTCAAAAATACT 1					
<b>RESULT 615</b>											
<b>AR047190/c</b>											
<b>LOCUS</b>						AR047190 17 bp DNA linear PAT 29-SEP-1999					
<b>DEFINITION</b>						Sequence 1983 from patent US 5817796.					
<b>ACCESSION</b>						AR047190					
<b>VERSION</b>						AR047190.1 GI:5968655					
<b>KEYWORDS</b>						Unknown.					
<b>SOURCE</b>						Unknown.					
<b>ORGANISM</b>						Unclassified.					
<b>REFERENCE</b>						1 (bases 1 to 17)					
<b>AUTHORS</b>						Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.					
<b>TITLE</b>						C-myb ribozymes having 2'-5'-linked adenylyate residues					
<b>JOURNAL</b>						Patent: US 5817796-A 1983 06-OCT-1998;					
<b>FEATURES</b>						Location/Qualifiers					
<b>source</b>						1..17					
						/organism="unknown"					
<b>BASE COUNT</b>						4 a 2 c 3 g 8 t					
<b>Query Match</b>						1.0%; Score 12.2; DB 1; Length 17;					
<b>Best Local Similarity</b>						82.4%; Pred. No. 5.8e+02;					
<b>Matches</b>						14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;					
<b>QY</b>						929 AAAAGTATTAGCCACCA 945					
<b>Db</b>											
						17 AAGATTATTAGCCACA 1					
<b>RESULT 616</b>											
<b>AR047354</b>											
<b>LOCUS</b>						AR047354 17 bp DNA linear PAT 29-SEP-1999					
<b>DEFINITION</b>						Sequence 2147 from patent US 5817796.					
<b>ACCESSION</b>						AR047354					
<b>VERSION</b>						AR047354.1 GI:5968819					
<b>KEYWORDS</b>						Unknown.					
<b>SOURCE</b>						Unknown.					
<b>ORGANISM</b>						Unclassified.					
<b>REFERENCE</b>						1 (bases 1 to 17)					
<b>AUTHORS</b>						Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.					
<b>TITLE</b>						C-myb ribozymes having 2'-5'-linked adenylyate residues					
<b>JOURNAL</b>						Patent: US 5817796-A 2147 06-OCT-1998;					
<b>FEATURES</b>						Location/Qualifiers					
<b>source</b>						1..17					
						/organism="unknown"					
<b>BASE COUNT</b>						3 a 1 c 0 g 13 t					
<b>Query Match</b>						1.0%; Score 12.2; DB 1; Length 17;					
<b>Best Local Similarity</b>						82.4%; Pred. No. 5.8e+02;					
<b>Matches</b>						14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;					
<b>QY</b>						1035 ACCATTATTATTAT 1051					
<b>Db</b>											

```

FEATURES
  source
    BASE COUNT      5 a      0 c      0 g      12 t
    Query Match      1.0%; Score 12.2; DB 1; Length 17;
    Best Local Similarity 82.4%; Pred. No. 5.8e+02;
    Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
  QY 1041 TTATTATTATTATT 1057
  Db 1 TTATTATTATTATT 17
  RESULT 620
  AR047604/c
  LOCUS      AR047604      17 bp      DNA      linear      PAT 29-SEP-1999
  DEFINITION Sequence 2397 from patent US 5817796.
  ACCESSION AR047604
  VERSION AR047604.1 GI:5969069
  KEYWORDS
  SOURCE      Unknown.
  ORGANISM    Unclassified.
  REFERENCE 1 (bases 1 to 17)
  AUTHORS    Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
  TITLE      C-myd ribozymes having 2'-5'-linked adenylate residues
  JOURNAL    Patent: US 5817796-A 2397 06-OCT-1998;
  FEATURES
    Location/Qualifiers
      source
        BASE COUNT      8 a      1 c      2 g      6 t
        Query Match      1.0%; Score 12.2; DB 1; Length 17;
        Best Local Similarity 82.4%; Pred. No. 5.8e+02;
        Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
  QY 640 AATATAAGCAATTTCT 656
  Db 17 AATATGATTTTCT 1
  RESULT 621
  AR057620
  LOCUS      AR057620      17 bp      DNA      linear      PAT 29-SEP-1999
  DEFINITION Sequence 1824 from patent US 5837542.
  ACCESSION AR057620
  VERSION AR057620.1 GI:5983197
  KEYWORDS
  SOURCE      Unknown.
  ORGANISM    Unclassified.
  REFERENCE 1 (bases 1 to 17)
  AUTHORS    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
  TITLE      Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL    Patent: US 5837542-A 1824 17-NOV-1998;
  FEATURES
    Location/Qualifiers
      source
        BASE COUNT      4 a      4 c      4 g      5 t
        Query Match      1.0%; Score 12.2; DB 1; Length 17;
        Best Local Similarity 82.4%; Pred. No. 5.8e+02;
        Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
  QY 977 TGGAGCACTTTCAGTT 993
  Db 1 TGGAGCTCTTCAGCT 17
  RESULT 622
  AR057641
  LOCUS      AR057641      17 bp      DNA      linear      PAT 29-SEP-1999
  DEFINITION Sequence 1845 from patent US 5837542.
  ACCESSION AR057641
  VERSION AR057641.1 GI:5983218
  KEYWORDS
  SOURCE      Unknown.
  ORGANISM    Unclassified.
  REFERENCE 1 (bases 1 to 17)
  AUTHORS    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
  TITLE      Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL    Patent: US 5837542-A 1845 17-NOV-1998;
  FEATURES
    Location/Qualifiers
      source
        BASE COUNT      6 a      1 c      1 g      9 t
        Query Match      1.0%; Score 12.2; DB 1; Length 17;
        Best Local Similarity 82.4%; Pred. No. 5.8e+02;
        Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
  QY 1050 ATGTATTATTATTACGA 1066
  Db 1 ATGTATTATTATTATCA 17
  RESULT 623
  AR057785
  LOCUS      AR057785      17 bp      DNA      linear      PAT 29-SEP-1999
  DEFINITION Sequence 1989 from patent US 5837542.
  ACCESSION AR057785
  VERSION AR057785.1 GI:5983362
  KEYWORDS
  SOURCE      Unknown.
  ORGANISM    Unclassified.
  REFERENCE 1 (bases 1 to 17)
  AUTHORS    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
  TITLE      Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL    Patent: US 5837542-A 1989 17-NOV-1998;
  FEATURES
    Location/Qualifiers
      source
        BASE COUNT      6 a      1 c      1 g      9 t
        Query Match      1.0%; Score 12.2; DB 1; Length 17;
        Best Local Similarity 82.4%; Pred. No. 5.8e+02;
        Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
  QY 1050 ATGTATTATTATTACGA 1066
  Db 1 ATGTATTATTATTATCA 17
  RESULT 624
  AR057803
  LOCUS      AR057803      17 bp      DNA      linear      PAT 29-SEP-1999
  DEFINITION Sequence 2007 from patent US 5837542.
  ACCESSION AR057803
  VERSION AR057803.1 GI:5983380
  KEYWORDS
  SOURCE      Unknown.
  ORGANISM    Unclassified.
  REFERENCE 1 (bases 1 to 17)
  AUTHORS    Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
  TITLE      Intercellular adhesion molecule-1 (ICAM-1) ribozymes
  JOURNAL    Patent: US 5837542-A 2007 17-NOV-1998;
  FEATURES
    Location/Qualifiers
      source

```

```

BASE COUNT      4 a      4 c      4 g      5 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 977 TGAAGACCTTTAAGTT 993
Db 1 TGAAGACTCTTCAAGCT 17

RESULT 625
AR057805
LOCUS      AR057805      17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 2009 from patent US 5837542.
ACCESSION AR057805
VERSION AR057805.1 GI:5983382
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT      4 a      4 c      4 g      5 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 977 TGAAGACCTTTAAGTT 993
Db 1 TGAAGACTCTTCAAGCT 17

RESULT 626
AR065109
LOCUS      AR065109      17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5849486.
ACCESSION AR065109
VERSION AR065109.1 GI:5995325
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT      9 a      0 c      0 g      8 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1610 AACATTAAATATAT 1626
Db 1 AAATTATATATATAT 17

RESULT 627
AR080426
LOCUS      AR080426      17 bp      DNA      linear      PAT 31-AUG-2000
DEFINITION Sequence 30 from patent US 5968776.
ACCESSION AR080426
VERSION AR080426.1 GI:10007161
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT      5 a      4 c      2 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1307 TGAACCTAACATCTCTAG 1323
Db 1 TGAACCTAACATCTCTAG 17

RESULT 628
AR092550
LOCUS      AR092550      17 bp      DNA      linear      PAT 08-SEP-2000
DEFINITION Sequence 30 from patent US 5998169.
ACCESSION AR092550
VERSION AR092550.1 GI:10019304
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT      5 a      4 c      2 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1307 TGAACCTAACATCTCTAG 1323
Db 1 TGAACCTAACATCTCTAG 17

RESULT 629
AR102595
LOCUS      AR102595      17 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 84 from patent US 6087093.
ACCESSION AR102595
VERSION AR102595.1 GI:12814183
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL

```

```

LOCUS      AR080426      17 bp      DNA      linear      PAT 31-AUG-2000
DEFINITION Sequence 30 from patent US 5968776.
ACCESSION AR080426
VERSION AR080426.1 GI:10007161
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT      5 a      4 c      2 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1307 TGAACCTAACATCTCTAG 1323
Db 1 TGAACCTAACATCTCTAG 17

RESULT 628
AR092550
LOCUS      AR092550      17 bp      DNA      linear      PAT 08-SEP-2000
DEFINITION Sequence 30 from patent US 5998169.
ACCESSION AR092550
VERSION AR092550.1 GI:10019304
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
BASE COUNT      5 a      4 c      2 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1307 TGAACCTAACATCTCTAG 1323
Db 1 TGAACCTAACATCTCTAG 17

RESULT 629
AR102595
LOCUS      AR102595      17 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 84 from patent US 6087093.
ACCESSION AR102595
VERSION AR102595.1 GI:12814183
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL

```



DB	1	AAGGAATTACATCAG	17	bp	DNA	linear	PAT 20-APR-2002
RESULT 637	AR186562	Sequence 2050 from patent US 6346398.	17	bp	DNA	linear	PAT 20-APR-2002
LOCUS	AR186562						
DEFINITION	AR186562						
ACCESSION	AR186562.1	GI:20232527					
VERSION							
KEYWORDS							
SOURCE	Unknown.						
ORGANISM	Unknown.						
REFERENCE	1 (bases 1 to 17)						
AUTHORS	Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.						
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor						
JOURNAL	Patent: US 6346398-A	2050 12-FEB-2002;					
FEATURES	Location/Qualifiers						
source	1..17						
BASE COUNT	4 a 2 c 5 g	6 t					
Query Match	1.0%;	Score 12.2;	DB 1;	Length 17;			
Best Local Similarity	82.4%;	Pred. No. 5.8e+02;					
Matches	14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;		
QY	441	CTTCAAGCAATCTACT 457					
Db	17	CTTCAAGCAATCCT 1					
LOCUS	AR186699	Sequence 2187 from patent US 6346398.	17	bp	DNA	linear	PAT 20-APR-2002
DEFINITION	AR186699						
ACCESSION	AR186699.1	GI:20232664					
VERSION							
KEYWORDS							
SOURCE	Unknown.						
ORGANISM	Unknown.						
REFERENCE	1 (bases 1 to 17)						
AUTHORS	Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.						
TITLE	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor						
JOURNAL	Patent: US 6346398-A	2187 12-FEB-2002;					
FEATURES	Location/Qualifiers						
source	1..17						
BASE COUNT	1 a 2 c 2 g	12 t					
Query Match	1.0%;	Score 12.2;	DB 1;	Length 17;			
Best Local Similarity	82.4%;	Pred. No. 5.8e+02;					
Matches	14;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;		
QY	1519	GCCTTATATTTTAACT 1535					
Db	1	GCCTTATTTTGTACT 17					
LOCUS	AR186816	Sequence 2304 from patent US 6346398.	17	bp	DNA	linear	PAT 20-APR-2002
DEFINITION	AR186816						
ACCESSION	AR186816.1	GI:20232781					
VERSION							
KEYWORDS							
SOURCE	Unknown.						
ORGANISM	Unknown.						
REFERENCE	1 (bases 1 to 17)						
AUTHORS	Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.						



related to levels of vascular endothelial growth factor receptor  
Patent: US 6346398-A 2700 12-FEB-2002;

**JOURNAL  
FEATURES**

source

**BASE COUNT**

Query Match

### Best Local Match

TE

1

RESULT 645

AR187213/C  
LOGIC

### DEFINITION

**VERSION**

**KEYWORDS**  
**SOURCE**

# ORGANISM

## REFERENCE

**TITLE**

**JOURNAL**

Source

BASE COTTON

•

### Best Local

2000

51

Db I

100

AR187227

### DEFINITION

ACCESSION  
NUMBER

## KEYWORDS

ORGANISM

## REFERENCE

AUTHORS
TITLE

**TOURNAI**

## FEATURES

THIRD PARTY

Query MacC  
Best Local

## Matches

90 Qy

D'b

```

JOURNAL Patent: US 6346398-A 2857 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 2 a 3 c 3 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 803 ATAAAGTCAAAATTAGC 819
DB 17 ATAAAGGCAAAATAGC 1

RESULT 650
ARI88360
LOCUS 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 3848 from patent US 6346398.
ACCESSION ARI88360
VERSION ARI88360.1 GI:20234325
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 3848 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 5 a 4 c 2 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1453 ACTGTTTATTATGCTAC 1469
DB 1 ACCAGTCTATTATGCTAC 17

RESULT 651
ARI88498/c
LOCUS 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 3996 from patent US 6346398.
ACCESSION ARI88498
VERSION ARI88498.1 GI:20234463
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 3986 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 7 a 3 c 1 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1133 TTATAGTAAATTTATT 1149
DB 17 TTAGAGCAAAATGATTT 1

RESULT 652
ARI88771/c
LOCUS 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4259 from patent US 6346398.
ACCESSION ARI88771
VERSION ARI88771.1 GI:20234736
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4259 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 2 a 6 c 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 969 AGGCATGTGGAGCAC 985
DB 17 AGGATATGGAGAGCAC 1

RESULT 653
ARI92457
LOCUS 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7945 from patent US 6346398.
ACCESSION ARI92457
VERSION ARI92457.1 GI:20238422
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7945 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
BASE COUNT 5 a 2 c 1 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 586 TTATATGTAAGTATTA 602
DB 1 TTTATCTCAGTATTA 17

RESULT 654
ARI92474
LOCUS 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7962 from patent US 6346398.
ACCESSION ARI92474
VERSION ARI92474.1 GI:20238439
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7962 12-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
```



```

FEATURES             Location/Qualifiers
  source              1..17
                     /organism="unknown"
BASE COUNT           6 a      2 c      1 g      8 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1152 TTTTGGATATTAATGA 1168
Db 1 TTTTATATCCATGA 17

RESULT 655
LOCUS AR192646/c 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 8134 from patent US 6346398.
ACCESSION AR192646
VERSION AR192646.1 GI:20238611
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 8134 12-FEB-2002;
FEATURES Location/Qualifiers
  source              1..17
                     /organism="unknown"
BASE COUNT           7 a      1 c      0 g      9 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1470 AATAGATTCTTAAAT 1486
Db 17 AATGATTATTAAT 1

RESULT 656
LOCUS AR196327/c 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 792 from patent US 6350934.
ACCESSION AR196327
VERSION AR196327.1 GI:20245764
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Zwick, M.G., Edington, B.E., McSwiggen, J.A., Merlo, P. Ann.Owens.,
Guo, L., Skokut, T.A., Young, S.A., Folkerts, O. and Merlo, D.J.
TITLE Nucleic acid encoding delta-9 desaturase
JOURNAL Patent: US 6350934-A 792 26-FEB-2002;
FEATURES Location/Qualifiers
  source              1..17
                     /organism="unknown"
BASE COUNT           6 a      3 c      1 g      7 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 640 AATATAGGATTTCTCT 656
Db 17 AAGATAGGATTTATCT 1

RESULT 657

```

```

AR207848
LOCUS AR207848 17 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 22 from patent US 6379928.
ACCESSION AR207848
VERSION AR207848.1 GI:21507708
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Berka, R. Michael., Cullen, D., Gray, G. Lawrence., Hayenga, K. James. and
Lawlis, V. Bryan.
TITLE Heterologous polypeptides expressed in filamentous fungi, processes
for making same, and vectors for making same
JOURNAL Patent: US 6379928-A 22 30-APR-2002;
FEATURES Location/Qualifiers
  source              1..17
                     /organism="unknown"
BASE COUNT           8 a      1 c      0 g      5 t      3 others

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1271 AGTATAAGTACATTA 1285
Db 2 ARTAYAAATATATTA 16

RESULT 658
LOCUS AR207851 17 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 25 from patent US 6379928.
ACCESSION AR207851
VERSION AR207851.1 GI:21507712
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Berka, R. Michael., Cullen, D., Gray, G. Lawrence., Hayenga, K. James. and
Lawlis, V. Bryan.
TITLE Heterologous polypeptides expressed in filamentous fungi, processes
for making same, and vectors for making same
JOURNAL Patent: US 6379928-A 25 30-APR-2002;
FEATURES Location/Qualifiers
  source              1..17
                     /organism="unknown"
BASE COUNT           8 a      3 c      0 g      3 t      3 others

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1271 AGTATAAGTACATTA 1285
Db 2 ARTAYAAATATATCA 16

RESULT 659
LOCUS AR207853 17 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 27 from patent US 6379928.
ACCESSION AR207853
VERSION AR207853.1 GI:21507715
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Berka, R. Michael., Cullen, D., Gray, G. Lawrence., Hayenga, K. James. and
Lawlis, V. Bryan.
TITLE Heterologous polypeptides expressed in filamentous fungi, processes

```



```

JOURNAL Patent: US 6331389-A 84 18-DEC-2001;
FEATURES Location/Qualifiers
SOURCE 1. .17
BASE COUNT 8 a 2 c 2 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1043 ATTATTATGTTATTTAT 1059
Db 17 ATCATCTATGTTATTCAT 1

RESULT 665
AR266625/c
LOCUS 17 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 63 from patent US 6495319.
ACCESSION AR266625
VERSION AR266625.1 GI:29695689
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES Location/Qualifiers
SOURCE 1. .17
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 615 TACAAAAAACACCAAT 631
Db 17 TAAAAAATAAAAAAAT 1

RESULT 666
AR286163
LOCUS 17 bp RNA linear PAT 10-APR-2003
DEFINITION Sequence 535 from patent US 6528640.
ACCESSION AR286163
VERSION AR286163.1 GI:29723759
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES Location/Qualifiers
SOURCE 1. .17
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1363 AGTGCTGTGTTGAATTA 1379
Db 1 AGTGATGTGTGAGTTA 17

RESULT 667

```

```

AX029315/c
LOCUS 17 bp DNA linear PAT 16-SEP-2000
DEFINITION Sequence 18 from Patent WO9902694.
ACCESSION AX029315
VERSION AX029315.1 GI:10190166
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES Location/Qualifiers
SOURCE 1. .17
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1363 AGTGCTGTGTTGAATTA 1379
Db 17 AATGCTGTGTAGAATA 1

RESULT 668
AX206986/c
LOCUS 17 bp DNA linear PAT 30-AUG-2001
DEFINITION Sequence 9 from Patent WO0155214.
ACCESSION AX206986
VERSION AX206986.1 GI:15394743
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES Location/Qualifiers
SOURCE 1. .17
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 862 TCTGCTAGCCAGGATCC 878
Db 17 TCTGCGAACCCGGATCC 1

RESULT 669
AX214665
LOCUS 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION Sequence 107 from Patent WO0159103.
ACCESSION AX214665
VERSION AX214665.1 GI:15524708
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES Location/Qualifiers
SOURCE 1. .17
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 862 TCTGCTAGCCAGGATCC 878
Db 17 TCTGCGAACCCGGATCC 1

```

```

REFERENCE
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
              nogo gene expression
JOURNAL      Patent: WO 0159103-A 107 16-AUG-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
              McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
BASE COUNT   7 a      2 c      5 g      3 t
              1. .17
              /organism="synthetic construct"
              /mol_type="mRNA"
              /db_xref="taxon:32630"
              /note="Nucleic Acid"
Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 425 GAAGATGCCAGTGAAC 441
Db 1 GAAATGTCAGTGAAGC 17

RESULT 670
AX215017/c
LOCUS        AX215017 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION   Sequence 459 from Patent WO0159103.
ACCESSION    AX215017
VERSION      AX215017.1 GI:15525060
KEYWORDS     .
SOURCE       synthetic construct
ORGANISM     synthetic construct
              artificial sequences.
REFERENCE    1
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
              nogo gene expression
JOURNAL      Patent: WO 0159103-A 459 16-AUG-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
              McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
BASE COUNT   5 a      2 c      1 g      9 t
              1. .17
              /organism="synthetic construct"
              /mol_type="mRNA"
              /db_xref="taxon:32630"
              /note="Nucleic Acid"
Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1092 AAAATAGAGATGAATC 1108
Db 17 AAATAGAAATGAATC 1

RESULT 671
AX215079/c
LOCUS        AX215079 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION   Sequence 521 from Patent WO0159103.
ACCESSION    AX215079
VERSION      AX215079.1 GI:15525122
KEYWORDS     .
SOURCE       synthetic construct
ORGANISM     synthetic construct
              artificial sequences.
REFERENCE    1
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
              nogo gene expression
JOURNAL      Patent: WO 0159103-A 521 16-AUG-2001;

```

```

RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
BASE COUNT   4 a      4 c      1 g      8 t
              1. .17
              /organism="synthetic construct"
              /mol_type="mRNA"
              /db_xref="taxon:32630"
              /note="Nucleic Acid"
Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1088 TGGAAATATAGAGATG 1104
Db 17 TGGAAATATAGCAGATG 1

RESULT 672
AX215156
LOCUS        AX215156 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION   Sequence 598 from Patent WO0159103.
ACCESSION    AX215156
VERSION      AX215156.1 GI:15525199
KEYWORDS     .
SOURCE       synthetic construct
ORGANISM     synthetic construct
              artificial sequences.
REFERENCE    1
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
              nogo gene expression
JOURNAL      Patent: WO 0159103-A 598 16-AUG-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
              McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
BASE COUNT   3 a      2 c      3 g      9 t
              1. .17
              /organism="synthetic construct"
              /mol_type="mRNA"
              /db_xref="taxon:32630"
              /note="Nucleic Acid"
Query Match   1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1286 TTGTTTATCTGAATTT 1302
Db 1 TTGATTCTCTGAATTT 17

RESULT 673
AX215198/c
LOCUS        AX215198 17 bp mRNA linear PAT 07-SEP-2001
DEFINITION   Sequence 640 from Patent WO0159103.
ACCESSION    AX215198
VERSION      AX215198.1 GI:15525241
KEYWORDS     .
SOURCE       synthetic construct
ORGANISM     synthetic construct
              artificial sequences.
REFERENCE    1
AUTHORS      Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE        Method and reagent for the modulation and diagnosis of cd20 and
              nogo gene expression
JOURNAL      Patent: WO 0159103-A 640 16-AUG-2001;
              RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
              McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
source
BASE COUNT   1. .17
              /organism="synthetic construct"

```

```

/mol_type="mRNA"
/db xref="taxon:32630"
/note="Nucleic Acid"
7 a 1 c 3 g 6 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

BASE COUNT
579 AACATCTTATATGTA 595
17 AACATCTTATGCAA 1

RESULT 674
AX215220
LOCUS
DEFINITION
Sequence 662 from Patent WO0159103.
ACCESSION
AX215220
VERSION
AX215220.1 GI:15525263
KEYWORDS
synthetic construct
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1
AUTHORS
Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE
Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL
Patent: WO 0159103-A 662 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db xref="taxon:32630"
/note="Nucleic Acid"
5 a 2 c 1 g 9 t

BASE COUNT
501 TATTATTGATCTAC 617
1 TATTATTGATATAC 17

RESULT 675
AX215570
LOCUS
DEFINITION
Sequence 1012 from Patent WO0159103.
ACCESSION
AX215570
VERSION
AX215570.1 GI:15525613
KEYWORDS
synthetic construct
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1
AUTHORS
Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE
Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL
Patent: WO 0159103-A 1012 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db xref="taxon:32630"
/note="Nucleic Acid"
7 a 2 c 4 g 4 t

BASE COUNT

```

```

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

BASE COUNT
426 AGATGCCAGTGAAC 442
1 AAATGTCAGTGAAGCT 17

RESULT 676
AX216249
LOCUS
DEFINITION
Sequence 1691 from Patent WO0159103.
ACCESSION
AX216249
VERSION
AX216249.1 GI:15526292
KEYWORDS
synthetic construct
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1
AUTHORS
Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE
Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL
Patent: WO 0159103-A 1691 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db xref="taxon:32630"
/note="Nucleic Acid"
8 a 1 c 4 g 4 t

BASE COUNT
Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

BASE COUNT
1104 GAATCATTTGATTGATA 1120
1 GAGTCATGATAGATA 17

RESULT 677
AX216420
LOCUS
DEFINITION
Sequence 1862 from Patent WO0159103.
ACCESSION
AX216420
VERSION
AX216420.1 GI:15526481
KEYWORDS
synthetic construct
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1
AUTHORS
Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE
Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL
Patent: WO 0159103-A 1862 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="synthetic construct"
/mol_type="mRNA"
/db xref="taxon:32630"
/note="Nucleic Acid"
6 a 2 c 4 g 5 t

BASE COUNT
Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

BASE COUNT
427 AGATGCCAGTGAAC 443

```

Db	AX217250 LOCUS DEFINITION ACCESSION VERSION KEYWORDS SOURCE ORGANISM REFERENCE AUTHORS TITLE JOURNAL FEATURES source	AX217250 Sequence 2692 from Patent WO0159103. AX217250 AX217250.1 GI:15527311 synthetic construct synthetic construct artificial sequences. 1 Blatt, L., McSwiggen, J. and Chowrira, B.M. Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression Patent: WO 0159103-A 2692 16-AUG-2001; RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US) Location/Qualifiers 1. .17 /organism="synthetic construct" /mol_type="mRNA" /db_xref="taxon:32630" /note="Nucleic Acid"	17 bp mRNA linear PAT 07-SEP-2001
BASE COUNT	6 a 1 c 3 g 7 t		
Query Match	1.0%; Score 12.2; DB 1; Length 17;		
Best Local Similarity	82.4%; Pred. No. 5.8e+02;		
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;		
QY	1049 TATGTATTATTATTAAAGC 1065		
Db	 1 TATGTATGGATTAAAC 17		
RESULT 681	AX217422/c		
LOCUS	AX217422	17 bp mRNA	linear PAT 07-SEP-2001
DEFINITION	Sequence 2864 from Patent WO0159103.		
ACCESSION	AX217422		
VERSION	AX217422.1 GI:15527483		
KEYWORDS	synthetic construct		
SOURCE	synthetic construct		
ORGANISM	artificial sequences.		
REFERENCE	1		
AUTHORS	Blatt, L., McSwiggen, J. and Chowrira, B.M.		
TITLE	Method and reagent for the modulation and diagnosis of cd20 and		
JOURNAL	nogo gene expression		
FEATURES	Patent: WO 0159103-A 2864 16-AUG-2001; RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US) Location/Qualifiers 1. .17 /organism="synthetic construct" /mol_type="mRNA" /db_xref="taxon:32630" /note="Nucleic Acid"		
BASE COUNT	7 a 2 c 1 g 7 t		
Query Match	1.0%; Score 12.2; DB 3; Length 17;		
Best Local Similarity	82.4%; Pred. No. 5.8e+02;		
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;		
QY	1175 ATTGATAAATTTCAAT 1191		
Db	 17 ATTGGAATAATTTCAAT 1		
RESULT 682	AX218022		
LOCUS	AX218022	17 bp mRNA	linear PAT 07-SEP-2001
DEFINITION	Sequence 3464 from Patent WO0159103.		
ACCESSION	AX218022		
VERSION	AX218022.1 GI:15528083		

---

Db	1 AAATGTCAGTGAAGCTT 17		
RESULT 678	AX216599		
LOCUS	AX216599	17 bp mRNA	linear PAT 07-SEP-2001
DEFINITION	Sequence 2041 from Patent WO0159103.		
ACCESSION	AX216599		
VERSION	AX216599.1 GI:15526660		
KEYWORDS	synthetic construct		
SOURCE	synthetic construct		
ORGANISM	artificial sequences.		
REFERENCE	1		
AUTHORS	Blatt, L., McSwiggen, J. and Chowrira, B.M.		
TITLE	Method and reagent for the modulation and diagnosis of cd20 and		
JOURNAL	nogo gene expression		
FEATURES	Patent: WO 0159103-A 2041 16-AUG-2001; RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US) Location/Qualifiers 1. .17 /organism="synthetic construct" /mol_type="mRNA" /db_xref="taxon:32630" /note="Nucleic Acid"		
BASE COUNT	4 a 1 c 3 g 9 t		
Query Match	1.0%; Score 12.2; DB 1; Length 17;		
Best Local Similarity	82.4%; Pred. No. 5.8e+02;		
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;		
QY	599 ATGATTATTATTGAATCT 615		
Db	 1 ATGATTATTATTGAATCT 17		
RESULT 679	AX216808/c		
LOCUS	AX216808	17 bp mRNA	linear PAT 07-SEP-2001
DEFINITION	Sequence 2250 from Patent WO0159103.		
ACCESSION	AX216808		
VERSION	AX216808.1 GI:15526869		
KEYWORDS	synthetic construct		
SOURCE	synthetic construct		
ORGANISM	artificial sequences.		
REFERENCE	1		
AUTHORS	Blatt, L., McSwiggen, J. and Chowrira, B.M.		
TITLE	Method and reagent for the modulation and diagnosis of cd20 and		
JOURNAL	nogo gene expression		
FEATURES	Patent: WO 0159103-A 2250 16-AUG-2001; RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US) Location/Qualifiers 1. .17 /organism="synthetic construct" /mol_type="mRNA" /db_xref="taxon:32630" /note="Nucleic Acid"		
BASE COUNT	8 a 1 c 2 g 6 t		
Query Match	1.0%; Score 12.2; DB 1; Length 17;		
Best Local Similarity	82.4%; Pred. No. 5.8e+02;		
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;		
QY	1292 ATCTGAATTTTAATTG 1308		
Db	 17 ATCTATAATTTCAATTG 1		
RESULT 680			

[illegible]

AUTHORS	Blatt, L., Mcswiggen, J. and Chowrira, B. M.
TITLE	Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
JOURNAL	PATENT: WO 0159103-A 3608 16-AUG-2001; RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); Mcswiggen, James (US); Chowrira, Bharat M. (US)
FEATURES	Location/Qualifiers
source	1..17
BASE COUNT	9 a 1 c 4 g 3 t
Query Match	1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. NO. 5.8e+02;
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	424 TGAAGATGCCAGTGA 440
DB	1 TGAAGAGACATGA 17
RESULT 685	
LOCUS	AX227049 17 bp mRNA linear PAT 11-SEP-2001
DEFINITION	Sequence 421 from Patent WO0157206.
ACCESSION	AX227049
VERSION	AX227049.1 GI:15556190
KEYWORDS	synthetic construct
SOURCE	synthetic construct
ORGANISM	artificial sequences.
REFERENCE	1
AUTHORS	Pattae, A.R., Jarvis, T., Mcswiggen, J., Bocher, R.N. and Holman, P.S.
TITLE	Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
JOURNAL	PATENT: WO 0157206-A 421 09-AUG-2001; RIBOZYME PHARMACEUTICALS, INC. (US); Fattaey, Ali R. (US)
FEATURES	Location/Qualifiers
source	1..17
BASE COUNT	6 a 3 c 3 g 5 t
Query Match	1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. NO. 5.8e+02;
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	949 TACCTCACAGTGATGT 965
DB	1 TAACCTCACAGGATATT 17
RESULT 686	
LOCUS	AX227468 17 bp mRNA linear PAT 10-SEP-2001
DEFINITION	Sequence 840 from Patent WO0157206.
ACCESSION	AX227468
VERSION	AX227468.1 GI:15556609
KEYWORDS	synthetic construct
SOURCE	synthetic construct
ORGANISM	artificial sequences.
REFERENCE	1
AUTHORS	Pattae, A.R., Jarvis, T., Mcswiggen, J., Bocher, R.N. and Holman, P.S.
TITLE	Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme
JOURNAL	PATENT: WO 0157206-A 840 09-AUG-2001; RIBOZYME PHARMACEUTICALS, INC. (US); Fattaey, Ali R. (US)
FEATURES	Location/Qualifiers
source	1..17

```

/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
2 a 3 c 6 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 462 CACTTCATGTTGTTGTT 478
Db 1 CACTTCATGTTGTTGTT 17

RESULT 687
AX263172
LOCUS AX263172 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 563 from Patent WO0173002.
ACCESSION AX263172
VERSION AX263172.1 GI:16511971
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Kmiec,B.B., Gampel,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 563 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
5 a 2 c 4 g 6 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1373 TGAATTACCGAATAATG 1389
Db 1 TGAATTACCGAATAATG 17

RESULT 688
AX263173/c
LOCUS AX263173/c 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 564 from Patent WO0173002.
ACCESSION AX263173
VERSION AX263173.1 GI:16511972
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Kmiec,B.B., Gampel,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 564 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
6 a 4 c 2 g 5 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;

```

```

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1373 TGAATTACCGAATAATG 1389
Db 1 TGAATTACCGAATAATG 1

RESULT 689
AX263380
LOCUS AX263380 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 771 from Patent WO0173002.
ACCESSION AX263380
VERSION AX263380.1 GI:16512179
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Kmiec,B.B., Gampel,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 771 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
6 a 0 c 7 g 4 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 921 TAAGTGGAAAAAGTATT 937
Db 1 TAAGTGGAAAAAGTATT 17

RESULT 690
AX263381/c
LOCUS AX263381/c 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 772 from Patent WO0173002.
ACCESSION AX263381
VERSION AX263381.1 GI:16512180
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Kmiec,B.B., Gampel,H.B. and Rice,M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 772 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
4 a 7 c 0 g 6 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 921 TAAGTGGAAAAAGTATT 937
Db 1 TAAGTGGAAAAAGTATT 1

```



```

RESULT 691
AX264332      17 bp      DNA      linear      PAT 26-OCT-2001
LOCUS
DEFINITION   Sequence 1723 from Patent WO0173002.
ACCESSION   AX264332
VERSION     AX264332.1 GI:16513131
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 1723 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT   8 a 6 c 2 g 1 t
Query Match  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1404 AAACAGCCAAACTCCA 1420
Db 1 AGACACCCAAAGTCCA 17
RESULT 692
AX264333/c
LOCUS
DEFINITION   Sequence 1724 from Patent WO0173002.
ACCESSION   AX264333
VERSION     AX264333.1 GI:16513132
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 1724 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT   1 a 2 c 6 g 8 t
Query Match  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1404 AAACAGCCAAACTCCA 1420
Db 17 AGACACCCAAAGTCCA 1
RESULT 693
AX264767
LOCUS
DEFINITION   Sequence 2158 from Patent WO0173002.
ACCESSION   AX264767
VERSION     AX264767.1 GI:16513566
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 2158 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT   8 a 2 c 3 g 4 t
Query Match  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1604 ATATGAACACTTTAAAA 1620
Db 1 AGATGAACCTTTAAGA 17

```

```

SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 2158 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT   8 a 2 c 3 g 4 t
Query Match  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1604 ATATGAACACTTTAAAA 1620
Db 1 AGATGAACCTTTAAGA 17
RESULT 694
AX264768/c
LOCUS
DEFINITION   Sequence 2159 from Patent WO0173002.
ACCESSION   AX264768
VERSION     AX264768.1 GI:16513567
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 2159 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT   4 a 3 c 2 g 8 t
Query Match  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1604 ATATGAACACTTTAAAA 1620
Db 17 AGATGAACCTTTAAGA 1
RESULT 695
AX265047
LOCUS
DEFINITION   Sequence 2438 from Patent WO0173002.
ACCESSION   AX265047
VERSION     AX265047.1 GI:16513846
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE       Targeted chromosomal genomic alterations with modified single
            stranded oligonucleotides
JOURNAL     Patent: WO 0173002-A 2438 04-OCT-2001;
            UNIVERSITY OF DELAWARE (US)
FEATURES
source      Location/Qualifiers
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT   4 a 3 c 2 g 8 t
Query Match  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1604 ATATGAACACTTTAAAA 1620
Db 17 AGATGAACCTTTAAGA 1

```

```
stranded oligonucleotides
Patent: WO 0173002-A 2438 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
LOCATION/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      6 a      2 c      4 g      5 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 980 AAGCACTTTAAGTTTTT 996
Db 1 AAGCAGGAGAGTTTTT 17

RESULT 696
AX265048/c
LOCUS
DEFINITION
Sequence 2439 from Patent WO0173002.
ACCESSION
AX265048
VERSION
AX265048.1 GI:16513847
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS
Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL
Patent: WO 0173002-A 2439 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      5 a      4 c      2 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 980 AAGCACTTTAAGTTTTT 996
Db 17 AAGCAGGAGAGTTTTT 1

RESULT 697
AX265051
LOCUS
DEFINITION
Sequence 2442 from Patent WO0173002.
ACCESSION
AX265051
VERSION
AX265051.1 GI:16513850
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS
Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL
Patent: WO 0173002-A 2442 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      4 a      2 c      5 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 980 AAGCACTTTAAGTTTTT 996
Db 17 AAGCAGGAGAGTTTTT 1

RESULT 699
AX265147
LOCUS
DEFINITION
Sequence 2538 from Patent WO0173002.
ACCESSION
AX265147
VERSION
AX265147.1 GI:16513946
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS
Kniec,E.B., Gamper,H.B. and Rice,M.C.
TITLE
Targeted chromosomal genomic alterations with modified single
stranded oligonucleotides
JOURNAL
Patent: WO 0173002-A 2538 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT      4 a      2 c      5 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```

QY 1491 TTTAAATGACTGCATTT 1507
Db 1 TTTAAATGGCGCAGTT 17

RESULT 700
AX265148/c
LOCUS AX265148 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2539 from Patent WO0173002.
ACCESSION AX265148
VERSION AX265148.1 GI:16513947
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2539 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 6 a 5 c 2 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1491 TTTAAATGACTGCATTT 1507
Db 17 TTTAAATGGCGCAGTT 1

RESULT 701
AX265151/c
LOCUS AX265151 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2542 from Patent WO0173002.
ACCESSION AX265151
VERSION AX265151.1 GI:16513950
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2542 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 4 a 2 c 5 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1491 TTTAAATGACTGCATTT 1507
Db 1 TTTAAATGGCGCAGTT 17

RESULT 702
AX265152/c
LOCUS AX265152 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2543 from Patent WO0173002.
ACCESSION AX265152
VERSION AX265152.1 GI:16513951
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2543 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 6 a 5 c 2 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1491 TTTAAATGACTGCATTT 1507
Db 17 TTTAAATGGCGCAGTT 1

RESULT 703
AX266795/c
LOCUS AX266795 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 4186 from Patent WO0173002.
ACCESSION AX266795
VERSION AX266795.1 GI:16515596
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 4186 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 5 a 3 c 0 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1124 ATAAAGATCTTACTA 1140
Db 17 ATAGAGATGATATAATA 1

RESULT 704
AX266796/c
LOCUS AX266796 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 4187 from Patent WO0173002.
ACCESSION AX266796
VERSION AX266796.1 GI:16515597
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens

```

```

LOCUS AX265152 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2543 from Patent WO0173002.
ACCESSION AX265152
VERSION AX265152.1 GI:16513951
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2543 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 6 a 5 c 2 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1491 TTTAAATGACTGCATTT 1507
Db 17 TTTAAATGGCGCAGTT 1

RESULT 703
AX266795/c
LOCUS AX266795 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 4186 from Patent WO0173002.
ACCESSION AX266795
VERSION AX266795.1 GI:16515596
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 4186 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
BASE COUNT 5 a 3 c 0 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1124 ATAAAGATCTTACTA 1140
Db 17 ATAGAGATGATATAATA 1

RESULT 704
AX266796/c
LOCUS AX266796 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 4187 from Patent WO0173002.
ACCESSION AX266796
VERSION AX266796.1 GI:16515597
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens

```



```

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1407 CAGCCAAATCCACAG 1423
DB 1 CAGCCAGAGCTCCCG 17

RESULT 709
AX324693/c
LOCUS AX324693 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 831 from Patent WO0192512.
ACCESSION AX324693
VERSION AX324693.1 GI:18095446
KEYWORDS Antirrhinum majus (snapdragon)
SOURCE Antirrhinum majus
ORGANISM Antirrhinum majus
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL Patent: WO 0192512-A 831 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source 1..17
/organism="Antirrhinum majus"
/mol_type="genomic DNA"
/db_xref="taxon:4151"
BASE COUNT 10 a 0 c 5 g 2 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1552 TGCTCTCCAAATTTTTT 1568
DB 1 TCCTCTTCACATTTTTT 1

RESULT 710
AX324694
LOCUS AX324694 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 832 from Patent WO0192512.
ACCESSION AX324694
VERSION AX324694.1 GI:18095447
KEYWORDS Antirrhinum majus (snapdragon)
SOURCE Antirrhinum majus
ORGANISM Antirrhinum majus
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL Patent: WO 0192512-A 832 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source 1..17
/organism="Antirrhinum majus"
/mol_type="genomic DNA"
/db_xref="taxon:4151"
BASE COUNT 2 a 5 c 0 g 10 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1552 TGCTCTCCAAATTTTTT 1568
DB 1 TCCTCTTCACATTTTTT 1

RESULT 711
AX325141/c
LOCUS AX325141 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 1279 from Patent WO0192512.
ACCESSION AX325141
VERSION AX325141.1 GI:18095896
KEYWORDS Triticum aestivum (bread wheat)
SOURCE Triticum aestivum
ORGANISM Triticum aestivum
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL Patent: WO 0192512-A 1279 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source 1..17
/organism="Triticum aestivum"
/mol_type="genomic DNA"
/db_xref="taxon:4565"
BASE COUNT 4 a 5 c 3 g 5 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 742 GGTTCCTAGATGCA 758
DB 1 GGAATCTAGATCTGA 1

RESULT 712
AX325142
LOCUS AX325142 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 1280 from Patent WO0192512.
ACCESSION AX325142
VERSION AX325142.1 GI:18095897
KEYWORDS Triticum aestivum (bread wheat)
SOURCE Triticum aestivum
ORGANISM Triticum aestivum
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL Patent: WO 0192512-A 1280 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source 1..17
/organism="Triticum aestivum"
/mol_type="genomic DNA"
/db_xref="taxon:4565"
BASE COUNT 5 a 3 c 5 g 4 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 742 GGTTCCTAGATGCA 758
DB 1 GGAATCTAGATCTGA 17

```

```

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1552 TGCTCTCCAAATTTTTT 1568
DB 1 TCCTCTTCACATTTTTT 17

RESULT 711
AX325141/c
LOCUS AX325141 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 1279 from Patent WO0192512.
ACCESSION AX325141
VERSION AX325141.1 GI:18095896
KEYWORDS Triticum aestivum (bread wheat)
SOURCE Triticum aestivum
ORGANISM Triticum aestivum
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL Patent: WO 0192512-A 1279 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source 1..17
/organism="Triticum aestivum"
/mol_type="genomic DNA"
/db_xref="taxon:4565"
BASE COUNT 4 a 5 c 3 g 5 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 742 GGTTCCTAGATGCA 758
DB 1 GGAATCTAGATCTGA 1

RESULT 712
AX325142
LOCUS AX325142 17 bp DNA linear PAT 02-SEP-2002
DEFINITION Sequence 1280 from Patent WO0192512.
ACCESSION AX325142
VERSION AX325142.1 GI:18095897
KEYWORDS Triticum aestivum (bread wheat)
SOURCE Triticum aestivum
ORGANISM Triticum aestivum
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE Targeted chromosomal genomic alterations in plants using modified
JOURNAL Patent: WO 0192512-A 1280 06-DEC-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source 1..17
/organism="Triticum aestivum"
/mol_type="genomic DNA"
/db_xref="taxon:4565"
BASE COUNT 5 a 3 c 5 g 4 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 742 GGTTCCTAGATGCA 758
DB 1 GGAATCTAGATCTGA 17

```

Thu Dec 18 07:29:18 2003

```
RESULT 713
AX326013/c
LOCUS          AX326013
DEFINITION     Sequence 2151 from Patent WO0192512.
ACCESSION      AX326013
VERSION        AX326013.1 GI:18096773
KEYWORDS       Helianthus annuus (common sunflower)
SOURCE         Helianthus annuus
ORGANISM       Helianthus annuus
REFERENCE      1
AUTHORS        Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE          Targeted chromosomal genomic alterations in plants using modified
               single stranded oligonucleotides
JOURNAL        Patent: WO 0192512-A 2151 06-DEC-2001;
               UNIVERSITY OF DELAWARE (US)
FEATURES       source
               Location/Qualifiers
               1..17
               /organism="Helianthus annuus"
               /mol_type="genomic DNA"
               /db_xref="taxon:4232"
BASE COUNT    4 a 9 c 0 g 4 t
               Query Match      1.0%; Score 12.2; DB 1; Length 17;
               Best Local Similarity 82.4%; Pred. No. 5.8e+02;
               Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 966 GTGAGGACATGTGGAG 982
Db 17 GTGAGGTTATGGGAG 1

RESULT 714
AX326014
LOCUS          AX326014
DEFINITION     Sequence 2152 from Patent WO0192512.
ACCESSION      AX326014
VERSION        AX326014.1 GI:18096774
KEYWORDS       Helianthus annuus (common sunflower)
SOURCE         Helianthus annuus
ORGANISM       Helianthus annuus
REFERENCE      1
AUTHORS        Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE          Targeted chromosomal genomic alterations in plants using modified
               single stranded oligonucleotides
JOURNAL        Patent: WO 0192512-A 2152 06-DEC-2001;
               UNIVERSITY OF DELAWARE (US)
FEATURES       source
               Location/Qualifiers
               1..17
               /organism="Helianthus annuus"
               /mol_type="genomic DNA"
               /db_xref="taxon:4232"
BASE COUNT    4 a 0 c 9 g 4 t
               Query Match      1.0%; Score 12.2; DB 1; Length 17;
               Best Local Similarity 82.4%; Pred. No. 5.8e+02;
               Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 966 GTGAGGACATGTGGAG 982
Db 1 GTGAGGTTATGGGAG 17

RESULT 715
AX326015/c
LOCUS          AX326015
DEFINITION     Sequence 2153 from Patent WO0192512.
ACCESSION      AX326015
VERSION        AX326015.1 GI:18096775
KEYWORDS       Helianthus annuus (common sunflower)
SOURCE         Helianthus annuus
ORGANISM       Helianthus annuus
REFERENCE      1
AUTHORS        Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE          Targeted chromosomal genomic alterations in plants using modified
               single stranded oligonucleotides
JOURNAL        Patent: WO 0192512-A 2153 06-DEC-2001;
               UNIVERSITY OF DELAWARE (US)
FEATURES       source
               Location/Qualifiers
               1..17
               /organism="Helianthus annuus"
               /mol_type="genomic DNA"
               /db_xref="taxon:4232"
BASE COUNT    4 a 0 c 9 g 4 t
               Query Match      1.0%; Score 12.2; DB 1; Length 17;
               Best Local Similarity 82.4%; Pred. No. 5.8e+02;
               Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 966 GTGAGGACATGTGGAG 982
Db 1 GTGAGGTTATGGGAG 17
```

```
AX326473
LOCUS          AX326473
DEFINITION     Sequence 2611 from Patent WO0192512.
ACCESSION      AX326473
VERSION        AX326473.1 GI:18097237
KEYWORDS       Glycine max (soybean)
SOURCE         Glycine max
ORGANISM       Glycine max
REFERENCE      1
AUTHORS        Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE          Targeted chromosomal genomic alterations in plants using modified
               single stranded oligonucleotides
JOURNAL        Patent: WO 0192512-A 2611 06-DEC-2001;
               UNIVERSITY OF DELAWARE (US)
FEATURES       source
               Location/Qualifiers
               1..17
               /organism="Glycine max"
               /mol_type="genomic DNA"
               /db_xref="taxon:3847"
BASE COUNT    4 a 4 c 3 g 6 t
               Query Match      1.0%; Score 12.2; DB 1; Length 17;
               Best Local Similarity 82.4%; Pred. No. 5.8e+02;
               Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1315 CAATCCTAGTTGTATAC 1331
Db 1 CAAGCTTAGTTGTATCC 17

RESULT 716
AX326474/c
LOCUS          AX326474
DEFINITION     Sequence 2612 from Patent WO0192512.
ACCESSION      AX326474
VERSION        AX326474.1 GI:18097238
KEYWORDS       Glycine max (soybean)
SOURCE         Glycine max
ORGANISM       Glycine max
REFERENCE      1
AUTHORS        Kmiec, E.B., Gamper, H.B., Rice, M.C. and Kim, J.
TITLE          Targeted chromosomal genomic alterations in plants using modified
               single stranded oligonucleotides
JOURNAL        Patent: WO 0192512-A 2612 06-DEC-2001;
               UNIVERSITY OF DELAWARE (US)
FEATURES       source
               Location/Qualifiers
               1..17
               /organism="Glycine max"
               /mol_type="genomic DNA"
               /db_xref="taxon:3847"
BASE COUNT    6 a 3 c 4 g 4 t
               Query Match      1.0%; Score 12.2; DB 1; Length 17;
               Best Local Similarity 82.4%; Pred. No. 5.8e+02;
               Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1315 CAATCCTAGTTGTATAC 1331
Db 1 CAAGCTTAGTTGTATCC 1
```

ACCESSION AX393409  
VERSION AX393409.1 GI:19701391  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS St Croix, B., Kinzler, K.W. and Vogelstein, B.  
TITLE Endothelial cell expression patterns  
JOURNAL Patent: WO 0210217-A 339 07-FEB-2002;  
The Johns Hopkins University (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 7 a 3 c 2 g 5 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1621 TATAATTTGTCACAA 1637  
Db 1 TACAATCGTGTCAAA 17  
RESULT 718  
AX421792  
LOCUS AX421792 17 bp mRNA linear PAT 18-JUN-2002  
DEFINITION Sequence 128 from Patent WO0188124.  
ACCESSION AX421792  
VERSION AX421792.1 GI:21525174  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and  
Randi, A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 128 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
BASE COUNT 5 a 3 c 2 g 7 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1473 TAGATCTTATAATTT 1489  
Db 1 TAGATCTTATCAGATT 17  
RESULT 719  
AX421950  
LOCUS AX421950 17 bp mRNA linear PAT 18-JUN-2002  
DEFINITION Sequence 286 from Patent WO0188124.  
ACCESSION AX421950  
VERSION AX421950.1 GI:21525332  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and  
Randi, A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 286 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
BASE COUNT 9 a 3 c 0 g 5 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1244 TTTCAGATAAACACAA 1260  
Db 1 TTTCATATCAAAACAA 17  
RESULT 720  
AX421950/c  
LOCUS AX421950 17 bp mRNA linear PAT 18-JUN-2002  
DEFINITION Sequence 286 from Patent WO0188124.  
ACCESSION AX421950  
VERSION AX421950.1 GI:21525332  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and  
Randi, A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 286 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
BASE COUNT 9 a 3 c 0 g 5 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1244 TTTCAGATAAACACAA 1260  
Db 1 TTTCATATCAAAACAA 17  
RESULT 721  
AX422015/c  
LOCUS AX422015 17 bp mRNA linear PAT 18-JUN-2002  
DEFINITION Sequence 351 from Patent WO0188124.  
ACCESSION AX422015  
VERSION AX422015.1 GI:21525397  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and  
Randi, A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 351 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
BASE COUNT 9 a 3 c 0 g 5 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1149 TTATTTTATGATATATA 1165  
Db 1 TTGTTTTCATATGAAA 1  
RESULT 721  
AX422015/c  
LOCUS AX422015 17 bp mRNA linear PAT 18-JUN-2002  
DEFINITION Sequence 351 from Patent WO0188124.  
ACCESSION AX422015  
VERSION AX422015.1 GI:21525397  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and  
Randi, A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 351 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"

```

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
3 a 2 c 2 g 10 t
BASE COUNT      3 a      2 c      2 g      10 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1204 ATTAACAACAACAACAA 1220
Db 17 ATTGACAACAACAAGAA 1

RESULT 722
AX422082
LOCUS AX422082
DEFINITION Sequence 418 from Patent WO0188124.
ACCESSION AX422082
VERSION AX422082.1 GI:21525464
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 418 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
6 a 2 c 1 g 8 t
BASE COUNT      6 a      2 c      1 g      8 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1042 TATATTTTGTATTTA 1058
Db 1 TATAACTTATGCACTTA 17

RESULT 723
AX422103/c
LOCUS AX422103
DEFINITION Sequence 439 from Patent WO0188124.
ACCESSION AX422103
VERSION AX422103.1 GI:21525485
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 439 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
6 a 2 c 1 g 8 t
BASE COUNT      6 a      2 c      1 g      8 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1107 TCATTGATTGAATAGTT 1123
Db 17 TCATTGCTTGAGAGTT 1

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1524 ATATTTTAACTTTAAG 1540
Db 17 ATATTTAAACATTAAG 1

RESULT 724
AX422116/c
LOCUS AX422116
DEFINITION Sequence 452 from Patent WO0188124.
ACCESSION AX422116
VERSION AX422116.1 GI:21525498
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 452 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
9 a 2 g 6 t
BASE COUNT      9 a      2 g      6 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1169 TGTTTTATTAGATAAAT 1185
Db 17 TATTTTATTACATCAT 1

RESULT 725
AX422708/c
LOCUS AX422708
DEFINITION Sequence 1044 from Patent WO0188124.
ACCESSION AX422708
VERSION AX422708.1 GI:21525090
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1044 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
7 a 4 c 2 g 4 t
BASE COUNT      7 a      4 c      2 g      4 t

Query Match
Best Local Similarity 1.0%; Score 12.2; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1107 TCATTGATTGAATAGTT 1123
Db 17 TCATTGCTTGAGAGTT 1

```



```

RESULT 726
AX423057/c
LOCUS AX423057 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1393 from Patent WO0188124.
ACCESSION AX423057
VERSION AX423057.1 GI:21526439
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1393 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
BASE COUNT 6 a 6 c 3 g 2 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1341 TGTCTATTCAGCTGTG 1357
Db 17 TGTCTATTCAGCTGTG 1
RESULT 727
AX423166
LOCUS AX423166 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1502 from Patent WO0188124.
ACCESSION AX423166
VERSION AX423166.1 GI:21526548
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1502 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
BASE COUNT 8 a 1 c 1 g 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 1467 TACAAATAGATCTTAT 1483
Db 1 TACAAATAGATCTTAT 17
RESULT 728
AX423293/c
LOCUS AX423293 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1629 from Patent WO0188124.
ACCESSION AX423293
VERSION AX423293.1 GI:21526675
KEYWORDS

```

```

SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1629 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
BASE COUNT 4 a 3 c 3 g 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 412 TCCAAGATCAGTGAAG 428
Db 17 TCCAAGATCAGTGAAG 1
RESULT 729
AX423315/c
LOCUS AX423315 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1651 from Patent WO0188124.
ACCESSION AX423315
VERSION AX423315.1 GI:21526697
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1651 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
BASE COUNT 7 a 3 c 3 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 392 AAAATTCATCTCTGTG 408
Db 17 AAAATTCATCTCTGTG 1
RESULT 730
AX423389/c
LOCUS AX423389 17 bp mRNA linear PAT 18-JUN-2002
DEFINITION Sequence 1725 from Patent WO0188124.
ACCESSION AX423389
VERSION AX423389.1 GI:21526771
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Jarvis, T., von Carlowitz, I., Mcswiggen, J.A., McLaughlin, F.G. and
Randi, A.M.

```

TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 1725 22-NOV-2001; GLAXO GROUP LIMITED (GB)  
RIBOZYME PHARMACEUTICALS, INC. (US);  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
BASE COUNT 7 a 1 c 2 g 7 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1236 AATTTCATTTCAGATA 1252  
Db 17 AATTTCATTTCAGAA 1  
RESULT 731  
AX423598/c  
LOCUS AX423598 17 bp mRNA linear PAT 18-JUN-2002  
DEFINITION Sequence 1234 from Patent WO0188124.  
ACCESSION AX423598  
VERSION AX423598.1 GI:21526980  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Jarvis, T., von Carlowitz, I., McSwiggen, J.A., McLaughlin, F.G. and Randi, A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 1934 22-NOV-2001; GLAXO GROUP LIMITED (GB)  
RIBOZYME PHARMACEUTICALS, INC. (US);  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
BASE COUNT 7 a 4 c 3 g 3 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 393 AAATTCATCTCTGTGG 409  
Db 17 AAGTTCATCTCTGTGG 1  
RESULT 732  
AX428711  
LOCUS AX428711 17 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 110 from Patent EP1201771.  
ACCESSION AX428711  
VERSION AX428711.1 GI:21538622  
KEYWORDS unidentified  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1  
AUTHORS Van Doorn, I.J., Kleter, B. and Ter Schegget, J.  
TITLE Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization  
JOURNAL Patent: EP 1201771-A 110 02-MAY-2002;  
INNOGENETICS N.V. (BE) Delfts Diagnostic laboratory B.V. (NL)  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"

BASE COUNT 5 a 1 c 5 g 6 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1619 AATATAATTGTGTCA 1635  
Db 1 AATGGAATTGTGTGCA 17  
RESULT 733  
AX499533  
LOCUS AX499533 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 840 from Patent EP1229046.  
ACCESSION AX499533  
VERSION AX499533.1 GI:23381826  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 840 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 5 a 6 c 4 g 2 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 496 GCCAGATGCAATACAG 512  
Db 1 GCCAGATGCAATACAG 17  
RESULT 734  
AX499867/c  
LOCUS AX499867 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 1174 from Patent EP1229046.  
ACCESSION AX499867  
VERSION AX499867.1 GI:23382160  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 1174 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 8 a 1 c 4 g 4 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1006 CATAAATTTTTCAG 1022  
Db 17 CCTCAATTTTTCAG 1

RESULT 735  
AX499868/c  
LOCUS AX499868 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 1175 from Patent EPI229046.  
ACCESSION AX499868  
VERSION AX499868.1 GI:23382161  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 1175 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 8 a 0 c 4 g 5 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 1005 ACATAAATTATTTCAA 1021  
Db 17 ACCTCAATTTTTTTCAA 1  
RESULT 736  
AX499997/c  
LOCUS AX499997 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 1304 from Patent EPI229046.  
ACCESSION AX499997  
VERSION AX499997.1 GI:23382290  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 1304 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 2 a 2 c 5 g 8 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 433 CAGTGAACCTTCAAGCA 449  
Db 17 CAGTGAACCTTAAAGCA 1  
RESULT 737  
AX502719/c  
LOCUS AX502719 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 4026 from Patent EPI229046.  
ACCESSION AX502719  
VERSION AX502719.1 GI:23385012  
KEYWORDS

SOURCE Homo sapiens (human)  
ORGANISM  
REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 4026 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 4 a 3 c 2 g 8 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 1097 AGAAGATGAATCATGGA 1113  
Db 17 ACAAGATTATCATGGA 1  
RESULT 738  
AX502968/c  
LOCUS AX502968 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 4275 from Patent EPI229046.  
ACCESSION AX502968  
VERSION AX502968.1 GI:23385261  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 4275 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 3 a 4 c 3 g 7 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 687 AAAATTGGGCCAAGGC 703  
Db 17 AAAATTAGGCATGAGC 1  
RESULT 739  
AX503052/c  
LOCUS AX503052 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 4359 from Patent EPI229046.  
ACCESSION AX503052  
VERSION AX503052.1 GI:23385345  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 4359 07-AUG-2002;  
Aeomica, Inc. (US)

```

FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT
  4 a 3 c 3 g 7 t

Query Match
  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1188 CAATCAGGGTTTGTAGA 1204
Db ||||| 17 CAATCAGGAATCTAGA 1

RESULT 740
AX527053/c
LOCUS AX527053 17 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 83 from Patent WO0226818.
ACCESSION AX527053
VERSION AX527053.1 GI:25171668
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Gu, Y. and Corrigan, A.
  HUMAN nedd-1
  Patent: WO 0226818-A 83 04-APR-2002;
  Aecomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT
  7 a 4 c 1 g 5 t

Query Match
  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1095 ATAGAGATGAATCATTT 1111
Db ||||| 17 ATAGAGGATGATCTTT 1

RESULT 741
AX527175
LOCUS AX527175 17 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 205 from Patent WO0226818.
ACCESSION AX527175
VERSION AX527175.1 GI:25171790
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Gu, Y. and Corrigan, A.
  HUMAN nedd-1
  Patent: WO 0226818-A 205 04-APR-2002;
  Aecomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT
  9 a 1 c 3 g 4 t

Query Match
  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1332 TCCAGTCTTGTCATTC 1348
Db ||||| 17 TCTCACTCTTGCTTC 1

RESULT 744
AX531483/c
LOCUS AX531483 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 864 from Patent EP1239051.
ACCESSION AX531483
VERSION AX531483.1 GI:25254493
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Shannon, M.
  Human posh-like protein 1
  Patent: EP 1239051-A 864 11-SEP-2002;
  Aecomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT
  8 a 2 c 6 g 1 t

Query Match
  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1333 CCCAGTCTTGTCATTC 1349
Db ||||| 17 CTCACCTCTTGCTTC 1

RESULT 743
AX531356/c
LOCUS AX531356 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 865 from Patent EP1239051.
ACCESSION AX531356
VERSION AX531356.1 GI:25254495
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 Shannon, M.
  Human posh-like protein 1
  Patent: EP 1239051-A 865 11-SEP-2002;
  Aecomica, Inc. (US)
FEATURES
  source
    Location/Qualifiers
      1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT
  8 a 2 c 6 g 1 t

Query Match
  1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1333 CCCAGTCTTGTCATTC 1349
Db ||||| 17 CTCACCTCTTGCTTC 1

```

LOCUS AX531483 17 bp DNA linear PAT 22-NOV-2002  
 DEFINITION Sequence 992 from Patent EP1239051.  
 ACCESSION AX531483  
 VERSION AX531483.1 GI:25254743  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1  
 AUTHORS Shannon, M.  
 TITLE Human pash-like protein 1  
 JOURNAL Patent: EP 1239051-A 992 11-SEP-2002;  
 Acemica, Inc. (US)  
 FEATURES  
 source Location/Qualifiers  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 5 a 2 c 4 g 6 t  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. NO. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 607 TTGGAATCTCAAAAA 623  
 |||||  
 Db 17 TTGGCTCTACAAACA 1  
 RESULT 745  
 AX532080/c  
 LOCUS AX532080 17 bp DNA linear PAT 22-NOV-2002  
 DEFINITION Sequence 1589 from Patent EP1239051.  
 ACCESSION AX532080  
 VERSION AX532080.1 GI:25255923  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1  
 AUTHORS Shannon, M.  
 TITLE Human pash-like protein 1  
 JOURNAL Patent: EP 1239051-A 1589 11-SEP-2002;  
 Acemica, Inc. (US)  
 FEATURES  
 source Location/Qualifiers  
 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 3 a 5 c 2 g 7 t  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. NO. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1083 GAATTCGAAAAATAGA 1099  
 |||||  
 Db 17 GAGCTCGAAACTAGA 1  
 RESULT 746  
 AX572026/c  
 LOCUS AX572026 17 bp DNA linear PAT 29-NOV-2002  
 DEFINITION Sequence 66 from Patent WO02055741.  
 ACCESSION AX572026  
 VERSION AX572026.1 GI:26004116  
 KEYWORDS  
 SOURCE Human immunodeficiency virus  
 ORGANISM  
 Human immunodeficiency virus  
 Viruses; Retroviridae; Retroviridae; Lentivirus; Primate  
 lentivirus group.

REFERENCE 1  
 AUTHORS de Smet, K. and Stuyver, L.  
 TITLE Method for detection of drug-induced mutations in the hiv reverse transcriptase gene  
 JOURNAL Patent: WO 02055741-A 66 18-JUL-2002;  
 INNOGENETICS N.V. (BE)  
 FEATURES  
 source Location/Qualifiers  
 1..17  
 /organism="Human immunodeficiency virus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:12721"  
 BASE COUNT 9 a 2 c 3 g 3 t  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. NO. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1571 ACTGTTCTCGATTGTAT 1587  
 |||||  
 Db 17 ACTGTTACTGATTCATT 1  
 RESULT 747  
 AX572825/c  
 LOCUS AX572825 17 bp DNA linear PAT 29-NOV-2002  
 DEFINITION Sequence 865 from Patent WO02055741.  
 ACCESSION AX572825  
 VERSION AX572825.1 GI:26004915  
 KEYWORDS  
 SOURCE Human immunodeficiency virus  
 ORGANISM  
 Human immunodeficiency virus  
 Viruses; Retroviridae; Retroviridae; Lentivirus; Primate  
 lentivirus group.  
 REFERENCE 1  
 AUTHORS de Smet, K. and Stuyver, L.  
 TITLE Method for detection of drug-induced mutations in the hiv reverse transcriptase gene  
 JOURNAL Patent: WO 02055741-A 865 18-JUL-2002;  
 INNOGENETICS N.V. (BE)  
 FEATURES  
 source Location/Qualifiers  
 1..17  
 /organism="Human immunodeficiency virus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:12721"  
 BASE COUNT 10 a 2 c 2 g 3 t  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. NO. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1571 ACTGTTCTCGATTGTAT 1587  
 |||||  
 Db 17 ACTGTTACTGATTCATT 1  
 RESULT 748  
 AX578220/c  
 LOCUS AX578220 17 bp mRNA linear PAT 10-JAN-2003  
 DEFINITION Sequence 58 from Patent WO0211674.  
 ACCESSION AX578220  
 VERSION AX578220.1 GI:27647422  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 REFERENCE 1  
 AUTHORS Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.  
 TITLE Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)  
 JOURNAL Patent: WO 0211674-A 58 14-FEB-2002;  
 RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);

```

FEATURES
source
Thompson, James (US)
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 2 c 1 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 675 TATACAAATAGCAAAAT 691
Db 17 TATACAGATATGAAAT 1
RESULT 749
AX578273
LOCUS AX578273 17 bp mRNA linear PAT 10-JAN-2003
DEFINITION Sequence 111 from Patent WO0211674.
ACCESSION AX578273
VERSION AX578273.1 GI:27647475
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 111 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 4 a 3 c 3 g 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 601 TATTATTGAACTAC 617
Db 1 TATCTGTTTGAGCTAC 17
RESULT 750
AX578687
LOCUS AX578687 17 bp mRNA linear PAT 10-JAN-2003
DEFINITION Sequence 525 from Patent WO0211674.
ACCESSION AX578687
VERSION AX578687.1 GI:27647889
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 525 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"

```

---

```

FEATURES
source
Thompson, James (US)
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 1 c 2 g 8 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 832 ATTITTTCTGTAAAT 848
Db 1 ATTITGTCAGATAAT 17
RESULT 751
AX578733
LOCUS AX578733 17 bp mRNA linear PAT 10-JAN-2003
DEFINITION Sequence 571 from Patent WO0211674.
ACCESSION AX578733
VERSION AX578733.1 GI:27647935
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 571 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 7 a 1 c 2 g 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1132 GTTATAGTAAATTTATT 1148
Db 1 GATATACTAAATGTATT 17
RESULT 752
AX578825
LOCUS AX578825 17 bp mRNA linear PAT 10-JAN-2003
DEFINITION Sequence 663 from Patent WO0211674.
ACCESSION AX578825
VERSION AX578825.1 GI:27648027
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szymkowski, D.E.
and Grupe, A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 663 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"

```

```

BASE COUNT      7 a      2 c      4 g      4 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      607 TTTCATCTACAAAAA 623
Db      1 TTTCAGCTACAGGAA 17

RESULT 753
AX579184/c
LOCUS      AX579184      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION      Sequence 1022 from Patent WO0211674.
ACCESSION      AX579184
VERSION      AX579184.1 GI:27648386
KEYWORDS      Homo sapiens (human)
ORGANISM      Homo sapiens
REFERENCE      1
AUTHORS      Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE      Thompson,J., McSwiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
JOURNAL      Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
Patent: WO 0211674-A 1022 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES      source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      5 a      5 c      3 g      4 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1186 TTCAATCAGGCTTTTA 1202
Db      17 TTCAATCAGGCTGTGA 1

RESULT 754
AX579358/c
LOCUS      AX579358      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION      Sequence 1196 from Patent WO0211674.
ACCESSION      AX579358
VERSION      AX579358.1 GI:27648560
KEYWORDS      Homo sapiens (human)
ORGANISM      Homo sapiens
REFERENCE      1
AUTHORS      Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE      Thompson,J., McSwiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
JOURNAL      Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
Patent: WO 0211674-A 1196 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES      source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      7 a      4 c      0 g      6 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;

```

```

Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1099 AACATGATCAATGATT 1115
Db      17 AGGATGATCAATATT 1

RESULT 755
AX579392/c
LOCUS      AX579392      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION      Sequence 1230 from Patent WO0211674.
ACCESSION      AX579392
VERSION      AX579392.1 GI:27648594
KEYWORDS      Homo sapiens (human)
ORGANISM      Homo sapiens
REFERENCE      1
AUTHORS      Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE      Thompson,J., McSwiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
JOURNAL      Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
Patent: WO 0211674-A 1230 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES      source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      5 a      3 c      3 g      6 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      602 ATTATTGAAATCTACA 618
Db      1 ATCTGTTGAAGCTACA 17

RESULT 756
AX579804/c
LOCUS      AX579804      17 bp      mRNA      linear      PAT 10-JAN-2003
DEFINITION      Sequence 1642 from Patent WO0211674.
ACCESSION      AX579804
VERSION      AX579804.1 GI:27649006
KEYWORDS      Homo sapiens (human)
ORGANISM      Homo sapiens
REFERENCE      1
AUTHORS      Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE      Thompson,J., McSwiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
JOURNAL      Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
Patent: WO 0211674-A 1642 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES      source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT      7 a      4 c      3 g      3 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 2281 CATTATGTTTAACTCA 1297
Db ||||| ||||| |||||
17 CATTGTTGTCAGCTGA 1

RESULT 757
AX579811
LOCUS AX579811 17 bp mRNA linear PAT 10-JAN-2003
DEFINITION Sequence 1549 from Patent WO0211674.
ACCESSION AX579811
VERSION AX579811.1 GI:27649013
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
TITLE Thompson, J., McSwiggen, J., McKenzie, T., Ayers, D., Szykowski, D.E.
and Grupe, A.
JOURNAL Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
PATENT: WO 0211674-A 1649 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 8 a 3 c 2 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1099 AGATCAATCATGATT 1115
Db ||||| ||||| |||||
1 AGATGAACACTCAT 17

RESULT 758
AX634690
LOCUS AX634690 17 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 1829 from Patent EP1260586.
ACCESSION AX634690
VERSION AX634690.1 GI:28470304
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A.,
Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J.,
McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1829 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 4 c 4 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 977 TGAAGCATTAACTT 993
Db ||||| ||||| |||||
1 TGAAGCTCTTCAGCT 17

RESULT 759
AX634732
LOCUS AX634732 17 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 1871 from Patent EP1260586.
ACCESSION AX634732
VERSION AX634732.1 GI:28470346
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A.,
Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J.,
McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1871 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 6 a 1 c 1 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1050 ATGTATTATTAAAGCA 1066
Db ||||| ||||| |||||
1 ATGTATTATTAAATCA 17

RESULT 760
AX634825
LOCUS AX634825 17 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 1964 from Patent EP1260586.
ACCESSION AX634825
VERSION AX634825.1 GI:28470439
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A.,
Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J.,
McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 1964 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 6 a 1 c 1 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1050 ATGTATTATTAAAGCA 1066
Db ||||| ||||| |||||
1 ATGTATTATTAAATCA 17

```



```

RESULT 761
AX634861
LOCUS AX634861 17 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 2000 from Patent EP1260586.
ACCESSION AX634861
VERSION AX634861.1 GI:28470475
KEYWORDS
SOURCE unidentifed
ORGANISM unidentifed
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="unidentifed"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 4 c 4 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 977 TGGAGCAGCTTTAAGTT 993
Db 1 TGGAGCTCTTCAGCT 17

RESULT 762
AX634864
LOCUS AX634864 17 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 2003 from Patent EP1260586.
ACCESSION AX634864
VERSION AX634864.1 GI:28470478
KEYWORDS
SOURCE unidentifed
ORGANISM unidentifed
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="unidentifed"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 4 c 4 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 977 TGGAGCAGCTTTAAGTT 993
Db 1 TGGAGCTCTTCAGCT 17

```

```

RESULT 763
AX648466/c
LOCUS AX648466 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 306 from Patent EP1273660.
ACCESSION AX648466
VERSION AX648466.1 GI:29151284
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 306 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 1 c 5 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1418 CCACAGTCAATATTAGT 1434
Db 17 CCACCTTCAATATCAGT 1

RESULT 764
AX648467/c
LOCUS AX648467 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 307 from Patent EP1273660.
ACCESSION AX648467
VERSION AX648467.1 GI:29151285
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 307 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 1 c 5 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1417 TCCACAGTCAATATTAG 1433
Db 17 TCCACTTCAATATCAG 1

RESULT 765
AX648579/c
LOCUS AX648579 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 419 from Patent EP1273660.
ACCESSION AX648579
VERSION AX648579.1 GI:29151397
KEYWORDS
SOURCE Homo sapiens (human)

```

```

ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu, Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 419 08-JAN-2003;
FEATURES
    source 1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT 8 a 5 c 2 g 2 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 959 TGATGTTGTGAGGACAT 975
Db 17 TGATGTTGTGCTGACTT 1

RESULT 766
AX648581/c
LOCUS 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 421 from Patent EP1273660.
ACCESSION AX648581
VERSION AX648581.1 GI:29151399
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu, Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 421 08-JAN-2003;
FEATURES
    source 1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT 7 a 5 c 2 g 3 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 957 AGTGATGTTGTGAGGAC 973
Db 17 ATTGATGTTGTGCTGAC 1

RESULT 767
AX648667/c
LOCUS 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 507 from Patent EP1273660.
ACCESSION AX648667
VERSION AX648667.1 GI:29151485
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu, Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 507 08-JAN-2003;
FEATURES
    source 1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT 9 a 4 c 3 g 1 t

ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu, Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 419 08-JAN-2003;
FEATURES
    source 1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT 6 a 5 c 0 g 6 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1616 TAAATATATAATTGTTG 1632
Db 17 TGAATATATAATTGGTG 1

RESULT 768
AX671571
LOCUS 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 16 from Patent WO03004526.
ACCESSION AX671571
VERSION AX671571.1 GI:29329919
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
JOURNAL Patent: WO 03004526-A 16 16-JAN-2003;
FEATURES
    source 1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT 11 a 1 c 1 g 4 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1249 GATAACACCAATAAT 1265
Db 1 GATCAAAATAATAAT 17

RESULT 769
AX671600
LOCUS 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 45 from Patent WO03004526.
ACCESSION AX671600
VERSION AX671600.1 GI:29329948
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
JOURNAL Patent: WO 03004526-A 45 16-JAN-2003;
FEATURES
    source 1..17
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="taxon:9606"
BASE COUNT 9 a 4 c 3 g 1 t

```

Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1203 GATTAAACAACAACA 1219  
 Db 1 GATCAACAACGACGA 17

RESULT 770  
 AX671657  
 LOCUS AX671657 17 bp DNA linear PAT 27-MAR-2003  
 DEFINITION Sequence 102 from Patent WO03004526.  
 ACCESSION AX671657  
 VERSION AX671657.1 GI:29330005  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 REFERENCE 1  
 AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines  
 JOURNAL Patent: WO 03004526-A 102 16-JAN-2003;  
 FEATURES Molecular Engines Laboratories (FR)  
 source Location/Qualifiers  
 1.17 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 6 a 3 c 2 g 6 t  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 519 GGTAAATTTCAATTC 535  
 Db 1 GATCAATTTGAATTC 17

RESULT 771  
 AX672578  
 LOCUS AX672578 17 bp DNA linear PAT 27-MAR-2003  
 DEFINITION Sequence 1023 from Patent WO03004526.  
 ACCESSION AX672578  
 VERSION AX672578.1 GI:29330926  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 REFERENCE 1  
 AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines  
 JOURNAL Patent: WO 03004526-A 1023 16-JAN-2003;  
 FEATURES Molecular Engines Laboratories (FR)  
 source Location/Qualifiers  
 1.17 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 5 a 6 c 2 g 4 t  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 874 GATCCACAAGTCCTCTGT 890  
 Db 1 GATCCACAAGTCCTCT 17

RESULT 772  
 AX672799/c  
 LOCUS AX672799 17 bp DNA linear PAT 27-MAR-2003  
 DEFINITION Sequence 1244 from Patent WO03004526.  
 ACCESSION AX672799  
 VERSION AX672799.1 GI:29331147  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 REFERENCE 1  
 AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines  
 JOURNAL Patent: WO 03004526-A 1244 16-JAN-2003;  
 FEATURES Molecular Engines Laboratories (FR)  
 source Location/Qualifiers  
 1.17 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 4 a 2 c 2 g 9 t  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1596 AAAAGTAATATCAAC 1612  
 Db 17 AAAAGTAATATGATC 1

RESULT 773  
 AX672898  
 LOCUS AX672898 17 bp DNA linear PAT 27-MAR-2003  
 DEFINITION Sequence 1343 from Patent WO03004526.  
 ACCESSION AX672898  
 VERSION AX672898.1 GI:29331246  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 REFERENCE 1  
 AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines  
 JOURNAL Patent: WO 03004526-A 1343 16-JAN-2003;  
 FEATURES Molecular Engines Laboratories (FR)  
 source Location/Qualifiers  
 1.17 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 BASE COUNT 2 a 4 c 3 g 8 t  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 874 GATCCACAAGTCCTCTGT 890  
 Db 1 GATCCATTTGTCCTCTGT 17

```
RESULT 774
AX673031
LOCUS AX673031 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1476 from Patent WO03004526.
ACCESSION AX673031
VERSION AX673031.1 GI:293331379
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Telerman,A., Amson,R. and Tuijinder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and their use as
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL Telerman,A., Amson,R. and Tuijinder,M.
PATENT: WO 03004526-A 1476 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 5 c 2 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1224 GGTACCCAGTCAATTT 1240
Db 1 GATCCCGAGTCAATTT 17
RESULT 775
AX673430/c
LOCUS AX673430 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 1875 from Patent WO03004526.
ACCESSION AX673430
VERSION AX673430.1 GI:293331778
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Telerman,A., Amson,R. and Tuijinder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and their use as
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL Telerman,A., Amson,R. and Tuijinder,M.
PATENT: WO 03004526-A 1875 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 3 a 7 c 3 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 861 GTCGTGACCGAGGATC 877
Db 17 GTCTGAGGCGAGGATC 1
RESULT 776
AX674727
LOCUS AX674727 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 3172 from Patent WO03004526.
ACCESSION AX674727
VERSION AX674727.1 GI:29410100
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Telerman,A., Amson,R. and Tuijinder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and their use as
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL Telerman,A., Amson,R. and Tuijinder,M.
PATENT: WO 03004526-A 3172 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 1 c 1 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 831 GATTTTTCGTTAAA 847
Db 1 GATCTTTTATATAAA 17
RESULT 778
AX687406/c
LOCUS AX687406 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 138 from Patent EP1281758.
ACCESSION AX687406
VERSION AX687406.1 GI:29410100
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Telerman,A., Amson,R. and Tuijinder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and their use as
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL Telerman,A., Amson,R. and Tuijinder,M.
PATENT: WO 03004526-A 3245 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 1 c 1 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 831 GATTTTTCGTTAAA 847
Db 1 GATCTTTTATATAAA 17
RESULT 779
AX687406/c
LOCUS AX687406 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 138 from Patent EP1281758.
ACCESSION AX687406
VERSION AX687406.1 GI:29410100
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE Telerman,A., Amson,R. and Tuijinder,M.
AUTHORS Sequences involved in phenomena of tumour suppression, tumour
TITLE reversion, apoptosis and/or resistance to viruses and their use as
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL Telerman,A., Amson,R. and Tuijinder,M.
PATENT: WO 03004526-A 3245 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 1 c 1 g 9 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 831 GATTTTTCGTTAAA 847
Db 1 GATCTTTTATATAAA 17
```

REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 138 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 7 a 4 c 3 g 3 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 975 TGTGGAGCCTTTAAG 991 17 bp DNA linear PAT 31-MAR-2003  
Db 17 TCTGGAGCCTTTAAG 1  
RESULT 779  
AX687451  
LOCUS AX687451 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 183 from Patent EP1281758.  
ACCESSION AX687451  
VERSION AX687451.1 GI:29410145  
KEYWORDS Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 183 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 3 a 2 c 6 g 6 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 1360 GSTAGTCTGTGTGAA 1376 17 bp DNA linear PAT 31-MAR-2003  
Db 1 GGTATTCTGTGTGAA 17  
RESULT 780  
AX691337  
LOCUS AX691337 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 4069 from Patent EP1281758.  
ACCESSION AX691337  
VERSION AX691337.1 GI:29414273  
KEYWORDS Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 4069 05-FEB-2003;  
Aeomica, Inc. (US)

FEATURES source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 7 a 2 c 3 g 5 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 1060 TTAAGCATCAATATT 1076 17 bp DNA linear PAT 31-MAR-2003  
Db 1 TTAAGCATCAATATT 17  
RESULT 781  
AX692522/c  
LOCUS AX692522 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 5254 from Patent EP1281758.  
ACCESSION AX692522  
VERSION AX692522.1 GI:29415480  
KEYWORDS Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 5254 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 1 a 1 c 0 g 15 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 618 AAAAAACAACAATAAT 634 17 bp DNA linear PAT 31-MAR-2003  
Db 17 AAAAAACAACAATAAT 1  
RESULT 782  
AX692526/c  
LOCUS AX692526 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 5258 from Patent EP1281758.  
ACCESSION AX692526  
VERSION AX692526.1 GI:29415484  
KEYWORDS Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 5258 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES source  
Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 0 a 0 c 1 g 16 t



KEYWORDS	Mus musculus (house mouse)
SOURCE	Mus musculus
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE	1
AUTHORS	Teleman,A., Anson,R. and Tuijnder,M.
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL	Patent: WO 03025176-A 4162 27-MAR-2003;
FEATURES	Molecular Engines Laboratories (FR)
source	Location/Qualifiers
BASE COUNT	5 a 5 c 3 g 4 t
Query Match	1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. No. 5.8e+02;
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy	405 TGTGGTATCCAGATC 421
Db	
	17 TGTGGTATCCAGGATC 1
RESULT 790	
LOCUS	AX726611/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 4298 from Patent WO03025176.
ACCESSION	AX726611
VERSION	AX726611.1 GI:30505954
KEYWORDS	Mus musculus (house mouse)
SOURCE	Mus musculus
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE	1
AUTHORS	Teleman,A., Anson,R. and Tuijnder,M.
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
JOURNAL	Patent: WO 03025176-A 4298 27-MAR-2003;
FEATURES	Molecular Engines Laboratories (FR)
source	Location/Qualifiers
BASE COUNT	10 a 3 c 1 g 3 t
Query Match	1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity	82.4%; Pred. No. 5.8e+02;
Matches	14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy	1052 GTATTATTATGATC 1068
Db	
	17 GTTTTITTTTARGGATC 1
RESULT 791	
LOCUS	AX726698 17 bp DNA linear PAT 08-MAY-2003
DEFINITION	Sequence 4385 from Patent WO03025176.
ACCESSION	AX726698
VERSION	AX726698.1 GI:30506041
KEYWORDS	Mus musculus (house mouse)
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

```

REFERENCE
AUTHORS      1 Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 4385 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     source
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   2 a 3 c 3 g 9 t
              Query Match 1.0%; Score 12.2; DB 1; Length 17;
              Best Local Similarity 82.4%; Pred. No. 5.8e+02;
              Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1540 GATGTTTTATGTGCTC 1556
Db 1 GATCTTTTATGTGCTC 17

RESULT 792
AX727922/c
LOCUS      AX727922
DEFINITION Sequence 5609 from Patent WO03025176.
ACCESSION  AX727922
VERSION     AX727922.1 GI:30507265
KEYWORDS   Mus musculus (house mouse)
SOURCE     Mus musculus
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS      1 Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 5609 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     source
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   6 a 4 c 3 g 4 t
              Query Match 1.0%; Score 12.2; DB 1; Length 17;
              Best Local Similarity 82.4%; Pred. No. 5.8e+02;
              Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 861 GTCTGTAGCCAGATC 877
Db 17 GTCTGTATACAGATC 1

RESULT 793
AX728060/c
LOCUS      AX728060
DEFINITION Sequence 5747 from Patent WO03025176.
ACCESSION  AX728060
VERSION     AX728060.1 GI:30507403
KEYWORDS   Mus musculus (house mouse)
SOURCE     Mus musculus
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS      1 Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines

```

```

JOURNAL      Patent: WO 03025176-A 5747 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     source
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   5 a 1 c 1 g 10 t
              Query Match 1.0%; Score 12.2; DB 1; Length 17;
              Best Local Similarity 82.4%; Pred. No. 5.8e+02;
              Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1475 GATCTTTTATATATAT 1491
Db 1 GATCTTTTATATATAT 17

RESULT 794
AX728122/c
LOCUS      AX728122
DEFINITION Sequence 5809 from Patent WO03025176.
ACCESSION  AX728122
VERSION     AX728122.1 GI:30507465
KEYWORDS   Mus musculus (house mouse)
SOURCE     Mus musculus
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS      1 Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 5809 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     source
              1..17
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /db_xref="taxon:10090"
BASE COUNT   4 a 2 c 2 g 9 t
              Query Match 1.0%; Score 12.2; DB 1; Length 17;
              Best Local Similarity 82.4%; Pred. No. 5.8e+02;
              Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1596 AAACTAAATATGAAAC 1612
Db 17 AAACTAAATATGGAAC 1

RESULT 795
AX728315/c
LOCUS      AX728315
DEFINITION Sequence 6002 from Patent WO03025176.
ACCESSION  AX728315
VERSION     AX728315.1 GI:30507658
KEYWORDS   Mus musculus (house mouse)
SOURCE     Mus musculus
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS      1 Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 6002 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     source
              1..17
              /organism="Mus musculus"

```



```

BASE COUNT      9 a      6 c      1 g      1 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
/db_xref="taxon:10090"
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1203 GATTAAACAAACAAACA 1219
|||||
Db 1 GATCAACAAACCCACACA 17

RESULT 796
AX728823
LOCUS      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 457 from Patent WO03025175.
ACCESSION  AX728823
VERSION     AX728823.1 GI:30508166
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Anson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025175-A 457 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      9 a      5 c      2 g      1 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1203 GATTAAACAAACAAACA 1219
|||||
Db 1 GATCAACAAACCCACACA 17

RESULT 797
AX728846
LOCUS      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 480 from Patent WO03025175.
ACCESSION  AX728846
VERSION     AX728846.1 GI:30508189
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Anson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025175-A 480 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      12 a      2 c      2 g      1 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;

```

```

Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1203 GATTAAACAAACAAACA 1219
|||||
Db 1 GATCAACAAACCCACACA 17

RESULT 798
AX728945/c
LOCUS      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 579 from Patent WO03025175.
ACCESSION  AX728945
VERSION     AX728945.1 GI:30508288
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Anson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025175-A 579 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      5 a      4 c      4 g      4 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 861 GTCTGCTAGCCAGGATC 877
|||||
Db 17 GCTTCAGTCCAGGATC 1

RESULT 799
AX730965/c
LOCUS      17 bp      DNA      linear      PAT 08-MAY-2003
DEFINITION Sequence 2599 from Patent WO03025175.
ACCESSION  AX730965
VERSION     AX730965.1 GI:30510308
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE   1
AUTHORS     Telerman,A., Anson,R. and Tuijnder,M.
TITLE       Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL     Patent: WO 03025175-A 2599 27-MAR-2003;
            Molecular Engines Laboratories (FR)
FEATURES    Location/Qualifiers
            source
            1..17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      4 a      5 c      2 g      6 t

Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1382 GAATAATGAGTTAGAAC 1398
|||||

```

```

Db      17 GAATACTAGGAGTAGATC 1
RESULT 800
AX731415
LOCUS      AX731415      17 bp      DNA
DEFINITION Sequence 3049 from Patent WO03025175.
ACCESSION AX731415
VERSION    AX731415.1 GI:30510758
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Telerman,A., Anson,R. and Tuijnder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL    Patent: WO 03025175-A 3049 27-MAR-2003;
FEATURES   Molecular Engines Laboratories (FR)
            source
            1. .17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      6 a      1 c      3 g      7 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1129 GATGTTATAGTAATTT 1145
Db      1 GATCTTGTAAGAAATTT 17

RESULT 801
AX732425
LOCUS      AX732425      17 bp      DNA
DEFINITION Sequence 4059 from Patent WO03025175.
ACCESSION AX732425
VERSION    AX732425.1 GI:30511768
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Telerman,A., Anson,R. and Tuijnder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL    Patent: WO 03025175-A 4059 27-MAR-2003;
FEATURES   Molecular Engines Laboratories (FR)
            source
            1. .17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      11 a      3 c      1 g      2 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1203 GATTAAACAAACAACA 1219
Db      1 GATCAAAATTTGAATTC 17

RESULT 802
AX733105/c
LOCUS      AX733105      17 bp      DNA
DEFINITION Sequence 4739 from Patent WO03025175.
ACCESSION AX733105
VERSION    AX733105.1 GI:30512448
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Telerman,A., Anson,R. and Tuijnder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL    Patent: WO 03025175-A 4739 27-MAR-2003;
FEATURES   Molecular Engines Laboratories (FR)
            source
            1. .17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      8 a      4 c      1 g      4 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1052 GTATTATTATAGCATC 1068
Db      17 GTATTATTATAGCATC 1

RESULT 803
AX733543
LOCUS      AX733543      17 bp      DNA
DEFINITION Sequence 5177 from Patent WO03025175.
ACCESSION AX733543
VERSION    AX733543.1 GI:30512886
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Telerman,A., Anson,R. and Tuijnder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
            reversion, apoptosis and/or virus resistance and their use as
            medicines
JOURNAL    Patent: WO 03025175-A 5177 27-MAR-2003;
FEATURES   Molecular Engines Laboratories (FR)
            source
            1. .17
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
BASE COUNT      6 a      3 c      2 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      519 GGTAAATTTGAATTC 535
Db      1 GATCAAAATTTGAATTC 17

RESULT 804
AX735047
LOCUS      AX735047      17 bp      DNA
DEFINITION Sequence 637 from Patent WO03025177.
ACCESSION AX735047
VERSION    AX735047.1 GI:30514324
KEYWORDS

```

SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Telerman,A., Amson,R. and Tuijinder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 637 27-MAR-2003;  
 Moлекулярные Лаборатории (FR)

FEATURES source  
 1. .17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 6 a 2 c 2 g 7 t

BASE COUNT  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1457 GTTATTATGTACAAAT 1473  
 Db 1 GATCATTTATGACATAT 17

RESULT 805  
 AX735909/c  
 LOCUS AX735909 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 1499 from Patent WO03025177.  
 ACCESSION AX735909  
 VERSION AX735909.1 GI:30515186  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Telerman,A., Amson,R. and Tuijinder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 1499 27-MAR-2003;  
 Moлекулярные Лаборатории (FR)

FEATURES source  
 1. .17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 8 a 3 c 2 g 4 t

BASE COUNT  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 598 TATTATTATTGATTC 614  
 Db 17 TATTATTATTGGGATC 1

RESULT 806  
 AX735978/c  
 LOCUS AX735978 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 1568 from Patent WO03025177.  
 ACCESSION AX735978  
 VERSION AX735978.1 GI:30515255  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1

AUTHORS Telerman,A., Amson,R. and Tuijinder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 1568 27-MAR-2003;  
 Moлекулярные Лаборатории (FR)

FEATURES source  
 1. .17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 7 a 2 c 3 g 5 t

BASE COUNT  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1239 TTTCATTTTCAGATAAAC 1255  
 Db 17 TTTCATTTTCAGAGAATC 1

RESULT 807  
 AX736175/c  
 LOCUS AX736175 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 1765 from Patent WO03025177.  
 ACCESSION AX736175  
 VERSION AX736175.1 GI:30515452  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Telerman,A., Amson,R. and Tuijinder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 1765 27-MAR-2003;  
 Moлекулярные Лаборатории (FR)

FEATURES source  
 1. .17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 5 a 4 c 2 g 6 t

BASE COUNT  
 Query Match 1.0%; Score 12.2; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 559 TTGTACCATGAAATATC 575  
 Db 17 TTGTACCATGGAAGATC 1

RESULT 808  
 AX736626/c  
 LOCUS AX736626 17 bp DNA linear PAT 08-MAY-2003  
 DEFINITION Sequence 2216 from Patent WO03025177.  
 ACCESSION AX736626  
 VERSION AX736626.1 GI:30515914  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Telerman,A., Amson,R. and Tuijinder,M.  
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
 JOURNAL Patent: WO 03025177-A 2216 27-MAR-2003;

```

FEATURES
  source
    Molecular Engines Laboratories (FR)
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      5 a      1 c      1 g      10 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1475 GATCTTTTAAATATAT 1491
Db 1 GATCTTTTAAATATAT 17

RESULT 809
AX737074/c
LOCUS AX737074 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2664 from Patent WO03025177.
ACCESSION AX737074
VERSION AX737074.1 GI:30516362
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
  TITLE Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or resistance to viruses and the use
  thereof as medicaments
JOURNAL Patent: WO 03025177-A 2664 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      8 a      4 c      1 g      4 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1052 GTATTATTATGATC 1068
Db 17 GTATTATTATGATC 1

RESULT 810
AX738139/c
LOCUS AX738139 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3729 from Patent WO03025177.
ACCESSION AX738139
VERSION AX738139.1 GI:30517427
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
  TITLE Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or resistance to viruses and the use
  thereof as medicaments
JOURNAL Patent: WO 03025177-A 3729 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"

```

---

```

BASE COUNT      8 a      2 c      1 g      6 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 598 TATTATTATTGATC 614
Db 17 TATAAATTATTGGATC 1

RESULT 811
AX738829
LOCUS AX738829 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4419 from Patent WO03025177.
ACCESSION AX738829
VERSION AX738829.1 GI:30518119
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
  TITLE Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or resistance to viruses and the use
  thereof as medicaments
JOURNAL Patent: WO 03025177-A 4419 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      4 a      5 c      3 g      5 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 874 GATCCACAGTCCTTGT 890
Db 1 GATCCACAGTCCTTGT 17

RESULT 812
AX738984/c
LOCUS AX738984 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 4574 from Patent WO03025177.
ACCESSION AX738984
VERSION AX738984.1 GI:30518274
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
  TITLE Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or resistance to viruses and the use
  thereof as medicaments
JOURNAL Patent: WO 03025177-A 4574 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
  source
    Location/Qualifiers
      1..17
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
BASE COUNT      7 a      2 c      4 g      4 t
Query Match      1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;

```

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1278 GTACATTTTGTTCATC 1294  
 |||||  
 DB 17 GTACATCTTCTTGATC 1

RESULT 813  
 AX744141

LOCUS AX744141 17 bp DNA linear PAT 14-MAY-2003

DEFINITION Sequence 106 from Patent WO03031621.

ACCESSION AX744141

VERSION AX744141.1 GI:30722808

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE

AUTHORS Zhang, J.

TITLE A human G protein coupled receptor

JOURNAL Patent: WO 03031621-A 106 17-APR-2003;

Amersham Biosciences (SV) Corp. (US)

FEATURES

source

1. .17

/organism="Homo sapiens"

/mol\_type="genomic DNA"

/db\_xref="taxon:9606"

BASE COUNT 4 a 3 c 4 g 6 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. NO. 5.8e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1513 TACAAGGCTTATATT 1529  
 |||||  
 DB 1 TACAAGGCTGCGATT 17

RESULT 814  
 AX745054

LOCUS AX745054 17 bp DNA linear PAT 15-MAY-2003

DEFINITION Sequence 1019 from Patent WO03031621.

ACCESSION AX745054

VERSION AX745054.1 GI:30723721

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE

AUTHORS Zhang, J.

TITLE A human G protein coupled receptor

JOURNAL Patent: WO 03031621-A 1019 17-APR-2003;

Amersham Biosciences (SV) Corp. (US)

FEATURES

source

1. .17

/organism="Homo sapiens"

/mol\_type="genomic DNA"

/db\_xref="taxon:9606"

BASE COUNT 9 a 1 c 1 g 6 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. NO. 5.8e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 630 ATAATTTTGAATATA 646  
 |||||  
 DB 1 AAAATTTTGAATCAAA 17

RESULT 815  
 AX745056

LOCUS AX745056 17 bp DNA linear PAT 14-MAY-2003

DEFINITION Sequence 1021 from Patent WO03031621.

ACCESSION AX745056

VERSION AX745056.1 GI:30723723

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE

AUTHORS Zhang, J.

TITLE A human G protein coupled receptor

JOURNAL Patent: WO 03031621-A 1021 17-APR-2003;

Amersham Biosciences (SV) Corp. (US)

FEATURES

source

1. .17

/organism="Homo sapiens"

/mol\_type="genomic DNA"

/db\_xref="taxon:9606"

BASE COUNT 8 a 1 c 2 g 6 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. NO. 5.8e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 632 AAATTTTGAATATAAGG 648  
 |||||  
 DB 1 AAATTTTGAATCAAAAG 17

RESULT 816  
 BD065996/c

LOCUS BD065996 17 bp DNA linear PAT 27-AUG-2002

DEFINITION An antisense oligonucleotide preparation method.

ACCESSION BD065996

VERSION BD065996.1 GI:22611599

KEYWORDS

SOURCE unidentified

ORGANISM unidentified

REFERENCE

AUTHORS Schlingsiepen, K.H. and Brysch, W.

TITLE An antisense oligonucleotide preparation method

JOURNAL Patent: JP 2001511000-A 631 07-AUG-2001;

BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK MBH

COMMENT

OS Unknown

PN JP 2001511000-A/631

PD 07-AUG-2001

PF 30-JAN-1998 JP 1998532533

PR 31-JAN-1997 EP 97101531.8

PI KARL HERMANN SCHLINGSIEPEN, WOLFGANG BRYSCH

PC C12N15/11, C07H21/04, A61K31/70

CC An antisense oligonucleotide preparation method FH Key

FT source 1. .17

/organism="Unknown"

FEATURES

source

1. .17

/organism="unidentified"

/mol\_type="genomic DNA"

/db\_xref="taxon:32644"

BASE COUNT 4 a 3 c 5 g 5 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. NO. 5.8e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 639 GAATATAAGGATTTCC 655  
 |||||  
 DB 17 GCATACAGGATCTTCC 1

RESULT 817

```

BD067425/c
LOCUS      BD067425          17 bp    RNA        linear        PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION  BD067425
VERSION    JP 2001511003-A/265
KEYWORDS   unclassified
SOURCE     unclassified
ORGANISM   unclassified.
REFERENCE  1. (bases 1 to 17)
AUTHORS    Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE      Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
JOURNAL    Patent: JP 2001511003-A 265 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS Unidentified
            PN JP 2001511003-A/265
            PD 07-AUG-2001
            PF 14-JAN-1998 JP 1998532913
            PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC Strandedness: Single;
            CC Topology: Linear;
            CC Enzymatic nucleic acid treatment of diseases or conditions CC
            related to
            CC levels of epidermal growth factor receptors
            FH Key Location/Qualifiers
            FT source 1. .17 /organism='Unidentified'.
FEATURES   source
            1. .17 Location/Qualifiers
            /organism='unidentified'
            /mol_type='genomic RNA'
            /db_xref='taxon:32644'
BASE COUNT 9 a 2 c 3 g 3 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 981 AGCACTTTTAAGTTT 997
Db 17 AGCACTTTGATCTTTT 1
RESULT 818
BD067935/c
LOCUS      BD067935          17 bp    RNA        linear        PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors.
ACCESSION  BD067935
VERSION    JP 2001511003-A/775
KEYWORDS   unclassified
SOURCE     unclassified
ORGANISM   unclassified.
REFERENCE  1. (bases 1 to 17)
AUTHORS    Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE      Enzymatic nucleic acid treatment of diseases or conditions related
            to levels of epidermal growth factor receptors
JOURNAL    Patent: JP 2001511003-A 775 07-AUG-2001;
            RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT     OS Unidentified
            PN JP 2001511003-A/775
            PD 07-AUG-2001
            PF 14-JAN-1998 JP 1998532913
            PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
            SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
            C12N9/00,C07K14/71
            CC Strandedness: Single;
            CC Topology: Linear;

```

```

CC Enzymatic nucleic acid treatment of diseases or conditions CC
related to
CC levels of epidermal growth factor receptors
FH Key Location/Qualifiers
FT source 1. .17 /organism='Unidentified'.
FEATURES   source
            1. .17 Location/Qualifiers
            /organism='unidentified'
            /mol_type='genomic RNA'
            /db_xref='taxon:32644'
BASE COUNT 7 a 2 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 514 TTCTGTGTTAAATTGA 530
Db 17 TTCTGTGTTAAATTGA 1
RESULT 819
BD073195/c
LOCUS      BD073195          17 bp    DNA        linear        PAT 27-AUG-2002
DEFINITION Nucleic acid sequence and method for selectively expressing protein
            in target cell and tissue.
ACCESSION  BD073195
VERSION    BD073195.1 GI:22618798
KEYWORDS   JP 2001509388-A/12.
SOURCE     synthetic construct
ORGANISM   artificial sequences.
REFERENCE  1. (bases 1 to 17)
AUTHORS    Flaser,I. and Joe,J.
TITLE      Nucleic acid sequence and method for selectively expressing protein
            in target cell and tissue
JOURNAL    Patent: JP 2001509388-A 12 24-JUL-2001;
            THE UNIVERSITY OF QUEENSLAND
COMMENT     OS Artificial Sequence
            PN JP 2001509388-A/12
            PD 24-JUL-2001
            PF 09-JUL-1998 JP 2000502189
            PR 09-JUL-1997 AU PO 7765.11-SEP-1997 AU PO 9467 PI
            IAN FLASER,JEAN JOE
            PC C12N15/09,A61K48/00,A61P35/00,A61P43/00,C12N5/10,C12N7/00// PC
            A61K35/76,
            PC C12N15/00,C12N5/00
            CC Description of Artificial Sequence: Oligonucleotide specific
            for Glu(GAA)
            CC Key Location/Qualifiers
            FT source 1. .17 /organism='Artificial Sequence'.
FEATURES   source
            1. .17 Location/Qualifiers
            /organism='synthetic construct'
            /mol_type='genomic DNA'
            /db_xref='taxon:32630'
BASE COUNT 5 a 4 c 1 g 7 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1363 AGTGCTGTGTTGAATTA 1379
Db 17 AATGCTGTGTTGAATTA 1
RESULT 820
BD087253
LOCUS      BD087253          17 bp    DNA        linear        PAT 27-AUG-2002
DEFINITION Hyaluronan synthase gene and utilization thereof.

```

```

ACCESSION BD087253
VERSION BD087253.1 GI:22632863
KEYWORDS JP 2001521741-A/5.
SOURCE Streptococcus dysgalactiae subsp. equisimilis
ORGANISM Streptococcus dysgalactiae subsp. equisimilis
Bacteria; Firmicutes; Lactobacillales; Streptococcaceae;
Streptococcus.
REFERENCE 1 (bases 1 to 17)
AUTHORS Weigel,P.H., Kumari,K. and Deangelis,P.
TITLE Hyaluronan synthase gene and utilization thereof
JOURNAL Patent: JP 2001521741-A 5 13-NOV-2001;
THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA
COMMENT OS Streptococcus equisimilis
PN JP 2001521741-A/5
PD 13-NOV-2001
PP 30-OCT-1998 JP 2000519083
PR 31-OCT-1997 US 607064435,26-OCT-1998 US 09/178951 PI
PAUL H WEIGEL,KSHAMA KUMARI,PAUL DEANGELIS
PC C12N15/09,A61K31/728,A61P43/00,C12N1/21,C12N9/10,C12P19/04, PC
C12Q1/68//
PC (C12N15/09,C12R1:46),C12N15/00,(C12N15/00,C12R1:46) CC
Hyaluronan synthase gene and utilization thereof PH Key
Location/Qualifiers 1..17
FT source
FT /organism='Streptococcus equisimilis'.
FEATURES
source Location/Qualifiers
1..17
/organism='Streptococcus dysgalactiae subsp. equisimilis'
/mol_type='genomic DNA'
/sub_species='subsp. equisimilis'
/db_xref='taxon:119602'
BASE COUNT 2 a 5 c 2 g 8 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1544 TTTTATGCTGCTCCCA 1560
||||| ||||| |||||
DB 1 TTTTACGCTGCTCCCA 17
RESULT 821
I32318
LOCUS 17 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 10 from patent US 5587300.
ACCESSION I32318
VERSION I32318.1 GI:1823109
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Malter,J.S.
TITLE Method to increase regulatory molecule production
JOURNAL Patent: US 5587300-A 10 24-DEC-1996;
Location/Qualifiers
source 1..17
/organism='unknown'
BASE COUNT 5 a 0 c 4 g 8 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1046 ATTATGATGATTATTTA 1062
||||| ||||| |||||
DB 1 ATGATGATGATGATGTA 17
RESULT 822
I32319/c
LOCUS 17 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 10 from patent US 5587300.
ACCESSION I32319
VERSION I32319.1 GI:1823110
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Malter,J.S.
TITLE Method to increase regulatory molecule production
JOURNAL Patent: US 5587300-A 11 24-DEC-1996;
Location/Qualifiers
source 1..17
/organism='unknown'
BASE COUNT 8 a 4 c 0 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1046 ATTATGATGATTATTTA 1062
||||| ||||| |||||
DB 1 ATGATGATGATGATGTA 17

```

```

DEFINITION Sequence 11 from patent US 5587300.
ACCESSION I32319
VERSION I32319.1 GI:1823110
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Malter,J.S.
TITLE Method to increase regulatory molecule production
JOURNAL Patent: US 5587300-A 11 24-DEC-1996;
Location/Qualifiers
source 1..17
/organism='unknown'
BASE COUNT 8 a 4 c 0 g 5 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1046 ATTATGATGATTATTTA 1062
||||| ||||| |||||
DB 1 ATGATGATGATGATGTA 17
RESULT 823
I53001
LOCUS 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 742 from patent US 5646042.
ACCESSION I53001
VERSION I53001.1 GI:2474204
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 742 08-JUL-1997;
Location/Qualifiers
source 1..17
/organism='unknown'
BASE COUNT 9 a 0 c 2 g 6 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1081 AAGAAATTTGGAAAAATA 1097
||||| ||||| |||||
DB 1 AAGAAATTTTAAAAATA 17
RESULT 824
I53051
LOCUS 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 792 from patent US 5646042.
ACCESSION I53051
VERSION I53051.1 GI:2474254
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 792 08-JUL-1997;
Location/Qualifiers
source 1..17
/organism='unknown'
BASE COUNT 11 a 1 c 1 g 4 t
Query Match 1.0%; Score 12.2; DB 1; Length 17;

```

```
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 619 AAAACACACAAATAAT 635
Db 1 AAAACACATAAATGATT 17

RESULT 825
I53051/c
LOCUS 153051 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 792 from patent US 5646042.
ACCESSION I53051
VERSION I53051.1 GI:2474254
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 792 08-JUL-1997;
FEATURES Location/Qualifiers
1..17
source
BASE COUNT 11 a 1 c 1 g 4 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 980 AAGCACTTTAAAGTTT 996
Db 17 AATCATTTATGTTTT 1

RESULT 826
I53219/c
LOCUS 153219 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 960 from patent US 5646042.
ACCESSION I53219
VERSION I53219.1 GI:2474422
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 960 08-JUL-1997;
FEATURES Location/Qualifiers
1..17
source
BASE COUNT 8 a 0 c 2 g 7 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1030 TATTAACCTTTATTA 1046
Db 17 TATAAACTTCTTA 1

RESULT 827
I53221/c
LOCUS 153221 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 962 from patent US 5646042.
ACCESSION I53221
VERSION I53221.1 GI:2474424
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1477 TTCTTATATATATTT 1493
Db 17 TTTTATAAACTATT 1

RESULT 828
I53307
LOCUS 153307 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 1048 from patent US 5646042.
ACCESSION I53307
VERSION I53307.1 GI:2474510
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1048 08-JUL-1997;
FEATURES Location/Qualifiers
1..17
source
BASE COUNT 5 a 0 c 0 g 12 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1145 TATTTTATTTAGATAT 1161
Db 1 TTTTAAATTTATATAT 17

RESULT 829
I53307/c
LOCUS 153307 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 1048 from patent US 5646042.
ACCESSION I53307
VERSION I53307.1 GI:2474510
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL Patent: US 5646042-A 1048 08-JUL-1997;
FEATURES Location/Qualifiers
1..17
source
BASE COUNT 5 a 0 c 0 g 12 t

Query Match 1.0%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 5.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1590 AAATATAAACTAATA 1606
Db 17 ATATATAAAATTAATAA 1
```







Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsids.

1  
REFERENCE  
AUTHORS  
Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., Derose, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharny, A.  
T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites  
EMBO Rep. 3 (12), 1152-1157 (2002)  
JOURNAL  
MEDLINE  
22363535  
PUBMED  
12446565  
REFERENCE  
2 (bases 1 to 17)  
AUTHORS  
Balzergue, S.  
TITLE  
Direct Substitution  
COMMENT  
Submitted (21-NOV-2002) Balzergue S., UMGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE  
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES  
source  
1..17  
/organism="Arabidopsis thaliana"  
/mol\_type="Genomic DNA"  
/cultivar="Wassillewskija"  
/db\_xref="taxon:3702"  
/clone="187B12"  
misc\_feature  
3..17  
/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"  
/note="T-DNA flanking sequence left border"  
BASE COUNT  
10 a 1 c 1 g 5 t  
Query Match 1.0%; Score 12.2; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 5.8e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 622 AACACCAATATTTT 638  
||| ||||| |||||  
Db 1 AAAACCAAAAGTTT 17

RESULT 841  
AR165969/c  
LOCUS  
AR165969  
DEFINITION  
Sequence 22 from patent US 6280942.  
ACCESSION  
AR165969  
VERSION  
AR165969.1 GI:16241085  
KEYWORDS  
Unknown.  
SOURCE  
ORGANISM  
Unclassified.  
REFERENCE  
1 (bases 1 to 18)  
AUTHORS  
Morishima, N., Mizumura, H. and Shibata, T.  
TITLE  
Endonuclease  
JOURNAL  
Patent: US 6280942-A 22 28-AUG-2001;  
FEATURES  
Location/Qualifiers  
source  
1..18  
/organism="unknown"  
BASE COUNT  
4 a 1 c 4 g 9 t  
Query Match 1.0%; Score 12.2; DB 1; Length 18;  
Best Local Similarity 82.4%; Pred. No. 6.3e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1045 TATTATGTATTATT 1061  
||| ||||| |||||  
Db 2 TATTATGTATTATT 18

RESULT 844  
AX643251/c  
LOCUS  
AX643251  
DEFINITION  
Sequence 117 from Patent WO2090999.  
ACCESSION  
AX643251  
VERSION  
AX643251.1 GI:28550449  
KEYWORDS  
Synthetic construct  
SOURCE  
Synthetic construct

Qy 1247 CAGATAACCAATA 1263  
||| ||||| |||||  
Db 17 CAGATAACCAATA 1

RESULT 842  
AR285276/c  
LOCUS  
AR285276  
DEFINITION  
Sequence 22 from patent US 6528296.  
ACCESSION  
AR285276  
VERSION  
AR285276.1 GI:29722376  
KEYWORDS  
Unknown.  
SOURCE  
ORGANISM  
Unclassified.  
REFERENCE  
1 (bases 1 to 18)  
AUTHORS  
Morishima, N., Mizumura, H. and Shibata, T.  
TITLE  
Endonuclease  
JOURNAL  
Patent: US 6528296-A 22 04-MAR-2003;  
FEATURES  
Location/Qualifiers  
source  
1..18  
/organism="unknown"  
BASE COUNT  
4 a 1 c 4 g 9 t  
Query Match 1.0%; Score 12.2; DB 1; Length 18;  
Best Local Similarity 82.4%; Pred. No. 6.3e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1247 CAGATAACCAATA 1263  
||| ||||| |||||  
Db 17 CAGATAACCAATA 1

RESULT 843  
AR643248  
LOCUS  
AR643248  
DEFINITION  
Sequence 114 from Patent WO2090999.  
ACCESSION  
AR643248  
VERSION  
AR643248.1 GI:28550445  
KEYWORDS  
Synthetic construct  
SOURCE  
ORGANISM  
Artificial sequences.  
REFERENCE  
1  
AUTHORS  
Penger, A., Sprenger, R. and Brinkmann, U.  
TITLE  
Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8 and their use in diagnostic and therapeutic applications  
JOURNAL  
Patent: WO 0209099-A 114 12-DEC-2002;  
FEATURES  
Location/Qualifiers  
source  
1..18  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
BASE COUNT  
4 a 0 c 3 g 11 t  
Query Match 1.0%; Score 12.2; DB 1; Length 18;  
Best Local Similarity 82.4%; Pred. No. 6.3e+02;  
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1045 TATTATGTATTATT 1061  
||| ||||| |||||  
Db 2 TATTATGTATTATT 18

RESULT 844  
AX643251/c  
LOCUS  
AX643251  
DEFINITION  
Sequence 117 from Patent WO2090999.  
ACCESSION  
AX643251  
VERSION  
AX643251.1 GI:28550449  
KEYWORDS  
Synthetic construct  
SOURCE  
Synthetic construct

```

ORGANISM      synthetic construct
REFERENCE      1
AUTHORS      Panger, A., Spranger, R. and Brinkmann, U.
TITLE      Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8
            and their use in diagnostic and therapeutic applications
JOURNAL      Patent: WO 02099099-A 117 12-DEC-2002;
            Epidauros Biotechnology AG (DE)
FEATURES      Location/Qualifiers
            source
            1..18
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
BASE COUNT    11 a 3 c 0 g 4 t
Query Match   1.0%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1045 TATTATGTTATTATT 1061
Db 17 TATTATGTTATTATG 1
RESULT 845
E60081/c
LOCUS      E60081
DEFINITION Endonuclease.
ACCESSION  E60081
VERSION     1 GI:13023331
KEYWORDS   JP 2000041686-A/21.
SOURCE     synthetic construct
ORGANISM   artificial sequences.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Kobuhiro, M., Hikaru, M. and Takehiko, S.
TITLE      Endonuclease
COMMENT     Patent: JP 2000041686-A 21 15-FEB-2000;
            RIKAGAKU KENKYUSHO
            OS Artificial Sequence
            PN JP 2000041686-A/21
            PD 15-FEB-2000
            PF 24-MAY-1999 JP 1999144005
            PR NOBUHIRO MORISHIMA, HIKARU MIZUMURA, TAKEHIKO SHIBATA
            PI C12N15/09, C12N1/19, C12N1/21, C12N5/10, C12N9/16// PC
            CC (C12N9/16, C12R1:19), C12N15/00, C12N5/00
            FH Key
            FT source
            FI Location/Qualifiers
FEATURES     source
            1..18
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
BASE COUNT    4 a 1 c 4 g 9 t
Query Match   1.0%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1247 CAGATAACCAACAATA 1263
Db 17 CAGATAACCAATAATTA 1
RESULT 846
AX599396
LOCUS      AX599396
DEFINITION Sequence 736 from Patent WO2077272.
ACCESSION  AX599396
VERSION     1 GI:28399540
AUTHORS     Mireglia, L.J., Nero, P., Graham, M.J., Monia, B.P. and Cowsett, L.M.

```

---

```

KEYWORDS      synthetic construct
SOURCE         synthetic construct
ORGANISM       artificial sequences.
REFERENCE      1
AUTHORS        Berlin, K., Braun, A., Distler, J., Guetig, D., Howe, A., Mueller, J.,
            Olek, A., Piepenbrock, C., Adorjan, P., Grabs, G., Lesche, R., Leu, E.,
            Lewin, A., Lipscher, E., Maier, S., Model, F., Mueller, V., Otto, T.,
            Pelet, C. and Ziebarth, H.
TITLE          Methods and nucleic acids for the analysis of hematopoietic cell
            proliferative disorders
JOURNAL        Patent: WO 02077272-A 736 03-OCT-2002;
            Epigenomics AG (DE)
FEATURES      Location/Qualifiers
            source
            1..18
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
            /note="Detection oligonucleotide for DAPKI"
BASE COUNT    3 a 0 c 4 g 11 t
Query Match   1.0%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 6.3e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1286 TTGTTTATCTGAATTT 1302
Db 1 TTGTTTATCTGAATTT 17
RESULT 847
AX419972/c
LOCUS      AX419972
DEFINITION Sequence 309 from Patent WO0198537.
ACCESSION  AX419972
VERSION     AX419972.1 GI:21524339
KEYWORDS
SOURCE      synthetic construct
ORGANISM     synthetic construct
            artificial sequences.
REFERENCE     1
AUTHORS      Lyamichev, V., Allawi, H., Dong, P., Neri, B.P. and Vener, I.T.
TITLE        Nucleic acid accessible hybridization sites
JOURNAL      Patent: WO 0198537-A 309 27-DEC-2001;
            THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES     Location/Qualifiers
            source
            1..20
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
BASE COUNT    7 a 5 c 2 g 6 t
Query Match   1.0%; Score 12.2; DB 1; Length 20;
Best Local Similarity 82.4%; Pred. No. 7.2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 552 TTTTTCATTTGACCATG 568
Db 17 TATTTCATGTTACATG 1
RESULT 848
BD138313
LOCUS      BD138313
DEFINITION Antisense modulation of human MDM2 expression.
ACCESSION  BD138313
VERSION     BD138313.1 GI:23233258
KEYWORDS   JP 2002508944-A/239.
SOURCE      unidentified
ORGANISM     unclassified.
            1 (bases 1 to 20)
REFERENCE     1
AUTHORS      Mireglia, L.J., Nero, P., Graham, M.J., Monia, B.P. and Cowsett, L.M.

```

TITLE Antisense modulation of human MDM2 expression  
JOURNAL Patent: JP 2002508944-A 239 26-MAR-2002;  
ISIS PHARMACEUTICALS INC

COMMENT OS Unidentified

PN JP 2002508944-A/239

PD 26-MAR-2002

PF 26-MAR-1999 JP 2000538025

PR 26-MAR-1998 US 09/048810

PI LOREN J MTRAGLIA, PAMELA NERO, MARK J GRAHAM, BRETT P MONIA, LEX M

PI CONSENT

PC C12N15/09, A61K48/00, A61P9/10, A61P17/06, A61P35/09, C07H21/04//

PC C12Q1/68,

PC C12N15/00

CC Strandedness: Single;

CC Topology: Linear;

CC Antisense modulation of human MDM2 expression FH Key

CC Location/Qualifiers

FT source 1..20

FT Location/Qualifiers

1..20 /organism="Unidentified".

/organism="unidentified"

/mol\_type="genomic DNA"

/db\_xref="taxon:32644"

9 a 1 c 2 g 8 t

Query Match 1.0%; Score 12.2; DB 1; Length 20;

Best Local Similarity 82.4%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1603 AATATGAACATTATA 1619

Db 2 AATAGTTACATTATA 18

RESULT 849

ATH552863/C

LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone

DEFINITION 20 bp DNA linear PLN 29-MAR-2003

ACCESSION 345E09

VERSION AJ552863

KEYWORDS left border; T-DNA flanking sequence.

SOURCE Arabidopsis thaliana (thale cress)

ORGANISM Arabidopsis thaliana

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

1

REFERENCE

AUTHORS Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, P.,

Chauvin, S., Bechtold, N., Cruaud, C., Dekosse, R., Pelletier, G.,

Lepiniec, L., Caboche, M. and Lecharny, A.

T-DNA integration into the Arabidopsis genome depends on sequences

of pre-insertion sites

EMBO Rep. 3 (12), 1152-1157 (2002)

22363535

12446565

REFERENCE

AUTHORS Balzergue, S.

Direct Submission

Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue

Gaston Cremieux, 91057 Evry cedex, FRANCE

PCR was performed on DNA from transformants of Arabidopsis thaliana

plants from INRA (Versailles). The DNA fragment(s) resulting from

the PCR were directly sequenced from the left or the right border

to determine the genomic sequence flanking the insertion. T-DNA

derived sequences were removed. Information to order the

corresponding mutant line and a link to a database providing a

graphical display of the insertion site are available at

http://dbsgap.versailles.inra.fr/publiclines/. This sequence has

been generated in the framework of the French plant genomics

program 'Genoplante' (http://www.genoplante.com and

http://genoplante-info.infobiogen.fr).

FEATURES

source

1..20

/organism="Arabidopsis thaliana"

/mol\_type="genomic DNA"

/cultivar="Wassiljewskaja"

/db\_xref="taxon:3702"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"

misc\_feature 1..20

/note="T-DNA flanking sequence"

left border"

13 a 4 c 0 g 3 t

BASE COUNT

Query Match 1.0%; Score 12.2; DB 1; Length 20;

Best Local Similarity 82.4%; Pred. No. 7.2e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 594 AAAGTATTATTATTG 610

Db 20 AAAGTTTGTGTTG 4

RESULT 850

AR236360/C

LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone

DEFINITION 21 bp RNA linear PAT 20-DEC-2002

ACCESSION AR236360

VERSION AR236360.1 GI:27280288

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 21)

AUTHORS Giordano, T., Beach, D.L. and Temeles, G.L.

TITLE Method for identifying compounds RNA/RNA binding protein

interactions

JOURNAL Patent: US 6465176-A 8 15-OCT-2002;

FEATURES

source

1..21

Location/Qualifiers

6 a 0 c 0 g 15 t

BASE COUNT

Query Match 1.0%; Score 12.2; DB 1; Length 21;

Best Local Similarity 82.4%; Pred. No. 7.6e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1590 AATATAAAGTAAATA 1606

Db 20 AATAAATAAATA 4

RESULT 851

A61502

LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone

DEFINITION Sequence 71 from Patent WO9710332.

ACCESSION A61502

VERSION A61502.1 GI:3715885

KEYWORDS

SOURCE unidentified

ORGANISM unidentified

REFERENCE 1

AUTHORS Schmidt, G.

TITLE CHINAERIC OLIGONUCLEOTIDES AND USES THEREOF IN THE IDENTIFICATION

OF ANTISENSE BINDING SITES

JOURNAL Patent: WO 9710332-A 71 20-MAR-1997;

BRAX GENOMICS LTD (GB)

FEATURES

source

1..12

/organism="unidentified"

/mol\_type="genomic DNA"

/db\_xref="taxon:32644"

```

BASE COUNT      3 a      0 c      0 g      9 t

Query Match
Best Local Similarity 1.0%; Score 12; DB 1; Length 12;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTTATTATTT 1049
  |||||
Db 1 TATTTATTATTT 12

RESULT 852
AR199094
LOCUS AR199094 12 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 42 from patent US 6355418.
ACCESSION AR199094
VERSION AR199094.1 GI:20249168
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Schmidt,G.
TITLE Chimeric oligonucleotides and uses thereof in the identification of
JOURNAL antisense binding sites
FEATURES Patent: US 6355418-A 42 12-MAR-2002;
Location/Qualifiers
1..12
source /organism="unknown"
BASE COUNT      3 a      0 c      0 g      9 t

Query Match
Best Local Similarity 1.0%; Score 12; DB 1; Length 12;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTTATTATTT 1049
  |||||
Db 1 TATTTATTATTT 12

RESULT 853
AR241715
LOCUS AR241715 13 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 3 from patent US 6472154.
ACCESSION AR241715
VERSION AR241715.1 GI:27287527
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 13)
AUTHORS Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
TITLE Polymorphic repeats in human genes
JOURNAL Patent: US 6472154-A 3 29-OCT-2002;
FEATURES Location/Qualifiers
1..13
source /organism="unknown"
BASE COUNT     10 a      3 c      0 g      0 t

Query Match
Best Local Similarity 1.0%; Score 12; DB 1; Length 13;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 616 ACAAAAACAC 627
  |||||
Db 2 ACAAAAACAC 13

RESULT 854
A88495
LOCUS A88495 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 643 from Patent WO9833904.
ACCESSION A88495

```

---

```

VERSION A88495.1 GI:6737065
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 643 06-AUG-1998; (DB)
FEATURES BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
Location/Qualifiers
1..14
source /organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT      5 a      1 c      7 t

Query Match
Best Local Similarity 1.0%; Score 12; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 TTTTGAATATAA 646
  |||||
Db 3 TTTTGAATATAA 14

RESULT 855
A88649
LOCUS A88649 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 797 from Patent WO9833904.
ACCESSION A88649
VERSION A88649.1 GI:6737219
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 797 06-AUG-1998;
FEATURES BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
Location/Qualifiers
1..14
source /organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT      7 a      0 c      2 g      5 t

Query Match
Best Local Similarity 1.0%; Score 12; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1156 AGATATTAAATG 1167
  |||||
Db 2 AGATATTAAATG 13

RESULT 856
A90462
LOCUS A90462 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 643 from Patent EP0856579.
ACCESSION A90462
VERSION A90462.1 GI:6738976
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 643 05-AUG-1998;
FEATURES BIOGNOSTIK GES (DE)
Location/Qualifiers

```

```

source      1. .14
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  5 a 1 c 1 g 7 t

Query Match      1.0%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 TTTTGAATATAA 646
    |||||
Db 3 TTTTGAATATAA 14

RESULT 857
A90616
LOCUS      14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 797 from Patent EP0856579.
ACCESSION A90616
VERSION A90616.1 GI:6739130
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 797 05-AUG-1998;
          BIOGNOSTIK GES (DE)
FEATURES
source      1. .14
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  7 a 0 c 2 g 5 t

Query Match      1.0%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1156 AGATATTAAATG 1167
    |||||
Db 2 AGATATTAAATG 13

RESULT 858
BD066008
LOCUS      14 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066008
VERSION BD066008.1 GI:22611611
KEYWORDS JP 2001511000-A/643.
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 14)
AUTHORS Schlingensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 643 07-AUG-2001;
          BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT
PN JP 2001511000-A/643
PD 07-AUG-2001
PR 30-JAN-1998 JP 1998532533
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FT source      1. .14
            /organism="Unknown".
            Location/Qualifiers
FEATURES
source      1. .14
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  7 a 0 c 2 g 5 t

Query Match      1.0%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1156 AGATATTAAATG 1167
    |||||
Db 2 AGATATTAAATG 13

RESULT 860
A15311
LOCUS      15 bp DNA linear PAT 23-MAR-1994
DEFINITION Oligonucleotide Cdl.
ACCESSION A15311
VERSION A15311.1 GI:512714
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Ueda,I., Niwa,M., Saito,Y., Yamada,H. and Ishii,Y.
TITLE A process for the production of alpha-human atrial natriuretic
          polypeptide
JOURNAL Patent: EP 0206769-A 50 30-DEC-1986;
          FUJISAWA PHARMACEUTICAL CO., LTD

```

```

source      1. .14
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  5 a 1 c 1 g 7 t

Query Match      1.0%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 TTTTGAATATAA 646
    |||||
Db 3 TTTTGAATATAA 14

RESULT 859
BD066162
LOCUS      14 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066162
VERSION BD066162.1 GI:22611765
KEYWORDS JP 2001511000-A/797.
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 14)
AUTHORS Schlingensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 797 07-AUG-2001;
          BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT
OS Unknown
PN JP 2001511000-A/797
PD 07-AUG-2001
PR 30-JAN-1998 JP 1998532533
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FT source      1. .14
            /organism="Unknown".
            Location/Qualifiers
FEATURES
source      1. .14
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT  7 a 0 c 2 g 5 t

Query Match      1.0%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1156 AGATATTAAATG 1167
    |||||
Db 2 AGATATTAAATG 13

RESULT 860
A15311
LOCUS      15 bp DNA linear PAT 23-MAR-1994
DEFINITION Oligonucleotide Cdl.
ACCESSION A15311
VERSION A15311.1 GI:512714
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 15)
AUTHORS Ueda,I., Niwa,M., Saito,Y., Yamada,H. and Ishii,Y.
TITLE A process for the production of alpha-human atrial natriuretic
          polypeptide
JOURNAL Patent: EP 0206769-A 50 30-DEC-1986;
          FUJISAWA PHARMACEUTICAL CO., LTD

```

```

FEATURES
  source
    1. .15
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"
  /db_4 c 0 g 5 t
BASE COUNT      6 a 4 c 0 g 5 t
Query Match
  Best Local Similarity 100.0%; Score 12; DB 1; Length 15;
  Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 452 TCTACTTCACCA 463
Db 2 TCTACTTCACCA 13
RESULT 861
A16511
LOCUS      15 bp DNA linear PAT 17-MAR-1994
DEFINITION oligonucleotide Cdl.
ACCESSION A16511
VERSION A16511.1 GI:489899
KEYWORDS  synthetic construct
SOURCE    synthetic construct
ORGANISM  artificial sequences.
REFERENCE 1 (bases 1 to 15)
AUTHORS  Ueda,I., Niwa,M., Saito,Y., Yamada,H. and Ishii,Y.
TITLE    A process for the production of alpha-human atrial natriuretic
JOURNAL  polypeptide
PATENT: EP 0440311-A 67 07-AUG-1991;
FUJISAWA PHARMACEUTICAL CO., LTD
FEATURES
  source
    1. .15
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"
  /db_6 a 4 c 0 g 5 t
BASE COUNT      6 a 4 c 0 g 5 t
Query Match
  Best Local Similarity 100.0%; Score 12; DB 1; Length 15;
  Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 452 TCTACTTCACCA 463
Db 2 TCTACTTCACCA 13
RESULT 862
A88496
LOCUS      15 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 644 from Patent WO9833904.
ACCESSION A88496
VERSION A88496.1 GI:6737066
KEYWORDS  unidentified
SOURCE    unidentified
ORGANISM  unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS  Brysch,W. and Schlingensiepen,K.
TITLE    AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL  Patent: WO 9833904-A 644 06-AUG-1998;
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
  source
    1. .15
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"
  /db_5 a 1 c 1 g 8 t
BASE COUNT      5 a 1 c 1 g 8 t
Query Match
  Best Local Similarity 100.0%; Score 12; DB 1; Length 15;
  Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 452 TCTACTTCACCA 463
Db 2 TCTACTTCACCA 13
RESULT 863
A88496
LOCUS      15 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 644 from Patent WO9833904.
ACCESSION A88496
VERSION A88496.1 GI:6737216
KEYWORDS  unidentified
SOURCE    unidentified
ORGANISM  unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS  Brysch,W. and Schlingensiepen,K.
TITLE    AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL  Patent: WO 9833904-A 794 06-AUG-1998;
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
  source
    1. .15
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"
  /db_5 a 1 c 1 g 8 t
BASE COUNT      5 a 1 c 1 g 8 t
Query Match
  Best Local Similarity 100.0%; Score 12; DB 1; Length 15;
  Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1293 TCTGAATTTTA 1304
Db 1 TCTGAATTTTA 12
RESULT 864
A90463
LOCUS      15 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 644 from Patent EP0856579.
ACCESSION A90463
VERSION A90463.1 GI:6738977
KEYWORDS  unidentified
SOURCE    unidentified
ORGANISM  unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS  Brysch,W.D. and Schlingensiepen,K.D.
TITLE    An antisense oligonucleotide preparation method
JOURNAL  Patent: EP 0856579-A 644 05-AUG-1998;
BIOGNOSTIK GES (DE)
FEATURES
  source
    1. .15
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"
  /db_5 a 1 c 1 g 8 t
BASE COUNT      5 a 1 c 1 g 8 t
Query Match
  Best Local Similarity 100.0%; Score 12; DB 1; Length 15;
  Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 635 TTTTGAATATAA 646
Db 4 TTTTGAATATAA 15
RESULT 865
A90613
LOCUS      15 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 794 from Patent EP0856579.
ACCESSION A90613

```



```

VERSION      A90613.1  GI:6739127
KEYWORDS
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1 (bases 1 to 15)
AUTHORS      Brysch,W.D. and Schlingensiepen,K.D.
TITLE        An antisense oligonucleotide preparation method
JOURNAL      Patent: EP 0856579-A 794 05-AUG-1998;
              BIOGNOSTIK GES (DE)
FEATURES     Location/Qualifiers
              source
                1..15
                /organism="unidentified"
                /mol_type="genomic DNA"
                /db_xref="taxon:32644"
BASE COUNT   5 a 1 c 1 g 8 t

Query Match  1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1293 TCTGAATTTTA 1304
Db  1 TCTGAATTTTA 12

RESULT 866
LOCUS      AR041397
DEFINITION Sequence 187 from patent US 5811300.
ACCESSION  AR041397
VERSION     AR041397.1  GI:5961893
KEYWORDS   Unknown.
SOURCE     Unknown.
REFERENCE  1 (bases 1 to 15)
AUTHORS    Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE      TNF-.alpha. ribozymes
JOURNAL    Patent: US 5811300-A 187 22-SEP-1998;
              Location/Qualifiers
              source
                1..15
                /organism="unknown"
BASE COUNT   4 a 0 c 1 g 10 t

Query Match  1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1038 TATTATTATT 1049
Db  4 TATTATTATT 15

RESULT 867
LOCUS      AR041405
DEFINITION Sequence 195 from patent US 5811300.
ACCESSION  AR041405
VERSION     AR041405.1  GI:5961901
KEYWORDS   Unknown.
SOURCE     Unknown.
REFERENCE  1 (bases 1 to 15)
AUTHORS    Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE      TNF-.alpha. ribozymes
JOURNAL    Patent: US 5811300-A 195 22-SEP-1998;
              Location/Qualifiers
              source
                1..15
                /organism="unknown"
BASE COUNT   4 a 0 c 0 g 11 t

```

```

Query Match  1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1038 TATTATTATT 1049
Db  4 TATTATTATT 15

RESULT 868
LOCUS      AR041418
DEFINITION Sequence 208 from patent US 5811300.
ACCESSION  AR041418
VERSION     AR041418.1  GI:5961914
KEYWORDS   Unknown.
SOURCE     Unknown.
REFERENCE  1 (bases 1 to 15)
AUTHORS    Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE      TNF-.alpha. ribozymes
JOURNAL    Patent: US 5811300-A 208 22-SEP-1998;
              Location/Qualifiers
              source
                1..15
                /organism="unknown"
BASE COUNT   4 a 0 c 2 g 9 t

Query Match  1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1050 ATGTATTATT 1061
Db  4 ATGTATTATT 15

RESULT 869
LOCUS      AR041419
DEFINITION Sequence 209 from patent US 5811300.
ACCESSION  AR041419
VERSION     AR041419.1  GI:5961915
KEYWORDS   Unknown.
SOURCE     Unknown.
REFERENCE  1 (bases 1 to 15)
AUTHORS    Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE      TNF-.alpha. ribozymes
JOURNAL    Patent: US 5811300-A 209 22-SEP-1998;
              Location/Qualifiers
              source
                1..15
                /organism="unknown"
BASE COUNT   4 a 0 c 3 g 8 t

Query Match  1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1050 ATGTATTATT 1061
Db  2 ATGTATTATT 13

RESULT 870
LOCUS      AR041420
DEFINITION Sequence 210 from patent US 5811300.
ACCESSION  AR041420
VERSION     AR041420.1  GI:5961916
KEYWORDS   Unknown.
SOURCE     Unknown.

```

```

ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE      TNF- $\alpha$ . ribozymes
JOURNAL      Patent: US 5811300-A 210 22-SEP-1998;
FEATURES      Location/Qualifiers
               1. .15
               /organism="unknown"
BASE COUNT    3 a 0 c 4 g 8 t
Query Match   1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 ATGTTATTATT 1061
Db 1 ATGTTATTATT 12

RESULT 871
AR041913
LOCUS      AR041913      15 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 703 from patent US 5811300.
ACCESSION      AR041913
VERSION      AR041913.1 GI:5962409
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE      TNF- $\alpha$ . ribozymes
JOURNAL      Patent: US 5811300-A 703 22-SEP-1998;
FEATURES      Location/Qualifiers
               1. .15
               /organism="unknown"
BASE COUNT    4 a 0 c 0 g 11 t
Query Match   1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTTATTATT 1049
Db 4 TATTTATTATT 15

RESULT 872
AR041914
LOCUS      AR041914      15 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 704 from patent US 5811300.
ACCESSION      AR041914
VERSION      AR041914.1 GI:5962410
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE      TNF- $\alpha$ . ribozymes
JOURNAL      Patent: US 5811300-A 704 22-SEP-1998;
FEATURES      Location/Qualifiers
               1. .15
               /organism="unknown"
BASE COUNT    4 a 0 c 0 g 11 t
Query Match   1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTTATTATT 1049
Db 4 TATTTATTATT 15

RESULT 873
AR041929
LOCUS      AR041929      15 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 719 from patent US 5811300.
ACCESSION      AR041929
VERSION      AR041929.1 GI:5962425
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE      TNF- $\alpha$ . ribozymes
JOURNAL      Patent: US 5811300-A 719 22-SEP-1998;
FEATURES      Location/Qualifiers
               1. .15
               /organism="unknown"
BASE COUNT    4 a 0 c 0 g 11 t
Query Match   1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTTATTATT 1049
Db 4 TATTTATTATT 15

RESULT 874
AR041939
LOCUS      AR041939      15 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 729 from patent US 5811300.
ACCESSION      AR041939
VERSION      AR041939.1 GI:5962435
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE      TNF- $\alpha$ . ribozymes
JOURNAL      Patent: US 5811300-A 729 22-SEP-1998;
FEATURES      Location/Qualifiers
               1. .15
               /organism="unknown"
BASE COUNT    4 a 0 c 2 g 9 t
Query Match   1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1050 ATGTTATTATT 1061
Db 4 ATGTTATTATT 15

RESULT 875
AR041940
LOCUS      AR041940      15 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION      Sequence 730 from patent US 5811300.
ACCESSION      AR041940
VERSION      AR041940.1 GI:5962436
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 15)
AUTHORS      Sullivan,S., Draper,K., Kisich,K., Stinchcomb,D.T. and McSwiggen,J.
TITLE      TNF- $\alpha$ . ribozymes
JOURNAL      Patent: US 5811300-A 730 22-SEP-1998;
FEATURES      Location/Qualifiers
               1. .15
               /organism="unknown"
BASE COUNT    4 a 0 c 0 g 11 t
Query Match   1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 TATTTATTATT 1049
Db 4 TATTTATTATT 15

```

FEATURES source Location/Qualifiers  
1. .15  
BASE COUNT 4 a 0 c 3 g 8 t  
Query Match 1.0%; Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1050 ATGTATTATT 1061  
Db 2 ATGTATTATT 13  
RESULT 876  
AR041941  
LOCUS 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 731 from patent US 5811300.  
ACCESSION AR041941  
VERSION AR041941.1 GI:5962437  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T., and McSwiggen, J.  
TITLE TNF- $\alpha$  ribozymes  
JOURNAL Patent: US 5811300-A 731 22-SEP-1998;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
BASE COUNT 4 a 0 c 3 g 8 t  
Query Match 1.0%; Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1050 ATGTATTATT 1061  
Db 1 ATGTATTATT 12  
RESULT 877  
AR056012  
LOCUS 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 216 from patent US 5837542.  
ACCESSION AR056012  
VERSION AR056012.1 GI:5981589  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 216 17-NOV-1998;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
BASE COUNT 4 a 1 c 2 g 8 t  
Query Match 1.0%; Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1049 TATGTATTATT 1060  
Db 3 TATGTATTATT 14  
RESULT 878  
AR056294/c

LOCUS 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 498 from patent US 5837542.  
ACCESSION AR056294  
VERSION AR056294.1 GI:5981871  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 498 17-NOV-1998;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
BASE COUNT 3 a 3 c 7 g 2 t  
Query Match 1.0%; Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 862 TCTGCTAGCCAG 873  
Db 13 TCTGCTAGCCAG 2  
RESULT 879  
AR056374/c  
LOCUS 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 578 from patent US 5837542.  
ACCESSION AR056374  
VERSION AR056374.1 GI:5981951  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 578 17-NOV-1998;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
BASE COUNT 3 a 3 c 7 g 2 t  
Query Match 1.0%; Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 862 TCTGCTAGCCAG 873  
Db 13 TCTGCTAGCCAG 2  
RESULT 880  
AR113770  
LOCUS 15 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 216 from patent US 6132967.  
ACCESSION AR113770  
VERSION AR113770.1 GI:14094092  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Grimm, S., Stinchcomb, D.T., McSwiggen, J., Sullivan, S. and Draper, K.G.  
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)  
JOURNAL Patent: US 6132967-A 216 17-OCT-2000;  
FEATURES Location/Qualifiers

```

source
1. .15
/organism="unknown"
4 a 1 c 2 g 8 t
BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1049 TATGTATTATT 1060
Db 3 TATGTATTATT 14

RESULT 881
AR114052/c
LOCUS AR114052 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 498 from patent US 6132967.
ACCESSION AR114052
VERSION AR114052.1 GI:14094374
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 498 17-OCT-2000;
FEATURES
source
1. .15
/organism="unknown"
3 a 3 c 7 g 2 t
BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 862 TCTGCTAGCCAG 873
Db 13 TCTGCTAGCCAG 2

RESULT 882
AR114132/c
LOCUS AR114132 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 578 from patent US 6132967.
ACCESSION AR114132
VERSION AR114132.1 GI:14094454
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 578 17-OCT-2000;
FEATURES
source
1. .15
/organism="unknown"
3 a 3 c 7 g 2 t
BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 862 TCTGCTAGCCAG 873
Db 13 TCTGCTAGCCAG 2

RESULT 883
AX633102
LOCUS AX633102 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 241 from Patent EP1260586.
ACCESSION AX633102
VERSION AX633102.1 GI:28468716
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 241 27-NOV-2002;
FEATURES
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. .15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
4 a 1 c 2 g 8 t
BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1049 TATGTATTATT 1060
Db 3 TATGTATTATT 14

RESULT 884
AX633446/c
LOCUS AX633446 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 585 from Patent EP1260586.
ACCESSION AX633446
VERSION AX633446.1 GI:28469060
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,P.E. and Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related genes
JOURNAL Patent: EP 1260586-A 585 27-NOV-2002;
FEATURES
RIBOZYME PHARMACEUTICALS, INC. (US)
Location/Qualifiers
1. .15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
3 a 3 c 7 g 2 t
BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 862 TCTGCTAGCCAG 873
Db 13 TCTGCTAGCCAG 2

RESULT 885

```

```

AX633616/c
LOCUS AX633616 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 755 from Patent EP1260586.
ACCESSION AX633616
VERSION AX633616.1 GI:28469230
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL
PATENT: EP 1260586-A 755 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 3 a 3 c 7 g 2 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 862 TCTGCTAGCCAG 873
Db 13 TCTGCTAGCCAG 2
RESULT 886
AX633389
LOCUS AX633389 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 2528 from Patent EP1260586.
ACCESSION AX633389
VERSION AX633389.1 GI:28471003
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL
PATENT: EP 1260586-A 2528 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 0 c 1 g 9 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1052 GTATTATTATTA 1063
Db 4 GTATTATTATTA 15
RESULT 887
AX635391
LOCUS AX635391 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 2530 from Patent EP1260586.
ACCESSION AX635391
VERSION AX635391.1 GI:28471005
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL
PATENT: EP 1260586-A 2530 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 0 c 1 g 9 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1052 GTATTATTATTA 1063
Db 3 GTATTATTATTA 14
RESULT 888
AX635393
LOCUS AX635393 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 2532 from Patent EP1260586.
ACCESSION AX635393
VERSION AX635393.1 GI:28471007
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
Karpelsky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL
PATENT: EP 1260586-A 2532 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 5 a 0 c 2 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1052 GTATTATTATTA 1063
Db 2 GTATTATTATTA 13
RESULT 889
AX635413/c
LOCUS AX635413 15 bp mRNA linear PAT 21-FEB-2003

```

```

DEFINITION Sequence 2552 from Patent EP1260586.
ACCESSION AX635413
VERSION AX635413.1 GI:28471027
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolff,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 2552 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 9 a 2 c 0 g 4 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1169 TCTTTATTAGG 1180
Db 13 TGTATTATTAGG 2
RESULT 890
AX636853
LOCUS AX636853 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 3992 from Patent EP1260586.
ACCESSION AX636853
VERSION AX636853.1 GI:28472467
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolff,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 3992 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 0 c 1 g 10 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATT 1049
Db 4 TATTATTATT 15
RESULT 891
AX636868
LOCUS AX636868 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4007 from Patent EP1260586.
ACCESSION AX636868
VERSION AX636868.1 GI:28472482
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolff,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 4007 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 0 c 0 g 11 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1038 TATTATTATT 1049
Db 4 TATTATTATT 15
RESULT 892
AX636894
LOCUS AX636894 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4033 from Patent EP1260586.
ACCESSION AX636894
VERSION AX636894.1 GI:28472508
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Wolff,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 4033 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source
1..15
/organism="unidentified"
/mol_type="mRNA"
/db_xref="taxon:32644"
BASE COUNT 4 a 0 c 2 g 9 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1050 ATGTATTATT 1061
Db 4 ATGTATTATT 15
RESULT 893
AX636896
LOCUS AX636896 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4035 from Patent EP1260586.
ACCESSION AX636896

```

```

VERSION      AX636896.1  GI:28472510
KEYWORDS
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1
AUTHORS      Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
              Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
              Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
              Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
              Woolf,T.
TITLE        Method and reagent for inhibiting the expression of disease related
genes
JOURNAL      Patent: EP 1260586-A 4035 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source       1. .15
              /organism="unidentified"
              /mol_type="mRNA"
              /db_xref="taxon:32644"
BASE COUNT   4 a - 0 c 3 g 8 t
              Query Match 1.0%; Score 12; DB 1; Length 15;
              Best Local Similarity 100.0%; Pred. No. 5.2e+02;
              Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1050 ATGTATTATT 1061
Db 2 ATGTATTATT 13

RESULT 894
AX636898
LOCUS        AX636898 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION   Sequence 4037 from Patent EP1260586.
ACCESSION    AX636898
VERSION      AX636898.1 GI:28472512
KEYWORDS
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1
AUTHORS      Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
              Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
              Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
              Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
              Woolf,T.
TITLE        Method and reagent for inhibiting the expression of disease related
genes
JOURNAL      Patent: EP 1260586-A 4037 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source       1. .15
              /organism="unidentified"
              /mol_type="mRNA"
              /db_xref="taxon:32644"
BASE COUNT   3 a - 0 c 4 g 8 t
              Query Match 1.0%; Score 12; DB 1; Length 15;
              Best Local Similarity 100.0%; Pred. No. 5.2e+02;
              Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1050 ATGTATTATT 1061
Db 1 ATGTATTATT 12

RESULT 895
AX637375
LOCUS        AX637375 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION   Sequence 4514 from Patent EP1260586.
ACCESSION    AX637375
VERSION      AX637375.1 GI:28472989
KEYWORDS
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1
AUTHORS      Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
              Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
              Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
              Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
              Woolf,T.
TITLE        Method and reagent for inhibiting the expression of disease related
genes
JOURNAL      Patent: EP 1260586-A 4514 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source       1. .15
              /organism="unidentified"
              /mol_type="mRNA"
              /db_xref="taxon:32644"
BASE COUNT   4 a - 0 c 0 g 11 t
              Query Match 1.0%; Score 12; DB 1; Length 15;
              Best Local Similarity 100.0%; Pred. No. 5.2e+02;
              Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATT 1049
Db 4 TATTATTATT 15

RESULT 896
AX637377
LOCUS        AX637377 15 bp mRNA linear PAT 24-FEB-2003
DEFINITION   Sequence 4516 from Patent EP1260586.
ACCESSION    AX637377
VERSION      AX637377.1 GI:28472991
KEYWORDS
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1
AUTHORS      Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
              Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
              Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
              Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
              Woolf,T.
TITLE        Method and reagent for inhibiting the expression of disease related
genes
JOURNAL      Patent: EP 1260586-A 4516 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source       1. .15
              /organism="unidentified"
              /mol_type="mRNA"
              /db_xref="taxon:32644"
BASE COUNT   4 a - 0 c 0 g 11 t
              Query Match 1.0%; Score 12; DB 1; Length 15;
              Best Local Similarity 100.0%; Pred. No. 5.2e+02;
              Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATT 1049
Db 4 TATTATTATT 15

RESULT 897
AX637407
LOCUS        AX637407 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION   Sequence 4546 from Patent EP1260586.
ACCESSION    AX637407
VERSION      AX637407.1 GI:28473021
KEYWORDS
SOURCE       unidentified
ORGANISM     unidentified
REFERENCE    1
AUTHORS      Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
              Karpelsky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
              Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
              Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
              Woolf,T.
TITLE        Method and reagent for inhibiting the expression of disease related
genes
JOURNAL      Patent: EP 1260586-A 4546 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source       1. .15
              /organism="unidentified"
              /mol_type="mRNA"
              /db_xref="taxon:32644"
BASE COUNT   4 a - 0 c 0 g 11 t
              Query Match 1.0%; Score 12; DB 1; Length 15;
              Best Local Similarity 100.0%; Pred. No. 5.2e+02;
              Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1038 TATTATTATT 1049
Db 4 TATTATTATT 15

```

```

SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 4546 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  4 a 0 c 0 g 11 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1038 TATTATTATT 1049
Db 4 TATTATTATT 15
RESULT 898
AX637423 LOCUS AX637423 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4562 from Patent EP1260586.
ACCESSION AX637423
VERSION AX637423.1 GI:28473037
KEYWORDS
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 4562 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  4 a 0 c 2 g 9 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1050 ATGTATTATT 1061
Db 4 ATGTATTATT 15
RESULT 899
AX637424 LOCUS AX637424 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4563 from Patent EP1260586.
ACCESSION AX637424
VERSION AX637424.1 GI:28473038
KEYWORDS
SOURCE      unidentified

```

```

ORGANISM    unidentified
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 4563 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  4 a 0 c 3 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1050 ATGTATTATT 1061
Db 2 ATGTATTATT 13
RESULT 900
AX637425 LOCUS AX637425 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 4564 from Patent EP1260586.
ACCESSION AX637425
VERSION AX637425.1 GI:28473039
KEYWORDS
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE   1
AUTHORS     Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,
            Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,
            McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
            Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
            Woolf,T.
TITLE       Method and reagent for inhibiting the expression of disease related
            genes
JOURNAL     Patent: EP 1260586-A 4564 27-NOV-2002;
            RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES    source
            1..15
            /organism="unidentified"
            /mol_type="mRNA"
            /db_xref="taxon:32644"
BASE COUNT  4 a 0 c 3 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1050 ATGTATTATT 1061
Db 1 ATGTATTATT 12
RESULT 901
AX638328/c LOCUS AX638328 15 bp mRNA linear PAT 21-FEB-2003
DEFINITION Sequence 5467 from Patent EP1260586.
ACCESSION AX638328
VERSION AX638328.1 GI:28473942
KEYWORDS
SOURCE      unidentified

```



unclassified.

REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES source 1. .15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
BASE COUNT 8 a 2 c 1 g 4 t  
Query Match 1.0%; Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 525 ATTTGAATTTC A 536  
|||||  
Db 12 ATTTGAATTTC A 1

RESULT 902  
AX638404/C  
LOCUS AX638404 15 bp mRNA linear PAT 21-FEB-2003  
DEFINITION Sequence 5543 from Patent EP1260586.  
ACCESSION AX638404  
VERSION AX638404.1 GI:28474018  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.

REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J., McSwiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES source 1. .15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
BASE COUNT 8 a 1 c 1 g 5 t  
Query Match 1.0%; Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1524 ATATTTTAACT 1535  
|||||  
Db 15 ATATTTTAACT 4

RESULT 903  
BD066009  
LOCUS BD066009 15 bp DNA linear PAT 27-AUG-2002  
DEFINITION An antisense oligonucleotide preparation method.  
ACCESSION BD066009  
VERSION BD066009.1 GI:22611612  
KEYWORDS JP 2001511000-A/644.  
SOURCE unidentified  
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 15)  
AUTHORS Schlingensiefen,K.H. and Brysch,W.  
TITLE An antisense oligonucleotide preparation method  
JOURNAL Patent: JP 2001511000-A 644 07-AUG-2001;  
COMMENT BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH  
OS Unknown  
PN JP 2001511000-A/644  
PD 07-AUG-2001  
PF 30-JAN-1998 JP 1998532533  
PR 31-JAN-1997 EP 97101531.8  
PI KARL HERMANN SCHLINGENSIEFEN,WOLFGANG BRYSCH  
PC C12N15/11,C07H21/04,A61K31/70  
CC An antisense oligonucleotide preparation method FH Key  
Location/Qualifiers  
FT source 1. .15  
/organism="Unknown".  
FEATURES source 1. .15  
Location/Qualifiers  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
BASE COUNT 5 a 1 c 1 g 8 t  
Query Match 1.0%; Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 TTTTGAATATAA 646  
|||||  
Db 4 TTTTGAATATAA 15

RESULT 904  
BD066159  
LOCUS BD066159 15 bp DNA linear PAT 27-AUG-2002  
DEFINITION An antisense oligonucleotide preparation method.  
ACCESSION BD066159  
VERSION BD066159.1 GI:22611762  
KEYWORDS JP 2001511000-A/794.  
SOURCE unidentified  
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 15)  
AUTHORS Schlingensiefen,K.H. and Brysch,W.  
TITLE An antisense oligonucleotide preparation method  
JOURNAL Patent: JP 2001511000-A 794 07-AUG-2001;  
COMMENT BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH  
OS Unknown  
PN JP 2001511000-A/794  
PD 07-AUG-2001  
PF 30-JAN-1998 JP 1998532533  
PR 31-JAN-1997 EP 97101531.8  
PI KARL HERMANN SCHLINGENSIEFEN,WOLFGANG BRYSCH  
PC C12N15/11,C07H21/04,A61K31/70  
CC An antisense oligonucleotide preparation method FH Key  
Location/Qualifiers  
FT source 1. .15  
/organism="Unknown".  
FEATURES source 1. .15  
Location/Qualifiers  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
BASE COUNT 5 a 1 c 1 g 8 t  
Query Match 1.0%; Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1293 TCTGAATTTTAA 1304  
|||||  
Db 1 TCTGAATTTTAA 12

BASE COUNT 5 a 0 c 1 g 9 t

Query Match 1.0%; Score 12; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1052 GTATTATTAA 1063  
 |||||  
 Db 3 GTATTATTAA 14

RESULT 908  
 I39130  
 LOCUS I39130 15 bp DNA linear PAT 13-MAY-1997  
 DEFINITION Sequence 168 from patent US 5616488.  
 ACCESSION I39130  
 VERSION I39130.1 GI:2083610  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.  
 TITLE IL-5 targeted ribozymes  
 JOURNAL Patent: US 5616488-A 188 01-APR-1997;  
 FEATURES Location/Qualifiers  
 1..15  
 source

BASE COUNT 5 a 0 c 2 g 8 t

Query Match 1.0%; Score 12; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1052 GTATTATTAA 1063  
 |||||  
 Db 2 GTATTATTAA 13

RESULT 909  
 I39140/c  
 LOCUS I39140 15 bp DNA linear PAT 13-MAY-1997  
 DEFINITION Sequence 178 from patent US 5616488.  
 ACCESSION I39140  
 VERSION I39140.1 GI:2083620  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.  
 TITLE IL-5 targeted ribozymes  
 JOURNAL Patent: US 5616488-A 178 01-APR-1997;  
 FEATURES Location/Qualifiers  
 1..15  
 source

BASE COUNT 9 a 2 c 0 g 4 t

Query Match 1.0%; Score 12; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1169 TGTATTATAGA 1180  
 |||||  
 Db 13 TGTATTATAGA 2

RESULT 910  
 I77804/c  
 LOCUS I77804 15 bp DNA linear PAT 03-APR-1998  
 DEFINITION Sequence 511 from patent US 5693532.  
 ACCESSION I77804

RESULT 905  
 I35095/c  
 LOCUS I35095 15 bp DNA linear PAT 13-MAY-1997  
 DEFINITION Sequence 63 from patent US 559706.  
 ACCESSION I35095  
 VERSION I35095.1 GI:2088063  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Stinchcomb, D.T., McSwiggen, J., Newton, R.S. and Ramharack, R.  
 TITLE Ribozymes targeted to apo(a) mRNA  
 JOURNAL Patent: US 559706-A 63 04-FEB-1997;  
 FEATURES Location/Qualifiers  
 1..15  
 source

BASE COUNT 3 a 6 c 2 g 4 t

Query Match 1.0%; Score 12; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 963 GTGTGAGGACA 974  
 |||||  
 Db 13 GTGTGAGGACA 2

RESULT 906  
 I39128  
 LOCUS I39128 15 bp DNA linear PAT 13-MAY-1997  
 DEFINITION Sequence 166 from patent US 5616488.  
 ACCESSION I39128  
 VERSION I39128.1 GI:2083608  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.  
 TITLE IL-5 targeted ribozymes  
 JOURNAL Patent: US 5616488-A 166 01-APR-1997;  
 FEATURES Location/Qualifiers  
 1..15  
 source

BASE COUNT 5 a 0 c 1 g 9 t

Query Match 1.0%; Score 12; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1052 GTATTATTAA 1063  
 |||||  
 Db 4 GTATTATTAA 15

RESULT 907  
 I39129  
 LOCUS I39129 15 bp DNA linear PAT 13-MAY-1997  
 DEFINITION Sequence 167 from patent US 5616488.  
 ACCESSION I39129  
 VERSION I39129.1 GI:2083609  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 15)  
 AUTHORS Sullivan, S., Draper, K.G., McSwiggen, J. and Stinchcomb, D.T.  
 TITLE IL-5 targeted ribozymes  
 JOURNAL Patent: US 5616488-A 167 01-APR-1997;  
 FEATURES Location/Qualifiers  
 1..15  
 source

Query Match	1.0%; Score 12; DB 1; Length 16;	
Best Local Similarity	100.0%; Pred. No. 5.8e+02;	
Matches 12; Conservative	0; Mismatches	0; Gaps 0;
QY	635 TTTTGAATATAA 646	
Db		
	5 TTTTGAATATAA 16	
RESULT 913		
A88647		
LOCUS	A88647 16 bp DNA linear	PAT 22-JAN-2000
DEFINITION	Sequence 795 from Patent WO9833904.	
ACCESSION	A88647	
VERSION	A88647.1 GI:6737217	
KEYWORDS	unidentified	
SOURCE	unidentified	
ORGANISM	unclassified.	
REFERENCE	1 (bases 1 to 16)	
AUTHORS	Brysch,W.D. and Schlingensiepen,K.	
TITLE	AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD	
JOURNAL	PATENT: WO 9833904-A 795 06-AUG-1998;	
FEATURES	BIOGNOSTIK GBS (DE); BRYSCH WOLFGANG (DE)	
Source	Location/Qualifiers	
	1..16	
	/organism="unidentified"	
	/mol_type="genomic DNA"	
	/db_xref="taxon:32644"	9 t
BASE COUNT	5 a 1 c 1 g	
Query Match	1.0%; Score 12; DB 1; Length 16;	
Best Local Similarity	100.0%; Pred. No. 5.8e+02;	
Matches 12; Conservative	0; Mismatches	0; Gaps 0;
QY	1293 TCTGAATTTTA 1304	
Db		
	2 TCTGAATTTTA 13	
RESULT 914		
A90464		
LOCUS	A90464 16 bp DNA linear	PAT 22-JAN-2000
DEFINITION	Sequence 645 from Patent EP0856579.	
ACCESSION	A90464	
VERSION	A90464.1 GI:6738978	
KEYWORDS	unidentified	
SOURCE	unidentified	
ORGANISM	unclassified.	
REFERENCE	1 (bases 1 to 16)	
AUTHORS	Brysch,W.D. and Schlingensiepen,K.D.	
TITLE	AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD	
JOURNAL	PATENT: EP 0856579-A 645 05-AUG-1998;	
FEATURES	BIOGNOSTIK GBS (DE)	
source	Location/Qualifiers	
	1..16	
	/organism="unidentified"	
	/mol_type="genomic DNA"	
	/db_xref="taxon:32644"	9 t
BASE COUNT	5 a 1 c 1 g	
Query Match	1.0%; Score 12; DB 1; Length 16;	
Best Local Similarity	100.0%; Pred. No. 5.8e+02;	
Matches 12; Conservative	0; Mismatches	0; Gaps 0;
QY	635 TTTTGAATATAA 646	
Db		
	5 TTTTGAATATAA 16	
RESULT 915		
A90614		

I77804.1 GI:3013958					
Unknown.					
Source Unknown.					
Organism Unclassified.					
REFERENCE 1 (bases 1 to 15)					
AUTHORS McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.					
TITLE Respiratory syncytial virus ribozymes					
JOURNAL Patent: US 5693532-A 511 02-DEC-1997;					
FEATURES Location/Qualifiers					
source 1..15					
BASE COUNT 8 a 2 c 1 g 4 t					
Query Match 1.0%; Score 12; DB 1; Length 15;					
Best Local Similarity 100.0%; Pred.No. 5.2e+02;					
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
 QY 525 ATTGAATTCA 536					
DB 12 ATTGAATTCA 1					
RESULT 911					
I77891/c					
LOCUS 177891 15 bp DNA linear PAT 03-APR-1998					
DEFINITION Sequence 598 from patent US 5693532.					
ACCESSION 177891					
VERSION 177891.1 GI:3014045					
KEYWORDS Location/Qualifiers					
SOURCE 1..15					
ORGANISM /organism="unknown"					
Unclassified.					
REFERENCE 1 (bases 1 to 15)					
AUTHORS McSwiggen,J., Draper,K., Pavco,P. and Woolf,T.					
TITLE Respiratory syncytial virus ribozymes					
JOURNAL Patent: US 5693532-A 598 02-DEC-1997;					
FEATURES Location/Qualifiers					
source 1..15					
BASE COUNT 8 a 1 c 1 g 5 t					
Query Match 1.0%; Score 12; DB 1; Length 15;					
Best Local Similarity 100.0%; Pred.No. 5.2e+02;					
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;					
 QY 1524 ATATTTTAACT 1535					
DB 15 ATATTTTAACT 4					
RESULT 912					
A88497					
LOCUS A88497 16 bp DNA linear PAT 22-JAN-2000					
DEFINITION Sequence 645 from Patent WO9833904.					
ACCESSION A88497					
VERSION A88497.1 GI:6737067					
KEYWORDS					
SOURCE unidentified					
ORGANISM unidentified					
Unclassified.					
REFERENCE 1 (bases 1 to 16)					
AUTHORS Brysch,W. and Schlingensiepen,K.					
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD					
JOURNAL Patent: WO 9833904-A 645 06-AUG-1998;					
FEATURES BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)					
Location/Qualifiers					
source 1..16					
/organism="unidentified"					
/mol_type="genomic DNA"					
/db_xref="taxon:3264"					
BASE COUNT 5 a 1 c 1 g 9 t					



VERSION AX736998.1 GI:30516286  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Rukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telesman,A., Anson,R. and Tuijinder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments  
JOURNAL Patent: WO 03025177-A 2588 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 8 a 3 c 1 g 5 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 769 ATCATATAAA 780  
Db 2 ATCATATAAA 13  
RESULT 920  
LOCUS A88498 17 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 646 from Patent WO9833904.  
ACCESSION A88498  
VERSION A88498.1 GI:6737068  
KEYWORDS unidentified  
SOURCE unclassified.  
ORGANISM 1 (bases 1 to 17)  
AUTHORS Brysch,W. and Schlingensiepen,K.  
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD  
JOURNAL Patent: WO 9833904-A 646 06-AUG-1998;  
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)  
FEATURES source  
1. .17  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
BASE COUNT 5 a 1 c 1 g 10 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 635 TTTTGAATATAA 646  
Db 6 TTTTGAATATAA 17  
RESULT 921  
LOCUS A90465 17 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 646 from Patent EP0856579.  
ACCESSION A90465  
VERSION A90465.1 GI:6738979  
KEYWORDS unidentified  
SOURCE unclassified.  
ORGANISM 1 (bases 1 to 17)  
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.  
TITLE An antisense oligonucleotide preparation method

JOURNAL Patent: EP 0856579-A 646 05-AUG-1998;  
BIOGNOSTIK GES (DE)  
FEATURES source  
1. .17  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
BASE COUNT 5 a 1 c 1 g 10 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 635 TTTTGAATATAA 646  
Db 6 TTTTGAATATAA 17  
RESULT 922  
LOCUS AR047246 17 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 2039 from patent US 5817796.  
ACCESSION AR047246  
VERSION AR047246.1 GI:5968711  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.  
TITLE C-myc ribozymes having 2'-5'-linked adenylate residues  
JOURNAL Patent: US 5817796-A 2039 06-OCT-1998;  
FEATURES source  
1. .17  
/organism="unknown"  
BASE COUNT 5 a 0 c 3 g 9 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 544 ATGAATAGTTTT 555  
Db 3 ATGAATAGTTTT 14  
RESULT 923  
LOCUS AR186564 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 2052 from patent US 6346398.  
ACCESSION AR186564  
VERSION AR186564.1 GI:20232529  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 2052 12-FEB-2002;  
FEATURES source  
1. .17  
/organism="unknown"  
BASE COUNT 6 a 3 c 2 g 6 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 441 CTTCAAGCAAT 452  
Db 6 CTTCAAGCAAT 17

related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 2 c 3 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
6 ATTTTCAAGTGT 17									
Db									
RESULT 927									
AR190443									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5931 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 3 g 9 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
5 ATTTTCAAGTGT 16									
Db									
RESULT 928									
AR190444									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5932 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 926									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 925									
AR187326									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 2814 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
2 a 1 c 6 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1578 CTGATTGTTATGG 1589									
1 CTGATTGTTATGG 12									
Db									
RESULT 924									
AR187325									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 2813 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
3 a 1 c 7 g 6 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1578 CTGATTGTTATGG 1589									
4 CTGATTGTTATGG 15									
Db									
RESULT 923									
AR187325									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 2814 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
2 a 1 c 6 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1578 CTGATTGTTATGG 1589									
1 CTGATTGTTATGG 12									
Db									
RESULT 922									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 921									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 920									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 919									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 918									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 917									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 916									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 915									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 914									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 913									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 912									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 911									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 910									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 909									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 908									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									
4 ATTTTCAAGTGT 15									
Db									
RESULT 907									
AR190442									
LOCUS									
DEFINITION									
ACCESSION									
VERSION									
KEYWORDS									
SOURCE									
ORGANISM									
REFERENCE									
1 (bases 1 to 17)									
Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.									
Method and reagent for the treatment of diseases or conditions									
related to levels of vascular endothelial growth factor receptor									
Patent: US 6346398-A 5930 12-FEB-2002;									
Location/Qualifiers									
1. .17									
/organism="unknown"									
4 a 1 c 4 g 8 t									
Query Match									
Best Local Similarity 1.0%; Score 12; DB 1; Length 17;									
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 1014 ATTTTCAAGTGT 1025									

RESULT 929  
AX214676/c  
LOCUS AX214676 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 118 from Patent WO0159103.  
ACCESSION AX214676  
VERSION AX214676.1 GI:15524719  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 118 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source  
location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
BASE COUNT 8 a 1 c 4 g 4 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 839 TCTGTTAAATCT 850  
Db 16 TCTGTTAAATCT 5  
RESULT 930  
AX214677/c  
LOCUS AX214677 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 119 from Patent WO0159103.  
ACCESSION AX214677  
VERSION AX214677.1 GI:15524720  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 119 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source  
location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
BASE COUNT 7 a 1 c 4 g 5 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 839 TCTGTTAAATCT 850  
Db 15 TCTGTTAAATCT 4  
RESULT 931  
AX214678/c  
LOCUS AX214678 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 120 from Patent WO0159103.

ACCESSION AX214678  
VERSION AX214678.1 GI:15524721  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 120 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source  
location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
BASE COUNT 7 a 1 c 4 g 5 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 839 TCTGTTAAATCT 850  
Db 14 TCTGTTAAATCT 3  
RESULT 932  
AX214795  
LOCUS AX214795 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 237 from Patent WO0159103.  
ACCESSION AX214795  
VERSION AX214795.1 GI:15524838  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 237 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US); McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source  
location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
BASE COUNT 14 a 0 c 2 g 1 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1091 AAAAATAGAAGA 1102  
Db 3 AAAAATAGAAGA 14  
RESULT 933  
AX214989  
LOCUS AX214989 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 431 from Patent WO0159103.  
ACCESSION AX214989  
VERSION AX214989.1 GI:15525032  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM

artificial sequences.

REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 433 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
5 a 1 c 9 t  
BASE COUNT 5 a 1 c 9 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 913 TTTATTTCTAAG 924  
|||||  
Db 4 TTTATTTCTAAG 15

RESULT 934  
AX214990  
LOCUS AX214990 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 432 from Patent WO0159103.  
ACCESSION AX214990  
VERSION AX214990.1 GI:15525033  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 432 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
6 a 1 c 8 t  
BASE COUNT 6 a 1 c 8 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 913 TTTATTTCTAAG 924  
|||||  
Db 3 TTTATTTCTAAG 14

RESULT 935  
AX214991  
LOCUS AX214991 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 433 from Patent WO0159103.  
ACCESSION AX214991  
VERSION AX214991.1 GI:15525034  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression

JOURNAL Patent: WO 0159103-A 433 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
6 a 1 c 7 t  
BASE COUNT 6 a 1 c 7 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 913 TTTATTTCTAAG 924  
|||||  
Db 2 TTTATTTCTAAG 13

RESULT 936  
AX215858  
LOCUS AX215858 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 1300 from Patent WO0159103.  
ACCESSION AX215858  
VERSION AX215858.1 GI:15525901  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 1300 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="synthetic construct"  
/mol\_type="mRNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"  
5 a 2 c 7 t  
BASE COUNT 5 a 2 c 7 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 913 TTTATTTCTAAG 924  
|||||  
Db 2 TTTATTTCTAAG 13

RESULT 937  
AX216684/c  
LOCUS AX216684 17 bp mRNA linear PAT 07-SEP-2001  
DEFINITION Sequence 2126 from Patent WO0159103.  
ACCESSION AX216684  
VERSION AX216684.1 GI:15526745  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 2126 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source Location/Qualifiers  
1. .17



/organism="synthetic construct"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:32630"  
 /note="Nucleic Acid"  
 6 a 1 c 4 g 6 t  
 BASE COUNT 6 a 1 c 4 g 6 t  
 Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 839 TCTGTTAAACT 850  
 Db 13 TCTGTTAAACT 2  
 RESULT 938  
 AX216730  
 LOCUS 17 bp mRNA linear PAT 07-SEP-2001  
 DEFINITION Sequence 2172 from Patent WO0159103.  
 ACCESSION AX216730  
 VERSION AX216730.1 GI:15526791  
 KEYWORDS  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 REFERENCE 1  
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
 TITLE Method and reagent for the modulation and diagnosis of cd20 and  
 JOURNAL nogo gene expression  
 PATENT: WO 0159103-A 2172 16-AUG-2001;  
 RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
 McSwiggen, James (US); Chowrira, Bharat M. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="synthetic construct"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:32630"  
 /note="Nucleic Acid"  
 14 a 0 c 2 g 1 t  
 BASE COUNT 14 a 0 c 2 g 1 t  
 Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1091 AAAAATAGAAGA 1102  
 Db 5 AAAAATAGAAGA 16  
 RESULT 939  
 AX217071  
 LOCUS 17 bp mRNA linear PAT 07-SEP-2001  
 DEFINITION Sequence 2513 from Patent WO0159103.  
 ACCESSION AX217071  
 VERSION AX217071.1 GI:15527132  
 KEYWORDS  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 REFERENCE 1  
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
 TITLE Method and reagent for the modulation and diagnosis of cd20 and  
 JOURNAL nogo gene expression  
 PATENT: WO 0159103-A 2513 16-AUG-2001;  
 RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
 McSwiggen, James (US); Chowrira, Bharat M. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="synthetic construct"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:32630"  
 /note="Nucleic Acid"  
 13 a 0 c 3 g 1 t  
 BASE COUNT 13 a 0 c 3 g 1 t

Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1091 AAAAATAGAAGA 1102  
 Db 2 AAAAATAGAAGA 13  
 RESULT 940  
 AX263260/c  
 LOCUS 17 bp DNA linear PAT 26-OCT-2001  
 DEFINITION Sequence 651 from Patent WO0173002.  
 ACCESSION AX263260  
 VERSION AX263260.1 GI:16512059  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 REFERENCE 1  
 AUTHORS Knies, E.B., Gamper, H.B. and Rice, M.C.  
 TITLE Targeted chromosomal genomic alterations with modified single  
 JOURNAL stranded oligonucleotides  
 PATENT: WO 0173002-A 651 04-OCT-2001;  
 UNIVERSITY OF DELAWARE (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 7 a 2 c 3 g 5 t  
 BASE COUNT 7 a 2 c 3 g 5 t  
 Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1293 TCTGAAATTTTA 1304  
 Db 12 TCTGAAATTTTA 1  
 RESULT 941  
 AX263261  
 LOCUS 17 bp DNA linear PAT 26-OCT-2001  
 DEFINITION Sequence 652 from Patent WO0173002.  
 ACCESSION AX263261  
 VERSION AX263261.1 GI:16512060  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 REFERENCE 1  
 AUTHORS Knies, E.B., Gamper, H.B. and Rice, M.C.  
 TITLE Targeted chromosomal genomic alterations with modified single  
 JOURNAL stranded oligonucleotides  
 PATENT: WO 0173002-A 652 04-OCT-2001;  
 UNIVERSITY OF DELAWARE (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 5 a 3 c 2 g 7 t  
 BASE COUNT 5 a 3 c 2 g 7 t  
 Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1293 TCTGAAATTTTA 1304



REFERENCE 1  
 AUTHORS Zhan,J.  
 TITLE Human testis expressed patched like protein  
 JOURNAL Patent: EP 1229046-A 1667 07-AUG-2002;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"

BASE COUNT 2 a 2 c 2 g 11 t

Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 680 AATAGCAAAAT 691

Db 17 AATAGCAAAAT 6

RESULT 947

AX500361/C  
 LOCUS AX500361 17 bp DNA linear PAT 27-SEP-2002  
 DEFINITION Sequence 1668 from Patent EP1229046.  
 ACCESSION AX500361  
 VERSION AX500361.1 GI:23382654  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Zhan,J.  
 TITLE Human testis expressed patched like protein  
 JOURNAL Patent: EP 1229046-A 1668 07-AUG-2002;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"

BASE COUNT 2 a 1 c 2 g 12 t

Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 680 AATAGCAAAAT 691

Db 16 AATAGCAAAAT 5

RESULT 948

AX500436  
 LOCUS AX500436 17 bp DNA linear PAT 27-SEP-2002  
 DEFINITION Sequence 1743 from Patent EP1229046.  
 ACCESSION AX500436  
 VERSION AX500436.1 GI:23382729  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Zhan,J.  
 TITLE Human testis expressed patched like protein  
 JOURNAL Patent: EP 1229046-A 1743 07-AUG-2002;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"

BASE COUNT 4 a 3 c 5 g 5 t

Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1442 TGCTGTTGAAA 1453

Db 6 TGCTGTTGAAA 17

RESULT 949

AX500437  
 LOCUS AX500437 17 bp DNA linear PAT 27-SEP-2002  
 DEFINITION Sequence 1744 from Patent EP1229046.  
 ACCESSION AX500437  
 VERSION AX500437.1 GI:23382730  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Zhan,J.  
 TITLE Human testis expressed patched like protein  
 JOURNAL Patent: EP 1229046-A 1744 07-AUG-2002;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"

BASE COUNT 5 a 3 c 4 g 5 t

Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1442 TGCTGTTGAAA 1453

Db 5 TGCTGTTGAAA 16

RESULT 950

AX500438  
 LOCUS AX500438 17 bp DNA linear PAT 27-SEP-2002  
 DEFINITION Sequence 1745 from Patent EP1229046.  
 ACCESSION AX500438  
 VERSION AX500438.1 GI:23382731  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Zhan,J.  
 TITLE Human testis expressed patched like protein  
 JOURNAL Patent: EP 1229046-A 1745 07-AUG-2002;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
 source 1..17  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"

BASE COUNT 6 a 2 c 4 g 5 t

Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1442 TGCTGTTGAAA 1453

|||||

```
Db 4 TGCTGGTTGAAA 15

RESULT 951
AX500439
LOCUS AX500439 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1746 from Patent EP1229046.
ACCESSION AX500439
VERSION AX500439.1 GI:23382732
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1746 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 1 c 5 g 5 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1442 TGCTGGTTGAAA 1453
Db 3 TGCTGGTTGAAA 14

RESULT 952
AX500440
LOCUS AX500440 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1747 from Patent EP1229046.
ACCESSION AX500440
VERSION AX500440.1 GI:23382733
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1747 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 6 a 1 c 6 g 4 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1442 TGCTGGTTGAAA 1453
Db 2 TGCTGGTTGAAA 13

RESULT 953
AX500441
LOCUS AX500441 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 1748 from Patent EP1229046.
ACCESSION AX500441
VERSION AX500441.1 GI:23382734

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
```

```
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Zhan,J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 1748 07-AUG-2002;
Aeomica, Inc. (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 5 a 2 c 6 g 4 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1442 TGCTGGTTGAAA 1453
Db 1 TGCTGGTTGAAA 12

RESULT 954
AX578690/c
LOCUS AX578690/c 17 bp mRNA linear PAT 10-JAN-2003
DEFINITION Sequence 528 from Patent WO0211674.
ACCESSION AX578690
VERSION AX578690.1 GI:27647892
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Thompson,J., Mcswiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
TITLE Method and reagent for the inhibition of calcium activated chloride
channel-1 (Clca-1)
JOURNAL Patent: WO 0211674-A 528 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);
Thompson, James (US)
FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
BASE COUNT 10 a 2 c 6 g 5 t

Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1142 ATTATTATTATT 1153
Db 12 ATTATTATTATT 1

RESULT 955
AX671598/c
LOCUS AX671598 17 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 43 from Patent WO03004526.
ACCESSION AX671598
VERSION AX671598.1 GI:29329946
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
```

**AUTHORS** Telerman,A., Amson,R. and Tuijnder,M.  
**TITLE** Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines  
**JOURNAL** Patent: WO 03004526-A 43 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
**FEATURES** Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 7 a 1 c 2 g 7 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
**QY** 626 ACAAAATAATTTT 637  
|||||  
**Db** 16 ACAAAATAATTTT 5  
**RESULT 956**  
**AX672197/c**  
**LOCUS** AX672197 17 bp DNA linear PAT 27-MAR-2003  
**DEFINITION** Sequence 642 from Patent WO03004526.  
**ACCESSION** AX672197  
**VERSION** AX672197.1 GI:29330545  
**KEYWORDS** Homo sapiens (human)  
**SOURCE** Homo sapiens  
**ORGANISM** Homo sapiens  
**REFERENCE** 1  
**AUTHORS** Telerman,A., Amson,R. and Tuijnder,M.  
**TITLE** Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines  
**JOURNAL** Patent: WO 03004526-A 642 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
**FEATURES** Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 9 a 1 c 2 g 5 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
**QY** 1041 TTATTATTATG 1052  
|||||  
**Db** 15 TTATTATTATG 4  
**RESULT 957**  
**AX672415**  
**LOCUS** AX672415 17 bp DNA linear PAT 27-MAR-2003  
**DEFINITION** Sequence 860 from Patent WO03004526.  
**ACCESSION** AX672415  
**VERSION** AX672415.1 GI:29330763  
**KEYWORDS** Homo sapiens (human)  
**SOURCE** Homo sapiens  
**ORGANISM** Homo sapiens  
**REFERENCE** 1  
**AUTHORS** Telerman,A., Amson,R. and Tuijnder,M.  
**TITLE** Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines  
**JOURNAL** Patent: WO 03004526-A 860 16-JAN-2003;

**FEATURES** Molecular Engines Laboratories (FR)  
source 1..17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 4 a 1 c 1 g 11 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
**QY** 1144 TTATTATTATTT 1155  
|||||  
**Db** 6 TTATTATTATTT 17  
**RESULT 958**  
**AX672536/c**  
**LOCUS** AX672536 17 bp DNA linear PAT 27-MAR-2003  
**DEFINITION** Sequence 981 from Patent WO03004526.  
**ACCESSION** AX672536  
**VERSION** AX672536.1 GI:29330884  
**KEYWORDS** Homo sapiens (human)  
**SOURCE** Homo sapiens  
**ORGANISM** Homo sapiens  
**REFERENCE** 1  
**AUTHORS** Telerman,A., Amson,R. and Tuijnder,M.  
**TITLE** Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines  
**JOURNAL** Patent: WO 03004526-A 981 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
**FEATURES** Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
BASE COUNT 7 a 3 c 3 g 4 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
**QY** 1432 AGTAATTTCTTG 1443  
|||||  
**Db** 16 AGTAATTTCTTG 5  
**RESULT 959**  
**AX673577**  
**LOCUS** AX673577 17 bp DNA linear PAT 27-MAR-2003  
**DEFINITION** Sequence 2022 from Patent WO03004526.  
**ACCESSION** AX673577  
**VERSION** AX673577.1 GI:29331925  
**KEYWORDS** Homo sapiens (human)  
**SOURCE** Homo sapiens  
**ORGANISM** Homo sapiens  
**REFERENCE** 1  
**AUTHORS** Telerman,A., Amson,R. and Tuijnder,M.  
**TITLE** Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines  
**JOURNAL** Patent: WO 03004526-A 2022 16-JAN-2003;  
Molecular Engines Laboratories (FR)  
**FEATURES** Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"

```
BASE COUNT      3 a      4 c      2 g      8 t
Query Match      1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 910 TCCTTTATTTCT 921
DB 3 TCCTTTATTTCT 14

RESULT 960
LOCUS AX723158 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 845 from Patent WO03025176.
ACCESSION AX723158
VERSION AX723158.1 GI:30423659
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 845 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source 1..17
Location/Qualifiers
BASE COUNT 6 a 1 c 2 g 8 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 601 TATTTATTTGAA 612
DB 5 TATTTATTTGAA 16

RESULT 961
LOCUS AX723252 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 939 from Patent WO03025176.
ACCESSION AX723252
VERSION AX723252.1 GI:30423753
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 939 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source 1..17
Location/Qualifiers
BASE COUNT 8 a 2 c 3 g 4 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1246 TCAGATAAACAA 1257
DB 3 TCAGATAAACAA 14

RESULT 962
LOCUS AX723252 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 939 from Patent WO03025176.
ACCESSION AX723252
VERSION AX723252.1 GI:30423753
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 939 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source 1..17
Location/Qualifiers
BASE COUNT 8 a 2 c 3 g 4 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1286 TTGTTTATCTGA 1297
DB 14 TTGTTTATCTGA 3

RESULT 963
LOCUS AX725994 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3681 from Patent WO03025176.
ACCESSION AX725994
VERSION AX725994.1 GI:30505337
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025176-A 3681 27-MAR-2003;
FEATURES Molecular Engines Laboratories (FR)
source 1..17
Location/Qualifiers
BASE COUNT 11 a 1 c 1 g 4 t
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1521 TTTATATTTTGA 1532
DB 17 TTTATATTTTGA 6
```

RESULT 964  
AX726152/c  
LOCUS  
DEFINITION Sequence 3839 from Patent WO03025176.  
ACCESSION AX726152  
VERSION AX726152.1 GI:30505495  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE  
1 Telerman, A., Anson, R. and Tuijnder, M.  
AUTHORS  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025176-A 3839 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
Location/Qualifiers  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:10090"  
BASE COUNT 7 a 1 c 2 g 7 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 626 ACAATAATTTT 637  
|||||  
Db 16 ACAATAATTTT 5  
RESULT 965  
AX727032  
LOCUS  
DEFINITION Sequence 4719 from Patent WO03025176.  
ACCESSION AX727032  
VERSION AX727032.1 GI:30506375  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE  
1 Telerman, A., Anson, R. and Tuijnder, M.  
AUTHORS  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025176-A 4719 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
Location/Qualifiers  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:10090"  
BASE COUNT 7 a 1 c 1 g 8 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1503 CATTTTTAAATA 1514  
|||||  
Db 4 CATTTTTAAATA 15  
RESULT 966  
AX727182/c  
LOCUS  
DEFINITION Sequence 429 from Patent WO03025175.  
ACCESSION AX727182  
VERSION AX727182.1 GI:30508138  
KEYWORDS  
SOURCE Homo sapiens (human)

DEFINITION Sequence 4869 from Patent WO03025176.  
ACCESSION AX727182  
VERSION AX727182.1 GI:30506525  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE  
1 Telerman, A., Anson, R. and Tuijnder, M.  
AUTHORS  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025176-A 4869 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
Location/Qualifiers  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:10090"  
BASE COUNT 7 a 3 c 4 g 3 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1240 TTCATTTCAGAT 1251  
|||||  
Db 13 TTCATTTCAGAT 2  
RESULT 967  
AX727214/c  
LOCUS  
DEFINITION Sequence 4901 from Patent WO03025176.  
ACCESSION AX727214  
VERSION AX727214.1 GI:30506557  
KEYWORDS  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE  
1 Telerman, A., Anson, R. and Tuijnder, M.  
AUTHORS  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines  
JOURNAL Patent: WO 03025176-A 4901 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
Location/Qualifiers  
/organism="Mus musculus"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:10090"  
BASE COUNT 6 a 3 c 1 g 7 t  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1158 ATATTAAATGAT 1169  
|||||  
Db 13 ATATTAAATGAT 2  
RESULT 968  
AX728795/c  
LOCUS  
DEFINITION Sequence 429 from Patent WO03025175.  
ACCESSION AX728795  
VERSION AX728795.1 GI:30508138  
KEYWORDS  
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens  
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 429 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
7 a 2 c 2 g 6 t  
BASE COUNT  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1006 CATAAATTATTT 1017  
Db 17 CATAAATTATTT 6  
RESULT 969  
AX730870  
LOCUS AX730870  
DEFINITION Sequence 2504 from Patent WO03025175.  
ACCESSION AX730870  
VERSION AX730870.1 GI:30510213  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
REFERENCE  
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 2504 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
3 a 3 c 3 g 8 t  
BASE COUNT  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1572 CTGTTTCTGATT 1593  
Db 4 CTGTTTCTGATT 15  
RESULT 970  
AX731363  
LOCUS AX731363  
DEFINITION Sequence 2997 from Patent WO03025175.  
ACCESSION AX731363  
VERSION AX731363.1 GI:30510706  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
REFERENCE  
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.

TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 2997 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
4 a 1 c 1 g 11 t  
BASE COUNT  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1144 TTATTTTATTTT 1155  
Db 6 TTATTTTATTTT 17  
RESULT 971  
AX732412  
LOCUS AX732412  
DEFINITION Sequence 4046 from Patent WO03025175.  
ACCESSION AX732412  
VERSION AX732412.1 GI:30511755  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
REFERENCE  
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 4046 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
8 a 3 c 1 g 5 t  
BASE COUNT  
Query Match 1.0%; Score 12; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1457 GTTATTATGTA 1468  
Db 17 GTTATTATGTA 6  
RESULT 972  
AX732979  
LOCUS AX732979  
DEFINITION Sequence 4613 from Patent WO03025175.  
ACCESSION AX732979  
VERSION AX732979.1 GI:30512322  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
REFERENCE  
AUTHORS Telerman, A., Anson, R. and Tuijinder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 4613 27-MAR-2003;  
Molecular Engines Laboratories (FR)



FEATURES source Location/Qualifiers

1..17 /organism="Homo sapiens" /mol\_type="genomic DNA" /db\_xref="taxon:9606" 6 t

BASE COUNT 9 a 1 c 1 g

Query Match 1.0%; Score 12; DB 1; Length 17; Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0; Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1148 TTATTATTAGAT 1159  
|||||

Db 13 TTATTATTAGAT 2

RESULT 973

AX733611 17 bp DNA linear PAT 08-MAY-2003

LOCUS

DEFINITION Sequence 5245 from Patent WO03025175.

ACCESSION AX733611

VERSION AX733611.1 GI:30512954

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

REFERENCE 1 Telerman,A., Anson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines Patent: WO 03025175-A 5245 27-MAR-2003; Molecular Engines Laboratories (FR)

JOURNAL

FEATURES source Location/Qualifiers

1..17 /organism="Homo sapiens" /mol\_type="genomic DNA" /db\_xref="taxon:9606" 4 t

BASE COUNT 8 a 4 c 1 g

Query Match 1.0%; Score 12; DB 1; Length 17; Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0; Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 612 ATCTACAAAAA 623  
|||||

Db 2 ATCTACAAAAA 13

RESULT 974

AX734657/c 17 bp DNA linear PAT 08-MAY-2003

LOCUS

DEFINITION Sequence 247 from Patent WO03025177.

ACCESSION AX734657

VERSION AX734657.1 GI:30513934

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens

REFERENCE 1 Telerman,A., Anson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments Patent: WO 03025177-A 247 27-MAR-2003; Molecular Engines Laboratories (FR)

JOURNAL

FEATURES source Location/Qualifiers

1..17 /organism="Homo sapiens" /mol\_type="genomic DNA" /db\_xref="taxon:9606"

BASE COUNT 7 a 1 c 4 g 5 t

Query Match 1.0%; Score 12; DB 1; Length 17; Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0; Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1240 TTCATTTCAGAT 1251  
|||||

Db 13 TTCATTTCAGAT 2

RESULT 975

BD066011 17 bp DNA linear PAT 27-AUG-2002

LOCUS

DEFINITION An antisense oligonucleotide preparation method.

ACCESSION BD066011

VERSION BD066011.1 GI:22611614

KEYWORDS JP 2001511000-A/646.

SOURCE unidentified

ORGANISM unidentified

REFERENCE 1 (bases 1 to 17) Schlingsiepen,K.H. and Brysch,W. An antisense oligonucleotide preparation method Patent: JP 2001511000-A 646 07-AUG-2001; BIOLOGISCHES INSTITUT FÜR BIOLOGISCHE DIAGNOSTIK MBH

JOURNAL

COMMENT OS Unknown

PN JP 2001511000-A/646

PD 07-AUG-2001

PP 30-JAN-1998 JP 1998532533

PR 31-JAN-1997 EP 97101531.8

PI KARL HERMANN SCHLINGSIEPEN WOLFGANG BRYSCH

PC C12N15/11,C07H21/04,A61K31/70

CC An antisense oligonucleotide preparation method FH Key

FEATURES source Location/Qualifiers

1..17 /organism="Unknown" /mol\_type="genomic DNA" /db\_xref="taxon:32644"

BASE COUNT 5 a 1 c 1 g 10 t

Query Match 1.0%; Score 12; DB 1; Length 17; Best Local Similarity 100.0%; Pred. No. 6.4e+02; Mismatches 0; Indels 0; Gaps 0; Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 TTTTGAATATAA 646  
|||||

Db 6 TTTTGAATATAA 17

RESULT 976

BD067356 17 bp RNA linear PAT 27-AUG-2002

LOCUS

DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors.

ACCESSION BD067356

VERSION BD067356.1 GI:22612959

KEYWORDS JP 2001511003-A/196.

SOURCE unidentified

ORGANISM unidentified

REFERENCE 1 (bases 1 to 17) Akhtar,S., Fell,P. and McSwiggen,J.A. Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors Patent: JP 2001511003-A 196 07-AUG-2001; RIBOZYME PHARMACEUTICALS INC,ASTON UNIV

JOURNAL

COMMENT OS Unidentified

PN JP 2001511003-A/196

PD 07-AUG-2001

```

PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476 04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC related to
CC levels of epidermal growth factor receptors
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Unidentified'.
FT Location/Qualifiers
FT 1..17
FT /organism='unidentified'
FT /mol_type='genomic RNA'
FT /db_xref='taxon:32644'
FT 7 a 1 c 4 g 5 t

BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 723 TAATTCAGGAA 734
DB 5 TAATTCAGGAA 16

RESULT 977
LOCUS
DEFINITION
Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION
VERSION BD067357.1 GI:22612960
KEYWORDS JP 2001511003-A/197.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 197 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT
OS Unidentified
PN JP 2001511003-A/197
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC related to
CC levels of epidermal growth factor receptors
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Unidentified'.
FT Location/Qualifiers
FT 1..17
FT /organism='unidentified'
FT /mol_type='genomic RNA'
FT /db_xref='taxon:32644'
FT 7 a 2 c 3 g 5 t

BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 723 TAATTCAGGAA 734
DB 5 TAATTCAGGAA 16

```

```

DB 4 TAATTCAGGAA 15

RESULT 978
LOCUS
DEFINITION
Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION
VERSION BD067673.1 GI:22613276
KEYWORDS JP 2001511003-A/513.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 513 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT
OS Unidentified
PN JP 2001511003-A/513
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC
CC related to
CC levels of epidermal growth factor receptors
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Unidentified'.
FT Location/Qualifiers
FT 1..17
FT /organism='unidentified'
FT /mol_type='genomic RNA'
FT /db_xref='taxon:32644'
FT 2 a 2 c 4 g 9 t

BASE COUNT
Query Match 1.0%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 6.4e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 550 AGTTTTCATTG 561
DB 6 AGTTTTCATTG 17

RESULT 979
LOCUS
DEFINITION
Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION
VERSION BD067873.1 GI:22613476
KEYWORDS JP 2001511003-A/713.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 713 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT
OS Unidentified
PN JP 2001511003-A/713
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI

```

SAGHIR AKHTAR, PATRICIA FELL, JAMES A MCSWIGGEN PC  
 C12N9/00, C07K14/71  
 CC Strandedness: Single;  
 CC Topology: Linear;  
 CC Enzymatic nucleic acid treatment of diseases or conditions CC  
 related to  
 CC levels of epidermal growth factor receptors  
 FT Key  
 FT source  
 1. .17  
 Location/Qualifiers  
 /organism="Unidentified".  
 1. .17  
 Location/Qualifiers  
 /organism="unidentified"  
 /mol\_type="genomic RNA"  
 /db\_xref="taxon:32644"  
 8 a 1 c 4 g 4 t  
 BASE COUNT 5 a 0 c 3 g 9 t

Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1599 AGTAATATGAA 1610  
 Db 6 AGTAATATGAA 17  
 |||||  
 |||||

RESULT 980  
 I54298  
 LOCUS 17 bp DNA linear PAT 07-OCT-1997  
 DEFINITION Sequence 2039 from patent US 5646042.  
 ACCESSION I54298  
 VERSION I54298.1 GI:2475501  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 Unclassified.  
 1 (bases 1 to 17)  
 AUTHORS Stinchcomb, D.T., Draper, K., McSwiggen, J. and Jarvis, T.  
 TITLE C-myc targeted ribozymes  
 JOURNAL Patent: US 5646042-A 2039 08-JUL-1997;  
 FEATURES  
 source Location/Qualifiers  
 1. .17  
 /organism="unknown"  
 5 a 0 c 3 g 9 t

Query Match 1.0%; Score 12; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 6.4e+02;  
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 544 ATGAATAGTTT 555  
 Db 3 ATGAATAGTTT 14  
 |||||  
 |||||

RESULT 981  
 AR041398/c  
 LOCUS 15 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 188 from patent US 5811300.  
 ACCESSION AR041398  
 VERSION AR041398.1 GI:5961894  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 Unclassified.  
 1 (bases 1 to 15)  
 AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.  
 TITLE TNF- $\alpha$  ribozymes  
 JOURNAL Patent: US 5811300-A 188 22-SEP-1998;  
 FEATURES  
 source Location/Qualifiers  
 1. .15  
 /organism="unknown"  
 5 a 0 c 0 g 10 t

Query Match 0.9%; Score 11.8; DB 1; Length 15;  
 Best Local Similarity 86.7%; Pred. No. 5.8e+02;  
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1251 TAAACACAATAAT 1265  
 Db 15 TAAATAATAATAAT 1  
 |||||  
 |||||

RESULT 982  
 AR041915/c  
 LOCUS 15 bp DNA linear PAT 29-SEP-1999  
 DEFINITION Sequence 705 from patent US 5811300.  
 ACCESSION AR041915  
 VERSION AR041915.1 GI:5962411  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 Unclassified.  
 1 (bases 1 to 15)  
 AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.  
 TITLE TNF- $\alpha$  ribozymes  
 JOURNAL Patent: US 5811300-A 705 22-SEP-1998;  
 FEATURES  
 source Location/Qualifiers  
 1. .15  
 /organism="unknown"  
 5 a 0 c 0 g 10 t

Query Match 0.9%; Score 11.8; DB 1; Length 15;  
 Best Local Similarity 86.7%; Pred. No. 5.8e+02;  
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1251 TAAACACAATAAT 1265  
 Db 15 TAAATAATAATAAT 1  
 |||||  
 |||||

RESULT 983  
 AX636855/c  
 LOCUS 15 bp mRNA linear PAT 21-FEB-2003  
 DEFINITION Sequence 3994 from Patent EP1260586.  
 ACCESSION AX636855  
 VERSION AX636855.1 GI:28472469  
 KEYWORDS  
 SOURCE unidentified  
 ORGANISM unidentified  
 Unclassified.  
 1  
 REFERENCE 1  
 AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Drenzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, P.E. and Woolf, T.  
 TITLE Method and reagent for inhibiting the expression of disease related genes  
 JOURNAL Patent: EP 1260586-A 3994 27-NOV-2002;  
 RIBOZYME PHARMACEUTICALS, INC. (US)  
 FEATURES  
 source Location/Qualifiers  
 1. .15  
 /organism="unidentified"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:32644"  
 5 a 0 c 0 g 10 t

Query Match 0.9%; Score 11.8; DB 1; Length 15;  
 Best Local Similarity 86.7%; Pred. No. 5.8e+02;  
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1251 TAAACACAATAAT 1265  
 Db 15 TAAATAATAATAAT 1  
 |||||  
 |||||

RESULT 984  
AX637379/c AX637379 15 bp mRNA linear PAT 21-FEB-2003  
LOCUS Sequence 4518 from Patent EP1260586.  
DEFINITION AX637379  
ACCESSION AX637379  
VERSION AX637379.1 GI:28472993  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
unclassified.

REFERENCE  
1 Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A.,  
Karpeisky,A., Draper,K.G., Kisch,K., Matulic-Adamic,J.,  
McSwiggan,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,  
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and  
Wolf,T.

TITLE Method and reagent for inhibiting the expression of disease related  
genes

JOURNAL  
Patent: EP 1260586-A 4518 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)

FEATURES  
Source  
1..15  
/organism="unidentified"  
/mol\_type="mRNA"  
/db\_xref="taxon:32644"  
5 a 0 c 0 g 10 t

BASE COUNT 5 a 0 c 0 g 10 t

Query Match 0.9%; Score 11.8; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. NO. 5.8e+02;  
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1251 TAAACACAAATAT 1265  
|||||  
Db 15 TAAATATATATAT 1

Search completed: December 18, 2003, 07:17:26  
Job time : 19 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 18, 2003, 07:20:09 ; Search time 13 Seconds  
(without alignments)  
2.704 Million cell updates/sec

Title: us-09-960-143-3

Perfect score: 1249

Sequence: 1 aaaaattctctctgtggt.....atataattgtgtcaagt 1249

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 835 seqs, 14073 residues

Total number of hits satisfying chosen parameters: 1670

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 984 summaries

Database : rng.seq.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	50	4.0	50	1	Human leukocyte ge
2	50	4.0	50	1	Human leukocyte ge
3	50	4.0	50	1	Human leukocyte ge
4	30	2.4	30	1	Human leukocyte ge
5	30	2.4	30	1	Nucleic acid synth
6	30	2.4	30	1	Nucleic acid synth
7	28.4	2.3	18	1	Interleukin 8 capt
8	26	2.1	26	1	PCR primer, 2767A
9	25	2.0	26	1	PCR primer, 2767A
10	24	1.9	24	1	Human beta thrombo
11	24	1.9	24	1	Human primer #2 to
12	24	1.9	24	1	Electronic microar
13	21	1.7	21	1	Peoriasis suscepti
14	21	1.7	21	1	IL8 hairpin/hammer
15	21	1.7	21	1	IL8 hairpin/hammer
16	21	1.7	21	1	Human interleukin-
17	21	1.7	21	1	Human interleukin-
18	20.8	1.7	24	1	Human nuclear tran
19	20	1.6	20	1	PCR primer for UC
20	20	1.6	20	1	PCR primer for UC
21	20	1.6	20	1	Human interleukin-
22	20	1.6	20	1	Human interleukin-
23	19	1.5	19	1	Human interleukin-
24	19	1.5	19	1	Human IL-8 antisen
25	19	1.5	19	1	Human interleukin-
26	19	1.5	19	1	Low adenosine anti
27	19	1.5	19	1	3' primer used to
28	19	1.5	25	1	Human CKalpha-3 PC
29	18.6	1.5	25	1	Dog genomic marker
30	18.2	1.5	24	1	Human pterin-molyb
31	17.6	1.4	25	1	Glutamate CRNA syn
32	17.4	1.4	21	1	ADUUA RNA target s
33	17.4	1.4	21	1	Human adenylate ur

34	17.4	1.4	21	1	AAL50228	Human ARE-mRNA seq
35	17.4	1.4	21	1	AAL53707	Adenylate Uridylat
36	17.4	1.4	24	1	AAL54044	Human macroprotein
37	17	1.4	24	1	AAT76273	Human MDCNF antise
38	17	1.4	17	1	AAX54070	Monocyte-derived n
39	17	1.4	17	1	AAX19636	Human monocyte der
40	17	1.4	17	1	AAA33514	Low adenosine anti
41	17	1.4	17	1	ABU46341	Human interleukin-
42	16.8	1.3	24	1	AAL45792	Human MGC-2413-31
43	16.8	1.3	24	1	ABA02441	Human CCR4 protein
44	16.6	1.3	26	1	AAD21908	PCR primer, 2767T
45	16.4	1.3	20	1	AAC92878	Human PI3 kinase p
46	16.4	1.3	22	1	AAT01237	Human chromosome 1
47	16.2	1.3	23	1	AAK10028	Human biallelic po
48	16.2	1.3	23	1	AAK33029	Human BRCA2 gene p
49	16.2	1.3	23	1	AAK32150	BRCA2 gene specifi
50	16.2	1.3	23	1	AAK92211	Aurone glycosyl tr
51	15.8	1.3	20	1	AAZ72999	Human biallelic ma
52	15.8	1.3	20	1	AH26837	Human osteoregulin
53	15.8	1.3	21	1	AAV67174	Nucleotide fragmen
54	15.8	1.3	21	1	AAC69186	Human ABC1 gene ex
55	15.8	1.3	21	1	APF93051	ABC1 polymorphism
56	15.6	1.2	22	1	ABQ37635	Porcine PERV locus
57	15.6	1.2	22	1	AAQ64706	2',5'-linked tetra
58	15.6	1.2	26	1	AAD21307	PCR primer, 2767A
59	15.4	1.2	17	1	AAZ22696	Integrin subunit b
60	15.4	1.2	17	1	AAZ22697	Integrin subunit b
61	15.4	1.2	17	1	AAZ22698	Integrin subunit b
62	15.4	1.2	17	1	AAZ22699	Integrin subunit b
63	15.4	1.2	17	1	AAZ22700	Integrin subunit b
64	15.4	1.2	17	1	AAZ22701	Integrin subunit b
65	15.4	1.2	17	1	AAZ22702	Integrin subunit b
66	15.4	1.2	17	1	AAZ22703	Integrin subunit b
67	15.4	1.2	17	1	AAZ22704	Integrin subunit b
68	15.4	1.2	17	1	AAZ22705	Integrin subunit b
69	15.4	1.2	17	1	AAZ22706	Integrin subunit b
70	15.4	1.2	17	1	AAZ22899	Integrin subunit b
71	15.4	1.2	17	1	AAZ22901	Integrin subunit b
72	15.4	1.2	17	1	AAZ22902	Integrin subunit b
73	15.4	1.2	17	1	AAZ22903	Integrin subunit b
74	15.4	1.2	17	1	AAZ22904	Human HTPPL scanin
75	15.4	1.2	17	1	AAV80426	Human adenylate ur
76	15.4	1.2	17	1	AAZ49440	Human ARE-mRNA seq
77	15.4	1.2	17	1	AAL50229	Adenylate Uridylat
78	15.4	1.2	17	1	AAL53708	Cellular inhibitor
79	15.4	1.2	18	1	AAZ41044	Human c-IAP-2 mRNA
80	15.4	1.2	18	1	AAZ22138	3' primer #5 used
81	15.4	1.2	19	1	AD37308	Human MEK3 antise
82	15.4	1.2	20	1	AAZ09117	Human COL9A2 PCR p
83	15.4	1.2	22	1	AAZ22289	Microsatellite rep
84	15.2	1.2	20	1	AAQ32809	Primer pair 10A CD
85	15.2	1.2	20	1	AAQ57832	Human/mouse casein
86	15.2	1.2	20	1	ABG67914	Oligonucleotide #1
87	15.2	1.2	20	1	ABK85435	HIV-1 DNA probe (g
88	15.2	1.2	21	1	AAQ20077	Cross-linking olig
89	15.2	1.2	21	1	AAQ20043	Oligomer IL2R503 f
90	15.2	1.2	21	1	AAQ30408	Oligomer IL2R505 f
91	15.2	1.2	21	1	AAQ30408	Reverse transcript
92	15.2	1.2	21	1	AAQ75643	PCR Primer E475783
93	15.2	1.2	21	1	AAZ29560	Human CD40L promot
94	15.2	1.2	21	1	AAZ74938	Human interleukin-
95	15	1.2	15	1	ABU46344	Human GMXIP-1 17-m
96	15	1.2	17	1	ABN07608	Human GMXIP-1 17-m
97	15	1.2	17	1	ABN07609	Human GMXIP-1 17-m
98	15	1.2	17	1	ABN07610	Human GMXIP-1 17-m
99	15	1.2	20	1	AAQ55403	Acromionum chrysog
100	15	1.2	21	1	AAQ79313	Human c-rai-1 onco
101	14.8	1.2	18	1	AAV14087	Probe HBP253 for
102	14.8	1.2	18	1	AAV90243	GRK4 allele specifi
103	14.8	1.2	18	1	ABU55998	Collagenase recogn
104	14.8	1.2	19	1	AAH82895	cdk4 ribozyme bind
105	14.8	1.2	19	1	AAH58057	Cell-cycle depende
106	14.8	1.2	20	1	AAV11919	Hepatocyte growth

C 107	14.8	1.2	20	1	AA237709	Human mdm2 phospho
C 108	14.8	1.2	20	1	AA298583	Human MAPK kinase
C 109	14.8	1.2	20	1	AAK95469	Neuregulin-1 gene
C 110	14.8	1.2	20	1	AAK96762	Neuregulin-1 gene
C 111	14.8	1.2	20	1	AAK96762	Mouse survivin ant
C 112	14.8	1.2	20	1	AAK96762	Mouse survivin ant
C 113	14.8	1.2	20	1	AAK96762	Human mdm2 antisen
C 114	14.8	1.2	20	1	AAK96762	Human mdm2 phospho
C 115	14.8	1.2	20	1	AAK96762	Casein kinase-2 an
C 116	14.8	1.2	20	1	AAK96762	Human neuregulin-1
C 117	14.8	1.2	20	1	AAK96762	Human neuregulin-1
C 118	14.8	1.2	20	1	AAK96762	Human TNF inducibl
C 119	14.8	1.2	20	1	AAK96762	Neuroblastoma-rela
C 120	14.8	1.2	20	1	AAK96762	Haematopoietic cel
C 121	14.8	1.2	21	1	AAK96762	B. burgdorferi exp
C 122	14.8	1.2	21	1	AAK96762	Human polymorphic
C 123	14.8	1.2	21	1	AAK96762	Human biallelic ma
C 124	14.8	1.2	21	1	AAK96762	Human cell death p
C 125	14.8	1.2	21	1	AAK96762	Per tyrosine kinas
C 126	14.8	1.2	21	1	AAK96762	CytochromeP19 poly
C 127	14.8	1.2	24	1	AAK96762	Human pterin-molyb
C 128	14.4	1.2	16	1	AAK96762	Lebilly pine SSR
C 129	14.4	1.2	16	1	AAK96762	Lebilly pine SSR
C 130	14.4	1.2	16	1	AAK96762	Human ovary specif
C 131	14.4	1.2	17	1	AAK96762	Integrin subunit b
C 132	14.4	1.2	17	1	AAK96762	Integrin subunit b
C 133	14.4	1.2	17	1	AAK96762	Human HTPL scannin
C 134	14.4	1.2	17	1	AAK96762	Human HTPL scannin
C 135	14.4	1.2	17	1	AAK96762	Tumour suppression
C 136	14.4	1.2	18	1	AAK96762	DNA sequencing 'pr
C 137	14.4	1.2	18	1	AAK96762	Haematopoietic cel
C 138	14.4	1.2	20	1	AAK96762	Rat opioid recepto
C 139	14.4	1.2	20	1	AAK96762	Streptococcus pyog
C 140	14.4	1.2	20	1	AAK96762	Human SAPL CDNA sp
C 141	14.4	1.2	19	1	AAK96762	Cry2A family gene
C 142	14.2	1.1	19	1	AAK96762	cdk7 ribozyme bind
C 143	14.2	1.1	19	1	AAK96762	Cell-cycle depende
C 144	14.2	1.1	19	1	AAK96762	PCR primer Lp132R
C 145	14.2	1.1	19	1	AAK96762	Haematopoietic cel
C 146	14.2	1.1	20	1	AAK96762	Reverse transcript
C 147	14.2	1.1	20	1	AAK96762	Tyrosinase gene 3'
C 148	14.2	1.1	20	1	AAK96762	Mouse bg critical
C 149	14.2	1.1	20	1	AAK96762	5' fragment #2 of
C 150	14.2	1.1	20	1	AAK96762	PCR primer used to
C 151	14.2	1.1	20	1	AAK96762	PCR primer used to
C 152	14.2	1.1	20	1	AAK96762	PCR primer used to
C 153	14.2	1.1	20	1	AAK96762	PCR primer RF-S4.
C 154	14.2	1.1	20	1	AAK96762	PCR primer RF-S5.
C 155	14.2	1.1	20	1	AAK96762	PCR primer RF-S5.
C 156	14.2	1.1	20	1	AAK96762	Oligonucleotide hy
C 157	14.2	1.1	20	1	AAK96762	Oligonucleotide hy
C 158	14.2	1.1	20	1	AAK96762	Oligonucleotide hy
C 159	14.2	1.1	20	1	AAK96762	Oligonucleotide hy
C 160	14.2	1.1	20	1	AAK96762	S. aureus groG ope
C 161	14.2	1.1	20	1	AAK96762	Nucleotide sequenc
C 162	14.2	1.1	20	1	AAK96762	Casein kinase-2 an
C 163	14.2	1.1	20	1	AAK96762	Human CAS gene ant
C 164	14.2	1.1	20	1	AAK96762	Human syntaxin 4 i
C 165	14.2	1.1	20	1	AAK96762	Human translocatin
C 166	14.2	1.1	20	1	AAK96762	Mouse phospholipas
C 167	14.2	1.1	20	1	AAK96762	Human IFNGR2 antis
C 168	14.2	1.1	20	1	AAK96762	Mouse TNF-a hammer
C 169	14.2	1.1	15	1	AAK96762	Human TNF-alpha ha
C 170	14.2	1.1	15	1	AAK96762	Human TNF-alpha ha
C 171	14.2	1.1	15	1	AAK96762	Human TNF-alpha ha
C 172	14.2	1.1	15	1	AAK96762	Hypocretin recepto
C 173	14.2	1.1	17	1	AAK96762	Human EGF-R target
C 174	14.2	1.1	17	1	AAK96762	Integrin subunit b
C 175	14.2	1.1	17	1	AAK96762	Integrin subunit b
C 176	14.2	1.1	17	1	AAK96762	Integrin subunit b
C 177	14.2	1.1	17	1	AAK96762	Integrin subunit b
C 178	14.2	1.1	17	1	AAK96762	Human genomic SNP
C 179	14.2	1.1	17	1	AAK96762	Human GDMLP-1 17-m
C 180	14.2	1.1	17	1	AAK96762	Human GDMLP-1 17-m
C 181	14.2	1.1	17	1	AAK96762	PCR primer used to
C 182	14.2	1.1	17	1	AAK96762	Chromosome 11 (loc
C 183	14.2	1.1	20	1	AAK96762	PCR primer used to
C 184	14.2	1.1	20	1	AAK96762	Human MAPK kinase
C 185	14.2	1.1	20	1	AAK96762	Simple sequence re
C 186	14.2	1.1	50	1	AAK96762	Human leukocyte ge
C 187	13.8	1.1	17	1	AAK96762	Human c-myc hamme
C 188	13.8	1.1	17	1	AAK96762	Potato citrate syn
C 189	13.8	1.1	17	1	AAK96762	Human TIR-2 subst
C 190	13.8	1.1	17	1	AAK96762	Integrin alpha 6 s
C 191	13.8	1.1	17	1	AAK96762	Integrin alpha 6 s
C 192	13.8	1.1	17	1	AAK96762	Integrin subunit b
C 193	13.8	1.1	17	1	AAK96762	Human C-raf target
C 194	13.8	1.1	17	1	AAK96762	Hammerhead ribozym
C 195	13.8	1.1	17	1	AAK96762	Oestrogen receptor
C 196	13.8	1.1	17	1	AAK96762	Oestrogen receptor
C 197	13.8	1.1	17	1	AAK96762	Oestrogen receptor
C 198	13.8	1.1	17	1	AAK96762	Human HTPL scannin
C 199	13.8	1.1	17	1	AAK96762	Human CLCA1 gene e
C 200	13.8	1.1	17	1	AAK96762	Human K-Ras DNazym
C 201	13.8	1.1	18	1	AAK96762	A. thaliana plant
C 202	13.8	1.1	18	1	AAK96762	Human biallelic po
C 203	13.8	1.1	18	1	AAK96762	Chlamydia Genus sp
C 204	13.8	1.1	18	1	AAK96762	Human biallelic ma
C 205	13.8	1.1	18	1	AAK96762	Human biallelic ma
C 206	13.8	1.1	18	1	AAK96762	Human 2 kinase hamme
C 207	13.8	1.1	18	1	AAK96762	Human GCPII gene e
C 208	13.8	1.1	18	1	AAK96762	Cdc 2 kinase hamme
C 209	13.8	1.1	18	1	AAK96762	Haematopoietic cel
C 210	13.8	1.1	19	1	AAK96762	PCR primer used in
C 211	13.8	1.1	19	1	AAK96762	Ligase Chain React
C 212	13.8	1.1	19	1	AAK96762	Ligase Chain React
C 213	13.8	1.1	19	1	AAK96762	5' end fragment of
C 214	13.8	1.1	19	1	AAK96762	5' end fragment of
C 215	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 216	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 217	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 218	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 219	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 220	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 221	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 222	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 223	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 224	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 225	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 226	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 227	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 228	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 229	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 230	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 231	13.8	1.1	19	1	AAK96762	Capped RNA influen
C 232	13.6	1.1	15	1	AAK96762	rb gene antisense
C 233	13.6	1.1	15	1	AAK96762	Human prostate can
C 234	13.6	1.1	19	1	AAK96762	Human biallelic ma
C 235	13.6	1.1	19	1	AAK96762	cdk-we-hu ribozyme
C 236	13.4	1.1	15	1	AAK96762	cdk-we-hu ribozyme
C 237	13.4	1.1	15	1	AAK96762	Human leukocyte ge
C 238	13.4	1.1	15	1	AAK96762	Human GPR31 gene p
C 239	13.4	1.1	15	1	AAK96762	Nucleotide sequenc
C 240	13.4	1.1	15	1	AAK96762	2',5'-linked tetra
C 241	13.4	1.1	15	1	AAK96762	Nucleic acid synth
C 242	13.4	1.1	15	1	AAK96762	Mouse TNF-a hammer
C 243	13.4	1.1	15	1	AAK96762	Mouse TNF-a hammer
C 244	13.4	1.1	15	1	AAK96762	Mouse TNF-a hammer
C 245	13.4	1.1	15	1	AAK96762	Mouse TNF-a hammer
C 246	13.4	1.1	15	1	AAK96762	Human TNF-alpha ha
C 247	13.4	1.1	15	1	AAK96762	Human TNF-alpha ha
C 248	13.4	1.1	15	1	AAK96762	Human TNF-alpha ha
C 249	13.4	1.1	15	1	AAK96762	Human TNF-alpha ha
C 250	13.4	1.1	15	1	AAK96762	Human TNF-alpha ha
C 251	13.4	1.1	15	1	AAK96762	Human TNF-alpha ha
C 252	13.4	1.1	15	1	AAK96762	Primer 1a used to
C 253	13.4	1.1	15	1	AAK96762	Group 1 intron sub
C 254	13.4	1.1	15	1	AAK96762	Probe ATT-3. Sync
C 255	13.4	1.1	15	1	AAK96762	Primer 1a for tetr
C 256	13.4	1.1	15	1	AAK96762	Human interferon-a
C 257	13.4	1.1	15	1	AAK96762	PTGS2 allele speci

253	13.4	1.1	15	1	AAFA48964	IGFBP3 oligonucleo	IGFBP3 oligonucleo	c 326	13.2	1.1	18	1	ABZ33767	HIV-1 reverse tran
254	13.4	1.1	15	1	AAFA48965	IGFBP3 oligonucleo	IGFBP3 oligonucleo	327	13.2	1.1	18	1	ABL30677	Human HLA gnotyp
255	13.4	1.1	15	1	AAFA48966	IGFBP3 oligonucleo	IGFBP3 oligonucleo	328	13.2	1.1	18	1	ABF79935	EST polymorphic DN
256	13.4	1.1	15	1	AAFA48967	IGFBP3 oligonucleo	IGFBP3 oligonucleo	329	13.2	1.1	18	1	ABZ10470	Haematopoietic cel
257	13.4	1.1	16	1	AAFA48968	DNA cleavage subst	DNA cleavage subst	330	13	1.0	13	1	ABC00856	Oligonucleotide SE
258	13.4	1.1	16	1	AAFA48969	Improved cleavage	Improved cleavage	331	13	1.0	13	1	ABC00857	Oligonucleotide SE
259	13.4	1.1	16	1	AAFA48970	Primer 1 for tetra	Primer 1 for tetra	332	13	1.0	13	1	ABC02380	Oligonucleotide SE
260	13.4	1.1	16	1	AAFA48971	Human uteroglobin	Human uteroglobin	333	13	1.0	13	1	ABC02381	Oligonucleotide SE
261	13.4	1.1	17	1	AAFA48972	Humicola grisea gl	Humicola grisea gl	334	13	1.0	13	1	ABC08774	Oligonucleotide SE
262	13.4	1.1	17	1	AAFA48973	Renilla reniformis	Renilla reniformis	335	13	1.0	13	1	ABC08775	Oligonucleotide SE
263	13.4	1.1	17	1	AAFA48974	Human c-myc hamme	Human c-myc hamme	336	13	1.0	13	1	ABC18132	Oligonucleotide SE
264	13.4	1.1	17	1	AAFA48975	Mouse flt-1 VEGF r	Mouse flt-1 VEGF r	337	13	1.0	13	1	ABC18133	Oligonucleotide SE
265	13.4	1.1	17	1	AAFA48976	Human flt-1 VEGF re	Human flt-1 VEGF re	338	13	1.0	13	1	ABC19108	Oligonucleotide SE
266	13.4	1.1	17	1	AAFA48977	Human flt-1 VEGF re	Human flt-1 VEGF re	339	13	1.0	13	1	ABC19109	Oligonucleotide SE
267	13.4	1.1	17	1	AAFA48978	ASO 2184dAN wild-t	ASO 2184dAN wild-t	340	13	1.0	13	1	ABC19440	Oligonucleotide SE
268	13.4	1.1	17	1	AAFA48979	Integrin alpha 6 s	Integrin alpha 6 s	341	13	1.0	13	1	ABC19441	Oligonucleotide SE
269	13.4	1.1	17	1	AAFA48980	Integrin alpha 6 s	Integrin alpha 6 s	342	13	1.0	13	1	ABC20820	Oligonucleotide SE
270	13.4	1.1	17	1	AAFA48981	Integrin alpha 6 s	Integrin alpha 6 s	343	13	1.0	13	1	ABC20821	Oligonucleotide SE
271	13.4	1.1	17	1	AAFA48982	Integrin alpha 6 s	Integrin alpha 6 s	344	13	1.0	13	1	ABC27496	Oligonucleotide SE
272	13.4	1.1	17	1	AAFA48983	Integrin subunit b	Integrin subunit b	345	13	1.0	13	1	ABC27497	Oligonucleotide SE
273	13.4	1.1	17	1	AAFA48984	Hammerhead ribozym	Hammerhead ribozym	346	13	1.0	13	1	ABC27750	Oligonucleotide SE
274	13.4	1.1	17	1	AAFA48985	Hammerhead ribozym	Hammerhead ribozym	347	13	1.0	13	1	ABC27751	Oligonucleotide SE
275	13.4	1.1	17	1	AAFA48986	Human HTPL scannin	Human HTPL scannin	348	13	1.0	13	1	ABC28094	Oligonucleotide SE
276	13.4	1.1	17	1	AAFA48987	Human HTPL scannin	Human HTPL scannin	349	13	1.0	13	1	ABC28095	Oligonucleotide SE
277	13.4	1.1	17	1	AAFA48988	Human ERG hamme	Human ERG hamme	350	13	1.0	13	1	ABC29508	Oligonucleotide SE
278	13.4	1.1	17	1	AAFA48989	Human ERG hamme	Human ERG hamme	351	13	1.0	13	1	ABC29509	Oligonucleotide SE
279	13.4	1.1	17	1	AAFA48990	Human ADAMTS-M PCR	Human ADAMTS-M PCR	352	13	1.0	13	1	ABC30110	Oligonucleotide SE
280	13.4	1.1	17	1	AAFA48991	Tumour suppression	Tumour suppression	353	13	1.0	13	1	ABC30111	Oligonucleotide SE
281	13.4	1.1	17	1	AAFA48992	Tumour suppression	Tumour suppression	354	13	1.0	13	1	ABC37546	Oligonucleotide SE
282	13.4	1.1	17	1	AAFA48993	Tumour suppression	Tumour suppression	355	13	1.0	13	1	ABC37547	Oligonucleotide SE
283	13.4	1.1	17	1	AAFA48994	Human K-Ras DNazym	Human K-Ras DNazym	356	13	1.0	13	1	ABC37938	Oligonucleotide SE
284	13.4	1.1	17	1	AAFA48995	PCR primer used to	PCR primer used to	357	13	1.0	13	1	ABC37939	Oligonucleotide SE
285	13.4	1.1	17	1	AAFA48996	Human sentrin phos	Human sentrin phos	358	13	1.0	13	1	ABC40556	Oligonucleotide SE
286	13.4	1.1	17	1	AAFA48997	Wild type sequence	Wild type sequence	359	13	1.0	13	1	ABC40557	Oligonucleotide SE
287	13.4	1.1	17	1	AAFA48998	PAF-AH DNA related	PAF-AH DNA related	360	13	1.0	13	1	ABC55322	Oligonucleotide SE
288	13.4	1.1	17	1	AAFA48999	Primer #2 to ampli	Primer #2 to ampli	361	13	1.0	13	1	ABC55323	Oligonucleotide SE
289	13.4	1.1	17	1	AAFA49000	Human IVS17 3'-acc	Human IVS17 3'-acc	362	13	1.0	13	1	ABC61518	Oligonucleotide SE
290	13.4	1.1	17	1	AAFA49001	Human biallelic ma	Human biallelic ma	363	13	1.0	13	1	ABC61519	Oligonucleotide SE
291	13.4	1.1	17	1	AAFA49002	Cyclin C ribozyme	Cyclin C ribozyme	364	13	1.0	13	1	ABC61822	Oligonucleotide SE
292	13.4	1.1	17	1	AAFA49003	Rat adenosine rece	Rat adenosine rece	365	13	1.0	13	1	ABC61823	Oligonucleotide SE
293	13.4	1.1	17	1	AAFA49004	Human inflammatory	Human inflammatory	366	13	1.0	13	1	ABC67270	Oligonucleotide SE
294	13.4	1.1	17	1	AAFA49005	S. aureus groB ope	S. aureus groB ope	367	13	1.0	13	1	ABC67271	Oligonucleotide SE
295	13.4	1.1	17	1	AAFA49006	Cyclin C ribozyme	Cyclin C ribozyme	368	13	1.0	13	1	ABC72812	Oligonucleotide SE
296	13.4	1.1	17	1	AAFA49007	Low abundance nucl	Low abundance nucl	369	13	1.0	13	1	ABC72813	Oligonucleotide SE
297	13.4	1.1	17	1	AAFA49008	Human CYP4501A2 Ex	Human CYP4501A2 Ex	370	13	1.0	13	1	ABC78656	Oligonucleotide SE
298	13.4	1.1	17	1	AAFA49009	Human MGC-2413-31	Human MGC-2413-31	371	13	1.0	13	1	ABC78657	Oligonucleotide SE
299	13.4	1.1	17	1	AAFA49010	Human CCR4 protein	Human CCR4 protein	372	13	1.0	13	1	ABC81442	Oligonucleotide SE
300	13.4	1.1	17	1	AAFA49011	Cross-linking olig	Cross-linking olig	373	13	1.0	13	1	ABC81443	Oligonucleotide SE
301	13.4	1.1	17	1	AAFA49012	Cross-linking olig	Cross-linking olig	374	13	1.0	13	1	ABC83552	Oligonucleotide SE
302	13.2	1.1	18	1	AAQ20152	Oligomer HSV723 fo	Oligomer HSV723 fo	375	13	1.0	13	1	ABC83553	Oligonucleotide SE
303	13.2	1.1	18	1	AAQ20160	Oligomer HSV702 fo	Oligomer HSV702 fo	376	13	1.0	13	1	ABC83558	Oligonucleotide SE
304	13.2	1.1	18	1	AAQ30310	Oligomer HUM beta	Oligomer HUM beta	377	13	1.0	13	1	ABC83569	Oligonucleotide SE
305	13.2	1.1	18	1	AAQ30362	Probe HBP-257 for	Probe HBP-257 for	378	13	1.0	13	1	ABF01934	Oligonucleotide SE
306	13.2	1.1	18	1	AAQ30368	Probe HBP-254 for	Probe HBP-254 for	379	13	1.0	13	1	ABF01935	Oligonucleotide SE
307	13.2	1.1	18	1	AAQ30369	Probe HBP-255 for	Probe HBP-255 for	380	13	1.0	13	1	ABF12532	Oligonucleotide SE
308	13.2	1.1	18	1	AAQ30370	Sense primer 1 for	Sense primer 1 for	381	13	1.0	13	1	ABF12533	Oligonucleotide SE
309	13.2	1.1	18	1	AAQ30371	Antisense oligonuc	Antisense oligonuc	382	13	1.0	13	1	ABF15742	Oligonucleotide SE
310	13.2	1.1	18	1	AAQ30372	GRK4 allele specif	GRK4 allele specif	383	13	1.0	13	1	ABF15743	Oligonucleotide SE
311	13.2	1.1	18	1	AAQ30373	PCR primer for con	PCR primer for con	384	13	1.0	13	1	ABF16636	Oligonucleotide SE
312	13.2	1.1	18	1	AAQ30374	PCR primer for Hum	PCR primer for Hum	385	13	1.0	13	1	ABF16637	Oligonucleotide SE
313	13.2	1.1	18	1	AAQ30375	Human biallelic ma	Human biallelic ma	386	13	1.0	13	1	ABF20442	Oligonucleotide SE
314	13.2	1.1	18	1	AAQ30376	Yersinia YopE spon	Yersinia YopE spon	387	13	1.0	13	1	ABF20443	Oligonucleotide SE
315	13.2	1.1	18	1	AAQ30377	Yersinia YopE spon	Yersinia YopE spon	388	13	1.0	13	1	ABF20500	Oligonucleotide SE
316	13.2	1.1	18	1	AAQ30378	Yersinia YopE spon	Yersinia YopE spon	389	13	1.0	13	1	ABF20501	Oligonucleotide SE
317	13.2	1.1	18	1	AAQ30379	Human GCPII gene e	Human GCPII gene e	390	13	1.0	13	1	ABF33284	Oligonucleotide SE
318	13.2	1.1	18	1	AAQ30380	Parathyroid hormon	Parathyroid hormon	391	13	1.0	13	1	ABF33285	Oligonucleotide SE
319	13.2	1.1	18	1	AAQ30381	Shrimp white spot	Shrimp white spot	392	13	1.0	13	1	ABF50618	Oligonucleotide SE
320	13.2	1.1	18	1	AAQ30382	Human Akt-3 antise	Human Akt-3 antise	393	13	1.0	13	1	ABF50619	Oligonucleotide SE
321	13.2	1.1	18	1	AAQ30383	Binary encoded seq	Binary encoded seq	394	13	1.0	13	1	ABF53014	Oligonucleotide SE
322	13.2	1.1	18	1	AAQ30384			395	13	1.0	13	1	ABF53015	Oligonucleotide SE
323	13.2	1.1	18	1	AAQ30385			396	13	1.0	13	1	ABF50866	Oligonucleotide SE
324	13.2	1.1	18	1	AAQ30386			397	13	1.0	13	1	ABF50867	Oligonucleotide SE
325	13.2	1.1	18	1	AAQ30387			398	13	1.0	13	1	ABF56362	Oligonucleotide SE

399	13	1.0	13	1	13	1	ABP65363	Oligonucleotide SE
C 400	13	1.0	13	1	13	1	ABP68618	Oligonucleotide SE
401	13	1.0	13	1	13	1	ABP68619	Oligonucleotide SE
402	13	1.0	13	1	13	1	ABP71788	Oligonucleotide SE
C 403	13	1.0	13	1	13	1	ABP71789	Oligonucleotide SE
C 404	13	1.0	13	1	13	1	ABP83258	Oligonucleotide SE
C 405	13	1.0	13	1	13	1	ABP83259	Oligonucleotide SE
C 406	13	1.0	13	1	13	1	ABP83902	Oligonucleotide SE
407	13	1.0	13	1	13	1	ABP83903	Oligonucleotide SE
C 408	13	1.0	13	1	13	1	ABP88502	Oligonucleotide SE
C 409	13	1.0	13	1	13	1	ABP88503	Oligonucleotide SE
410	13	1.0	13	1	13	1	ABP94864	Oligonucleotide SE
C 411	13	1.0	13	1	13	1	ABP94865	Oligonucleotide SE
412	13	1.0	13	1	13	1	ABH13810	Oligonucleotide SE
C 413	13	1.0	13	1	13	1	ABH13811	Oligonucleotide SE
C 414	13	1.0	13	1	13	1	ABH231148	Oligonucleotide SE
C 415	13	1.0	13	1	13	1	ABH231149	Oligonucleotide SE
C 416	13	1.0	13	1	13	1	ABH27672	Oligonucleotide SE
C 417	13	1.0	13	1	13	1	ABH27673	Oligonucleotide SE
418	13	1.0	13	1	13	1	ABH29396	Oligonucleotide SE
C 419	13	1.0	13	1	13	1	ABH29397	Oligonucleotide SE
420	13	1.0	13	1	13	1	ABH37864	Oligonucleotide SE
C 421	13	1.0	13	1	13	1	ABH37865	Oligonucleotide SE
C 422	13	1.0	13	1	13	1	ABH48890	Oligonucleotide SE
C 423	13	1.0	13	1	13	1	ABH48891	Oligonucleotide SE
C 424	13	1.0	13	1	13	1	ABH49486	Oligonucleotide SE
425	13	1.0	13	1	13	1	ABH49487	Oligonucleotide SE
C 426	13	1.0	13	1	13	1	ABH53272	Oligonucleotide SE
427	13	1.0	13	1	13	1	ABH53273	Oligonucleotide SE
C 428	13	1.0	13	1	13	1	ABH53668	Oligonucleotide SE
C 429	13	1.0	13	1	13	1	ABH53669	Oligonucleotide SE
430	13	1.0	13	1	13	1	ABH55558	Oligonucleotide SE
C 431	13	1.0	13	1	13	1	ABH55559	Oligonucleotide SE
C 432	13	1.0	13	1	13	1	ABH57674	Oligonucleotide SE
C 433	13	1.0	13	1	13	1	ABH57675	Oligonucleotide SE
C 434	13	1.0	13	1	13	1	ABH58412	Oligonucleotide SE
C 435	13	1.0	13	1	13	1	ABH58413	Oligonucleotide SE
C 436	13	1.0	13	1	13	1	ABH62638	Oligonucleotide SE
C 437	13	1.0	13	1	13	1	ABH62639	Oligonucleotide SE
C 438	13	1.0	13	1	13	1	ABH66082	Oligonucleotide SE
439	13	1.0	13	1	13	1	ABH66083	Oligonucleotide SE
440	13	1.0	13	1	13	1	ABH66348	Mouse TNF-a hammer
441	13	1.0	13	1	13	1	AAT56318	Human TNF-alpha ha
442	13	1.0	13	1	13	1	AAT55809	Human TNF-alpha ha
443	13	1.0	13	1	13	1	AAT55794	RSV N hammerhead r
C 444	13	1.0	13	1	13	1	AAT57265	Antitumoural phosph
C 445	13	1.0	13	1	13	1	AAT57265	Human TNFRSF11B 9e
446	13	1.0	13	1	13	1	AAF70088	Human TNFRSF11B 9e
C 447	13	1.0	13	1	13	1	AAF70070	Human ovary specific
C 448	13	1.0	13	1	13	1	ABT04008	Pro-UK probe T6 (T
C 449	13	1.0	13	1	13	1	AAQ23015	Type II procollage
C 450	13	1.0	13	1	13	1	AAQ5895	Human EGF-R target
451	13	1.0	13	1	13	1	AAV97734	Human EGF-R target
452	13	1.0	13	1	13	1	AAV97735	Human EGF-R target
453	13	1.0	13	1	13	1	AAV97736	Human EGF-R target
454	13	1.0	13	1	13	1	AAV97737	Integrin subunit b
455	13	1.0	13	1	13	1	AAA22686	Integrin subunit b
456	13	1.0	13	1	13	1	AAA22687	Integrin subunit b
457	13	1.0	13	1	13	1	AAA22688	Integrin subunit b
458	13	1.0	13	1	13	1	AAA22689	Integrin subunit b
C 459	13	1.0	13	1	13	1	AAA22806	Integrin subunit b
C 460	13	1.0	13	1	13	1	AAA22811	Integrin subunit b
461	13	1.0	13	1	13	1	AAV93569	Human B-raf subtr
462	13	1.0	13	1	13	1	AAV93570	Hammerhead ribozym
C 463	13	1.0	13	1	13	1	AAV93570	Hammerhead ribozym
C 464	13	1.0	13	1	13	1	AAV93570	Hammerhead ribozym
C 465	13	1.0	13	1	13	1	AAV93570	Hammerhead ribozym
C 466	13	1.0	13	1	13	1	AAV93570	Hammerhead ribozym
467	13	1.0	13	1	13	1	AAV93570	Hammerhead ribozym
C 468	13	1.0	13	1	13	1	AAV93570	Hammerhead ribozym
C 469	13	1.0	13	1	13	1	AAV93570	Hammerhead ribozym
C 470	13	1.0	13	1	13	1	AAV93570	Hammerhead ribozym
C 471	13	1.0	13	1	13	1	AAV93570	Hammerhead ribozym



C 545	12.8	1.0	17	1	AAH61737	Cdc 2 kinase hamme	C 618	12.8	1.0	18	1	ABS54315	P. falciparum DHPR
C 546	12.8	1.0	17	1	AAH56150	Staphylococcus aur	C 619	12.8	1.0	18	1	ABQ65395	Human gene methyl
C 547	12.8	1.0	17	1	ABK00430	Human NOGO Hammerh	C 620	12.8	1.0	18	1	ABK34044	Human NFI probe #2
C 548	12.8	1.0	17	1	ABK00457	Human NOGO Hammerh	C 621	12.8	1.0	18	1	ABK40096	Human super oxide
C 549	12.8	1.0	17	1	ABK01316	Human NOGO Inozyme	C 622	12.8	1.0	18	1	ABK83553	Mouse Mp-1 antisen
C 550	12.8	1.0	17	1	ABK01612	Human NOGO G-Cleav	C 623	12.8	1.0	18	1	ABZ70969	Human bcl-2 relate
C 551	12.8	1.0	17	1	ABK021193	Human NOGO DNazyme	C 624	12.8	1.0	18	1	ABZ10410	Haematopoietic cel
C 552	12.8	1.0	17	1	ABV80693	Human HTPL scannin	C 625	12.8	1.0	18	1	ABZ10519	Haematopoietic cel
C 553	12.8	1.0	17	1	ABV80695	Human HTPL scannin	C 626	12.8	1.0	18	1	ABZ10596	Haematopoietic cel
C 554	12.8	1.0	17	1	ABV83076	Human HTPL scannin	C 627	12.8	1.0	18	1	ABZ10922	Haematopoietic cel
C 555	12.8	1.0	17	1	ABV83077	Human HTPL scannin	C 628	12.8	1.0	19	1	AAH81135	cdk7 ribozyme bind
C 556	12.8	1.0	17	1	ABV90149	Human POSHL1 scann	C 629	12.8	1.0	19	1	AAH58297	Cell-cycle depende
C 557	12.8	1.0	17	1	ABV90150	Human POSHL1 scann	C 630	12.6	1.0	13	1	ABC05468	Oligonucleotide SE
C 558	12.8	1.0	17	1	ABK56195	Human CLCA1 gene e	C 631	12.6	1.0	13	1	ABC05469	Oligonucleotide SE
C 559	12.8	1.0	17	1	ABK56693	Human CLCA1 gene e	C 632	12.6	1.0	13	1	ABC12854	Oligonucleotide SE
C 560	12.8	1.0	17	1	ABK56852	Human CLCA1 gene e	C 633	12.6	1.0	13	1	ABC12855	Oligonucleotide SE
C 561	12.8	1.0	17	1	ABK56963	Human CLCA1 gene e	C 634	12.6	1.0	13	1	ABC13828	Oligonucleotide SE
C 562	12.8	1.0	17	1	ABK57058	Human CLCA1 gene e	C 635	12.6	1.0	13	1	ABC13829	Oligonucleotide SE
C 563	12.8	1.0	17	1	ABK18668	Human ERG G-cleave	C 636	12.6	1.0	13	1	ABC23680	Oligonucleotide SE
C 564	12.8	1.0	17	1	ABK18697	Human ERG G-cleave	C 637	12.6	1.0	13	1	ABC23681	Oligonucleotide SE
C 565	12.8	1.0	17	1	ABT34683	Tumour suppression	C 638	12.6	1.0	13	1	ABC26934	Oligonucleotide SE
C 566	12.8	1.0	17	1	ABT34698	Tumour suppression	C 639	12.6	1.0	13	1	ABC26935	Oligonucleotide SE
C 567	12.8	1.0	17	1	ABT35053	Tumour suppression	C 640	12.6	1.0	13	1	ABC45016	Oligonucleotide SE
C 568	12.8	1.0	17	1	ABT35977	Tumour suppression	C 641	12.6	1.0	13	1	ABC45017	Oligonucleotide SE
C 569	12.8	1.0	17	1	ABT36351	Tumour suppression	C 642	12.6	1.0	13	1	ABC52710	Oligonucleotide SE
C 570	12.8	1.0	17	1	ABT36416	Tumour suppression	C 643	12.6	1.0	13	1	ABC52711	Oligonucleotide SE
C 571	12.8	1.0	17	1	ABT37756	Tumour suppression	C 644	12.6	1.0	13	1	ABC55940	Oligonucleotide SE
C 572	12.8	1.0	17	1	ABT38062	Tumour suppression	C 645	12.6	1.0	13	1	ABC55941	Oligonucleotide SE
C 573	12.8	1.0	17	1	ABT38413	Tumour suppression	C 646	12.6	1.0	13	1	ABC72766	Oligonucleotide SE
C 574	12.8	1.0	17	1	ABT39158	Tumour suppression	C 647	12.6	1.0	13	1	ABC72767	Oligonucleotide SE
C 575	12.8	1.0	17	1	ABT39376	Tumour suppression	C 648	12.6	1.0	13	1	ABC75212	Oligonucleotide SE
C 576	12.8	1.0	17	1	ABT39378	Tumour suppression	C 649	12.6	1.0	13	1	ABC75213	Oligonucleotide SE
C 577	12.8	1.0	17	1	ABT39979	Tumour suppression	C 650	12.6	1.0	13	1	ABC80810	Oligonucleotide SE
C 578	12.8	1.0	17	1	ABT40081	Tumour suppression	C 651	12.6	1.0	13	1	ABC80811	Oligonucleotide SE
C 579	12.8	1.0	17	1	ABZ60208	Human K-Ras DNazym	C 652	12.6	1.0	13	1	ABC93680	Oligonucleotide SE
C 580	12.8	1.0	17	1	ABZ60265	Human K-Ras DNazym	C 653	12.6	1.0	13	1	ABC93681	Oligonucleotide SE
C 581	12.8	1.0	17	1	ABZ60471	Human K-Ras DNazym	C 654	12.6	1.0	13	1	ABC95530	Oligonucleotide SE
C 582	12.8	1.0	17	1	ABZ60554	Human K-Ras DNazym	C 655	12.6	1.0	13	1	ABC95531	Oligonucleotide SE
C 583	12.8	1.0	17	1	ABZ60733	Human K-Ras DNazym	C 656	12.6	1.0	13	1	ABC95532	Oligonucleotide SE
C 584	12.8	1.0	17	1	ABZ61054	Human K-Ras DNazym	C 657	12.6	1.0	13	1	ABP24642	Oligonucleotide SE
C 585	12.8	1.0	17	1	ABZ61098	Human K-Ras DNazym	C 658	12.6	1.0	13	1	ABP24643	Oligonucleotide SE
C 586	12.8	1.0	17	1	ABZ61149	Human K-Ras DNazym	C 659	12.6	1.0	13	1	ABF46540	Oligonucleotide SE
C 587	12.8	1.0	17	1	ABZ61155	Human K-Ras DNazym	C 660	12.6	1.0	13	1	ABF46541	Oligonucleotide SE
C 588	12.8	1.0	17	1	ABZ61203	Human K-Ras DNazym	C 661	12.6	1.0	13	1	ABF52838	Oligonucleotide SE
C 589	12.8	1.0	17	1	ABZ61621	Human H-Ras DNazym	C 662	12.6	1.0	13	1	ABF53002	Oligonucleotide SE
C 590	12.8	1.0	18	1	AAH43555	HIVTH01 microsatel	C 663	12.6	1.0	13	1	ABF53003	Oligonucleotide SE
C 591	12.8	1.0	18	1	AAV60776	HIV-1 strain YBF30	C 664	12.6	1.0	13	1	ABF54452	Oligonucleotide SE
C 592	12.8	1.0	18	1	AAV49122	rb gene antisense	C 665	12.6	1.0	13	1	ABF54453	Oligonucleotide SE
C 593	12.8	1.0	18	1	AAV36410	Antisense oligonuc	C 666	12.6	1.0	13	1	ABF57444	Oligonucleotide SE
C 594	12.8	1.0	18	1	AAV36411	Sense oligonucleot	C 667	12.6	1.0	13	1	ABF57445	Oligonucleotide SE
C 595	12.8	1.0	18	1	AAV34526	Chemokine receptor	C 668	12.6	1.0	13	1	ABF59176	Oligonucleotide SE
C 596	12.8	1.0	18	1	AAZ41004	Human RhoC phospho	C 669	12.6	1.0	13	1	ABF59177	Oligonucleotide SE
C 597	12.8	1.0	18	1	AAZ56787	WO9922023 probe 23	C 670	12.6	1.0	13	1	ABP72046	Oligonucleotide SE
C 598	12.8	1.0	18	1	AAZ37761	Staphylococcus sp.	C 671	12.6	1.0	13	1	ABP72047	Oligonucleotide SE
C 599	12.8	1.0	18	1	AAV82030	Moraxella lactofer	C 672	12.6	1.0	13	1	ABF76626	Oligonucleotide SE
C 600	12.8	1.0	18	1	AAV82031	Moraxella lactofer	C 673	12.6	1.0	13	1	ABF76627	Oligonucleotide SE
C 601	12.8	1.0	18	1	AAZ25754	RT-PCR primer RT-N	C 674	12.6	1.0	13	1	ABF78844	Oligonucleotide SE
C 602	12.8	1.0	18	1	AAZ70894	Human biallelic ma	C 675	12.6	1.0	13	1	ABF78845	Oligonucleotide SE
C 603	12.8	1.0	18	1	AAZ71730	Human biallelic ma	C 676	12.6	1.0	13	1	ABP79012	Oligonucleotide SE
C 604	12.8	1.0	18	1	AAH86605	Cdc 2 kinase hamme	C 677	12.6	1.0	13	1	ABP79013	Oligonucleotide SE
C 605	12.8	1.0	18	1	AAH86607	Cdc 2 kinase hamme	C 678	12.6	1.0	13	1	ABP98558	Oligonucleotide SE
C 606	12.8	1.0	18	1	AAH86759	Cdc 2 kinase hamme	C 679	12.6	1.0	13	1	ABP98559	Oligonucleotide SE
C 607	12.8	1.0	18	1	AAH10824	G-alpha-11 antisen	C 680	12.6	1.0	13	1	ABH23016	Oligonucleotide SE
C 608	12.8	1.0	18	1	AAZ59449	Human Ship-2 phosph	C 681	12.6	1.0	13	1	ABH23017	Oligonucleotide SE
C 609	12.8	1.0	18	1	AAZ37341	Interleukin-15 ant	C 682	12.6	1.0	13	1	ABH36948	Oligonucleotide SE
C 610	12.8	1.0	18	1	AAH61773	Cdc 2 kinase hamme	C 683	12.6	1.0	13	1	ABH36949	Oligonucleotide SE
C 611	12.8	1.0	18	1	AAH61773	Cdc 2 kinase hamme	C 684	12.6	1.0	13	1	ABH40538	Oligonucleotide SE
C 612	12.8	1.0	18	1	AAH61925	Cdc 2 kinase hamme	C 685	12.6	1.0	13	1	ABH40539	Oligonucleotide SE
C 613	12.8	1.0	18	1	AAH61925	Cdc 2 kinase hamme	C 686	12.6	1.0	13	1	ABH50358	Oligonucleotide SE
C 614	12.8	1.0	18	1	AAH61925	Rho C antisense ph	C 687	12.6	1.0	13	1	ABH50359	Oligonucleotide SE
C 615	12.8	1.0	18	1	AAH61925	Primer T-PA2. Uni	C 688	12.6	1.0	13	1	ABH58638	Oligonucleotide SE
C 616	12.8	1.0	18	1	AAH61925	Genomic DNA methyl	C 689	12.6	1.0	13	1	ABH58639	Oligonucleotide SE
C 617	12.8	1.0	18	1	ABS54314	Mined element RESI	C 690	12.6	1.0	13	1	ABH60060	Oligonucleotide SE
						P. falciparum DHPR							

c 691	12.6	1.0	13	1	ABH60061	Oligonucleotide SE	764	12.4	1.0	17	1	AAK69623	Human flt1 VEGF re
c 692	12.6	1.0	13	1	ABH64678	Oligonucleotide SE	765	12.4	1.0	17	1	AAK69624	Human flt1 VEGF re
c 693	12.6	1.0	13	1	ABH64679	Oligonucleotide SE	766	12.4	1.0	17	1	AAK69328	Human flt1 VEGF re
c 694	12.6	1.0	15	1	AAD49641	Human adenylate ur	767	12.4	1.0	17	1	AAK69088	Human EGF-R target
c 695	12.6	1.0	15	1	AAL50230	Human ARE-mRNA seq	768	12.4	1.0	17	1	AAV97418	Solanidine glucosy
c 696	12.6	1.0	15	1	AAL53709	Adenylate Uridylat	c 769	12.4	1.0	17	1	AAV95855	Solanidine glucosy
c 697	12.6	1.0	17	1	AAW71403	Sequence of hybrid	c 770	12.4	1.0	17	1	AAV95856	Primer C5 for Cyt
c 698	12.6	1.0	17	1	AAQ78885	Humicola grisea gl	c 771	12.4	1.0	17	1	AAV58890	Primer CSR for Cyt
c 699	12.6	1.0	18	1	ABK85464	5'-degenerate sequ	772	12.4	1.0	17	1	AAV58891	Aryl hydrocarbon n
c 700	12.4	1.0	14	1	AAV22349	A promoter regulat	773	12.4	1.0	17	1	AAV17432	Integrin alpha 6 s
c 701	12.4	1.0	14	1	AAV22279	ISRE gene promoter	774	12.4	1.0	17	1	AAV20578	Integrin alpha 6 s
c 702	12.4	1.0	14	1	AAZ32432	8-mer minor groove	775	12.4	1.0	17	1	AAV20579	Integrin alpha 6 s
c 703	12.4	1.0	14	1	AAD20794	PNA16/DNA oligo, u	776	12.4	1.0	17	1	AAV21204	Integrin alpha 6 s
c 704	12.4	1.0	14	1	AAK10742	Solid-state DNA se	777	12.4	1.0	17	1	AAV21208	Integrin alpha 6 s
c 705	12.4	1.0	14	1	AAD07293	PNA16/DNA primer.	c 778	12.4	1.0	17	1	AAV21356	Integrin alpha 6 s
c 706	12.4	1.0	14	1	ABK98758	Solid state sequen	c 779	12.4	1.0	17	1	AAV21375	Integrin alpha 6 s
c 707	12.4	1.0	14	1	ABL55256	Vector 1-8 Sleepin	780	12.4	1.0	17	1	AAV21375	Integrin alpha 6 s
c 708	12.4	1.0	14	1	ABZ21280	FIXa aptamer oligo	781	12.4	1.0	17	1	AAV21377	Integrin alpha 6 s
c 709	12.4	1.0	15	1	AAQ55455	Detection primer f	782	12.4	1.0	17	1	AAV21423	Integrin alpha 6 s
c 710	12.4	1.0	15	1	AAT56342	Mouse TNF-a hamme	783	12.4	1.0	17	1	AAV22894	Integrin subunit b
c 711	12.4	1.0	15	1	AAT54316	Human II-5 hamme	c 784	12.4	1.0	17	1	AAV22895	Integrin subunit b
c 712	12.4	1.0	15	1	AAT54316	Human II-5 hamme	c 785	12.4	1.0	17	1	AAV78370	Human BRCA2 5374de
c 713	12.4	1.0	15	1	AAT55821	Human TNF-alpha ha	c 786	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 714	12.4	1.0	15	1	AAT55803	Human TNF-alpha ha	c 787	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 715	12.4	1.0	15	1	AAT52043	Human ICAM hamme	c 788	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 716	12.4	1.0	15	1	AAT56823	RSV 1B hammerhead	c 789	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 717	12.4	1.0	15	1	AAT52338	Mouse ICAM hamme	c 790	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 718	12.4	1.0	15	1	AAT52338	Mouse ICAM hamme	c 791	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 719	12.4	1.0	15	1	AAK66586	Human CD40 hamme	c 792	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 720	12.4	1.0	15	1	AAK65399	Mouse B7-1 hamme	c 793	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 721	12.4	1.0	15	1	AAV75738	Human flt-1 and KD	c 794	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 722	12.4	1.0	15	1	AAV06916	Probe PP15-TGT-TO	c 795	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 723	12.4	1.0	15	1	AAZ36372	Antisense oligonuc	c 796	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 724	12.4	1.0	15	1	AAZ95561	Pyrene modified RN	c 797	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 725	12.4	1.0	15	1	AAZ95562	Pyrene modified RN	c 798	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 726	12.4	1.0	15	1	AAZ95563	Pyrene modified RN	c 799	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 727	12.4	1.0	15	1	AAZ95564	Pyrene modified DN	c 800	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 728	12.4	1.0	15	1	AAZ95565	Pyrene modified DN	c 801	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 729	12.4	1.0	15	1	AAZ95566	Human interleukin-	c 802	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 730	12.4	1.0	15	1	AAZ39954	Complex PCR amplif	c 803	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 731	12.4	1.0	15	1	AAZ20775	Complex PCR amplif	c 804	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 732	12.4	1.0	15	1	AAZ20782	Human IGFBP3 allele	c 805	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 733	12.4	1.0	15	1	AAZ98089	Human IGFBP3 allele	c 806	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 734	12.4	1.0	15	1	AAZ98091	IGFBP3 oligonucleo	c 807	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 735	12.4	1.0	15	1	AAZ98093	IGFBP3 oligonucleo	c 808	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 736	12.4	1.0	15	1	AAZ98096	IGFBP3 oligonucleo	c 809	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 737	12.4	1.0	15	1	AAZ98096	IGFBP3 oligonucleo	c 810	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 738	12.4	1.0	15	1	AAZ98097	IGFBP3 oligonucleo	c 811	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 739	12.4	1.0	15	1	AAZ98098	P. falciparum chit	c 812	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 740	12.4	1.0	15	1	AAZ98098	Resistance Gene li	c 813	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 741	12.4	1.0	15	1	AAZ98098	Human neurotrophin	c 814	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 742	12.4	1.0	15	1	AAZ98098	Human ALAS2 gene a	c 815	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 743	12.4	1.0	15	1	AAZ98098	Human interferon g	c 816	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 744	12.4	1.0	15	1	AAZ98098	Duck hepatitis B v	c 817	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 745	12.4	1.0	15	1	AAZ98098	Duck hepatitis B v	c 818	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 746	12.4	1.0	15	1	AAZ98098	EST polymorphic DN	c 819	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 747	12.4	1.0	15	1	AAZ98098	Bacillus thuringie	c 820	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 748	12.4	1.0	15	1	AAZ98098	B. thuringiensis t	c 821	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 749	12.4	1.0	16	1	AAZ98098	rb gene antisense	c 822	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 750	12.4	1.0	16	1	AAZ98098	rb gene antisense	c 823	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 751	12.4	1.0	16	1	AAZ98098	junB gene antisens	c 824	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 752	12.4	1.0	16	1	AAZ98098	Lactococcus lactis	c 825	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 753	12.4	1.0	16	1	AAZ98098	Bacillus thuringie	c 826	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 754	12.4	1.0	16	1	AAZ98098	Bacillus thuringie	c 827	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 755	12.4	1.0	16	1	AAZ98098	Nucleic acid quant	c 828	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 756	12.4	1.0	17	1	AAZ98098	Humicola grisea gl	c 829	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 757	12.4	1.0	17	1	AAZ98098	Rabbit stromelysin	c 830	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 758	12.4	1.0	17	1	AAZ98098	Mouse fit-1 VEGF r	c 831	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 759	12.4	1.0	17	1	AAZ98098	Mouse fit-1 VEGF r	c 832	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 760	12.4	1.0	17	1	AAZ98098	Mouse fit-1 VEGF r	c 833	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 761	12.4	1.0	17	1	AAZ98098	Mouse fix-1 VEGF r	c 834	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 762	12.4	1.0	17	1	AAZ98098	Human KOR VEGF rec	c 835	12.4	1.0	17	1	AAV78370	Hammerhead ribozym
c 763	12.4	1.0	17	1	AAZ98098	Human KOR VEGF rec	c 836	12.4	1.0	17	1	AAV78370	Hammerhead ribozym

C 837	12.4	1.0	17	1	ABT35721	Tumour suppression	C 910	11.6	0.9	20	1	ABK85435	Oligonucleotide #1
C 838	12.4	1.0	17	1	ABT36211	Tumour suppression	911	11.6	0.9	20	1	ABL51148	Human TNF inducibl
C 839	12.4	1.0	17	1	ABT36218	Tumour suppression	912	11.6	0.9	20	1	ABQ75568	Reverse transcript
C 840	12.4	1.0	17	1	ABT36376	Tumour suppression	C 913	11.6	0.9	20	1	AAV47265	5' fragment #2 of
C 841	12.4	1.0	17	1	ABT37154	Tumour suppression	914	11.6	0.9	21	1	AAV67374	Nucleotide fragmen
C 842	12.4	1.0	17	1	ABT37150	Tumour suppression	915	11.6	0.9	21	1	AAQ20077	Hiv-1 DNA probe (g
C 843	12.4	1.0	17	1	ABT37886	Tumour suppression	916	11.6	0.9	17	1	AAQ75643	Reverse transcript
C 844	12.4	1.0	17	1	ABT38326	Tumour suppression	917	11.4	0.9	17	1	AAV91422	Human C-raf target
C 845	12.4	1.0	17	1	ABT39589	Tumour suppression	C 918	11.4	0.9	17	1	AAV70035	Human flt1 VEGF re
C 846	12.4	1.0	17	1	ACA06849	NFKB sub-unit modu	C 919	11.4	0.9	17	1	AAV21376	Integrin alpha 6 s
C 847	12.4	1.0	17	1	ACA08322	Necrosis factor ka	C 920	11.4	0.9	20	1	AAQ09117	Human MEKK2 antise
C 848	12.4	1.0	17	1	ABZ60207	Human K-Ras DNazym	C 921	11.4	0.9	21	1	AAQ30406	Oligomer IL2R503 f
C 849	12.4	1.0	17	1	ABZ61180	Human X-Ras DNazym	C 922	11.4	0.9	21	1	AAZ26565	Human polymorphic
C 850	12.4	1.0	25	1	AAQ66457	Dog genomic marker	923	11.2	0.9	16	1	AAV74329	Lobolilly pine SSR
C 851	12.4	1.0	30	1	AAV55125	Nucleic acid synth	924	11.2	0.9	16	1	AAV74330	Lobolilly pine SSR
C 852	12.2	1.0	17	1	AAZ22700	Integrin subunit b	C 925	11.2	0.9	16	1	AAV09052	Improved cleavage
C 853	12.2	1.0	17	1	AAZ22703	Integrin subunit b	C 926	11.2	0.9	17	1	AAV09052	Primer 1 for tetra
C 854	12.2	1.0	17	1	AAZ22706	Integrin subunit b	C 927	11.2	0.9	17	1	AAZ22698	Integrin subunit b
C 855	12.2	1.0	17	1	AAZ22899	Integrin subunit b	C 928	11.2	0.9	17	1	AAZ22699	Integrin subunit b
C 856	12.2	1.0	17	1	AAZ22900	Integrin subunit b	C 929	11.2	0.9	17	1	AAZ22701	Integrin subunit b
C 857	12.2	1.0	17	1	AAZ22901	Integrin subunit b	C 930	11.2	0.9	17	1	AAZ22702	Integrin subunit b
C 858	12.2	1.0	17	1	AAZ22902	Integrin subunit b	C 931	11.2	0.9	17	1	AAZ22704	Integrin subunit b
C 859	12.2	1.0	17	1	AAZ22903	Integrin subunit b	C 932	11.2	0.9	17	1	AAZ22705	Integrin subunit b
C 860	12.2	1.0	17	1	AAZ22908	Integrin subunit b	C 933	11.2	0.9	17	1	AAZ22705	Integrin subunit b
C 861	12.2	1.0	18	1	ABZ67982	PAP-AH DNA related	C 934	11.2	0.9	17	1	AAZ22708	Human adenylate ur
C 862	12.2	1.0	18	1	AAQ20160	Cross-linking olig	C 935	11.2	0.9	17	1	AAZ22707	Human ARE-mRNA seq
C 863	12.2	1.0	18	1	AAQ30310	Oligomer HSV723 fo	C 936	11.2	0.9	17	1	AAZ22707	Integrin subunit b
C 864	12.2	1.0	18	1	AAQ30368	Oligomer HUM beta	C 937	11.2	0.9	17	1	ABT37900	Tumour suppression
C 865	12.2	1.0	18	1	ABZ10596	Haematopoietic cel	C 938	11.2	0.9	17	1	AAV96639	Potato citrate syn
C 866	12.2	1.0	20	1	ABL46342	Human interleukin-	939	11.2	0.9	17	1	AAZ21468	Integrin alpha 6 s
C 867	12.2	1.0	20	1	AAZ37709	Human mdm2 phospho	C 940	11.2	0.9	17	1	AAZ22904	Integrin subunit b
C 868	12.2	1.0	20	1	AAZ29478	Human mdm2 antisen	C 941	11.2	0.9	17	1	AAV96640	Potato citrate syn
C 869	12.2	1.0	20	1	AAZ08863	Human mdm2 phospho	942	11.2	0.9	17	1	AAZ22898	Integrin subunit b
C 870	12.2	1.0	21	1	AAZ14463	AUUA RNA target s	943	11.2	0.9	17	1	AAZ23454	Oestrogen receptor
C 871	12.2	1.0	21	1	AAZ49639	Human adenylate ur	C 944	11.2	0.9	17	1	ABK56852	Human C-RAF gene e
C 872	12.2	1.0	21	1	AAZ50228	Human ARB-mRNA seq	C 945	11.2	0.9	17	1	ABZ60733	Human K-Ras DNazym
C 873	12.2	1.0	21	1	AAZ53707	Adenylate Uridylat	C 946	11.2	0.9	17	1	ABZ61098	Human K-Ras DNazym
C 874	12	1.0	17	1	AAV58890	Primer C5 for Cyt	C 947	11.2	0.9	17	1	AAV74782	Mouse flt-1 VEGF r
C 875	12	1.0	17	1	AAV58891	Primer CSR for Cyt	C 948	11.2	0.9	17	1	AAV69088	Human flt1 VEGF re
C 876	12	1.0	20	1	AAZ52331	Human IFNGR2 antis	C 949	11.2	0.9	17	1	AAZ31377	Integrin alpha 6 s
C 877	12	1.0	21	1	AAZ74938	Human CD40L promot	C 950	11.2	0.9	17	1	ABZ74671	Human PAPP-Ha asso
C 878	11.8	0.9	15	1	AAZ56318	Mouse TNF-a hamme	C 951	11.2	0.9	17	1	ABZ74672	Human PAPP-Ha asso
C 879	11.8	0.9	15	1	AAZ57594	Human TNF-alpha ha	C 952	11.2	0.9	17	1	ABT36211	Tumour suppression
C 880	11.8	0.9	17	1	AAQ202084	Renilla reniformis	C 953	11.2	0.9	17	1	ABT38326	Tumour suppression
C 881	11.8	0.9	17	1	AAQ202054	Hammerhead ribozym	954	11.2	0.9	18	1	ABT79673	Human Akt-3 antise
C 882	11.8	0.9	17	1	ABT39376	Tumour suppression	955	11.2	0.9	18	1	AAZ37761	Staphylococcus sp.
C 883	11.8	0.9	17	1	ABZ60265	Human K-Ras DNazym	C 956	11.2	0.9	18	1	ABK34044	Human NF1 probe #2
C 884	11.8	0.9	17	1	AAZ05526	Hammerhead ribozym	C 957	11.2	0.9	19	1	AAZ37308	3' primer #5 used
C 885	11.8	0.9	18	1	ABZ10595	Haematopoietic cel	C 958	11.2	0.9	19	1	AAH90994	Human inflammatory
C 886	11.8	0.9	18	1	AAV82030	Moraxella lactofer	959	11.2	0.9	24	1	AAZ54044	Human macroprotein
C 887	11.8	0.9	18	1	AAV82031	Moraxella lactofer	C 960	11	0.9	13	1	ABF53002	Oligonucleotide SE
C 888	11.8	0.9	19	1	AAH56758	S. aureus groE ope	961	11	0.9	13	1	ABF53003	Oligonucleotide SE
C 889	11.8	0.9	24	1	AAH76783	Human nuclear tran	962	11	0.9	17	1	AAZ15106	Human C-myb hamme
C 890	11.8	0.9	25	1	AAH45430	Glutamate tRNA syn	963	11	0.9	17	1	AAZ15107	Human C-myb hamme
C 891	11.8	0.9	38	1	AAZ51650	Interleukin 8 capt	C 964	11	0.9	17	1	AAZ45553	PCR primer for DNA
C 892	11.6	0.9	18	1	AAZ86606	Cdc 2 kinase hamme	C 965	11	0.9	17	1	AAZ45555	PCR primer for DNA
C 893	11.6	0.9	18	1	AAH61772	Cdc 2 kinase hamme	C 966	11	0.9	17	1	AAZ71403	Sequence of hybrid
C 894	11.6	0.9	18	1	ABZ11062	Haematopoietic cel	C 967	11	0.9	17	1	AAQ78885	Hemicola grisea gl
C 895	11.6	0.9	19	1	AAZ62676	Cry2A family gene	968	11	0.9	20	1	AAV44676	PCR primer for UC
C 896	11.6	0.9	19	1	AAZ74905	5' end fragment of	969	11	0.9	20	1	AAV44678	PCR primer for UC
C 897	11.6	0.9	19	1	AAZ49298	5' end fragment of	C 970	11	0.9	20	1	AAZ30727	Human interleukin-
C 898	11.6	0.9	19	1	AAZ47269	Capped RNA influen	C 971	11	0.9	20	1	AAZ31760	Mouse Surivin ant
C 899	11.6	0.9	19	1	AAZ47270	Capped RNA influen	972	11	0.9	20	1	AAH80901	Oligonucleotide hy
C 900	11.6	0.9	19	1	AAZ47271	Capped RNA influen	C 973	11	0.9	21	1	AAQ79313	Human C-raf-1 onco
C 901	11.6	0.9	19	1	AAZ47272	Capped RNA influen	974	11	0.9	21	1	AAH62202	Per tyrosine kinas
C 902	11.6	0.9	19	1	AAZ47273	Capped RNA influen	C 975	11	0.9	50	1	ABZ00185	Human leukocyte ge
C 903	11.6	0.9	19	1	AAZ47267	Capped RNA influen	C 976	10.8	0.9	15	1	AAZ56320	Mouse TNF-a hamme
C 904	11.6	0.9	19	1	AAZ47264	5' fragment of aif	C 977	10.8	0.9	15	1	AAZ55811	Human TNF-alpha ha
C 905	11.6	0.9	19	1	AAZ47276	Capped RNA influen	C 978	10.8	0.9	15	1	AAZ55796	Human TNF-alpha ha
C 906	11.6	0.9	19	1	AAZ47277	Capped RNA influen	C 979	10.8	0.9	15	1	AAZ56348	Mouse TNF-a hamme
C 907	11.6	0.9	19	1	AAZ47278	Capped RNA influen	C 980	10.8	0.9	15	1	AAZ55809	Human TNF-alpha ha
C 908	11.6	0.9	19	1	AAZ47279	Capped RNA influen	C 981	10.8	0.9	15	1	AAZ70070	Human TNFRSF11B ge
C 909	11.6	0.9	20	1	AAZ92878	Human PI3 kinase p	982	10.8	0.9	15	1	ABT04008	Human ovary specif

983 10.8 0.9 15 1 AAX65399 Mouse B7-1 hammerh  
984 10.8 0.9 15 1 AAZ39954 Human interleukin-

ALIGNMENTS

RESULT 1  
ABZ00185  
ID ABZ00185 standard; DNA; 50 BP.  
XX AC ABZ00185;  
XX AC  
XX 09-JAN-2003 (first entry)  
XX Human leukocyte gene expression profiling probe SEQ ID NO 176.  
XX  
XX T7; leukocyte; gene expression profiling; allograft rejection;  
XX atherosclerosis; congestive heart failure; systemic lupus erythematosus;  
XX rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection;  
XX probe; ss.  
XX Homo sapiens.  
XX OS  
XX WO200257414-A2.  
XX PN  
XX 25-JUL-2002.  
XX PD  
XX  
XX 22-OCT-2001; 2001WO-US47856.  
XX PF  
XX 20-OCT-2000; 2000US-241994P.  
XX PR  
XX 08-JUN-2001; 2001US-296764P.  
XX PP  
XX (BIOC-) BIOCARDIA INC.  
XX PA  
XX Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;  
XX Ly N, Woodward R, Quettermous T, Johnson F;  
XX WPI; 2002-636525/68.  
XX DR  
XX New system for leukocyte expression profiling, diagnosing a disease, or  
XX monitoring (the rate of) progression of a disease, e.g. atherosclerosis  
XX or congestive heart failure, comprises diagnostic oligonucleotides -  
XX  
XX Claim 1; Page 332; 2038pp; English.  
XX  
XX The invention relates to a system for detecting gene expression, which  
XX comprises one or two isolated DNA molecules that detect expression of a  
XX gene, where the gene corresponds to any of 8143 oligonucleotides  
XX (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful  
XX for leukocyte expression profiling. It is particularly useful for  
XX diagnosing a disease, monitoring (rate of) progression of a disease,  
XX predicting therapeutic outcome, determining prognosis for a patient,  
XX to treatment in an individual. The diseases include cardiac allograft  
XX rejection, kidney allograft rejection, liver allograft rejection,  
XX atherosclerosis, congestive heart failure, systemic lupus erythematosus,  
XX rheumatoid arthritis, osteoarthritis or cytomegalovirus infection.  
XX  
XX Sequence 50 BP; 14 A; 4 C; 15 G; 17 T; 0 other;  
XX  
XX Query Match 4.0%; Score 50; DB 1; Length 50;  
XX Best Local Similarity 100.0%; Pred. No. 1.1e-05;  
XX Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX 1351 AGCTGTGTTGCTAGTCTGTTGTAATTCAGGAATATGAGTTAGAACTA 1400  
XX  
XX 1 AGCTGTGTTGCTAGTCTGTTGTAATTCAGGAATATGAGTTAGAACTA 50  
XX  
RESULT 2  
ABZ01793  
ID ABZ01793 standard; DNA; 50 BP.

XX AC ABZ01793;  
XX 09-JAN-2003 (first entry)  
XX Human leukocyte gene expression profiling probe SEQ ID NO 1784.  
XX  
XX T7; leukocyte; gene expression profiling; allograft rejection;  
XX atherosclerosis; congestive heart failure; systemic lupus erythematosus;  
XX rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection;  
XX probe; ss.  
XX Homo sapiens.  
XX OS  
XX WO200257414-A2.  
XX PN  
XX 25-JUL-2002.  
XX PD  
XX  
XX 22-OCT-2001; 2001WO-US47856.  
XX PF  
XX 20-OCT-2000; 2000US-241994P.  
XX PR  
XX 08-JUN-2001; 2001US-296764P.  
XX PP  
XX (BIOC-) BIOCARDIA INC.  
XX PA  
XX Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;  
XX Ly N, Woodward R, Quettermous T, Johnson F;  
XX WPI; 2002-636525/68.  
XX DR  
XX New system for leukocyte expression profiling, diagnosing a disease, or  
XX monitoring (the rate of) progression of a disease, e.g. atherosclerosis  
XX or congestive heart failure, comprises diagnostic oligonucleotides -  
XX  
XX Claim 1; Page 382; 2038pp; English.  
XX  
XX The invention relates to a system for detecting gene expression, which  
XX comprises one or two isolated DNA molecules that detect expression of a  
XX gene, where the gene corresponds to any of 8143 oligonucleotides  
XX (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful  
XX for leukocyte expression profiling. It is particularly useful for  
XX diagnosing a disease, monitoring (rate of) progression of a disease,  
XX predicting therapeutic outcome, determining prognosis for a patient,  
XX predicting disease complications in an individual or monitoring response  
XX to treatment in an individual. The diseases include cardiac allograft  
XX rejection, kidney allograft rejection, liver allograft rejection,  
XX atherosclerosis, congestive heart failure, systemic lupus erythematosus,  
XX rheumatoid arthritis, osteoarthritis or cytomegalovirus infection.  
XX  
XX Sequence 50 BP; 17 A; 8 C; 13 G; 12 T; 0 other;  
XX  
XX Query Match 4.0%; Score 50; DB 1; Length 50;  
XX Best Local Similarity 100.0%; Pred. No. 1.1e-05;  
XX Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX 695 GCCAAGGGCCCAAGAGAATATCCGAATCTTAATTCAGGAATTCGAATGGGT 744  
XX  
XX 1 GCCAAGGGCCCAAGAGAATATCCGAATCTTAATTCAGGAATTCGAATGGGT 50  
XX  
RESULT 3  
ABZ01980  
ID ABZ01980 standard; DNA; 50 BP.  
XX AC ABZ01980;  
XX  
XX 09-JAN-2003 (first entry)  
XX Human leukocyte gene expression profiling probe SEQ ID NO 1971.  
XX  
XX T7; leukocyte; gene expression profiling; allograft rejection;  
XX atherosclerosis; congestive heart failure; systemic lupus erythematosus;  
XX rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection;  
XX probe; ss.

probe; ss.

Homo sapiens.

WO200257414-A2.

25-JUL-2002.

22-OCT-2001; 2001WO-US47856.

20-OCT-2000; 2000US-241994P.

08-JUN-2001; 2001US-296764P.

(BIOC-) BIOCARDIA INC.

Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;  
Ly N, Woodward R, Quertermous T, Johnson F;  
WPI; 2002-636525/68.

New system for leukocyte expression profiling, diagnosing a disease, or monitoring (the rate of) progression of a disease, e.g. atherosclerosis or congestive heart failure, comprises diagnostic oligonucleotides -

Claim 1; Page 389; 2038pp; English.

The invention relates to a system for detecting gene expression, which comprises one or two isolated DNA molecules that detect expression of a gene, where the gene corresponds to any of 8143 oligonucleotides (AB200010-AB208152) each having 50 base pairs (bp). The system is useful for leukocyte expression profiling. It is particularly useful for diagnosing a disease, monitoring (rate of) progression of a disease, predicting therapeutic outcome, determining prognosis for a patient, predicting disease complications in an individual or monitoring response to treatment in an individual. The diseases include cardiac allograft rejection, kidney allograft rejection, liver allograft rejection, atherosclerosis, congestive heart failure, systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis or cytomegalovirus infection.

Sequence 50 BP; 19 A; 10 C; 7 G; 14 T; 0 other;

Query Match 4.0%; Score 50; DB 1; Length 50;  
Best Local Similarity 100.0%; Pred.No.1.1e-05;  
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1403 AAAACACCCAAAAGCTCCACAGTCAATATTAGTAATTTCTTGCTGTTGAA 1452  
|||||  
1 AAAACACCCAAAAGCTCCACAGTCAATATTAGTAATTTCTTGCTGTTGAA 50

RESULT 4  
ABL46338/c  
ID ID ABL46338 standard; DNA; 30 BP.  
XX AC ABL46338;  
XX  
XX 26-APR-2002 (first entry)  
XX Human interleukin-1 beta oligonucleotide SEQ ID NO:305.  
XX  
XX Nucleic acid accessible hybridisation site; detection; hybridisation;  
KW characterisation; identification; nucleic acid structure; diagnosis;  
XX PCR primer; probe; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX WO200198537-A2.  
XX  
XX 27-DEC-2001.  
XX  
XX 15-JUN-2001; 2001WO-US19401.  
XX

XX Example 1; Page 62; 107pp; Japanese.  
PS The invention relates to a novel method for synthesising a target base  
CC sequence-containing nucleic acids. The method comprises the formation of  
CC single-stranded nucleic acids; synthesis of complementary strand by  
CC annealing; and producing single-stranded nucleic acid from a target base  
CC sequence by the synthesis of a complementary strand by annealing of a  
CC complementary base sequence. The method is useful for synthesising a  
CC target base sequence-containing nucleic acids, which is applicable in  
CC detecting SNP (single nucleotide polymorphism) in genes, identifying  
CC genetic diseases, cancer and microorganisms. Such a method can be  
CC easily, rapidly and freely carried out without being influenced by  
CC contamination or complicated temperature control, but with improved  
CC reaction specificity, high accuracy and efficiency, operable at low cost.  
CC This polynucleotide sequence represents a PCR primer used in the  
XX synthesising method of the invention.  
XX Sequence 30 BP; 13 A; 3 C; 5 G; 9 T; 0 other;  
SQ  
Query Match 2.4%; Score 30; DB 1; Length 30;  
Best Local Similarity 100.0%; Pred. No. 0.15;  
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1065 CATCAATATTGTCGACGAATTTGMAAA 1094  
DB 1 CATCAATATTGTCGACGAATTTGMAAA 30  
RESULT 6  
AAL55126/c  
ID AAL55126 standard; DNA; 30 BP.  
XX  
AC AAL55126;  
XX  
DT 16-APR-2003 (first entry)  
XX  
DE Nucleic acid synthesising method related PCR primer, SEQ ID No 7.  
XX  
KW Synthesising; target base sequence; annealing; genetic disease; SNP;  
KW single nucleotide polymorphism; cancer; PCR; primer; ss.  
XX  
OS Unidentified.  
XX  
PN WO200290538-A1.  
XX  
PD 14-NOV-2002.  
XX  
PF 08-MAY-2002; 2002WO-JP04479.  
XX  
PR 08-MAY-2001; 2001JP-0137060.  
PR 18-JUN-2001; 2001JP-0184131.  
XX  
PA (EIKS ) EIKEN KAGAKU KK.  
XX  
PI Nagamine K;  
XX  
DR WPI; 2003-120547/11.  
XX  
PT Synthesizing target base sequence-containing nucleic acids constituting  
PT complementary base sequences against template by the LAMP method,  
PT applicable in identifying genetic diseases, cancerization and  
PT microorganisms -  
XX  
PS Example 1; Page 62; 107pp; Japanese.  
XX  
CC The invention relates to a novel method for synthesising a target base  
CC sequence-containing nucleic acids. The method comprises the formation of  
CC single-stranded nucleic acids; synthesis of complementary strand by  
CC annealing; and producing single-stranded nucleic acid from a target base  
CC sequence by the synthesis of a complementary strand by annealing of a  
CC complementary base sequence. The method is useful for synthesising a  
CC target base sequence-containing nucleic acids, which is applicable in  
CC detecting SNP (single nucleotide polymorphism) in genes, identifying  
CC genetic diseases, cancer and microorganisms. Such a method can be  
CC easily, rapidly and freely carried out without being influenced by  
CC contamination or complicated temperature control, but with improved  
CC reaction specificity, high accuracy and efficiency, operable at low cost.  
CC This polynucleotide sequence represents a PCR primer used in the  
XX synthesising method of the invention.  
XX Sequence 30 BP; 13 A; 3 C; 5 G; 9 T; 0 other;  
SQ  
Query Match 2.4%; Score 30; DB 1; Length 30;  
Best Local Similarity 100.0%; Pred. No. 0.15;  
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1065 CATCAATATTGTCGACGAATTTGMAAA 1094  
DB 1 CATCAATATTGTCGACGAATTTGMAAA 30

CC detecting SNP (single nucleotide polymorphism) in genes, identifying  
CC genetic diseases, cancer and microorganisms. Such a method can be  
CC easily, rapidly and freely carried out without being influenced by  
CC contamination or complicated temperature control, but with improved  
CC reaction specificity, high accuracy and efficiency, operable at low cost.  
CC This polynucleotide sequence represents a PCR primer used in the  
XX synthesising method of the invention.  
XX Sequence 30 BP; 15 A; 2 C; 2 G; 11 T; 0 other;  
SQ  
Query Match 2.4%; Score 30; DB 1; Length 30;  
Best Local Similarity 100.0%; Pred. No. 0.15;  
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1045 TATTTAGCTATTATTATTAAGCATCAAAATAT 1074  
DB 30 TATTTAGCTATTATTATTAAGCATCAAAATAT 1  
RESULT 7  
AAL51650  
ID AAL51650 standard; DNA; 38 BP.  
XX  
AC AAL51650;  
XX  
DT 17-APR-2003 (first entry)  
XX  
DE Interleukin 8 capture probe.  
XX  
KW Probe; ss; messenger RNA amplification; capture probe;  
KW rolling circle replication; nucleic acid detection; disease detection;  
KW mutation detection; gene expression profiling; RNA expression profiling;  
KW gene discovery; gene mapping; agricultural research; virus detection;  
KW cancer; cystic fibrosis; muscular dystrophy; diabetes; haemophilia;  
KW sickle cell anaemia.  
XX  
OS Unidentified.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1 /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Modified with NH2-Cl2"  
XX  
PN WO2003008538-A2.  
XX  
PD 30-JAN-2003.  
XX  
PF 10-MAY-2002; 2002WO-US15045.  
XX  
PR 20-JUL-2001; 2001US-0910383.  
XX  
PA (MOLE-) MOLECULAR STAGING INC.  
XX  
PI Nallur GN, Luo C, Chowdhury K, Pinard R;  
XX  
DR WPI; 2003-221847/21.  
XX  
PT Amplifying messenger RNA for manipulating and detecting nucleic acid,  
PT disease and mutation detection, gene or RNA expression profiling and  
PT gene discovery, comprises associating a rolling circle replication  
PT primer with a cDNA strand -  
XX  
PS Example 3; Page 69; 103pp; English.  
XX  
CC The invention comprises a method for amplifying messenger RNA (mRNA). The  
CC method involves: mixing reverse transcription (RT) primers with a nucleic  
CC acid sample and reverse transcribing to produce cDNA strands; mixing the  
CC strands with capture probes, then with rolling circle replication  
CC primers; mixing amplification target circles with the primers; and  
CC incubating the circles to promote replication of the target circles - to  
CC form tandem sequence DNA. The method of the invention is useful for  
CC amplifying mRNA. The method is useful for manipulating and detecting

CC nucleic acids, disease and mutation detection, gene or RNA expression  
 CC profiling, gene discovery, gene mapping, agricultural research and virus  
 CC detection. Disorders which can be diagnosed by the method of the  
 CC invention include: cancer; cystic fibrosis; muscular dystrophy; diabetes;  
 CC haemophilia; sickle cell anaemia. The present DNA sequence represents a  
 CC capture probe used in an example of the invention.  
 XX  
 SQ Sequence 38 BP; 25 A; 1 C; 5 G; 7 T; 0 other;

Query Match 2.3%; Score 28.4; DB 1; Length 38;  
 Best Local Similarity 96.7%; Pred. No. 0.46;  
 Matches 29; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1091 AAAAATGAGATGATTCATTGATTAATA 1120  
 DB 9 AAAAAGAGATGATTCATTGATTAATA 38

RESULT 8  
 AAD21908  
 ID AAD21908 standard; DNA; 26 BP.  
 XX  
 AC AAD21908;  
 XX  
 DT 12-FEB-2002 (first entry)  
 XX  
 DE PCR primer, 2767T used to determine the genotype of human IL-8 gene.  
 XX  
 KW Human; Genetic variant identification; interleukin 8; RSV bronchiolitis;  
 KW respiratory syncytial virus; PCR primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177382-A2.  
 XX  
 PD 18-OCT-2001.  
 XX

PF 11-APR-2001; 2001WO-GB01634.  
 XX  
 PR 11-APR-2000; 2000GB-0008910.  
 XX  
 PA (ISIS-) ISIS INNOVATION LTD.  
 XX  
 PI Hull J, Kwiatkowski DP;  
 XX  
 DR WPI; 2002-017472/02.  
 XX  
 PT Nucleic acid comprising a sequence corresponding to variant allele of  
 PT human interleukin 8 gene, useful for determining susceptibility to  
 PT respiratory syncytial virus bronchiolitis in humans -  
 XX  
 PS Claim 42; Page 47; 49pp; English.  
 XX

CC The patent discloses methods for identification of genetic variants  
 CC at the interleukin 8 (IL-8) locus. The invention relates to nucleic  
 CC acid molecules corresponding to various alleles at the IL8 locus  
 CC and kits for the detection of the presence of variant alleles. The  
 CC polymorphic variants of the IL-8 locus are useful for screening a  
 CC human subject for susceptibility to a disease such as respiratory  
 CC syncytial virus (RSV) bronchiolitis for which increased production  
 CC of IL-8 is a risk factor. The polymorphic variants of IL-8 locus are  
 CC also useful for determining the likelihood that a patient previously  
 CC identified as infected with RSV will develop severe disease. They are  
 CC useful as probes and primers for genotyping. They are also useful for  
 CC initiating DNA synthesis or amplification for detecting the presence  
 CC of IL-8 genetic variants. The single nucleotide polymorphisms have a  
 CC general utility as a genetic marker. The present DNA sequence is PCR  
 CC primer, 2767T which is used to determine the genotype of human  
 CC IL-8 gene.  
 XX

SQ Sequence 26 BP; 9 A; 5 C; 2 G; 10 T; 0 other;

Query Match 2.1%; Score 26; DB 1; Length 26;

Best Local Similarity 100.0%; Pred. No. 1;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1228 CCAGTTAAATTTTCATTTCAGATAA 1253  
 DB 1 CCAGTTAAATTTTCATTTCAGATAA 26

RESULT 9  
 AAD21907  
 ID AAD21907 standard; DNA; 26 BP.  
 XX  
 AC AAD21907;  
 XX  
 DT 12-FEB-2002 (first entry)  
 XX  
 DE PCR primer, 2767A used to determine the genotype of human IL-8 gene.  
 XX  
 KW Human; Genetic variant identification; interleukin 8; RSV bronchiolitis;  
 KW respiratory syncytial virus; PCR primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200177382-A2.  
 XX  
 PD 18-OCT-2001.  
 XX

PF 11-APR-2001; 2001WO-GB01634.  
 XX  
 PR 11-APR-2000; 2000GB-0008910.  
 XX  
 PA (ISIS-) ISIS INNOVATION LTD.  
 XX  
 PI Hull J, Kwiatkowski DP;  
 XX  
 DR WPI; 2002-017472/02.  
 XX  
 PT Nucleic acid comprising a sequence corresponding to variant allele of  
 PT human interleukin 8 gene, useful for determining susceptibility to  
 PT respiratory syncytial virus bronchiolitis in humans -  
 XX  
 PS Claim 42; Page 47; 49pp; English.  
 XX

CC The patent discloses methods for identification of genetic variants  
 CC at the interleukin 8 (IL-8) locus. The invention relates to nucleic  
 CC acid molecules corresponding to various alleles at the IL8 locus  
 CC and kits for the detection of the presence of variant alleles. The  
 CC polymorphic variants of the IL-8 locus are useful for screening a  
 CC human subject for susceptibility to a disease such as respiratory  
 CC syncytial virus (RSV) bronchiolitis for which increased production  
 CC of IL-8 is a risk factor. The polymorphic variants of IL-8 locus are  
 CC also useful for determining the likelihood that a patient previously  
 CC identified as infected with RSV will develop severe disease. They are  
 CC useful as probes and primers for genotyping. They are also useful for  
 CC initiating DNA synthesis or amplification for detecting the presence  
 CC of IL-8 genetic variants. The single nucleotide polymorphisms have a  
 CC general utility as a genetic marker. The present DNA sequence is PCR  
 CC primer, 2767A which is used to determine the genotype of human  
 CC IL-8 gene.  
 XX

SQ Sequence 26 BP; 8 A; 5 C; 2 G; 11 T; 0 other;

Query Match 2.0%; Score 25; DB 1; Length 26;  
 Best Local Similarity 100.0%; Pred. No. 1.7;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1228 CCAGTTAAATTTTCATTTCAGATA 1252  
 DB 1 CCAGTTAAATTTTCATTTCAGATA 25

RESULT 10  
 ABS98731/c



ID ABS98731 standard; DNA; 24 BP.  
XX  
AC ABS98731;  
XX  
DT 18-DEC-2002 (first entry)  
XX  
DE Human beta thromboglobulin-like protein PCR primer #2.  
XX  
KW PCR; ss; primer; electronic microarray; primer extension;  
KW RNA polymerase recognition site; oncogenesis; cell growth;  
KW differentiation.  
XX  
OS Homo sapiens.  
XX  
PN US2002119484-A1.  
XX  
PD 29-AUG-2002.  
XX  
PF 12-FEB-2002; 2002US-0075579.  
XX  
PR 09-NOV-2000; 2000US-0710200.  
PR 07-JUL-1994; 94US-0271882.  
PR 24-JAN-2000; 2000US-0490965.  
XX  
PA (NANO-) NANOGEN INC.  
XX  
PI Weidenhammer EM, Xu X, Heller MJ, Kahl BP;  
XX  
PS WPI; 2002-750052/81.  
XX  
CC Determining mRNA expression in sample, by producing shortened amplicons  
CC from mRNA isolated from sample, electronically hybridizing amplicons to  
CC probes bound to a support, and detecting the amount of hybridized  
CC amplicons -  
XX  
XX Example 6; Page 14; 37pp; English.  
XX  
XX The invention relates to detecting (M1) relative amounts of at least 2  
XX mRNA sequences in a biological sample (BS), comprises isolating mRNA from  
XX BS, amplifying at least 2 mRNA transcripts from each BS to produce  
XX amplicons (A) less than about 300 bases in length, electronically  
XX hybridizing (A) to at least 2 probes bound to a support at  
XX predetermined locations, and detecting amounts of each (A) hybridised  
XX to the bound probes. Also included are (1) preserving (M2) and reusing a  
XX nucleic acid library produced from a patient biological sample, by:  
XX (a) isolating mRNA from a patient biological sample; (b) reverse-  
XX transcribing the mRNA to produce a cDNA library; (c) amplifying the cDNA  
XX library by a DNA polymerase reaction utilising at least one chimeric  
XX primer comprising a RNA polymerase recognition site upstream of a  
XX sequence specific for a mRNA transcript of interest and a fill-in primer  
XX for the complementary nucleic acid strand chosen from sequence specific  
XX primers and random primers (at least 1 of the primers used is chosen from  
XX 5' affinity-moiety labeled chimeric primers and 5' affinity-moiety  
XX labeled sequence specific fill-in primers); (d) binding the amplification  
XX products to a solid support coated with an affinity-binding moiety;  
XX (e) utilising the bound amplification products as a template for an in  
XX vitro transcription reaction; (f) separating the in vitro transcription  
XX products from the amplification products bound to the solid support; and  
XX (g) utilising the bound amplification products from step (h) as a  
XX template for at least one additional in vitro transcription reaction (the  
XX amount of in vitro transcription product produced is not significantly  
XX less than that produced in step (e)); (2) detecting (M3) the extent of  
XX hybridisation of a nucleic acid in a sample to a probe nucleic acid  
XX sequence; and (3) providing (M4) an internal control for an individual  
XX test site in a nucleic acid hybridisation reaction assay to determine the  
XX presence of at least one nucleic acid sequence of interest in at least one  
XX nucleic acid containing sample (the nucleic acid hybridisation assay is  
XX performed on an electronically controlled microarray comprising at  
XX least two test sites). M1 is useful for detecting the relative amounts  
XX of at least two mRNA sequences in a biological sample. M1 is useful for  
XX determining the level of mRNA expression in the cells of a biological  
XX sample, for gathering data to correlate difference in expression patterns  
XX with specific physiological and/or pathological states, for studying

CC expression of genes in organisms under various physiological conditions,  
CC for studying the role of gene expression in diseases and oncogenesis,  
CC physio-chemical cellular responses to stimuli, and cell growth and  
CC differentiation, for titrating the amount of amplified mRNA present in a  
CC sample, and to compare, side by side, the expression levels of mRNA in a  
CC cell type that has undergone two physical or chemical stimuli.  
CC The method uses primer extension and an active electronic microarray.  
CC The present sequence is a gene specific primer used in the method  
CC of the invention.  
XX  
SQ Sequence 24 BP; 9 A; 11 C; 3 G; 1 T; 0 other;  
Query Match 1.9%; Score 24; DB 1; Length 24;  
Best Local Similarity 100.0%; Pred. No. 2.5;  
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 475 GTGTGGGTCTGTGTAGGGTTGCC 498  
DB 24 GTGTGGGTCTGTGTAGGGTTGCC 1  
RESULT 11  
AAD39937/C  
ID AAD39937 standard; DNA; 24 BP.  
XX  
AC AAD39937;  
XX  
DT 22-OCT-2002 (first entry)  
XX  
DE Human primer #2 to amplify beta-thromboglobulin-like protein target gene.  
XX  
KW Human; amplicon; electronic hybridisation; gene expression; oncogenesis;  
KW physio-chemical cellular response; stimuli; cell growth; differentiation;  
KW PCR; primer; beta-thromboglobulin-like protein; ss.  
XX  
OS Homo sapiens.  
XX  
PN US6379897-B1.  
XX  
PD 30-APR-2002.  
XX  
PF 09-NOV-2000; 2000US-0710200.  
XX  
PR 09-NOV-2000; 2000US-0710200.  
XX  
PA (NANO-) NANOGEN INC.  
XX  
PI Weidenhammer EM, Wang L, Xu X, Heller MJ, Kahl BP;  
XX  
PS WPI; 2002-424785/45.  
XX  
CC Detecting relative amounts of at least two different mRNAs in  
XX biological samples by electronically hybridizing amplicons to probes,  
XX useful to monitor gene expression in disease and in cell response  
XX studies -  
XX  
XX Example 6; Column 51; 36pp; English.  
XX  
XX The invention relates to a method for detecting the relative amounts of  
XX at least two different mRNA sequences in biological samples. The method  
XX comprising isolating sample mRNA, amplifying at least two mRNAs to  
XX produce amplicons of not more than 300 bases, electronically hybridising  
XX the amplicons to probes bound to a support at predetermined locations and  
XX detecting amounts of hybridised amplicons. The method may be used to  
XX monitor gene expression in the study of disease and oncogenesis, physio-  
XX chemical cellular responses to stimuli and cell growth and  
XX differentiation. The present sequence is a human PCR primer used for  
XX amplifying beta-thromboglobulin-like protein target gene.  
XX  
SQ Sequence 24 BP; 9 A; 11 C; 3 G; 1 T; 0 other;  
Query Match 1.9%; Score 24; DB 1; Length 24;  
Best Local Similarity 100.0%; Pred. No. 2.5;



Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GTGCGGCTCTGTGAGGTTGCC 498  
 |||||  
 DB 24 GTGCGGCTCTGTGAGGTTGCC 1

RESULT 12  
 ABX79046/c  
 ID ABX79046 standard; DNA; 24 BP.

AC ABX79046;  
 XX  
 XX  
 XX 15-APR-2003 (first entry)  
 DE Electronic microarray associated oligonucleotide #2.  
 XX  
 XX Electronic microarray; utilizing gene expression experimental model;  
 KW oncogenesis; physio-chemical cellular response; cell growth;  
 KW cell differentiation; ss.  
 XX  
 XX Homo sapiens.  
 OS  
 XX US2002150917-A1.  
 FN  
 XX 17-OCT-2002.  
 PD  
 XX 10-OCT-2001; 2001US-0975408.  
 PF  
 XX 09-NOV-2000; 2000US-0710200.  
 PR  
 XX (NANO-) NANOGEN INC.  
 PA  
 XX Weidenhammer EM, Wang L, Xu X, Heller MJ, Kahl BP;  
 PI WPI; 2003-198284/19.  
 DR  
 XX  
 XX Detecting relative amounts of at least two mRNA utilizing  
 PT microelectronic arrays in a sample, useful for studying disease and  
 PT oncogenesis, physio-chemical cellular responses to stimuli, and cell  
 PT growth and differentiation -  
 XX  
 XX Example 6; Page 15; 39pp; English.

PS The invention describes a method of detecting the relative amounts of at  
 CC least two mRNA sequences in at least one biological sample, comprising:  
 CC (a) isolating mRNA from the sample;  
 CC (b) amplifying at least two mRNA transcripts to produce amplicons;  
 CC (c) electronically hybridising the amplicons produced to at least two  
 CC probes bound to a support at predetermined locations; and  
 CC (d) detecting the amounts of each amplicon hybridised to the bound  
 CC probes at the predetermined locations.  
 CC The methods and compositions are useful for utilising gene expression  
 CC experimental models for use in studying disease and oncogenesis.  
 CC Physio-chemical cellular responses to stimuli, and cell growth and  
 CC differentiation. This sequence represents an oligonucleotide targeted  
 CC to a human gene and used to demonstrate the methods described in  
 CC the invention.  
 XX  
 XX Sequence 24 BP; 9 A; 11 C; 3 G; 1 T; 0 other;

Query Match 1.9%; Score 24; DB 1; Length 24;  
 Best Local Similarity 100.0%; Pred.No. 2.5;  
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GTGCGGCTCTGTGAGGTTGCC 498  
 |||||  
 DB 24 GTGCGGCTCTGTGAGGTTGCC 1

RESULT 13  
 AAT06866/c  
 ID AAT06866 standard; DNA; 21 BP.

XX AAT06866;  
 AC  
 XX 27-JUN-1996 (first entry)  
 DT  
 XX Psoriasis susceptibility probe #10.  
 DE  
 XX Interleukin enhancer binding factor; ILF; probe; psoriasis; gene therapy;  
 KW interleukin-8; IL-8; familial psoriasis; linkage analysis; chromosome 17;  
 KW ss.  
 XX  
 XX Synthetic.  
 OS  
 XX WO9533208-A1.  
 FN  
 XX 30-NOV-1995.  
 PD  
 XX 19-MAY-1995; 95WO-US06356.  
 PF  
 XX 20-MAY-1994; 94US-0246855.  
 PR  
 XX (TEXA) UNIV TEXAS SYSTEM.  
 PA  
 XX Bowcock A, Gaynor R, Menter A, Tomfohrde J;  
 XX WPI; 1996-020600/02.  
 DR  
 XX Screening families for susceptibility to psoriasis - by hybridising  
 PT DNA to probe corresponding to susceptibility locus, also new locus  
 PT and psoriasis genes located on chromosome 17q  
 XX  
 XX Claim 18; Page 75; 93pp; English.

PS AAT06866 represent sequences used in the method of the invention  
 CC for screening for psoriasis susceptibility. In the method, DNA is  
 CC obtained from an unaffected and an affected family member. A family  
 CC specific allele of a polymorphism present in the patients sample is  
 CC identified. The polymorphism is linked with a gene for interleukin  
 CC enhancer binding factor (ILF) or interleukin-8 (IL-8). This thereby  
 CC identifies a familial psoriasis susceptibility locus. A probe sequence  
 CC (such as this sequence) is prepared and used to screen nucleic acid  
 CC samples from members of the family. This sequence represents a psoriasis  
 CC susceptibility probe of the invention. The probes can be used in linkage  
 CC analysis and hybridisation studies on chromosome 17 (where the psoriasis  
 CC gene is located), and for detecting a genetic lesion or polymorphism in a  
 CC 17q distal region. Polymorphism in a gene from this region indicates an  
 CC inherited germ-line mutation related to familial psoriasis. Wild type  
 CC forms of psoriasis genes may be used in gene therapy of this disease.

XX Sequence 21 BP; 6 A; 5 C; 4 G; 6 T; 0 other;  
 SQ

Query Match 1.7%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred.No. 9.9;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 403 TCTGTGATATCCAGATTCAG 423  
 |||||  
 DB 21 TCTGTGATATCCAGATTCAG 1

RESULT 14  
 AAH62016  
 ID AAH62016 standard; DNA; 21 BP.

XX  
 AC AAH62016;  
 XX  
 XX 10-SEP-2001 (first entry)  
 DT  
 XX IL8 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4440.  
 DE  
 XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
 KW recognition site; target; ribozyme binding site; eye disease; vulnary;  
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;

KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
 KW antickling; ophthalmological; keratolytic; gene therapy; viral wart;  
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
 KW sickle cell retinopathy; ss.  
 OS Homo sapiens.  
 OS Synthetic.  
 XX WO200130362-A2.  
 FN 03-MAY-2001.  
 XX 26-OCT-2000; 2000WO-US29500.  
 XX 26-OCT-1999; 99US-0161532.  
 XX (IMMU-) IMMUSOL INC.  
 PA Robbins JM, Tritz R;  
 PI WPI; 2001-300427/31.  
 DR Treating proliferative skin or eye diseases and scarring, using  
 XX ribozymes that cleave RNA encoding cytokines involved in inflammation,  
 PT matrix metalloproteinases, growth factors and cell-cycle dependent  
 PT kinases -  
 XX Example 1; Page 22; 408pp; English.  
 PS The present invention describes a method for treating a proliferative  
 CC skin or eye disease and scarring. The method involves administering a  
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
 CC dependent kinase, growth factor or a reductase, or administering a  
 CC nucleic acid molecule (II) comprising a promoter operably linked to a  
 CC nucleic acid segment encoding (I). (I) can have antipsoriatic,  
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antickling,  
 CC ophthalmological, vulnary, keratolytic and virucide activities, and  
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
 CC in gene therapy. (I) and (II) are useful for treating proliferative  
 CC skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
 CC also be used for treating proliferative eye diseases such as diabetic  
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
 CC prematurity and retinal detachment, and for treating and preventing  
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
 CC scar. AAH57577 to AAH62099 represent sequences used in the  
 CC exemplification of the present invention.  
 XX Sequence 21 BP; 1 A; 1 C; 10 G; 9 T; 0 other;  
 SQ Query Match 1.7%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 9.9;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 473 TTGTGCGGCTGTGTGAGG 493  
 DB 1 TTGTGCGGCTGTGTGAGG 21  
 RESULT 15  
 ID AAH62018 standard; DNA; 21 BP.  
 XX AAH62018;  
 AC AAH62018;  
 XX 10-SEP-2001 (first entry)  
 DT IL6 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4442.  
 DB IL6 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4442.  
 XX

KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
 KW recognition site; target; ribozyme binding site; eye disease; vulnary;  
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
 KW antickling; ophthalmological; keratolytic; gene therapy; viral wart;  
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
 KW sickle cell retinopathy; ss.  
 XX Homo sapiens.  
 OS Synthetic.  
 XX WO200130362-A2.  
 FN 03-MAY-2001.  
 XX 26-OCT-2000; 2000WO-US29500.  
 XX 26-OCT-1999; 99US-0161532.  
 XX (IMMU-) IMMUSOL INC.  
 PA Robbins JM, Tritz R;  
 PI WPI; 2001-300427/31.  
 DR Treating proliferative skin or eye diseases and scarring, using  
 XX ribozymes that cleave RNA encoding cytokines involved in inflammation,  
 PT matrix metalloproteinases, growth factors and cell-cycle dependent  
 PT kinases -  
 XX Example 1; Page 22; 408pp; English.  
 PS The present invention describes a method for treating a proliferative  
 CC skin or eye disease and scarring. The method involves administering a  
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
 CC dependent kinase, growth factor or a reductase, or administering a  
 CC nucleic acid molecule (II) comprising a promoter operably linked to a  
 CC nucleic acid segment encoding (I). (I) can have antipsoriatic,  
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antickling,  
 CC ophthalmological, vulnary, keratolytic and virucide activities, and  
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
 CC in gene therapy. (I) and (II) are useful for treating proliferative  
 CC skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
 CC also be used for treating proliferative eye diseases such as diabetic  
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
 CC prematurity and retinal detachment, and for treating and preventing  
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
 CC scar. AAH57577 to AAH62099 represent sequences used in the  
 CC exemplification of the present invention.  
 XX Sequence 21 BP; 5 A; 8 C; 4 G; 4 T; 0 other;  
 SQ Query Match 1.7%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 9.9;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 853 CAACCTAGTCTGTGAGCAG 873  
 DB 1 CAACCTAGTCTGTGAGCAG 21  
 RESULT 16  
 ID ABL46343 standard; DNA; 21 BP.  
 XX ABL46343;  
 AC ABL46343;  
 XX 26-APR-2002 (first entry)  
 DT

XX DE Human interleukin-1 beta oligonucleotide SEQ ID NO:310.  
XX KW Nucleic acid accessible hybridisation site; detection; hybridisation;  
KW characterisation; identification; nucleic acid structure; diagnosis;  
XX PCR primer; probe; ss.  
XX OS Homo sapiens.  
OS Synthetic.  
XX PN WO200198537-A2.  
XX PD 27-DEC-2001.  
XX PF 15-JUN-2001; 2001WO-US19401.  
XX PR 17-JUN-2000; 2000US-212308P.  
XX PR 15-JUN-2001; 2001US-0212308.  
XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX PI Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;  
XX MPI; 2002-049698/06.  
XX PT Identifying oligonucleotides hybridizing to nucleic acids containing  
PT secondary structure, useful in clinical diagnosis, comprises  
PT identifying primers that interact with the target to form an extension  
PT product under amplification conditions -  
XX FS Claim 48; Fig 81A; 409pp; English.  
XX CC The present invention describes a method for identifying oligonucleotides  
CC with desired hybridisation properties to nucleic acid targets containing  
CC secondary structure. The method comprises amplifying a target nucleic  
CC acid having at least one accessible and one inaccessible site. Primers  
CC that form an extension product are identified as the oligonucleotides  
CC from the present invention can be used in novel detection methods for  
CC clinical diagnostic purposes, including the detection and identification  
CC of pathogenic organisms (e.g. HIV). The method allows the ability to  
CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent  
XX sequences used in the exemplification of the present invention.  
XX SQ Sequence 21 BP; 7 A; 2 C; 4 G; 8 T; 0 other;  
Query Match 1.7%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 9.9;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 717 GAACCTTTAATTTCAGGAATTG 737  
Db 1 GAACCTTTAATTTCAGGAATTG 21  
RESULT 17  
ABL46345  
ID ABL46345 standard; DNA; 21 BP.  
XX AC ABL46345;  
XX DT 26-APR-2002 (first entry)  
XX DE Human interleukin-1 beta oligonucleotide SEQ ID NO:312.  
XX KW Nucleic acid accessible hybridisation site; detection; hybridisation;  
KW characterisation; identification; nucleic acid structure; diagnosis;  
XX PCR primer; probe; ss.  
XX OS Homo sapiens.  
OS Synthetic.  
XX PN WO200198537-A2.

XX PD 27-DEC-2001.  
XX PF 15-JUN-2001; 2001WO-US19401.  
XX PR 17-JUN-2000; 2000US-212308P.  
XX PR 15-JUN-2001; 2001US-0212308.  
XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX PI Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;  
XX MPI; 2002-049698/06.  
XX PT Identifying oligonucleotides hybridizing to nucleic acids containing  
PT secondary structure, useful in clinical diagnosis, comprises  
PT identifying primers that interact with the target to form an extension  
PT product under amplification conditions -  
XX FS Claim 48; Fig 81A; 409pp; English.  
XX CC The present invention describes a method for identifying oligonucleotides  
CC with desired hybridisation properties to nucleic acid targets containing  
CC secondary structure. The method comprises amplifying a target nucleic  
CC acid having at least one accessible and one inaccessible site. Primers  
CC that form an extension product are identified as the oligonucleotides  
CC from the present invention can be used in novel detection methods for  
CC clinical diagnostic purposes, including the detection and identification  
CC of pathogenic organisms (e.g. HIV). The method allows the ability to  
CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent  
XX sequences used in the exemplification of the present invention.  
XX SQ Sequence 21 BP; 7 A; 4 C; 2 G; 8 T; 0 other;  
Query Match 1.7%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 9.9;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 1017 TTCAGGTGTAACCTTAATAC 1037  
Db 1 TTCAGGTGTAACCTTAATAC 21  
RESULT 18  
AAH76783/c  
ID AAH76783 standard; DNA; 24 BP.  
XX AC AAH76783;  
XX DT 14-DEC-2001 (first entry)  
XX DE Human nuclear transforming protein 13 RT-PCR primer, SEQ ID NO:4.  
XX KW Human; nuclear transforming protein 13; ATP/GTP binding domain;  
KW recombinant production; malignant tumour; cancer; blood disease;  
KW HIV infection; human immunodeficiency virus; immune disorder;  
KW inflammatory condition; cytostatic; anti-HIV; antiinflammatory;  
KW immunomodulator; reverse transcription-PCR; RT-PCR primer; ss.  
XX OS Homo sapiens.  
XX PN WO200172800-A1.  
XX PD 04-OCT-2001.  
XX PF 26-MAR-2001; 2001WO-CN00437.  
XX PR 27-MAR-2000; 2000CN-0115183.  
XX PA (SHAN-) SHANGHAI BIONDOWN GENE DEV INC.  
XX PI Mao Y, Xie Y;

XX WPI; 2001-597103/67.  
 XX Human nuclear transforming protein 13 containing ATP/GTP binding domain  
 PT and encoded polynucleotide, applicable in diagnosis and treatment of  
 PT malignant neoplasm, hemopathy, HIV infection, immunological diseases  
 PT and inflammations  
 XX  
 XX Example 2; Page 18; 37pp; Chinese.  
 PS  
 XX The invention relates to human nuclear transforming protein 13  
 CC (AAG66744), nucleic acids encoding it (AAH76781), and a method for the  
 CC recombinant production of nuclear transforming protein 13. The protein  
 CC contains an ATP/GTP binding domain and has a molecular weight of 13 kD.  
 CC The present invention additionally discloses an antagonist of nuclear  
 CC transforming protein 13 for therapeutic use, and an antibody which  
 CC specifically binds to human nuclear transforming protein 13. Nuclear  
 CC transforming protein 13, and nucleotides which encode it may be used  
 CC for treating a variety of diseases, such as malignant tumours, blood  
 CC diseases, HIV (human immunodeficiency virus) infection, immune disorders  
 CC and inflammatory conditions. The protein may also be used to screen for  
 CC modulators of its activity or for peptide fingerprinting identification.  
 CC The polynucleotide can be used as a primer for nucleic acid amplification  
 CC reactions or as a probe for hybridisation reactions, or in producing gene  
 CC chips or microarrays. Sequences AAH76782-AAH76783 represent reverse  
 CC transcription-PCR (RT-PCR) primers used in an exemplification of the  
 CC invention to isolate human nuclear transforming protein 13 cDNA.  
 XX  
 SQ Sequence 24 BP; 6 A; 4 C; 1 G; 13 T; 0 other;  
 Query Match 1.7%; Score 20.8; DB 1; Length 24;  
 Best Local Similarity 91.7%; Pred. No. 13;  
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1062 AAGCATCAAAATATTGTGCAAGAA 1085  
 Db 24 AAGATATAAATATTGTGCAAGAA 1  
 |||||  
 RESULT 19  
 AAV44676/c  
 ID AAV44676 standard; DNA; 20 BP.  
 XX AAV44676;  
 AC  
 XX 08-OCT-1998 (first entry)  
 DT  
 XX PCR primer for UC Band#325-1.  
 DE  
 XX DNA marker; metastatic prostate cancer; human; detection; PCR primer;  
 KW disease marker identification; lupus erythematosus; rheumatoid arthritis;  
 KW multiple sclerosis; asthma; myasthenia gravis; autoimmune thyroiditis;  
 KW amyloid lateral sclerosis; interstitial cystitis; prostatitis;  
 KW UC Band#325-1; ss.  
 OS Synthetic.  
 OS Homo sapiens.  
 XX WO9824935-A1.  
 PN  
 XX 11-JUN-1998.  
 PD  
 XX 05-DEC-1997; 97WO-US22105.  
 XX  
 XX 24-MAR-1997; 97US-0041576.  
 PR 06-DEC-1996; 96US-0032619.  
 PR 12-DEC-1996; 96US-0032701.  
 XX (UROC-) UROCOR INC.  
 PA  
 XX An G, O'Hara M, Ralph D, Veltri R;  
 PI WPI; 1998-333350/29.

XX Identifying markers for disease states - by amplifying RNA from  
 PT peripheral blood and identifying RNA which is differential expressed  
 PT between normal and disease state subjects  
 XX  
 XX Example 3; Page 91; 158pp; English.  
 PS  
 XX This sequence is a PCR primer for the marker DNA sequence UC Band#325-1  
 CC and was used in the method of the invention. The method is for  
 CC identifying markers for a disease state, and comprises: (a) providing a  
 CC first set of peripheral blood mRNAs from one or more subjects known to  
 CC exhibit the disease state and a second set of peripheral blood mRNAs from  
 CC one or more normal subjects; (b) amplifying both sets of mRNAs to provide  
 CC nucleic acid amplification products; (c) comparing the sets of  
 CC amplification products; and (d) identifying those mRNAs that are  
 CC differentially expressed between normal subjects and subjects exhibiting  
 CC the disease state; where a difference in quantity of expression of an  
 CC mRNA is indicative of a disease marker. The identified marker  
 CC sequence can be used in a method of detecting a metastatic cancer disease  
 CC state, especially for detection prostate cancer. Using the methods, a  
 CC disease state may be detected, diagnosed, or a prognosis may be delivered  
 CC by examining a blood sample rather than relying on a more invasive, or  
 CC less sensitive test. In addition, a subject may be monitored for disease  
 CC progression, status and response to therapies through monitoring of  
 CC differentially expressed disease markers. The methods can be used for  
 CC diseases such as cancer (especially metastatic or prostate cancer),  
 CC asthma, lupus erythematosus, rheumatoid arthritis, multiple sclerosis,  
 CC myasthenia gravis, autoimmune thyroiditis, amyloid lateral sclerosis,  
 CC interstitial cystitis, prostatitis or other systemic or chronic conditions.  
 XX  
 SQ Sequence 20 BP; 7 A; 8 C; 3 G; 2 T; 0 other;  
 Query Match 1.6%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 15;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 480 GGTCTGTTGTAGGGTTGCCA 499  
 Db 20 GGTCTGTTGTAGGGTTGCCA 1  
 |||||  
 RESULT 20  
 AAV44678/c  
 ID AAV44678 standard; DNA; 20 BP.  
 XX AAV44678;  
 AC  
 XX 08-OCT-1998 (first entry)  
 DT  
 XX PCR primer for UC Band#325-2.  
 DE  
 XX DNA marker; metastatic prostate cancer; human; detection; PCR primer;  
 KW disease marker identification; lupus erythematosus; rheumatoid arthritis;  
 KW multiple sclerosis; asthma; myasthenia gravis; autoimmune thyroiditis;  
 KW amyloid lateral sclerosis; interstitial cystitis; prostatitis;  
 KW UC Band#325-2; ss.  
 OS Synthetic.  
 OS Homo sapiens.  
 XX WO9824935-A1.  
 PN  
 XX 11-JUN-1998.  
 PD  
 XX 05-DEC-1997; 97WO-US22105.  
 XX  
 XX 24-MAR-1997; 97US-0041576.  
 PR 06-DEC-1996; 96US-0032619.  
 PR 12-DEC-1996; 96US-0032701.  
 XX (UROC-) UROCOR INC.  
 PA  
 XX An G, O'Hara M, Ralph D, Veltri R;  
 PI

XX DR WPI; 1998-333350/29.  
 XX CC  
 PT Identifying markers for disease states - by amplifying RNA from  
 PT peripheral blood and identifying RNA which is differential expressed  
 PT between normal and disease state subjects  
 XX CC  
 PS Example 3; Page 91; 158pp; English.  
 XX CC  
 CC This sequence is a PCR primer for the marker DNA sequence UC Band#325-2  
 CC and was used in the method of the invention. The method is for  
 CC identifying markers for a disease state, and comprises: (a) providing a  
 CC first set of peripheral blood mRNAs from one or more subjects known to  
 CC exhibit the disease state and a second set of peripheral blood mRNAs from  
 CC one or more normal subjects; (b) amplifying both sets of mRNAs to provide  
 CC nucleic acid amplification products; (c) comparing the sets of  
 CC amplification products; and (d) identifying those mRNAs that are  
 CC differentially expressed between normal subjects and subjects exhibiting  
 CC the disease state; where a difference in quantity of expression of an  
 CC mRNA is indicative of a disease marker. The identified marker  
 CC sequence can be used in a method of detecting a metastatic cancer disease  
 CC state, especially for detection, diagnosed, or a prognosis may be delivered  
 CC by examining a blood sample rather than relying on a core invasive, or  
 CC less sensitive test. In addition, a subject may be monitored for disease  
 CC progression, status and response to therapies through monitoring of  
 CC differentially expressed disease markers. The methods can be used for  
 CC diseases such as cancer (especially metastatic or prostate cancer),  
 CC asthma, lupus erythematosus, rheumatoid arthritis, multiple sclerosis,  
 CC myasthenia gravis, autoimmune thyroiditis, amyloid lateral sclerosis,  
 CC interstitial cystitis, prostatitis or other systemic or chronic conditions.  
 XX SQ Sequence 20 BP; 7 A; 8 C; 3 G; 2 T; 0 other;

Query Match 1.6%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 15;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 GGTCTGTGTAGGGTTCGA 499  
 DB 20 GGTCTGTGTAGGGTTCGA 1

RESULT 21  
 AAZ30727/c  
 ID AAZ30727 standard; DNA; 20 BP.  
 AC AAZ30727;  
 DT 19-JAN-2000 (first entry)  
 DE Human interleukin-8 (IL-8) RT-PCR primer #11.  
 KW Interleukin-8; IL-8; marker; expression; diagnosis;  
 KW differential; disease; cancer; metastatic; breast cancer; prostate;  
 KW peripheral leukocyte; immune response; asthma; lupus erythematosus;  
 KW rheumatoid arthritis; multiple sclerosis; myasthenia gravis;  
 KW autoimmune thyroiditis; amyotrophic lateral sclerosis; ALS;  
 KW interstitial cystitis; prostatitis; mRNA; reverse transcriptase PCR;  
 KW RT-PCR; screening; early; diagnosis; prognosis; monitoring; primer; ss.  
 XX OS Synthetic.  
 OS Homo sapiens.  
 PV WO9949083-A1.  
 XX 30-SEP-1999.  
 XX 24-MAR-1999; 99WO-US06488.  
 XX 24-MAR-1998; 98US-0046894.  
 XX (UROC-) UROCOR INC.

XX PI Ralph D, An G, O'Hara SM, Veltri RW;  
 XX WPI; 1999-591105/50.  
 DR Identifying markers of human disease, specifically for diagnosis of  
 PT metastatic prostatic and breast cancers -  
 XX CC  
 PS Example 3; Page 122; 225pp; English.  
 XX CC  
 CC This sequence represents human interleukin-8 (IL-8) reverse  
 CC transcriptase-PCR (RT-PCR) primer #11, used with primers #10 (AAZ30726)  
 CC or #12 (AAZ30728) to amplify 2 different IL-8 cDNAs (AAZ30714-230715)  
 CC from peripheral leukocyte RNA. IL-8 cDNA is referred to in this  
 CC specification as UC Band #325-1, while an IL-8 cDNA containing intron #3  
 CC is referred to as UC Band #325-2. The IL-8 gene was found to be  
 CC differentially expressed between healthy subjects and patients with  
 CC metastatic cancers (especially those of the prostate or breast) and may  
 CC therefore be used as a marker for such diseases. Detecting levels of such  
 CC human disease markers is used for diagnosis (also prognosis and  
 CC monitoring) of diseases, including metastatic or organ-confined cancers,  
 CC and diseases which also elicit an immune response such as asthma, lupus  
 CC erythematosus, rheumatoid arthritis, multiple sclerosis, myasthenia  
 CC gravis, autoimmune thyroiditis, amyotrophic lateral sclerosis (ALS),  
 CC interstitial cystitis and prostatitis, but especially metastatic  
 CC prostatic and breast cancer. A particular use is differentiating between  
 CC prostatic cancer and benign prostatic hypertrophy, and between advanced  
 CC and localised prostatic cancer, by multivariate analysis of several  
 CC different markers. Cancers can be treated by administering sequences  
 CC antisense to sequences that encode human disease markers. This method  
 CC detects a leukocyte response to disease rather than products of diseased  
 CC cells, so is suitable for large-scale screening of asymptomatic subjects.  
 CC Disease can be detected at an early stage, when few, if any, diseased  
 CC cells are present in the circulation. Analysis of blood samples  
 CC eliminates the need for more invasive methods for obtaining samples.  
 XX SQ Sequence 20 BP; 7 A; 8 C; 3 G; 2 T; 0 other;

Query Match 1.6%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 15;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 GGTCTGTGTAGGGTTCGA 499  
 DB 20 GGTCTGTGTAGGGTTCGA 1

RESULT 22  
 ABL46342  
 ID ABL46342 standard; DNA; 20 BP.  
 AC ABL46342;  
 XX 26-APR-2002 (first entry)  
 DT Human interleukin-1 beta oligonucleotide SEQ ID NO:309.  
 DE Nucleic acid accessible hybridisation site; detection; hybridisation;  
 DE characterisation; identification; nucleic acid structure; diagnosis;  
 KW PCR primer; probe; ss.  
 XX OS Homo sapiens.  
 OS Synthetic.  
 PV WO200198537-A2.  
 XX 27-DEC-2001.  
 XX 15-JUN-2001; 2001WO-US19401.  
 XX 17-JUN-2000; 2000US-212308P.  
 XX 15-JUN-2001; 2001US-0212308.

PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
 XX Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;  
 XX WPI; 2002-049698/06.  
 XX Identifying oligonucleotides hybridizing to nucleic acids containing  
 PT secondary structure, useful in clinical diagnosis, comprises  
 PT identifying primers that interact with the target to form an extension  
 PT product under amplification conditions -  
 XX  
 PS Claim 48; Fig 81A; 409pp; English.  
 XX  
 CC The present invention describes a method for identifying oligonucleotides  
 CC with desired hybridisation properties to nucleic acid targets containing  
 CC secondary structure. The method comprises amplifying a target nucleic  
 CC acid having at least one accessible and one inaccessible site. Primers  
 CC that form an extension product are identified as the oligonucleotides  
 CC which can interact with the folded target nucleic acid. Oligonucleotides  
 CC from the present invention can be used in novel detection methods for  
 CC clinical diagnostic purposes, including the detection and identification  
 CC of pathogenic organisms (e.g. HIV). The method allows the ability to  
 CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent  
 CC sequences used in the exemplification of the present invention.  
 XX  
 SQ Sequence 20 BP; 7 A; 5 C; 2 G; 6 T; 0 other;  
 XX  
 Query Match 1.6%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 15;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX  
 QY 557 CATTGTACCATGAATATCC 576  
 DB 1 CATTGTACCATGAATATCC 20  
 XX  
 RESULT 23  
 AAT76367/c  
 ID AAT76367 standard; DNA; 19 BP.  
 XX  
 AC AAT76367;  
 XX  
 DT 15-SEP-1997 (first entry)  
 XX  
 DE Human interleukin 8 antisense oligonucleotide HUMIL8AAS4.  
 XX  
 KW Asthma; airway epithelium; adenosine free; cystic fibrosis;  
 KW chronic obstructive pulmonary disease; bronchitis; ss.  
 XX  
 OS Synthetic.  
 XX  
 FN WO9640162-A1.  
 XX  
 PD 19-DEC-1996.  
 XX  
 PF 06-JUN-1996; 96WO-US09306.  
 XX  
 PR 07-JUN-1995; 95US-0474497.  
 XX  
 PA (UYEC-) UNIV EAST CAROLINA.  
 XX  
 PI Metzger WJ, Nyce JW;  
 XX  
 WPI; 1997-051871/05.  
 XX  
 XX Treatment of airway diseases such as asthma - by topically applying  
 PT adenosine-free antisense oligo:nucleotide to airway epithelium of  
 PT subject  
 XX  
 PS Claim 5; Page 36; 71pp; English.  
 XX  
 CC A method for treating airway disease in a subject has been produced,  
 CC which involves the topical administration of an essentially adenosine

CC free antisense oligonucleotide (ON) to the airway epithelium of the  
 CC subject. The present sequence is an antisense oligonucleotide  
 CC HUMIL8AAS4 specific for the human interleukin 8. The method can  
 CC be used to treat airway diseases such as cystic fibrosis, asthma,  
 CC chronic obstructive pulmonary disease, bronchitis and other  
 CC airway diseases characterised by an inflammatory response. By  
 CC eliminating adenosine from the antisense ON, its liberation upon  
 CC antisense degradation is prevented, thereby preventing adenosine-  
 CC induced bronchoconstriction in patients with hyper-reactive airways.  
 XX  
 SQ Sequence 19 BP; 0 A; 8 C; 4 G; 7 T; 0 other;  
 XX  
 Query Match 1.5%; Score 19; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 24;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX  
 QY 693 GGGCCACAGGGCCACAGAGAA 711  
 DB 19 GGGCCACAGGGCCACAGAGAA 1  
 XX  
 RESULT 24  
 AAX54168/c  
 ID AAX54168 standard; DNA; 19 BP.  
 XX  
 AC AAX54168;  
 XX  
 DT 05-JUL-1999 (first entry)  
 XX  
 DE Human IL-3 antisense oligonucleotide fragment.  
 XX  
 KW Antisense oligonucleotide; multiple target; antisense treatment;  
 KW impaired respiration; inflammation; lung disease;  
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;  
 KW acute asthma; allergy; asthma; impeded respiration;  
 KW respiratory distress syndrome; pain; cystic fibrosis;  
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;  
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;  
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;  
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;  
 KW prostate cancer; ss.  
 XX  
 OS Synthetic.  
 XX  
 FN WO9913886-A1.  
 XX  
 PD 25-MAR-1999.  
 XX  
 PF 17-SEP-1998; 98WO-US19419.  
 XX  
 PR 09-JUN-1998; 98US-0093972.  
 PR 17-SEP-1997; 97US-0059160.  
 XX  
 PA (UYEC-) UNIV EAST CAROLINA.  
 XX  
 PI Nyce JW;  
 XX  
 WPI; 1999-229400/19.  
 XX  
 DR New antisense oligonucleotides used in treatment of, e.g. pulmonary  
 PT vasoconstriction  
 XX  
 PS Disclosure; Page 55; 120pp; English.  
 XX  
 CC The specification describes antisense oligonucleotides (AAX52869-X55271)  
 CC directed against at least 2 mRNAs selected from target genes, coding and  
 CC non-coding regions of mRNAs corresponding to target genes, gene  
 CC initiation codons, genomic flanking regions, intron-exon borders, the  
 CC 5'-end, the 3'-end and the junction between coding and non-coding  
 CC regions and all segments of mRNAs encoding proteins associated with one  
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides  
 CC may be derived from sequences AAX5272-74. These multiple target  
 CC oligonucleotides (specifically AAX55180-271) can be used for the

CC antineoplastic treatment of diseases and conditions. Typical diseases and  
 CC conditions are those associated with impaired respiration and  
 CC inflammation, including lung diseases, pulmonary vasoconstriction,  
 CC inflammation, allergic rhinitis, acute asthma, allergies, asthma, impeded  
 CC respiration, respiratory distress syndrome, pain, cystic fibrosis,  
 CC pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic  
 CC obstructive pulmonary disease (COPD), and cancers such as leukemias,  
 CC lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer,  
 CC pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma,  
 CC hepatic metastases, as well as all types of cancers which may metastasize  
 CC or have metastasized to the lungs, including breast and prostate cancer.  
 CC  
 XX Sequence 19 BP; 0 A; 8 C; 4 G; 7 T; 0 other;

Query Match 1.5%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 24;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 693 GGGCCAGGGCCAGAGAA 711

Db 19 GGGCCAGGGCCAGAGAA 1

RESULT 25

AAF19734/C

ID AAF19734 standard; DNA; 19 BP.

XX AAF19734;

AC AAF19734;

XX 14-MAR-2001 (first entry)

XX Human interleukin-8 polynucleotide fragment #1301.

XX

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;

XX human; airway disorder; bronchoconstriction; lung inflammation;

XX surfactant depletion; respiratory bronchodilator; antiinflammatory;

XX immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;

XX respiratory obstruction; pulmonary obstruction; impeded respiration;

XX surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;

XX respiratory distress syndrome; pulmonary vasoconstriction; asthma; RDS;

XX pulmonary hypertension; emphysema; pulmonary transplantation rejection;

XX chronic obstructive pulmonary disease; pulmonary infection; bronchitis;

XX cancer; ss.

XX

XX Homo sapiens.

XX

XX WO200062736-A2.

XX

XX 26-OCT-2000.

XX

XX 24-MAR-2000; 2000WO-US08020.

XX

XX 06-APR-1999; 99US-0127958.

XX

XX (UYEC-) UNIV EAST CAROLINA.

XX (NYCE/) NYCE J W.

XX

XX Nyce JW;

XX

XX WPI; 2000-679539/66.

XX

XX Low adenosine (A) content antisense oligonucleotides which do not

XX trigger adenosine receptors during metabolism, useful e.g. for treating

XX cancers and respiratory obstructions.

XX

XX Claim 14; Page 236; 1592pp; English.

XX

XX The present invention describes low adenosine (A) content antisense

XX oligonucleotides and compositions (I) comprising them. In the antisense

XX oligonucleotides the A is replaced by a 'Universal' or alternative base.

XX (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,

XX immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.

XX The antisense oligonucleotides and (I) can be used to down-regulate the

CC expression and or activity of target polypeptides associated with  
 CC lung/respiratory disorders and malignancies, such as stimulating and  
 CC activating peptide factors and transmitters, transcription factors,  
 CC immunoglobulins and antibodies, antibody receptors, cytokines and  
 CC chemokines, endogenously produced specific and non-specific enzymes,  
 CC binding proteins, adhesion molecules and their receptors, cytokine and  
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central  
 CC nervous system (CNS) and peripheral nervous and non-nervous system  
 CC receptors, CNS and peripheral nervous and non-nervous system peptide  
 CC transmitters, defensins growth factors, vasoactive peptides and  
 CC receptors, binding proteins and malignancy associated proteins. The  
 CC antisense oligonucleotides may be used in this way to treat disorders  
 CC including respiratory obstruction (especially pulmonary obstruction  
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)  
 CC and/or surfactant hypoproduction which are associated with a disease or  
 CC condition selected from pulmonary vasoconstriction, inflammation,  
 CC allergies, asthma, impeded respiration, respiratory distress syndrome  
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary  
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),  
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,  
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide  
 CC fragments and antisense oligonucleotides used in the exemplification of  
 CC the present invention.  
 CC  
 XX

SQ Sequence 19 BP; 0 A; 8 C; 4 G; 7 T; 0 other;

Query Match 1.5%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 24;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 693 GGGCCAGGGCCAGAGAA 711

Db 19 GGGCCAGGGCCAGAGAA 1

RESULT 26

AAA33612/C

ID AAA33612 standard; DNA; 19 BP.

XX

XX AAA33612;

XX

XX 28-JUL-2000 (first entry)

XX

XX Low adenosine antisense oligonucleotide SEQ ID NO:1301.

XX

XX Human; adenosine receptor; low adenosine antisense oligonucleotide;

XX phosphorothioate; impaired respiration; inflammation; allergy;

XX allergic disease; bronchoconstriction; inhibitor; antiinflammatory;

XX antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;

XX lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;

XX respiratory distress syndrome; pain; cystic fibrosis; emphysema;

XX pulmonary hypertension; chronic obstructive pulmonary disease; COPD;

XX cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX

XX Homo sapiens.

XX

XX WO200009525-A2.

XX

XX 24-FEB-2000.

XX

XX 03-AUG-1999; 99WO-US17712.

XX

XX 03-AUG-1999; 98US-0095212.

XX

XX (UYEC-) UNIV EAST CAROLINA.

XX

XX Nyce JW;

XX

XX WPI; 2000-205971/18.

XX

XX New antisense oligonucleotides useful for treating e.g. pulmonary

XX vasoconstriction, inflammation, allergies, asthma, hypertension,

XX bronchitis, emphysema, respiratory distress syndrome, ischemia or

XX



```

PT cancers
PS Claim 18; Page 427; 1343pp; English.
XX
CC The present invention describes a new composition comprising an
CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antasthmatic, cytostatic and anesthetic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies,
CC asthma, impaired respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC carcinomas, and cancers which may metastasise to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of
CC the ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
CC differ from the previously named sequences. SEQ ID NO:11 to 1680
CC (AAA32323 to AAA3392) are specifically claimed ONs from the present
CC invention. N.B. Sequences given in the disclosure of the present
CC invention do not match up with their corresponding SEQ ID NO: sequences
CC given in the sequence listing.
XX
SQ Sequence 19 BP; 0 A; 8 C; 4 G; 7 T; 0 other;

Query Match 1.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 693 GGGCCAGGCGCCAGAGAA 711
DB 19 GGGCCAGGCGCCAGAGAA 1

RESULT 27
ABX11405
XX ID ABX11405 standard; DNA; 27 BP.
XX AC ABX11405;
XX
XX 28-APR-2003 (first entry)
XX
XX 3' primer used to amplify human chemokine alpha-3 for use in pQE-9.
XX
XX ss; primer; human; chemokine alpha-3; gene therapy; chemotactic cytokine;
XX chronic infection; mycobacterial infection; parasitic infection; asthma;
XX T-cell mediated autoimmune disease; psoriasis; fibrotic disorder; sepsis;
XX liver cirrhosis; osteoarthritis; pulmonary fibrosis; allergy; rhinitis;
XX schistosomiasis; trichinosis; ascariasis; bone marrow protection; ARDS;
XX haemopoiesis regulation; growth factor activity; stem cell mobilisation;
XX angiogenesis inhibition; adult respiratory distress syndrome; silicosis;
XX endotoxic shock; wound healing; multiple sclerosis; chronic urticaria;
XX insulin-dependent diabetes; idiopathic hyperoesinophilic syndrome; PCR;
XX sarcoidosis; idiopathic pulmonary fibrosis; atopic dermatitis; eczema;
XX atherosclerosis; acute inflammatory pulmonary disease; aplastic anaemia;
XX chronic inflammatory pulmonary disease; degenerative arthropathy; pQE-9;
XX inflammatory arthropathy; prostaglandin-independent fever; leukaemia;
XX myelodysplastic syndrome; subepithelial basement membrane fibrosis;
XX tumour.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX US2002132305-A1.
XX
XX 19-SEP-2002.
XX

```

```

XX 10-MAY-2002; 2002US-0141938.
XX
XX 18-MAR-1996; 96US-0136157.
XX 18-MAR-1997; 97US-0816772.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Ni J, Li H, Su JY;
XX
XX WPI; 2003-237898/23.
XX
XX New human chemokine alpha-3 polypeptides and polynucleotides, useful in
XX gene therapy, and for treating e.g. tumors, chronic infections,
XX leukemia, T-cell mediated autoimmune diseases, parasitic infections,
XX psoriasis, and allergy
XX
XX Example 1; Page 17; 29pp; English.
XX
XX The invention relates to an isolated polynucleotide which encodes a
XX member of the (chemotactic cytokine) chemokine alpha subfamily. An
XX antagonist of the polypeptide is useful in a method of treating a patient
XX in need of inhibiting chemokine alpha-3 polypeptide. The polypeptide is
XX useful in a method of treating a patient in need of chemokine alpha-3.
XX The human chemokine alpha-3 polypeptides and polynucleotides are useful
XX in gene therapy, for treating tumors, chronic infections (e.g.
XX mycobacterial infections), leukaemia, T-cell mediated autoimmune
XX diseases, parasitic infections, psoriasis, fibrotic disorders (e.g. liver
XX cirrhosis, osteoarthritis and pulmonary fibrosis), allergy, trichinosis,
XX schistosomiasis, ascariasis, asthma and sepsis, for protecting bone
XX marrow during chemotherapy, for regulating haemopoiesis, for stimulating
XX growth factor activity and stem cell mobilisation, for inhibiting
XX angiogenesis and adult respiratory distress syndrome (ARDS) and for
XX promoting wound healing. Human cytokine alpha-3 antagonists can be used
XX to treat multiple sclerosis, insulin-dependent diabetes, silicosis,
XX sarcoidosis, idiopathic pulmonary fibrosis, idiopathic hyperoesinophilic
XX syndrome, rhinitis, endotoxic shock, chronic urticaria, atherosclerosis,
XX atopic dermatitis, eczema, acute inflammatory pulmonary disease, chronic
XX inflammatory pulmonary disease, degenerative arthropathy, inflammatory
XX arthropathy, aplastic anaemia, prostaglandin-independent fever, fibrosis.
XX myelodysplastic syndrome and subepithelial basement membrane fibrosis.
XX The present sequence represents the 3' primer used to amplify human
XX chemokine alpha-3 so that it can be cloned into the bacterial expression
XX vector pQE-9.
XX
XX Sequence 27 BP; 3 A; 10 C; 4 G; 10 T; 0 other;

Query Match 1.5%; Score 19; DB 1; Length 27;
Best Local Similarity 81.5%; Pred. No. 36;
Matches 22; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 870 CCAGATCCCAAGTCCTTGTTCCACT 896
DB 1 CCGGATCCTCGTTCGTGTTCCACT 27

RESULT 28
ABQ77073
XX ID ABQ77073 standard; DNA; 27 BP.
XX AC ABQ77073;
XX
XX 27-MAR-2003 (first entry)
XX
XX Human CKAlpha-3 PCR primer SEQ ID 4.
XX
XX Chemokine alpha-3; human; cytokine; antirheumatic; rheumatoid arthritis;
XX antinflammatory; antiarteriosclerotic; antiasthmatic; atopic dermatitis;
XX chemokine antagonist; gene therapy; allergic rhinitis; PCR; primer; ss.
XX
XX Homo sapiens.
XX
XX US2002150994-A1.
XX

```



```

XX PD 17-OCT-2002.
XX PF
XX PP
XX PR 10-MAY-2002; 2002US-0142046.
XX PR 18-MAR-1996; 96US-013615P.
XX PR 18-MAR-1997; 97US-0816772.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX PI Ni J, Li H, Su J;
XX PI WPI; 2003-182501/18.
XX DR
XX XX New polynucleotide human chemokine alpha-3 polynucleotide, useful for
XX PF producing a medicament for treating atherosclerosis, atopic dermatitis,
XX PT asthma, allergic rhinitis or rheumatoid arthritis -
XX PT
XX PS Example 1; Page 17; 31pp; English.
XX CC This invention describes a novel human chemotactic cytokine, chemokine
XX CC alpha-3 (CKalpha-3) which has antirheumatic, antiinflammatory,
XX CC antiarteriosclerotic and antiasthmatic activity. CKalpha-3 is a chemokine
XX CC antagonist which can be used for gene therapy and for producing a
XX CC medicament to treat atherosclerosis, atopic dermatitis, asthma, allergic
XX CC rhinitis or rheumatoid arthritis. This sequence represents a PCR primer
XX CC used in the expression and purification of mature human CKalpha-3 using
XX CC bacteria.
XX SQ Sequence 27 BP; 3 A; 10 C; 4 G; 10 T; 0 other;

  Query Match      1.5%; Score 19; DB 1; Length 27;
  Best Local Similarity 81.5%; Pred. No. 36;
  Matches 22; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Oy 870 CCAGATCCACAAAGTCCTTGTTCACCT 896
Db 1 CCCGATCCTCAGTTCTTGTTCACCT 27

RESULT 29
AAA66457
ID AAA66457 standard; DNA; 25 BP.
XX AC
XX AC AAA66457;
XX DT
XX DT 09-OCT-2000 (first entry)
XX DE Dog genomic marker oligonucleotide sequence SEQ ID NO:319.
XX XX Dog; genome; genomic marker; radiation hybrid map; identification;
XX KW chromosome location; gene marker; polymorphic microsatellite marker;
XX KW phenotype; behaviour; pedigree; ss.
XX OS
XX OS Canis familiaris.
XX PN
XX PN WO200029615-A2.
XX XX
XX XX 25-MAY-2000.
XX XX
XX XX 15-NOV-1999; 99WO-IB01907.
XX XX
XX XX 13-NOV-1998; 98US-0108193.
XX XX (CNRS ) CNRS CENT NAT RECH SCI.
XX PA Galibert F, Andre C;
XX PI
XX PI WPI; 2000-387821/33.
XX DR
XX XX New radiation hybrid map of the dog, Canine familiaris, genome, useful
XX PF for e.g. identifying genes implicated in phenotypic and behavioral
XX PT traits or in genetic diseases and for studying dog pedigrees -

```

```

XX Claim 1; Page 66; 87pp; English.
XX FS
XX CC The present invention describes a radiation hybrid map of the dog
XX CC (Canine familiaris) genome comprising the genome location of a marker
XX CC selected from AAA66139 to AAA66942. The radiation hybrid map is useful
XX CC for identifying and localising dog genes, since it covers approximately
XX CC 80 % of the dog genome and provides a dense map integrating different
XX CC types (i.e. Type I and Type II) of markers. The map and the dog genome
XX CC markers (or complementary sequences) are especially useful to identify
XX CC genes responsible for phenotypic and behavioural traits in dogs, to
XX CC identify morbid genes, to analyse diseases and identify implicated genes
XX CC in such diseases and their alleles, and to study dog pedigrees. They
XX CC may also be useful for isolating corresponding human gene sequences.
XX CC e.g. genes involved in genetic diseases.
XX SQ Sequence 25 BP; 12 A; 5 C; 3 G; 5 T; 0 other;

  Query Match      1.5%; Score 18.6; DB 1; Length 25;
  Best Local Similarity 84.0%; Pred. No. 40;
  Matches 21; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 431 GCCAGTCGAACTTCAAGCAAAATCTA 455
Db 1 GCCAATGAGACTTCAAAAAAATCTA 25

RESULT 30
AAI66531/C
ID AAI66531 standard; DNA; 24 BP.
XX AC
XX AC AAI66531;
XX DT
XX DT 11-DEC-2001 (first entry)
XX DE Human pterin-molybdenum oxidoreductase 10 cDNA PCR primer #1.
XX XX Human; pterin-molybdenum oxidoreductase 10; cancer; haemopathy;
XX KW immunological disease; HIV infection; inflammation; gene therapy;
XX KW PCR primer; ss.
XX OS
XX OS Homo sapiens.
XX PN
XX PN WO200172788-A1.
XX XX
XX XX 04-OCT-2001.
XX XX
XX XX 23-MAR-2001; 2001WO-CN00393.
XX XX
XX XX 24-MAR-2000; 2000CN-0115110.
XX PR (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.
XX PA
XX PA Mao Y, Xie Y;
XX PI
XX PI WPI; 2001-602841/68.
XX DR
XX DR New polypeptide for the diagnosis and treatment of malignant neoplasm,
XX PT hemopathy, HIV infection, immunological diseases and inflammations,
XX PT comprises the human pterin-molybdenum oxidoreductase 10 protein -
XX XX
XX XX Example 2; Page 17; 36pp; Chinese.
XX CC The present invention provides the protein and coding sequences of human
XX CC pterin-molybdenum oxidoreductase 10. The sequences can be used in the
XX CC treatment of cancer, haemopathy, HIV infection, immunological diseases
XX CC and inflammation. The present sequence is a PCR primer for the coding
XX CC sequence of the invention.
XX SQ Sequence 24 BP; 10 A; 2 C; 0 G; 12 T; 0 other;

  Query Match      1.5%; Score 18.2; DB 1; Length 24;
  Best Local Similarity 87.0%; Pred. No. 47;

```

Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 590 ATGTAAAGTATTATTATTGAA 612  
 DB 24 ATGTAAATATTATTATTAAA 2

RESULT 31  
 AAH45430  
 ID AAH45430 standard; DNA; 25 BP.  
 XX  
 AC AAH45430;  
 XX  
 DT 06-SEP-2001 (first entry)  
 XX  
 DE Glutamate tRNA synthetase 58 cDNA specific PCR primer.  
 XX  
 KW Human; glutamate tRNA synthetase 58; malignant tumour; haemopathy;  
 KW HIV infection; immunological disease; inflammatory condition; cytostatic;  
 KW haemostatic; virucide; immunomodulatory; antiinflammatory;  
 KW PCR primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200138371-A1.  
 XX  
 PD 31-MAY-2001.  
 XX  
 XX 20-NOV-2000; 2000WO-CN00475.  
 XX  
 XX 24-NOV-1999; 99CN-0124102.  
 XX  
 PA (BIOR-) BIORAD GENE DEV LTD SHANGHAI.  
 XX  
 PI Mao Y, Xie Y;  
 XX  
 DR WPI; 2001-355891/37.  
 XX  
 XX New human glutamate tRNA synthase 58 for diagnosing and treating  
 PT cancer, hemopathy, human immunodeficiency virus (HIV) infection,  
 PT immunological diseases and inflammation -  
 XX  
 XX Example 3; Page 12; 36pp; Chinese.

This invention relates to human glutamate tRNA synthetase 58, and the  
 cDNA sequence encoding it. The invention includes a vector containing the  
 cDNA sequence, a host cell transformed with the vector, and an antibody  
 targeting the glutamate tRNA synthetase 58 protein. The glutamate tRNA  
 synthetase 58 protein and cDNA may be used in the diagnosis and treatment  
 of malignant tumours, haemopathy, human immunodeficiency virus (HIV)  
 infection, immunological diseases and various inflammatory conditions.  
 Use of the protein or cDNA for treatment, may result in cytostatic,  
 haemostatic, virucide, immunomodulatory, or antiinflammatory activity.  
 The present sequence represents a PCR primer specific for cDNA encoding  
 human glutamate tRNA synthetase 58.

Sequence 25 BP; 5 A; 1 C; 0 G; 19 T; 0 other;  
 Query Match 1.4%; Score 17.6; DB 1; Length 25;  
 Best Local Similarity 83.3%; Pred. No. 66;  
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1139 TAAATTTATTATTATTAGATATT 1162  
 DB 1 TCATTTTATTATTATTATTATTATT 24

RESULT 32  
 AAA14463  
 ID AAA14463 standard; RNA; 21 BP.  
 XX  
 AC AAA14463;  
 XX

21-AUG-2000 (first entry)  
 XX  
 DE AUUUA RNA target sequence.  
 XX  
 KW AUUUA sequence; RNA target molecule; RNA binding protein identification;  
 KW ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200020637-A1.  
 XX  
 PD 13-APR-2000.  
 XX  
 PF 16-SEP-1999; 99WO-US21672.  
 XX  
 PR 02-OCT-1998; 98US-0165868.  
 XX  
 PA (MESS-) MESSAGE PHARM INC.  
 XX  
 PI Giordano T, Beach DL, Temeles GL;  
 XX  
 DR WPI; 2000-303802/26.  
 XX  
 XX Nucleic acid molecules useful for identifying compounds affecting  
 PT interactions between RNA molecules and identifying RNA binding proteins  
 PT -  
 XX  
 PS Example 1; Page 33; 58pp; English.

The invention relates to mRNA sequences which bind to RNA binding  
 proteins, and their use for identifying RNA binding proteins and  
 compounds which have an effect on the interactions between an RNA  
 binding protein and an RNA molecule. The disclosed sequences are the 3'  
 untranslated region (3' UTR) sequences APP-R1, APP-D3 and APP-I1 from  
 the human amyloid precursor protein mRNA (AAAI4456-A14458); the 3' UTR  
 of human interleukin-10 (IL-10) mRNA (AAAI4459); the 3' UTR of human  
 erb-B2 mRNA (AAAI4460); and the 5' UTR of human insulin-like growth  
 factor I receptor (IGF-IR) mRNA (AAAI4461). The disclosed mRNA sequences  
 may be used to identify compounds affecting interactions between an RNA  
 molecule comprising the sequence and an RNA binding protein. Such  
 compounds can then be included with a carrier in pharmaceutical  
 compositions for altering expression of a gene comprising the sequences,  
 which can be administered to individuals or cells requiring altered  
 expression of the gene. The mRNA sequences are also useful to identify  
 RNA binding proteins which interact with them. Compounds identified as  
 having the ability to affect such RNA binding interactions may therefore  
 be useful as drugs for modulating protein levels in disease states. The  
 present sequence represents an AUUUA RNA sequence used as a target  
 molecule in an exemplification of the invention in an assay for  
 detecting interactions between RNA molecules and RNA binding proteins.

Sequence 21 BP; 6 A; 0 C; 0 G; 15 U; 0 other;  
 Query Match 1.4%; Score 17.4; DB 1; Length 21;  
 Best Local Similarity 26.3%; Pred. No. 60;  
 Matches 5; Conservative 13; Mismatches 1; Indels 0; Gaps 0;

QY 1044 TTATTATCTATTATTATTA 1062  
 DB 3 UUAUUUUUUUUUUUUUUUU 21

RESULT 33  
 AAD49639  
 ID AAD49639 standard; mRNA; 21 BP.  
 XX  
 AC AAD49639;  
 XX  
 XX 24-MAR-2003 (first entry)  
 XX  
 DE Human adenylate uridylylate-rich element (ARE) motif mRNA #1.  
 XX  
 KW Amyloidosis; haemophilia; Alzheimer's disease; atherosclerosis; cancer;



PT Identifying a test compound that binds to a target RNA molecule by  
PT separating the detectably labeled target RNA: support-attached test  
PT compound complex from uncomplexed target RNA molecules and test  
PT compounds by flow cytometry -  
XX  
PS Disclosure; Page 16; 131pp; English.  
XX  
CC The invention relates to a novel method for identifying a test compound  
CC that binds to a target RNA molecule comprising separating the detectably  
CC labeled target RNA: support-attached test compound complex from  
CC uncomplexed target RNA molecules and test compounds. The separating  
CC process is carried out by flow cytometry and determining a structure of  
CC the type of test compound of the RNA: support-attached test compound  
CC complex by mass spectrometry. The method is useful for high-throughput  
CC screening of libraries of compounds to identify pharmaceutical leads.  
CC This polynucleotide sequence represents one of the target RNA motifs/  
CC regions of the invention.  
XX  
SQ Sequence 21 BP; 6 A; 0 C; 0 G; 15 U; 0 other;  
  
Query Match 1.4%; Score 17.4; DB 1; Length 21;  
Best Local Similarity 26.3%; Pred. No. 60;  
Matches 5; Conservative 13; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1044 TTATTATGTTATTATTA 1062  
DB 3 UUAUUUUUUUUUUUUUU 21  
  
RESULT 36  
AAL54044/c  
ID AAL54044 standard; DNA; 24 BP.  
XX  
AC AAL54044;  
XX  
XX 06-MAR-2003 (first entry)  
DT Human macroprotein 16-39 PCR primer 1.  
XX  
DE Human macroprotein 16.39; embryonic development deformity; tumour;  
XX  
KW Human macroprotein 16.39; embryonic development deformity; tumour;  
KW DNA recombination; PCR; primer; ss.  
XX  
OS Homo sapiens.  
XX  
XX CN1342711-A.  
XX  
PN 03-APR-2002.  
XX  
PD 12-SEP-2000; 2000CN-0125188.  
XX  
PF 12-SEP-2000; 2000CN-0125188.  
XX  
PR (BODE-) BODE GENE DEV CO LTD SHANGHAI.  
XX  
PA Mao Y, Xie Y;  
XX  
PI WPI; 2002-529786/57.  
XX  
DR Polypeptide-human macroprotein 16.39 and polynucleotide for coding it -  
XX  
PT Example 2; Page 19 (Disclosure); 35pp; Chinese.  
PS  
XX  
CC The invention relates to the novel human macroprotein 16.39. The  
CC invention also relates to the polynucleotide for coding the protein, the  
CC process for preparing the protein by DNA recombination technique, the  
CC application of the protein in treating several diseases such as embryonic  
CC development deformity and tumours, the antagonist against this protein  
CC and its therapeutic action, and the application of the polynucleotide  
CC coding this new human macroprotein 16.35. This polynucleotide sequence  
CC represents a PCR primer of the human macroprotein 16.39 of the invention.  
XX  
SQ Sequence 24 BP; 7 A; 2 C; 2 G; 13 T; 0 other;

Query Match 1.4%; Score 17.4; DB 1; Length 24;  
Best Local Similarity 94.7%; Pred. No. 70;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1590 AAATATAAAGTAAATATG 1608  
DB 21 AAAAATAAAGTAAATATG 3  
  
RESULT 37  
AAT76273/c  
ID AAT76273 standard; DNA; 17 BP.  
XX  
AC AAT76273;  
XX  
DT 15-SEP-1997 (first entry)  
XX  
DE Human MDNCF antisense oligonucleotide H5MDNCFAS3.  
XX  
KW Asthma; airway epithelium; adenosine free; cystic fibrosis;  
KW chronic obstructive pulmonary disease; bronchitis;  
KW monocyte-derived neutrophil chemotactic factor; ss.  
XX  
OS Synthetic.  
XX  
PN WO9640162-A1.  
XX  
PD 19-DEC-1996.  
XX  
PF 06-JUN-1996; 96WO-US09306.  
XX  
PR 07-JUN-1995; 95US-0474497.  
XX  
PA (UYEC-) UNIV EAST CAROLINA.  
XX  
PI Metzger WJ, Nyce JW;  
XX  
DR WPI; 1997-051871/05.  
XX  
PT Treatment of airway diseases such as asthma - by topically applying  
PT adenosine-free antisense oligonucleotide to airway epithelium of  
PT subject  
XX  
PS Claim 5; Page 33; 71pp; English.  
XX  
CC A method for treating airway disease in a subject has been produced,  
CC which involves the topical administration of an essentially adenosine  
CC free antisense oligonucleotide (ON) to the airway epithelium of the  
CC subject. The present sequence is an antisense oligonucleotide  
CC H5MDNCFAS3 specific for the human monocyte-derived neutrophil  
CC chemotactic factor. The method can be used to treat airway diseases  
CC such as cystic fibrosis, asthma, chronic obstructive pulmonary disease,  
CC bronchitis and other airway diseases characterised by an inflammatory  
CC response. By eliminating adenosine from the antisense ON, its  
CC liberation upon antisense degradation is prevented, thereby preventing  
CC adenosine-induced bronchoconstriction in patients with hyper-reactive  
CC airways.  
XX  
SQ Sequence 17 BP; 0 A; 6 C; 4 G; 7 T; 0 other;  
  
Query Match 1.4%; Score 17; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 58;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 695 GCCAAGGGGCCAAGAGAA 711  
DB 17 GCCAAGGGGCCAAGAGAA 1  
  
RESULT 38  
AAK54070/c  
ID AAK54070 standard; DNA; 17 BP.  
XX

AC AAX54070;  
 XX 05-JUL-1999 (first entry)  
 XX Monocyte-derived neutrophil chemotactic factor antisense oligo.  
 XX  
 DE Antisense oligonucleotide; multiple target; antisense treatment;  
 KW impaired respiration; inflammation; lung disease;  
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;  
 KW acute asthma; allergy; asthma; impeded respiration;  
 KW respiratory distress syndrome; pain; cystic fibrosis;  
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;  
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;  
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;  
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;  
 KW prostate cancer; ss.  
 XX Synthetic.  
 XX OS  
 XX WO9913886-A1.  
 XX PN  
 XX 25-MAR-1999.  
 XX PD  
 XX 17-SEP-1998; 98WO-US19419.  
 XX PF  
 XX 09-JUN-1998; 98US-0093972.  
 XX PR  
 XX 17-SEP-1997; 97US-0059160.  
 XX PA  
 XX (UYEC-) UNIV EAST CAROLINA.  
 XX PI  
 XX Nyce JW;  
 XX WPI; 1998-229400/19.  
 XX DR  
 XX New antisense oligonucleotides used in treatment of, e.g. pulmonary  
 PT vasoconstriction  
 XX  
 PS Disclosure; Page 51; 120pp; English.  
 XX  
 CC The specification describes antisense oligonucleotides (AAX52869-X55271)  
 CC directed against at least 2 mRNAs selected from target genes, coding and  
 CC non-coding regions of RNAs corresponding to target genes, gene  
 CC initiation codons, genomic flanking regions, intron-exon borders, the  
 CC 5'-end, the 3'-end and the juxta-section between coding and non-coding  
 CC regions and all segments of RNAs encoding proteins associated with one  
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides  
 CC may be derived from sequences AAX5272-74. These multiple target  
 CC oligonucleotides (specifically AAX55180-271) can be used for the  
 CC antisense treatment of diseases and conditions. Typical diseases and  
 CC conditions are those associated with impaired respiration and  
 CC inflammation, including lung diseases, pulmonary vasoconstriction,  
 CC inflammation, allergic rhinitis, acute asthma, allergies, asthma, impeded  
 CC respiration, respiratory distress syndrome, pain, cystic fibrosis,  
 CC pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic  
 CC obstructive pulmonary disease (COPD), and cancers such as leukemias,  
 CC lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer,  
 CC pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma,  
 CC hepatic metastases, as well as all types of cancers which may metastasize  
 CC or have metastasized to the lungs, including breast and prostate cancer.  
 XX Sequence 17 BP; 0 A; 6 C; 4 G; 7 T; 0 other;  
 SQ

Query Match 1-4%; Score 17; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 58;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 695 GCCAAGGGCCCAAGAGAA 711  
 |||||  
 Db 17 GCCAAGGGCCCAAGAGAA 1  
 RESULT 39  
 AAF19636/c

ID AAF19636 standard; DNA; 17 BP.  
 XX AAF19636;  
 XX 14-MAR-2001 (first entry)  
 XX Human monocyte derived neutrophil chemotactic factor DNA fragment #1203.  
 DE Low adenosine antisense oligonucleotide; phosphorothioate; allergy;  
 KW human; airway disorder; bronchoconstriction; lung inflammation;  
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;  
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytosstatic;  
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;  
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;  
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;  
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;  
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;  
 KW cancer; ss.  
 XX Homo sapiens.  
 XX OS  
 XX WO200062736-A2.  
 XX PN  
 XX 26-OCT-2000.  
 XX PD  
 XX 24-MAR-2000; 2000WO-US08020.  
 XX PF  
 XX 06-APR-1999; 99US-0127958.  
 XX PR  
 XX (UYEC-) UNIV EAST CAROLINA.  
 XX PA  
 XX (NYCE/) NYCE J W.  
 XX PI  
 XX Nyce JW;  
 XX WPI; 2000-679539/66.  
 XX DR  
 XX Low adenosine (A) content antisense oligonucleotides which do not  
 PT trigger adenosine receptors during metabolism, useful e.g. for treating  
 PT cancers and respiratory obstructions -  
 XX Claim 14; Page 210; 1592pp; English.  
 XX  
 CC The present invention describes low adenosine (A) content antisense  
 CC oligonucleotides and compositions (I) comprising them. In the antisense  
 CC oligonucleotides the A is replaced by a 'universal' or alternative base.  
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,  
 CC immunosuppressive, antiasthmatic, hypotensive and cytosstatic activities.  
 CC The antisense oligonucleotides and (I) can be used to down-regulate the  
 CC expression and/or activity of target polypeptides associated with  
 CC lung/respiratory disorders and malignancies, such as stimulating and  
 CC activating peptide factors and transmitters, transcription factors,  
 CC immunoglobulins and antibodies, antibody receptors, cytokines and  
 CC chemokines, endogenously produced specific and non-specific enzymes,  
 CC binding proteins, adhesion molecules and their receptors, cytokine and  
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central  
 CC nervous system (CNS) and peripheral nervous and non-nervous system  
 CC receptors, CNS and peripheral nervous and non-nervous system peptide  
 CC transmitters, defensins, growth factors, vasoactive peptides and  
 CC receptors, binding proteins and malignancy associated proteins. The  
 CC antisense oligonucleotides may be used in this way to treat disorders  
 CC including respiratory obstruction (especially pulmonary obstruction  
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)  
 CC and/or surfactant hypoproduction which are associated with a disease or  
 CC condition selected from pulmonary vasoconstriction, inflammation,  
 CC allergies, asthma, impeded respiration, respiratory distress syndrome  
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary  
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),  
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,  
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide  
 CC fragments and antisense oligonucleotides used in the exemplification of  
 CC the present invention.  
 XX Sequence 17 BP; 0 A; 6 C; 4 G; 7 T; 0 other;  
 SQ

CC	(AAA33223 to AAA33992) are specifically claimed ONs from the present invention. N.B. Sequences given in the disclosure of the present invention do not match up with their corresponding SEQ ID NO: sequences CC given in the sequence listing.																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
----	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

QY 417 GAATCACTGAGATGCC 433  
 Db 1 GAATCACTGAGATGCC 17

## RESULT 42

AAL45792  
 ID AAL45792 standard; DNA; 24 BP.

AC AAL45792;  
 XX 28-JUN-2002 (first entry)

DE Human MGC-2413-31 coding sequence PCR primer #2.

XX Human; MGC-2413.31; cancer; haemopathy; development disorder;  
 KW cytostatic; haemostatic; virucide; immunomodulatory; antiinflammatory;  
 KW immune disorder; HIV infection; inflammation; gene therapy; PCR;  
 KW primer; ss.

OS Homo sapiens.

XX WO200220776-A1.

XX 14-MAR-2002.

XX 29-JUN-2001; 2001WO-CN01088.

XX 30-JUN-2000; 2000CN-0116945.

XX (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.

XX Mao Y, Xie Y;

XX WPI; 2002-259028/30.

XX Polypeptide-MGC-2413.31 and encoding polynucleotide, used in diagnosis  
 PT and treatment of malignant tumors, hemopathy, human immunodeficiency  
 PT virus infection, immunological diseases and inflammation -

XX Example 2; Page 17; 34pp; Chinese.

XX The present invention provides the protein and coding sequences of human  
 CC MGC-2413.31. The sequences can be used in the treatment of cancer,  
 CC haemopathy, development disorders, HIV infection, immune disorders and  
 CC inflammation. The present sequence is a PCR primer for the coding  
 CC sequence of the invention.

XX Sequence 24 BP; 8 A; 2 C; 1 G; 13 T; 0 other;

Query Match 1.3%; Score 16.8; DB 1; Length 24;

Best Local Similarity 90.0%; Pred. No. 93;  
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1137 AGTAAATTTATTTATTTA 1156

Db 4 ATTGAATTTATTTATTTA 23

## RESULT 43

ABA02441

ID ABA02441 standard; DNA; 24 BP.

XX ABA02441;

XX 04-MAR-2002 (first entry)

DE Human CCR4 protein 10 RT-PCR primer, SEQ ID NO:3.

XX Human; CCR4 protein 10; recombinant production;  
 KW malignant tumour; cancer; blood disease; HIV infection;  
 KW human immunodeficiency virus; immune disorder; inflammatory condition;  
 KW gene therapy; cytostatic; anti-HIV; antiinflammatory; immunomodulator;

reverse transcription-PCR; RT-PCR primer; ss.

OS Homo sapiens.

XX WO200187947-A1.

XX 22-NOV-2001.

XX 08-MAY-2001; 2001WO-CN00700.

XX 09-MAY-2000; 2000CN-0115620.

XX (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.

XX Mao Y, Xie Y;

XX WPI; 2002-066676/09.

XX Human CCR4 protein 10 and encoding polynucleotide, used in diagnosis  
 PT and treatment of malignant tumors, hemopathy, human immunodeficiency  
 PT virus infection, immunological diseases and inflammation -

XX Example 2; Page 17; 37pp; Chinese.

XX The invention relates to human CCR4 protein 10 (AAM52938), nucleic acids  
 CC encoding it (ABA02440), and a method for the recombinant production of  
 CC CCR4 protein 10. The protein has a molecular weight of 10 kD. The  
 CC present invention additionally discloses an antagonist of CCR4 protein  
 CC 10 for therapeutic use, and an antibody which specifically binds to CCR4  
 CC protein 10. CCR4 protein 10, and nucleotides which encode it may be used  
 CC for treating a variety of diseases, such as malignant tumours, blood  
 CC diseases, HIV (human immunodeficiency virus) infection, immune disorders  
 CC and inflammatory conditions. The protein may also be used to screen for  
 CC modulators of its activity or for peptide fingerprinting identification.  
 CC The polynucleotide can be used as a primer for nucleic acid amplification  
 CC reactions or as a probe for hybridisation reactions, or in producing gene  
 CC chips or microarrays. Sequences ABA02441-ABA02442 represent reverse  
 CC transcription-PCR (RT-PCR) primers used in an exemplification of the  
 CC invention to isolate human CCR4 protein 10 cDNA.

XX Sequence 24 BP; 5 A; 3 C; 0 G; 16 T; 0 other;

Query Match 1.3%; Score 16.8; DB 1; Length 24;

Best Local Similarity 90.0%; Pred. No. 93;  
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1042 TATTATTATGTTATTTATTT 1061

Db 5 TTATTATTATTATTATTT 24

## RESULT 44

AAD21908/C

ID AAD21908 standard; DNA; 26 BP.

XX AAD21908;

XX 12-FEB-2002 (first entry)

DE PCR primer, 2767T used to determine the genotype of human IL-8 gene.

XX Human; genetic variant identification; interleukin 8; RSV bronchiolitis;  
 KW respiratory syncytial virus; PCR primer; ss.

OS Homo sapiens.

XX WO200177382-A2.

XX 18-OCT-2001.

XX 11-APR-2001; 2001WO-GB01834.

XX 11-APR-2000; 2000GB-0008910.

XX PA (ISIS-) ISIS INNOVATION LTD.  
 XX PI Hull J, Kwiatkowski DP;  
 XX XX WPI; 2002-017472/02.  
 DR XX  
 XX Nucleic acid comprising a sequence corresponding to variant allele of  
 PT human interleukin 8 gene, useful for determining susceptibility to  
 PT respiratory syncytial virus bronchiolitis in humans -  
 XX XX  
 XX Claim 42; Page 47; 49pp; English.  
 XX CC The patent discloses methods for identification of genetic variants  
 CC at the interleukin 8 (IL-8) locus. The invention relates to nucleic  
 CC acid molecules corresponding to various alleles at the IL8 locus  
 CC and kits for the detection of the presence of variant alleles. The  
 CC polymorphic variants of the IL-8 locus are useful for screening a  
 CC human subject for susceptibility to a disease such as respiratory  
 CC syncytial virus (RSV) bronchiolitis for which increased production  
 CC of IL-8 is a risk factor. The polymorphic variants of IL-8 locus are  
 CC also useful for determining the likelihood that a patient previously  
 CC identified as infected with RSV will develop severe disease. They are  
 CC useful as probes and primers for genotyping. They are also useful for  
 CC initiating DNA synthesis or amplification for detecting the presence  
 CC of IL-8 genetic variants. The single nucleotide polymorphisms have a  
 CC general utility as a genetic marker. The present DNA sequence is PCR  
 CC primer, 2767T which is used to determine the genotype of human  
 CC IL-8 Gene.  
 XX SQ Sequence 26 BP; 9 A; 5 C; 2 G; 10 T; 0 other;  
 Query Match 1.3%; Score 16.6; DB 1; Length 26;  
 Best Local Similarity 82.6%; Pred. No. 1.1e+02;  
 Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1290 TTATCTGAATTTTAAATGAAT 1312  
 DB 26 TTATCTGAATTTTAAATGAAT 4  
 |||||  
 |||||

RESULT 45  
 AAC92878/c  
 ID AAC92878 standard; DNA; 20 BP.  
 AC AAC92878;  
 XX 27-MAR-2001 (first entry)  
 DE Human PI3 kinase p55 gamma antisense oligonucleotide, SEQ ID NO:61.  
 KW Human phosphatidylinositol 3-kinase p55 gamma regulatory subunit;  
 KW PI3 kinase p55 gamma; hp55-gamma; p55-gamma; PIK3R3; p55PIK;  
 KW signal transduction; downstream effector; receptor tyrosine kinase;  
 KW insulin receptor; IR; insulin-like growth factor receptor; IGFRI;  
 KW cell growth; differentiation; apoptosis; developmental regulation;  
 KW alternative splicing; tumour formation; cancer; inflammation;  
 KW infection; expression inhibition; phosphorothioate;  
 KW antisense oligonucleotide; ss.  
 XX OS Homo sapiens.  
 XX XX US6165790-A.  
 XX PD 26-DEC-2000.  
 XX 03-NOV-1999; 99US-0433694.  
 XX 03-NOV-1999; 99US-0433694.  
 XX (ISIS-) ISIS PHARM INC.  
 XX Borchers AH, Cowseert LM, Ward DT;

XX WPI; 2001-101697/11.  
 XX Novel antisense compound targeted to human PI3 kinase p55 gamma  
 PT specifically hybridizes with and inhibits the expression of human PI3  
 PT kinase p55 gamma, useful for modulating the expression of PI3 kinase  
 PT p55 gamma in cells -  
 XX XX  
 XX Example 15; Column 41-42; 39pp; English.  
 XX CC Sequences AAC92827-C92906 represent phosphorothioate antisense  
 CC oligonucleotides targeted to the phosphatidylinositol 3-kinase p55  
 CC gamma regulatory subunit (PI3 kinase p55 gamma) gene, which inhibit its  
 CC expression. The antisense oligonucleotides were designed to target  
 CC different regions of human PI3 kinase p55 mRNA species, and were  
 CC analysed for their effect on PI3 kinase p55 mRNA levels by quantitative  
 CC real-time PCR. PI3 kinase p55 gamma (also known as hp55-gamma,  
 CC p55-gamma, PIK3R3 and p55PIK) is one of several PI3 kinase regulatory  
 CC subunits that may associate with the PI3 kinase catalytic subunit to form  
 CC a heterodimeric PI3 kinase holoenzyme. PI3 kinases act as downstream  
 CC effectors of receptor tyrosine kinases such as growth factor and  
 CC hormone receptors and oncogene products, and are found in association  
 CC with the cytoplasmic domains of such receptors. PI3 kinase p55 gamma  
 CC is able to interact with both the insulin receptor (IR) and the  
 CC insulin-like growth factor receptor (IGFR), which play important roles  
 CC in growth, differentiation and apoptosis. PI3 kinase p55 gamma is  
 CC thought to be developmentally regulated, as four distinct mRNA  
 CC species are found in adult tissues, while only the larger mRNA is  
 CC expressed in foetal tissues. The oligonucleotides of the invention are  
 CC useful for diagnosis, prevention and treatment of conditions associated  
 CC with PI3 kinase p55 expression, such as tumour formation, inflammation  
 CC and certain infections, and allow expression level modulation of the  
 CC alternatively spliced forms of PI3 kinase p55.  
 XX SQ Sequence 20 BP; 7 A; 1 C; 1 G; 11 T; 0 other;  
 Query Match 1.3%; Score 16.4; DB 1; Length 20;  
 Best Local Similarity 94.4%; Pred. No. 93;  
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1606 ATGAACACATTAAATAT 1623  
 |||||  
 |||||  
 DB 20 ATGAACACATTAAATAT 3  
 |||||  
 |||||

RESULT 46  
 AAT01237/c  
 ID AAT01237 standard; DNA; 22 BP.  
 AC AAT01237;  
 XX 25-MAR-2003 (updated)  
 DT 07-DEC-1995 (first entry)  
 XX Human chromosome 13 gene based 13-STS11 antisense primer.  
 DE Normalised cDNA library; directionally cloned cDNA library;  
 KW screening; hybridisation; human chromosome 13; exon mapping; STS;  
 KW sequence tagged site; ss.  
 XX OS Synthetic.  
 XX XX WO9508647-A1.  
 XX PD 30-MAR-1995.  
 XX 23-SEP-1994; 94WO-US10821.  
 XX 24-SEP-1993; 93US-0126594.  
 XX (UYCO ) UNIV COLUMBIA NEW YORK.  
 XX Efstratiadis A, Soares MB;



XX WPI; 1995-139615/18.  
 DR  
 PT New normalised directional cDNA libraries - used for isolating  
 PT novel cDNA's, including tissue-specific and development-specific  
 PT DNA.  
 XX  
 PS Disclosure; Page 125; 186pp; English.  
 XX  
 CC To initiate exon-mapping of human chromosome 13, cDNAs present in a  
 CC normalised library were hybridised to arrayed chromosome-specific  
 CC phage lambda clones. Part of the procedure involved PCR  
 CC amplification of chromosome 13 sequences using primer pairs based  
 CC on the 3' (and/or optionally the 5') terminal 300 nucleotides of  
 CC each cDNA (see RAT01228-T01257).  
 CC (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 XX Sequence 22 BP; 7 A; 2 C; 5 G; 8 T; 0 other;  
 SQ  
 Query Match 1.3%; Score 16.2; DB 1; Length 22;  
 Best Local Similarity 85.7%; Pred. No. 1.1e+02;  
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1068 CAATATTTGTCAGAAATTT 1088  
 DB 21 CAAAAATTTGCCAGAAATTT 1  
 RESULT 47  
 AAX10028/c  
 ID AAX10028 standard; DNA; 23 BP.  
 XX  
 AC AAX10028;  
 XX  
 DT 24-MAR-1999 (first entry)  
 XX  
 DE Human biallelic polymorphic marker downstream primer #334.  
 XX  
 KW Polymorphism; biallelic; human; forensic; paternity testing; disease;  
 KW detection; phenotypic typing; characteristic; infection; hereditary;  
 KW autoimmune disease; cancer; inflammation; drug; therapy; medication;  
 KW treatment; marker; primer; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN WO9820165-A2.  
 XX  
 PD 14-MAY-1998.  
 XX  
 PF 05-NOV-1997; 97WO-US20313.  
 XX  
 PR 06-NOV-1996; 96US-0030455.  
 XX  
 PA (WHED ) WHITEHEAD INST BIOMEDICAL RES.  
 XX  
 PI Hudson T, Lander ES, Wang D;  
 XX  
 DR WPI; 1998-286974/25.  
 XX  
 PT New isolated nucleic acid segments from the human genome - used for  
 PT determining polymorphic forms for use in e.g. forensics, paternity  
 PT testing or phenotypic typing for disease  
 XX  
 PS Claim 16; Page 93; 310pp; English.  
 XX  
 CC AAX09121-X10268 are allele-specific oligonucleotide primers used in the  
 CC isolation of various biallelic polymorphic markers found in the human  
 CC genome (represented in AAX10269-X12937). These primers can be used in a  
 CC method for determining polymorphic forms in an individual for use in  
 CC e.g. forensics, paternity testing or for phenotypic typing for diseases  
 CC such as agammaglobulinemia, diabetes insipidus, Leach-Nyhan syndrome,  
 CC muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial

CC hypercholesterolemia, polycystic kidney disease, hereditary  
 CC spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary  
 CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos  
 CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,  
 CC autoimmune diseases, inflammation, cancer, diseases of the nervous  
 CC system, infection by pathogenic microorganisms, and characteristics such  
 CC as longevity, appearance (e.g. baldness, obesity), strength, speed,  
 CC endurance, fertility, and susceptibility or receptivity to particular  
 CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid  
 CC segments can also be used to produce medicaments for the treatment or  
 CC prophylaxis of such diseases.  
 XX  
 SQ Sequence 23 BP; 6 A; 2 C; 7 G; 8 T; 0 other;  
 Query Match 1.3%; Score 16.2; DB 1; Length 23;  
 Best Local Similarity 85.7%; Pred. No. 1.2e+02;  
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 448 CAAATCTACTTCAACACTTCA 468  
 DB 22 CAAATCCAGTTTAAACACTTCA 2  
 RESULT 48  
 AAX33029/c  
 ID AAX33029 standard; DNA; 23 BP.  
 XX  
 AC AAX33029;  
 XX  
 DT 21-JUN-1999 (first entry)  
 XX  
 DE Human BRCA2 gene PCR primer SEQ ID NO:42.  
 XX  
 KW Human; BRCA2; genetic testing; protein therapy; haplotype; detection;  
 KW gene therapy; breast cancer; ovarian cancer; PCR primer; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN W09909164-A1.  
 XX  
 PD 25-FEB-1999.  
 XX  
 PF 14-AUG-1998; 98WO-US16905.  
 XX  
 PR 22-MAY-1998; 98US-0084471.  
 PR 15-AUG-1997; 97US-0055784.  
 PR 07-NOV-1997; 97US-0064926.  
 PR 12-NOV-1997; 97US-0065367.  
 PR 01-MAY-1998; 98US-0071715.  
 XX  
 PA (ONCO-) ONCORMED INC.  
 XX  
 PI Eskandari T, Jackson GM, Murphy PD, Olson SJ, Park M;  
 PI Rabin MB, Schryer B, White MB, Yoshikawa M;  
 XX  
 DR WPI; 1999-190163/16.  
 XX  
 PT New coding sequence haplotypes of the human BRCA2 gene - used to  
 PT develop products for determining susceptibility to, detection and  
 PT treatment of breast or ovarian cancer  
 XX  
 PS Example 1; Page 32; 236pp; English.  
 XX  
 CC The present invention describes genomic DNA which contains a BRCA2 gene  
 CC where the first 12 nucleotides beginning exon 5 are 5'-TCCTGTTGTTCT-3',  
 CC as in sequence (I) (see AAX03249), where nucleotides numbers  
 CC 5782-5790 are GTTGTGTT as in sequence (IV) (see AAX30255), and where  
 CC the last 20 nucleotides encoding exon 15 are 5'-CTGGGTGTTCTCAAAACAG-3',  
 CC as in sequence (II) (see AAX30251) and the first 20 nucleotides  
 CC beginning exon 16 are 5'-CTGTATACGATGCGTTC-3', as in sequence (III)  
 CC (see AAX30253). Products and methods from the present invention can be  
 CC used for identifying mutations in the BRCA2 gene leading to

CC predisposition or higher susceptibility to breast or ovarian cancer. They  
 CC can also be used for detection and gene therapy for breast and ovarian  
 CC cancers. They can be used in methods for monitoring disease progression,  
 CC for determining patients suited for gene and protein replacement  
 CC progression, or for detecting the presence or quantifying the amount of a  
 CC tumour growth inhibitor following such therapy. The BRCA2 protein,  
 CC polypeptides, their functional equivalents, antibodies, and FNs may also  
 CC be useful in the study of the characteristics of BRCA2 proteins, such as  
 CC structure and function of BRCA2 in oncogenesis or subcellular  
 CC localisation of BRCA2 protein in normal and cancerous cells. AAX33001 to  
 CC AAX33097 represent PCR primers used in the amplification of the human  
 CC BRCA2 gene.

XX Sequence 23 BP; 4 A; 4 C; 3 G; 12 T; 0 other;

Query Match 1.3%; Score 16.2; DB 1; Length 23;  
 Best Local Similarity 85.7%; Pred. No. 1.2e+02;  
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 763 TGAAGCATCATATAAAATGA 783  
 DB 22 TAAAGCAGCATATAAAATGA 2

## RESULT 49

AAX32150/C  
 ID AAX32150 standard; DNA; 23 BP.

XX AAX32150;

DT 14-JUN-1999 (first entry)

DE BRCA2 gene specific primer.

XX Allele profile; diagnosis; treatment; pharmacogenetic; breast cancer;  
 KW CPTX; cystic fibrosis; dystrophin; Duchenne muscular dystrophy; p53;  
 KW Becker muscular dystrophy; Li-Fraumeni syndrome; neurofibromatosis;  
 KW colorectal cancer; MSH2 gene; MLH1 gene; BRCA1 gene; BRCA2 gene;  
 KW BAP1 gene; PCR primer; ss.

XX Synthetic.

XX WO9906598-A2.

PD 11-FEB-1999.

PF 04-AUG-1998; 98WO-US16574.

XX 22-MAY-1998; 98US-0084471.

PR 04-AUG-1997; 97US-0905772.

XX (ONCO-) ONCOMED INC.

XX Murphy PD;

DR WPI; 1999-153820/13.

XX Determining common functional alleles in a population - useful in  
 PT the diagnosis of disease associated with allelic heterogeneity

XX Example 5; Page 37; 78pp; English.

XX The invention relates to methods of determining a functional allele  
 CC profile of a gene in a population. Functional allele profiles comprise  
 CC the commonly occurring alleles in a population, and the relative  
 CC frequencies at which such alleles of a given gene occur. The methods  
 CC are used to identify and determine the frequency of the functional  
 CC alleles of genes which display extensive allelic heterogeneity,  
 CC particularly those implicated in disease or conditions, such as the  
 CC BRCA1 gene associated with breast cancer, CPTX associated with cystic  
 CC fibrosis, dystrophin associated with Duchenne muscular dystrophy and  
 CC Becker muscular dystrophy, and p53 associated with Li-Fraumeni syndrome.  
 CC The methods can also be employed for diseases where allelic and genetic

CC heterogeneity exist, such as breast cancer, neurofibromatosis, and  
 CC hereditary non-polyposis colorectal cancer. Identification of functional  
 CC alleles is necessary for identification of mutations which may be  
 CC implicated in the disease. Sequences AAX32001-172 represent primers for  
 CC determining the functional allele profiles of various genes. The  
 CC primers are specific for genes such as MSH2 gene, MLH1 gene, BRCA1 gene,  
 CC BRCA2 gene and BAP1 gene.

XX Sequence 23 BP; 4 A; 4 C; 3 G; 12 T; 0 other;

Query Match 1.3%; Score 16.2; DB 1; Length 23;  
 Best Local Similarity 85.7%; Pred. No. 1.2e+02;  
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 763 TGAAGCATCATATAAAATGA 783  
 DB 22 TAAAGCAGCATATAAAATGA 2

## RESULT 50

AA92211/C  
 ID AA92211 standard; DNA; 23 BP.

XX AA92211;

DT 05-JAN-2001 (first entry)

DE Aurone glycosyl transferase related PCR primer SEQ ID NO:14.

XX Aurone; glycosyl transferase; plant; yellow pigment; flower;  
 KW PCR primer; ss.

XX Synthetic.

XX WO200049155-A1.

XX 24-AUG-2000.

PD 16-FEB-2000; 2000WO-JP00876.

XX 16-FEB-1999; 99JP-0036801.

XX (SUNR) SUNTORY LTD.

XX Sakakibara K, Fukui Y, Tanaka Y, Kusumi T, Yoshikawa T;

XX WPI; 2000-543757/49.

XX Plant gene encoding an aurone glycosyltransferase for producing plant  
 PT varieties having stable yellow flower coloration -

XX Example 8; Page 18; 51pp; Japanese.

XX The present invention describes a protein which has aurone glycosyl  
 CC transferase activity. Introduction of the aurone glycosyl transferase  
 CC gene into a plant in which it is absent results in the production of  
 CC the yellow pigment aurone in the flowers in a stable form. The gene is  
 CC used for the production of plants which have flowers with a stable  
 CC yellow colour. The present sequence represents a PCR primer which is  
 CC used in an example from the present invention.

XX Sequence 23 BP; 7 A; 6 C; 3 G; 7 T; 0 other;

Query Match 1.3%; Score 16.2; DB 1; Length 23;  
 Best Local Similarity 85.7%; Pred. No. 1.2e+02;

Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 546 GAAATAGTTTTCATGTACCA 566  
 DB 22 GAAATAGTTTTCATGTACCA 2

## RESULT 51

```

AAZ72999
ID  AAZ72999 standard; DNA; 20 BP.
AC  AAZ72999;
XX
XX  10-SEP-2001 (first entry)
DT
DE  Human biallelic marker upstream amplification primer SEQ ID NO:7355.
XX
XX  Human genome; biallelic marker; high density disequilibrium map;
KW  genomic map; haplotype; phenotype; polymorphic base; genotyping;
KW  haplotyping; hybridisation; identification; characterisation;
KW  amplification; single nucleotide polymorphism; SNP; PCR primer;
KW  diagnosis; ss.
XX
XX  Homo sapiens.
OS
XX  WO9954500-A2.
PN
XX  28-OCT-1999.
PD
XX  21-APR-1999; 99WO-IB00822.
PF
XX  21-APR-1998; 98US-0082614.
PR
XX  23-NOV-1998; 98US-0109732.
XX
XX  (GEST ) GENSET.
PA
XX
XX  Cohen D, Blumenfeld M, Chumakov I;
PI
XX  WPI; 2000-013267/01.
DR
XX
XX  Novel biallelic markers used to construct a high density disequilibrium
PT  map of the human genome -
PT
XX
XX  Claim 9; Page 1799; 2745pp; English.
PS
XX
XX  AAZ65654 to AAZ69578 represent human biallelic markers from the present
CC  invention, which contain a polymorphic base at position 24 of their
CC  nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
CC  primers for the biallelic markers. The biallelic markers of the
CC  invention have a variety of uses: they can be used for high density
CC  mapping of the human genome, and in complex association studies and
CC  haplotyping studies which are useful in determining the genetic basis
CC  for disease states. Compositions and methods of the invention can also
CC  be useful for the identification of the targets for the development of
CC  pharmaceutical agents and diagnostic methods, as well as the
CC  characterisation of the differential efficacious responses to and side
CC  effects from pharmaceutical agents acting on a disease as well as other
CC  treatment.
CC  N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
CC  and 3367, are not actually given a sequence in the Sequence Listing
CC  from the present invention.
XX
XX  Sequence 20 BP; 1 A; 3 C; 5 G; 11 T; 0 other;
SQ
    Query Match      1.3%; Score 15.8; DB 1; Length 20;
    Best Local Similarity 89.5%; Pred. No. 1.2e+02;
    Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  901 CTGGTTTCTCTCTTTATT 919
Db  1 CTGGTTTCTCTCTTTATT 19

RESULT 52
AAH26837
ID  AAH26837 standard; DNA; 20 BP.
XX
XX  AAZ26837;
AC
XX
XX  21-DEC-2001 (first entry)
DT
XX
XX

```

```

DE  Human osteoregulin gene PCR primer.
XX
XX  Osteoregulin; human; bone; homeostasis; adipose; calcification;
KW  atherosclerosis; osteoporosis; osteopathic; antiarteriosclerotic;
KW  therapy; PCR primer; ss.
XX
XX  Homo sapiens.
OS
XX  BP1130098-A2.
PN
XX  05-SEP-2001.
PD
XX  27-FEB-2001; 2001EP-0301768.
PF
XX  29-FEB-2000; 2000US-185617P.
PR  22-SEP-2000; 2000US-234500P.
XX
XX  (PFIZ ) PFIZER PROD INC.
PA
XX
XX  Brown TA, De Wet JR, Gowen LC, Hames LM;
PI  WPI; 2001-604111/59.
XX
XX  Novel osteoregulin polypeptide useful for regulating bone homeostasis,
PT  adiposity and calcification of atherosclerotic plaques comprises
PT  measuring the activity of osteoregulin -
PT
XX
XX  Example; Page 37; 90pp; English.
PS
XX
XX  The present sequence is that of a human osteoregulin gene PCR
CC  primer, which is one of a set of primers (see AAH26837-40) used in
CC  first and second round PCR amplifications of human osteoregulin
CC  cDNA from human osteoblast SaOS cells. A 433 bp product was
CC  obtained, which allowed compilation of complete sequences for
CC  human osteoregulin splice variant cDNAs (see AAH26808 and
CC  AAH26809). Human osteoregulin (see AAH26820-21) is a novel protein
CC  that plays a role in regulating bone homeostasis, adiposity and the
CC  calcification of atherosclerotic plaques. The invention provides
CC  osteoregulin proteins, nucleic acids which encode them, vectors,
CC  antibodies, host cells, and animal cells and mammals with a targeted
CC  disruption of an osteoregulin gene. It also provides screening
CC  assays to identify modulators of osteoregulin activity useful for
CC  treating a mammal in need of regulation of bone mass and/or density,
CC  adiposity, vascular flexibility, and/or atherosclerotic plaque
CC  calcification, for treating and preventing osteoporosis, and for
CC  stimulating bone repair and regeneration.
XX
XX  Sequence 20 BP; 9 A; 4 C; 1 G; 6 T; 0 other;
SQ
    Query Match      1.3%; Score 15.8; DB 1; Length 20;
    Best Local Similarity 89.5%; Pred. No. 1.2e+02;
    Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  716 CGAACTTTAATTTTCAGGAA 734
Db  1 CGAACTTTAATTTTCAGGAA 19

RESULT 53
AAV67374/c
ID  AAV67374 standard; DNA; 21 BP.
XX
XX  AAV67374;
AC
XX
XX  21-DEC-1998 (first entry)
DT
XX
XX  Nucleotide fragment containing polymorphic site, WI-5865 (i).
DE
XX  ss; polymorphic site; nucleic acid analysis; diagnosis; monitoring;
KW  cancer; inflammation; heart disease; CNS disease.
XX
XX  Homo sapiens.
OS
XX

```



XX KW High density lipoprotein-cholesterol; HDL-C; cardiovascular; ABC1; ds.  
 XX OS Homo sapiens.  
 XX FN WO200115676-A2.  
 XX PD 08-MAR-2001.  
 XX PF 01-SEP-2000; 2000WO-IB01492.  
 XX PR 01-SEP-1999; 95US-0151977.  
 XX PR 15-MAR-2000; 2000US-0526193.  
 XX PR 23-JUN-2000; 2000US-0213958.  
 XX PA (UYBR-) UNIV BRITISH COLUMBIA.  
 XX PA (XENO-) XENON GENETICS INC.  
 XX PI Hayden MR, Brooks-Wilson AR, Pimstone SN, Clee SM;  
 XX WPI; 2001-244356/25.  
 XX DR Treating a lower than normal high density lipoprotein-cholesterol  
 PT (HDL-C) level, a higher than normal triglyceride level, or a  
 PT cardiovascular disease, by administering a compound that modulates LXR-  
 PT or RXR-mediated transcriptional activity.  
 XX PS Disclosure; Fig 17; 317pp; English.  
 XX CC The present invention relates to a method for treating a patient  
 CC diagnosed as having a lower than normal high density  
 CC lipoprotein-cholesterol (HDL-C) level, a higher than normal  
 CC triglyceride level, or a cardiovascular disease, involving  
 CC administering a compound that modulates LXR- or RXR-mediated  
 CC transcriptional activity or ABC1 expression or activity.  
 CC The LXR gene product may be used in an assay to identify  
 CC compounds useful for the treatment of a disease or condition selected a  
 CC lower than normal HDL cholesterol level, a higher than normal  
 CC triglyceride level, and a cardiovascular disease.  
 XX SQ Sequence 21 BP; 7 A; 5 C; 3 G; 6 T; 0 other;  
 Query Match 1.3%; Score 15.8; DB 1; Length 21;  
 Best Local Similarity 89.5%; Pred. No. 1.3e+02;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 516 CCTGGTTAAATTGAAATT 534  
 Db 21 CCTGGAGAAATTGAAATT 3  
 RESULT 56  
 ABZ37635  
 ID ABZ37635 standard; DNA; 22 BP.  
 XX AC ABZ37635;  
 XX DT 26-FEB-2003 (first entry)  
 XX DE Porcine PERV locus 3' flanking sequence PCR primer 5'G16.  
 XX KW Porcine; flanking sequence; porcine endogenous retrovirus; PERV; pig;  
 XX KW xenograft; insertion site; PCR; primer; ss.  
 XX OS Sus scrofa.  
 XX FN WO2002083838-A2.  
 XX PD 24-OCT-2002.  
 XX PP 28-MAR-2002; 2002WO-US10168.  
 XX PR 28-MAR-2001; 2001US-279337P.

XX PA (NEXT-) NEXTRAN INC.  
 XX PI Cui C, Diamond LE, Logan JS;  
 XX WPI; 2003-093004/08.  
 XX DR New isolated porcine nucleic acid sequence comprising a 3' end or 5'  
 XX PT end flanking sequence of an infectious porcine endogenous retrovirus  
 XX PT (PERV) insertion site, useful for selectively breeding a pig for use as  
 XX PT a xenograft donor.  
 XX PS Disclosure; Page 75; 91pp; English.  
 XX CC The invention relates to a novel isolated porcine nucleic acid sequence  
 CC comprising a 3' end or 5' end flanking sequence of an infectious porcine  
 CC endogenous retrovirus (PERV) insertion site. A probe of the invention is  
 CC useful for detecting the presence of potentially infectious PERV in  
 CC biological sample. The method is useful for selectively breeding a pig  
 CC for use as a xenograft donor, thereby reducing the risk of transmission  
 CC of PERV from porcine tissues suitable for use as xenografts. The nucleic  
 CC acid sequences are useful for constructing the probes. The sequences  
 CC shown in ABZ37605 - ABZ37664 represent PCR primers used in the invention  
 CC to amplify probes corresponding to the 3' flanking PERV integration  
 CC sequences.  
 XX SQ Sequence 22 BP; 5 A; 9 C; 3 G; 5 T; 0 other;  
 Query Match 1.3%; Score 15.8; DB 1; Length 22;  
 Best Local Similarity 89.5%; Pred. No. 1.4e+02;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 940 CCACCATCTTACCTCAG 958  
 Db 4 CCACCATCTTACCTCAG 22  
 RESULT 57  
 AAQ64706/c  
 ID AAQ64706 standard; cDNA to mRNA; 22 BP.  
 XX AC AAQ64706;  
 XX DT 25-MAR-2003 (updated)  
 XX DT 04-JAN-1995 (first entry)  
 XX DE 2',5'-linked tetraadenylate-antisense oligonucleotide chimeric mol.  
 XX KW antisense; 2',5'-tetraadenylate; 2-5A dependent RNase activator;  
 XX KW RNA cleavage; antiviral therapy; chimeric molecule; ss.  
 XX OS Synthetic.  
 XX PH Key Location/Qualifiers  
 XX FT misc\_feature 1...4  
 XX FT /tag= a  
 XX FT /label= 2',5'-linked tetraadenylate  
 XX FT /note= "nucleotides linked through phosphodiester  
 XX FT bonds at hydroxyl groups of 2' and 5'  
 XX FT carbons"  
 XX FT misc\_feature 5..22  
 XX FT /tag= b  
 XX FT /note= "antisense region"  
 XX FN WO9409129-A2.  
 XX XX 28-APR-1994.  
 XX XX 20-OCT-1993; 93WO-US10103.  
 XX XX 21-OCT-1992; 92US-0965666.  
 XX XX 17-SEP-1993; 93US-0123449.

PA (CLEV-) CLEVELAND CLINIC RES INST.  
 PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.  
 XX Lesiak K, Maitra R, Silverman R, Torrence P;  
 XX WPI; 1994-151315/18.  
 XX Specific cleavage of RNA, useful partic. for treating viral  
 PT infection, cancers, etc. - by using anti-sense oligo:nucleotide  
 PT coupled to activator of 2-5A dependent RNase  
 XX Example 1; Page 68; 86pp; English.  
 XX This sequence is an example of a 2-5A-antisense oligonucleotide  
 CC chimeric molecule. The antisense region targets the chimeric  
 CC molecule to a particular region of RNA to be specifically  
 CC cleaved and the 2',5'-linked tetraadenylate tail activates  
 CC the 2-5A RNase. Typical applications are treatment of viral  
 CC infections (esp. for cleavage of an RNA virus genome), cancer;  
 CC leukemia, cardiovascular disorders (e.g. restenosis after  
 CC angioplasty), genetic disorders, osteoarthritis or rheumatoid  
 CC arthritis.  
 CC (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 XX Sequence 22 BP; 4 A; 0 C; 0 G; 18 T; 0 other;

Query Match 1.2%; Score 15.6; DB 1; Length 22;  
 Best Local Similarity 81.8%; Pred. No. 1.5e+02;  
 Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 616 ACAGAAACACCAATTAATTTT 637  
 ||||| ||||| ||||| |||||  
 DB 22 AAAAAAAAAAAAAAAAAAATTTT 1

RESULT 59  
 AAD21907/C  
 ID AAD21907 standard; DNA; 26 BP.  
 XX  
 AC AAD21907;  
 XX  
 DT 12-FEB-2002 (first entry)  
 DE PCR primer, 2767A used to determine the genotype of human IL-8 gene.  
 XX Human; genetic variant identification; interleukin 8; RSV bronchiolitis;  
 XX respiratory syncytial virus; PCR primer; ss.  
 XX Homo sapiens.  
 XX WO200177382-A2.  
 XX  
 PD 18-OCT-2001.  
 XX  
 PF 11-APR-2001; 2001WO-GB01634.  
 XX  
 PR 11-APR-2000; 2000GB-0008910.  
 XX  
 PA (ISIS-) ISIS INNOVATION LTD.  
 XX  
 PI Hull J, Kwiatkowski DP;  
 XX WPI; 2002-017472/02.

XX Nucleic acid comprising a sequence corresponding to variant allele of  
 PT human interleukin 8 gene, useful for determining susceptibility to  
 PT respiratory syncytial virus bronchiolitis in humans -  
 XX  
 XX Claim 42; Page 47; 49pp; English.  
 XX The patent discloses methods for identification of genetic variants  
 CC at the interleukin 8 (IL-8) locus. The invention relates to nucleic  
 CC acid molecules corresponding to various alleles at the IL8 locus

CC and kits for the detection of the presence of variant alleles. The  
 CC polymorphic variants of the IL-8 locus are useful for screening a  
 CC human subject for susceptibility to a disease such as respiratory  
 CC syncytial virus (RSV) bronchiolitis for which increased production  
 CC of IL-8 is a risk factor. The polymorphic variants of IL-8 locus are  
 CC also useful for determining the likelihood that a patient previously  
 CC identified as infected with RSV will develop severe disease. They are  
 CC useful as probes and primers for genotyping. They are also useful for  
 CC initiating DNA synthesis or amplification for detecting the presence  
 CC of IL-8 genetic variants. The single nucleotide polymorphisms have a  
 CC general utility as a genetic marker. The present DNA sequence is PCR  
 CC primer, 2767A which is used to determine the genotype of human  
 CC IL-8 gene.

XX Sequence 26 BP; 8 A; 5 C; 2 G; 11 T; 0 other;

Query Match 1.2%; Score 15.6; DB 1; Length 26;  
 Best Local Similarity 81.8%; Pred. No. 1.8e+02;  
 Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1291 TATCTGAAATTTTAATTTGAAT 1312  
 ||||| ||||| ||||| |||||  
 DB 25 TATCTGAAATGAAATTTTAAT 4

RESULT 59  
 AAA22696  
 ID AAA22696 standard; RNA; 17 BP.

XX  
 AC AAA22696;  
 XX  
 DT 19-JUN-2000 (first entry)

DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5922.

XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
 XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 XX hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
 XX ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 XX dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 XX age related macular degeneration; inflammation; neovascular glaucoma;  
 XX myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 XX tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;  
 XX Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

XX Homo sapiens.

XX WO9950403-A2.

XX 07-OCT-1999.

XX 24-MAR-1999; 99WO-US06507.

XX 27-MAR-1998; 98US-0079678.

XX (RIBO-) RIBOZYME PHARM INC.

XX Pavco PA, Roberts B, Jarvis T, Coeshott C, McSwiggen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or  
 PT stability of an mRNA encoding an angiogenic factors -

XX Claim 54; Page 236; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with  
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to

CC AA19154 represent ribozyme sequences for Tie-2, and AA18386 to AA19086  
CC and AA19155 to AA19222 represent their corresponding target sequences;  
CC AA19223 to AA20361 and AA21501 to AA21595 represent ribozyme  
CC sequences for integrin alpha 6 subunit, and AA20362 to AA21500 and  
CC AA21596 to AA21688 represent their corresponding target sequences;  
CC AA21689 to AA22475 and AA22342 represent ribozyme sequences  
CC for integrin subunit beta 3, and AA22476 to AA22342 to  
CC AA22343 to  
CC AA22342 represent their corresponding target sequences. The ribozymes of  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3.  
SQ Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 23.5%; Pred. No. 1.3e+02;  
Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

Qy 1040 TTATTATTATGTTT 1056  
Db 1 UUAUUUUUUUUUUUU 17  
AA222697  
AA222697 standard; RNA; 17 BP.  
AA222697;  
19-JUN-2000 (first entry)  
Integrin subunit beta 3 substrate sequence SEQ ID NO:5923.

Human; aryl hydrocarbon nuclear transporter; ARNT; TIE-2; angiogenesis;  
integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
age related macular degeneration; inflammation; neovascular glaucoma;  
myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;  
Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
Homo sapiens.  
WO9950403-A2.  
07-OCT-1999.  
24-MAR-1999; 99WO-US06507.  
27-MAR-1998; 98US-0079678.  
(RIBO-) RIBOZYME PHARM INC.  
Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;  
WPI; 1999-591315/50.  
Novel ribozymes for modulating the synthesis, expression and/or  
stability of an mRNA encoding an angiogenic factors -  
Claim 54; Page 236; 30pp; English.

CC The present invention describes enzymatic cleavage of nucleic acid molecules with  
CC RNA cleaving activity, which specifically cleaves RNA encoded by an aryl

CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AA16775 to  
CC AA17167 and AA17561 to AA17622 represent ribozyme sequences for ARNT,  
CC and AA17168 to AA17560 and AA17623 to AA17684 represent their  
CC corresponding target sequences; AA17685 to AA18385 and AA19087 to  
CC AA19154 represent ribozyme sequences for Tie-2, and AA18386 to AA19086  
CC and AA19155 to AA19222 represent their corresponding target sequences;  
CC AA19223 to AA20361 and AA21501 to AA21595 represent ribozyme  
CC sequences for integrin alpha 6 subunit, and AA20362 to AA21500 and  
CC AA21596 to AA21688 represent their corresponding target sequences;  
CC AA21689 to AA22475 and AA22342 to AA22343 to  
CC for integrin subunit beta 3, and AA22476 to AA22342 to  
CC AA22343 to  
CC AA22342 represent their corresponding target sequences. The ribozymes of  
CC the invention are used for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
CC especially used to treat cancer, diabetic retinopathy, age related  
CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3.  
SQ Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 23.5%; Pred. No. 1.3e+02;  
Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

Qy 1041 TTATTATTATGTTT 1057  
Db 1 UUAUUUUUUUUUUUU 17  
AA222698  
AA222698 standard; RNA; 17 BP.  
AA222698;  
19-JUN-2000 (first entry)  
Integrin subunit beta 3 substrate sequence SEQ ID NO:5924.

Human; aryl hydrocarbon nuclear transporter; ARNT; TIE-2; angiogenesis;  
integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
age related macular degeneration; inflammation; neovascular glaucoma;  
myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;  
Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
Homo sapiens.  
WO9950403-A2.  
07-OCT-1999.  
24-MAR-1999; 99WO-US06507.  
27-MAR-1998; 98US-0079678.  
(RIBO-) RIBOZYME PHARM INC.  
Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;  
WPI; 1999-591315/50.

CC Novel ribozymes for modulating the synthesis, expression and/or  
CC stability of an mRNA encoding an angiogenic factors -



XX PS Claim 54; Page 236; 305pp; English.

XX CC The present invention describes enzymatic cleavage of nucleic acid molecules with

XX CC RNA cleaving activity, which specifically cleaves RNA encoded by an aryl

CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3

CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to

CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,

CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their

CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to

CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086

CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and

CC AAA21596 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequences

CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to

CC AAA23422 represent their corresponding target sequences. The ribozymes of

CC the invention are used for modulating the synthesis, expression and/or

CC stability of an mRNA encoding angiogenic factor, especially ARNT,

CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are

CC especially used to treat cancer, diabetic retinopathy, age related

CC macular degeneration (ARMD), inflammation, and arthritis, as well as

CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,

CC angioid fibroma of tuberous sclerosis, pot-wine stains, Sturge Weber

CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,

CC and other syndromes and diseases related to the levels of ARNT, Tie-2,

CC integrin subunit alpha-6, or integrin subunit beta-3.

XX CC Sequence 17 BP; 5 A; 0 C; 0 G; 12 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 29.4%; Pred. No. 1.3e+02;  
Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;

OY 1042 TATTATTATGTTATTA 1058  
Db 1 UAUUUUUUUUUUUUUU 17

RESULT 62  
ID AAA22699  
XX ID AAA22699 standard; RNA; 17 BP.  
XX AC AAA22699;  
XX 19-JUN-2000 (first entry)  
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5925.  
XX Human; aryl hydrocarbon nuclear transporter; ARNT; TIR-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angioid fibroma;  
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX Homo sapiens.  
XX WO9950403-A2.  
XX 07-OCT-1999.  
XX 24-MAR-1999; 99WO-US06507.  
XX 27-MAR-1998; 98US-0079678.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or

XX stability of an mRNA encoding an angiogenic factor

XX Claim 54; Page 237; 305pp; English.

XX The present invention describes enzymatic cleavage of nucleic acid molecules with

CC RNA cleaving activity, which specifically cleaves RNA encoded by an aryl

CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3

CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to

CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,

CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their

CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to

CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086

CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and

CC AAA21596 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequences

CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to

CC AAA23422 represent their corresponding target sequences. The ribozymes of

CC the invention are used for modulating the synthesis, expression and/or

CC stability of an mRNA encoding angiogenic factor, especially ARNT,

CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are

CC especially used to treat cancer, diabetic retinopathy, age related

CC macular degeneration (ARMD), inflammation, and arthritis, as well as

CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,

CC angioid fibroma of tuberous sclerosis, pot-wine stains, Sturge Weber

CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,

CC and other syndromes and diseases related to the levels of ARNT, Tie-2,

CC integrin subunit alpha-6, or integrin subunit beta-3.

XX Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 23.5%; Pred. No. 1.3e+02;  
Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

OY 1044 TTATTATGTTATTTATT 1060  
Db 1 UUAUUUUUUUUUUUUU 17

RESULT 63  
ID AAA22700  
XX ID AAA22700 standard; RNA; 17 BP.  
XX AC AAA22700;  
XX 19-JUN-2000 (first entry)  
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5926.  
XX Human; aryl hydrocarbon nuclear transporter; ARNT; TIE-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angioid fibroma;  
KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX Homo sapiens.  
XX WO9950403-A2.  
XX 07-OCT-1999.  
XX 24-MAR-1999; 99WO-US06507.



```

PR 27-MAR-1998; 98US-0079678.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX PA Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX
XX PI WPI; 1999-591315/50.
XX
XX DR Novel ribozymes for modulating the synthesis, expression and/or
XX stability of an mRNA encoding an angiogenic factors
XX
XX PS Claim 54; Page 237; 305pp; English.
XX
XX CC The present invention describes enzymatic cleavage of nucleic acid molecules with
XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl
XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AA16775 to
XX AA17167 and AA17561 to AA17622 represent ribozyme sequences for ARNT,
XX and AA17168 to AA17560 and AA17623 to AA17684 represent their
XX corresponding target sequences; AA17685 to AA18385 and AA19087 to
XX AA19154 represent ribozyme sequences for Tie-2, and AA18386 to AA19086
XX AA19155 represent ribozyme sequences for integrin subunit beta-3, and
XX AA19223 to AA20361 and AA21501 to AA21595 represent ribozyme
XX sequences for integrin alpha 6 subunit, and AA20362 to AA21500 and
XX AA21596 to AA21688 represent their corresponding target sequences;
XX AA21689 to AA22475 and AA23263 to AA23442 represent ribozyme sequences
XX for integrin subunit beta 3, and AA22476 to AA23262, AA23343 to
XX AA23422 represent their corresponding target sequences. The ribozymes of
XX the invention are used for modulating the synthesis, expression and/or
XX stability of an mRNA encoding angiogenic factor, especially ARNT,
XX integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
XX especially used to treat cancer, diabetic retinopathy, age related
XX macular degeneration (ARMD), inflammation, and arthritis, as well as
XX neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
XX angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
XX syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
XX and other syndromes and diseases related to the levels of ARNT, Tie-2,
XX integrin subunit alpha-6, or integrin subunit beta-3.
XX
XX SQ Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;
XX
XX Query Match 1.2%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 23.5%; Pred. No. 1.3e+02;
XX Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1045 TATTTATGTAATTTATTT 1061
XX Db 1 UAUUUUUUUUUUUUUUUU 17
XX
XX RESULT 64
XX AAA22701
XX ID AAA22701 standard; RNA, 17 BP.
XX
XX AC AAA22701;
XX
XX DT 19-JUN-2000 (first entry)
XX
XX DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5927.
XX
XX KW Human; aryl hydrocarbon nuclear transporter; ARNT; TIE-2; angiogenesis;
XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
XX hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
XX ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
XX dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
XX age related macular degeneration; inflammation; neovascular glaucoma;
XX myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
XX Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO9950403-A2.

```

```

XX PD 07-OCT-1999.
XX
XX PF 24-MAR-1999; 99WO-US06507.
XX
XX PR 27-MAR-1998; 98US-0079678.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX
XX DR WPI; 1999-591315/50.
XX
XX PS Novel ribozymes for modulating the synthesis, expression and/or
XX stability of an mRNA encoding an angiogenic factors
XX
XX CC Claim 54; Page 237; 305pp; English.
XX
XX CC The present invention describes enzymatic cleavage of nucleic acid molecules with
XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl
XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AA16775 to
XX AA17167 and AA17561 to AA17622 represent ribozyme sequences for ARNT,
XX and AA17168 to AA17560 and AA17623 to AA17684 represent their
XX corresponding target sequences; AA17685 to AA18385 and AA19087 to
XX AA19154 represent ribozyme sequences for Tie-2, and AA18386 to AA19086
XX AA19155 to AA19222 represent their corresponding target sequences;
XX and AA19223 to AA20361 and AA21501 to AA21595 represent ribozyme
XX sequences for integrin alpha 6 subunit, and AA20362 to AA21500 and
XX AA21596 to AA21688 represent their corresponding target sequences;
XX AA21689 to AA22475 and AA23263 to AA23442 represent ribozyme sequences
XX for integrin subunit beta 3, and AA22476 to AA23262, AA23343 to
XX AA23422 represent their corresponding target sequences. The ribozymes of
XX the invention are used for modulating the synthesis, expression and/or
XX stability of an mRNA encoding angiogenic factor, especially ARNT,
XX integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
XX especially used to treat cancer, diabetic retinopathy, age related
XX macular degeneration (ARMD), inflammation, and arthritis, as well as
XX neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
XX angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber
XX syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
XX and other syndromes and diseases related to the levels of ARNT, Tie-2,
XX integrin subunit alpha-6, or integrin subunit beta-3.
XX
XX SQ Sequence 17 BP; 5 A; 0 C; 0 G; 12 U; 0 other;
XX
XX Query Match 1.2%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 29.4%; Pred. No. 1.3e+02;
XX Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1046 ATTATGTAATTTATTTA 1062
XX Db 1 AUUUUUUUUUUUUUUUUA 17
XX
XX RESULT 65
XX AAA22702
XX ID AAA22702 standard; RNA, 17 BP.
XX
XX AC AAA22702;
XX
XX DT 19-JUN-2000 (first entry)
XX
XX DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5928.
XX
XX KW Human; aryl hydrocarbon nuclear transporter; ARNT; TIE-2; angiogenesis;
XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
XX hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;
XX ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
XX dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
XX age related macular degeneration; inflammation; neovascular glaucoma;
XX myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
XX tuberous sclerosis; psoriasis; verruca vulgaris; Sturge Weber syndrome;
XX

```

KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
OS Homo sapiens.  
XX W09950403-A2.  
XX 07-OCT-1999.  
XX 24-MAR-1999; 99WO-US06507.  
XX 27-MAR-1998; 98US-0079678.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;  
XX WPI; 1999-591315/50.  
XX Novel ribozymes for modulating the synthesis, expression and/or  
XX stability of an mRNA encoding an angiogenic factors -  
XX Claim 54; Page 237; 305pp; English.  
XX The present invention describes enzymatic cleave acid molecules with  
XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl  
XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
XX AAA19155 to AAA19222 represent their corresponding target sequences;  
XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
XX AAA21596 to AAA21688 represent their corresponding target sequences;  
XX AAA21689 to AAA22475 and AAA23263 to AAA23262, AAA23343 to  
XX AAA23422 represent their corresponding target sequences. The ribozymes of  
XX the invention are used for modulating the synthesis, expression and/or  
XX stability of an mRNA encoding angiogenic factor, especially ARNT,  
XX integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
XX especially used to treat cancer, diabetic retinopathy, age related  
XX macular degeneration (ARMD), inflammation, and arthritis, as well as  
XX neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
XX angiofibroma of tuberosus sclerosus, pot-wine stains, Sturge Weber  
XX syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
XX and other syndromes and diseases related to the levels of ARNT, Tie-2,  
XX integrin subunit alpha-6, or integrin subunit beta-3.  
XX Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;  
Query Match 1.2%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 23.5%; Pred. NO. 1.3e+02;  
Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;  
QY 1044 TATTATGATTTATTT 1060  
Db 1 UAUUUUUUUUUUUUUU 17  
RESULT 66  
AAA22703  
ID AAA22703 standard; RNA; 17 BP.  
XX AAA22703;  
XX 19-JUN-2000 (first entry)  
XX Integrin subunit beta 3 substrate sequence SEQ ID NO:5929.  
XX Human; aryl hydrocarbon nuclear transporter; ARNT; Tie-2; angiogenesis;  
XX integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
XX hammerhead ribozyme; angiogenic factor; cytosstatic; antidiabetic;

KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberosus sclerosus; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX Homo sapiens.  
XX W09950403-A2.  
XX 07-OCT-1999.  
XX 24-MAR-1999; 99WO-US06507.  
XX 27-MAR-1998; 98US-0079678.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;  
XX WPI; 1999-591315/50.  
XX Novel ribozymes for modulating the synthesis, expression and/or  
XX stability of an mRNA encoding an angiogenic factors -  
XX Claim 54; Page 237; 305pp; English.  
XX The present invention describes enzymatic cleave acid molecules with  
XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl  
XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
XX AAA19155 to AAA19222 represent their corresponding target sequences;  
XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
XX AAA21596 to AAA21688 represent their corresponding target sequences;  
XX AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequences  
XX for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
XX AAA23422 represent their corresponding target sequences. The ribozymes of  
XX the invention are used for modulating the synthesis, expression and/or  
XX stability of an mRNA encoding angiogenic factor, especially ARNT,  
XX integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
XX especially used to treat cancer, diabetic retinopathy, age related  
XX macular degeneration (ARMD), inflammation, and arthritis, as well as  
XX neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
XX angiofibroma of tuberosus sclerosus, pot-wine stains, Sturge Weber  
XX syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
XX and other syndromes and diseases related to the levels of ARNT, Tie-2,  
XX integrin subunit alpha-6, or integrin subunit beta-3.  
XX Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;  
Query Match 1.2%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 23.5%; Pred. NO. 1.3e+02;  
Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;  
QY 1045 TATTATGATTTATTT 1061  
Db 1 UAUUUUUUUUUUUUUU 17  
RESULT 67  
AAA22704  
ID AAA22704 standard; RNA; 17 BP.  
XX AAA22704;  
XX 19-JUN-2000 (first entry)  
XX

```

DE XX Integrin subunit beta 3 substrate sequence SEQ ID NO:5930.
KW Human; aryl hydrocarbon nuclear transport; ARNT; Tie-2; angiogenesis;
KW integrin alpha 5 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiobroma;
KW tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX Homo sapiens.
OS
XX WO9950403-A2.
XX 07-OCT-1999.
XX 24-MAR-1999; 99WO-US06507.
XX 27-MAR-1998; 98US-0079678.
XX (RIBO-) RIBOZYME PHARM INC.
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX WPI; 1999-591315/50.
XX Novel ribozymes for modulating the synthesis, expression and/or
XX stability of an mRNA encoding an angiogenic factors -
XX Claim 54; Page 237; 305pp; English.
XX The present invention describes enzymatic cleave RNA molecules with
XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl
XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to
XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
XX AAA19223 to AAA21688 represent their corresponding target sequences;
XX AAA19155 to AAA19222 represent their corresponding ribozyme
XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
XX AAA21595 to AAA22475 and AAA23263 to AAA23342 represent ribozyme
XX sequences for integrin subunit beta 3, and AAA22476 to AAA23262,
XX AAA23422 represent their corresponding target sequences. The ribozymes of
XX the invention are used for modulating the synthesis, expression and/or
XX stability of an mRNA encoding angiogenic factor, especially ARNT,
XX especially used to treat cancer, diabetic retinopathy, age related
XX macular degeneration (ARMD), inflammation, and arthritis, as well as
XX neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
XX angiobroma of tubercous sclerosis, pot-wine stains, Sturge Weber
XX syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
XX and other syndromes and diseases related to the levels of ARNT, Tie-2,
XX integrin subunit alpha-6, or integrin subunit beta-3.
XX Sequence 17 BP; 5 A; 0 C; 0 G; 12 U; 0 other;
SQ
Query Match 1.2%; Score 15.4; DB 1; Length 17;
Best Local Similarity 29.4%; Pred. No. 1.3e+02;
Matches 5; Conservative 11; Mismatches 1; Indels 0; Gaps 0;
QY 1046 ATTATGATGATTTATTTA 1062
DB 1 AUUUUUUUUUUUUU 17
RESULT 68
AAA22705
ID AAA22705 standard; RNA; 17 BP.

```

```

XX AAA22705;
AC 19-JUN-2000 (first entry)
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5931.
KW Human; aryl hydrocarbon nuclear transport; ARNT; Tie-2; angiogenesis;
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
KW age related macular degeneration; inflammation; neovascular glaucoma;
KW myopic degeneration; psoriasis; verruca vulgaris; angiobroma;
KW tubercous sclerosis; pot-wine stain; Sturge Weber syndrome;
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
XX Homo sapiens.
OS
XX WO9950403-A2.
XX 07-OCT-1999.
XX 24-MAR-1999; 99WO-US06507.
XX 27-MAR-1998; 98US-0079678.
XX (RIBO-) RIBOZYME PHARM INC.
XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
XX WPI; 1999-591315/50.
XX Novel ribozymes for modulating the synthesis, expression and/or
XX stability of an mRNA encoding an angiogenic factors -
XX Claim 54; Page 237; 305pp; English.
XX The present invention describes enzymatic cleave RNA molecules with
XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl
XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to
XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
XX AAA21595 to AAA21688 represent their corresponding target sequences;
XX AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme
XX sequences for integrin subunit beta 3, and AAA22476 to AAA23262,
XX AAA23422 represent their corresponding target sequences. The ribozymes of
XX the invention are used for modulating the synthesis, expression and/or
XX stability of an mRNA encoding angiogenic factor, especially ARNT,
XX especially used to treat cancer, diabetic retinopathy, age related
XX macular degeneration (ARMD), inflammation, and arthritis, as well as
XX neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
XX angiobroma of tubercous sclerosis, pot-wine stains, Sturge Weber
XX syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
XX and other syndromes and diseases related to the levels of ARNT, Tie-2,
XX integrin subunit alpha-6, or integrin subunit beta-3.
XX Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;
SQ
Query Match 1.2%; Score 15.4; DB 1; Length 17;
Best Local Similarity 23.5%; Pred. No. 1.3e+02;
Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;
QY 1044 TTATTTATGATTTATTTT 1060
DB 1 UUAUUUUUUUUUUUU 17

```

Matches 4; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

RESULT 69  
 ID AAA22706 standard; RNA; 17 BP.  
 AC AAA22706;  
 XX  
 XX 19-JUN-2000 (first entry)  
 DE Integrin subunit beta 3 substrate sequence SEQ ID NO:5932.  
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KW age related macular degeneration; inflammation; neovascular glaucoma;  
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;  
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 XX W09950403-A2.  
 PN  
 XX  
 PD 07-OCT-1999.  
 XX  
 XX 24-MAR-1999; 99WO-US06507.  
 PF  
 XX  
 XX 27-MAR-1998; 98US-0079678.  
 PR  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;  
 XX WPI; 1999-591315/50.  
 DR  
 XX  
 XX Novel ribozymes for modulating the synthesis, expression and/or  
 PT stability of an mRNA encoding an angiogenic factors -  
 XX  
 XX Claim 54; Page 237; 305pp; English.  
 XX  
 CC The present invention describes enzymatic cleave RNA molecules with  
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC and AAA17168 to AAA17560 and AAA17623 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequences  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT.  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3.  
 XX  
 XX Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 23.5%; Pred. No. 1.3e+02;

QY 1045 TATTATGCTATTATTT 1061  
 :|:::|:|:::|:::  
 DB 1 UAUUUUUUUUUUUUU 17  
 RESULT 70  
 AAA22899/c  
 ID AAA22899 standard; RNA; 17 BP.  
 XX  
 AC AAA22899;  
 XX  
 XX 19-JUN-2000 (first entry)  
 DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6125.  
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KW age related macular degeneration; inflammation; neovascular glaucoma;  
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KW tuberous sclerosis; pot-wine stain; Sturge Weber syndrome;  
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 XX W09950403-A2.  
 PN  
 XX  
 PD 07-OCT-1999.  
 XX  
 XX 24-MAR-1999; 99WO-US06507.  
 PF  
 XX  
 XX 27-MAR-1998; 98US-0079678.  
 PR  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;  
 XX WPI; 1999-591315/50.  
 DR  
 XX  
 XX Novel ribozymes for modulating the synthesis, expression and/or  
 PT stability of an mRNA encoding an angiogenic factors -  
 XX  
 XX Claim 54; Page 249; 305pp; English.  
 XX  
 CC The present invention describes enzymatic cleave RNA molecules with  
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC and AAA17168 to AAA17560 and AAA17623 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequences  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT.  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3.

XX SQ Sequence 17 BP; 13 A; 0 C; 0 G; 4 U; 0 other;  
Query Match 1.2%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.3e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1045 TATTATGTTATTATT 1061  
DB 17 TATTATTATTATTATT 1  
RESULT 71  
AAA22900/c  
ID AAA22900 standard; RNA; 17 BP.  
XX AAA22900;  
DT 19-JUN-2000 (first entry)  
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6126.  
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIR-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX OS Homo sapiens.  
XX WO9950403-A2.  
XX 07-OCT-1999.  
XX 24-MAR-1999; 99WO-US06507.  
XX 27-MAR-1998; 98US-0079678.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX Pavco PA, Roberts B, Jarvis T, Coeshott C, McSwiggen JA;  
XX WPI; 1999-591315/50.  
XX Novel ribozymes for modulating the synthesis, expression and/or  
XX stability of an mRNA encoding an angiogenic factors -  
XX Claim 54; Page 249; 305pp; English.  
XX The present invention describes enzymatic cleave nucleic acid molecules with  
XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl  
XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
XX and AAA19155 to AAA19222 represent their corresponding target sequences;  
XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
XX AAA21596 to AAA21688 represent their corresponding target sequences;  
XX AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme  
XX sequences for integrin subunit beta-3, integrin subunit alpha-5, or Tie-2. ARNT,  
XX especially used to treat cancer, diabetic retinopathy, age related  
XX macular degeneration (ARMD), inflammation, and arthritis, as well as

CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber  
CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
CC integrin subunit alpha-6, or integrin subunit beta-3.  
XX SQ Sequence 17 BP; 13 A; 0 C; 0 G; 4 U; 0 other;  
Query Match 1.2%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.3e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1045 TATTATGTTATTATT 1061  
DB 17 TATTATTATTATTATT 1  
RESULT 72  
AAA22901/c  
ID AAA22901 standard; RNA; 17 BP.  
XX AAA22901;  
DT 19-JUN-2000 (first entry)  
DE Integrin subunit beta 3 substrate sequence SEQ ID NO:6127.  
KW Human; aryl hydrocarbon nuclear transport; ARNT; TIR-2; angiogenesis;  
KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;  
KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
KW age related macular degeneration; inflammation; neovascular glaucoma;  
KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;  
KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
XX OS Homo sapiens.  
XX WO9950403-A2.  
XX 07-OCT-1999.  
XX 24-MAR-1999; 99WO-US06507.  
XX 27-MAR-1998; 98US-0079678.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX Pavco PA, Roberts B, Jarvis T, Coeshott C, McSwiggen JA;  
XX WPI; 1999-591315/50.  
XX Novel ribozymes for modulating the synthesis, expression and/or  
XX stability of an mRNA encoding an angiogenic factors -  
XX Claim 54; Page 249; 305pp; English.  
XX The present invention describes enzymatic cleave nucleic acid molecules with  
XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl  
XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
XX and AAA19155 to AAA19222 represent their corresponding target sequences;  
XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
XX AAA21596 to AAA21688 represent their corresponding target sequences;  
XX AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme  
XX sequences for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
XX AAA23422 represent their corresponding target sequences. The ribozymes of

CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3.

XX Sequence 17 BP; 13 A; 0 C; 0 G; 4 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred. No. 1.3e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1045 TATTTATGTTATTTATTT 1061

Db 17 TATTTATTTATTTATTT 1

RESULT 73  
 AAA22902/c  
 ID AAA22902 standard; RNA; 17 BP.

XX AAA22902;

XX 19-JUN-2000 (first entry)

XX Integrin subunit beta 3 substrate sequence SEQ ID NO:6128.

XX Human; aryl hydrocarbon nuclear transport; ARNT; Tie-2; angiogenesis;  
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;  
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KW age related macular degeneration; inflammation; neovascular glaucoma;  
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;  
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

XX Homo sapiens.

OS WO9950403-A2.

XX 07-OCT-1999.

XX 24-MAR-1999; 99WO-US06507.

XX 27-MAR-1998; 98US-0079678.

XX (RIBO-) RIBOZYME PHARM INC.

XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or  
 PT stability of an mRNA encoding an angiogenic factors -

XX Claim 54; Page 249; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with  
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme

CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA21688 represent their corresponding target sequences;  
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3.

XX Sequence 17 BP; 13 A; 0 C; 0 G; 4 U; 0 other;

Query Match 1.2%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 1.3e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1045 TATTTATGTTATTTATTT 1061

Db 17 TATTTATTTATTTATTT 1

RESULT 74

AAA22903/c

ID AAA22903 standard; RNA; 17 BP.

XX AAA22903;

XX 19-JUN-2000 (first entry)

XX Integrin subunit beta 3 substrate sequence SEQ ID NO:6129.

XX Human; aryl hydrocarbon nuclear transport; ARNT; Tie-2; angiogenesis;  
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;  
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KW age related macular degeneration; inflammation; neovascular glaucoma;  
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;  
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.

XX Homo sapiens.

XX WO9950403-A2.

XX 07-OCT-1999.

XX 24-MAR-1999; 99WO-US06507.

XX 27-MAR-1998; 98US-0079678.

XX (RIBO-) RIBOZYME PHARM INC.

XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;

XX WPI; 1999-591315/50.

XX Novel ribozymes for modulating the synthesis, expression and/or  
 PT stability of an mRNA encoding an angiogenic factors -

XX Claim 54; Page 249; 305pp; English.

XX The present invention describes enzymatic nucleic acid molecules with  
 CC RNA cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,



CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tle-2, and AAA18386 to AAA19086  
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA21688 represent their corresponding target sequences;  
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequences  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tle-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tuberous sclerosis, pot-wine staining, Sturge Weber  
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tle-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3.  
 XX  
 SQ Sequence 17 BP; 13 A; 0 C; 0 G; 4 U; 0 other;  
 Query Match 1.2%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred. No. 1.3e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1045 TATTATGATTTATT 1061  
 ||||| |||||  
 Db 17 TATTATTTATTATT 1  
 RESULT 75  
 ABV80426/c  
 ID ABV80426 standard; DNA; 17 BP.  
 AC ABV80426;  
 XX  
 DT 03-JAN-2003 (first entry)  
 XX  
 DE Human HTPL scanning oligonucleotide SEQ ID 1672.  
 XX  
 KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
 KW human testis expressed patched like protein; testis; adrenal; liver;  
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FN EP1229046-A2.  
 XX  
 PD 07-AUG-2002.  
 XX  
 PF 28-JAN-2002; 2002EP-0001167.  
 XX  
 PR 30-JAN-2001; 2001WO-US00663.  
 PR 30-JAN-2001; 2001WO-US00664.  
 PR 30-JAN-2001; 2001WO-US00665.  
 PR 30-JAN-2001; 2001WO-US00667.  
 PR 30-JAN-2001; 2001WO-US00668.  
 PR 30-JAN-2001; 2001WO-US00669.  
 PR 23-MAY-2001; 2001US-0864761.  
 PR 09-OCT-2001; 2001US-0327899.  
 XX  
 PA (ABOM-) ABOMICA INC.  
 XX  
 PI Zhan J;  
 XX  
 DR WPI; 2002-676582/73.  
 XX  
 PT Novel isolated human testis expressed patched like protein (HTPL),  
 PT useful for identifying agonist and antagonist and specific binding  
 PT partners, and for treating subjects having defects in HTPL -

XX Example 2; Page 283; 718pp; English.  
 PS  
 CC The present invention relates to human testis expressed Patched like  
 CC protein (HTPL, see ABV78759 to ABV78762 and ABV98519 to ABV98520). HTPL  
 CC has two isoforms, with a few single base pair differences between the  
 CC two. One of the single base pair changes introduces a premature stop  
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
 CC shares an overall structure organisation with the Patched protein. The  
 CC shared structural features strongly imply that HTPL plays a role similar  
 CC to that of Patched, and is a potential tumour suppressor. HTPL is  
 CC important in regulating male germ cell development, and the HTPL gene was  
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
 CC therapy and manufacture of a medicament for treatment or prevention of  
 CC such disorder associated with decreased expression or activity of human  
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
 CC clinically useful diagnostic markers and potential therapeutic agents for  
 CC male infertility and cancer. The present oligonucleotide was used in an  
 CC example from the invention.  
 XX  
 SQ Sequence 17 BP; 4 A; 1 C; 1 G; 11 T; 0 other;  
 Query Match 1.2%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred. No. 1.3e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 675 TATACAAATAGCAAAAT 691  
 ||||| |||||  
 Db 17 TATACAAATAGCAAAAT 1  
 RESULT 76  
 AAD49640  
 ID AAD49640 standard; mRNA; 17 BP.  
 AC AAD49640;  
 XX  
 DT 24-MAR-2003 (first entry)  
 XX  
 DE Human adenylylate uridylylate-rich element (ARE) motif mRNA #2.  
 XX  
 KW Amyloidosis; haemophilia; Alzheimer's disease; atherosclerosis; cancer;  
 KW gigantism; dwarfism; hypothyroidism; hyperthyroidism; cystic fibrosis;  
 KW autoimmune disorder; aging; inflammation; diabetes; obesity; anorectic;  
 KW neurodegenerative disorder; Parkinson's disease; gene therapy; virucide;  
 KW haemostatic; antibacterial; nootropic; neuroprotective; cytostatic;  
 KW fungicide; human; adenylylate uridylylate-rich element; ARE; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200283953-A1.  
 XX  
 PD 24-OCT-2002.  
 XX  
 PR 11-APR-2002; 2002WO-US11757.  
 XX  
 PR 11-APR-2001; 2001US-282965P.  
 XX  
 PA (PTCT-) PTC THERAPEUTICS INC.  
 XX  
 PI Rando R, Welch E;  
 XX  
 DR WPI; 2003-075561/07.  
 XX  
 PT Identifying a test compound that binds to a target RNA molecule for  
 PT treating or preventing amyloidosis, hemophilia, cancer, gigantism,  
 PT diabetes, by contacting a detectably labeled target RNA molecule with a  
 PT library of test compounds -  
 XX  
 PS Disclosure; Page 18; 152pp; English.





RESULT 79  
AAZ41044  
ID AAZ41044 standard; DNA; 18 BP.  
XX  
AC AAZ41044;  
XX  
DT 26-JAN-2000 (first entry)  
XX  
DE Cellular inhibitor of apoptosis-2 phosphorothioate antisense oligo #36.  
XX  
KW Identification; genetic target; gene modulation; human; probe;  
KW antisense oligonucleotide; phosphorothioate; PCR primer;  
KW nucleotide sequence-based technology; antisense drug discovery;  
KW target validation; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
PN WO953101-A1.  
XX  
PD 21-OCT-1999.  
XX  
PF 13-APR-1999; 99WO-US08268.  
XX  
PR 13-APR-1998; 98US-0081483.  
PR 28-APR-1998; 98US-0067638.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Cowseert LM, Baker BF, McNeill J, Freier SM, Sasmor HM, Brooks DG;  
PI Ohasi C, Wyatt JR, Borchers AH, Vickers TA;  
XX  
DR WPI; 1999-620446/53.  
XX  
XX Identifying compounds which modulate expression of nucleic acids, used  
PT to provide compounds having defined physical, chemical or bioactive  
PT properties, e.g. antisense activity -  
XX  
PS Example 21; Page 101; 264pp; English.  
XX  
CC A method has been developed of defining a set of compounds that modulate  
CC the expression of a target nucleic acid (tNA) sequence via binding of  
CC the compounds with the tNA sequence. The method comprises generating a  
CC library of virtual compounds in silico according to defined criteria,  
CC and evaluating in silico the binding of the virtual compounds with the  
CC tNA according to defined criteria. Also described are: (1) a method of  
CC defining a set of oligonucleotides (ONs) that modulate the expression of  
CC a tNA sequence via binding of the ONs with the tNA sequence comprising  
CC generating a library of virtual compounds in silico according to defined  
CC criteria, and evaluating in silico the binding of the virtual ONs with  
CC the tNA according to defined criteria; and (2) a method of defining a  
CC set of compounds that modulate the expression of a tNA sequence via  
CC binding of the compounds with the tNA. The methods can be used for the  
CC generation and identification of synthetic compounds having defined  
CC physical, chemical or bioactive properties. Information gathered from  
CC assays of such compounds is used to identify nucleic acid sequences that  
CC are tractable to a variety of nucleotide sequence-based technologies,  
CC e.g. antisense drug discovery and target validation. AAZ40852 to  
CC AAZ41220, and AAY52701 to AAY52706, represent sequences used in the  
CC exemplification of the present invention.  
XX  
SQ Sequence 18 BP; 6 A; 1 C; 3 G; 8 T; 0 other;  
Query Match 1.2%; Score 15.4; DB 1; Length 18;  
Best Local Similarity 94.1%; Pred. No. 1.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1294 CTGAATTTTAAATGAA 1310  
DB 1 CTGAATTTTAAATGAA 17

RESULT 80  
AAZ22138  
ID AAZ22138 standard; DNA; 18 BP.  
XX  
AC AAZ22138;  
XX  
DT 26-NOV-1999 (first entry)  
XX  
DE Human c-IAP-2 mRNA inhibiting antisense oligo ISIS #23447.  
XX  
KW Cellular inhibitor of Apoptosis-2; antisense; diagnostic; therapeutic;  
KW c-IAP-2; prophylaxis; infection; inflammation; tumor formation; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
PN US5958771-A.  
XX  
PD 28-SEP-1999.  
XX  
PF 03-DEC-1998; 98US-0205144.  
XX  
PR 03-DEC-1998; 98US-0205144.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Bennett CF, Cowseert LM, Ackermann EJ;  
XX  
DR WPI; 1999-561046/47.  
XX  
XX Antisense compounds complementary to Cellular Inhibitor of Apoptosis-2  
PT useful for e.g. diagnostics, therapeutics, and as research reagents -  
XX  
PS Example 15; Column 39; 33pp; English.  
XX  
CC The invention provides antisense compounds of 8-30 nucleotides that  
CC inhibit the expression of human Cellular Inhibitor of Apoptosis-2  
CC (c-IAP-2). The antisense compounds may be used for diagnostics,  
CC therapeutics (for modulating the expression of c-IAP-2), prophylaxis  
CC (e.g. to prevent or delay infection, inflammation, or tumor formation),  
CC as research reagents (e.g. to distinguish between members of a  
CC biological pathway) and in kits. Sequences AAZ22103-142 represent  
CC phosphorothioate oligonucleotides used for antisense inhibition of  
CC cellular inhibitor of apoptosis-2.  
XX  
SQ Sequence 18 BP; 6 A; 1 C; 3 G; 8 T; 0 other;  
Query Match 1.2%; Score 15.4; DB 1; Length 18;  
Best Local Similarity 94.1%; Pred. No. 1.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1294 CTGAATTTTAAATGAA 1310  
DB 1 CTGAATTTTAAATGAA 17

RESULT 81  
AAD37308/c  
ID AAD37308 standard; DNA; 19 BP.  
XX  
AC AAD37308;  
XX  
DT 21-AUG-2002 (first entry)  
XX  
DE 3' primer #5 used for selective amplification of human ARE mRNAs.  
XX  
KW Human; untranslated region; UTR; adenylate uridylylate-rich element; ARE;  
KW cancer; gene expression; PCR; primer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200183691-A2.



PA (UYAL-) UNIV ALLEGHENY HEALTH SCI.  
 PA (UYOE-) UNIV JEFFERSON THOMAS.  
 PA (UYOU-) UNIV OULU.  
 XX  
 PI Prockop DJ, Spotila LD, Deltas CD, Sareda L, Westerhausen Larson A;  
 PI Pack M, Collge A, Early J, Koerkke J, Ala-Kokko L, Annunen S;  
 PI Pihlajamaa T, Vuoristo M, Paasilta P;  
 XX  
 DR MPI; 2001-432201/46.  
 XX  
 XX Detecting collagen gene alteration, useful for diagnosing osteoporosis,  
 PT multiple epiphyseal dysplasia, osteogenesis imperfecta, shortness of  
 PT stature and low bone density in humans -  
 XX Claim 8; Fig 24; 617pp; English.  
 PS  
 XX The invention relates to Detecting a collagen gene alteration associated  
 CC with a pathological condition in a human subject by obtaining from the  
 CC subject a sample nucleic acid containing a portion of at least 15  
 CC consecutive nucleotides of the segment of the COL1A1 gene extending in  
 CC the 5' to 3' direction from 78 nucleotides of intron 27 located adjacent  
 CC exon 28 through the 3' end of intron 51, where the portion contains an  
 CC intronic nucleotide and a first and second site, determining the sequence  
 CC of the portion and comparing the sequence of the portion with the  
 CC corresponding consensus sequence of the COL1A1 gene where a difference  
 CC between the sequence of the portion and the consensus sequence indicates  
 CC the presence of the collagen alteration in the subject. The method is  
 CC used for detecting abnormalities in a COL1 or COL9 gene is useful for  
 CC determining whether a subject is afflicted with pathological conditions  
 CC associated with an altered collagen gene such as osteoporosis, multiple  
 CC epiphyseal dysplasia, osteogenesis imperfecta, shortness of stature and  
 CC low bone density. Identification of an abnormality in a collagen gene is  
 CC also useful for designing a therapeutic nucleotide or gene therapy agent  
 CC which can be administered to the subject to correct or alleviate the  
 CC abnormality. The method is useful for detecting mutations in both the  
 CC coding and non-coding sequences of any of the COL1 or COL9 genes.  
 CC Therefore the method can be used to detect collagen gene alterations  
 CC which affect either the primary sequence of a collagen protein chain,  
 CC splicing of the mRNA encoding such chains or regulation of expression of  
 CC the genes encoding such chains. The present sequence is a PCR primer  
 CC which amplifies a nucleic acid from a collagen gene of the invention.  
 XX  
 SQ Sequence 22 BP; 7 A; 5 C; 8 G; 2 T; 0 other;  
 Query Match 1.2%; Score 15.4; DB 1; Length 22;  
 Best Local Similarity 94.1%; Pred. No. 1.7e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 OY 421 CAGTGAAGATGCCAGTG 437  
 Db 1 CAGTGAAGATGCCAGG 17  
 RESULT 84  
 AAQ32809/c  
 ID AAQ32809 standard; DNA; 20 BP.  
 XX  
 AC AAQ32809;  
 XX  
 DT 25-MAR-2003 (updated)  
 DT 05-MAY-1993 (first entry)  
 DE Microsatellite repeat polymorphic DNA marker PCR primer.  
 XX  
 KW PIC; high polymorphism information content; forensic; screening;  
 KW polymerase chain reaction; genetic mapping; paternity; prenatal.  
 XX  
 OS Synthetic.  
 XX  
 FN WO9221693-A1.  
 XX  
 PD 10-DEC-1992.

PF 27-MAY-1992; 92WO-US04195.  
 XX  
 PR 29-MAY-1991; 91US-0707501.  
 PR 27-NOV-1991; 91US-0799828.  
 XX  
 PA (USSH ) US DEPT HEALTH & HUMAN SERVICE.  
 XX  
 PI Merrill CR, Polymeropoulos MH;  
 PI MPI; 1992-433606/52.  
 DR  
 XX Oligo-nucleotide primers for polymerase chain reaction  
 PT amplification - which detect DNA polymorphisms and are useful for  
 PT prenatal and paternity screening, and genetic mapping  
 XX  
 PS Disclosure; Fig 29; 44pp; English.  
 XX  
 CC This is a PCR primer which is used (with AAQ32808) to characterise  
 CC a unique microsatellite repeat polymorphic DNA marker which has a  
 CC high polymorphism information content. The marker is useful for  
 CC human individualisation, in forensic screening, in paternity and  
 CC prenatal screening as well as in genetic mapping.  
 CC (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 other;  
 Query Match 1.2%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.7e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 OY 427 AGATGCCAGTGAACTTCAA 446  
 Db 20 ACATGCCAGTGACACTTCCA 1  
 RESULT 85  
 AAQ57832/c  
 ID AAQ57832 standard; DNA; 20 BP.  
 XX  
 AC AAQ57832;  
 XX  
 DT 25-MAR-2003 (updated)  
 DT 21-AUG-1994 (first entry)  
 XX  
 XX Primer pair 10A CD-19 detection primer #2.  
 XX  
 KW Primer; assay; subtle difference; dinucleotide; tetranucleotide;  
 KW repeat; polymorphism; PCR; polymerase chain reaction; amplify; PAGE;  
 KW autoradiography; migration pattern; length variation; genetic mapping;  
 KW forensic screening; paternity; prenatal; screening; microsatellite;  
 KW human; ss.  
 XX  
 OS Synthetic.  
 XX  
 FN WO9403640-A1.  
 XX  
 PD 17-FEB-1994.  
 XX  
 PP 30-JUL-1993; 93WO-US07183.  
 XX  
 PR 31-JUL-1992; 92US-0922723.  
 PR 28-SEP-1992; 92US-0952277.  
 XX  
 PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.  
 XX  
 PI Merrill CR, Polymeropoulos MH;  
 XX  
 DR MPI; 1994-065727/08.  
 XX  
 FT New polynucleotide sequences - derived from polymorphic  
 FT microsatellite repeats, used for characterising human  
 FT individuals for forensic, paternity and prenatal screening and  
 FT genetic mapping

XX PS Disclosure; Page 39; 72pp; English.

XX CC The sequences given in AAQ57782-866 are primers which were used in

XX CC an assay for measuring the subtle differences in genetic material

XX CC regarding an added or omitted set of dinucleotide or tetranucleotide

XX CC repeat polymorphisms. The method comprises obtaining polynucleotide

XX CC segments comprising the repeat polymorphisms in an amount effective

XX CC for testing and amplifying the segments by a PCR procedure using a

XX CC pair of oligonucleotide primers capable of amplifying the polymorphism

XX CC containing sequence. The amplified sequences are resolved using PAGE

XX CC and the resolved sequences are compared by autoradiography to observe

XX CC the differences in migration pattern due to length variation. The

XX CC polynucleotides provide a fast and accurate test for measuring the

XX CC subtle differences in individuals in eg. forensic screening, paternity

XX CC and prenatal screening and genetic mapping. The polynucleotides are

XX CC specific for polymorphic microsatellite repeats based on previously

XX CC sequenced human genes.

XX CC (Updated on 25-MAR-2003 to correct PN field.)

SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 other;

Query Match 1.2%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.7e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 427 AGATGCCAGTGAACCTTCAA 446

DB 20 ACATGCCAGTGAACCTTCAA 1

RESULT 86

ABS67914/c

ID ABS67914 standard; DNA; 20 BP.

AC ABS67914;

XX 29-NOV-2002 (first entry)

DT Human/mouse casein kinase 2-alpha prime antisense oligonucleotide #62.

DE Human; mouse; casein kinase 2-alpha prime; diabetes mellitus;

XX hyperproliferative disorder; breast cancer; prostate cancer;

XX liver cancer; infection; inflammation; tumour formation;

XX cytosolic; antidiabetic; antiinflammatory; antimicrobial;

XX phosphorothioate; antisense therapy; ss.

OS Homo sapiens.

OS Mus musculus.

XX WO200262951-A2.

PN 15-AUG-2002.

XX 01-FEB-2002; 2002WO-US02772.

XX 08-FEB-2001; 2001US-0780173.

XX (ISIS-) ISIS PHARM INC.

XX McKay R, Freier SM, Wyatt JR;

XX WPI; 2002-627539/67.

XX New antisense oligonucleotides targeted to nucleic acid encoding casein

XX kinase 2-alpha prime, useful for diagnosing and/or treating a disease

XX or condition associated with expression of casein kinase 2-alpha prime

XX

XX Example 15; Page 96; 129pp; English.

XX The present invention relates to antisense oligonucleotides and

XX methods for modulating the expression of human or mouse casein

CC kinase 2-alpha prime. The antisense oligonucleotides are useful

CC for inhibiting the expression of casein kinase 2-alpha prime, and

CC for treating diseases or conditions associated with aberrant

CC expression of casein kinase 2-alpha prime. Such diseases include

CC diabetes mellitus, and hyperproliferative disorders (particularly

CC cancers e.g. breast cancer, prostate cancer, or liver cancer).

CC The antisense compounds are also useful for diagnostics,

CC therapeutics, prophylaxis, e.g. to prevent or delay infection,

CC inflammation or tumour formation, as research reagents and kits,

CC and in distinguishing between functions of various members of a

CC biological pathway. ABS67840-ABS67917 represent human or mouse

CC casein kinase 2-alpha prime antisense oligonucleotides which

CC comprise a phosphorothioate backbone.

XX Sequence 20 BP; 9 A; 3 C; 0 G; 8 T; 0 other;

SQ

Query Match 1.2%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.7e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 633 ATTATTGAATATAAGGATTT 652

DB 20 ATTATTGAATATAAGGATTT 1

RESULT 87

ABK85435

ID ABK85435 standard; DNA; 20 BP.

AC ABK85435;

XX 14-AUG-2002 (first entry)

DT Oligonucleotide #13 binding to specific site of HIV-1 RNA.

DE Human immunodeficiency virus type 1; HIV-1 detection method;

XX primer; probe; ss.

XX Human immunodeficiency virus type 1.

OS BP1203826-A2.

PN 08-MAY-2002.

XX 30-OCT-2001; 2001EP-0125378.

XX 30-OCT-2000; 2000JP-0334937.

XX (TOYJ ) TOSOH CORP.

XX Ishizuka T, Ishiguro T, Saitoh J;

XX WPI; 2002-473032/51.

XX An oligonucleotide useful for detection of an RNA derived from HIV-1 in

XX clinical tests and diagnosis -

XX Claim 1; Page 16; 34pp; English.

XX The present invention relates to oligonucleotides binding to specific

XX sites of human immunodeficiency virus type 1 (HIV-1) RNA. The

XX oligonucleotides are useful for detecting HIV-1 in clinical tests

XX and diagnosis. The oligonucleotides provide simple, speedy and

XX sensitive detection of HIV-1 RNA which can bind to an intramolecularly

XX free region of the genomic RNA of HIV-1 at relatively low and constant

XX temperatures. The detection method comprises synthesising a cDNA by

XX the action of an RNA-dependent DNA polymerase by using a specific

XX sequence in an RNA derived from HIV-1 anticipated in a sample as a

XX template, a first primer containing a sequence complementary to the

XX specific sequence and a second primer containing a sequence homologous

XX to the specific sequence (either of which additionally has a promoter

XX sequence for the RNA polymerase at the 5' end). ABK85423-ABK85440

XX represent oligonucleotides binding to specific sites of HIV-1 RNA.

CC They can be used either as first primers or probes.

XX Sequence 20 BP; 6 A; 2 C; 0 G; 12 T; 0 other;  
SQ Query Match 1.2%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. NO. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1476 ATTCTTATATATTATTAA 1495  
||||| |||||  
Db 1 ATTCTTACTATTATTATTAA 20

RESULT 88

AAQ20077/c  
ID AAQ20077 standard; DNA; 21 BP.  
XX AC AAQ20077;  
XX DT 25-MAR-2003 (updated)  
XX DT 24-MAR-1992 (first entry)  
XX DE HIV-1 DNA probe (gag region).  
XX XX Styrene glycol; reagent; spacer; polymer; primer; probe; ss.  
XX OS Synthetic.  
XX PN EP462644-A.  
XX XX 27-DEC-1991.  
XX PF 10-JUN-1991; 91EP-0201420.  
XX PF 18-JUN-1990; 90US-0539774.  
XX XX (EAST ) EASTMAN KODAK CO.  
XX PA (CLIN-) CLINICAL DIAGNOSTIC SYSTEMS INC.  
XX PA (JOHN-) JOHNSON & JOHNSON CLINICAL DIAGNOSTICS INC.  
XX PI Sutton RC, Danielson SJ, Findlay JB, Oakes FT, Oenick MDB;  
XX PI Ponticello IS, Warren HC;  
XX XX WPI; 1992-001022/01.  
XX XX Insoluble particles of copolymer with reactive surface carboxy  
FT sps. - derived from monomers with long spacer between carboxy and  
FT unsaturated site, covalently attached to biological cpd.  
XX Example 12; Page 23; 53pp; English.

XX The 5' end comprises an ethylene glycol spacer which has been  
CC attached according to US-A-4914210. The sequence is complementary  
CC to a portion of HIV-1 DNA in the gag region. The oligonucleotide was  
CC covalently bound to polymeric particles and used in nucleic assays  
CC to detect HIV-1 DNA, beta-globin DNA or both.  
CC Primers used in the amplification of HIV-1 and beta-globin DNA are  
CC represented in Q2078-81.  
CC See also AAQ20075-95.  
CC (Updated on 25-MAR-2003 to correct PA field.)  
XX SQ Sequence 21 BP; 13 A; 0 C; 2 G; 6 T; 0 other;  
SQ Query Match 1.2%; Score 15.2; DB 1; Length 21;  
Best Local Similarity 85.0%; Pred. NO. 1.8e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1476 ATTCTTATATATTATTAA 1495  
||||| |||||  
Db 21 ATTCTTACTATTATTATTAA 2

RESULT 89

AAQ20043  
ID AAQ20043 standard; DNA; 21 BP.  
XX AC AAQ20043;  
XX DT 01-APR-1992 (first entry)  
XX XX Cross-linking oligomer 505 for targeting human IL-2 receptor gene.  
XX DE deoxyribonucleic acid; major groove; ethanoamino group;  
XX KW interleukin; IL-2R; aziridinylcytosine; cross-linking group; ss.  
XX OS Synthetic.  
XX XX Key Location/Qualifiers  
FT modified\_base 1 /tag= a  
FT /mod\_base= OTHER  
FT /note= "N4N4-ethanocytosine"  
FT modified\_base 2 /tag= b  
FT /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT modified\_base 5 /tag= c  
FT /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT modified\_base 6 /tag= d  
FT /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT modified\_base 10 /tag= e  
FT /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT modified\_base 14 /tag= f  
FT /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT modified\_base 17 /tag= g  
FT /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT modified\_base 18 /tag= h  
FT /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT modified\_base 21 /tag= i  
FT /mod\_base= OTHER  
FT /note= "N-methyl-8-oxo-2'-deoxyadenine"  
FT XX W09118997-A.  
XX XX 12-DEC-1991.  
XX XX 24-MAY-1991; 91WO-1003680.  
XX XX 14-JAN-1991; 91US-0640654.  
XX XX 25-MAY-1990; 90US-0529346.  
XX XX (GILB-) GILB- SCIE INC.  
XX XX Matteucci MD, Krawczyk S;  
XX WPI; 1992-007480/01.  
XX XX New sequence-specific non-photo-activated crosslinking agents -  
XX PT bind to the major groove of duplex DNA and are esp. useful for  
XX PT treating latent infections e.g. HIV  
XX PS Example 4; Page 26; 42pp; English.

```
CC The oligomer is an example of several which were designed to target
CC the Human interleukin-2 receptor gene, the exon 8 target and
CC flanks, specifically beginning at nucleotide 1114, and to covalently
CC cross-link to the target via the N4N4-ethanocytosine group.
CC See also AAQ20041-Q20045.
XX
SQ Sequence 21 BP; 8 A; 1 C; 0 G; 12 T; 0 other;

  Query Match      1.2%; Score 15.2; DB 1; Length 21;
  Best Local Similarity 85.0%; Pred. No. 1.8e+02;
  Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

  QY 1031 ATTAACCTATTATTATTTA 1050
  Db 2 ATTAATTATTATTATTA 21

RESULT 91
AAQ30406
ID AAQ30406 standard; DNA; 21 BP.
XX
AC AAQ30406;
XX
DT 25-MAR-2003 (updated)
DT 07-DEC-1992 (first entry)
XX
XX Oligomer IL2R503 for forming triplex with HUMIL2 receptor target duplex.
XX
XX Human interleukin- 2 receptor gene; HUMIL2R8; herpes simplex; AIDS;
XX modified; HIV; RSV; HPV; malignancy; hepatitis; inflammation; ss.
XX
XX Synthetic.
XX
FH Key Location/Qualifiers
FH modified_base 1 /*tag= a
FH /*mod_base= OTHER
FH /*note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FH modified_base 2 /*tag= b
FH /*mod_base= OTHER
FH /*note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FH modified_base 5 /*tag= c
FH /*mod_base= OTHER
FH /*note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FH modified_base 6 /*tag= d
FH /*mod_base= OTHER
FH /*note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FH modified_base 10 /*tag= e
FH /*mod_base= OTHER
FH /*note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FH modified_base 14 /*tag= f
FH /*mod_base= OTHER
FH /*note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FH modified_base 17 /*tag= g
FH /*mod_base= OTHER
FH /*note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FH modified_base 18 /*tag= h
FH /*mod_base= OTHER
FH /*note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
FH modified_base 21 /*tag= i
FH /*mod_base= OTHER
FH /*note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"
XX
PN W09209705-A1.
XX
```

```
PD 11-JUN-1992.
XX
XX 25-NOV-1991; 91WO-US08811.
XX
XX 23-NOV-1990; 90US-0617907.
XX 18-JAN-1991; 91US-0643382.
XX 08-APR-1991; 91US-0683420.
XX 17-APR-1991; 91US-0686544.
XX 17-APR-1991; 91US-0686546.
XX 17-APR-1991; 91US-0686547.
XX 27-SEP-1991; 91US-0768733.
XX
XX (GILE-) GILEAD SCI INC.
XX
XX Froehler B, Krawczyk S, Matteucci MD, Milligan J;
XX WPI; 1992-217083/26.
XX
XX New oligomers contg. modified bases - which form a triplex with
XX G-C doublet in a DNA duplex, for treating and diagnosing HIV,
XX hepatitis, herpes, malignancy and inflammation
XX
XX Claim 12; Page 71; 77pp; English.
XX
XX The synthetic oligomer is capable of forming a triplex at
XX physiological pH with a purine rich target sequence by coupling
XX into the major groove of the duplex. The specific target sequence
XX of this oligomer is the human interleukin-2 receptor gene exon 8
XX target and flanks beginning at nucleotide 1114 contg. a purine rich
XX sequence contd. on one strand of the duplex. The oligomer, and others
XX like it are useful in diagnosis and therapy of diseases characterised
XX by specific DNA duplex targets, e.g. HPV; HEP; HIV; hepatitis B; herpes,
XX malignant tumours and inflammation. The triple helices form under mild
XX conditions thus assays may be carried out without subjecting the test
XX specimen to harsh conditions.
XX See also AAQ25452-25501 and AAQ30226-448.
XX (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 21 BP; 9 A; 0 C; 0 G; 12 T; 0 other;
SQ
  Query Match      1.2%; Score 15.2; DB 1; Length 21;
  Best Local Similarity 85.0%; Pred. No. 1.8e+02;
  Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

  QY 1031 ATTAACCTATTATTATTTA 1050
  Db 2 ATTAATTATTATTATTA 21

RESULT 91
AAQ30408
ID AAQ30408 standard; DNA; 21 BP.
XX
AC AAQ30408;
XX
DT 25-MAR-2003 (updated)
DT 07-DEC-1992 (first entry)
XX
XX Oligomer IL2R505 for forming triplex with HUMIL2 receptor target duplex.
XX
XX Human interleukin- 2 receptor gene; HUMIL2R8; herpes simplex; AIDS;
XX modified; HIV; RSV; HPV; malignancy; hepatitis; inflammation; ss.
XX
XX Synthetic.
XX
FH Key Location/Qualifiers
FH modified_base 1 /*tag= a
FH /*mod_base= OTHER
FH /*note= "OTHER= N4 N4 ethanocytosine"
FH modified_base 2 /*tag= b
FH /*mod_base= OTHER
XX
```

FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"  
 FT 5 /tag= c  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"  
 FT 6 /tag= d  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"  
 FT 10 /tag= e  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"  
 FT 14 /tag= f  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"  
 FT 17 /tag= g  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"  
 FT 18 /tag= h  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"  
 FT 21 /tag= i  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= N6 methyl-8-oxo 2' deoxyadenine"  
 FT 27-SEP-1991; 91US-0766733.  
 XX (GILE-) GILEAD SCI INC.  
 PA Froehler B, Krawczyk S, Matteucci MD, Milligan J;  
 PI WPI; 1992-217083/26.  
 XX New oligomers contg. modified bases - which form a triplex with  
 PT G-C doublet in a DNA duplex, for treating and diagnosing HIV,  
 PT hepatitis, herpes, malignancy and inflammation  
 XX Claim 12; Page 71; 77pp; English.  
 CC The synthetic oligomer is capable of forming a triplex at  
 CC physiological pH with a purine rich target sequence by coupling  
 CC into the major groove of the duplex. The specific target sequence  
 CC of this oligomer is the human interleukin-2 receptor gene exon 8  
 CC target and flanks beginning at nucleotide 1114 contg. a purine rich  
 CC sequence concd. on one strand of the duplex. The oligomer, and others  
 CC like it are useful in diagnosis and therapy of diseases characterised  
 CC by specific DNA duplex targets, e.g. HPV; HER; HIV, hepatitis B, herpes,  
 CC malignant tumours and inflammation. The triple helices form under mild  
 CC conditions thus assays may be carried out without subjecting the test  
 CC specimen to harsh conditions.  
 CC See also AAQ25452-25501 and AAQ30226-448.  
 CC (Updated on 25-MAR-2003 to correct PN field.)  
 XX Sequence 21 BP; 8 A; 1 C; 0 G; 12 T; 0 other;  
 SQ Query Match 1.2%; Score 15.2; DB 1; Length 21;

Best Local Similarity 85.0%; Pred. No. 1.8e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 Qy 1031 ATTAACCTATTATTATTA 1050  
 Db 2 ATTAATTATTATTATTA 21  
 RESULT 92  
 AAQ75643/c  
 ID AAQ75643 standard; DNA; 21 BP.  
 XX AC AAQ75643;  
 XX 04-AUG-1995 (first entry)  
 XX Reverse transcription primer used in cDNA analysis technique.  
 XX Analysis; gene expression, reverse transcription; primer; cDNA;  
 XX aggregate; restriction enzyme; ss.  
 XX Synthetic.  
 XX JP06303997-A.  
 XX 01-NOV-1994.  
 XX 16-APR-1993; 93JP-0112515.  
 XX 16-APR-1993; 93JP-0112515.  
 XX (NITE ) NIPPON TELEGRAPH & TELEPHONE CORP.  
 XX WPI; 1995-018287/03.  
 XX Analysis of cDNA and gene expression - by amplification of mRNA  
 XX followed by digestion with restriction enzymes  
 XX Disclosure; Page 6; 11pp; Japanese.  
 XX A method for the analysis of cDNA comprises (a) preparing an  
 XX aggregate of double-stranded cDNAs by using an aggregate of mRNAs  
 XX and a plural type of labelled reverse transcription primers  
 XX (GENBSEQ files AAQ75547-075798) and using the aggregate of mRNAs as the  
 XX template for each reverse transcription primer; (b) digesting each of  
 XX the prepared aggregates of the double-stranded cDNAs with restriction  
 XX enzyme and; (c) electrophoresing the digested aggregate of cDNAs in  
 XX separate lanes. The method can be used to analyse gene expression  
 XX rapidly and easily.  
 SQ Sequence 21 BP; 1 A; 0 C; 2 G; 18 T; 0 other;  
 Query Match 1.2%; Score 15.2; DB 1; Length 21;  
 Best Local Similarity 85.0%; Pred. No. 1.8e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 Qy 614 CTACAAAAAACACAAATAA 633  
 Db 21 CTACAAAAAACAAAAAAA 2  
 RESULT 93  
 AAQ29560/c  
 ID AAQ29560 standard; DNA; 21 BP.  
 XX AC AAQ29560;  
 XX 22-MAR-2000 (first entry)  
 XX PCR Primer E475783, used for amplification of BSAB031 genomic DNA.  
 XX BSAB031; PCR Primer; E475783; amplification; strain ATCC 43617;  
 XX diagnosis; treatment; otitis media; pneumonia; sinusitis; antibody;

KW nosocomial infection; screening; hybridisation probe; ortholog; ss.  
XX Synthetic.  
OS Moraxella catarrhalis.  
XX  
XX PN WO9964448-A2.  
XX  
XX PD 16-DEC-1999.  
XX  
XX PF 31-MAY-1999; 99WO-EP03823.  
XX  
XX PR 05-JUN-1998; 98GB-0012163.  
XX  
XX PA (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.  
XX  
XX PI Ruelle J, Tommassen JPM, Vinals-Bassols C;  
XX  
XX DR WPI; 2000-116523/10.  
XX  
XX PT Novel polypeptides used as vaccines for treating Moraxella catarrhalis  
XX infections like otitis media and pneumonia -  
XX  
XX PS Example 1; Page 49; 121pp; English.  
XX  
XX CC The present sequence is the PCR Primer E475783, used for amplification  
XX of the BASB031 genomic DNA. This is done to experimentally confirm the  
XX sequence of BASB031 gene, from Moraxella catarrhalis, strain ATCC 43617.  
XX  
XX CC  
XX  
XX SQ Sequence 21 BP; 8 A; 5 C; 2 G; 6 T; 0 other;  
  
Query Match 1.2%; Score 15.2; DB 1; Length 21;  
Best Local Similarity 85.0%; Pred. No. 1.8e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 1420 ACAGTCATATAGTAATT 1439  
DB 20 ACTGTCATATGGTAATT 1  
  
RESULT 94  
AAF74938  
ID AAF74938 standard; DNA; 21 BP.  
XX  
XX AC AAF74938;  
XX  
XX DT 23-MAY-2001 (first entry)  
XX  
XX DE Human CD40L promoter sequence PCR primer Pcd3 SEQ ID NO:35.  
XX  
XX KW Human; CD40L; promoter; CD40 ligand promoter; rheumatoid arthritis;  
XX diagnosis; antiarthritic; antirheumatic; immunosuppressive;  
XX antinflammatory; inflammatory disease; autoimmune disease;  
XX PCR primer; ss.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO200119844-A1.  
XX  
XX PD 22-MAR-2001.  
XX  
XX PF 13-SEP-2000; 2000WO-US24966.  
XX  
XX PR 13-SEP-1999; 99US-0153625.  
XX  
XX PA (NYRE-) NEW YORK SOC RELIEF RUPTURED & CRIPPLED.  
XX  
XX PI Crow MK, Li Y;  
XX  
XX DR WPI; 2001-244776/25.  
XX  
XX PT New altered CD40L promoter for use in the study, diagnosis and  
XX treatment of a variety of inflammatory disorders and autoimmune  
XX diseases, such as rheumatoid arthritis -

XX  
XX PS Example 1; Fig 2; 90pp; English.  
XX  
XX CC The present invention describes an isolated, purified nucleic acid,  
XX which is an altered CD40 ligand (CD40L) promoter (I) for CD40 ligand,  
XX having residues 331-455 of the sequence comprising 455 nucleotides given  
XX in AAF74905 where A in the wild type sequence at position 331  
XX (corresponding to position -125) is replaced with C. (I) has  
XX antiarthritic, antirheumatic, immunosuppressive and antinflammatory  
XX activities, and can be used in gene therapy. (I) is useful in the study,  
XX diagnosis and treatment of inflammatory and autoimmune diseases, as well  
XX as diseases in which elevated expression of CD40L is a factor,  
XX e.g., rheumatoid arthritis. The present sequence represents a PCR primer  
XX for the human CD40L promoter sequence, which is used in an example from  
XX the present invention.  
XX  
XX SQ Sequence 21 BP; 5 A; 4 C; 2 G; 10 T; 0 other;  
  
Query Match 1.2%; Score 15.2; DB 1; Length 21;  
Best Local Similarity 85.0%; Pred. No. 1.8e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
QY 1450 GAACTTCTTTATTATGTAC 1469  
DB 2 GAACTTCTTTCTTCTTTAC 21  
  
RESULT 95  
ABL46344  
ID ABL46344 standard; DNA; 15 BP.  
XX  
XX AC ABL46344;  
XX  
XX DT 26-APR-2002 (first entry)  
XX  
XX DE Human interleukin-1 beta oligonucleotide SEQ ID NO:311.  
XX  
XX KW Nucleic acid accessible hybridisation site; detection; hybridisation;  
XX characterisation; identification; nucleic acid structure; diagnosis;  
XX PCR primer; probe; ss.  
XX  
XX OS Homo sapiens.  
XX  
XX OS Synthetic.  
XX  
XX PN WO200198537-A2.  
XX  
XX PD 27-DEC-2001.  
XX  
XX PF 15-JUN-2001; 2001WO-US19401.  
XX  
XX PR 17-JUN-2000; 2000US-212308P.  
XX  
XX PR 15-JUN-2001; 2001US-0212308.  
XX  
XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX  
XX PI Lyamichev V, Allawi H, Dong P, Neri BP, Vener IT;  
XX  
XX DR WPI; 2002-049698/06.  
XX  
XX PT Identifying oligonucleotides hybridizing to nucleic acids containing  
XX secondary structure, useful in clinical diagnosis, comprises  
XX identifying primers that interact with the target to form an extension  
XX product under amplification conditions -  
XX  
XX PS Claim 48; Fig 81A; 409pp; English.  
XX  
XX CC The present invention describes a method for identifying oligonucleotides  
XX with desired hybridisation properties to nucleic acid targets containing  
XX secondary structure. The method comprises amplifying a target nucleic  
XX acid having at least one accessible and one inaccessible site. Primers  
XX that form an extension product are identified as the oligonucleotides  
XX which can interact with the folded target nucleic acid. Oligonucleotides  
XX from the present invention can be used in novel detection methods for



CC clinical diagnostic purposes, including the detection and identification  
 CC of pathogenic organisms (e.g. HIV). The method allows the ability to  
 CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent  
 CC sequences used in the exemplification of the present invention.

XX Sequence 15 BP; 2 A; 6 C; 3 G; 4 T; 0 other;

SQ Query Match 1.2%; Score 15; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 856 CCTAGTCTGCTAGC 870

Db 1 CCTAGTCTGCTAGC 15

RESULT 96

ABN07608

ID ABN07608 standard; DNA; 17 BP.

XX AC ABN07608;

XX XX 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7600.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
 XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 XX skeletal muscle disorder; ampicillin; screening; ss.

XX OS Homo sapiens.

XX XX WO200192524-A2.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US16981.

XX PR 26-MAY-2000; 2000US-207456P.

XX PR 21-SEP-2000; 2000US-234687P.

XX PR 27-SEP-2000; 2000US-236359P.

XX PR 04-OCT-2000; 2000GB-0024263.

XX PR 30-JAN-2001; 2001WO-US00661.

XX PR 30-JAN-2001; 2001WO-US00662.

XX PR 30-JAN-2001; 2001WO-US00663.

XX PR 30-JAN-2001; 2001WO-US00664.

XX PR 30-JAN-2001; 2001WO-US00665.

XX PR 30-JAN-2001; 2001WO-US00666.

XX PR 30-JAN-2001; 2001WO-US00667.

XX PR 30-JAN-2001; 2001WO-US00668.

XX PR 30-JAN-2001; 2001WO-US00669.

XX PR 05-FEB-2001; 2001US-266860P.

XX PA (AEOM-) AEOMICA INC.

XX XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1

XX proteins, or as specific biomolecule capture probes for

XX surface-enhanced laser desorption/ionization, comprises human

XX myosin-like protein hGDMPLP-1 -

XX Disclosure; SEQ ID 7600; 214pp; English.

CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and  
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may  
 CC be used as immunogens to raise antibodies that specifically recognise  
 CC hGDMPLP-1 proteins, as standards in assays used to determine the  
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific  
 CC biomolecule capture probes for surface-enhanced laser desorption  
 CC ionisation, as therapeutic supplement in patients having specific  
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement  
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for  
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in  
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to  
 CC chromosome 22. The present sequence represents an oligomer used in the  
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present  
 CC invention.

CC N.B. The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence.

XX SQ Sequence 17 BP; 3 A; 7 C; 2 G; 5 T; 0 other;

Query Match 1.2%; Score 15; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 939 GCCACCATCTTACT 953

Db 3 GCCACCATCTTACT 17

RESULT 97

ABN07609

ID ABN07609 standard; DNA; 17 BP.

XX AC ABN07609;

XX XX 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7601.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
 XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 XX skeletal muscle disorder; ampicillin; screening; ss.

XX OS Homo sapiens.

XX XX WO200192524-A2.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US16981.

XX PR 26-MAY-2000; 2000US-207456P.

XX PR 21-SEP-2000; 2000US-234687P.

XX PR 27-SEP-2000; 2000US-236359P.

XX PR 04-OCT-2000; 2000GB-0024263.

XX PR 30-JAN-2001; 2001WO-US00661.

XX PR 30-JAN-2001; 2001WO-US00662.

XX PR 30-JAN-2001; 2001WO-US00663.

XX PR 30-JAN-2001; 2001WO-US00664.

XX PR 30-JAN-2001; 2001WO-US00665.

XX PR 30-JAN-2001; 2001WO-US00666.

XX PR 30-JAN-2001; 2001WO-US00667.

XX PR 30-JAN-2001; 2001WO-US00668.

XX PR 30-JAN-2001; 2001WO-US00669.

XX PR 05-FEB-2001; 2001US-266860P.

XX PA (AEOM-) AEOMICA INC.

XX XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

XX WPI; 2002-179446/23.





XX SQ Sequence 18 BP; 8 A; 0 C; 3 G; 7 T; 0 other;  
 Query Match 1.2%; Score 14.8; DB 1; Length 18;  
 Best Local Similarity 88.9%; Pred. No. 1.8e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1123 TATAAAGATGTTATAGTA 1140  
 |||||  
 DB 1 TATATAGATGATATAGTA 18

RESULT 102  
 AAX90243  
 ID AAX90243 standard; DNA; 18 BP.  
 XX  
 AC AAX90243;  
 XX  
 DT 23-SEP-1999 (first entry)  
 XX  
 DE GRK4 allele specific probe #10.  
 XX  
 KW Human; antibody; G-protein-related kinase; GRK4; mutant; hypertension;  
 XX probe; ss.  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN W09935279-Al.  
 XX  
 PD 15-JUL-1999.  
 XX  
 PF 12-JAN-1999; 99WO-US00663.  
 XX  
 PR 28-AUG-1998; 98US-0098279.  
 PR 12-JAN-1998; 98US-0071199.  
 XX  
 XX (GEOU) UNIV GEORGETOWN MEDICAL CENT.  
 PA (UYVI-) UNIV VIRGINIA PATENT FOUND.  
 PI Felder R, Jose P;  
 XX  
 WPI; 1999-444199/37.  
 XX  
 G protein-coupled receptor kinase 4 mutants associated with  
 essential hypertension, useful for identifying anti-hypertensive  
 drugs  
 Disclosure; Page 20; 54pp; English.  
 The present invention describes an isolated nucleic acid molecule  
 encoding a G protein-coupled receptor kinase (GRK) 4 protein having an  
 R65L, A142V or R65L, A486 double mutation or an R65L, A142V, A486V  
 triple mutation. A transgenic animal, comprising a diploid genome  
 comprising a transgene encoding a GRK4 protein which is expressed in  
 renal cells to produce the GRK4 protein, and where expression of the  
 transgene causes the transgenic animal to exhibit a state of essential  
 hypertension compared to a normotensive animal whose renal cells do not  
 express the GRK4 protein. The transgenic animal, especially a mouse, is  
 useful as a model for essential hypertension. The transgenic animal's  
 renal cells have a decreased ability to reject sodium compared to a  
 normotensive animal whose renal cells do not express GRK4. The animal  
 model, and reconstituted whole cell system, can be used to identify  
 putative anti-hypertensive agents. The GRK4 protein complex and  
 immortalized kidney cell cultures can also be used to identify putative  
 anti-hypertensive agents. Drugs, e.g. antisense GRK4 RNA, a GRK4  
 ribozyme or a GRK4 dominant negative mutant DNA molecule, that interact  
 with GRK4 can be used to increase natriuresis (decrease sodium  
 transport) in essential hypertensive individuals. The present sequence  
 represents a GRK4 allele specific probe from the present invention.  
 Sequence 18 BP; 2 A; 3 C; 7 G; 6 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 18;  
 Best Local Similarity 88.9%; Pred. No. 1.8e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 484 TGTGTAGGCTTGCAGCA 501  
 |||||  
 DB 1 TGTGTAGGCTGCTGCA 18

RESULT 103  
 ABL55998  
 ID ABL55998 standard; DNA; 18 BP.  
 XX  
 AC ABL55998;  
 XX  
 DT 17-JUN-2002 (first entry)  
 XX  
 DE Collagenase recognition site related PCR primer 2.  
 XX  
 KW Human; growth hormone; collagenase; recognition site; PCR; primer; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN KR289691-B.  
 XX  
 PD 15-MAY-2001.  
 XX  
 PF 28-DEC-1993; 93KR-0030318.  
 XX  
 PR 28-DEC-1993; 93KR-0030318.  
 XX  
 PA (GLDS) LG CHEM LTD.  
 XX  
 PI Yoo JG, Song YH;  
 XX  
 WPI; 2002-185396/24.  
 XX  
 Recombinant human growth hormone having collagenase recognition region -  
 Disclosure; Page 3; 8pp; Korean.  
 The invention relates to recombinant human growth hormone having a  
 collagenase recognition region. The present sequence is that of a PCR  
 primer, useful to the invention.  
 Sequence 18 BP; 7 A; 2 C; 2 G; 7 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 18;  
 Best Local Similarity 88.9%; Pred. No. 1.8e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1507 TTTAAATACAAAGCTTTA 1524  
 |||||  
 DB 1 TTTAAATCAAGACTTTA 18

RESULT 104  
 AAA82895/c  
 ID AAA82895 standard; DNA; 19 BP.  
 XX  
 AC AAA82895;  
 XX  
 DT 04-DEC-2000 (first entry)  
 XX  
 DE cdk4 ribozyme binding site #76.  
 XX  
 KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;  
 XX restenosis; ss.  
 XX  
 OS Mammalia.  
 XX  
 PN W0200032765-A2.  
 XX

PD 08-JUN-2000.  
 XX  
 XX 06-DEC-1999; 99WO-US28772.  
 XX  
 XX 04-DEC-1998; 98US-0110954.  
 PR  
 XX (IMMU-) IMMUSOL INC.  
 PA  
 XX Tritz R, Welch PJ, Barber JR, Robbins JM;  
 PI  
 XX WPI; 2000-412314/35.  
 XX  
 XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
 XX RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
 PT PCNA and Cyclin B1  
 PT  
 XX Disclosure; Page 53; 109pp; English.  
 PS  
 XX The present invention relates to a hairpin or hammerhead ribozyme,  
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
 CC Representative examples of ribozyme recognition sites are given in  
 CC AA82415 to AA86787. The ribozyme of the invention is useful for  
 CC inhibiting restenosis by introduction of the ribozyme into cells.  
 CC The ribozyme is resistant to endonuclease activity and hence is  
 CC efficient in restenosis treatment.  
 CC  
 XX Sequence 19 BP; 2 A; 2 C; 8 G; 7 T; 0 other;  
 SQ Query Match 1.2%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.9e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1404 AAACAGCCAAACTCCAC 1421  
 DB 18 ATACAGCCAACTCCAC 1  
 RESULT 105  
 AAH58057/C  
 ID AAH58057 standard; DNA; 19 BP.  
 XX  
 AC AAH58057;  
 XX  
 DT 10-SEP-2001 (first entry)  
 XX  
 DE Cell-cycle dependent kinase cdk4 ribozyme binding site SEQ ID NO:481.  
 KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
 KW recognition site; target; ribozyme binding site; eye disease; vulnary;  
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; WMP;  
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
 KW antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;  
 KW antiskinning; ophthalmological; keratolytic; gene therapy; viral wart;  
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
 KW sickle cell retinopathy; ss.  
 XX  
 XX Homo sapiens.  
 OS Synthetic.  
 XX  
 XX WO200130362-A2.  
 FN  
 XX  
 XX 03-MAY-2001.  
 PD  
 XX  
 XX 26-OCT-2000; 2000WO-US29500.  
 PP  
 XX  
 XX 26-OCT-1999; 99US-0161532.  
 PR  
 XX (IMMU-) IMMUSOL INC.  
 PA  
 XX Robbins JM, Tritz R;  
 PI

XX WPI; 2001-300427/31.  
 DR  
 XX Treating proliferative skin or eye diseases and scarring, using  
 XX ribozymes that cleave RNA encoding cytokines involved in inflammation,  
 PT matrix metalloproteinases, growth factors and cell-cycle dependent  
 PT kinases -  
 PT  
 XX Example 1; Page 107; 409pp; English.  
 PS  
 XX The present invention describes a method for treating a proliferative  
 CC skin or eye disease and scarring. The method involves administering a  
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
 CC dependent kinase, growth factor or a reductase, or administering a  
 CC nucleic acid molecule (II) comprising a promoter operably linked to a  
 CC nucleic acid segment encoding (i). (i) can have antiproliferative,  
 CC dermatological, cytostatic, antiseborrheic, antidiabetic activities, and  
 CC ophthalmological, vulnary, keratolytic and virucide activities, and  
 CC cleaves RNA encoding cytokine involved in inflammation. (i) can be used  
 CC in gene therapy. (I) and (II) are useful for treating proliferative  
 CC skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
 CC also be used for treating proliferative eye diseases such as diabetic  
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
 CC prematurity and retinal detachment, and for treating and preventing  
 CC scarring such as keloid, adhesion, and hypertrophic or hypertrophic burn  
 CC scar. AAH57577 to AAH62093 represent sequences used in the  
 CC exemplification of the present invention.  
 XX  
 XX Sequence 19 BP; 2 A; 2 C; 8 G; 7 T; 0 other;  
 SQ Query Match 1.2%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.9e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1404 AAACAGCCAAACTCCAC 1421  
 DB 18 ATACAGCCAACTCCAC 1  
 RESULT 106  
 AAH11919  
 ID AAH11919 standard; DNA; 20 BP.  
 XX  
 AC AAH11919;  
 XX  
 DT 13-AUG-1998 (first entry)  
 XX  
 DE Hepatocyte growth factor inhibiting oligonucleotide #11.  
 XX  
 XX Hepatocyte growth factor; HGF; c-Met; modulator; inhibitor;  
 XX antitumour agent; anti-metastasis agent; primer; ss.  
 XX  
 OS Synthetic.  
 XX  
 XX JP10127286-A.  
 FN  
 XX 19-MAY-1998.  
 PD  
 XX  
 XX 01-NOV-1996; 96JP-0291499.  
 XX  
 XX 01-NOV-1996; 96JP-0291499.  
 PR  
 XX (TERU ) TERUMO CORP.  
 XX  
 XX WPI; 1998-340665/30.  
 XX  
 XX Oligo-nucleotide inhibiting HGF production - useful as antitumour  
 PT and anti-metastatic agent  
 PT  
 XX Disclosure; Page 10; 15pp; Japanese.  
 PS  
 XX

CC AAV11909-V11925, AAV11927 and AAV11928 are oligonucleotide primers used  
 CC to identify sequences which modulate or inhibit expression, production  
 CC or reception of hepatocyte growth factor (HGF) or expression of c-Met.  
 CC Such oligonucleotides are useful as antitumor or anti-metastasis  
 CC agents.  
 CC  
 XX SQ Sequence 20 BP; 0 A; 0 C; 11 G; 9 T; 0 other;  
 Query Match 1.2%; Score 14.8; DB 1; Length 20;  
 Best Local Similarity 88.9%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 477 GTGGGTCGTGTGTACGGT 494  
 DB 1 GTGGGTCGTGTGTACGGT 18  
 RESULT 107  
 AAZ37709/C  
 ID AAZ37709 standard; DNA; 20 BP.  
 XX  
 AC AAZ37709;  
 XX  
 DT 07-JAN-2000 (first entry)  
 XX  
 DE Human mdm2 phosphorothioate oligodeoxynucleotide #239.  
 XX  
 KW Human mdm2 gene; proliferation; tumour; phosphorothioate; p53;  
 KW cancer; antisense; modulation; oligonucleotide; expression;  
 KW inhibition; hyperproliferation; blood cancer; brain cancer;  
 KW breast cancer; lung cancer; soft tissue cancer; psoriasis; fibrosis;  
 KW atherosclerosis; restenosis; ss.  
 XX  
 OS Synthetic.  
 OS Homo sapiens.  
 XX  
 PN W09949065-A1.  
 XX  
 PD 30-SEP-1999.  
 XX  
 PF 26-MAR-1999; 99WO-US06702.  
 XX  
 PR 26-MAR-1998; 98US-0048810.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowsett LM;  
 XX  
 DR WPI; 1999-610754/52.  
 XX  
 PT New antisense compounds used to treat eg. hyperproliferative conditions  
 XX  
 PS Example 9; Page 54; 157pp; English.  
 XX  
 CC AAZ37473-Z37738 represent human mdm2 phosphorothioate oligonucleotides.  
 CC AAZ37471, AAZ37472, AAZ37739, AAZ37740 and AAZ37741 are used in the  
 CC exemplification of the present invention. The present invention  
 CC describes novel nucleotide antisense compounds, targeted to the 5'  
 CC untranslated, translation termination codon, or 3' untranslated region  
 CC of a nucleic acid encoding human mdm2, that modulates expression of  
 CC human mdm2. The oligonucleotides mediate their effect by antisense  
 CC inhibition of hyperproliferative gene expression. The antisense compound  
 CC is used to treat an animal having a disease or condition associated  
 CC with mdm2, particularly a hyperproliferative condition, more  
 CC particularly cancer, especially of the blood, brain, breast, lung or soft  
 CC tissue, or psoriasis, fibrosis, atherosclerosis or restenosis.  
 XX  
 SQ Sequence 20 BP; 9 A; 1 C; 2 G; 8 T; 0 other;  
 Query Match 1.2%; Score 14.8; DB 1; Length 20;  
 Best Local Similarity 88.9%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1017 TTCAAGTGAACCTATTATTA 1034  
 DB 18 TTAAATGTAACCTATTATTA 1  
 RESULT 108  
 AAZ98583  
 ID AAZ98583 standard; DNA; 20 BP.  
 XX  
 AC AAZ98583;  
 XX  
 DT 19-JUN-2000 (first entry)  
 XX  
 DE Human MAPK kinase 6 inhibiting antisense oligo ISIS# 101504.  
 XX  
 KW Mitogen-activated protein kinase; MAPK; MAPK kinase 6; antisense;  
 KW sandwich assay; human; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US6033910-A.  
 XX  
 PD 07-MAR-2000.  
 XX  
 PF 19-JUL-1999; 99US-0357073.  
 XX  
 PR 19-JUL-1999; 99US-0357073.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Monia BP, Cowsett LM;  
 XX  
 DR WPI; 2000-269479/23.  
 XX  
 PT Novel antisense oligonucleotides used for inhibition of  
 PT Mitogen-activated protein kinase 6 expression -  
 XX  
 PS Claim 11; Column 41; 33pp; English.  
 XX  
 CC The invention provides antisense oligonucleotides which are targeted to  
 CC a nucleic acid encoding a mitogen-activated protein kinase (MAPK) kinase  
 CC 6. The antisense oligonucleotides are used to inhibit MAPK kinase 6  
 CC expression, and so are used to treat diseases mediated by MAPK kinase 6  
 CC expression. They may also be used to detect MAPK kinase 6, e.g. in  
 CC sandwich assays. Sequences AAZ98583-597 represent antisense oligos  
 CC inhibiting human MAPK kinase 6 mRNA.  
 XX  
 SQ Sequence 20 BP; 6 A; 4 C; 3 G; 7 T; 0 other;  
 Query Match 1.2%; Score 14.8; DB 1; Length 20;  
 Best Local Similarity 88.9%; Pred. No. 2e+02; 2; Indels 0; Gaps 0;  
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 407 TCGTATCCAGATCAGT 424  
 DB 2 TAGTCTCCAGATCAGT 19  
 RESULT 109  
 AAZ95269/C  
 ID AAZ95269 standard; DNA; 20 BP.  
 XX  
 AC AAZ95269;  
 XX  
 DT 17-DEC-2001 (first entry)  
 XX  
 DE Neuregulin-1 gene polymorphic microsatellite marker 473C15-533 forward.  
 XX  
 KW Human; neuregulin-1 associated gene 1; NRG1AG1; Schizophrenia gene;  
 KW gene therapy; microsatellite marker; ds.  
 XX  
 OS Homo sapiens.

```

XX FN W0200164876-A2.
XX PD 07-SEP-2001.
XX PR 28-FEB-2001; 2001WO-US06376.
XX PF 28-FEB-2000; 2000US-0515715.
XX PA (DECO-) DECODE GENETICS EHP.
XX PI Stefansson H, Steinthorsdottir V, Gulcher JR;
XX DR WPI; 2001-550179/61.
XX PT Neuregulin-1 associated gene 1 nucleic acids and fragments, useful for
XX PF preventing diagnosing and treating schizophrenia -
XX PS Disclosure; Page 504; 750pp; English.
XX CC This sequence represents a microsatellite marker from the human
XX CC neuregulin-1 associated gene 1 (NRG1AG1) of the invention. The NRG1AG1
XX CC gene is also referred to as the human Schizophrenia gene. The invention
XX CC also relates to fragments or variants of the gene and the NRG1AG1
XX CC polypeptides they encode. The NRG1AG1 nucleic acids and polypeptides may
XX CC be used in the prevention, diagnosis and treatment of diseases associated
XX CC with inappropriate NRG1AG1 expression. For example, they may be used to
XX CC treat disorders associated with decreased expression by rectifying
XX CC mutations or deletions in a patient's genome that affect the activity of
XX CC NRG1AG1 by expressing inactive proteins or to supplement the patients own
XX CC production of NRG1AG1. Additionally, the gene may be used to produce
XX CC NRG1AG1 polypeptides, by inserting the nucleic acids into a host cell and
XX CC culturing the cell to express the protein. The gene may also be used as
XX CC DNA probes and primers in diagnostic assays to detect and quantitate the
XX CC presence of similar nucleic acids in samples, and therefore which
XX CC patients may be in need of restorative therapy. The NRG1AG1 polypeptides
XX CC may also be used as antigens in the production of antibodies against
XX CC NRG1AG1 and in assays to identify modulators of NRG1AG1 expression and
XX CC activity. Anti-NRG1AG1 antibodies and antagonists may also be used to
XX CC down regulate expression and activity. Anti-NRG1AG1 antibodies may
XX CC also be used as diagnostic agents for detecting the presence of NRG1AG1
XX CC polypeptides in samples. NRG1AG1 is associated with schizophrenia which
XX CC may be prevented, diagnosed and/or treated by the above methods.
XX SQ Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1352 GCTGTGTTGGTAGTCTG 1369
DB 20 GCTGTGTTGGTAGTCTG 3

RESULT 110
AAK96762/c
ID AAK96762 standard; DNA; 20 BP.
AC AAK96762;
XX 17-DEC-2001 (first entry)
XX DE Neuregulin-1 gene polymorphic microsatellite marker 473C15-533 forward.
XX KW Human; neuregulin 1 gene; schizophrenia; gene therapy;
XX KW microsatellite marker; ds.
XX OS Homo sapiens.
XX PN W0200164877-A2.
XX PD 07-SEP-2001.

```

```

XX PF 28-FEB-2001; 2001WO-US06377.
XX PR 28-FEB-2000; 2000US-0515716.
XX PA (DECO-) DECODE GENETICS EHP.
XX PI Stefansson H, Steinthorsdottir V, Gulcher JR;
XX DR WPI; 2001-514841/56.
XX PT Neuregulin 1 nucleic acids and proteins useful for diagnosing
XX PF preventing and treating schizophrenia -
XX PS Disclosure; Page 89; 756pp; English.
XX CC This sequence represents a microsatellite marker from the human
XX CC neuregulin 1 gene of the invention. The invention also relates to
XX CC fragments or variants of the neuregulin 1 gene. The gene and its proteins
XX CC may be used in the prevention, diagnosis and treatment of diseases
XX CC associated with inappropriate neuregulin 1 expression, such as
XX CC schizophrenia. For example they may be used to treat disorders associated
XX CC with decreased neuregulin 1 expression by rectifying mutations or
XX CC deletions in a patient's genome that affect the activity of neuregulin 1
XX CC by expressing inactive proteins or to supplement the patients own
XX CC production of polypeptides. Additionally, the gene may be used to produce
XX CC the neuregulin 1 protein, by inserting the nucleic acids into a host cell
XX CC and culturing the cell to express the protein. The gene and its
XX CC complementary sequences may also be used as DNA probes in diagnostic
XX CC assays to detect and quantitate the presence of similar nucleic acids in
XX CC samples, and therefore which patients may be in need of restorative
XX CC therapy. The protein may also be used as antigens in the production of
XX CC antibodies against neuregulin 1 and in assays to identify modulators of
XX CC neuregulin 1 expression and activity. The antibodies and antagonists may
XX CC also be used to down regulate expression and activity. The antibodies may
XX CC also be used as diagnostic agents for detecting the presence of
XX CC neuregulin 1 in samples.
XX SQ Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1352 GCTGTGTTGGTAGTCTG 1369
DB 20 GCTGTGTTGGTAGTCTG 3

RESULT 111
AAK21759
ID AAK21759 standard; DNA; 20 BP.
AC AAK21759;
XX 21-NOV-2001 (first entry)
XX DE Mouse Survivin antisense oligonucleotide #61.
XX KW Survivin; human; mouse; cytostatic; antisense oligonucleotide;
XX KW hyperproliferative condition; cancer; apoptosis; cytokinesis; ss.
XX OS Mus musculus.
XX OS Synthetic.
XX PN W0200157059-A1.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US02939.
XX PR 02-FEB-2000; 2000US-0496694.
XX

```

PA (ISIS-) ISIS PHARM INC.  
 XX Bennett CF, Ackermann EJ, Swayze EE, Cowseert LM;  
 PI WPI; 2001-488863/53.  
 DR  
 XX Novel antisense compounds for modulating the expression of Survivin and  
 PT treatment of cancer -  
 FT  
 PS Example 18; Page 62; 120pp; English.  
 XX  
 CC The invention relates to antisense oligonucleotides targeted to a nucleic  
 CC acid molecule encoding human Survivin, where the antisense  
 CC oligonucleotide inhibits the expression of human Survivin. These  
 CC antisense oligonucleotides are used in the treatment of an animal  
 CC suffering from a disease or condition associated with Survivin, e.g. a  
 CC hyperproliferative condition such as cancer, and comprises administering  
 CC a therapeutically or prophylactically effective amount of the antisense  
 CC oligonucleotide so that expression of Survivin is inhibited. The  
 CC oligonucleotide can also be used to treat a human suffering from a  
 CC disease or condition characterised by a reduction in apoptosis  
 CC comprising administering the antisense oligonucleotide to a human. In  
 CC addition, the antisense oligonucleotide and a cytotoxic chemotherapeutic  
 CC agent e.g. taxol or cisplatin, can be used to modulate apoptosis,  
 CC cytokinesis or the cell cycle, or inhibit the proliferation in a cancer  
 CC cell by contacting the cell with the antisense oligonucleotide.  
 CC AAS21521-AAS21768 represent Survivin nucleic acids, and antisense  
 CC oligonucleotides targeted to Survivin, used in the method of the  
 CC invention.  
 XX  
 SQ Sequence 20 BP; 5 A; 0 C; 3 G; 12 T; 0 other;  
 Query Match 1.2%; Score 14.8; DB 1; Length 20;  
 Best Local Similarity 88.9%; Pred. No. 2e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1039 ATTATTATTATTGTTT 1056  
 DB | | | | | | | | | | | | | | | |  
 2 AGTTATTATTGTTTATT 19  
 RESULT 112  
 AAS21760  
 ID AAS21760 standard; DNA; 20 BP.  
 XX  
 AC AAS21760;  
 XX  
 DT 21-NOV-2001 (first entry)  
 XX  
 DE Mouse Survivin antisense oligonucleotide #62.  
 XX  
 KW Survivin; human; mouse; cytostatic; antisense oligonucleotide;  
 KW hyperproliferative condition; cancer; apoptosis; cytokinesis; ss.  
 XX  
 OS Mus musculus.  
 OS Synthetic.  
 OS  
 XX WO200157059-A1.  
 PN  
 XX 09-AUG-2001.  
 PD  
 XX 30-JAN-2001; 2001WO-US02939.  
 XX  
 PF 02-FEB-2000; 2000US-0496694.  
 PR  
 XX (ISIS-) ISIS PHARM INC.  
 PA  
 XX Bennett CF, Ackermann EJ, Swayze EE, Cowseert LM;  
 PI WPI; 2001-488863/53.  
 DR  
 XX Novel antisense compounds for modulating the expression of Survivin and  
 PT treatment of cancer -

XX Example 18; Page 62; 120pp; English.  
 XX  
 CC The invention relates to antisense oligonucleotides targeted to a nucleic  
 CC acid molecule encoding human Survivin, where the antisense  
 CC oligonucleotide inhibits the expression of human Survivin. These  
 CC antisense oligonucleotides are used in the treatment of an animal  
 CC suffering from a disease or condition associated with Survivin, e.g. a  
 CC hyperproliferative condition such as cancer, and comprises administering  
 CC a therapeutically or prophylactically effective amount of the antisense  
 CC oligonucleotide so that expression of Survivin is inhibited. The  
 CC oligonucleotide can also be used to treat a human suffering from a  
 CC disease or condition characterised by a reduction in apoptosis  
 CC comprising administering the antisense oligonucleotide to a human. In  
 CC addition, the antisense oligonucleotide and a cytotoxic chemotherapeutic  
 CC agent e.g. taxol or cisplatin, can be used to modulate apoptosis,  
 CC cytokinesis or the cell cycle, or inhibit the proliferation in a cancer  
 CC cell by contacting the cell with the antisense oligonucleotide.  
 CC AAS21521-AAS21768 represent Survivin nucleic acids, and antisense  
 CC oligonucleotides targeted to Survivin, used in the method of the  
 CC invention.  
 XX  
 SQ Sequence 20 BP; 6 A; 0 C; 2 G; 12 T; 0 other;  
 Query Match 1.2%; Score 14.8; DB 1; Length 20;  
 Best Local Similarity 88.9%; Pred. No. 2e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1039 ATTATTATTATTGTTT 1056  
 DB | | | | | | | | | | | | | | | |  
 3 AGTTATTATTGTTTATT 20  
 RESULT 113  
 AAS29478/c  
 ID AAS29478 standard; DNA; 20 BP.  
 XX  
 AC AAS29478;  
 XX  
 DT 21-NOV-2001 (first entry)  
 XX  
 DE Human mdm2 antisense oligonucleotide 31618.  
 XX  
 KW Human; mdm2; hyperproliferative disorder; cancer; psoriasis;  
 KW atherosclerosis; tumour; cytostatic; anti psoriatic;  
 KW anti arteriosclerotic; vasotropic; antisense; phosphorothioate; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /tag= a  
 FT /mod\_base= OTHER  
 FT /note= "OTHER= All phosphorothioate linkages,  
 FT additionally bases 1-6 and bases 15-20 are  
 FT 2'-O-methoxyethyl bases, and bases 7-14 are  
 FT deoxynucleotides"  
 XX  
 PN US2001016575-A1.  
 XX  
 PD 23-AUG-2001.  
 XX  
 PF 02-JAN-2001; 2001US-0752983.  
 XX  
 PR 26-MAR-1999; 99US-0280805.  
 PR 26-MAR-1998; 98US-0048810.  
 XX  
 XX (MIRA/) MIRAGLIA L J.  
 XX (NERO/) NERO P.  
 XX (GRAH/) GRAHAM M J.  
 XX (MONI/) MONIA B P.  
 XX (COWS/) COWSEERT L M.  
 XX



PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowseert LM;  
 DR WPI; 2001-535565/59.  
 XX  
 XX An antisense compound, useful for treating e.g. cancer, comprises  
 PT nucleobases targeted a region (e.g. translation termination codon  
 PT region) of a nucleic acid encoding human mdm2 -  
 XX  
 XX Example 9; Page 18; 81pp; English.  
 PS  
 XX The present invention relates to antisense compounds, 8-30 nucleobases  
 CC in length targeted to the 5' untranslated region, translation  
 CC termination codon region, 3' untranslated region, coding region or  
 CC translation start site of a nucleic acid encoding human mdm2, where  
 CC the antisense compound modulates the expression of human mdm2. The  
 CC antisense oligonucleotides of the invention are useful for encoding  
 CC human mdm2 and for inhibiting the expression of human mdm2. They may be  
 CC used for treating an animal having a disease or condition associated  
 CC with amplification of mdm2 gene or overexpression of mdm2 e.g. a  
 CC hyperproliferative disorder such as cancer (blood, brain, breast, lung,  
 CC or a soft tissue cancer) and psoriasis, fibrosis, atherosclerosis or  
 CC restenosis, tumours, colorectal carcinoma and chronic myelogenous  
 CC leukemia. The antisense compound may be administered with a  
 CC chemotherapeutic agent to overcome drug resistance. The antisense  
 CC compound reduces hyperproliferation of human cells. The method, which  
 CC involves the use of the antisense compound, is also useful for detecting  
 CC the role of mdm2 expression in various cell functions and physiological  
 CC processes and useful in both clinical research and diagnostic tools.  
 CC AAS29242-AAS29507 represent the human mdm2 antisense oligonucleotides  
 CC of the present invention.  
 XX  
 XX Sequence 20 BP; 9 A; 1 C; 2 G; 8 T; 0 other;  
 SQ  
 Query Match 1.2%; Score 14.8; DB 1; Length 20;  
 Best Local Similarity 88.9%; Pred. No. 2e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1017 TTCAAGTGTAACTTATTA 1034  
 DB |||||  
 18 TTTAAATGTAACTTATTA 1  
 RESULT 114  
 AAF80863/c  
 ID AAF80863 standard; DNA; 20 BP.  
 XX  
 AC AAF80863;  
 XX  
 DT 02-MAY-2001 (first entry)  
 XX  
 XX Human mdm2 phosphorothioate oligonucleotide #237.  
 DE  
 XX Antisense; mdm2; hyperproliferation; cancer; psoriasis; ss.  
 KW  
 OS Homo sapiens.  
 XX  
 XX US6184212-B1.  
 PN  
 XX  
 PD 06-FEB-2001.  
 XX  
 XX 26-MAR-1999; 99US-0280805.  
 PF  
 XX  
 XX 26-MAR-1998; 98US-0048810.  
 PR  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 PA  
 XX  
 XX Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowseert LM;  
 FI WPI; 2001-190948/19.  
 DR  
 XX  
 XX Novel antisense compound 8-30 nucleobases in length targeted to a  
 PT nucleic acid molecule encoding human mdm-2 useful for modulating the  
 PT expression of human mdm-2 and reducing hyperproliferation of human

PT cells -  
 XX  
 PS Example 9; Column 31; 77pp; English.  
 XX  
 CC The present invention relates to an antisense compound 8-30  
 CC nucleobases in length targeted to nucleobases 1-308 of the  
 CC 5' untranslated region, 1776-1806 of the translation termination  
 CC codon region or 1818-2370 of the 3' untranslated region of a  
 CC nucleic acid molecule encoding human mdm-2. The invention is  
 CC useful for reducing hyperproliferation of human cells,  
 CC modulating the expression of mdm2 in human cells or tissues  
 CC or in vitro. The hyperproliferative disorder includes cancer or  
 CC psoriasis.  
 CC  
 XX Sequence 20 BP; 9 A; 1 C; 2 G; 8 T; 0 other;  
 SQ  
 Query Match 1.2%; Score 14.8; DB 1; Length 20;  
 Best Local Similarity 88.9%; Pred. No. 2e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1017 TTCAAGTGTAACTTATTA 1034  
 DB |||||  
 18 TTTAAATGTAACTTATTA 1  
 RESULT 115  
 ABS67649  
 ID ABS67649 standard; DNA; 20 BP.  
 XX  
 AC ABS67649;  
 XX  
 DT 29-NOV-2002 (first entry)  
 XX  
 XX Casein kinase-2 antisense oligonucleotide ISIS127149.  
 DE  
 XX ss; antisense therapy; casein kinase-2 alpha; cytostatic; antidiabetic;  
 KW antinflammatory; diabetes; hyperproliferative disorder; cancer; human;  
 KW breast cancer; prostate cancer; liver cancer; infection; inflammation;  
 KW tumour.  
 XX  
 OS Homo sapiens.  
 XX  
 XX Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /tag= a  
 FT /label= OTHER  
 FT /note= "All cytidines are 5-methylcytidine.  
 FT Phosphorothioate backbone"  
 FT modified\_base 1..5  
 FT /tag= b  
 FT /label= OTHER  
 FT /note= "2'-methoxyethyl nucleotides"  
 FT modified\_base 16..20  
 FT /tag= c  
 FT /label= OTHER  
 FT /note= "2'-methoxyethyl nucleotides"  
 XX  
 XX WO200262818-A2.  
 PN  
 XX  
 XX 15-AUG-2002.  
 PD  
 XX  
 XX 31-JAN-2002; 2002WO-US02942.  
 PF  
 XX  
 XX 08-FEB-2001; 2001US-0780172.  
 PR  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 PA  
 XX  
 XX McKay R, Freier SM, Wyatt JR;  
 FI WPI; 2002-627521/67.  
 DR  
 XX  
 XX New antisense oligonucleotides targeted to nucleic acid encoding casein  
 PT kinase 2-alpha, useful in diagnostic and research applications, or for

PT treating a disease or condition associated with expression of casein  
 PT kinase 2-alpha -  
 XX  
 PS Claim 3; Page 95; 166pp; English.  
 XX  
 CC The invention relates to a compound 8-50 nucleobases in length targeted  
 CC to a nucleic acid molecule encoding casein kinase 2-alpha. The compound  
 CC specifically hybridizes with and inhibits the expression of casein  
 CC kinase 2-alpha, or specifically hybridizes with at least an  
 CC 8-nucleobase portion of an active site on a nucleic acid molecule  
 CC encoding casein kinase 2-alpha i.e. an antisense oligonucleotide.  
 CC Also included are: (1) a composition comprising the compound and a  
 CC carrier or diluent; (2) inhibiting the expression of casein kinase  
 CC 2-alpha in cells or tissues by contacting the cells or tissues with the  
 CC novel compound; and (3) treating an animal having a disease or condition  
 CC associated with casein kinase 2-alpha by administering to the animal the  
 CC compound cited above so that expression of casein kinase 2-alpha is  
 CC inhibited. The antisense compounds are useful for modulating the  
 CC expression of casein kinase 2-alpha and for treating diseases or  
 CC conditions associated with expression of casein kinase 2-alpha, e.g.  
 CC diabetes or hyperproliferative disorder, particularly cancer, such as  
 CC breast cancer, prostate cancer, or liver cancer. The antisense  
 CC compounds are also useful for diagnostics, therapeutics, prophylaxis,  
 CC e.g. to prevent or delay infection, inflammation or tumor formation, as  
 CC research reagents and kits, and in distinguishing between functions of  
 CC various members of a biological pathway. The present sequence is a  
 CC casein kinase-2 alpha antisense oligonucleotide of the invention.  
 XX  
 SQ Sequence 20 BP; 2 A; 7 C; 3 G; 8 T; 0 other;  
 Query Match 1.2%; Score 14.8; DB 1; Length 20;  
 Best Local Similarity 88.9%; Pred. No. 2e+02; Mismatches 0; Gaps 0;  
 Matches 16; Conservative 0; Indels 2; Indels 0; Gaps 0;  
 QY 393 AATTCATTCCTCTGGT 410  
 DB 3 ACATTCCTCTCTGGT 20  
 RESULT 116  
 ABT00039/c  
 ID ABT00039 standard; DNA; 20 BP.  
 XX  
 AC ABT00039;  
 XX  
 DT 07-NOV-2002 (first entry)  
 XX  
 DE Human neuregulin-1-associated gene 1 microsatellite marker #29.  
 XX  
 KW Human; neuregulin 1; neuregulin-1-associated gene 1; NRGL1; NRGL1G1;  
 KW schizophrenia; chromosome 8p12; single nucleotide polymorphism; SNP;  
 KW neuroleptic; gene therapy; splice variant; microsatellite marker; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 FN US2002045577-A1.  
 XX  
 PD 18-APR-2002.  
 XX  
 PF 28-FEB-2001; 2001US-0795668.  
 XX  
 PR 28-FEB-2000; 2000US-0515716.  
 XX  
 PA (DECO-) DECODE GENETICS EHF.  
 XX  
 PI Stefansson H, Steinthorsdottir V, Gulcher JR;  
 XX WPI; 2002-425447/45.  
 DR  
 XX New neuregulin 1 gene, schizophrenia gene residing in 1.5 Mb segment on  
 PT human chromosome 8p12, useful for diagnosing susceptibility to or  
 PT treating schizophrenia and for screening schizophrenia treating agents  
 PT

XX Disclosure; Page 445; 700pp; English.  
 XX  
 CC The present invention relates to the human neuregulin 1 gene (NRGL1),  
 CC single nucleotide polymorphisms within which were identified as being  
 CC associated with an increased susceptibility to schizophrenia, which is  
 CC located on chromosome 8p12. Also found within the same sequence is the  
 CC neuregulin-1-associated gene 1 (NRGL1G1). The gene is useful for treating  
 CC schizophrenia in an individual, for diagnosing susceptibility to  
 CC schizophrenia, and for screening for agents useful in the treatment of  
 CC the disease. The present sequence is a microsatellite marker identified  
 CC within the gene of the invention.  
 XX  
 SQ Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 other;  
 Query Match 1.2%; Score 14.8; DB 1; Length 20;  
 Best Local Similarity 88.9%; Pred. No. 2e+02; Mismatches 0; Gaps 0;  
 Matches 16; Conservative 0; Indels 2; Indels 0; Gaps 0;  
 QY 1352 GCTGTGTGGTGGTGGTGGT 1369  
 DB 20 GCTGTGTGGTGGTGGTGGT 3  
 RESULT 117  
 ABT01532/c  
 ID ABT01532 standard; DNA; 20 BP.  
 XX  
 AC ABT01532;  
 XX  
 DT 07-NOV-2002 (first entry)  
 XX  
 DE Human neuregulin-1-associated gene 1 microsatellite marker #29.  
 XX  
 KW Human; neuregulin 1; neuregulin-1-associated gene 1; NRGL1; NRGL1G1;  
 KW schizophrenia; chromosome 8p12; single nucleotide polymorphism; SNP;  
 KW neuroleptic; gene therapy; splice variant; microsatellite marker; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 FN US2002094954-A1.  
 XX  
 PD 18-JUL-2002.  
 XX  
 PF 28-FEB-2001; 2001US-0795686.  
 XX  
 PR 28-FEB-2000; 2000US-0515715.  
 XX  
 PA (DECO-) DECODE GENETICS EHF.  
 XX  
 PI Stefansson H, Steinthorsdottir V, Gulcher JR;  
 XX WPI; 2002-665799/71.  
 DR  
 XX NRGL1G1, useful for treating or diagnosing susceptibility to  
 PT schizophrenia, or for assaying a sample for the presence of NRGL1G1  
 PT nucleic acid -  
 PT  
 XX Disclosure; Page 444; 700pp; English.  
 XX  
 CC The present invention relates to the human neuregulin-1-associated gene  
 CC 1 (NRGL1G1), single nucleotide polymorphisms within which were identified  
 CC as being associated with an increased susceptibility to schizophrenia,  
 CC which is located on chromosome 8p12. Also found within the same sequence  
 CC is the neuregulin 1 gene (NRGL1). The gene is useful for treating  
 CC schizophrenia in an individual, for diagnosing susceptibility to  
 CC schizophrenia, and for screening for agents useful in the treatment of  
 CC the disease. The present sequence is a microsatellite marker identified  
 CC within the gene of the invention.  
 XX  
 SQ Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 other;  
 Query Match 1.2%; Score 14.8; DB 1; Length 20;  
 XX

CC prevent or delay infection, inflammation or tumour formation. (1) is  
CC also useful as therapeutic, diagnostic and research reagent, for  
CC distinguishing functions of various members of a biological pathway, and  
CC in antisense gene therapy. The present sequence represents an antisense  
CC oligonucleotide for human TNF inducible protein A20, from the present  
CC invention.  
XX  
SQ Sequence 20 BP; 7 A; 2 C; 4 G; 7 T; 0 other;  
Query Match 1.2%; Score 14.8; DB 1; Length 20;  
Best Local Similarity 88.9%; Pred. No. 2e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1237 ATTTCATTTCAGATAAA 1254  
DB 18 ATTGCATTTCAGACAAA 1  
RESULT 119  
ABT32456  
ID ABT32456 standard; DNA; 20 BP.  
XX  
AC ABT32456;  
XX  
DT 08-MAY-2003 (first entry)  
XX  
DE Neuroblastoma-related oligonucleotide #233.  
XX  
KW Neuroblastoma; prognosis; spontaneous regression; primer; probe; ds;  
KW high malignancy.  
XX  
OS Unidentified.  
XX  
FN WO200297093-A1.  
XX  
PD 05-DEC-2002.  
XX  
PF 30-MAY-2002; 2002WO-JP05294.  
XX  
PR 30-MAY-2001; 2001JP-0162775.  
PR 24-AUG-2001; 2001JP-0255226.  
XX  
PA (CHIB-) CHIBA PREFECTURE.  
PA (HISM) HISAMITSU PHARM CO LTD.  
XX  
PI Nakagawara A;  
XX  
DR WPI; 2003-140476/13.  
XX  
PT Nucleic acids having higher expression in human neuroblastoma with poor  
PT prognosis for diagnostic prediction of neuroblastoma prognosis -  
XX  
PS Example 5; Page 27; 111pp; Japanese.  
XX  
CC The invention comprises nucleic acids that show increased expression in  
CC human neuroblastomas with poor prognosis over those with a good  
CC prognosis. The nucleic acids of the invention are useful as a tool for  
CC distinguishing neuroblastomas with a favourable prognosis (spontaneous  
CC regression) from neuroblastomas with a poor prognosis (high malignancy).  
CC The DNA sequences ABT32224 - ABT32571 represent oligonucleotides used in  
CC an example of the invention.  
XX  
SQ Sequence 20 BP; 7 A; 3 C; 5 G; 5 T; 0 other;  
Query Match 1.2%; Score 14.8; DB 1; Length 20;  
Best Local Similarity 88.9%; Pred. No. 2e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1076 TTGCGCAGATTTCGAAA 1093  
DB 1 TGGGCAATTAATTTCGAAA 18

Best Local Similarity 88.9%; Pred. No. 2e+02; 0; Gaps 0;  
Matches 16; Conservative 0; Mismatches 2; Indels 0;  
QY 1352 GCTGCTGTTGCTAGCTG 1369  
DB 20 GCTGCTGTTGCTAGCTG 3  
RESULT 118  
ABL51148/c  
ID ABL51148 standard; DNA; 20 BP.  
XX  
AC ABL51148;  
XX  
DT 27-JUN-2002 (first entry)  
XX  
DE Human TNF inducible protein A20 antisense oligonucleotide SEQ ID:26.  
XX  
KW Human; tumour necrosis factor inducible protein A20; phosphorothioate;  
KW antisense modulation; antisense oligonucleotide; antiinflammatory;  
KW cytostatic; antiviral; gene therapy; TNF inducible protein A20;  
KW inflammatory disorder; viral infection; hyperproliferative disorder;  
KW cancer; inflammation; tumour formation; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "2'-methoxyethyl (MOE) nucleotide wings and a  
FT deoxy gap with a phosphorothioate backbone"  
FT modified\_base 1..5  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "2'-O-methoxyethyl nucleotides"  
FT modified\_base 15..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'-O-methoxyethyl nucleotides"  
XX  
PN WO200220545-A1.  
XX  
PD 14-MAR-2002.  
XX  
PF 07-SEP-2001; 2001WO-US28116.  
XX  
PR 08-SEP-2000; 2000US-0658687.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Bennett CP, Wyatt JR;  
XX  
DR WPI; 2002-362238/39.  
XX  
PT New antisense compound useful for preventing or delaying infection,  
PT inflammation or tumor formation, hybridizes and inhibits a nucleic acid  
PT molecule encoding tumor necrosis factor inducible protein, A20 -  
XX  
PS Claim 3; Page 91; 121pp; English.  
XX  
CC The present invention describes a compound (I) of 8 - 50 nucleotides  
CC targeted to a nucleic acid molecule (II) encoding tumour necrosis factor  
CC (TNF) inducible protein, A20, and which specifically hybridises with and  
CC inhibits expression of A20, or a compound (Ia) of 8 - 50 nucleotides  
CC which specifically hybridises with an 8-nucleotide portion of an active  
CC site on (II). (I) have antiinflammatory, cytostatic and antiviral  
CC activities. (I) can be used as inhibitors of TNF inducible protein, A20.  
CC (I) is useful for inhibiting the expression of A20 in cells or tissues,  
CC and for treating an animal having a disease condition associated with  
CC A20, e.g. a inflammatory disorder, viral infection and hyperproliferative  
CC disorder e.g. cancer. (I) is also useful prophylactically, e.g. to

RESULT 120  
ABZ10278  
ID ABZ10278 standard; DNA; 20 BP.  
XX  
AC ABZ10278;  
XX  
DT 16-JAN-2003 (first entry)  
XX  
DE Haematopoietic cell proliferation disorder related primer SEQ ID NO:418.  
XX  
DE Human; haematopoietic cell proliferation disorder; cytostatic;  
KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;  
KW cytosine methylation state; probe; primer; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FN WO200277272-A2.  
XX  
PD 03-OCT-2002.  
XX  
PF 26-MAR-2002; 2002WO-EP03401.  
XX  
PR 26-MAR-2001; 2001US-278333P.  
XX  
PA (EPIC-) EPIGENOMICS AG.  
XX  
PI Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;  
PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;  
PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;  
PI Pelet C, Schwöpe I, Ziebarth H;  
XX  
DR WPI; 2003-018942/01.  
XX  
PT Detecting and differentiating between hematopoietic cell proliferative  
PT disorders, comprises contacting a target nucleic acid with a reagent  
PT that distinguishes between methylated and non-methylated CpG  
PT dinucleotides -  
XX  
PS Claim 11; Page 33; 117pp; English.  
XX  
CC The present invention describes a method for detecting and  
CC differentiating between haematopoietic cell proliferative disorders  
CC associated with at least 1 gene and/or their regulatory regions in a  
CC subject. The method comprises contacting a target nucleic acid in a  
CC biological sample obtained from the subject with at least 1 reagent,  
CC which distinguishes between methylated and non-methylated CpG  
CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ1118  
CC represent specifically claimed nucleotide sequences from the present  
CC invention. Oligonucleotides from the present invention can be used: for  
CC differentiating between healthy haematopoietic cells and proliferative  
CC disorder haematopoietic cells; for differentiating between acute  
CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for  
CC determining the cytosine methylation state and/or single nucleotide  
CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder  
CC related sequences and their complements; and as primers for the  
CC amplification of haematopoietic cell proliferation disorder related  
CC DNA sequences. The nucleotide sequences from the present invention can  
CC also be used for detecting a predisposition to, differentiation between  
CC subclasses, diagnosis, prognosis, treatment and/or monitoring of  
CC haematopoietic cell proliferative disorders. The present method enables  
CC a highly specific classification of haematopoietic cell proliferative  
CC disorders allowing for improved and informed treatment of patients.  
XX  
SQ Sequence 20 BP; 8 A; 8 C; 0 G; 4 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 20;  
Best Local Similarity 88.9%; Pred. No. 2e+02; Indels 0; Gaps 0;  
Matches 16; Conservative 0; Mismatches 2;  
QY 439 AACTTCAGCAATCTAC 456  
DB 3 AACTTCAGCAATCTCC 20

RESULT 121  
AAT10936/C  
ID AAT10936 standard; DNA; 21 BP.  
XX  
AC AAT10936;  
XX  
DT 31-JUL-1996 (first entry)  
XX  
DE B. burgdorferi exported plasmid protein A (EppA) gene PCR primer.  
XX EppA; Lyme disease; antigenic; immune response; detection; virulent;  
KW infection; polymerase chain reaction; ss.  
XX  
OS Synthetic.  
XX  
FN WO9535114-A1.  
XX  
PD 28-DEC-1995.  
XX  
PF 16-JUN-1995; 95WO-US07748.  
XX  
PR 17-JUN-1994; 94US-0261825.  
XX  
PA (RSCC) UNIV CALIFORNIA.  
XX  
PI Blanco DR, Champion CI, Haake DA, Lovett MA, Miller JN;  
XX WPI; 1996-058208/06.  
XX  
PT Borrelia burgdorferi exported plasmid protein A - used to develop  
PT prods. to induce an immune response to B.burgdorferi and as  
PT diagnostic markers for Lyme disease  
XX  
PS Example 5; Page 34; 67pp; English.  
XX  
CC AAT10933-T10937 are PCR primers used for the amplification of a DNA  
CC sequence from Borrelia burgdorferi which encodes the exported plasmid  
CC protein A (EppA). EppA is a virulent protein of about 17 kD. EppA and  
CC its active fragments can be used to induce an immune response to  
CC pathogenic Borrelia burgdorferi (BB) in an animal. The sequence may  
CC be used to produce recombinant EppA expressed in E. coli. EppA is  
CC exported beyond the inner membrane and is present during the  
CC infectious, in vivo stages of virulent BB growth. Polynucleotides  
CC encoding EppA and anti-EppA antibodies can be used for the detection  
CC of pathogenic BB in a sample.  
XX  
SQ Sequence 21 BP; 10 A; 0 C; 4 G; 7 T; 0 other;

Query Match 1.2%; Score 14.8; DB 1; Length 21;  
Best Local Similarity 88.9%; Pred. No. 2.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 542 CAATCAATAGTTTTCAT 559  
DB 18 CAATAAATATTTTTCAT 1

RESULT 122  
AAZ26565  
ID AAZ26565 standard; DNA; 21 BP.  
XX  
AC AAZ26565;  
XX  
DT 30-NOV-1999 (first entry)  
XX  
DE Human polymorphic region 754.  
XX  
DE Polymorphism; human; inhibitor; cancer; treatment; cell growth; LOH;  
KW cell viability; loss of heterozygosity; precancerous condition; ASI;  
KW allele specific inhibitor; somatic cell; diagnosis; prevention;  
KW atherosclerotic plaque; premalignant metaplastic lesion; endometriosis;

KW dysplastic lesion; benign tumour; polycystic kidney disease; transplant;  
 KW graft versus host disease; malignant cell removal; bone marrow; ss.  
 XX Homo sapiens.

OS

XX WO9841648-A2.

XX 24-SEP-1998.

XX 15-MAR-1998; 98WO-US05419.

XX 20-MAR-1997; 97US-0041057.

XX (VARI-) VARIAGENICS INC.

XX Housman D, Ledley FD, Stanton VP;

XX WPI; 1998-521232/44.

XX Identifying target genes for allele-specific drugs - used for

XX diagnosis, prevention and treatment of, e.g. cancers, atherosclerotic

XX plaque, dysplastic lesions, endometriosis or graft versus host disease

XX Disclosure; Figure 7; 60pp; English.

XX This invention describes a novel method for identifying an inhibitor

XX potentially useful for treatment of cancer, where the inhibitor is

XX active on a gene vital for cell growth or viability, and where the gene

XX is subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is

XX used for preventing the development of cancer in a patient having a

XX precancerous condition, by administering to the patient a first allele

XX specific inhibitor (ASI) targeted to an allele of a first essential gene

XX present in cells of the precancerous condition, where the normal somatic

XX cells of the patient are heterozygous for the first gene, the inhibitor

XX is active on at least one but less than all allelic forms of the gene

XX present in a population and targets only one allelic form present in the

XX normal somatic cells, and the first gene. The products and methods can

XX be used in the diagnosis, prevention and treatment of LOH disorders,

XX e.g. cancers, atherosclerotic plaques, premalignant metaplastic or

XX dysplastic lesions, benign tumours, endometriosis, polycystic kidney

XX disease, and graft versus host disease. The method can also be used to

XX remove malignant cells from bone marrow transplants. AA225812-226825

XX represent human polymorphic sites described in the method of the

XX invention.

XX SQ Sequence 21 BP; 8 A; 1 C; 0 G; 12 T; 0 other;

XX Query Match 1.2%; Score 14.8; DB 1; Length 21;

XX Best Local Similarity 88.9%; Pred. No. 2.1e+02;

XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX QY 1521 TTTATATTTTAACTTTA 1538

XX Db 4 TTTATATTTTAACTTTA 21

XX RESULT 123

XX AA276395/C

XX ID AA276395 standard; DNA; 21 BP.

XX AC AA276395;

XX 10-SEP-2001 (first entry)

XX Human biallelic marker downstream amplification primer SEQ ID NO:10751.

XX Human genome; biallelic marker; high density disequilibrium map;

XX genomic map; haplotype; phenotype; polymorphic base; genotyping;

XX haplotyping; hybridisation; identification; characterisation;

XX amplification; single nucleotide polymorphism; SNP; PCR primer;

XX diagnosis; ss.

XX OS Homo sapiens.

XX

EN

XX WO954500-A2.

XX 28-OCT-1999.

XX 21-APR-1999; 99WO-IB00822.

XX 21-APR-1998; 98US-0082614.

XX 23-NOV-1998; 98US-0109732.

XX (BEST ) GENSET.

XX Cohen D, Blumenfeld M, Chumakov I;

XX WPI; 2000-013267/01.

XX Novel biallelic markers used to construct a high density disequilibrium

XX map of the human genome -

XX Claim 9; Page 2522; 2745pp; English.

XX AA265654 to AA269578 represent human biallelic markers from the present

XX invention, which contain a polymorphic base at position 24 of their

XX nucleotide sequences. AA269579 to AA27440 represent amplification

XX primers for the biallelic markers. The biallelic markers of the

XX invention have a variety of uses: they can be used for high density

XX mapping of the human genome, and in complex association studies and

XX haplotyping studies which are useful in determining the genetic basis

XX for disease states. Compositions and methods of the invention can also

XX be useful for the identification of the targets for the development of

XX pharmaceutical agents and diagnostic methods, as well as the

XX characterisation of the differential efficacious responses to and side

XX effects from pharmaceutical agents acting on a disease as well as other

XX treatment.

XX N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297

XX and 3367, are not actually given a sequence in the Sequence Listing

XX from the present invention.

XX SQ Sequence 21 BP; 3 A; 7 C; 0 G; 11 T; 0 other;

XX Query Match 1.2%; Score 14.8; DB 1; Length 21;

XX Best Local Similarity 88.9%; Pred. No. 2.1e+02;

XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX QY 1593 TATAAAGTAAATATGAA 1610

XX Db 20 TATAAAGGAAAGATGAA 3

XX RESULT 124

XX AAH84289

XX ID AAH84289 standard; cDNA; 21 BP.

XX AC AAH84289;

XX 21-SEP-2001 (first entry)

XX Human cell death protective cDNA clone CMI-00721 ORF8, SEQ:307.

XX Cell death protective; apoptosis; necrosis; human; drug screening;

XX cell death-associated disorder; central nervous system disorder;

XX psychiatric disorder; neurological disorder; ischaemia-related disorder;

XX stroke; cerebral infarction; ischaemic encephalopathy;

XX neurodegenerative disorder; Alzheimer's disease; Huntington's disease;

XX Parkinson's disease; infection; meningitis; malaria; trypanosomiasis;

XX vascular disease; ophthalmological disorder; diabetic retinopathy;

XX macular degeneration; hypertension; myocardial infarction;

XX atherosclerosis; respiratory disorder; asthma; transgenic animal;

XX chronic obstructive pulmonary disease; neoplastic condition; cancer;

XX benign tumour; anaemia; gastrointestinal disorder; gastritis;

XX ulcerative colitis; liver disease; biliary cirrhosis; kidney disorder;

XX glomerulonephritis; cystitis; endometriosis; endocrine disorder;

XX Grave's disease; Hashimoto's thyroiditis; skin condition; dermatitis;

urticaria; immune disorder; acquired immunodeficiency syndrome; AIDS;  
open reading frame; ORF; ss.  
Homo sapiens.  
WO2000145638-A2.  
28-JUN-2001.  
11-DEC-2000; 2000WO-US33547.  
14-DEC-1999; 99US-0461697.  
(COGE-) COGENT NEUROSCIENCE INC.  
Lo DC, Barney S, Thomas MB, Portbury SD, Puranam K, Katz LC;  
MPI; 2001-390297/41.  
P-PSDB; AAG98756.  
Novel protective sequence polynucleotides and polypeptides, used to  
identify modulators of their expression and activity, which are used in  
to treat central nervous system conditions, diseases and disorders -  
Claim 2; Fig 11H; 325pp; English.  
Sequences AAH84132-AAH84370 represent human nucleic acid sequences which  
protect against cell death (i.e., apoptosis or necrosis). Sequences  
AAH84132, AAH84145, AAH84170, AAH84201, AAH84226, AAH84265,  
AAH84281, AAH84315 and AAH84367 represent 10 full-length cDNA clones,  
while the remaining nucleic acid sequences within the range given above  
represent the open reading frames (ORFs) of these cDNA clones. Sequences  
AAG98610-AAG98829 represent the polypeptides encoded by the cell death  
protective ORFs. The cell death protective cDNA clones are able to  
prevent, delay or reverse progression through the apoptotic or necrotic  
pathways when injected into a cell predisposed to or undergoing cell  
death. The cell death protective nucleic acids and polypeptides can be  
used in the diagnosis and treatment of disorders associated with cell  
death, and to screen for compounds which modulate their activity or  
expression. Such modulators, preferably a small organic molecule, an  
antibody, a ribozyme, or an antisense molecule, can also be used to treat  
cell death-related diseases. Such diseases include those associated with  
the central nervous system including psychiatric or neurological  
disorders, especially ischaemia-related conditions such as strokes, and  
also includes neurodegenerative disorders such as Alzheimer's disease,  
Huntington's disease, or Parkinson's disease. The modulators may also be  
used to treat infections such as meningitis, malaria, or trypanosomiasis;  
vascular diseases such as ischaemic encephalopathy or cerebral  
infarction; eye conditions such as diabetic retinopathy or macular  
degeneration; hypertension; myocardial infarction; atherosclerosis;  
respiratory conditions such as asthma or chronic obstructive pulmonary  
disease; neoplastic conditions such as cancers or benign tumours; blood  
cell conditions such as anaemia; gastrointestinal conditions such as  
gastritis or ulcerative colitis; liver conditions such as biliary  
cirrhosis; kidney disorders such as glomerulonephritis; cystitis;  
endometriosis; endocrine disorders such as Grave's disease or Hashimoto's  
thyroiditis; skin conditions such as dermatitis or urticaria; or immune  
system disorders such as acquired immunodeficiency syndrome (AIDS). The  
nucleic acids may additionally be used to generate animal models of  
cell death-associated disorders. The present sequence represents a  
cell death protective ORF.  
Sequence 21 BP; 4 A; 1 C; 5 G; 11 T; 0 other;  
Query Match 1.2%; Score 14.8; DB 1; Length 21;  
Best Local Similarity 88.9%; Pred. No. 2.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 830 GGATTTTTCCTGTTAAA 847  
|||||  
DB 4 GGATTTTTCCTGTTAA 21

RESULT 125  
AAH62202/c  
ID AAH62202 standard; DNA; 21 BP.  
XX  
AC AAH62202;  
XX  
DT 12-SEP-2001 (first entry)  
XX  
DE Per tyrosine kinase polymorphism containing DNA fragment #103.  
XX  
KW Single nucleotide polymorphism; SNP; human; cancer; inflammation;  
KW heart disease; paternity testing; forensic science; ds.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT Variation replace(11,G)  
FT /\*tag= a  
FT /standard\_name= "single nucleotide polymorphism"  
XX  
PN WO200138576-A2.  
XX  
PD 31-MAY-2001.  
XX  
PF 17-NOV-2000; 2000WO-US31639.  
XX  
PR 24-NOV-1999; 99US-0167334.  
XX  
PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.  
XX  
PI Cargill M, Ireland JS, Lander BS;  
XX  
DR MPI; 2001-367705/38.  
XX  
PT New nucleic acid segments of the human genome, particularly from genes  
PT including polymorphic sites, for phenotype correlation, forensics,  
PT paternity testing, medicine and genetic analysis -  
PS Claim 1; Page 38; 80pp; English.  
XX  
CC DNA sequences AAH62100 - AAH62688 represent segments of human genes which  
CC contain single nucleotide polymorphisms (SNPs). A method is included in  
CC the invention for analysing a nucleic acid sample, which consists of  
CC determining the base occupying any one of the polymorphic sites given in  
CC the SNP containing sequences. The nucleotide sequences can be used in the  
CC diagnosis or monitoring of diseases, such as cancer, inflammation, heart  
CC diseases, diseases of the cardiovascular system, and infection by  
CC microorganisms. The oligonucleotides are also useful in the manufacture  
CC of a medicament for the treatment or prophylaxis of the diseases, and as  
CC a pharmaceutical. SNP containing oligonucleotides are useful in  
CC applications such as phenotype correlation, forensics, paternity testing,  
CC medicine and genetic analysis.  
XX  
SQ Sequence 21 BP; 11 A; 1 C; 4 G; 5 T; 0 other;  
Query Match 1.2%; Score 14.8; DB 1; Length 21;  
Best Local Similarity 88.9%; Pred. No. 2.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1561 AATTTCCTTCTGTTTC 1578  
|||||  
DB 20 AATTTCCTTCTGTTTC 3  
RESULT 126  
AAH62464/c  
ID AAH62464 standard; DNA; 21 BP.  
XX  
AC AAH62464;  
XX  
DT 12-SEP-2001 (first entry)  
XX  
DE CytochromeP19 polymorphism containing DNA fragment #365.

```

XX Single nucleotide polymorphism; SNP; human; cancer; inflammation;
KW heart disease; paternity testing; forensic science; ds.
OS
XX Homo sapiens.
XX Key Location/Qualifiers
XX Variation replace(11,C)
XX PT /tag= a
XX FT /standard_name= "single nucleotide polymorphism"
XX
XX WO200138576-A2.
XX
XX 31-MAY-2001.
XX
XX 17-NOV-2000; 2000WO-US31639.
XX
XX 24-NOV-1999; 99US-0167334.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX
XX Cargill M, Ireland JS, Lander ES;
XX
XX WPI; 2001-367705/38.
XX
XX New nucleic acid segments of the human genome, particularly from genes
XX including polymorphic sites, for phenotype correlation, forensics,
XX paternity testing, medicine and genetic analysis -
XX
XX Claim 1; Page 58; 80pp; English.
XX
XX DNA sequences AAH62100 - AAH62688 represent segments of human genes which
XX contain single nucleotide polymorphisms (SNPs). A method is included in
XX the invention for analysing a nucleic acid sample, which consists of
XX determining the base occupying any one of the polymorphic sites given in
XX the SNP containing sequences. The nucleotide sequences can be used in the
XX diagnosis or monitoring of diseases, such as cancer, inflammation, heart
XX diseases, diseases of the cardiovascular system, and infection by
XX microorganisms. The oligonucleotides are also useful in the manufacture
XX of a medicament for the treatment or prophylaxis of the diseases, and as
XX a pharmaceutical. SNP containing oligonucleotides are useful in
XX applications such as phenotype correlation, forensics, paternity testing,
XX medicine and genetic analysis.
XX
XX Sequence 21 BP; 10 A; 2 C; 5 G; 4 T; 0 other;
XX
XX Query Match 1.2%; Score 14.8; DB 1; Length 21;
XX Best Local Similarity 88.9%; Pred. No. 2.1e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 822 GAATCTCGATTTT 839
XX ||||| |||||
XX DB 21 GAATCTCGATCTTTT 4
XX
XX RESULT 127
XX AA166531
XX ID AA166531 standard; DNA; 24 BP.
XX
XX AC AA166531;
XX
XX 11-DEC-2001 (first entry)
XX
XX Human pterin-molybdenum oxidoreductase 10 cDNA PCR primer #1.
XX
XX Human; pterin-molybdenum oxidoreductase 10; cancer; haemopathy;
XX immunological disease; HIV infection; inflammation; gene therapy;
XX PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200172788-A1.
XX

```

```

PD 04-OCT-2001.
XX
XX 23-MAR-2001; 2001WO-CN00393.
XX
XX 24-MAR-2000; 2000CN-0115110.
XX
XX (SHAN-) SHANGHAI BIOWINDOW GENE DEV INC.
XX
XX Mao Y, Xie Y;
XX
XX WPI; 2001-602841/58.
XX
XX New polypeptide for the diagnosis and treatment of malignant neoplasm,
XX hemopathy, HIV infection, immunological diseases and inflammations,
XX comprises the human pterin-molybdenum oxidoreductase 10 protein -
XX
XX Example 2; Page 17; 36pp; Chinese.
XX
XX The present invention provides the protein and coding sequences of human
XX pterin-molybdenum oxidoreductase 10. The sequences can be used in the
XX treatment of cancer, haemopathy, HIV infection, immunological diseases
XX and inflammation. The present sequence is a PCR primer for the coding
XX sequence of the invention.
XX
XX Sequence 24 BP; 10 A; 2 C; 0 G; 12 T; 0 other;
XX
XX Query Match 1.2%; Score 14.6; DB 1; Length 24;
XX Best Local Similarity 81.0%; Pred. No. 2.6e+02;
XX Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
XX QY 1139 TAAATTATTATTATTACAT 1159
XX ||||| ||||| ||||| |||||
XX DB 4 TAAATATATAATATTACAT 24
XX
XX RESULT 128
XX AAAT74329/c
XX ID AAAT74329 standard; DNA; 16 BP.
XX
XX AC AAAT74329;
XX
XX 29-NOV-2000 (first entry)
XX
XX Loblolly pine SSR repeat of locus RIPPT67.
XX
XX Loblolly pine; Simple Sequence Repeat; SSR;
XX microsatellite DNA repeat; genetic marker; mapping; inheritance study;
XX population genetics study; plant breeding programme; ss.
XX
XX Pinus taeda.
XX
XX WO200042210-A2.
XX
XX 20-JUL-2000.
XX
XX 06-JAN-2000; 2000WO-US00325.
XX
XX 15-JAN-1999; 99US-0232884.
XX
XX 19-JAN-1999; 99US-0232785.
XX
XX (INTO ) INT PAPER CO.
XX
XX (ECMT/) ECMT C S.
XX
XX (NELS/) NELSON C D.
XX
XX (USDA ) US SEC OF AGRIC.
XX
XX Echt CS, Nelson CD;
XX
XX WPI; 2000-482836/42.
XX
XX Polynucleotide having simple sequence repeat useful as markers in
XX plants for genetic characterization e.g. genetic mapping study, an
XX inheritance study of a commercially important trait in a plant breeding
XX program -
XX

```





KW age related macular degeneration; inflammation; neovascular glaucoma;  
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KW tuberculous scleriosis; pot-wine stain; Sturge Weber syndrome;  
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 XX Homo sapiens.  
 OS  
 XX  
 XX WO9950403-A2.  
 PN  
 XX  
 PD 07-OCT-1999.  
 XX  
 XX 24-MAR-1999; 99WO-US060507.  
 PF  
 XX 27-MAR-1998; 98US-0079678.  
 PR  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;  
 PI WPI; 1999-591315/50.  
 XX  
 DR Novel ribozymes for modulating the synthesis, expression and/or  
 XX stability of an mRNA encoding an angiogenic factors -  
 PT  
 XX Claim 54; Page 237; 305pp; English.  
 PS  
 XX The present invention describes enzymatic nucleic acid molecules with  
 XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17467 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC AAA17168 and AAA17560 and AAA17623 to AAA17684 represent their  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA21688 represent their corresponding target sequences;  
 CC AAA21689 to AAA22475 and AAA22623 to AAA23342 represent ribozyme sequence  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (AMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tuberous sclerosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3.  
 XX  
 XX Sequence 17 BP; 4 A; 0 C; 0 G; 13 U; 0 other;  
 SQ  
 Query Match 1.2%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 25.0%; Pred. No. 2.1e+02;  
 Matches 4; Conservative 11; Mismatches 1; Indels 0; Gaps 0;  
 QY 1046 ATTATGATATTATT 1061  
 DB 1 AUAUAUAUAUAUAUUU 16  
 RESULT 132  
 AA171138/c  
 ID AA171138 standard; DNA; 17 BP.  
 XX  
 XX AA171138;  
 AC  
 XX  
 XX 18-DEC-2001 (first entry)  
 DT  
 XX  
 XX Detection probe SEQ ID NO:38.  
 DE  
 XX

KW Shigella; Salmonella; differentiation; determination; primer; probe;  
 KW detection; microorganism; bacterium; ss.  
 XX  
 OS Salmonella sp.  
 XX  
 XX JP2001245677-A.  
 PN  
 XX 11-SEP-2001.  
 PD  
 XX 27-DEC-2000; 2000JP-0398087.  
 PF  
 XX 27-DEC-1999; 99JP-0368920.  
 PR  
 XX (SRLS-) SRL KK.  
 PA (KAIY-) KAIYO BIOTECHNOLOGY KENKYUSHO KK.  
 PA (NIGE-) NIPPON GENE KK.  
 XX  
 XX WPI; 2001-610077/70.  
 DR  
 XX Determination of Shigella or Salmonella spp. bacteria comprises using  
 XX nucleic acid probes with different base sequences -  
 PT  
 XX Claim 16; Page 10; 40pp; Japanese.  
 PS  
 XX The present invention describes a method for differentiating bacteria  
 CC by using primers or probes having different base sequences. The method  
 CC can be used for the differentiation or detection of Shigella flexneri,  
 CC Shigella boydii, Shigella sonnei or Salmonella typhi, Salmonella  
 CC paratyphiA, Salmonella typhimurium, Salmonella chester, Salmonella  
 CC enteritidis, and Salmonella oranienburg spp. bacteria. The method can  
 CC be used for rapid differentiation of 9 lines of bacteria for prevention,  
 CC diagnosis and treatment of diseases caused by these bacteria. The  
 CC present sequence represents a detection probe which is used in an  
 CC example from the present invention.  
 XX  
 XX Sequence 17 BP; 3 A; 6 C; 0 G; 8 T; 0 other;  
 SQ  
 Query Match 1.2%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 2.1e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1088 TGGAAAATAGAGAT 1103  
 DB 16 TGGAGAAATAGAGAT 1  
 RESULT 133  
 ABV80425/c  
 ID ABV80425 standard; DNA; 17 BP.  
 XX  
 XX ABV80425;  
 AC  
 XX  
 XX 03-JAN-2003 (first entry)  
 DT  
 XX Human HTPL scanning oligonucleotide SEQ ID 1671.  
 DE  
 XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
 XX human testis expressed Patched like protein; testis; adrenal; liver;  
 XX male germ cell development; bone marrow; brain; kidney; lung; placenta;  
 XX prostate; skeletal muscle; colon; male infertility; cancer; ss.  
 XX  
 XX Homo sapiens.  
 OS  
 XX  
 XX EPI229046-A2.  
 PN  
 XX 07-AUG-2002.  
 PD  
 XX 28-JAN-2002; 2002EP-0001167.  
 PF  
 XX 30-JAN-2001; 2001WO-US00663.  
 PR 30-JAN-2001; 2001WO-US00664.  
 PR 30-JAN-2001; 2001WO-US00665.  
 PR 30-JAN-2001; 2001WO-US00667.  
 PR

PR 30-JAN-2001; 2001WO-US00668.  
PR 30-JAN-2001; 2001WO-US00669.  
PR 23-MAY-2001; 2001US-0864761.  
PR 09-OCT-2001; 2001US-0327898.  
XX (AEOM-) AEOMICA INC.  
XX Zhan J;  
XX WPI; 2002-676582/73.  
XX Novel isolated human testis expressed Patched like protein (HTPL),  
PT useful for identifying agonist and antagonist and specific binding  
PT partners, and for treating subjects having defects in HTPL -  
XX Example 2; Page 282; 718pp; English.  
XX The present invention relates to human testis expressed Patched like  
CC protein (HTPL), see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop  
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
CC shares an overall structure organisation with the Patched protein. The  
CC shared structural features strongly imply that HTPL plays a role similar  
CC to that of Patched, and is a potential tumour suppressor. HTPL is  
CC important in regulating male germ cell development, and the HTPL gene was  
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
CC therapy and manufacture of a medicament for treatment or prevention of  
CC such disorder associated with decreased expression or activity of human  
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
CC clinically useful diagnostic markers and potential therapeutic agents for  
CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention.  
XX Sequence 17 BP; 3 A; 1 C; 1 G; 12 T; 0 other;  
SQ Query Match 1.2%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 675 ATACAAATAGCAAAAT 691  
Db 17 ATACAAATAGCAAAAT 2  
RESULT 134  
ABV80427/C  
ID ABV80427 standard; DNA; 17 BP.  
XX AC ABV80427;  
XX 03-JAN-2003 (first entry)  
XX Human HTPL scanning oligonucleotide SEQ ID 1673.  
XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
KW human testis expressed Patched like protein; testis; adrenal; liver;  
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
XX Homo sapiens.  
XX EP1229046-A2.  
XX 07-AUG-2002.  
XX 28-JAN-2002; 2002EP-0001167.  
XX 30-JAN-2001; 2001WO-US00663.  
PR 30-JAN-2001; 2001WO-US00664.

PR 30-JAN-2001; 2001WO-US00665.  
PR 30-JAN-2001; 2001WO-US00667.  
PR 30-JAN-2001; 2001WO-US00668.  
PR 30-JAN-2001; 2001WO-US00669.  
PR 23-MAY-2001; 2001US-0864761.  
PR 09-OCT-2001; 2001US-0327898.  
XX (AEOM-) AEOMICA INC.  
XX Zhan J;  
XX WPI; 2002-676582/73.  
XX Novel isolated human testis expressed Patched like protein (HTPL),  
PT useful for identifying agonist and antagonist and specific binding  
PT partners, and for treating subjects having defects in HTPL -  
XX Example 2; Page 283; 718pp; English.  
XX The present invention relates to human testis expressed Patched like  
CC protein (HTPL), see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop  
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
CC shares an overall structure organisation with the Patched protein. The  
CC shared structural features strongly imply that HTPL plays a role similar  
CC to that of Patched, and is a potential tumour suppressor. HTPL is  
CC important in regulating male germ cell development, and the HTPL gene was  
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
CC therapy and manufacture of a medicament for treatment or prevention of  
CC such disorder associated with decreased expression or activity of human  
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
CC clinically useful diagnostic markers and potential therapeutic agents for  
CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention.  
XX Sequence 17 BP; 4 A; 1 C; 1 G; 11 T; 0 other;  
SQ Query Match 1.2%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 675 TATACAAATAGCAAAA 690  
Db 16 TATACAAATAGCAAAA 1  
RESULT 135  
ABT37900/C  
ID ABT37900 standard; DNA; 17 BP.  
XX AC ABT37900;  
XX 12-JUN-2003 (first entry)  
XX Tumour suppression related human fukutin oligo SEQ ID No 3537.  
DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX Homo sapiens.  
XX WO2003025175-A2.  
XX 27-MAR-2003.  
XX 17-SEP-2002; 2002WO-IB04208.  
XX